

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2008218542 B2**

(54) Title
Genetic susceptibility variants associated with cardiovascular disease

(51) International Patent Classification(s)
C12Q 1/68 (2006.01)

(21) Application No: **2008218542** (22) Date of Filing: **2008.02.21**

(87) WIPO No: **WO08/102380**

(30) Priority Data

(31) Number	(32) Date	(33) Country
8613	2007.02.21	IS
8701	2007.12.21	IS
8640	2007.04.30	IS

(43) Publication Date: **2008.08.28**

(44) Accepted Journal Date: **2014.06.26**

(71) Applicant(s)
deCODE Genetics ehf.

(72) Inventor(s)
Helgadottir, Anna;Manolescu, Andrei;Thorleifsson, Gudmar

(74) Agent / Attorney
Freehills Patent Attorneys, Level 43 101 Collins Street, Melbourne, VIC, 3000

(56) Related Art
WO 2005056837
WO 2004081186
WO 2005087953
WO 2005110039
US 20060057564
US 20050228172
DBSNP NCBI Accession No. ss66735836, RefSNP rs1333040, submitted 9
November 2006

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2008 (28.08.2008)

PCT

(10) International Publication Number
WO 2008/102380 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/IS2008/000007

(22) International Filing Date:
21 February 2008 (21.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
8613 21 February 2007 (21.02.2007) IS
8640 30 April 2007 (30.04.2007) IS
8701 21 December 2007 (21.12.2007) IS

(71) Applicant (for all designated States except US): **DECODE GENETICS EHF** [IS/IS]; Sturlugata 8, IS-101 Reykjavik (IS).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HELGADOTTIR, Anna** [IS/IS]; Hamravik 86, IS-112 Reykjavik (IS). **THORLEIFSSON, Gudmar** [IS/IS]; Vesturberg 155, IS-111 Reykjavik (IS). **MANOLESCU, Andrei** [RO/IS]; Eskihlid 22a, IS-105 Reykjavik (IS).

(74) Agent: **JONSSON, Thorlakur**; deCODE genetics ehf, Sturlugata 8, IS-101 Reykjavik (IS).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE

(57) Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease, MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.



WO 2008/102380 A1

GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE

BACKGROUND OF THE INVENTION

5 Coronary artery disease and myocardial infarction

The major complications of Coronary Artery Disease, i.e. Myocardial infarction (MI) and Acute Coronary Syndrome (ACS), are the leading causes of hospital admissions in industrialized countries. Cardiovascular disease continues to be the principle cause of death in the United States, Europe and Japan. The costs of the disease are high both in terms of morbidity and
10 mortality, as well as in terms of the financial burden on health care systems.

Myocardial infarction generally occurs when there is an abrupt decrease in coronary blood flow following a thrombotic occlusion of a coronary artery previously damaged by atherosclerosis (i.e. in subjects with coronary artery disease). In most cases, infarction occurs when an atherosclerotic plaque fissures, ruptures or ulcerates and when conditions favor
15 thrombogenesis. In rare cases, infarction may be due to coronary artery occlusion caused by coronary emboli, congenital abnormalities, coronary spasm, and a wide variety of systemic, particularly inflammatory diseases. Medical risk factors for MI include cigarette smoking, diabetes, hypertension and serum total cholesterol levels > 200 mg/dL, elevated serum LDL cholesterol, and low serum HDL cholesterol. Event rates in individuals without a prior history of
20 cardiovascular disease are about 1%. In individuals who have had a first MI or ACS, the risk of a repeat MI within the next year is 10-14%, despite maximal medical management including angioplasty and stent placement.

Atherosclerosis can affect vascular beds in many large and medium arteries. Myocardial infarction and unstable angina (acute coronary syndrome (ACS)) stem from coronary
25 artery atherosclerosis (Coronary Artery Disease), while ischemic stroke most frequently is a consequence of carotid or cerebral artery atherosclerosis. Limb ischemia caused by peripheral arterial occlusive disease (PAOD) may occur as a consequence of iliac, femoral and popliteal artery atherosclerosis. The atherosclerotic diseases remain common despite the wide-spread use of medications that inhibit thrombosis (aspirin) or treat medical risk factors such as elevated
30 cholesterol levels in blood (statins), diabetes, or hypertension (diuretics and anti-hypertensives).

Atherosclerotic disease is initiated by the accumulation of lipids within the artery wall, and in particular, the accumulation of low-density lipoprotein (LDL) cholesterol. The trapped LDL becomes oxidized and internalized by macrophages. This causes the formation of atherosclerotic lesions containing accumulations of cholesterol-engorged macrophages, referred to as "foam

cells". As disease progresses, smooth muscle cells proliferate and grow into the artery wall forming a "fibrous cap" of extracellular matrix enclosing a lipid-rich, necrotic core. Present in the arterial walls of most people throughout their lifetimes, fibrous atherosclerotic plaques are relatively stable. Such fibrous lesions cause extensive remodeling of the arterial wall, outwardly displacing the external, elastic membrane, without reduction in luminal diameter or serious impact on delivery of oxygen to the heart. Accordingly, patients can develop large, fibrous atherosclerotic lesions without luminal narrowing until late in the disease process. However, the coronary arterial lumen can become gradually narrowed over time and in some cases compromise blood flow to the heart, especially under high demand states such as exercise. This can result in reversible ischemia causing chest pain relieved by rest called stable angina.

In contrast to the relative stability of fibrous atherosclerotic lesions, the culprit lesions associated with myocardial infarction and unstable angina (each of which are part of the acute coronary syndrome) are characterized by a thin fibrous cap, a large lipid core, and infiltration of inflammatory cells such as T-lymphocytes and monocyte/macrophages. Non-invasive imaging techniques have shown that most MI's occur at sites with low- or intermediate- grade stenoses, indicating that coronary artery occlusion is due most frequently to rupture of culprit lesions with consequent formation of a thrombus or blood clot and not solely due to luminal narrowing by stenosis. Plaque rupture may be due to erosion or uneven thinning of the fibrous cap, usually at the margins of the lesion where macrophages enter, accumulate, and become activated by a local inflammatory process. Thinning of the fibrous cap may result from degradation of the extracellular matrix by proteases released from activated macrophages. These changes producing plaque instability and risk of MI may be augmented by production of tissue-factor procoagulant and other factors increasing the likelihood of thrombosis.

In acute coronary syndrome, the culprit lesion showing rupture or erosion with local thrombosis typically is treated by angioplasty or by balloon dilation and placement of a stent to maintain luminal patency. Patients experiencing ACS are at high risk for a second coronary event due to the multi-vessel nature of coronary artery disease with event rates approaching 10-14% within 12 months after the first incident.

The emerging view of MI is as an inflammatory disease of the arterial vessel wall on preexisting chronic atherosclerotic lesions, sometimes triggering rupture of culprit lesions and leading to local thrombosis and subsequent myocardial infarction. The process that triggers and sustains arterial wall inflammation leading to plaque instability is unknown, however, it results in the release into the circulation of tumor necrosis factor alpha and interleukin-6. These and other cytokines or biological mediators released from the damaged vessel wall stimulate an inflammatory response in the liver causing elevation in several non-specific general inflammatory markers including C-reactive protein. Although not specific to atherosclerosis, elevated C-reactive protein (CRP) and serum amyloid A appear to predict risk for MI, perhaps as surrogates for vessel wall inflammation. Many general inflammatory markers predict risk of coronary heart disease, although these markers are not specific to atherosclerosis. For example, Stein (Stein,

S., *Am J Cardiol*, 87 (suppl):21A-26A (2001)) discusses the use of any one of the following serum inflammatory markers as surrogates for predicting risk of coronary heart disease including C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, and matrix metalloprotease type-9. Elevation in one more of these serum inflammatory markers is not specific to coronary heart disease but also occurs with age or in association with cerebrovascular disease, peripheral vascular disease, non-insulin dependent diabetes, osteoarthritis, bacterial infection, and sepsis.

Elevated CRP or other serum inflammatory markers is also prognostic for increased risk of a second myocardial infarct in patients with a previous myocardial infarct (Retterstol, L. *et al.*, *Atheroscler.*, 160: 433-440 (2002)).

Although classical risk factors such as smoking, hyperlipidemia, hypertension, and diabetes are associated with many cases of coronary heart disease (CHD) and MI, many patients do not have involvement of these risk factors. In fact, many patients who exhibit one or more of these risk factors do not develop MI. Family history has long been recognized as one of the major risk factors. Although some of the familial clustering of MI reflects the genetic contribution to the other conventional risk factors, a large number of studies have suggested that there are significant genetic susceptibility factors, beyond those of the known risk factors (Friedlander Y, *et al.*, *Br. Heart J.* 1985; 53:382-7, Shea S. *et al.*, *J. Am. Coll. Cardiol.* 1984; 4:793-801, and Hopkins P.N., *et al.*, *Am. J. Cardiol.* 1988; 62:703-7). Major genetic susceptibility factors have only been identified for the rare Mendelian forms of hyperlipidemia such as a familial hypercholesterolemia.

Genetic risk is conferred by subtle differences in genes among individuals in a population. Genes differ between individuals most frequently due to single nucleotide polymorphisms (SNP), although other variations are also important. SNP are located on average every 1000 base pairs in the human genome. Accordingly, a typical human gene containing 250,000 base pairs may contain 250 different SNP. Only a minor number of SNPs are located in exons and alter the amino acid sequence of the protein encoded by the gene. Most SNPs may have little or no effect on gene function, while others may alter transcription, splicing, translation, or stability of the mRNA encoded by the gene. Additional genetic polymorphism in the human genome is caused by insertion, deletion, translocation, or inversion of either short or long stretches of DNA. Genetic polymorphisms conferring disease risk may therefore directly alter the amino acid sequence of proteins, may increase the amount of protein produced from the gene, or may decrease the amount of protein produced by the gene.

As genetic polymorphisms conferring risk of disease are uncovered, genetic testing for such risk factors is becoming important for clinical medicine. Examples are apolipoprotein E testing to identify genetic carriers of the apoE4 polymorphism in dementia patients for the

differential diagnosis of Alzheimer's disease, and of Factor V Leiden testing for predisposition to deep venous thrombosis. More importantly, in the treatment of cancer, diagnosis of genetic variants in tumor cells is used for the selection of the most appropriate treatment regime for the individual patient. In breast cancer, genetic variation in estrogen receptor expression or heregulin type 2 (Her2) receptor tyrosine kinase expression determine if anti-estrogenic drugs (tamoxifen) or anti-Her2 antibody (Herceptin) will be incorporated into the treatment plan. In chronic myeloid leukemia (CML) diagnosis of the Philadelphia chromosome genetic translocation fusing the genes encoding the Bcr and Abl receptor tyrosine kinases indicates that Gleevec (STI571), a specific inhibitor of the Bcr-Abl kinase should be used for treatment of the cancer. For CML patients with such a genetic alteration, inhibition of the Bcr-Abl kinase leads to rapid elimination of the tumor cells and remission from leukemia.

Restenosis

Coronary balloon angioplasty was introduced in the late 1970s as a less invasive method for revascularization of coronary artery disease patients than the coronary artery bypass graft (CABG) surgeries. Since then there has been a quick progress in the development of new percutaneous devices to revascularize areas with limited blood flow. However, the expanded use of angioplasty has shown that the arteries react to angioplasty by a proliferative process that limits the success of this treatment. This process is known as restenosis.

Restenosis is defined as a re-narrowing of the treated segment, which equals or exceeds 50% of the lumen in the adjacent normal segment of the artery. Depending on the patient population studied, the restenosis rates range from 30% to 44% of lesions treated by balloon dilation. This problem prompted a search for interventional techniques that minimizes the risk of restenosis. Several clinical trials have shown a significant reduction in the restenosis rates with endovascular stenting. The purpose of stenting is to maintain the arterial lumen by a scaffolding process that provides radial support. Stents, usually made of stainless steel, are placed in the artery either by a self-expanding mechanism or, using balloon expansion. However, in-stent restenosis still remains a major problem in the field of percutaneous, transluminal coronary angioplasty (PTCA), requiring patients to undergo repeated procedures and surgery. Restenosis is the result of the formation of neointima, a composition of smooth muscle-like cells in a collagen matrix. The current treatment modalities for in-stent restenosis include repeat balloon angioplasty, repeat stenting, cutting balloon angioplasty, directional coronary atherectomy, rotational coronary atherectomy, brachytherapy, and drug-eluting stents (DES). The restenosis problem can be minimised by local intravascular irradiation (intracoronary brachytherapy) and by the introduction of DES and these treatments have been shown to successfully preventing cell proliferation after stent implantation or angioplasty.

Intracoronary brachytherapy is a treatment in which sealed sources of radioactive material are used to deliver radiation at a very short distance by placing them in the artery lumen at the site of the atherosclerotic lesion. The physical benefit of brachytherapy is that

doses of radiation can be delivered almost directly to the target with a very rapid falloff of dose to the surrounding normal tissue. The rationale underlining this modality is based on the ability of ionizing radiation to inhibit cell proliferation, in this case, the proliferation of smooth muscle cells that tend to form a neointima. In the near future, it would be important to be able to

5 classify patients with respect to the risk of having in-stent restenosis. This classification can potentially be made on the basis of genetic risk factors. The outcome of the classification may determine which therapy is most appropriate and also where coronary bypass surgery has to be considered.

Aneurysms

10 Degenerative changes of the arterial wall may cause localized dilatation, or aneurysm, of the artery, including abdominal aorta aneurysm (AAA) and intracranial aneurysm (IA). Atherosclerotic changes of the vessel wall are found in the majority of AAA that are characterized histopathologically by chronic inflammation, destructive remodelling of elastic media and depletion of medial smooth muscle cells resulting in marked weakening of the aortic wall. In

15 contrast, berry aneurysms of intracranial arteries are not associated with atherosclerosis. Furthermore, the histopathological features of IA are different. The typical berry aneurysms of intracranial arteries, located at arterial bifurcations, have a thin, or no, media and the internal elastic lamina is either absent or severely fragmented.

Both AAA and IA represent a degenerative process of the arteries leading to their

20 enlargement that is usually asymptomatic with natural history culminating in either a therapeutic intervention or rupture. Rupture of IA leads to subarachnoid haemorrhage, and rupture of both IA and AAA have high morbidity and mortality. In the case of AAA the rupture risk increases with the growth rate as well as the size of the aneurysm.

25 *Intracranial aneurysm (IA)*, also called cerebral aneurysm or brain aneurysm is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel.

A common location of cerebral aneurysms is on the arteries at the base of the brain, known as the Circle of Willis. Approximately 85% of cerebral aneurysms develop in the anterior

30 part of the Circle of Willis, and involve the internal carotid arteries and their major branches that supply the anterior and middle sections of the brain. It is believed that aneurysms may result from congenital defects, preexisting conditions such as high blood pressure and atherosclerosis, or head trauma. Cerebral aneurysms occur more commonly in adults than in children but they may occur at any age.

35 Cerebral aneurysms are classified both by size and shape. Small aneurysms have a diameter of less than 15mm. Larger aneurysms include those classified as large (15 to 25mm),

giant (25 to 50mm), and super giant (over 50mm). Saccular aneurysms are those with a saccular outpouching and are the most common form of cerebral aneurysm. Berry aneurysms are saccular aneurysms with necks or stems resembling a berry. Fusiform aneurysms are aneurysms without stems.

- 5 A small, unchanging aneurysm will produce no symptoms. Before a larger aneurysm ruptures, the individual may experience such symptoms as a sudden and unusually severe headache, nausea, vision impairment, vomiting, and loss of consciousness, or the individual may be asymptomatic, experiencing no symptoms at all. Onset is usually sudden and without warning. Rupture of a cerebral aneurysm is dangerous and usually results in bleeding into the
- 10 meninges or the brain itself, leading to a subarachnoid hemorrhage (SAH) or intracranial hematoma (ICH), either of which constitutes a stroke. Rebleeding, hydrocephalus (the excessive accumulation of cerebrospinal fluid), vasospasm (spasm, or narrowing, of the blood vessels), or multiple aneurysms may also occur. The risk of rupture from an unruptured cerebral aneurysm varies according to the size of an aneurysm, with the risk rising as the aneurysm size increases.
- 15 The overall rate of aneurysm rupture is estimated at 1.3% per year. The risk of short term re-rupture increases dramatically after an aneurysm has bled, though after approximately 6 weeks the risk returns to baseline.

- Emergency treatment for individuals with a ruptured cerebral aneurysm generally includes restoring deteriorating respiration and reducing intracranial pressure. Currently there
- 20 are two treatment options for brain aneurysms: surgical clipping or endovascular coiling. Either surgical clipping or endovascular coiling is usually performed within the first three days to occlude the ruptured aneurysm and reduce the risk of rebleeding.

- The prognosis for a patient with a ruptured cerebral aneurysm depends on the extent and location of the aneurysm, the person's age, general health, and neurological condition. Some
- 25 individuals with a ruptured cerebral aneurysm die from the initial bleeding. Other individuals with cerebral aneurysm recover with little or no neurological deficit. The most significant factors in determining outcome are severity of the aneurysm and age.

- Abdominal aortic aneurysm (AAA)* is a localized dilatation of the abdominal aorta, that exceeds the normal diameter by more than 50%. The normal diameter of the infrarenal aorta is
- 30 2 cm. It is caused by a degenerative process of the aortic wall. The aneurysm is most commonly located infrarenally (90%), other possible locations are suprarenal and pararenal. The aneurysm can extend to include one or both of the iliac arteries. An aortic aneurysm may also occur in the thorax.

- AAA is uncommon in individuals of African, African American, Asian, and Hispanic
- 35 heritage. The frequency varies strongly between males and females. The peak incidence is among males around 70 years of age, the prevalence among males over 60 years totals 2-6%. The frequency is much higher in smokers than in non-smokers (8:1). Other risk factors include

hypertension and male sex. In the US, the incidence of AAA is 2-4% in the adult population. Rupture of the AAA occurs in 1-3% of men aged 65 or more, the mortality being 70-95%.

The exact causes of the degenerative process remain unclear. Known risk factors include genetic factors, hemodynamic influences, atherosclerosis, and various other factors such as infection, trauma, connective tissue disorders, arterities, etc. AAAs are commonly divided according to their size and symptomatology. An aneurysm is usually considered to be present if the measured outer aortic diameter is over 3 cm (normal diameter of aorta is around 2 cm). The natural history is of increasing diameter over time, followed eventually by the development of symptoms (usually rupture). If the outer diameter exceeds 5 cm, the aneurysm is considered to be large. For aneurysms under 5 cm, the risk of rupture is low, so that the risks of surgery usually outweigh the risk of rupture. Aneurysms less than 5cm are therefore usually kept under surveillance until such time as they become large enough to warrant repair, or develop symptoms. The vast majority of aneurysms are asymptomatic. The risk of rupture is high in a symptomatic aneurysm, which is therefore considered an indication for surgery. Possible symptoms include low back pain, flank pain, abdominal pain, groin pain or pulsating abdominal mass. The complications include rupture, peripheral embolisation, acute aortic occlusion, aortocaval or aortoduodenal fistulae. On physical examination, a palpable abdominal mass can be noted. Bruits can be present in case of renal or visceral arterial stenosis.

The main treatment options for asymptomatic AAA are immediate repair and surveillance with a view to eventual repair. Surveillance is indicated in small aneurysms, where the risk of repair exceeds the risk of rupture. As an AAA grows in diameter the risk of rupture increases. Although some controversy exists around the world, most vascular surgeons would not consider repair until the aneurysm reached a diameter of 5cm. The threshold for repair varies slightly from individual to individual, depending on the balance of risks and benefits when considering repair versus ongoing surveillance. The size of an individual's native aorta may influence this, along with the presence of comorbidities that increase operative risk or decrease life expectancy. Currently, the main modes of repair available for an AAA are open aneurysm repair (OR), and endovascular aneurysm repair (EVAR). Open repair is indicated in young patients as an elective procedure, or in growing or large, symptomatic or ruptured aneurysms. Open repair has been the mainstay of intervention from the 1950's until recently. Endovascular repair first became practical in the 1990's and although it is now an established alternative to open repair, its role is yet to be clearly defined. It is generally indicated in older, high-risk patients or patients unfit for open repair. However, endovascular repair is feasible for only a proportion of AAA's, depending on the morphology of the aneurysm. The main advantage over open repair is that the peri-operative period has less impact on the patient.

Stroke

Stroke is a group of diverse disorders encompassing several pathophysiological mechanisms. The clinical phenotype of stroke is complex but is broadly divided into: ischemic

and hemorrhagic stroke. The majority of stroke events, appr 80%, is due to ischemia (cerebral infarction), that occurs when a cerebral artery becomes completely occluded and the blood supply to a part of the brain is totally or partially blocked (due to thrombosis or an embolism). Ischemic stroke is further subdivided into large artery disease (LAA) (also called large vessel disease, LVD), cardioembolic stroke and small vessel disease. Approximately 25% of ischemic stroke events are due to large-artery disease of the carotid and vertebral arteries, the two pairs of large arteries that supply the brain with blood. The most common cause of large-artery disease is atherosclerosis. Cardioembolic strokes are caused by an embolism that originates inside the heart. Embolism of cardiac origin accounts for about 1/4 of ischemic strokes. Strokes due to cardioembolism are in general severe and prone to early and long-term recurrence. Ischemic heart disease, rheumatic mitral stenosis, and prosthetic cardiac valves are major sources of cardioembolic stroke but atrial fibrillation remains the commonest cause.

There is a continued and great need to understand the genetic variants conferring risk (increased and decreased) of the cardiovascular diseases. The present invention provides genetic variants that have been shown to be associated with susceptibility to cardiovascular disease, including MI, Coronary Artery Disease (CAD), Intracranial aneurysm (IA), Abdominal Aorta Aneurysm (AAA), Peripheral Arterial Disease (PAD) and Restenosis. These variants are useful in risk management and methods for therapeutic intervention of cardiovascular diseases.

SUMMARY OF THE INVENTION

The present invention relates to methods of determining a susceptibility to cardiovascular diseases, including Coronary Artery Disease, Myocardial Infarction, Peripheral Artery Disease, Stroke, Restenosis, Intracranial Aneurysm and Abdominal Aorta Aneurysm. The invention also relates to various uses, kits, procedures and apparati useful in the determination of a susceptibility to cardiovascular disease based on evaluation of certain polymorphic markers and/or haplotypes that have been found to be associated with susceptibility to cardiovascular disease.

In one aspect, the invention relates to a method for determining a susceptibility to cardiovascular disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to cardiovascular disease. The method may in one embodiment relate to determination of the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual. In another embodiment, the method relates to determination of the presence or absence of at least one

allele of at least one polymorphic marker in a genotype dataset derived from the individual. The genotype dataset is derived from the individual in the sense that the information that is relates to a particular nucleic acid sample as a template relates to a single individual, for whom genetic information is derived.

5 In another aspect, the present invention relates to a method of determining a susceptibility to cardiovascular disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from markers associated with LD Block C09 (SEQ ID NO:94), wherein determination of the
10 presence or absence of the at least one allele is indicative of a susceptibility to cardiovascular disease. In one embodiment, the at least one polymorphic marker is selected from the markers set forth in Table 3, and markers in linkage disequilibrium therewith.

In an alternative aspect, the invention relates to a method of diagnosing a susceptibility to Cardiovascular Disease in a human individual, the method comprising determining the
15 presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the group of markers associated with LD block C09, wherein the presence of the at least one allele is indicative of a susceptibility to Cardiovascular Disease. In one embodiment, linkage disequilibrium is used as a quantitative
20 measure of the degree to which specific markers are associated with LD Block C09.

In another aspect, the invention relates to a method of determining a susceptibility to cardiovascular disease in a human individual, comprising determining whether at least one at-risk allele in at least one polymorphic marker is present in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the markers within the
25 LD Block C09 (SEQ ID NO:94), and markers in linkage disequilibrium therewith, and wherein determination of the presence of the at least one at-risk allele is indicative of increased susceptibility to cardiovascular disease in the individual.

The genotype dataset comprises in one embodiment information about marker identity, and the allelic status of the individual, i.e. information about the identity of the two alleles
30 carried by the individual for the marker. The genotype dataset may comprise allelic information about one or more marker, including two or more markers, three or more markers, five or more markers, one hundred or more markers, etc. In some embodiments, the genotype dataset comprises genotype information from a whole-genome assessment of the individual including hundreds of thousands of markers, or even one million or more markers.

35 In one embodiment, the at least one polymorphic marker is present within the genomic segment LD Block C09, with the nucleotide sequence as set forth in SEQ ID NO:94. In another embodiment, the at least one polymorphic marker comprises at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970,

rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker is selected from rs10757278, rs10757274, and rs10333049, and markers in linkage disequilibrium therewith. In another embodiment, the at least one
5 polymorphic marker comprises at least one marker in strong linkage disequilibrium, as defined by numeric values for $|D' |$ of greater than 0.8 and/or r^2 of greater than 0.2, with one or more markers selected from the group consisting of the markers set forth in Table 3.

In one embodiment, the method of determining a susceptibility, or diagnosing a susceptibility of, cardiovascular disease, further comprises assessing the frequency of at least
10 one haplotype in the individual. In one such embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker within the genomic segment LD Block C09 (SEQ ID NO:94). In another embodiment, the at least one haplotype is selected from haplotypes that are in linkage disequilibrium with at least one marker as set forth in Table 3. In another embodiment, the at least one haplotype is selected from the haplotypes that
15 comprise at least one polymorphic marker selected from at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith.

In another aspect, the invention relates to a method of determining a susceptibility to
20 Cardiovascular disease in a human individual, comprising determining whether at least one at-risk allele in at least one polymorphic marker is present in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the markers set forth in Table 3, and markers in linkage disequilibrium therewith, and wherein determination of the presence of the at least one at-risk allele is indicative of increased susceptibility to
25 Cardiovascular disease in the individual. The genotype dataset comprises in one embodiment information about marker identity, and the allelic status of the individual, i.e. information about the identity of the two alleles carried by the individual for the marker. The genotype dataset may comprise allelic information about one or more marker, including two or more markers, three or more markers, five or more markers, one hundred or more markers, etc. In some
30 embodiments, the genotype dataset comprises genotype information from a whole-genome assessment of the individual including hundreds of thousands of markers, or even one million or more markers.

In one embodiment, the at least one polymorphic marker is present within SEQ ID NO:94, as set forth herein. In another embodiment, the at least one polymorphic marker
35 comprises at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs1333049, D9S1870, and markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker comprises at least one marker in strong linkage disequilibrium, as defined by numeric values for $|D' |$ of greater than 0.8

and/or r^2 of greater than 0.2, with one or more markers selected from the group consisting of the markers set forth in Table 3. In one preferred embodiment, the at least one polymorphic marker is selected from markers rs10757278, rs10757274, and rs1333049, and markers in linkage disequilibrium therewith. In another preferred embodiment, the at least one polymorphic marker is selected from markers rs10757278, rs10757274, and rs1333049. In yet another embodiment, the at least one polymorphic marker is selected from markers associated with LD Block C09 (SEQ ID NO:94). In one such embodiment, the at least one polymorphic marker is in linkage disequilibrium with at least one polymorphic marker within LD Block C09 (SEQ ID NO:94).

In one embodiment, the method of determining a susceptibility, or diagnosing a susceptibility of, Cardiovascular disease, further comprises assessing the frequency of at least one haplotype in the individual. In one such embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker as set forth in Table 10, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker as set forth in Table 3, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one haplotype is selected from the haplotypes that comprise at least one polymorphic marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, and markers in linkage disequilibrium therewith.

In certain embodiments of the invention, determination of the presence of at least one at-risk allele of at least one polymorphic marker in a nucleic acid sample from the individual is indicative of an increased susceptibility to the Cardiovascular disease. In one embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.15. In another embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.20. In another embodiment, the increased susceptibility is characterized by a relative risk (RR) or odds ratio (OR) of at least 1.30.

In some embodiments, the presence of rs7041637 allele A, rs2811712 allele A, rs3218018 allele A, rs3217992 allele A, rs2069426 allele C, rs2069422 allele A, rs1333034 allele A, rs1011970 allele G, rs10116277 allele T, rs1333040 allele T, rs2383207 allele G, rs1333050 allele T, D9S1814 allele O, rs10757278 allele G, rs1333049 allele C, rs10757274 allele G, and/or D9S1870 allele X (composite allele of all alleles smaller than 2) is indicative of increased susceptibility of the Cardiovascular disease.

In particular embodiments, the presence of at least one protective allele in a nucleic acid sample from the individual is indicative of a decreased susceptibility of Cardiovascular disease. In another embodiment, the absence of at least one at-risk allele in a nucleic acid sample from the individual is indicative of a decreased susceptibility of Cardiovascular disease.

Another aspect of the invention relates to a method of assessing a susceptibility to Cardiovascular disease in a human individual, comprising screening a nucleic acid from the individual for at least one polymorphic marker or haplotype in the genomic segment with the sequence as set forth in SEQ ID NO:94, that correlates with increased occurrence of

Cardiovascular disease in a human population, wherein the presence of an at-risk marker allele in the at least one polymorphism or an at-risk haplotype in the nucleic acid identifies the individual as having elevated susceptibility to the Cardiovascular disease, and wherein the absence of the at least one at-risk marker allele or at-risk haplotype in the nucleic acid identifies the individual as not having the elevated susceptibility.

In one such embodiment, the at least one polymorphic marker or haplotype comprises at least one polymorphic marker selected from the markers set forth in Table 10, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one marker or haplotype comprises at least one polymorphic marker selected from the markers set forth in Table 3, and polymorphic markers in linkage disequilibrium therewith. In another embodiment, the at least one polymorphic marker or haplotype comprises at least one polymorphic marker selected from the markers rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, and markers in linkage disequilibrium therewith. In certain embodiments, linkage disequilibrium is characterized by numeric values for $|D'|$ of greater than 0.8 and/or r^2 of greater than 0.2.

Certain embodiments of the invention further comprise a step of screening the nucleic acid for the presence of at least one at-risk genetic variant for a Cardiovascular disease not associated with LD Block C09 (SEQ ID NO:94). Such additional genetic variants can in specific embodiments include any variant that has been identified as a susceptibility or risk variant for Cardiovascular disease.

In another aspect of the present invention, the presence of the marker or haplotype found to be associated with Cardiovascular disease, and as such useful for determining a susceptibility to Cardiovascular disease, is indicative of a different response rate of the subject to a particular treatment modality for Cardiovascular disease.

In another aspect, the invention relates to a method of identification of a marker for use in assessing susceptibility to a Cardiovascular disease in human individuals, the method comprising:

identifying at least one polymorphic marker in linkage disequilibrium with at least one of the markers within LD Block C09 (SEQ ID NO:94);

determining the genotype status of a sample of individuals diagnosed with, or having a susceptibility to, Cardiovascular disease; and

determining the genotype status of a sample of control individuals;

wherein a significant difference in frequency of at least one allele in at least one polymorphism in individuals diagnosed with, or having a susceptibility to, the Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing susceptibility to the Cardiovascular disease.

In one embodiment, "significant" is determined by statistical means, *e.g.* the difference is statistically significant. In one such embodiment, statistical significance is characterized by a P-value of less than 0.05. In other embodiments, the statistical significance is characterized a P-value of less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, less than 0.000000001, or less than 0.000000001.

In one embodiment, the at least one polymorphic marker is in linkage disequilibrium, as characterized by numerical values of r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8 with at least one marker selected from markers set forth in Table 21. In another embodiment, the at least one polymorphic marker is in linkage disequilibrium, as characterized by numerical values of r^2 of greater than 0.2 and/or $|D'|$ of greater than 0.8 with at least one marker selected from markers rs10757278, rs10757274, and rs1333049.

In one embodiment, an increase in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, a Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample, is indicative of the at least one polymorphism being useful for assessing increased susceptibility to the Cardiovascular disease. In another embodiment, a decrease in frequency of the at least one allele in the at least one polymorphism in individuals diagnosed with, or having a susceptibility to, a Cardiovascular disease, as compared with the frequency of the at least one allele in the control sample is indicative of the at least one polymorphism being useful for assessing decreased susceptibility to, or protection against, the Cardiovascular disease.

Another aspect of the invention relates to a method of genotyping a nucleic acid sample obtained from a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in the sample, wherein the at least one marker is selected from the markers set forth in Table 3 and Table 21, and markers in linkage disequilibrium therewith, and wherein determination of the presence or absence of the at least one allele of the at least one polymorphic marker is predictive of a susceptibility of a Cardiovascular disease.

In one embodiment, genotyping comprises amplifying a segment of a nucleic acid that comprises the at least one polymorphic marker by Polymerase Chain Reaction (PCR), using a nucleotide primer pair flanking the at least one polymorphic marker. In another embodiment, genotyping is performed using a process selected from allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, nucleic acid sequencing, 5'-exonuclease

digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation analysis. In one particular embodiment, the process comprises allele-specific probe hybridization. In another embodiment, the process comprises DNA sequencing. In a preferred embodiment, the method comprises:

- 5 1) contacting copies of the nucleic acid with a detection oligonucleotide probe and an enhancer oligonucleotide probe under conditions for specific hybridization of the oligonucleotide probe with the nucleic acid;

 wherein
 - 10 a) the detection oligonucleotide probe is from 5-100 nucleotides in length and specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is given by SEQ ID NO:94 that comprises at least one polymorphic site;
 - b) the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus;
 - 15 c) the enhancer oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; and
 - 20 d) a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides;
- 25 2) treating the nucleic acid with an endonuclease that will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid; and
- 3) measuring free detectable label, wherein the presence of the free detectable label indicates that the detection probe specifically hybridizes to the first segment of the nucleic acid, and indicates the sequence of the polymorphic site as the complement of the detection probe.

30 In a particular embodiment, the copies of the nucleic acid are provided by amplification by Polymerase Chain Reaction (PCR). In another embodiment, the susceptibility determined is increased susceptibility. In another embodiment, the susceptibility determined is decreased susceptibility.

Another aspect of the invention relates to a method of assessing an individual for probability of response to a therapeutic agent for preventing and/or ameliorating symptoms associated with a Cardiovascular disease, comprising: determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the markers set forth in Table 21, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele of the at least one marker is indicative of a probability of a positive response to the Cardiovascular disease therapeutic agent. In one embodiment, the at least one polymorphic marker is selected from marker rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith. In one embodiment, the therapeutic agent is selected from beta blockers, anticoagulation agents, including heparin and/or low molecular weight heparin, antiplatelet agents, such as clopidogrel, aspirin, beta blockers, including metoprolol and carvedilol, ACE inhibitors, Statins, Aldosterone antagonists, including eplerenone, leukotriene synthesis inhibitors, the agents set forth in Agent Table I, Agent Table II, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, atreleuton, and 4-[(S)-2-[4-(4-Chloro-phenoxy)-phenoxy-methyl]-pyrrolidin-1-yl]-butyramide, also known as DG-051. Other embodiments may include any one or a combination of the therapeutic agents described herein to be useful for therapeutic intervention of Cardiovascular disease.

Yet another aspect of the invention relates to a method of predicting prognosis of an individual diagnosed with, a Cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele is indicative of a worse prognosis of the Cardiovascular disease in the individual. The prognosis may in certain embodiment relate to susceptibility of recurrent MI events, recurrent stroke events, or susceptibility to other complications relating to a Cardiovascular disease.

A further aspect of the invention relates to a method of monitoring progress of a treatment of an individual undergoing treatment for a Cardiovascular disease, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, wherein the at least one polymorphic marker is selected from the group consisting of rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith, wherein determination of the presence of the at least one allele is indicative of the treatment outcome of the individual. The treatment may in certain embodiments be surgical treatment. In other embodiments, the treatment is by administration of a therapeutic agent, optionally including lifestyle changes or alterations in environmental exposure to risk factors for cardiovascular disease, as described further herein.

In one embodiment, the method further comprises assessing at least one biomarker in a sample from the individual. The biomarker is in certain embodiments a cardiac marker or an inflammatory marker. In one embodiment, the at least one biomarker is selected from creatin kinase, troponin, glycogen phosphorylase, C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, serum sCD40L, leukotrienes, leukotriene metabolites, interleukin-6, tissue necrosis factor-alpha, myeloperoxidase (MPO), and N-tyrosine. In one embodiment, the leukotriene is selected from LTB4, LTC4, LTD4 and LTE4. In another embodiment, the method further comprises analyzing non-genetic information to make risk assessment, diagnosis, or prognosis of the individual. The non-genetic information is in one embodiment selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of Cardiovascular disease, biochemical measurements, and clinical measurements. In a particular preferred embodiment, a further step comprising calculating overall risk is employed.

Another aspect of the invention relates to analyzing a sample comprising genomic DNA from a human individual or a genotype dataset derived from a human individual for the presence or absence of at least one at-risk allele of at least one at-risk variant for cardiovascular disease not in linkage disequilibrium with any one of the markers set forth in Table 10. Thus, the variants described herein to be associated with Cardiovascular disease may be combined with other genetic variants for Cardiovascular disease, that are not genetically related (*i.e.*, not in linkage disequilibrium with) the markers described herein. Such analysis may be undertaken in combination with any of the methods described herein. Furthermore any two markers herein, or any other combination of markers and/or haplotypes described herein to be associated with cardiovascular disease may be combined to assess an increased susceptibility to cardiovascular disease.

In some embodiments of the methods of the invention, non-genetic information is analyzed, to make risk assessment, diagnosis, or prognosis of the individual. The non-genetic information is in certain embodiments selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of cardiovascular disease, biochemical measurements, and clinical measurements. Combined genetic factors and/or combinations of genetic and non-genetic factors may be analyzed by known methods, to generate a combined risk.

The invention also relates to a kit for assessing susceptibility to a Cardiovascular disease in a human individual, the kit comprising reagents for selectively detecting the presence or absence of at least one allele of at least one polymorphic marker in the genome of the individual, wherein the polymorphic marker is selected from the markers set forth in Tables 10,, and markers in linkage disequilibrium therewith, and wherein the presence of the at least one allele is indicative of a susceptibility to a Cardiovascular diseases.

In one embodiment, the at least one polymorphic marker is present within the genomic segment with the sequence as set forth in SEQ ID NO:94. In another embodiment, the at least one polymorphic marker is selected from the group of markers set forth in Table 21, and markers in linkage disequilibrium therewith. In another embodiment, the at least one
5 polymorphic markers is selected from rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith.

In one embodiment, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising the at least one polymorphic marker, a buffer and a detectable label. In one embodiment, the reagents comprise at least one
10 pair of oligonucleotides that hybridize to opposite strands of a genomic nucleic acid segment obtained from the subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the individual that includes one polymorphic marker, and wherein the fragment is at least 30 base pairs in size. In a particular embodiment the at least one oligonucleotide is completely complementary to the genome of the individual. In another
15 embodiment, the at least one oligonucleotide can comprise at least one mismatch to the genome of the individual. In one embodiment, the oligonucleotide is about 18 to about 50 nucleotides in length. In another embodiment, the oligonucleotide is 20-30 nucleotides in length.

In one preferred embodiment, the kit comprises:

a detection oligonucleotide probe that is from 5-100 nucleotides in length; an enhancer
20 oligonucleotide probe that is from 5-100 nucleotides in length; and an endonuclease enzyme;

wherein the detection oligonucleotide probe specifically hybridizes to a first segment of the nucleic acid whose nucleotide sequence is given by SEQ ID NO:94 that comprises at least one polymorphic site; and wherein the detection oligonucleotide probe comprises a detectable label at its 3' terminus and a quenching moiety at its 5' terminus; wherein the enhancer
25 oligonucleotide is from 5-100 nucleotides in length and is complementary to a second segment of the nucleotide sequence that is 5' relative to the oligonucleotide probe, such that the enhancer oligonucleotide is located 3' relative to the detection oligonucleotide probe when both oligonucleotides are hybridized to the nucleic acid; wherein a single base gap exists between the first segment and the second segment, such that when the oligonucleotide probe and the
30 enhancer oligonucleotide probe are both hybridized to the nucleic acid, a single base gap exists between the oligonucleotides; and wherein treating the nucleic acid with the endonuclease will cleave the detectable label from the 3' terminus of the detection probe to release free detectable label when the detection probe is hybridized to the nucleic acid.

A further aspect of the invention relates to the use of an oligonucleotide probe in the
35 manufacture of a diagnostic reagent for diagnosing and/or assessing susceptibility to Cardiovascular disease in a human individual, wherein the probe hybridizes to a segment of a nucleic acid whose nucleotide sequence is given by SEQ ID NO: 94 that comprises at least one polymorphic site, wherein the fragment is 15-500 nucleotides in length. In one embodiment, the

polymorphic site is selected from the polymorphic markers rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith

Yet another aspect of the invention relates to a computer-readable medium on which is stored: an identifier for at least one polymorphic marker; an indicator of the frequency of at least one allele of said at least one polymorphic marker in a plurality of individuals diagnosed with a Cardiovascular disease; and an indicator of the frequency of the least one allele of said at least one polymorphic markers in a plurality of reference individuals; wherein the at least one polymorphic marker is selected from the polymorphic markers set forth in Table 10, and markers in linkage disequilibrium therewith. In one embodiment, the at least one polymorphic marker is selected from rs1333040, rs10116277, rs2383207 and rs10757278, and markers in linkage disequilibrium therewith.

Another aspect relates to an apparatus for determining a genetic indicator for Type 2 diabetes in a human individual, comprising: a computer readable memory; and a routine stored on the computer readable memory; wherein the routine is adapted to be executed on a processor to analyze marker and/or haplotype information for at least one human individual with respect to at least one polymorphic marker selected from the markers set forth in Table 10, and markers in linkage disequilibrium therewith, and generate an output based on the marker or haplotype information, wherein the output comprises a risk measure of the at least one marker or haplotype as a genetic indicator of a Cardiovascular disease for the human individual.

In one embodiment, the routine further comprises an indicator of the frequency of at least one allele of at least one polymorphic marker or at least one haplotype in a plurality of individuals diagnosed with a Cardiovascular disease, and an indicator of the frequency of at the least one allele of at least one polymorphic marker or at least one haplotype in a plurality of reference individuals, and wherein a risk measure is based on a comparison of the at least one marker and/or haplotype status for the human individual to the indicator of the frequency of the at least one marker and/or haplotype information for the plurality of individuals diagnosed with the Cardiovascular disease.

The present invention, as described herein, may be reduced to practice using any one, or a combination of, the polymorphic markers described herein as being useful for the determination of a susceptibility to cardiovascular disease. This includes markers that are shown herein to be associated with cardiovascular disease, but also includes markers that are in linkage disequilibrium with such variants. In one embodiment, the at least one marker is selected from the markers set forth in any of the Tables 3, 10, 21 and 26. In another embodiment, the at least one marker is selected from the markers set forth in Table 10. In another embodiment, the at least one marker is selected from the markers set forth in Table 3 and Table 21. In another embodiment, the at least one marker is selected from the markers set forth in Table 3. In another embodiment, the at least one marker is selected from the markers set forth in Table 21. In another embodiment, the at least one marker is selected from markers in linkage

disequilibrium with the CDKN2A and/or CDKN2B genes. In another embodiment, the at least one marker is selected from the markers rs10811650, rs10116277, rs1333040, rs10738607, rs4977574, rs6475608, D9S1870, rs2383207, rs1333045, rs1333046, rs10757278 and rs1333048. In another embodiment, the at least one marker is selected from the markers
5 rs1333040, rs10116277, rs2383207 and rs10757278. In another embodiment the at least one marker is rs1333040 (SEQ ID NO:59). In another embodiment, the at least one marker is rs10116277 (SEQ ID NO:56). In another embodiment, the at least one marker is rs2383207 (SEQ ID NO:82). In another embodiment, the at least one marker is rs10757278 (SEQ ID NO:88). In some embodiments, the at least one marker is further optionally selected from
10 markers in linkage disequilibrium with any one or a combination of more than one of the above mentioned markers.

The Cardiovascular disease in the various aspects of the invention relating to methods, uses, apparatus or kits is in some embodiments an arterial disease. In one such embodiment, the arterial disease phenotype is selected from Myocardial Infarction, Acute Coronary Syndrome
15 (ACS), Coronary Artery Disease, Stroke, Peripheral Artery Disease, Restenosis, Intracranial Aneurysm and Aorta Abdominal Aneurysm, transluminal coronary angioplasty (PTCA), and coronary artery bypass surgery (CABG). In one embodiment, the Cardiovascular disease is Myocardial Infarction. In another embodiment, the Cardiovascular disease is Myocardial Infarction or Coronary Artery Disease. In yet another embodiment, the Cardiovascular disease is
20 Myocardial Infarction, Coronary Artery Disease, Aorta Abdominal Aneurysm or Intracranial Aneurysm. In another embodiment, the Cardiovascular Disease is Myocardial Infarction, Coronary Artery Disease, Restenosis, Aorta Abdominal Aneurysm or Intracranial Aneurysm. In one embodiment, the Stroke phenotype is Large Artery Atherosclerotic Stroke and/or Cardiogenic Stroke. The Restenosis phenotype is in one embodiment Coronary In-stent
25 Restenosis. In certain embodiments, the In-stent Restenosis is either Restenosis following Bare Metal Stent (BMS) placement, or it is Restenosis following placement of a Drug Eluting Stent (DES).

Variants (markers and/or haplotypes comprising polymorphic markers) in linkage disequilibrium with the markers and haplotypes of the present invention are also useful for the
30 methods and kits of the invention. The invention therefore also pertains to markers in linkage disequilibrium with the markers and haplotypes of the invention. In certain embodiments of the methods, uses, apparatus or kits of the invention, linkage disequilibrium is characterized by specific cutoff values for a quantitative measure of linkage disequilibrium. In one such embodiment, linkage disequilibrium is characterized by specific cutoff values for r^2 . In another
35 such embodiment, linkage disequilibrium is characterized by specific cutoff values for $|D'|$. In yet another embodiment, linkage disequilibrium is characterized by specific cutoff values for r^2 and $|D'|$. In one preferred embodiment, linkage disequilibrium is characterized by values for r^2 of greater than 0.1. In another preferred embodiment, linkage disequilibrium is characterized by values for r^2 of greater than 0.2. Other cutoff values for r^2 are also possible, including, but not
40 limited to, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, 0.96, 0.97, 0.98, 0.99. In another preferred

embodiment, linkage disequilibrium is characterized by values for $|D'|$ of greater than 0.5. In another preferred embodiment, linkage disequilibrium is characterized by values for $|D'|$ of greater than 0.8. Other cutoff values for $|D'|$ are also possible, including, but not limited to, 0.2, 0.3, 0.4, 0.6, 0.7, 0.8, 0.9, 0.95, 0.96, 0.97, 0.98 and 0.99. In certain embodiments, linkage disequilibrium is characterized by numeric cutoff values for either $|D'|$ and r^2 . In one such embodiment linkage disequilibrium is characterized by numeric cutoff values for either $|D'|$ of greater than 0.8 and r^2 of greater than 0.2, or both.

In certain other embodiments of the methods, uses, apparatus or kits of the invention, the individual is of a specific human ancestry. In one embodiment, the ancestry is selected from black African ancestry, Caucasian ancestry and Chinese ancestry. In another embodiment, the ancestry is black African ancestry. In another embodiment, the ancestry is African American ancestry. In another embodiment, the ancestry is European ancestry. In another embodiment, the ancestry is Caucasian ancestry. The ancestry is in certain embodiment self-reported by the individual who undergoes genetic analysis or genotyping. In other embodiments, the ancestry is determined by genetic determination comprising detecting at least one allele of at least one polymorphic marker in a nucleic acid sample from the individual, wherein the presence or absence of the allele is indicative of the ancestry of the individual.

In other particular other embodiments of the methods, uses, apparatus or kits of the invention, the presence of at least one at-risk variant, i.e. an at-risk allele in at least one polymorphic marker or an at-risk haplotype, is indicative of an earlyonset of the Cardiovascular disease. Early onset is in some embodiments categorized as onset before age 75. In other embodiments, early onset is categorized as onset before age 70, before age 65, before age 60, before age 55, before age 50, before age 45, or before age 40. Other values for categorization of age at onset are also contemplated, including, but not limited to, all integer values of age, and such age categories are also within scope of the invention. In certain embodiments, the Cardiovascular disease is Myocardial Infarction, and the age at onset is below 50 for males and/or below 60 for females.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude other additives, components, integers or steps.

Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment, or any form of suggestion, that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other aspects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention.

FIG. 1 shows a) Association results for 127 SNPs located in a 1 Mb interval (21.6 – 22.6 Mb, Build 34) on chromosome 9. Plotted is $-\log P$, where P is the P -value adjusted for relatedness of the individual against the chromosomal location of the SNPs. b) The corresponding pair-wise correlation r^2 between 1004 common SNPs in the same region from the HapMap release 19 for

2008218542 23 May 2014

the CEU population. c) Location of two recombination hot-spots based on the HapMap dataset (*Nature* 437, 1299-1320 (27 October 2005)) that define the LD-block (position 21,920,147 to 21,149,982 in NCBI Build 36; SEQ ID NO:94 that includes the strongest association results. d) The pair-wise correlation structure in the region measured by D' for the same set of SNPs as used in panel *b*. All four panel use the same horizontal Mb scale indicated in panel *a*.

DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.

10 Definitions

Unless otherwise indicated, nucleic acid sequences are written left to right in a 5' to 3' orientation. Numeric ranges recited within the specification are inclusive of the numbers defining the range and include each integer or any non-integer fraction within the defined range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by the ordinary person skilled in the art to which the invention pertains.

The following terms shall, in the present context, have the meaning as indicated:

A "polymorphic marker", sometime referred to as a "marker", as described herein, refers to a genomic polymorphic site. Each polymorphic marker has at least two sequence variations characteristic of particular alleles at the polymorphic site. Thus, genetic association to a polymorphic marker implies that there is association to at least one specific allele of that particular polymorphic marker. The marker can comprise any allele of any variant type found in the genome, including SNPs, microsatellites, insertions, deletions, duplications and translocations.

An "allele" refers to the nucleotide sequence of a given locus (position) on a chromosome. A polymorphic marker allele thus refers to the composition (i.e., sequence) of the marker on a chromosome. Genomic DNA from an individual contains two alleles (e.g., allele-specific sequences) for any given polymorphic marker, representative of each copy of the marker on each chromosome. Sequence codes for nucleotides used herein are: A = 1, C = 2, G = 3, T = 4. For microsatellite alleles, the CEPH sample (Centre d'Etudes du Polymorphisme Humain, genomics repository, CEPH sample 1347-02) is used as a reference, the shorter allele of each microsatellite in this sample is set as 0 and all other alleles in other samples are numbered in relation to this reference. Thus, e.g., allele 1 is 1 bp longer than the shorter allele in the CEPH sample, allele 2 is 2 bp longer than the shorter allele in the CEPH sample, allele 3 is 3 bp longer than the lower allele in the CEPH sample, etc., and allele -1 is 1 bp shorter than the shorter

allele in the CEPH sample, allele -2 is 2 bp shorter than the shorter allele in the CEPH sample, etc.

Sequence conucleotide ambiguity as described herein is as proposed by IUPAC-IUB. These codes are compatible with the codes used by the EMBL, GenBank, and PIR databases.

IUB code	Meaning
A	Adenosine
C	Cytidine
G	Guanine
T	Thymidine
R	G or A
Y	T or C
K	G or T
M	A or C
S	G or C
W	A or T
B	C G or T
D	A G or T
H	A C or T
V	A C or G
N	A C G or T (Any base)

5

A nucleotide position at which more than one sequence is possible in a population (either a natural population or a synthetic population, e.g., a library of synthetic molecules) is referred to herein as a "polymorphic site".

10 A "Single Nucleotide Polymorphism" or "SNP" is a DNA sequence variation occurring when a single nucleotide at a specific location in the genome differs between members of a species or between paired chromosomes in an individual. Most SNP polymorphisms have two alleles. Each individual is in this instance either homozygous for one allele of the polymorphism (i.e. both chromosomal copies of the individual have the same nucleotide at the SNP location), or the individual is heterozygous (i.e. the two sister chromosomes of the individual contain different
15 nucleotides). The SNP nomenclature as reported herein refers to the official Reference SNP (rs) ID identification tag as assigned to each unique SNP by the National Center for Biotechnological Information (NCBI).

A "variant", as described herein, refers to a segment of DNA that differs from the reference DNA. A "marker" or a "polymorphic marker", as defined herein, is a variant. Alleles
20 that differ from the reference are referred to as "variant" alleles.

A "microsatellite" is a polymorphic marker that has multiple small repeats of bases that are 2-8 nucleotides in length (such as CA repeats) at a particular site, in which the number of repeat lengths varies in the general population. An "indel" is a common form of polymorphism comprising a small insertion or deletion that is typically only a few nucleotides long.

A "haplotype," as described herein, refers to a segment of genomic DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus. In a certain embodiment, the haplotype can comprise two or
5 more alleles, three or more alleles, four or more alleles, or five or more alleles. Haplotypes are described herein in the context of the marker name and the allele of the marker in that haplotype, e.g., "G rs10757278" refers to the 3 allele of marker rs7758851 being in the haplotype, and is equivalent to "rs10757278 allele G". Furthermore, allelic codes in haplotypes are as for individual markers, i.e. 1 = A, 2 = C, 3 = G and 4 = T.

10 The term "susceptibility", as described herein, refers to an individual (or group of individuals) being prone to developing a certain state (e.g., a certain trait, phenotype or disease), or being less able to resist a particular state than the average individual. The term encompasses both increased susceptibility and decreased susceptibility. Thus, particular alleles at polymorphic markers and/or haplotypes of the invention as described herein may be
15 characteristic of increased susceptibility (i.e., increased risk) of cardiovascular disease, as characterized by a relative risk (RR) or odds ratio (OR) of greater than one for the particular allele or haplotype. Alternatively, the markers and/or haplotypes of the invention are characteristic of decreased susceptibility (i.e., decreased risk) of cardiovascular disease, as characterized by a relative risk of less than one.

20 The term "and/or" shall in the present context be understood to indicate that either or both of the items connected by it are involved. In other words, the term herein shall be taken to mean "one or the other or both".

The term "look-up table", as described herein, is a table that correlates one form of data to another form, or one or more forms of data to a predicted outcome to which the data is
25 relevant, such as phenotype or trait. For example, a look-up table can comprise a correlation between allelic data for at least one polymorphic marker and a particular trait or phenotype, such as a particular disease diagnosis, that an individual who comprises the particular allelic data is likely to display, or is more likely to display than individuals who do not comprise the particular allelic data. Look-up tables can be multidimensional, i.e. they can contain information
30 about multiple alleles for single markers simultaneously, or they can contain information about multiple markers, and they may also comprise other factors, such as particulars about diseases diagnoses, racial information, biomarkers, biochemical measurements, therapeutic methods or drugs, etc.

A "computer-readable medium", is an information storage medium that can be accessed
35 by a computer using a commercially available or custom-made interface. Exemplary computer-readable media include memory (e.g., RAM, ROM, flash memory, etc.), optical storage media (e.g., CD-ROM), magnetic storage media (e.g., computer hard drives, floppy disks, etc.), punch cards, or other commercially available media. Information may be transferred between a system

of interest and a medium, between computers, or between computers and the computer-readable medium for storage or access of stored information. Such transmission can be electrical, or by other available methods, such as IR links, wireless connections, etc.

5 A "nucleic acid sample" is a sample obtained from an individual that contains nucleic acid. In certain embodiments, i.e. the detection of specific polymorphic markers and/or haplotypes, the nucleic acid sample comprises genomic DNA. Such a nucleic acid sample can be obtained from any source that contains genomic DNA, including as a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs.

10 The term "cardiovascular disease therapeutic agent", as described herein, refers to an agent that can be used to ameliorate or prevent symptoms associated with a cardiovascular disease.

15 The term "coronary artery disease therapeutic agent", as described herein, refers to an agent that can be used to ameliorate or prevent symptoms associated with coronary artery disease. Such agents can for example be statins, beta blockers, calcium channel blockers, cardiac glycosides, antihypertensive agents, diuretics, agents acting on the renin-angiotensin system, and aspirin.

20 The term "coronary stenosis" or "coronary stenosis therapeutic method", as described herein, refers to methods that can be used to ameliorate or prevent symptoms associated with coronary artery disease. Such methods can be balloon angioplasty, stenting, cutting balloon angioplasty, percutaneous transluminal coronary angioplasty (PTCA), directional coronary atherectomy, rotational coronary atherectomy, brachytherapy, drug-eluting stent (DES) insertion, metal stent insertion, or coronary artery surgeries, such as Coronary Artery Bypass Surgery (CABG).

25 The term "cardiovascular disease-associated nucleic acid", as described herein, refers to a nucleic acid that has been found to be associated to cardiovascular disease. This includes, but is not limited to, the markers and haplotypes described herein and markers and haplotypes in strong linkage disequilibrium (LD) therewith.

30 The term "LD Block C09", as described herein, refers to the Linkage Disequilibrium (LD) block on Chromosome 9 between positions 21,920,147 and 22,149,982 base pairs on Chromosome 9 of NCBI (National Center for Biotechnology Information) Build 34, Build 35 and Build 36. The nucleotide sequence of the LD Block region from these Builds is set forth in SEQ ID NO:94.

35 The term "cardiovascular disease", as described herein, refers to the class of diseases that involve the heart or blood vessels (arteries and veins). In one embodiment, the invention pertains to arterial disease, which relate to atherosclerotic events, which are believed to have

similar causes and mechanisms. Cardiovascular diseases have certain common risk factors (age, smoking, Diabetes mellitus, hypercholesterolemia, obesity, high blood pressure, stress, depression, elevated heart rate, sleep deprivation, environmental exposure).

The abbreviations "PCTA", "CABG", "MI", "PAD", "CAD", "LAA", "IA", and "AAA", as described herein, refer to the following: "PCTA" refers to Transluminal Coronary Angiopathy, "CABG" refers to Coronary Artery Bypass Surgery, "MI" refers to Myocardial Infarction, "PAD" refers to Peripheral Artery Disease, "CAD" refers to Coronary Artery Disease, "LAA Stroke" refers to Large Artery Atherosclerotic Stroke, "IA" refers to Intracranial Aneurysm and "AAA" refers to Abdominal Aortic Aneurysm.

The term "early onset", as described herein, refers to onset of a disease that is lower than is typically observed. In the present exemplary context, the term, as applied to the MI phenotype, is defined as a MI event before the age of 50 for males and before the age of 60 for females. The term can, in alternative embodiments of the invention, be defined in alternative manner as known to the skilled person and described in further detail herein.

Association of genetic variants to Coronary Artery Disease

Through an association study between SNP markers on a chip containing approximately 317,000 such SNPs, the present invention has identified association of certain markers on chromosome 9 with cardiovascular diseases. The original discovery was made when an analysis of SNP data from patients diagnosed with Myocardial Infarction was made, as illustrated in Table 1 and Table 12. Several markers in a region described herein as LD block C09 were found to be strongly associated with MI, with RR values as high as 1.2. Two microsatellites within the region, D9S1814 and D9S1870, were found also to be correlated with the MI phenotype. The composite allele X of D9S1870 (a composite of all alleles shorter than 2 (alleles, -6, -4, -2 and 0, respectively), was found to associate strongly with MI (Table 1). Further investigations identified close to 90 additional markers that are strongly correlated with the five markers giving strongest association to MI (rs10116277, rs1333040, rs2383207, D9S1814 and D9S1870; see Table 3). These markers could thus serve as surrogate markers for any of these five markers and therefore be used in the methods of the present invention.

The D9S1870 marker was subsequently genotyped in a very large sample of individuals (over 70,000), including additional MI cases as well as other cardiovascular diseases, plus tens of thousands of additional population controls. A replication study in three cohorts from the US was also performed, all containing individuals of Caucasian origin. Results of these studies for the phenotype MI revealed replication of the original finding (Table 4 and 12-14), with a combined p-value of approximately 10^{-12} . The corresponding population attributable risk is about 17% for this variant.

Further studies of this variant revealed a significant correlation to age at onset of MI. Arbitrarily defining early-onset MI as MI before age 50 for males and below age 60 for females revealed an increase in this early-onset group of 1.33, compared to 1.21 for all MI cases. Multiple regression of the number of copies of the composite X allele of D9S1870 and the age of onset of MI revealed a very significant decrease in age at onset for each copy of X carried by the MI individuals (Table 8). This shows that other definitions of age at onset of MI than the cutoff of 50 for males and 60 for females could also be used for detecting this trend in age at onset with carrier status for the X allele.

The present invention has also identified association between other cardiovascular diseases and variants within the LD block C09, using the X allele of D9S1870 as surrogate marker. Thus significant association was found to Peripheral Artery Disease (PAD), even after removing individuals diagnosed with MI from the PAD cohort. We also observed increased risk of Stroke as broad phenotype, as well as the Stroke subphenotype Large Vessel disease (LVD) (Table 5 and Table 29). We have also investigated association of the at-risk variants to the related disorders peripheral artery disease (PAD) and abdominal aorta aneurysm (AAA). As can be seen in Table 29, these markers are associated with these related disorders. The association is particularly compelling for AAA, wherein significant association is observed for a large number of markers in addition to these three, as shown in Table 30. These results illustrate that the markers and haplotypes of the invention are indeed reflective of disorders related to coronary artery disease, MI and in-stent restenosis, such as abdominal aorta aneurysm.

A further analysis of individuals with diagnosis of in-stent restenosis was performed (Table 9). Significant association was detected for both mild restenosis (<50%) and severe restenosis (>50%). This indicates that the present invention can be used to indicate which individuals are at increased risk of in-stent restenosis after undergoing transluminal coronary angioplasty (PTCA).

The known genes located within the LD block C09, are called CDKN2A and CDKN2B. These genes encode three proteins that are known as ARF (also known as p19^{ARF} and p14^{ARF}), p15^{INK4b} and p16^{INK4a}, all of which encode tumor suppressor proteins. p15^{INK4b} has its own open reading frame, but p16^{INK4a} and ARF have different first exons that are spliced to a common second and third exons. Despite the sharing of exons between p16^{INK4a} and ARF the proteins are encoded in different reading frames. Therefore, p16^{INK4a} and ARF are proteins that do not share homology. The products of these genes have been extensively studied and are known to play a widespread role in tumor suppression. Recent data has suggested that the ARF, p15^{INK4b} and p16^{INK4a} locus also has a role in aging of cells, i.e. the decline of replicative potential of self-renewing cells. Several groups have shown that the expression of p16^{INK4a} increases with aging in many tissues of rodents and humans. It has even been proposed that the expression of p16^{INK4a} could be used as a biomarker of physiologic, as opposed to chronologic age.

Human cancers frequently have homozygous deletions of the ARF, p15^{INK4b} and p16^{INK4a} locus with reduced expression of all three proteins, and decreased tumor suppressor activity. Knock-out studies of mice deficient for ARF, p15^{INK4b} or p16^{INK4a} have revealed that these strains are more prone to cancers than wild-type mice. Furthermore, mice with overexpression of the ARF, p15^{INK4b} or p16^{INK4a} locus show reduction in incidence of spontaneous cancers. Since cancer is the principal cause of death in mice on this background one may argue that the tumor resistance of the mice overexpressing the ARF, p15^{INK4b} or p16^{INK4a} locus would also lead to longer lifespan of these mice. However, this is not the case since these mice demonstrate a normal lifespan. This may suggest that the increased ARF, p15^{INK4b} or p16^{INK4a} locus function and diminished tumor incidence may come at the expense of excess mortality from non-malignant causes related to aging (Cell, 127, Oct. 20, 2006), such as atherosclerotic disease.

Sequencing of the exons of CDKN2A and CDKN2B regions, including exons, exon-intron junctions and potential regulatory regions was performed using the primers as indicated in Table 12, resulting in the identification of a number of SNPs, as shown in Table 13. Three of those SNPs were not found in public databases, and the flanking sequences of those SNPs are indicated in Table 14. As it is possible that SNP markers or other polymorphisms in LD with the markers found to be associating to MI in this region of chromosome 9 show association with a higher risk, we genotyped these additional markers by sequencing, as indicated in Table 13. Several of the markers show association to MI with RR values as high as 1.7-1.8, in particular markers SG09S291 and rs2069416. These markers, and/or other markers within the CDKN2A and CDKN2B genes that are in LD with the markers of the present invention as described herein, are thus also within the scope of the invention, as those markers may represent either true disease-causing variants, or variants in strong LD with an underlying causative variant(s).

Investigation of association of the rs10757278 variant to Intracranial Aneurysm shows significant association to this phenotype in the original Icelandic cohort, as well as replication in independent cohorts from the Netherlands and Finland (e.g., Table 32). Furthermore, the original finding of association to AAA was replicated in several cohorts from Belgium, Canada, USA, Netherlands, UK and New Zealand (Table 32). These results show that the rs10757278 marker, and markers in LD therewith, are indeed significantly associated with cardiovascular disorders, including the arterial diseases than myocardial infarction, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm.

The original discovery of the association between variants on chromosome 9p21 and cardiovascular diseases described herein (see also Helgadottir, A., et. al., *Science* **316**:1491-3 2007) has been replicated in several independent studies, including studies of subjects with CAD and controls. The association with CAD/MI in Caucasians has been replicated in 4,251 cases and 4,443 controls of the PROCARDIS Consortium (*Hum Mol Genet.* Epub 2007 Nov 29.), in an Italian population including 416 MI cases and 308 controls (*J Hum Genet.* 2008;**53**(2):144-50. Epub 2007 Dec 8.), in participants of the Framingham Heart Study (*BMC Med Genet.* 2007 Sep 19;8 Suppl 1:S5.), and in the Northwick Park Heart Study II (*Clin Chem.* Epub 2008 Feb 4).

The association of rs10757278, as well as other correlated SNPs, with CAD has also been confirmed in Asian populations from Japan and Korea with comparable odds ratios as published for Caucasians (see *Arterioscler Thromb Vasc Biol.* 2008 Feb; **28(2)**:360-5. Epub 2007 Nov 29, and *J Hum Genet.* Epub 2008 Feb 9). These studies, together with the data shown herein,
5 clearly indicate that variants within the LD Block C09 region on Chromosome 9p21 are associated with cardiovascular disease in all populations.

Assessment for markers and haplotypes

The genomic sequence within populations is not identical when individuals are compared.
10 Rather, the genome exhibits sequence variability between individuals at many locations in the genome. Such variations in sequence are commonly referred to as polymorphisms, and there are many such sites within each genome. For example, the human genome exhibits sequence variations which occur on average every 500 base pairs. The most common sequence variant consists of base variations at a single base position in the genome, and such sequence variants,
15 or polymorphisms, are commonly called Single Nucleotide Polymorphisms ("SNPs"). These SNPs are believed to have occurred in a single mutational event, and therefore there are usually two possible alleles possible at each SNPsite; the original allele and the mutated allele. Due to natural genetic drift and possibly also selective pressure, the original mutation has resulted in a polymorphism characterized by a particular frequency of its alleles in any given population.
20 Many other types of sequence variants are found in the human genome, including microsatellites, insertions, deletions, inversions and copy number variations. A polymorphic microsatellite has multiple small repeats of bases (such as CA repeats, TG on the complimentary strand) at a particular site in which the number of repeat lengths varies in the general population. In general terms, each version of the sequence with respect to the polymorphic site
25 represents a specific allele of the polymorphic site. These sequence variants can all be referred to as polymorphisms, occurring at specific polymorphic sites characteristic of the sequence variant in question. In general terms, polymorphisms can comprise any number of specific alleles. Thus in one embodiment of the invention, the polymorphism is characterized by the presence of two or more alleles in any given population. In another embodiment, the
30 polymorphism is characterized by the presence of three or more alleles. In other embodiments, the polymorphism is characterized by four or more alleles, five or more alleles, six or more alleles, seven or more alleles, nine or more alleles, or ten or more alleles. All such polymorphisms can be utilized in the methods and kits of the present invention, and are thus within the scope of the invention.

35 In some instances, reference is made to different alleles at a polymorphic site without choosing a reference allele. Alternatively, a reference sequence can be referred to for a particular polymorphic site. The reference allele is sometimes referred to as the "wild-type"

allele and it usually is chosen as either the first sequenced allele or as the allele from a "non-affected" individual (*e.g.*, an individual that does not display a trait or disease phenotype).

Alleles for SNP markers as referred to herein refer to the bases A, C, G or T as they occur at the polymorphic site in the SNP assay employed. The allele codes for SNPs used herein are as follows: 1= A, 2=C, 3=G, 4=T. The person skilled in the art will however realise that by assaying or reading the opposite DNA strand, the complementary allele can in each case be measured. Thus, for a polymorphic site (polymorphic marker) containing an A/G polymorphism, the assay employed may either measure the percentage or ratio of the two bases possible, *i.e.* A and G. Alternatively, by designing an assay that determines the opposite strand on the DNA template, the percentage or ratio of the complementary bases T/C can be measured. Quantitatively (for example, in terms of relative risk), identical results would be obtained from measurement of either DNA strand (+ strand or - strand). Polymorphic sites (polymorphic markers) can allow for differences in sequences based on substitutions, insertions or deletions. For example, a polymorphic microsatellite has multiple small repeats of bases (such as CA repeats) at a particular site in which the number of repeat lengths varies in the general population. Each version of the sequence with respect to the polymorphic site represents a specific allele of the polymorphic site.

Typically, a reference sequence is referred to for a particular sequence. Alleles that differ from the reference are referred to as "variant" alleles. For example, the genomic DNA sequence from position 21,920,147 to position 22,149,982 base pairs on Chromosome 9 of NCBI Build 34 ("LD block C09"; SEQ ID NO:94) represents a reference sequence. A variant sequence, as used herein, refers to a sequence that differs from the reference sequence but is otherwise substantially similar. Alleles at the polymorphic genetic markers that make up the haplotypes described herein are variants. Additional variants can include changes that affect a polypeptide. Sequence differences, when compared to a reference nucleotide sequence, can include the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift; the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of the coding sequence of a reading frame; duplication of all or a part of a sequence; transposition; or a rearrangement of a nucleotide sequence, as described in detail herein. Such sequence changes alter the polypeptide encoded by the nucleic acid. For example, if the change in the nucleic acid sequence causes a frame shift, the frame shift can result in a change in the encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with coronary artery disease and in-stent restenosis or a susceptibility to coronary artery disease and in-stent restenosis can be a synonymous change in one or more nucleotides (*i.e.*, a change that does not result in a change in the amino acid sequence). Such a polymorphism can, for example, alter splice sites, affect the stability or

transport of mRNA, or otherwise affect the transcription or translation of an encoded polypeptide. It can also alter DNA to increase the possibility that structural changes, such as amplifications or deletions, occur at the somatic level. The polypeptide encoded by the reference nucleotide sequence is the "reference" polypeptide with a particular reference amino acid sequence, and polypeptides encoded by variant alleles are referred to as "variant" polypeptides with variant amino acid sequences.

A haplotype refers to a segment of DNA that is characterized by a specific combination of alleles arranged along the segment. For diploid organisms such as humans, a haplotype comprises one member of the pair of alleles for each polymorphic marker or locus. In a certain embodiment, the haplotype can comprise two or more alleles, three or more alleles, four or more alleles, or five or more alleles, each allele corresponding to a specific polymorphic marker along the segment. Haplotypes can comprise a combination of various polymorphic markers, *e.g.*, SNPs and microsatellites, having particular alleles at the polymorphic sites. The haplotypes thus comprise a combination of alleles at various genetic markers.

Detecting specific polymorphic markers and/or haplotypes can be accomplished by methods known in the art for detecting sequences at polymorphic sites. For example, standard techniques for genotyping for the presence of SNPs and/or microsatellite markers can be used, such as fluorescence-based techniques (*e.g.*, Chen, X. *et al.*, *Genome Res.* 9(5): 492-98 (1999); Kutyavin *et al.*, *Nucleic Acid Res.* 34:e128 (2006)), utilizing PCR, LCR, Nested PCR and other techniques for nucleic acid amplification. Specific methodologies available for SNP genotyping include, but are not limited to, TaqMan genotyping assays and SNPlex platforms (Applied Biosystems), mass spectrometry (*e.g.*, MassARRAY system from Sequenom), minisequencing methods, real-time PCR, Bio-Plex system (BioRad), CEQ and SNPstream systems (Beckman), Molecular Inversion Probe array technology (*e.g.*, Affymetrix GeneChip), and BeadArray Technologies (*e.g.*, Illumina GoldenGate and Infinium assays). By these or other methods available to the person skilled in the art, one or more alleles at polymorphic markers, including microsatellites, SNPs or other types of polymorphic markers, can be identified.

In certain methods described herein, an individual who is at an increased susceptibility (*i.e.*, at risk) for cardiovascular disease is an individual in whom at least one specific allele at one or more polymorphic marker or haplotype conferring increased susceptibility for cardiovascular disease is identified (*i.e.*, at-risk marker alleles or haplotypes). In one aspect, the at-risk marker or haplotype is one that confers a significant increased risk (or susceptibility) of cardiovascular disease. In one embodiment, significance associated with a marker or haplotype is measured by a relative risk. In one embodiment, significance associated with a marker or haplotype is measured by a relative risk (RR). In another embodiment, significance associated with a marker or haplotype is measured by an odds ratio (OR). In a further embodiment, the significance is measured by a percentage. In one embodiment, a significant increased risk is measured as a risk (relative risk and/or odds ratio) of at least 1.2, including but not limited to: at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, 1.8, at least 1.9, at least 2.0, at

least 2.5, at least 3.0, at least 4.0, and at least 5.0. In a particular embodiment, a risk (relative risk and/or odds ratio) of at least 1.2 is significant. In another particular embodiment, a risk of at least 1.3 is significant. In yet another embodiment, a risk of at least 1.4 is significant. In a further embodiment, a relative risk of at least 1.5 is significant. In another further embodiment, a significant increase in risk is at least 1.7 is significant. However, other cutoffs are also contemplated, e.g., at least 1.15, 1.25, 1.35, and so on, and such cutoffs are also within scope of the present invention. In other embodiments, a significant increase in risk is at least about 20%, including but not limited to about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, and 500%. In one particular embodiment, a significant increase in risk is at least 20%. In other embodiments, a significant increase in risk is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and at least 100%. Other cutoffs or ranges as deemed suitable by the person skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention. In certain embodiments, a significant increase in risk is characterized by a p-value, such as a p-value of less than 0.05, less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, or less than 0.00000001.

An at-risk polymorphic marker or haplotype of the present invention is one where at least one allele of at least one marker or haplotype is more frequently present in an individual at risk for cardiovascular disease (affected), compared to the frequency of its presence in a healthy individual (control), and wherein the presence of the marker or haplotype is indicative of susceptibility to cardiovascular disease. The control group may in one embodiment be a population sample, i.e. a random sample from the general population. In another embodiment, the control group is represented by a group of individuals who are disease-free. Such disease-free control may in one embodiment be characterized by the absence of one or more specific disease-associated symptoms. In another embodiment, the disease-free control group is characterized by the absence of one or more disease-specific risk factors. Such risk factors are in one embodiment at least one environmental risk factor. Representative environmental factors are natural products, minerals or other chemicals which are known to affect, or contemplated to affect, the risk of developing the specific disease or trait. Other environmental risk factors are risk factors related to lifestyle, including but not limited to food and drink habits, geographical location of main habitat, and occupational risk factors. In another embodiment, the risk factors comprise at least one additional genetic risk factor.

As an example of a simple test for correlation would be a Fisher-exact test on a two by two table. Given a cohort of chromosomes, the two by two table is constructed out of the number of chromosomes that include both of the markers or haplotypes, one of the markers or haplotypes but not the other and neither of the markers or haplotypes. Other statistical tests of association known to the skilled person are also contemplated and are also within scope of the invention.

In other embodiments of the invention, an individual who is at a decreased susceptibility (i.e., at a decreased risk) for a disease or trait is an individual in whom at least one specific allele at one or more polymorphic marker or haplotype conferring decreased susceptibility for the disease or trait is identified. The marker alleles and/or haplotypes conferring decreased risk are also said to be protective. In one aspect, the protective marker or haplotype is one that confers a significant decreased risk (or susceptibility) of the disease or trait. In one embodiment, significant decreased risk is measured as a relative risk (or odds ratio) of less than 0.9, including but not limited to less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2 and less than 0.1. In one particular embodiment, significant decreased risk is less than 0.7. In another embodiment, significant decreased risk is less than 0.5. In yet another embodiment, significant decreased risk is less than 0.3. In another embodiment, the decrease in risk (or susceptibility) is at least 20%, including but not limited to at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and at least 98%. In one particular embodiment, a significant decrease in risk is at least about 30%. In another embodiment, a significant decrease in risk is at least about 50%. In another embodiment, the decrease in risk is at least about 70%. Other cutoffs or ranges as deemed suitable by the person skilled in the art to characterize the invention are however also contemplated, and those are also within scope of the present invention.

The person skilled in the art will appreciate that for markers with two alleles present in the population being studied (such as SNPs), and wherein one allele is found in increased frequency in a group of individuals with a trait or disease in the population, compared with controls, the other allele of the marker will be found in decreased frequency in the group of individuals with the trait or disease, compared with controls. In such a case, one allele of the marker (the one found in increased frequency in individuals with the trait or disease) will be the at-risk allele, while the other allele will be a protective allele.

A genetic variant associated with a disease or a trait (e.g. cardiovascular disease) can be used alone to predict the risk of the disease for a given genotype. For a biallelic marker, such as a SNP, there are 3 possible genotypes: homozygote for the at risk variant, heterozygote, and non carrier of the at risk variant. Risk associated with variants at multiple loci can be used to estimate overall risk. For multiple SNP variants, there are k possible genotypes $k = 3^n \times 2^p$; where n is the number autosomal loci and p the number of gonosomal (sex chromosomal) loci. Overall risk assessment calculations usually assume that the relative risks of different genetic variants multiply, i.e. the overall risk (e.g., RR or OR) associated with a particular genotype combination is the product of the risk values for the genotype at each locus. If the risk presented is the relative risk for a person, or a specific genotype for a person, compared to a reference population with matched gender and ethnicity, then the combined risk – is the product of the locus specific risk values – and which also corresponds to an overall risk estimate compared with the population. If the risk for a person is based on a comparison to non-carriers of the at risk allele, then the combined risk corresponds to an estimate that compares the person

with a given combination of genotypes at all loci to a group of individuals who do not carry risk variants at any of those loci. The group of non-carriers of any at risk variant has the lowest estimated risk and has a combined risk, compared with itself (*i.e.*, non-carriers) of 1.0, but has an overall risk, compare with the population, of less than 1.0. It should be noted that the group of non-carriers can potentially be very small, especially for large number of loci, and in that case, its relevance is correspondingly small.

The multiplicative model is a parsimonious model that usually fits the data of complex traits reasonably well. Deviations from multiplicity have been rarely described in the context of common variants for common diseases, and if reported are usually only suggestive since very large sample sizes are usually required to be able to demonstrate statistical interactions between loci.

By way of an example, let us consider a total of eight variants that have been described to associate with prostate cancer (Gudmundsson, J., *et al.*, *Nat Genet* **39**:631-7 (2007), Gudmundsson, J., *et al.*, *Nat Genet* **39**:977-83 (2007); Yeager, M., *et al.*, *Nat Genet* **39**:645-49 (2007), Amundadottir, L., *et al.*, *Nat Genet* **38**:652-8 (2006); Haiman, C.A., *et al.*, *Nat Genet* **39**:638-44 (2007)). Seven of these loci are on autosomes, and the remaining locus is on chromosome X. The total number of theoretical genotypic combinations is then $3^7 \times 2^1 = 4374$. Some of those genotypic classes are very rare, but are still possible, and should be considered for overall risk assessment. It is likely that the multiplicative model applied in the case of multiple genetic variant will also be valid in conjugation with non-genetic risk variants assuming that the genetic variant does not clearly correlate with the "environmental" factor. In other words, genetic and non-genetic at-risk variants can be assessed under the multiplicative model to estimate combined risk, assuming that the non-genetic and genetic risk factors do not interact.

Using the same quantitative approach, the combined or overall risk associated with a plurality of variants associated with any cardiovascular disease, as described herein, may be assessed.

Linkage Disequilibrium

The natural phenomenon of recombination, which occurs on average once for each chromosomal pair during each meiotic event, represents one way in which nature provides variations in sequence (and biological function by consequence). It has been discovered that recombination does not occur randomly in the genome; rather, there are large variations in the frequency of recombination rates, resulting in small regions of high recombination frequency (also called recombination hotspots) and larger regions of low recombination frequency, which are commonly referred to as Linkage Disequilibrium (LD) blocks (Myers, S. *et al.*, *Biochem Soc*

Trans 34:526-530 (2006); Jeffreys, A.J., *et al.*, *Nature Genet* 29:217-222 (2001); May, C.A., *et al.*, *Nature Genet* 31:272-275(2002)).

Linkage Disequilibrium (LD) refers to a non-random assortment of two genetic elements. For example, if a particular genetic element (*e.g.*, "alleles" of a polymorphic marker) occurs in a population at a frequency of 0.50 (50%) and another occurs at a frequency of 0.50 (50%), then the predicted occurrence of a person's having both elements is 0.25 (25%), assuming a random distribution of the elements. However, if it is discovered that the two elements occur together at a frequency higher than 0.25, then the elements are said to be in linkage disequilibrium, since they tend to be inherited together at a higher rate than what their independent allele frequencies would predict. Roughly speaking, LD is generally correlated with the frequency of recombination events between the two elements. Allele or haplotype frequencies can be determined in a population by genotyping individuals in a population and determining the frequency of the occurrence of each allele or haplotype in the population. For populations of diploids, *e.g.*, human populations, individuals will typically have two alleles or allelic combinations for each genetic element (*e.g.*, a marker, haplotype or gene).

Many different measures have been proposed for assessing the strength of linkage disequilibrium (LD). Most capture the strength of association between pairs of biallelic sites. Two important pairwise measures of LD are r^2 (sometimes denoted Δ^2) and $|D'|$. Both measures range from 0 (no disequilibrium) to 1 ('complete' disequilibrium), but their interpretation is slightly different. $|D'|$ is defined in such a way that it is equal to 1 if just two or three of the possible haplotypes are present, and it is <1 if all four possible haplotypes are present. Therefore, a value of $|D'|$ that is <1 indicates that historical recombination may have occurred between two sites (recurrent mutation can also cause $|D'|$ to be <1 , but for single nucleotide polymorphisms (SNPs) this is usually regarded as being less likely than recombination). The measure r^2 represents the statistical correlation between two sites, and takes the value of 1 if only two haplotypes are present.

The r^2 measure is arguably the most relevant measure for association mapping, because there is a simple inverse relationship between r^2 and the sample size required to detect association between susceptibility loci and SNPs. These measures are defined for pairs of sites, but for some applications a determination of how strong LD is across an entire region that contains many polymorphic sites might be desirable (*e.g.*, testing whether the strength of LD differs significantly among loci or across populations, or whether there is more or less LD in a region than predicted under a particular model). Measuring LD across a region is not straightforward, but one approach is to use the measure r , which was developed in population genetics. Roughly speaking, r measures how much recombination would be required under a particular population model to generate the LD that is seen in the data. This type of method can potentially also provide a statistically rigorous approach to the problem of determining whether LD data provide evidence for the presence of recombination hotspots. For the methods described herein, a significant r^2 value can be at least 0.1 such as at least 0.1, 0.15, 0.2, 0.25,

0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or at least 0.99. In one preferred embodiment, the significant r^2 value can be at least 0.2. Alternatively, linkage disequilibrium as described herein, refers to linkage disequilibrium characterized by values of $|D'|$ of at least 0.2, such as 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.85, 0.9, 0.95, 0.96, 0.97, 0.98, or at least 0.99. Thus, linkage disequilibrium represents a correlation between alleles of distinct markers. It is measured by correlation coefficient or $|D'|$ (r^2 up to 1.0 and $|D'|$ up to 1.0). In certain embodiments, linkage disequilibrium is defined in terms of values for both the r^2 and $|D'|$ measures. In one such embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.1$ and $|D'| > 0.8$. In another embodiment, a significant linkage disequilibrium is defined as $r^2 > 0.2$ and $|D'| > 0.9$. Other combinations and permutations of values of r^2 and $|D'|$ for determining linkage disequilibrium are also contemplated, and are also within the scope of the invention. Linkage disequilibrium can be determined in a single human population, as defined herein, or it can be determined in a collection of samples comprising individuals from more than one human population. In one embodiment of the invention, LD is determined in a sample from one or more of the HapMap populations (caucasian, african, japanese, chinese), as defined (<http://www.hapmap.org>). In one such embodiment, LD is determined in the CEU population of the HapMap samples. In another embodiment, LD is determined in the YRI population. In yet another embodiment, LD is determined in samples from the Icelandic population.

If all polymorphisms in the genome were independent at the population level (*i.e.*, no LD), then every single one of them would need to be investigated in association studies, to assess all the different polymorphic states. However, due to linkage disequilibrium between polymorphisms, tightly linked polymorphisms are strongly correlated, which reduces the number of polymorphisms that need to be investigated in an association study to observe a significant association. Another consequence of LD is that many polymorphisms may give an association signal due to the fact that these polymorphisms are strongly correlated.

Genomic LD maps have been generated across the genome, and such LD maps have been proposed to serve as framework for mapping disease-genes (Risch, N. & Merikangas, K, *Science* 273:1516-1517 (1996); Maniatis, N., *et al.*, *Proc Natl Acad Sci USA* 99:2228-2233 (2002); Reich, DE *et al.*, *Nature* 411:199-204 (2001)). It is also now established that many portions of the human genome can be broken into series of discrete haplotype blocks containing a few common haplotypes; for these blocks, linkage disequilibrium data provides little evidence indicating recombination (see, *e.g.*, Wall, J.D. and Pritchard, J.K., *Nature Reviews Genetics* 4:587-597 (2003); Daly, M. *et al.*, *Nature Genet.* 29:229-232 (2001); Gabriel, S.B. *et al.*, *Science* 296:2225-2229 (2002); Patil, N. *et al.*, *Science* 294:1719-1723 (2001); Dawson, E. *et al.*, *Nature* 418:544-548 (2002); Phillips, M.S. *et al.*, *Nature Genet.* 33:382-387 (2003)). There are two main methods for defining these haplotype blocks: blocks can be defined as regions of DNA that have limited haplotype diversity (see, *e.g.*, Daly, M. *et al.*, *Nature Genet.* 29:229-232 (2001); Patil, N. *et al.*, *Science* 294:1719-1723 (2001); Dawson, E. *et al.*, *Nature* 418:544-548 (2002); Zhang, K. *et al.*, *Proc. Natl. Acad. Sci. USA* 99:7335-7339 (2002)), or as regions

between transition zones having extensive historical recombination, identified using linkage disequilibrium (see, e.g., Gabriel, S.B. *et al.*, *Science* 296:2225-2229 (2002); Phillips, M.S. *et al.*, *Nature Genet.* 33:382-387 (2003); Wang, N. *et al.*, *Am. J. Hum. Genet.* 71:1227-1234 (2002); Stumpf, M.P., and Goldstein, D.B., *Curr. Biol.* 13:1-8 (2003)). More recently, a fine-scale map of recombination rates and corresponding hotspots across the human genome has been generated (Myers, S., *et al.*, *Science* 310:321-32324 (2005); Myers, S. *et al.*, *Biochem Soc Trans* 34:526530 (2006)). The map reveals the enormous variation in recombination across the genome, with recombination rates as high as 10-60 cM/Mb in hotspots, while closer to 0 in intervening regions, which thus represent regions of limited haplotype diversity and high LD.

The map can therefore be used to define haplotype blocks/LD blocks as regions flanked by recombination hotspots. As used herein, the terms "haplotype block" or "LD block" includes blocks defined by any of the above described characteristics, or other alternative methods used by the person skilled in the art to define such regions. Haplotype blocks (LD blocks) can be used to map associations between phenotype and haplotype status, using single markers or haplotypes comprising a plurality of markers. The main haplotypes can be identified in each haplotype block, and then a set of "tagging" SNPs or markers (the smallest set of SNPs or markers needed to distinguish among the haplotypes) can then be identified. These tagging SNPs or markers can then be used in assessment of samples from groups of individuals, in order to identify association between phenotype and haplotype. If desired, neighboring haplotype blocks can be assessed concurrently, as there may also exist linkage disequilibrium among the haplotype blocks.

It has thus become apparent that for any given observed association to a polymorphic marker in the genome, it is likely that additional markers in the genome also show association. This is a natural consequence of the uneven distribution of LD across the genome, as observed by the large variation in recombination rates. The markers used to detect association thus in a sense represent "tags" for a genomic region (i.e., a haplotype block or LD block; e.g., the C09 LD block) that is associating with a given disease or trait, and as such are useful for use in the methods and kits of the present invention. One or more causative (functional) variants or mutations may reside within the region found to be associating to the disease or trait. Such variants may confer a higher relative risk (RR) or odds ratio (OR) than observed for the tagging markers used to detect the association. The present invention thus refers to the markers used for detecting association to the disease, as described herein, as well as markers in linkage disequilibrium with the markers. Thus, in certain embodiments of the invention, markers that are in LD with the markers and/or haplotypes of the invention, as described herein, may be used as surrogate markers. The surrogate markers have in one embodiment relative risk (RR) and/or odds ratio (OR) values smaller than for the markers or haplotypes initially found to be associating with the disease, as described herein. In other embodiments, the surrogate markers have RR or OR values greater than those initially determined for the markers initially found to be associating with the disease, as described herein. An example of such an embodiment would be a rare, or relatively rare (such as < 10% allelic population frequency) variant in LD with a more

common variant (> 10% population frequency) initially found to be associating with the disease, such as the variants described herein. Identifying and using such markers for detecting the association discovered by the inventors as described herein can be performed by routine methods well known to the person skilled in the art, and are therefore within the scope of the present invention.

Determination of haplotype frequency

The frequencies of haplotypes in patient and control groups can be estimated using an expectation-maximization algorithm (Dempster A. et al., *J. R. Stat. Soc. B*, 39:1-38 (1977)). An implementation of this algorithm that can handle missing genotypes and uncertainty with the phase can be used. Under the null hypothesis, the patients and the controls are assumed to have identical frequencies. Using a likelihood approach, an alternative hypothesis is tested, where a candidate at-risk-haplotype, which can include the markers described herein, is allowed to have a higher frequency in patients than controls, while the ratios of the frequencies of other haplotypes are assumed to be the same in both groups. Likelihoods are maximized separately under both hypotheses and a corresponding 1-df likelihood ratio statistic is used to evaluate the statistical significance.

To look for at-risk and protective markers and haplotypes within a linkage region, for example, association of all possible combinations of genotyped markers is studied, provided those markers span a practical region. The combined patient and control groups can be randomly divided into two sets, equal in size to the original group of patients and controls. The marker and haplotype analysis is then repeated and the most significant p-value registered is determined. This randomization scheme can be repeated, for example, over 100 times to construct an empirical distribution of p-values. In a preferred embodiment, a p-value of <0.05 is indicative of an significant marker and/or haplotype association.

Haplotype Analysis

One general approach to haplotype analysis involves using likelihood-based inference applied to NEsted MOdels (Gretarsdottir S., et al., *Nat. Genet.* 35:131-38 (2003)). The method is implemented in the program NEMO, which allows for many polymorphic markers, SNPs and microsatellites. The method and software are specifically designed for case-control studies where the purpose is to identify haplotype groups that confer different risks. It is also a tool for studying LD structures. In NEMO, maximum likelihood estimates, likelihood ratios and p-values are calculated directly, with the aid of the EM algorithm, for the observed data treating it as a missing-data problem.

Even though likelihood ratio tests based on likelihoods computed directly for the observed data, which have captured the information loss due to uncertainty in phase and missing genotypes, can be relied on to give valid p-values, it would still be of interest to know how much information had been lost due to the information being incomplete. The information measure for haplotype analysis is described in Nicolae and Kong (Technical Report 537, Department of Statistics, University of Statistics, University of Chicago; *Biometrics*, 60(2):368-75 (2004)) as a natural extension of information measures defined for linkage analysis, and is implemented in NEMO.

For single marker association to a disease, the Fisher exact test can be used to calculate two-sided p-values for each individual allele. Usually, all p-values are presented unadjusted for multiple comparisons unless specifically indicated. The presented frequencies (for microsatellites, SNPs and haplotypes) are allelic frequencies as opposed to carrier frequencies. To minimize any bias due the relatedness of the patients who were recruited as families for the linkage analysis, first and second-degree relatives can be eliminated from the patient list. Furthermore, the test can be repeated for association correcting for any remaining relatedness among the patients, by extending a variance adjustment procedure described in Risch, N. & Teng, J. (*Genome Res.*, 8:1273-1288 (1998)), DNA pooling (*ibid*) for sibships so that it can be applied to general familial relationships, and present both adjusted and unadjusted p-values for comparison. The differences are in general very small as expected. To assess the significance of single-marker association corrected for multiple testing we can carry out a randomization test using the same genotype data. Cohorts of patients and controls can be randomized and the association analysis redone multiple times (e.g., up to 500,000 times) and the p-value is the fraction of replications that produced a p-value for some marker allele that is lower than or equal to the p-value we observed using the original patient and control cohorts.

For both single-marker and haplotype analyses, relative risk (RR) and the population attributable risk (PAR) can be calculated assuming a multiplicative model (haplotype relative risk model) (Terwilliger, J.D. & Ott, J., *Hum. Hered.* 42:337-46 (1992) and Falk, C.T. & Rubinstein, P., *Ann. Hum. Genet.* 51 (Pt 3):227-33 (1987)), i.e., that the risks of the two alleles/haplotypes a person carries multiply. For example, if RR is the risk of A relative to a, then the risk of a person homozygote AA will be RR times that of a heterozygote Aa and RR^2 times that of a homozygote aa. The multiplicative model has a nice property that simplifies analysis and computations — haplotypes are independent, i.e., in Hardy-Weinberg equilibrium, within the affected population as well as within the control population. As a consequence, haplotype counts of the affecteds and controls each have multinomial distributions, but with different haplotype frequencies under the alternative hypothesis. Specifically, for two haplotypes, h_i and h_j , $\text{risk}(h_i)/\text{risk}(h_j) = (f_i/p_i)/(f_j/p_j)$, where f and p denote, respectively, frequencies in the affected population and in the control population. While there is some power loss if the true model is not multiplicative, the loss tends to be mild except for extreme cases. Most importantly, p-values are always valid since they are computed with respect to null hypothesis.

Linkage Disequilibrium Using NEMO

LD between pairs of markers can be calculated using the standard definition of D' and r^2 (Lewontin, R., *Genetics* 49:49-67 (1964); Hill, W.G. & Robertson, A. *Theor. Appl. Genet.* 22:226-231 (1968)). Using NEMO, frequencies of the two marker allele combinations are estimated by maximum likelihood and deviation from linkage equilibrium is evaluated by a likelihood ratio test. The definitions of D' and r^2 are extended to include microsatellites by averaging over the values for all possible allele combination of the two markers weighted by the marginal allele probabilities.

Risk assessment and Diagnostics

Within any given population, there is an absolute risk of developing a disease or trait, defined as the chance of a person developing the specific disease or trait over a specified time-period. For example, a woman's lifetime absolute risk of breast cancer is one in nine. That is to say, one woman in every nine will develop breast cancer at some point in their lives. Risk is typically measured by looking at very large numbers of people, rather than at a particular individual. Risk is often presented in terms of Absolute Risk (AR) and Relative Risk (RR). Relative Risk is used to compare risks associating with two variants or the risks of two different groups of people. For example, it can be used to compare a group of people with a certain genotype with another group having a different genotype. For a disease, a relative risk of 2 means that one group has twice the chance of developing a disease as the other group. The Risk presented is usually the relative risk for a person, or a specific genotype of a person, compared to the population with matched gender and ethnicity. Risks of two individuals of the same gender and ethnicity could be compared in a simple manner. For example, if, compared to the population, the first individual has relative risk 1.5 and the second has relative risk 0.5, then the risk of the first individual compared to the second individual is $1.5/0.5 = 3$.

As described herein, certain polymorphic markers and haplotypes comprising such markers are found to be useful for risk assessment of cardiovascular disease, e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm. Risk assessment can involve the use of the markers for diagnosing a susceptibility to the cardiovascular disease. Particular alleles of polymorphic markers are found more frequently in individuals with cardiovascular disease, than in individuals without diagnosis of cardiovascular disease. Therefore, these marker alleles have predictive value for detecting cardiovascular disease, or a susceptibility to cardiovascular disease, in an individual. Tagging markers within haplotype blocks or LD blocks comprising at-risk markers, such as the markers of the present invention, can be used as surrogates for other markers and/or haplotypes within the haplotype block or LD

block. Markers with values of r^2 equal to 1 are perfect surrogates for the at-risk variants, i.e. genotypes for one marker perfectly predicts genotypes for the other. Markers with smaller values of r^2 than 1 can also be surrogates for the at-risk variant, or alternatively represent variants with relative risk values as high as or possibly even higher than the at-risk variant. The at-risk variant identified may not be the functional variant itself, but is in this instance in linkage disequilibrium with the true functional variant. The present invention encompasses the assessment of such surrogate markers for the markers as disclosed herein. Such markers are annotated, mapped and listed in public databases, as well known to the skilled person, or can alternatively be readily identified by sequencing the region or a part of the region identified by the markers of the present invention in a group of individuals, and identify polymorphisms in the resulting group of sequences. As a consequence, the person skilled in the art can readily and without undue experimentation genotype surrogate markers in linkage disequilibrium with the markers and/or haplotypes as described herein. The tagging or surrogate markers in LD with the at-risk variants detected, also have predictive value for detecting association to the cardiovascular disease, or a susceptibility to the cardiovascular disease, in an individual. These tagging or surrogate markers that are in LD with the markers of the present invention can also include other markers that distinguish among haplotypes, as these similarly have predictive value for detecting susceptibility to cardiovascular disease.

The present invention can in certain embodiments be practiced by assessing a sample comprising genomic DNA from an individual for the presence of variants described herein to be associated with cardiovascular disease. Such assessment includes steps of detecting the presence or absence of at least one allele of at least one polymorphic marker, using methods well known to the skilled person and further described herein, and based on the outcome of such assessment, determine whether the individual from whom the sample is derived is at increased or decreased risk (increased or decreased susceptibility) of cardiovascular disease. Alternatively, the invention can be practiced utilizing a dataset comprising information about the genotype status of at least one polymorphic marker described herein to be associated with cardiovascular disease (or markers in linkage disequilibrium with at least one marker shown herein to be associated with cardiovascular disease). In other words, a dataset containing information about such genetic status, for example in the form of genotype counts at a certain polymorphic marker, or a plurality of markers (e.g., an indication of the presence or absence of certain at-risk alleles), or actual genotypes for one or more markers, can be queried for the presence or absence of certain at-risk alleles at certain polymorphic markers shown by the present inventors to be associated with cardiovascular disease. A positive result for a variant (e.g., marker allele) associated with cardiovascular disease, as shown herein, is indicative of the individual from which the dataset is derived is at increased susceptibility (increased risk) of at least one cardiovascular disease (e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm).

In certain embodiments of the invention, a polymorphic marker is correlated to a cardiovascular disease by referencing genotype data for the polymorphic marker to a look-up table that comprises correlations between at least one allele of the polymorphism and the disease. In some embodiments, the table comprises a correlation for one polymorphism. In other embodiments, the table comprises a correlation for a plurality of polymorphisms. In both scenarios, by referencing to a look-up table that gives an indication of a correlation between a marker and cardiovascular disease, a risk for cardiovascular disease, or a susceptibility to cardiovascular disease, can be identified in the individual from whom the sample is derived. In some embodiments, the correlation is reported as a statistical measure. The statistical measure may be reported as a risk measure, such as a relative risk (RR), an absolute risk (AR) or an odds ratio (OR).

The markers and haplotypes of the invention, e.g., the markers presented in Tables 1-36 herein, e.g. the markers in Table 3, 10 and 21, may be useful for risk assessment and diagnostic purposes for cardiovascular disease (e.g., arterial diseases, e.g. myocardial infarction, coronary artery disease, restenosis, peripheral artery disease, stroke, intracranial aneurysm and abdominal aortic aneurysm), either alone or in combination. Thus, even in the cases where the increase in risk by individual markers is relatively modest, i.e. on the order of 10-30%, the association may have significant implications. Thus, relatively common variants may have significant contribution to the overall risk (Population Attributable Risk is high), or combination of markers can be used to define groups of individual who, based on the combined risk of the markers, is at significant combined risk of developing a cardiovascular disease.

Biomarkers

The cardiovascular diseases are known to have several common biomarkers, which are believed to relate to increased risk of developing cardiovascular disease. These include elevated fibrinogen, PAI-1, homocysteine, asymmetric dimethylarginine, C-reactive protein and B-type natriuretic peptide (BNP). These common biomarkers underscore the common etiology for the cardiovascular diseases. Recently, urinary peptides have been shown to be promising biomarkers for Cardiovascular disease, in particular Coronary Artery Disease (CAD) (Zimmerli, L.U., et al., *Mol Cell Proteomics* 7:290-8 (2008)). These have the advantage of being non-invasive, only requiring a urine sample from the individual to be assessed. In one application, a pattern of polypeptides in the urine sample is characteristic of increased risk of CAD.

Many general inflammatory markers are predictive of risk of coronary heart disease, including CAD and MI, although these markers are not specific to atherosclerosis. For example, Stein (Stein, S., *Am J Cardiol*, 87 (suppl):21A-26A (2001)) discusses the use of any one of the following serum inflammatory markers as surrogates for predicting risk of coronary heart disease including C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion

molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, and matrix metalloprotease type-9.

A significant association between CRP levels in serum and increased risk for coronary heart disease was found in the Women's Health Study, with the highest relative risk of 4.5 seen for those women in the highest quintile of serum CRP (Ridker, P.M. *et al.*, *New England. J. Med.*, 347: 1557-1565 (2001)). A similar correlation between increased serum CRP and increased risk for coronary heart disease in women has been reported (Ridker, P.M. *et al.*, *New England. J. Med.*, 342:836-843 (2000); Bermudez, E.A. *et al.*, *Arterioscler. Thromb. Vasc. Biol.*, 22: 1668-1673 (2002)). A similar correlation between increased serum inflammatory markers such as CRP and increased risk for coronary heart disease has been reported for men (Doggen, C.J.M. *et al.*, *J. Internal Med.*, 248:406-414 (2000) and Ridker, P.M. *et al.*, *New England. J. Med.*, 336: 973-979 (1997)). Elevated CRP or other serum inflammatory markers is also prognostic for increased risk of a second myocardial infarct in patients with a previous myocardial infarct (Retterstol, L. *et al.*, *Atheroscler.*, 160: 433-440 (2002)). Emerging evidence also suggests that elevated CRP is an independent risk factor for adverse clinical outcomes. See, *e.g.*, Ridker *et al.*, *N. Engl. J. Med.* 352: 1 (January 6, 2005).

The end products of the leukotriene pathway are potent inflammatory lipid mediators derived from arachidonic acid. They can potentially contribute to development of atherosclerosis and destabilization of atherosclerotic plaques through lipid oxidation and/or proinflammatory effects, and LTC₄, LTD₄, and LTE₄, are known to induce vasoconstriction. On the other hand, LTB₄ is a strong proinflammatory agent. Increased production of these end products of the leukotriene pathway, could therefore serve as a risk factor for MI and atherosclerosis, whereas both inflammation and vasoconstriction/vasospasm have a well established role in the pathogenesis of MI and atherosclerosis.

In certain embodiments of the invention, the genetic risk variants for cardiovascular disease, such as MI, CAD, AAA, IA, stroke and/or PAD are assessed in combination with at least one biomarker. For example, levels of an inflammatory marker in an appropriate test sample (*e.g.*, serum, plasma or urine) can be measured and the determination of the biomarker level in the sample, relative to a control (either a normal, disease-free control, or a random sample from the population) is made. The result of the analysis can be analyzed in combination with genetic risk conferred by the variants described herein, to determine overall risk. Representative inflammatory markers include: C-reactive protein (CRP), serum amyloid A, fibrinogen, serum sCD40L, a leukotriene (*e.g.*, LTB₄, LTC₄, LTD₄, LTE₄), a leukotriene metabolite, interleukin-6, tissue necrosis factor- α , soluble vascular cell adhesion molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, myeloperoxidase (MPO), and N-tyrosine. In a preferred embodiment, the marker is CRP, sCD40L or MPO. The determination of biomarkers can be made by standard methods known to the skilled person. For example, in one embodiment, production of a leukotriene metabolite is

stimulated in a first test sample from the individual, using a calcium ionophore. The level of production is compared with a control level. The control level is a level that is typically found in control individual(s), such as individual who are not at risk for MI, CAD, AAA, IA, stroke or PAD; alternatively, a control level is the level that is found by comparison of disease risk in a population associated with the lowest band of measurement (e.g., below the mean or median, the lowest quartile or the lowest quintile) compared to higher bands of measurement (e.g., above the mean or median, the second, third or fourth quartile; the second, third, fourth or fifth quintile).

As described in the above, the haplotype block structure of the human genome has the effect that a large number of variants (markers and/or haplotypes) in linkage disequilibrium with the variant originally associated with a disease or trait may be used as surrogate markers for assessing association to the disease or trait. The number of such surrogate markers will depend on factors such as the historical recombination rate in the region, the mutational frequency in the region (i.e., the number of polymorphic sites or markers in the region), and the extent of LD (size of the LD block) in the region. These markers are usually located within the physical boundaries of the LD block or haplotype block in question as defined using the methods described herein, or by other methods known to the person skilled in the art. However, sometimes marker and haplotype association is found to extend beyond the physical boundaries of the haplotype block as defined. Such markers and/or haplotypes may in those cases be also used as surrogate markers and/or haplotypes for the markers and/or haplotypes physically residing within the haplotype block as defined. As a consequence, markers and haplotypes in LD (typically characterized by r^2 greater than 0.1, such as r^2 greater than 0.2, including r^2 greater than 0.3, also including r^2 greater than 0.4) with the markers and haplotypes of the present invention are also within the scope of the invention, even if they are physically located beyond the boundaries of the haplotype block as defined. This includes markers that are described herein (e.g., Tables 1-36; e.g., Tables 3, 10, and 21), but may also include other markers that are in strong LD (e.g., characterized by r^2 greater than 0.1 or 0.2 and/or $|D'| > 0.8$) with one or more of the markers listed in Tables 1-35, including the markers set forth in Tables 3, 10 and 21.

For the SNP markers described herein, the opposite allele to the allele found to be in excess in patients (at-risk allele) is found in decreased frequency in cardiovascular disease. These markers and haplotypes are thus protective for cardiovascular disease, i.e. they confer a decreased risk or susceptibility of individuals carrying these markers and/or haplotypes developing cardiovascular disease.

Certain variants of the present invention, including certain haplotypes comprise, in some cases, a combination of various genetic markers, e.g., SNPs and microsatellites. Detecting haplotypes can be accomplished by methods known in the art and/or described herein for

detecting sequences at polymorphic sites. Furthermore, correlation between certain haplotypes or sets of markers and disease phenotype can be verified using standard techniques. A representative example of a simple test for correlation would be a Fisher-exact test on a two by two table.

5 In specific embodiments, a marker allele or haplotype associated with cardiovascular disease (e.g., marker alleles as listed in Tables 3, 10 and 21) is one in which the marker allele or haplotype is more frequently present in an individual at risk for cardiovascular disease, (affected), compared to the frequency of its presence in a healthy individual (control), wherein the presence of the marker allele or haplotype is indicative of cardiovascular disease or
10 a susceptibility to cardiovascular disease. In other embodiments, at-risk markers in linkage disequilibrium with one or more markers found to be associated with cardiovascular disease, including coronary artery disease and in-stent restenosis (e.g., markers as listed in Tables 3, 10 and 21) are tagging markers that are more frequently present in an individual at risk for cardiovascular disease (affected), compared to the frequency of their presence in a healthy
15 individual (control), wherein the presence of the tagging markers is indicative of increased susceptibility to cardiovascular disease. In a further embodiment, at-risk markers alleles (i.e. conferring increased susceptibility) in linkage disequilibrium with one or more markers found to be associated with cardiovascular disease (e.g., marker alleles as listed in Tables 3, 10 and 21, and markers in linkage disequilibrium therewith), are markers comprising one or more allele that
20 is more frequently present in an individual at risk for cardiovascular disease, compared to the frequency of their presence in a healthy individual (control), wherein the presence of the markers is indicative of increased susceptibility to the cardiovascular disease.

Study population

25 In a general sense, the methods and kits of the invention can be utilized from samples containing nucleic acid material (DNA or RNA) from any source and from any individual. In preferred embodiments, the individual is a human individual. The individual can be an adult, child, or fetus. The nucleic acid source may be any sample comprising nucleic acid material, including biological samples, or a sample comprising nucleic acid material derived therefrom.
30 The present invention also provides for assessing markers and/or haplotypes in individuals who are members of a target population. Such a target population is in one embodiment a population or group of individuals at risk of developing the disease, based on other genetic factors, biomarkers, biophysical parameters (e.g., weight, BMD, blood pressure), or general health and/or lifestyle parameters (e.g., history of disease or related diseases, previous
35 diagnosis of disease, family history of disease).

The invention provides for embodiments that include individuals from specific age subgroups, such as those over the age of 40, over age of 45, or over age of 50, 55, 60, 65, 70, 75, 80, or 85. Other embodiments of the invention pertain to other age groups, such as

individuals aged less than 85, such as less than age 80, less than age 75, or less than age 70, 65, 60, 55, 50, 45, 40, 35, or age 30. Other embodiments relate to individuals with age at onset of the disease in any of the age ranges described in the above. It is also contemplated that a range of ages may be relevant in certain embodiments, such as age at onset at more than age 45 but less than age 60. Other age ranges are however also contemplated, including all age ranges bracketed by the age values listed in the above. The invention furthermore relates to individuals of either gender, males or females.

The Icelandic population is a Caucasian population of Northern European ancestry. A large number of studies reporting results of genetic linkage and association in the Icelandic population have been published in the last few years. Many of those studies show replication of variants, originally identified in the Icelandic population as being associating with a particular disease, in other populations (Stacey, S.N., *et al.*, *Nat Genet.* May 27 2007 (Epub ahead of print; Helgadóttir, A., *et al.*, *Science* **316**:1491-93 (2007); Steinthorsdóttir, V., *et al.*, *Nat Genet.* **39**:770-75 (2007); Gudmundsson, J., *et al.*, *Nat Genet.* **39**:631-37 (2007); Amundadóttir, L.T., *et al.*, *Nat Genet.* **38**:652-58 (2006); Grant, S.F., *et al.*, *Nat Genet.* **38**:320-23 (2006)). Thus, genetic findings in the Icelandic population have in general been replicated in other populations, including populations from Africa and Asia.

The markers of the present invention found to be associated with cardiovascular disease are believed to show similar association in other human populations. Particular embodiments comprising individual human populations are thus also contemplated and within the scope of the invention. Such embodiments relate to human subjects that are from one or more human population including, but not limited to, Caucasian populations, European populations, American populations, Eurasian populations, Asian populations, Central/South Asian populations, East Asian populations, Middle Eastern populations, African populations, Hispanic populations, and Oceanian populations. European populations include, but are not limited to, Swedish, Norwegian, Finnish, Russian, Danish, Icelandic, Irish, Kelt, English, Scottish, Dutch, Belgian, French, German, Spanish, Portugues, Italian, Polish, Bulgarian, Slavic, Serbian, Bosnian, Czech, Greek and Turkish populations. The invention furthermore in other embodiments can be practiced in specific human populations that include Bantu, Mandenk, Yoruba, San, Mbuti Pygmy, Orcadian, Adygel, Russian, Sardinian, Tuscan, Mozabite, Bedouin, Druze, Palestinian, Balochi, Brahui, Makrani, Sindhi, Pathan, Burusho, Hazara, Uygur, Kalash, Han, Dai, Daur, Hezhen, Lahu, Miao, Oroqen, She, Tujia, Tu, Xibo, Yi, Mongolian, Naxi, Cambodian, Japanese, Yakut, Melanesian, Papuan, Karitlanan, Surui, Colombian, Maya and Pima.

In one preferred embodiment, the invention relates to populations that include black African ancestry such as populations comprising persons of African descent or lineage. Black African ancestry may be determined by self reporting as African-Americans, Afro-Americans, Black Americans, being a member of the black race or being a member of the negro race. For example, African Americans or Black Americans are those persons living in North America and having origins in any of the black racial groups of Africa. In another example, self-reported

persons of black African ancestry may have at least one parent of black African ancestry or at least one grandparent of black African ancestry. In another embodiment, the invention relates to individuals of Caucasian origin.

The racial contribution in individual subjects may also be determined by genetic analysis. Genetic analysis of ancestry may be carried out using unlinked microsatellite markers such as those set out in Smith *et al.* (*Am J Hum Genet* **74**, 1001-13 (2004)).

In certain embodiments, the invention relates to markers and/or haplotypes identified in specific populations, as described in the above. The person skilled in the art will appreciate that measures of linkage disequilibrium (LD) may give different results when applied to different populations. This is due to different population history of different human populations as well as differential selective pressures that may have led to differences in LD in specific genomic regions. It is also well known to the person skilled in the art that certain markers, e.g. SNP markers, have different population frequency in different populations, or are polymorphic in one population but not in another. The person skilled in the art will however apply the methods available and as thought herein to practice the present invention in any given human population. This may include assessment of polymorphic markers in the LD region of the present invention, so as to identify those markers that give strongest association within the specific population. Thus, the at-risk variants of the present invention may reside on different haplotype background and in different frequencies in various human populations. However, utilizing methods known in the art and the markers of the present invention, the invention can be practiced in any given human population.

Utility of Genetic Testing

The person skilled in the art will appreciate and understand that the variants described herein in general do not, by themselves, provide an absolute identification of individuals who will develop a particular cardiovascular disease. The variants described herein do however indicate increased and/or decreased likelihood that individuals carrying the at-risk or protective variants of the invention will develop symptoms associated with at least one cardiovascular disease (e.g., MI, CAD, IA, AAA, restenosis, stroke PAD). This information is however extremely valuable in itself, as outlined in more detail in the below, as it can be used to, for example, initiate preventive measures at an early stage, perform regular physical and/or mental exams to monitor the progress and/or appearance of symptoms, or to schedule exams at a regular interval to identify early symptoms, so as to be able to apply treatment at an early stage.

The knowledge about a genetic variant that confers a risk of developing cardiovascular disease offers the opportunity to apply a genetic test to distinguish between individuals with increased risk of developing the disease (i.e. carriers of the at-risk variant) and those with decreased risk of developing the disease (i.e. carriers of the protective variant). The core values

of genetic testing, for individuals belonging to both of the above mentioned groups, are the possibilities of being able to diagnose disease, or a predisposition to disease, at an early stage and provide information to the clinician about prognosis/aggressiveness of disease in order to be able to apply the most appropriate treatment.

5 Individuals with a family history of cardiovascular diseases and carriers of at-risk variants may benefit from genetic testing since the knowledge of the presence of a genetic risk factor, or evidence for increased risk of being a carrier of one or more risk factors, may provide increased incentive for implementing a healthier lifestyle (*e.g.*, lose weight, increase exercise, give up smoking, reduce stress, etc.), by avoiding or minimizing known environmental risk factors for
10 cardiovascular diseases. Genetic testing of patients may furthermore give valuable information about the primary cause of the cardiovascular disease and can aid the clinician in selecting the best treatment options and medication for each individual.

 The present invention can be thus be used for risk assessment for cardiovascular disease, including diagnosing whether an individual is at risk for developing a cardiovascular disease,
15 such as Myocardial Infarction, Coronary Artery Disease, PAD, AAA, IA, stroke or restenosis. The polymorphic markers of the present invention can be used alone or in combination, as well as in combination with other factors, including known biomarkers, for risk assessment of an individual for cardiovascular disease. Many factors known to affect the predisposition of individual towards developing risk of developing Cardiovascular disease are known to the person skilled in the art
20 and can be utilized in such assessment. These include, but are not limited to, age, gender, smoking status, physical activity, waist-to-hip circumference ratio, family history of Cardiovascular Disease, previously diagnosed cardiovascular disease, obesity, diagnosis of Diabetes mellitus, stress, depression, elevated heart rate, hypertriglyceridemia, low HDL cholesterol, hypertension, elevated blood pressure, cholesterol levels, HDL cholesterol, LDL
25 cholesterol, triglycerides, apolipoprotein AI and B levels, fibrinogen, ferritin, C-reactive protein and leukotriene levels. Methods known in the art can be used for such assessment, including multivariate analyses or logistic regression, as described further herein.

METHODS

30 Methods for risk assessment cardiovascular disease are described herein and are encompassed by the invention. The invention also encompasses methods of assessing an individual for probability of response to a therapeutic agent for a cardiovascular disease, methods for predicting the effectiveness of a therapeutic agent for cardiovascular disease, nucleic acids, polypeptides and antibodies and computer-implemented functions. Kits for
35 assaying a sample from a subject to detect susceptibility to cardiovascular disease are also encompassed by the invention.

Diagnostic methods

In certain embodiments, the present invention pertains to methods of diagnosing, or aiding in the diagnosis of, cardiovascular disease (e.g., MI, CAD, IA, AAA, stroke, PAD, restenosis) or a susceptibility to cardiovascular disease, by detecting particular alleles at genetic markers that appear more frequently in subjects with at least one cardiovascular disease or subjects who are susceptible to cardiovascular disease. In a particular embodiment, the invention is a method of diagnosing a susceptibility to cardiovascular disease by detecting at least one allele of at least one polymorphic marker (e.g., the markers described herein). The present invention describes methods whereby detection of particular alleles of particular markers or haplotypes is indicative of a susceptibility to cardiovascular disease. Such prognostic or predictive assays can also be used to determine prophylactic treatment of a subject prior to the onset of symptoms of the cardiovascular disease. The present invention pertains in some embodiments to methods of clinical applications of diagnosis, e.g., diagnosis performed by a medical professional. In other embodiments, the invention pertains to methods of diagnosis or determination of a susceptibility performed by a layman. Recent technological advances in genotyping technologies, including high-throughput genotyping of SNP markers, such as Molecular Inversion Probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g., Illumina GoldenGate and Infinium assays) have made it possible for individuals to have their own genome assessed for up to one million SNPs simultaneously, at relatively little cost. The resulting genotype information, made available to the individual can be compared to information from the public literature about disease or trait risk associated with various SNPs. The diagnostic application of disease-associated alleles as described herein, can thus be performed either by the individual, through analysis of his/her genotype data, or by a health professional based on results of a clinical test. In other words, the diagnosis or assessment of a susceptibility based on genetic risk can be made by health professionals, genetic counselors or by the layman, based on information about his/her genotype and publications on various risk factors. In the present context, the term "diagnosing", "diagnose a susceptibility" and "determine a susceptibility" is meant to refer to any available diagnostic method, including those mentioned above.

In addition, in certain other embodiments, the present invention pertains to methods of diagnosing, or aiding in the diagnosis of, a decreased susceptibility to cardiovascular disease, by detecting particular genetic marker alleles or haplotypes that appear less frequently in patients diagnosed with cardiovascular disease than in individual not diagnosed with cardiovascular disease or in the general population.

As described and exemplified herein, particular marker alleles or haplotypes (e.g. the markers and haplotypes as listed in Tables 3, 10 and 21, and markers in linkage disequilibrium therewith) are associated with cardiovascular disease. In one embodiment, the marker allele or haplotype is one that confers a significant risk or susceptibility to cardiovascular disease. In another embodiment, the invention relates to a method of diagnosing a susceptibility to

cardiovascular disease in a human individual, the method comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual, or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the group consisting of the polymorphic markers listed in Table 3, 10 or 21, and markers in linkage disequilibrium therewith. In another embodiment, the invention pertains to methods of diagnosing a susceptibility to cardiovascular disease in a human individual, by screening for at least one marker allele or haplotype as listed in Table 21 or markers in linkage disequilibrium therewith. In another embodiment, the marker allele or haplotype is more frequently present in a subject having, or who is susceptible to, cardiovascular disease (affected), as compared to the frequency of its presence in a healthy subject (control, such as population controls). In certain embodiments, the significance of association of the at least one marker allele or haplotype is characterized by a p value < 0.05. In other embodiments, the significance of association is characterized by smaller p-values, such as < 0.01, <0.001, <0.0001, <0.00001, <0.000001, <0.0000001, <0.00000001 or <0.000000001.

In these embodiments, the presence of the at least one marker allele or haplotype is indicative of a susceptibility to cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD). These diagnostic methods involve detecting the presence or absence of at least one marker allele or haplotype that is associated with cardiovascular disease. The haplotypes described herein include combinations of alleles at various genetic markers (e.g., SNPs, microsatellites). The detection of the particular genetic marker alleles that make up the particular haplotypes can be performed by a variety of methods described herein and/or known in the art. For example, genetic markers can be detected at the nucleic acid level (e.g., by direct nucleotide sequencing or by other means known to the skilled in the art) or at the amino acid level if the genetic marker affects the coding sequence of a protein encoded by a cardiovascular disease, including coronary artery disease and in-stent restenosis -associated nucleic acid (e.g., by protein sequencing or by immunoassays using antibodies that recognize such a protein). The marker alleles or haplotypes of the present invention correspond to fragments of a genomic DNA sequence associated with cardiovascular disease. Such fragments encompass the DNA sequence of the polymorphic marker or haplotype in question, but may also include DNA segments in strong LD (linkage disequilibrium) with the marker or haplotype (e.g., as determined by particular values of r^2 and/or $|D'|$).

In one embodiment, diagnosis of a susceptibility to cardiovascular disease can be accomplished using hybridization methods, including, but not limited to, Southern analysis, Northern analysis, and/or *in situ* hybridizations (see Current Protocols in Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons, including all supplements). The presence of a specific marker allele can be indicated by sequence-specific hybridization of a nucleic acid probe specific for the particular allele. The presence of more than one specific marker allele or a specific haplotype can be indicated by using several sequence-specific nucleic acid probes, each being specific for a particular allele. In one embodiment, a haplotype can be indicated by a

single nucleic acid probe that is specific for the specific haplotype (i.e., hybridizes specifically to a DNA strand comprising the specific marker alleles characteristic of the haplotype). A sequence-specific probe can be directed to hybridize to genomic DNA, RNA, or cDNA. A "nucleic acid probe", as used herein, can be a DNA probe or an RNA probe that hybridizes to a complementary sequence. One of skill in the art would know how to design such a probe so that sequence specific hybridization will occur only if a particular allele is present in a genomic sequence from a test sample.

To determine or diagnose a susceptibility to cardiovascular disease, a hybridization sample is formed by contacting the test sample containing an cardiovascular disease -associated nucleic acid, such as a genomic DNA sample, with at least one nucleic acid probe. A non-limiting example of a probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe that is capable of hybridizing to mRNA or genomic DNA sequences described herein. The nucleic acid probe can be, for example, a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length that is sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. For example, the nucleic acid probe can comprise all or a portion of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), as described herein, optionally comprising at least one allele of a marker described herein, or at least one haplotype described herein, or the probe can be the complementary sequence of such a sequence. In a particular embodiment, the nucleic acid probe is a portion of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), as described herein, optionally comprising at least one allele of a marker described herein, or at least one allele of one polymorphic marker or haplotype comprising at least one polymorphic marker described herein, or the probe can be the complementary sequence of such a sequence. Other suitable probes for use in the diagnostic assays of the invention are described herein.

Hybridization can be performed by methods well known to the person skilled in the art (see, e.g., Current Protocols in Molecular Biology, Ausubel, F. et al., eds., John Wiley & Sons, including all supplements). In one embodiment, hybridization refers to specific hybridization, i.e., hybridization with no mismatches (exact hybridization). In one embodiment, the hybridization conditions for specific hybridization are high stringency.

Specific hybridization, if present, is then detected using standard methods. If specific hybridization occurs between the nucleic acid probe and the coronary artery disease and in-stent restenosis -associated nucleic acid in the test sample, then the sample contains the allele that is complementary to the nucleotide that is present in the nucleic acid probe. The process can be repeated for other markers of the present invention, or markers that make up a haplotype of the present invention, or multiple probes can be used concurrently to detect more than one marker alleles at a time. It is also possible to design a single probe containing more than one marker alleles of a particular haplotype (e.g., a probe containing alleles complementary to 2, 3, 4, 5 or all of the markers that make up a particular haplotype). Detection of the particular markers of the haplotype in the sample is indicative that the source of the sample has the particular

haplotype (e.g., a haplotype) and therefore is susceptible to cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD).

In one preferred embodiment, a method utilizing a detection oligonucleotide probe comprising a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer oligonucleotide, is employed, as described by Kuttyavin *et al.* (*Nucleic Acid Res.* **34**:e128 (2006)). The fluorescent moiety can be Gig Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template. The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.

The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.

In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.

Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

In another hybridization method, Northern analysis (see Current Protocols in Molecular Biology, Ausubel, F. *et al.*, eds., John Wiley & Sons, *supra*) is used to identify the presence of a polymorphism associated with cardiovascular disease. For Northern analysis, a test sample of RNA is obtained from the subject by appropriate means. As described herein, specific
5 hybridization of a nucleic acid probe to RNA from the subject is indicative of a particular allele complementary to the probe. For representative examples of use of nucleic acid probes, see, for example, U.S. Patent Nos. 5,288,611 and 4,851,330.

Additionally, or alternatively, a peptide nucleic acid (PNA) probe can be used in addition to, or instead of, a nucleic acid probe in the hybridization methods described herein. A PNA is a
10 DNA mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P., *et al.*, *Bioconjug. Chem.* 5:3-7 (1994)). The PNA probe can be designed to specifically hybridize to a molecule in a sample suspected of containing one or more of the marker alleles or haplotypes that are associated with cardiovascular disease.
15 Hybridization of the PNA probe is thus diagnostic for cardiovascular disease.

In one embodiment of the invention, a test sample containing genomic DNA obtained from the subject is collected and the polymerase chain reaction (PCR) is used to amplify a fragment comprising one or more markers or haplotypes of the present invention. As described herein, identification of a particular marker allele or haplotype associated with cardiovascular
20 disease, can be accomplished using a variety of methods (e.g., sequence analysis, analysis by restriction digestion, specific hybridization, single stranded conformation polymorphism assays (SSCP), electrophoretic analysis, etc.). In another embodiment, diagnosis is accomplished by expression analysis using quantitative PCR (kinetic thermal cycling). This technique can, for example, utilize commercially available technologies, such as TaqMan® (Applied Biosystems,
25 Foster City, CA). The technique can assess the presence of an alteration in the expression or composition of a polypeptide or splicing variant(s) that is encoded by a nucleic acid associated with a cardiovascular disease. Further, the expression of the variant(s) can be quantified as physically or functionally different.

In another embodiment of the methods of the invention, analysis by restriction digestion
30 can be used to detect a particular allele if the allele results in the creation or elimination of a restriction site relative to a reference sequence. A test sample containing genomic DNA is obtained from the subject. PCR can be used to amplify particular regions that are associated with cardiovascular disease (e.g. the polymorphic markers and haplotypes of Table 3, 10 or 21, and markers in linkage disequilibrium therewith) nucleic acid in the test sample from the test
35 subject. Restriction fragment length polymorphism (RFLP) analysis can be conducted, e.g., as described in Current Protocols in Molecular Biology, *supra*. The digestion pattern of the relevant DNA fragment indicates the presence or absence of the particular allele in the sample.

Sequence analysis can also be used to detect specific alleles at polymorphic sites associated with cardiovascular disease, including coronary artery disease and in-stent restenosis (e.g. the polymorphic markers and haplotypes of Table 3, 10 or 21, and markers in linkage disequilibrium therewith). Therefore, in one embodiment, determination of the presence or absence of a particular marker alleles or haplotypes comprises sequence analysis. For example, a test sample of DNA or RNA can be obtained from the test subject. PCR or other appropriate methods can be used to amplify a portion of a nucleic acid associated with cardiovascular disease, and the presence of a specific allele can then be detected directly by sequencing the polymorphic site (or multiple polymorphic sites) of the genomic DNA in the sample.

In another embodiment, arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from a subject, can be used to identify polymorphisms in a nucleic acid associated with cardiovascular disease (e.g. the polymorphic markers of Table 3, 10, and 21, and markers in linkage disequilibrium therewith). For example, an oligonucleotide array can be used. Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods that incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis methods, or by other methods known to the person skilled in the art (see, e.g., Fodor, S. *et al.*, *Science*, 251:767-773 (1991); Pirrung *et al.*, U.S. Patent No. 5,143,854 (see also published PCT Application No. WO 90/15070); and Fodor, S. *et al.*, published PCT Application No. WO 92/10092 and U.S. Patent No. 5,424,186, the entire teachings of each of which are incorporated by reference herein). Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Patent No. 5,384,261; the entire teachings of which are incorporated by reference herein. In another example, linear arrays can be utilized. Additional descriptions of use of oligonucleotide arrays for detection of polymorphisms can be found, for example, in U.S. Patent Nos. 5,858,659 and 5,837,832, the entire teachings of both of which are incorporated by reference herein.

Other methods of nucleic acid analysis that are available to those skilled in the art can be used to detect a particular allele at a polymorphic site associated with cardiovascular disease. Representative methods include, for example, direct manual sequencing (Church and Gilbert, *Proc. Natl. Acad. Sci. USA*, 81: 1991-1995 (1988); Sanger, F., *et al.*, *Proc. Natl. Acad. Sci. USA*, 74:5463-5467 (1977); Beavis, *et al.*, U.S. Patent No. 5,288,644); automated fluorescent sequencing; single-stranded conformation polymorphism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V., *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:232-236 (1989)), mobility shift analysis (Orita, M., *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:2766-2770 (1989)), restriction enzyme analysis (Flavell, R., *et al.*, *Cell*, 15:25-41 (1978); Geever, R., *et al.*, *Proc. Natl. Acad. Sci. USA*, 78:5081-5085 (1981)); heteroduplex analysis; chemical mismatch cleavage (CMC) (Cotton, R., *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:4397-4401 (1985)); RNase protection assays (Myers, R., *et al.*, *Science*, 230:1242-

1246 (1985); use of polypeptides that recognize nucleotide mismatches, such as *E. coli* mutS protein; and allele-specific PCR.

In another embodiment of the invention, diagnosis of cardiovascular disease or a susceptibility to cardiovascular disease can be made by examining expression and/or composition of a polypeptide encoded by a nucleic acid associated with cardiovascular disease in those instances where the genetic marker(s) or haplotype(s) of the present invention result in a change in the composition or expression of the polypeptide. Thus, diagnosis of a susceptibility to cardiovascular disease can be made by examining expression and/or composition of one of these polypeptides, or another polypeptide encoded by a nucleic acid associated with cardiovascular disease, in those instances where the genetic marker or haplotype of the present invention results in a change in the composition or expression of the polypeptide. The haplotypes and markers of the present invention that show association to cardiovascular disease may play a role through their effect on one or more of these nearby genes (e.g., the CDKN2A and CDKN2B genes). Possible mechanisms affecting these genes include, e.g., effects on transcription, effects on RNA splicing, alterations in relative amounts of alternative splice forms of mRNA, effects on RNA stability, effects on transport from the nucleus to cytoplasm, and effects on the efficiency and accuracy of translation.

Thus, in another embodiment, the variants (markers or haplotypes) of the invention showing association to cardiovascular disease affect the expression of a nearby gene (e.g., CDKN2A and/or CDKN2B). It is well known that regulatory element affecting gene expression may be located far away, even as far as tenths or hundreds of kilobases away, from the promoter region of a gene. By assaying for the presence or absence of at least one allele of at least one polymorphic marker of the present invention, it is thus possible to assess the expression level of such nearby genes. It is thus contemplated that the detection of the markers or haplotypes of the present invention can be used for assessing expression for one or more of the CDKN2A and/or CDKN2B genes.

A variety of methods can be used for detecting protein expression levels, including enzyme linked immunosorbent assays (ELISA), Western blots, immunoprecipitations and immunofluorescence. A test sample from a subject is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by a nucleic acid associated with cardiovascular disease. An alteration in expression of a polypeptide encoded by a nucleic acid associated with cardiovascular disease can be, for example, an alteration in the quantitative polypeptide expression (i.e., the amount of polypeptide produced). An alteration in the composition of a polypeptide encoded by a nucleic acid associated with a cardiovascular disease is an alteration in the qualitative polypeptide expression (e.g., expression of a mutant polypeptide or of a different splicing variant). In one embodiment, diagnosis of a susceptibility to cardiovascular disease is made by detecting a particular splicing variant encoded by a nucleic acid associated with cardiovascular disease, or a particular pattern of splicing variants.

Both such alterations (quantitative and qualitative) can also be present. An "alteration" in the polypeptide expression or composition (e.g., the CDKN2A and/or CDKN2B polypeptides), as used herein, refers to an alteration in expression or composition in a test sample, as compared to the expression or composition of the polypeptide in a control sample. A control sample is a sample that corresponds to the test sample (e.g., is from the same type of cells), and is from a subject who is not affected by, and/or who does not have a susceptibility to, cardiovascular disease. In one embodiment, the control sample is from a subject that does not possess a marker allele or haplotype associated with cardiovascular disease, as described herein. Similarly, the presence of one or more different splicing variants in the test sample, or the presence of significantly different amounts of different splicing variants in the test sample, as compared with the control sample, can be indicative of a susceptibility to cardiovascular disease. An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample, can be indicative of a specific allele in the instance where the allele alters a splice site relative to the reference in the control sample. Various means of examining expression or composition of a polypeptide encoded by a nucleic acid are known to the person skilled in the art and can be used, including spectroscopy, colorimetry, electrophoresis, isoelectric focusing, and immunoassays (e.g., David *et al.*, U.S. Pat. No. 4,376,110) such as immunoblotting (see, e.g., Current Protocols in Molecular Biology, particularly chapter 10, *supra*).

For example, in one embodiment, an antibody (e.g., an antibody with a detectable label) that is capable of binding to a polypeptide encoded by a nucleic acid associated with cardiovascular disease (e.g., CDKN2A and/or CDKN2B polypeptides) can be used. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g., Fv, Fab, Fab', F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a labeled secondary antibody (e.g., a fluorescently-labeled secondary antibody) and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.

In one embodiment of this method, the level or amount of polypeptide encoded by a nucleic acid associated with cardiovascular disease in a test sample is compared with the level or amount of the polypeptide in a control sample. A level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by the nucleic acid, and is diagnostic for a particular allele or haplotype responsible for causing the difference in expression. Alternatively, the composition of the polypeptide in a test sample is compared with the composition of the polypeptide in a control sample. In another embodiment, both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample.

In another embodiment, the diagnosis of a susceptibility to cardiovascular disease is made by detecting at least one marker or haplotypes of the present invention (e.g., associated alleles of the markers listed in Table 3, 10 and/or 21, and markers in linkage disequilibrium therewith), in combination with an additional protein-based, RNA-based or DNA-based assay.

5

Kits

Kits useful in the methods of the invention comprise components useful in any of the methods described herein, including for example, primers for nucleic acid amplification, hybridization probes, restriction enzymes (e.g., for RFLP analysis), allele-specific
10 oligonucleotides, antibodies that bind to an altered polypeptide encoded by a nucleic acid associated with cardiovascular disease (e.g., MI, CAD, IA, Stroke, AAA, restenosis, PAD) (e.g., antibodies that bind to a polypeptide encoded by LD Block C09 (SEQ ID NO:94), or the CDKN2A and/or CDKN2B genes or fragments thereof, e.g., a genomic segment comprising at least one polymorphic marker and/or haplotype of the present invention) or to a non-altered (native)
15 polypeptide encoded by a nucleic acid associated with a cardiovascular disease, means for amplification of a nucleic acid associated with a cardiovascular disease, means for analyzing the nucleic acid sequence of a nucleic acid associated with a cardiovascular disease, means for analyzing the amino acid sequence of a polypeptide encoded by a nucleic acid associated with a cardiovascular disease, etc. The kits can for example include necessary buffers, nucleic acid
20 primers for amplifying nucleic acids of the invention (e.g., a nucleic acid segment comprising one or more of the polymorphic markers as described herein), and reagents for allele-specific detection of the fragments amplified using such primers and necessary enzymes (e.g., DNA polymerase). Additionally, kits can provide reagents for assays to be used in combination with the methods of the present invention, e.g., reagents for use with other diagnostic assays as
25 described herein.

In one embodiment, the invention pertains to a kit for assaying a sample from a subject to detect cardiovascular disease or a susceptibility to cardiovascular disease, wherein the kit comprises reagents necessary for selectively detecting at least one allele of at least one polymorphism of the present invention in the genome of the individual. In a particular
30 embodiment, the reagents comprise at least one contiguous oligonucleotide that hybridizes to a fragment of the genome of the individual comprising at least one polymorphism of the present invention. In another embodiment, the reagents comprise at least one pair of oligonucleotides that hybridize to opposite strands of a genomic segment obtained from a subject, wherein each oligonucleotide primer pair is designed to selectively amplify a fragment of the genome of the
35 individual that includes one polymorphism, wherein the polymorphism is selected from the group consisting of the polymorphisms as listed in any of the Tables 3, 10 and 21, and polymorphic markers in linkage disequilibrium therewith. In yet another embodiment the fragment is at least 20 base pairs in size. Such oligonucleotides or nucleic acids (e.g., oligonucleotide primers) can

be designed using portions of the nucleic acids flanking polymorphisms (e.g., SNPs or microsatellites) that are indicative of a cardiovascular disease. In another embodiment, the kit comprises one or more labeled nucleic acids capable of detecting one or more specific polymorphic markers or haplotypes associated with cardiovascular disease, and reagents for
5 detection of the label. Suitable labels include, e.g., a radioisotope, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

In particular embodiments, the polymorphic marker or haplotype to be detected by the reagents of the kit comprises one or more markers, two or more markers, three or more markers, four or more markers or five or more markers selected from the group consisting of the
10 markers in Table 3, 10 and 21, and markers in linkage disequilibrium therewith. In another embodiment, the marker or haplotype to be detected comprises the markers listed in Table 3, 10 or 21. In another embodiment, the marker or haplotype to be detected comprises at least one marker from the group of markers in strong linkage disequilibrium, as defined by values of r^2 greater than 0.2, to at least one of the group of markers consisting of rs10757278, rs10116277,
15 rs1333040, D9S1814, D9S1870 and rs2383207. In yet another embodiment, the marker or haplotype to be detected comprises at least one marker selected from the group of markers consisting of rs10757278, rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, and D9S1870.

In one preferred embodiment, the kit for detecting the markers of the invention comprises a detection oligonucleotide probe, that hybridizes to a segment of template DNA containing a SNP polymorphisms to be detected, an enhancer oligonucleotide probe and an endonuclease. As explained in the above, the detection oligonucleotide probe comprises a fluorescent moiety or group at its 3' terminus and a quencher at its 5' terminus, and an enhancer
25 oligonucleotide, is employed, as described by Kutyavin *et al.* (*Nucleic Acid Res.* **34**:e128 (2006)). The fluorescent moiety can be Gig Harbor Green or Yakima Yellow, or other suitable fluorescent moieties. The detection probe is designed to hybridize to a short nucleotide sequence that includes the SNP polymorphism to be detected. Preferably, the SNP is anywhere from the terminal residue to -6 residues from the 3' end of the detection probe. The enhancer is a short
30 oligonucleotide probe which hybridizes to the DNA template 3' relative to the detection probe. The probes are designed such that a single nucleotide gap exists between the detection probe and the enhancer nucleotide probe when both are bound to the template. The gap creates a synthetic abasic site that is recognized by an endonuclease, such as Endonuclease IV. The enzyme cleaves the dye off the fully complementary detection probe, but cannot cleave a
35 detection probe containing a mismatch. Thus, by measuring the fluorescence of the released fluorescent moiety, assessment of the presence of a particular allele defined by nucleotide sequence of the detection probe can be performed.

The detection probe can be of any suitable size, although preferably the probe is relatively short. In one embodiment, the probe is from 5-100 nucleotides in length. In another

embodiment, the probe is from 10-50 nucleotides in length, and in another embodiment, the probe is from 12-30 nucleotides in length. Other lengths of the probe are possible and within scope of the skill of the average person skilled in the art.

5 In a preferred embodiment, the DNA template containing the SNP polymorphism is amplified by Polymerase Chain Reaction (PCR) prior to detection, and primers for such amplification are included in the reagent kit. In such an embodiment, the amplified DNA serves as the template for the detection probe and the enhancer probe.

10 Certain embodiments of the detection probe, the enhancer probe, and/or the primers used for amplification of the template by PCR include the use of modified bases, including modified A and modified G. The use of modified bases can be useful for adjusting the melting temperature of the nucleotide molecule (probe and/or primer) to the template DNA, for example for increasing the melting temperature in regions containing a low percentage of G or C bases, in which modified A with the capability of forming three hydrogen bonds to its complementary T can be used, or for decreasing the melting temperature in regions containing a high percentage of G or C bases, for example by using modified G bases that form only two hydrogen bonds to their complementary C base in a double stranded DNA molecule. In a preferred embodiment, modified bases are used in the design of the detection nucleotide probe. Any modified base known to the skilled person can be selected in these methods, and the selection of suitable bases is well within the scope of the skilled person based on the teachings herein and known bases available from commercial sources as known to the skilled person.

25 In one such embodiment, the presence of the marker or haplotype is indicative of a susceptibility (increased susceptibility or decreased susceptibility) to Cardiovascular disease. In another embodiment, the presence of the marker or haplotype is indicative of response to a therapeutic agent for a Cardiovascular disease. In another embodiment, the presence of the marker or haplotype is indicative of prognosis of a Cardiovascular disease. In yet another embodiment, the presence of the marker or haplotype is indicative of progress of treatment of a cardiovascular disease. Such treatment may include intervention by surgery, medication or by other means (e.g., lifestyle changes).

30 In a further aspect of the present invention, a pharmaceutical pack (kit) is provided, the pack comprising a therapeutic agent and a set of instructions for administration of the therapeutic agent to humans diagnostically tested for one or more variants of the present invention, as disclosed herein. The therapeutic agent can be a small molecule drug, an antibody, a peptide, an antisense or RNAi molecule, or other therapeutic molecules. In one embodiment, an individual identified as a carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In one such embodiment, an individual identified as a homozygous carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent. In another embodiment, an individual identified

as a non-carrier of at least one variant of the present invention is instructed to take a prescribed dose of the therapeutic agent.

In certain embodiments, the kit further comprises a set of instructions for using the reagents comprising the kit.

5

Therapeutic agents

Variants of the present invention (*e.g.*, the markers and/or haplotypes of the invention as described herein, *e.g.*, the markers listed in Table 3, 10 and 21) can be used to identify novel therapeutic targets for cardiovascular disease. For example, genes containing, or in linkage disequilibrium with, variants (markers and/or haplotypes) associated with cardiovascular disease, or their products (*e.g.*, the CDKN2A and CDKN2B genes and their gene products), as well as genes or their products that are directly or indirectly regulated by or interact with these genes or their products, can be targeted for the development of therapeutic agents to treat cardiovascular disease, or prevent or delay onset of symptoms associated with cardiovascular disease. Therapeutic agents may comprise one or more of, for example, small non-protein and non-nucleic acid molecules, proteins, peptides, protein fragments, nucleic acids (DNA, RNA), PNA (peptide nucleic acids), or their derivatives or mimetics which can modulate the function and/or levels of the target genes or their gene products.

The nucleic acids and/or variants of the invention, or nucleic acids comprising their complementary sequence, may be used as antisense constructs to control gene expression in cells, tissues or organs. The methodology associated with antisense techniques is well known to the skilled artisan, and is described and reviewed in *Antisense Drug Technology: Principles, Strategies, and Applications*, Crooke, ed., Marcel Dekker Inc., New York (2001). In general, antisense nucleic acid molecules are designed to be complementary to a region of mRNA expressed by a gene, so that the antisense molecule hybridizes to the mRNA, thus blocking translation of the mRNA into protein. Several classes of antisense oligonucleotide are known to those skilled in the art, including cleavers and blockers. The former bind to target RNA sites, activate intracellular nucleases (*e.g.*, RNaseH or RNase L), that cleave the target RNA. Blockers bind to target RNA, inhibit protein translation by steric hindrance of the ribosomes. Examples of blockers include nucleic acids, morpholino compounds, locked nucleic acids and methylphosphonates (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). Antisense oligonucleotides are useful directly as therapeutic agents, and are also useful for determining and validating gene function, for example by gene knock-out or gene knock-down experiments. Antisense technology is further described in Lavery *et al.*, *Curr. Opin. Drug Discov. Devel.* 6:561-569 (2003), Stephens *et al.*, *Curr. Opin. Mol. Ther.* 5:118-122 (2003), Kurreck, *Eur. J. Biochem.* 270:1628-44 (2003), Dias *et al.*, *Mol. Cancer Ther.* 1:347-55 (2002), Chen, *Methods Mol. Med.* 75:621-636 (2003), Wang *et al.*, *Curr. Cancer Drug Targets* 1:177-96 (2001), and Bennett, *Antisense Nucleic Acid Drug Dev.* 12:215-24 (2002)

The variants described herein can be used for the selection and design of antisense reagents that are specific for particular variants. Using information about the variants described herein, antisense oligonucleotides or other antisense molecules that specifically target mRNA molecules that contain one or more variants of the invention can be designed. In this manner, expression of mRNA molecules that contain one or more variant of the present invention (markers and/or haplotypes) can be inhibited or blocked. In one embodiment, the antisense molecules are designed to specifically bind a particular allelic form (i.e., one or several variants (alleles and/or haplotypes)) of the target nucleic acid, thereby inhibiting translation of a product originating from this specific allele or haplotype, but which do not bind other or alternate variants at the specific polymorphic sites of the target nucleic acid molecule.

As antisense molecules can be used to inactivate mRNA so as to inhibit gene expression, and thus protein expression, the molecules can be used to treat a disease or disorder, such as a cardiovascular disease. The methodology can involve cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Such mRNA regions include, for example, protein-coding regions, in particular protein-coding regions corresponding to catalytic activity, substrate and/or ligand binding sites, or other functional domains of a protein.

The phenomenon of RNA interference (RNAi) has been actively studied for the last decade, since its original discovery in *C. elegans* (Fire *et al.*, *Nature* 391:806-11 (1998)), and in recent years its potential use in treatment of human disease has been actively pursued (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)). RNA interference (RNAi), also called gene silencing, is based on using double-stranded RNA molecules (dsRNA) to turn off specific genes. In the cell, cytoplasmic double-stranded RNA molecules (dsRNA) are processed by cellular complexes into small interfering RNA (siRNA). The siRNA guide the targeting of a protein-RNA complex to specific sites on a target mRNA, leading to cleavage of the mRNA (Thompson, *Drug Discovery Today*, 7:912-917 (2002)). The siRNA molecules are typically about 20, 21, 22 or 23 nucleotides in length. Thus, one aspect of the invention relates to isolated nucleic acid molecules, and the use of those molecules for RNA interference, i.e. as small interfering RNA molecules (siRNA). In one embodiment, the isolated nucleic acid molecules are 18-26 nucleotides in length, preferably 19-25 nucleotides in length, more preferably 20-24 nucleotides in length, and more preferably 21, 22 or 23 nucleotides in length.

Another pathway for RNAi-mediated gene silencing originates in endogenously encoded primary microRNA (pri-miRNA) transcripts, which are processed in the cell to generate precursor miRNA (pre-miRNA). These miRNA molecules are exported from the nucleus to the cytoplasm, where they undergo processing to generate mature miRNA molecules (miRNA), which direct translational inhibition by recognizing target sites in the 3' untranslated regions of mRNAs, and subsequent mRNA degradation by processing P-bodies (reviewed in Kim & Rossi, *Nature Rev. Genet.* 8:173-204 (2007)).

Clinical applications of RNAi include the incorporation of synthetic siRNA duplexes, which preferably are approximately 20-23 nucleotides in size, and preferably have 3' overlaps of 2 nucleotides. Knockdown of gene expression is established by sequence-specific design for the target mRNA. Several commercial sites for optimal design and synthesis of such molecules are known to those skilled in the art.

Other applications provide longer siRNA molecules (typically 25-30 nucleotides in length, preferably about 27 nucleotides), as well as small hairpin RNAs (shRNAs; typically about 29 nucleotides in length). The latter are naturally expressed, as described in Amarzguioui *et al.* (*FEBS Lett.* 579:5974-81 (2005)). Chemically synthetic siRNAs and shRNAs are substrates for *in vivo* processing, and in some cases provide more potent gene-silencing than shorter designs (Kim *et al.*, *Nature Biotechnol.* 23:222-226 (2005); Siolas *et al.*, *Nature Biotechnol.* 23:227-231 (2005)). In general siRNAs provide for transient silencing of gene expression, because their intracellular concentration is diluted by subsequent cell divisions. By contrast, expressed shRNAs mediate long-term, stable knockdown of target transcripts, for as long as transcription of the shRNA takes place (Marques *et al.*, *Nature Biotechnol.* 23:559-565 (2006); Brummelkamp *et al.*, *Science* 296: 550-553 (2002)).

Since RNAi molecules, including siRNA, miRNA and shRNA, act in a sequence-dependent manner, the variants of the present invention (e.g., the markers and haplotypes set forth in Tables 3, 10 and 21) can be used to design RNAi reagents that recognize specific nucleic acid molecules comprising specific alleles and/or haplotypes (e.g., the alleles and/or haplotypes of the present invention), while not recognizing nucleic acid molecules comprising other alleles or haplotypes. These RNAi reagents can thus recognize and destroy the target nucleic acid molecules. As with antisense reagents, RNAi reagents can be useful as therapeutic agents (i.e., for turning off disease-associated genes or disease-associated gene variants), but may also be useful for characterizing and validating gene function (e.g., by gene knock-out or gene knock-down experiments).

Delivery of RNAi may be performed by a range of methodologies known to those skilled in the art. Methods utilizing non-viral delivery include cholesterol, stable nucleic acid-lipid particle (SNALP), heavy-chain antibody fragment (Fab), aptamers and nanoparticles. Viral delivery methods include use of lentivirus, adenovirus and adeno-associated virus. The siRNA molecules are in some embodiments chemically modified to increase their stability. This can include modifications at the 2' position of the ribose, including 2'-O-methylpurines and 2'-fluoropyrimidines, which provide resistance to Rnase activity. Other chemical modifications are possible and known to those skilled in the art.

The following references provide a further summary of RNAi, and possibilities for targeting specific genes using RNAi: Kim & Rossi, *Nat. Rev. Genet.* 8:173-184 (2007), Chen & Rajewsky, *Nat. Rev. Genet.* 8: 93-103 (2007), Reynolds, *et al.*, *Nat. Biotechnol.* 22:326-330 (2004), Chi *et al.*, *Proc. Natl. Acad. Sci. USA* 100:6343-6346 (2003), Vickers *et al.*, *J. Biol.*

Chem. 278:7108-7118 (2003), Agami, *Curr. Opin. Chem. Biol.* 6:829-834 (2002), Lavery, *et al.*, *Curr. Opin. Drug Discov. Devel.* 6:561-569 (2003), Shi, *Trends Genet.* 19:9-12 (2003), Shuey *et al.*, *Drug Discov. Today* 7:1040-46 (2002), McManus *et al.*, *Nat. Rev. Genet.* 3:737-747 (2002), Xia *et al.*, *Nat. Biotechnol.* 20:1006-10 (2002), Plasterk *et al.*, *curr. Opin. Genet. Dev.* 10:562-7 (2000), Boshier *et al.*, *Nat. Cell Biol.* 2:E31-6 (2000), and Hunter, *Curr. Biol.* 9:R440-442 (1999).

A genetic defect leading to increased predisposition or risk for development of a cardiovascular disease, or a defect causing the disease, may be corrected permanently by administering to a subject carrying the defect a nucleic acid fragment that incorporates a repair sequence that supplies the normal/wild-type nucleotide(s) at the site of the genetic defect. Such site-specific repair sequence may encompass an RNA/DNA oligonucleotide that operates to promote endogenous repair of a subject's genomic DNA. The administration of the repair sequence may be performed by an appropriate vehicle, such as a complex with polyethelenimine, encapsulated in anionic liposomes, a viral vector such as an adenovirus vector, or other pharmaceutical compositions suitable for promoting intracellular uptake of the administered nucleic acid. The genetic defect may then be overcome, since the chimeric oligonucleotides induce the incorporation of the normal sequence into the genome of the subject, leading to expression of the normal/wild-type gene product. The replacement is propagated, thus rendering a permanent repair and alleviation of the symptoms associated with the disease or condition.

The present invention provides methods for identifying compounds or agents that can be used to treat cardiovascular disease. Thus, the variants of the invention are useful as targets for the identification and/or development of therapeutic agents. In certain embodiments, such methods include assaying the ability of an agent or compound to modulate the activity and/or expression of a nucleic acid that includes at least one of the variants (markers and/or haplotypes) of the present invention, or the encoded product of the nucleic acid (e.g., one or both of the CDKN2A and CDKN2B genes). This in turn can be used to identify agents or compounds that inhibit or alter the undesired activity or expression of the encoded nucleic acid product. Assays for performing such experiments can be performed in cell-based systems or in cell-free systems, as known to the skilled person. Cell-based systems include cells naturally expressing the nucleic acid molecules of interest, or recombinant cells that have been genetically modified so as to express a certain desired nucleic acid molecule.

Variant gene expression in a patient can be assessed by expression of a variant-containing nucleic acid sequence (for example, a gene containing at least one variant of the present invention, which can be transcribed into RNA containing the at least one variant, and in turn translated into protein), or by altered expression of a normal/wild-type nucleic acid sequence due to variants affecting the level or pattern of expression of the normal transcripts, for example variants in the regulatory or control region of the gene. Assays for gene expression include direct nucleic acid assays (mRNA), assays for expressed protein levels, or assays of collateral compounds involved in a pathway, for example a signal pathway. Furthermore, the

expression of genes that are up- or down-regulated in response to the signal pathway can also be assayed. One embodiment includes operably linking a reporter gene, such as luciferase, to the regulatory region of the gene(s) of interest.

Modulators of gene expression can in one embodiment be identified when a cell is
5 contacted with a candidate compound or agent, and the expression of mRNA is determined. The expression level of mRNA in the presence of the candidate compound or agent is compared to the expression level in the absence of the compound or agent. Based on this comparison, candidate compounds or agents for treating cardiovascular disease can be identified as those modulating the gene expression of the variant gene. When expression of mRNA or the encoded
10 protein is statistically significantly greater in the presence of the candidate compound or agent than in its absence, then the candidate compound or agent is identified as a stimulator or up-regulator of expression of the nucleic acid. When nucleic acid expression or protein level is statistically significantly less in the presence of the candidate compound or agent than in its absence, then the candidate compound is identified as an inhibitor or down-regulator of the
15 nucleic acid expression.

The invention further provides methods of treatment using a compound identified through drug (compound and/or agent) screening as a gene modulator (i.e. stimulator and/or inhibitor of gene expression).

20 *Methods of assessing probability of response to therapeutic agents and methods, methods of monitoring treatment progress and methods for treating cardiovascular disease*

As is known in the art, individuals can have differential responses to a particular therapy (e.g., a therapeutic agent or therapeutic method). Pharmacogenomics addresses the issue of how genetic variations (e.g., the variants (markers and/or haplotypes) of the present invention)
25 affect drug response, due to altered drug disposition and/or abnormal or altered action of the drug. Thus, the basis of the differential response may be genetically determined in part. Clinical outcomes due to genetic variations affecting drug response may result in toxicity of the drug in certain individuals (e.g., carriers or non-carriers of the genetic variants of the present invention), or therapeutic failure of the drug. Therefore, the variants of the present invention may
30 determine the manner in which a therapeutic agent and/or method acts on the body, or the way in which the body metabolizes the therapeutic agent.

Accordingly, in one embodiment, the presence of a particular allele of a polymorphic marker, or the presence of a haplotype as described herein is indicative of a different response rate to a particular treatment modality for a cardiovascular disease. This means that a patient
35 diagnosed with cardiovascular disease, or at risk for a cardiovascular disease, and carrying a certain allele at a polymorphic or haplotype of the present invention (e.g., the at-risk alleles and/or haplotypes of the invention) would respond better to, or worse to, a specific therapeutic,

drug and/or other therapy used to treat the cardiovascular disease. Therefore, the presence or absence of the marker allele or haplotype could aid in deciding what treatment should be used for a the patient. For example, for a newly diagnosed patient, the presence of a marker or haplotype of the present invention may be assessed (*e.g.*, through testing DNA derived from a blood sample or other sample containing genomic DNA, as described herein). If the patient is positive for a marker allele or haplotype at (that is, at least one specific allele of the marker, or haplotype, is present), then the physician recommends one particular therapy (*e.g.*, one particular therapeutic agent or a combination of therapeutic agents), while if the patient is negative for the at least one allele of a marker, or a haplotype, then a different course of therapy may be recommended (which may include recommending that no immediate therapy, other than serial monitoring for progression of the disease, be performed). Thus, the patient's carrier status could be used to help determine whether a particular treatment modality should be administered. The value lies within the possibilities of being able to diagnose the disease at an early stage and provide information to the clinician about prognosis/aggressiveness of the disease in order to be able to apply the most appropriate treatment.

As one example, the application of a genetic test for restenosis can identify subjects who are at high risk of developing restenosis after coronary stent procedure. While it is know that some treatment methods for coronary artery disease, such as introducing drug-eluting stents and brachytherapy, are associated with decreased risk of in-stent restenosis, the use of these methods are restricted because of number of reasons, including economical reasons. Identification of individuals within the group of those undergoing coronary stent procedure who are carriers of genetic risk variants for in-stent restenosis will allow targeting of those individuals that would benefit most from therapy associated with decreased risk of in-stent restenosis.

The present invention also relates to methods of monitoring effectiveness of a treatment for a cardiovascular disease, including coronary artery disease, MI, stroke, PAD, IA, AAA and restenosis. This can be done based on the genotype and/or haplotype status of the markers and haplotypes of the present invention, or by monitoring expression of genes that are associated with the variants (markers and haplotypes) of the present invention (*e.g.*, CDKN2A and CDKN2B). The risk gene mRNA or the encoded polypeptide can be measured in a tissue sample (*e.g.*, a peripheral blood sample, or a biopsy sample). Expression levels and/or mRNA levels can thus be determined before and during treatment to monitor its effectiveness. Alternatively, or concomitantly, the genotype and/or haplotype status of at least one risk variant for cardiovascular disease as presented herein is determined before and during treatment to monitor its effectiveness.

The treatment modules of a cardiovascular disease to which the invention pertains includes, but is not limited to, methods of treatment for myocardial infarction or susceptibility to myocardial infarction; methods of phophylaxis therapy for myocardial infarction; methods of treatment for transient ischemic attack or stroke, or susceptibility to stroke; methods of treatment for claudication, PAD or susceptibility to PAD; methods of treatment for acute

coronary syndrome (e.g., unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)); methods for reducing risk of MI, stroke or PAD; methods for decreasing risk of a second myocardial infarction or stroke; methods of treatment for atherosclerosis, such as for patients requiring treatment (e.g., angioplasty, stents, revascularization procedure) to restore blood flow in arteries (e.g., coronary, carotid, and/or femoral arteries); methods of treatment for asymptomatic ankle/brachial index of less than 0.9; and/or methods for decreasing leukotriene synthesis (e.g., for treatment of myocardial infarction, stroke or PAD), methods for treatment of abdominal aorta aneurysm, methods for treatment of intracranial aneurysm.

Treatment of coronary artery disease and MI may be categorized as (i) preventive treatment and (ii) disease management. The main goal of the latter is to minimize damage to the heart and prevent further complications. The first line of disease management typically includes one or more of administration of oxygen, aspirin, glyceryl nitrate (nitroglycerin) and analgesia, such as morphine or related drugs. Once diagnosis of MI is made, additional therapy may include beta blockers, anticoagulation agents, including heparin and/or low molecular weight heparin, and possibly also antiplatelet agents, such as clopidogrel. Secondary prevention, i.e. the management of risk of a recurrent MI, typically includes one or more of the following: Antiplatelet drug therapy, including aspirin and/or clopidogrel, beta blocker therapy, including metoprolol and carvedilol, ACE inhibitor therapy, Statin therapy, Aldosterone antagonist therapy, including eplerenone. Further, non-therapeutic administration of food supplements such as omega-3 fatty acids may be beneficial.

New preventive therapy for cardiovascular disease, including CAD, MI and stroke, includes agents that act on the formation and/or rupture of plaques, and also includes phosphodiesterase inhibitors. Such therapeutic agents are useful in the methods of the invention, as described herein. This includes, but is not limited to, agents that target the leukotriene synthesis pathway. The leukotriene synthesis inhibitor can be any agent that inhibits or antagonizes a member of the leukotriene synthesis pathway (e.g., FLAP, 5-LO, LTC4S, LTA4H, and LTB4DH). For example, the leukotriene synthesis inhibitor can be an agent that inhibits or antagonizes FLAP polypeptide activity (e.g., a FLAP inhibitor) and/or FLAP nucleic acid expression (e.g., a FLAP nucleic acid antagonist). In another embodiment, the leukotriene synthesis inhibitor is an agent that inhibits or antagonizes polypeptide activity and/or nucleic acid expression of another member of the leukotriene biosynthetic pathway (e.g., LTC4S, LTA4H) or that increases breakdown of leukotrienes (e.g., LTB4DH). In preferred embodiments, the agent alters activity and/or nucleic acid expression of FLAP, LTA4H or of 5-LO. Preferred agents include those set forth in the Agent Table I herein. In another embodiment, preferred agents can be: 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-0591, (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, otherwise known as BAY-x-1005, 3-(3-(1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl)-2,2-dimethylpropionaldehyde oxime-0-2-acetic acid otherwise known as A-81834; or can be zileuton, atreleuton, 6-((3-fluoro-5-






(tetrahydro-4-methoxy-2H-pyran-4yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone otherwise known as ZD-2138, 1-((4-chlorophenyl)methyl)-3-((1,1dimethylethyl)thio)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-Indole-2-propanoic acid otherwise known as MK-886, 4-(3-(4-(2-Methyl-imidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide otherwise known as CJ-13610. Additional agents include those described in Penning *et al.*, *Med Chem.* 2002 45(16):3482-90, Penning, *Curr Pharm Des.* 2001, 7(3):163-79 and Penning *et al.*, *J Med Chem.* 2000 43(4):721-35. In another embodiment, the agent alters metabolism or activity of a leukotriene (*e.g.*, LTA₄, LTB₄, LTC₄, LTD₄, LTE₄, Cys LT₁, Cys LT₂), such as leukotriene antagonists or antibodies to leukotrienes, as well as agents which alter activity of a leukotriene receptor (*e.g.*, BLT₁, BLT₂, CysLTR₁, and CysLTR₂).

In other preferred embodiments, the agent alters activity and/or nucleic acid expression of LTA₄H. Preferred agents include those set forth in the Agent Table II; but also include the following agents: 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-tetrazolylpiperidine; 1-[2-[4-(4-oxazolyl)phenoxy]phenoxy]ethylpyrrolidine; 3-[methyl[3-[4-(2-thienylmethyl)phenoxy]propyl]amino]propionic acid; methyl 3-[methyl[3-[4-(2-thienylmethyl)phenoxy]propyl]amino]propionate; 3-[methyl[3-[4-(3-thienylmethyl)phenoxy]propyl]amino]propionic acid; methyl-3-[methyl[3-[4-(3-thienylmethyl)phenoxy]propyl]amino]propionate; 3-[methyl[3-[4-(4-fluorophenoxy)phenoxy]propyl]amino]propionic acid; 3-[methyl[3-[4-(4-biphenyloxy)phenoxy]propyl]amino]propionic acid; N-[3-[[3-[4-(phenylmethyl)phenoxy]propyl]methylamino]propionyl]benzenesulfonamide; 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-2-methyl-4-(1H-tetrazol-5-yl)piperidine; 1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-(1H-tetrazol-5-yl)piperidine. In another embodiment, preferred agents can be: ethyl-1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-piperidine-carboxylate, otherwise known as SC-56938; [4-[5-(3-Phenyl-propyl)thiophen-2-yl]butoxy]acetic acid, otherwise known as RP64966; (R)-S-[[4-(dimethylamino)phenyl]methyl]-N-(3-mercapto-2methyl-1-oxopropyl-L-cysteine, otherwise known as SA6541. In one preferred embodiment, the therapeutic agent is 4-[(S)-2-[4-(4-Chloro-phenoxy)-phenoxy]methyl]-pyrrolidin-1-yl]-butyramide, also known as DG-051.






The agents for treating or preventing a cardiovascular disease can be administered alone, or in combination with a statin. Statins include, but are not limited to, the agents roxuvastatin, fluvastatin, atorvastatin, lovastatin (also known as mevinolin), simvastatin, pravastatin, pitavastatin, mevastatin, crevastatin, ML-236A, ML-236B, MBV-530A and MB-530B.

All agents listed in the above and in Agent Table I and Agent Table II also include their optically pure enantiomers, salts, chemical derivatives, and analogues.

Agent Table I

	Product Name (Code)	Structure	Chemical Name	Patent Ref	Date Patent Issued/Applica tion Published	MOA
Abbott	atrelleuton (ABT-761)		(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxurea	US 5288751, US 5288743, US 5616596	2/22/94 04/01/97	5-LPO inhibitor
Abbott	A-81834		3-(3-{1,1-dimethylethylthio-5-(quinoline-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl}-2,2-dimethylpropionaldehyde oxime-O-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	FLAP inhibitor
Abbott	A-86886		3-(3-{1,1-dimethylethylthio-5-(pyridin-2-ylmethoxy)-1-(4-chloromethylphenyl)indole-2-yl}-2,2-dimethylpropionaldehyde oxime-O-2-acetic acid	WO9203132, US 5459150	3/5/1992, 10/17/95	5-LPO inhibitor
Abbott	A-93178					FLAP inhibitor
AstraZeneca				EP 623614	09/11/94	5-LPO inhibitor

Agent Table I

AstraZeneca	ZD-2138		6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-1-methyl-2(1H)-quinolinone (alternatively NH can be N-methyl)	EP 456452		5-LPO inhibitor
Bayer	BAY-X-1005		(R)-(+)-alpha-cyclopentyl 4-(2-quinolinylmethoxy)-Benzenecarboxylic acid	US 4970215 EP 344519, DE 19880531		FLAP inhibitor
Merck	MK-0591		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		FLAP inhibitor
Merck	MK-866		(3-(4-chlorobenzyl)-3-butylthio-5-isopropylindol-2-yl)2,2-dimethylpropanoic acid			5-LPO inhibitor
Merck	MK-886		1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)alpha, alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid	EP 419049, US 19890822		5-LPO inhibitor
Pfizer	CJ-13610		4-(3-(4-(2-Methylimidazol-1-yl)-phenylsulfanyl)-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			5-LPO inhibitor

Agent Table II

Target	Compound ID	Chemical Name	Patent / Reference
LTA4H Inhibitor	SC-57461A	3-[methyl[3-[4-(phenylmethyl)phenoxy]-propyl]amino]propionic acid	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139. ibid, (2002), 12, 3383-3386
LTA4H Inhibitor	SC-56938	Ethyl-1-[2-[4-(phenylmethyl)phenoxy]ethyl]-4-piperidine-carboxylate	Penning, T.D. et.al. Bioorg Med. Chem. Letters (2003), 13, 1137-1139. ibid, (2002), 12, 3383-3386. US 6,506,87 6A1
LTA4H Inhibitor	RP 64966	[4-[5-(3-Phenyl-propyl)thiophen-2-yl]butoxy]acetic acid	WO9627585
LTA4H Inhibitor	SA 6541	(R)-S-[[4-(dimethylamino)phenyl]methyl]-N-(3-mercapto-2methyl-1-oxopropyl-L-cysteine	WO9809943
LTA4H Inhibitor	SA-9499/ SA-6541	(R)-3-(4-Dimethylamino-benzylsulfanyl)-2-((R)-3-mercapto-2-methyl-propionylamino)-propionic acid	
LTB4 Receptor Antagonist	Amelubant/ BIIL-284	Carbamic acid,((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-ethyl ester	US 6,576,669
LTB4 Receptor Antagonist	BIRZ-227	5-Chloro-2-[3-(4-methoxy-phenyl)-2-pyridin-2-yl-pyrrolidin-1-yl]-benzooxazole	Journal of Organic Chemistry 1998,63:2(326-330).
LTB4 Receptor Antagonist	CP 195543	2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid	Process: WO 98/11085 1998, priority US 60/26372 1996; J. Pharmacology and Expert. Therapy, 1998, 285: 946-54
LTB4 Receptor Antagonist	Ebselen	2-Phenyl-benzo[d]isoseleazol-3-one	Journal of Cerebral Blood Flow and Metabolism 1995, July 2-6 (S162); Drugs of the Future 1995, 20:10 (1057)
LTB4 Receptor Antagonist	LTB 019; CGS-25019C	4-[5-(4-Carbamimidoyl-phenoxy)-pentyloxy]-N,N-diisopropyl-3-methoxy-benzamide maleate	ACS Meeting 1994, 207th:San Diego (MEDI 003); International Congress of the Inflammation Research Association 1994, 7th:White Haven (Abs W23)
LTB4 Receptor Antagonist	LY 210073	5-(2-Carboxy-ethyl)-6-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-9-oxo-9H-xanthene-2-carboxylic acid	J Med Chem 1993 36 (12) 1726-1734
LTB4 Receptor Antagonist	LY 213024	5-(3-carboxybenzoyl)-2-(decyloxy)benzenepropanoic acid	J Med Chem 1993 36 (12) 1726-1734

Target	Compound ID	Chemical Name	Patent / Reference
LTB4 Receptor Antagonist	LY 255283	1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone	EP 276064 B 1990, priority US 2479 1987
LTB4 Receptor Antagonist	LY 264086	7-carboxy-3-(decyloxy)-9-oxo-9H-xanthene-4-propanoic acid	US 4996230 1991, priority US 481413 1990
LTB4 Receptor Antagonist	LY 292728	7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-9H-xanthene-4-propanoic acid disodium salt	EP 743064 A 1996, priority US 443179 1995
LTB4 Receptor Antagonist	LY-293111 (VML-295)	Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-biphenyl)-4-yl)oxy)propoxy)-2-propylphenoxy)-	Proceedings of the American Society for Clinical Oncology 2002, 21:1 (Abs 343) [LY-293111 for Cancer] SCRIP World Pharmaceutical News 1997, 2272 (13) [for VML-295]
LTB4 Receptor Antagonist	ONO 4057; LB 457	(E)-2-(4-carboxybutoxy)-6-[[6-(4-methoxyphenyl)-5-hexenyl]oxy]benzenepropanoic acid	EP 405116 A 1991
LTB4 Receptor Antagonist	PF 10042	1-[5-hydroxy-5-[8-(1-hydroxy-2-phenylethyl)-2-dibenzofuranyl]-1-oxopentyl]pyrrolidine	EP 422329 B 1995, priority US 409630 1989
LTB4 Receptor Antagonist	RG-14893	8-Benzyloxy-4-[(methylphenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid	SCRIP World Pharmaceutical News 1996, 2168 (20)
LTB4 Receptor Antagonist	SB-201993	3-{6-(2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid	WO-09500487
LTB4 Receptor Antagonist	SC-52798	7-[3-(2-Cyclopropylmethyl-3-methoxy-4-thiazol-4-ylphenoxy)-propoxy]-8-propyl-chroman-2-carboxylic acid	Bioorganic and Medicinal Chemistry Letters 1994, 4:6 (811-816); Journal of Medicinal Chemistry 1995, 38:6 (858-868)
LTB4 Receptor Antagonist	SC-53228	3-{7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoylphenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid	International Congress of the Inflammation Research Association 1994, 7th:White Haven (Abs W5)
LTB4 Receptor Antagonist	WAY 121006	3-fluoro-4'-(2-quinolinylmethoxy)-[1,1'-biphenyl]-4-acetic acid	Drugs under Experimental and Clinical research 1991, 17:8 (381-387)
LTB4 Receptor Antagonist	ZD-2138	3-Amino-3-(4-methoxy-tetrahydro-pyran-4-yl)-acrylic acid 1-methyl-2-oxo-1,2-dihydro-quinolin-6-ylmethyl ester	International Symposium on Medicinal Chemistry 1994, 13th:Paris (P 197)

Alternatively, biological networks or metabolic pathways related to the markers and haplotypes of the present invention can be monitored by determining mRNA and/or polypeptide levels. This can be done for example, by monitoring expression levels or polypeptides for
5 several genes belonging to the network and/or pathway, in samples taken before and during treatment. Alternatively, metabolites belonging to the biological network or metabolic pathway can be determined before and during treatment. Effectiveness of the treatment is determined by comparing observed changes in expression levels/metabolite levels during treatment to corresponding data from healthy subjects.

10 In a further aspect, the markers of the present invention can be used to increase power and effectiveness of clinical trials. Thus, individuals who are carriers of the at-risk variants of the present invention may be more likely to respond to a particular treatment modality. In one embodiment, individuals who carry at-risk variants for gene(s) in a pathway and/or metabolic network for which a particular treatment (e.g., small molecule drug, e.g. the small molecule
15 drugs as listed in the above, e.g., the drugs listed in Agent Table I and Agent Table II) is targeting, are more likely to be responders to the treatment. In another embodiment, individuals who carry at-risk variants for a gene, which expression and/or function is altered by the at-risk variant, are more likely to be responders to a treatment modality targeting that gene, its expression or its gene product.

20 In a further aspect, the markers and haplotypes of the present invention can be used for targeting the selection of pharmaceutical agents for specific individuals. Personalized selection of treatment modalities, lifestyle changes (e.g., change in diet, exercise, weight loss program, smoking abstinence, less stressful lifestyle, etc.) or combination of the two, can be realized by the utilization of the at-risk variants of the present invention. Thus, the knowledge of an
25 individual's status for particular markers of the present invention, can be useful for selection of treatment options that target genes or gene products affected by the at-risk variants of the invention. Certain combinations of variants may be suitable for one selection of treatment options, while other gene variant combinations may target other treatment options. Such combination of variant may include one variant, two variants, three variants, or four or more
30 variants, as needed to determine with clinically reliable accuracy the selection of treatment module.

In addition to the diagnostic and therapeutic uses of the variants of the present invention, the variants (markers and haplotypes) can also be useful markers for human identification, and as such be useful in forensics, paternity testing and in biometrics. The specific
35 use of SNPs for forensic purposes is reviewed by Gill (*Int. J. Legal Med.* 114:204-10 (2001)). Genetic variations in genomic DNA between individuals can be used as genetic markers to identify individuals and to associate a biological sample with an individual. Genetic markers, including SNPs and microsatellites, can be useful to distinguish individuals. The more markers

that are analyzed, the lower the probability that the allelic combination of the markers in any given individual is the same as in an unrelated individual (assuming that the markers are unrelated, i.e. that the markers are in perfect linkage equilibrium). Thus, the variants used for these purposes are preferably unrelated, i.e. they are inherited independently. Thus, preferred
5 markers can be selected from available markers, such as the markers of the present invention, and the selected markers may comprise markers from different regions in the human genome, including markers on different chromosomes.

In certain applications, the SNPs useful for forensic testing are from degenerate codon positions (i.e., the third position in certain codons such that the variation of the SNP does not
10 affect the amino acid encoded by the codon). In other applications, such for applications for predicting phenotypic characteristics including race, ancestry or physical characteristics, it may be more useful and desirable to utilize SNPs that affect the amino acid sequence of the encoded protein. In other such embodiments, the variant (SNP or other polymorphic marker) affects the expression level of a nearby gene, thus leading to altered protein expression.

15

Computer-implemented aspects

The present invention also relates to computer-implemented applications of the polymorphic markers and haplotypes described herein to be associated with cardiovascular disease. Such applications can be useful for storing, manipulating or otherwise analyzing
20 genotype data that is useful in the methods of the invention. One example pertains to storing genotype information derived from an individual on readable media, so as to be able to provide the genotype information to a third party (e.g., the individual), or for deriving information from the genotype data, e.g., by comparing the genotype data to information about genetic risk factors contributing to increased susceptibility to cardiovascular disease, and reporting results
25 based on such comparison.

One such aspect relates to computer-readable media. In general terms, such medium has capabilities of storing (i) identifier information for at least one polymorphic marker or a haplotype; (ii) an indicator of the frequency of at least one allele of said at least one marker, or the frequency of a haplotype, in individuals with cardiovascular disease (e.g., MI; CAD, IA, AAA,
30 stroke, restenosis, PAD); and an indicator of the frequency of at least one allele of said at least one marker, or the frequency of a haplotype, in a reference population. The reference population can be a disease-free population of individuals. Alternatively, the reference population is a random sample from the general population, and is thus representative of the population at large. The frequency indicator may be a calculated frequency, a count of alleles
35 and/or haplotype copies, or normalized or otherwise manipulated values of the actual frequencies that are suitable for the particular medium.

Additional information about the individual can be stored on the medium, such as ancestry information, information about sex, physical attributes or characteristics (including height and weight), biochemical measurements (such as blood pressure, blood lipid levels, lipid levels, such as cholesterol levels), biomarkers relevant for cardiovascular disease, as described further herein, or other useful information that is desirable to store or manipulate in the context of the genotype status of a particular individual.

The invention furthermore relates to an apparatus that is suitable for determination or manipulation of genetic data useful for determining a susceptibility to cardiovascular disease in a human individual. Such an apparatus can include a computer-readable memory, a routine for manipulating data stored on the computer-readable memory, and a routine for generating an output that includes a measure of the genetic data. Such measure can include values such as allelic or haplotype frequencies, genotype counts, sex, age, phenotype information, values for odds ratio (OR) or relative risk (RR), population attributable risk (PAR), or other useful information that is either a direct statistic of the original genotype data or based on calculations based on the genetic data.

The markers and haplotypes shown herein to be associated with increased susceptibility (e.g., increased risk) of cardiovascular disease, are in certain embodiments useful for interpretation and/or analysis of genotype data. Thus in certain embodiments, an identification of an at-risk allele for a cardiovascular disease, as shown herein, or an allele at a polymorphic marker in LD with any one of the markers shown herein to be associated with cardiovascular disease, is indicative of the individual from whom the genotype data originates is at increased risk of cardiovascular disease. In one such embodiment, genotype data is generated for at least one polymorphic marker shown herein to be associated with cardiovascular disease, or a marker in linkage disequilibrium therewith. The genotype data is subsequently made available to the individual from whom the data originates, for example via a user interface accessible over the internet, together with an interpretation of the genotype data, e.g., in the form of a risk measure (such as an absolute risk (AR), risk ratio (RR) or odds ration (OR)) for the cardiovascular disease. In another embodiment, at-risk markers identified in a genotype dataset derived from an individual are assessed and results from the assessment of the risk conferred by the presence of such at-risk variants in the dataset are made available to the individual, for example via a secure web interface, or by other communication means. The results of such risk assessment can be reported in numeric form (e.g., by risk values, such as absolute risk, relative risk, and/or an odds ratio, or by a percentage increase in risk compared with a reference), by graphical means, or by other means suitable to illustrate the risk to the individual from whom the genotype data is derived. In particular embodiments, the results of risk assessment is made available to a third party, e.g., a physician, other healthcare worker or genetic counselor.

Markers useful in various aspects of the invention

The above-described applications can all be practiced with the markers and haplotypes of the invention that have in more detail been described with respect to methods of assessing susceptibility to cardiovascular disease and described in detail herein. Thus, these applications can in general be reduced to practice using any of the markers listed in Tables 1-35, and markers in linkage disequilibrium therewith. In some embodiments, the marker is selected from the markers set forth in Tables 3, 10 or 21, and markers in linkage disequilibrium therewith. In one embodiment, the markers or haplotypes are present within the genomic segment whose sequence is set forth in SEQ ID NO:94. In another embodiment, the markers and haplotypes comprise at least one marker selected from rs7041637, rs2811712, rs3218018, rs3217992, rs2069426, rs2069422, rs1333034, rs1011970, rs10116277, rs1333040, rs2383207, rs1333050, D9S1814, rs10757278, rs10757274, rs10333049, D9S1870, optionally including markers in linkage disequilibrium therewith. In one specific embodiment, linkage disequilibrium is defined by numerical values for r^2 of greater than 0.2. In another embodiment, the marker or haplotype comprises at least one marker selected from rs7041637 allele A, rs2811712 allele A, rs3218018 allele A, rs3217992 allele A, rs2069426 allele C, rs2069422 allele A, rs1333034 allele A, rs1011970 allele G, rs10116277 allele T, rs1333040 allele T, rs2383207 allele G, rs1333050 allele T, D9S1814 allele O, rs10757278 allele G, rs1333049 allele C, rs10757274 allele G, and/or D9S1870 allele X (composite allele of all alleles smaller than 2), wherein the indicated allele is indicative of increased susceptibility of the Cardiovascular disease.

Nucleic acids and polypeptides

The nucleic acids and polypeptides described herein can be used in methods and kits of the present invention. An "isolated" nucleic acid molecule, as used herein, is one that is separated from nucleic acids that normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (e.g., as in an RNA library). For example, an isolated nucleic acid of the invention can be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material can be purified to essential homogeneity, for example as determined by polyacrylamide gel electrophoresis (PAGE) or column chromatography (e.g., HPLC). An isolated nucleic acid molecule of the invention can comprise at least about 50%, at least about 80% or at least about 90% (on a molar basis) of all macromolecular species present. With regard to genomic DNA, the term "isolated" also can refer to nucleic acid molecules that are separated from the chromosome with which the genomic DNA is naturally associated. For example, the isolated nucleic acid molecule can contain less than about 250 kb,

200 kb, 150 kb, 100 kb, 75 kb, 50 kb, 25 kb, 10 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of the nucleotides that flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.

The nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated. Thus, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells or heterologous organisms, as well as partially or substantially purified DNA molecules in solution. "Isolated" nucleic acid molecules also encompass *in vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention. An isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence that is synthesized chemically or by recombinant means. Such isolated nucleotide sequences are useful, for example, in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by *in situ* hybridization with chromosomes), or for detecting expression of the gene in tissue (e.g., human tissue), such as by Northern blot analysis or other hybridization techniques.

The invention also pertains to nucleic acid molecules that hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (e.g., nucleic acid molecules that specifically hybridize to a nucleotide sequence containing a polymorphic site associated with a haplotype described herein). In one embodiment, the invention includes variants that hybridize under high stringency hybridization and wash conditions (e.g., for selective hybridization) to a nucleotide sequence that comprises the nucleotide sequence of LD Block C09 (SEQ ID NO:94) or a fragment thereof (or a nucleotide sequence comprising the complement of the nucleotide sequence of LD Block C09 as set forth in SEQ ID NO:94), wherein the nucleotide sequence comprises at least one at-risk allele of at least one polymorphic marker, or at least one haplotype, as described herein.

The percent identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions x 100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%, of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical algorithm. A non-limiting example of such a mathematical algorithm is described in Karlin, S. and Altschul, S., *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0), as described in Altschul, S. *et al.*, *Nucleic Acids Res.*, 25:3389-3402 (1997). When utilizing BLAST and Gapped

BLAST programs, the default parameters of the respective programs (e.g., NBLAST) can be used. See the website on the world wide web at ncbi.nlm.nih.gov. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (e.g., W=5 or W=20). Other examples include the algorithm of Myers and Miller, CABIOS (1989), ADVANCE and ADAM as described in Torellis, A. and Robotti, C., *Comput. Appl. Biosci.* 10:3-5 (1994); and FASTA described in Pearson, W. and Lipman, D., *Proc. Natl. Acad. Sci. USA*, 85:2444-48 (1988). In another embodiment, the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG software package (Accelrys, Cambridge, UK).

The present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleic acid that comprises, or consists of, the nucleotide sequence of LD Block C09 (SEQ ID NO:94), or a nucleotide sequence comprising, or consisting of, the complement of the nucleotide sequence of LD Block C09 (SEQ ID NO:94), wherein the nucleotide sequence comprises at least one polymorphic allele contained in the markers and haplotypes described herein. The nucleic acid fragments of the invention are at least about 15, at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200, 500, 1000, 10,000 or more nucleotides in length.

The nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein. "Probes" or "primers" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of a nucleic acid molecule. In addition to DNA and RNA, such probes and primers include polypeptide nucleic acids (PNA), as described in Nielsen, P. et al., *Science* 254:1497-1500 (1991). A probe or primer comprises a region of nucleotide sequence that hybridizes to at least about 15, typically about 20-25, and in certain embodiments about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule comprising a contiguous nucleotide sequence from LD Block C09 and comprising at least one allele of at least one polymorphic marker or at least one haplotype described herein, or the complement thereof. In particular embodiments, a probe or primer can comprise 100 or fewer nucleotides; for example, in certain embodiments from 6 to 50 nucleotides, or, for example, from 12 to 30 nucleotides. In other embodiments, the probe or primer is at least 70% identical, at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical, to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. In another embodiment, the probe or primer is capable of selectively hybridizing to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. Often, the probe or primer further comprises a label, e.g., a radioisotope, a fluorescent label, an enzyme label, an enzyme co-factor label, a magnetic label, a spin label, an epitope label.

The nucleic acid molecules of the invention, such as those described above, can be identified and isolated using standard molecular biology techniques and the sequence information provided by the nucleotide sequence of LD Block C09 (SEQ ID NO:94). See generally *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich,

Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (Eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila, P. et al., *Nucleic Acids Res.*, 19:4967-4973 (1991); Eckert, K. and Kunkel, T., *PCR Methods and Applications*, 1:17-24 (1991); PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202, the entire teachings of each of which are incorporated herein by reference.

In general, the isolated nucleic acid sequences of the invention can be used as molecular weight markers on Southern gels, and as chromosome markers that are labeled to map related gene positions. The nucleic acid sequences can also be used to compare with endogenous DNA sequences in patients to identify a susceptibility to a cardiovascular disease, and as probes, such as to hybridize and discover related DNA sequences or to subtract out known sequences from a sample (e.g., subtractive hybridization). The nucleic acid sequences can further be used to derive primers for genetic fingerprinting, to raise anti-polypeptide antibodies using immunization techniques, and/or as an antigen to raise anti-DNA antibodies or elicit immune responses.

Two polypeptides, as described herein (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least about 45-55%. In other embodiments, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when they are at least about 70-75%, at least about 80-85%, at least about 90%, at least about 95% homologous or identical, or are identical. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid molecule comprising the nucleotide sequence of LD Block C09 (SEQ ID NO:94) or a portion thereof, and further comprising at least one polymorphism as shown in Table 3, 10 or 21, wherein the encoding nucleic acid will hybridize to the nucleotide sequence of LD Block C09 (SEQ ID NO:94), under stringent conditions as more particularly described herein. In one embodiment, the polypeptide comprises all or a portion of the amino acid sequence of CDKN2A and/or CDKN2B.

Antibodies

Polyclonal antibodies and/or monoclonal antibodies that specifically bind one form of the gene product but not to the other form of the gene product are also provided. Antibodies are also provided which bind a portion of either the variant or the reference gene product that contains the polymorphic site or sites. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain antigen-binding sites that specifically bind an antigen. A molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind to a polypeptide of the invention. The term

"monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of a polypeptide of the invention. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, e.g., polypeptide of the invention or a fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein, *Nature* 256:495-497 (1975), the human B cell hybridoma technique (Kozbor *et al.*, *Immunol. Today* 4: 72 (1983)), the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology* (1994) Coligan *et al.*, (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating a monoclonal antibody to a polypeptide of the invention (see, e.g., *Current Protocols in Immunology*, *supra*; Galfre *et al.*, *Nature* 266:55052 (1977); R.H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner, *Yale J. Biol. Med.* 54:387-402 (1981)). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™* Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT

Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs *et al.*, *Bio/Technology* 9: 1370-1372 (1991); Hay *et al.*, *Hum. Antibod. Hybridomas* 3:81-85 (1992); Huse *et al.*, *Science* 246: 1275-1281 (1989); and Griffiths *et al.*, *EMBO J.* 12:725-734 (1993).

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.

In general, antibodies of the invention (e.g., a monoclonal antibody) can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. A polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells. Moreover, an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (e.g., in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. The antibody can be coupled to a detectable substance to facilitate its detection. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibodies may also be useful in pharmacogenomic analysis. In such embodiments, antibodies against variant proteins encoded by nucleic acids according to the invention, such as variant proteins that are encoded by nucleic acids that contain at least one polymorphic marker of the invention, can be used to identify individuals that require modified treatment modalities.

Antibodies can furthermore be useful for assessing expression of variant proteins in disease states, such as in active stages of a cardiovascular disease, or in an individual with a predisposition to a disease related to the function of the protein, in particular a cardiovascular disease. Examples are provided by biomarker (e.g., cardiac markers), as described further herein.. Antibodies specific for a variant protein of the present invention that is encoded by a

nucleic acid that comprises at least one polymorphic marker or haplotype as described herein (e.g., CDKN2A and/or CDKN2B)can be used to screen for the presence of the variant protein, for example to screen for a predisposition to cardiovascular disease as indicated by the presence of the variant protein.

5 Antibodies can be used in other methods. Thus, antibodies are useful as diagnostic tools for evaluating proteins, such as variant proteins of the invention, in conjunction with analysis by electrophoretic mobility, isoelectric point, tryptic or other protease digest, or for use in other physical assays known to those skilled in the art. Antibodies may also be used in tissue typing. In one such embodiment, a specific variant protein has been correlated with expression in a
10 specific tissue type, and antibodies specific for the variant protein can then be used to identify the specific tissue type.

 Subcellular localization of proteins, including variant proteins, can also be determined using antibodies, and can be applied to assess aberrant subcellular localization of the protein in cells in various tissues. Such use can be applied in genetic testing, but also in monitoring a
15 particular treatment modality. In the case where treatment is aimed at correcting the expression level or presence of the variant protein or aberrant tissue distribution or developmental expression of the variant protein, antibodies specific for the variant protein or fragments thereof can be used to monitor therapeutic efficacy.

 Antibodies are further useful for inhibiting variant protein function (e.g., CDKN2A and/or
20 CDKN2B), for example by blocking the binding of a variant protein to a binding molecule or partner. Such uses can also be applied in a therapeutic context in which treatment involves inhibiting a variant protein's function. An antibody can be for example be used to block or competitively inhibit binding, thereby modulating (i.e., agonizing or antagonizing) the activity of the protein. Antibodies can be prepared against specific protein fragments containing sites
25 required for specific function or against an intact protein that is associated with a cell or cell membrane. For administration *in vivo*, an antibody may be linked with an additional therapeutic payload, such as radionuclide, an enzyme, an immunogenic epitope, or a cytotoxic agent, including bacterial toxins (diphtheria or plant toxins, such as ricin). The *in vivo* half-life of an antibody or a fragment thereof may be increased by pegylation through conjugation to
30 polyethylene glycol.

 The present invention further relates to kits for using antibodies in the methods described herein. This includes, but is not limited to, kits for detecting the presence of a variant protein in a test sample. One preferred embodiment comprises antibodies such as a labelled or labelable antibody and a compound or agent for detecting variant proteins in a biological sample, means
35 for determining the amount or the presence and/or absence of variant protein in the sample, and means for comparing the amount of variant protein in the sample with a standard, as well as instructions for use of the kit.

 The present invention will now be exemplified by the following non-limiting examples.

EXEMPLIFICATION

The following contains description of the identification of susceptibility factors found to be associated with coronary artery disease and in-stent restenosis through single-point analysis of SNP markers and microsatellite markers.

METHODS

The study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee.

Icelandic coronary artery disease and in-stent restenosis cohort

The association between markers in LD block C09 to coronary artery disease was originally discovered as an association between the markers and myocardial infarction, which is the most feared complication of coronary artery disease (subphenotype of coronary artery disease).

Over the last eight years individuals who have suffered an MI we have been recruited through cardiovascular disease (CVD) genetic programs at deCODE. Currently blood samples have been collected from 2525 MI patients. The individuals who had suffered an MI were identified from a registry of over 10,000 individuals who: a) had an MI before the age of 75 in Iceland in the years 1981 to 2002 and satisfy the MONICA criteria (*J Clin Epidemiol* **41**, 105-14 (1988)); b) participated in a large prospective epidemiology study (1) done by the Icelandic Heart Association (IHA) over the past 30 years and had MI prior to 1981; c) had MI discharge diagnosis from the major hospitals in Reykjavik in the years 2003 and 2004. MI diagnoses of all individuals in the registry follow strict diagnostic rules based on signs, symptoms, electrocardiograms, cardiac enzymes and necropsy findings (2). The patients were contacted through collaborating physicians in the CVD genetic programs at deCODE. Most of the participants in the study visited the IHA and had their blood drawn, although participants who lived outside the Reykjavik area visited their local health care center.

Additional subjects with coronary artery disease, but are without known history of myocardial infarction, are identified from a list of those who have undergone coronary stent procedure in the major hospitals in Reykjavik in the years 1993 and 2003.

For over 700 subjects on this list, information on in-stent restenosis is available, including subjects with variable degree of restenosis (0-100% in-stent restenosis). A confirmed proband

with restenosis is a subject who has 50% in-stent stenosis or more as determined by coronary angiography read by an intervention cardio/radiologist.

The controls used for the study were recruited as a part of various genetic programs at deCODE. The medical history for the controls were unknown unless if the control subjects also had participated in any of the CVD genetic programs (i.e. MI, stroke, peripheral vascular disease, type II diabetes, obesity, familial combined hyperlipidemia, coronary restenosis, and hypertension genetic programs). Individuals with known MI, stroke, peripheral vascular or coronary artery disease were excluded as controls.

Subjects from the United States

Cohort from Philadelphia

The study participants from Philadelphia were enrolled at the University of Pennsylvania Medical Center through the PENN CATH study program which studies the association of biochemical and genetic factors to coronary artery disease (CAD) in subjects undergoing cardiac catheterization. A total of 3850 subjects have participated. For the purpose of the current study we selected from the PENN CATH study individuals diagnosed with one of the following coronary artery disease: MI based on criteria for acute MI in terms of elevations of cardiac enzymes and electrocardiographic changes, or a self-reported history of MI, history of coronary artery bypass surgery (CABG) or percutaneous, transluminal coronary angioplasty (PTCA). To use as controls we selected individuals who were without significant luminal stenosis on coronary angiography (luminal stenosis less than 50%). Ethnicity information was self-reported.

The University of Pennsylvania Institutional Review Board approved the study and all subjects provided written informed consent.

Cohort from Cleveland

The study participants were enrolled at the Cleveland Clinic Heart Center through the Genebank program, which is a registry of data in conjunction with biological samples for individuals undergoing coronary catheterization. The diagnostic criteria for MI were based on at least two of the following: prolonged chest pain, ECG patterns consistent with acute MI or significant elevation of cardiac enzymes. Subjects from the Genebank registry who were without significant luminal stenosis (<50% stenosis), as assessed with coronary angiography, and were without previous history of CAD, were selected as controls for the current study.

This study was approved by the Cleveland Clinic Foundation Institutional Review Board on Human Subjects and all subjects gave written informed consent.

Cohort from Atlanta

5 The study participants were enrolled at the Emory University Hospital, the Emory Clinic and Grady Memorial Hospitals through its Emory Genebank study and Clinical Registry in Neurology (CRIN). The Emory Genebank studies the association of biochemical and genetic factors with CAD in subjects undergoing cardiac catheterization. For the purpose of the current study those subjects who had a self-reported history of MI, CABG, or PTCA, were selected and
10 used as a patient group. Control subjects were selected from a group of individuals with non-vascular neurological diseases (mainly Parkinson's and Alzheimer's diseases) recruited from CRIN, their spouses, unrelated friends and community volunteers. These subjects were matched for age, and ethnicity to the patient population. Controls were excluded if they had a known history of MI or coronary artery disease. All subjects provided written informed consent.
15 Information on ethnicity was self-reported.

Genotyping

 A genome-wide scan of 1570 Icelandic individuals diagnosed with myocardial infarction (MI) and 7088 population controls was performed using Infinium HumanHap300 SNP chips from
20 Illumina for assaying approximately 317,000 single nucleotide polymorphisms (SNPs) on a single chip (Illumina, San Diego, CA, USA). SNP genotyping for replication in other case-control cohorts was carried using the Centaurus platform (Nanogen).

Statistical Methods for Association Analysis

25 To test individual markers for association to disease phenotypes such as coronary artery disease or myocardial infarction, we use a likelihood ratio test to calculate a two-sided P-value for each allele of the markers. We calculate relative risk (RR) and population attributable risk (PAR) assuming a multiplicative model (C. T. Falk, P. Rubinstein, *Ann Hum Genet* 51 (Pt 3), 227 (1987); J. D. Terwilliger, J. Ott, *Hum Hered* 42, 337 (1992)). To elucidate the linkage
30 disequilibrium between markers in the region we used the CEPH Caucasian HapMap data. We calculated LD between pairs of SNPs using the standard definition of D' (R. C. Lewontin, *Genetics* 50, 757 (1964)) and for the correlation coefficient r^2 (W. G. Hill, A. Robertson, *Genetics* 60, 615 (Nov, 1968). For the Icelandic cohort, to take into account that some of the individuals are related to each other, we obtained the null statistic of the test statistic either by simulating
35 genotypes through the Icelandic genealogy or from the test statistic for all the 300,000 tested

for association in the initial genome-wide association scan (citation). Model-free estimates of the genotype relative risk are generated as follows: RR of genotype G_1 compared to genotype G_0 was estimated by $[n(G_1)/n(G_0)]/[m(G_1)/m(G_0)]$ where n and m denote genotype counts in patients and controls respectively. Results from different cohorts were combined using a Mantel-Hanzenel
5 model (citation) where cohorts are allowed to have different population frequencies for the alleles/genotypes but assume to have common relative risks.

We use multiple regression to test for association between markers and quantitative traits, such as age of onset of MI in the cases, where the number of copies of the at-risk variant carried by an individual is taken as explanatory variable and the quantitative trait as the
10 response variable. The association is adjusted for age and gender, where appropriate, by including corresponding terms in the regression analysis as explanatory variables.

Correction for relatedness of the subjects and Genomic Control

Some of the individuals in both the Icelandic patient and control groups are related to
15 each other, causing the chi-square test statistic to have a mean >1 and median >0.675 (Devlin, B & Roeder, K., *Biometrics* **55**, 997 (1999)). We estimated the inflation factor for the genome-wide association by calculating the average of the 305,953 chi-square statistics, which was a method of genomic control (Devlin, B & Roeder, K., *Biometrics* **55**, 997 (1999)) to adjust for both relatedness and potential population stratification. The inflation factor was estimated as
20 1.129 and the results presented from the genome-wide association are based on adjusting the chi-square statistics by dividing each of them by 1.129. For the Icelandic replication cohort and the combined Icelandic replication and discovery cohort, we used a previously described procedure where we simulated genotypes through the genealogy of 708,683 Icelanders to estimate the adjustment factor (S9). The corresponding adjustment factors were 1.092 and
25 1.029, respectively.

PCR screening of cDNA libraries

cDNA libraries were constructed from whole blood (pool of 90 individuals), EBV-transformed human lymphoblastoid cells (pool of 90 individuals), human cardiac myocyte cells
30 (Sciencell, Cat.no. 6200), human aortic smooth muscle cells (Sciencell, Cat.no. 6110), human cardiac fibroblast ventricular cells (Sciencell Cat.no. 6310) and human primary umbilical vein endothelial cells (HUVEC) (pool of 4 individuals). Total RNA was isolated using the RNeasy RNA isolation kit (Qiagen, Cat.no. 75144), the RNeasy RNA isolation from whole blood kit (Qiagen, Cat.no. 52304) or the mirVana RNA isolation kit, using the total RNA isolation procedure (Ambion
35 Inc. Cat.no. 1560) according to manufacturer's recommendations. cDNA libraries were prepared at deCODE using the High Capacity cDNA Archive Kit with random primers (Applied Biosystems PN 4322171). In addition to the libraries above, two commercial cDNA libraries from whole heart (Clontech-639304) and aorta (Clontech-639325) were screened.

PCR screening was carried out using the Advantage2® Polymerase mix (Clontech cat.no. 639202) according to manufacturer's instructions with primers from Operon Biotechnologies. The PCR reactions were carried out in 10 µl volume at a final concentration of 3.5 µM of forward and reverse primers, 2 mM dNTP, 1x Advantage 2 PCR buffer, 0.2 µl of Advantage enzyme and 0.5 µl of cDNA library. (See **Table 23**). Expression was detected for all of the ESTs in several of the libraries tested (**Table 24**). None of the ESTs have an open reading frame larger than 77 bp. Many of them overlap with a recently reported antisense non-coding RNA whose expression has been shown to cocluster with p14/ARF (Pasmant, E., *et al.*, *Cancer Res* **67**, 3963 (2007)).

10 *Sequencing of CDKN2A and CDKN2B*

PCR amplifications and sequencing reactions were set up on Zymark SciClone ALH300 robotic workstations and amplified on MJR Tetrads. PCR products were verified for correct length by agarose gel electrophoresis and purified using AMPure (Agencourt Bioscience). Purified products were sequenced using an ABI PRISM Fluorescent Dye Terminator system, repurified using CleanSEQ (Agencourt), and resolved on Applied Biosystems 3730 capillary sequencers. SNP calling from primary sequence data was carried out using deCODE Genetics Sequence Miner software. All *CDKN2A* and *CDKN2B* variants identified by the automated systems were confirmed by manual inspection of primary signal traces. Samples from 96 early onset MI patients were sequenced using primers indicated in **Table 25** and a list of the SNPs identified is provided in **Table 26**.

Surveying for candidate regulatory variants in the candidate region

The University of California Santa Cruz genome browser (genome.ucsc.edu) was used to extract positions of SNPs and conserved TF binding sites for a 600 kb surrounding the MI region (hg release 17, chromosome 9, bases 21800000 to 22400000). The two tables were cross referenced with Python scripts and SNPs that resided in binding sites were interrogated for LD with rs1333040 in the CEU sample of Hapmap (release 22). The analyses were implemented for release 18 of the human genome, and the results converted to hg 17 coordinates.

This bioinformatic analysis of 600 kb surrounding the MI region yielded 16 SNPs which coincide with conserved binding sites for transcription factors (**Table 27**). Lack of LD to SNPs tagging the MI haplotype enabled exclusion of a half of the 16 SNPs from this candidate list. The remaining polymorphisms could impact gene function by altering conserved TF binding sites. In parallel we looked for correlation between SNPs located in conserved blocks (based on Multiz alignments available through the UCSC genome browser, release hg 18) and the MI haplotype tagging SNPs. While about half of the 74 SNPs are represented in HapMap, we found none that were highly correlated with the MI haplotype (data not shown). In sum, these analyses do not identify particular SNPs as putative regulatory variants on the MI haplotypes. Note of caution, the analysis will only detect a proportion of the functional candidates in the region because; i) the MI haplotypes have not been sequenced fully, ii) several candidate SNPs are not typed in

Hapmap, hence it is unknown whether they sit on the risk conferring haplotypes. In addition, it is a realistic possibility that polymorphisms in less conserved regions are the functional MI variants.

Example 1.

5 *Genome-wide association study*

We successfully genotyped 1570 Icelandic myocardial infarction patients and 7088 population control individuals without known history of coronary artery disease (Cohort A) using the Illumina 330K chip. We performed a genome-wide scan for association to MI, testing individually each of the 309,091 SNPs that was successfully genotyped. Three markers
 10 (rs10116277, rs1333040, rs2383207), all located in a single LD block (denoted herein as LD block C09) on chromosome 9p show strong association to MI (see Figure 1 and Table 1a). All three markers are strongly correlated (Table 2) and the population frequency of the at-risk variants range from 42% to 49%, and the corresponding relative risk is approximately 1.2. The risk alleles of the same three markers also showed a significant correlation to lower age at onset
 15 within the MI patient – individuals carrying the at-risk variant are at significant risk of developing MI at a younger age than individuals who are non-carriers of the at-risk allele (Table 8a).

The LD-block LD block C09 containing the three associated marker is flanked and defined by two recombination hot-spots – one at approximately 21,920,000bp in Build 34, the other approximately 22,150,000bp on chromosome 9 (*Nature* **437**, 1299-1320 (27 October 2005))).
 20 Investigating other genetic markers in LD block C09, we identified two micro-satellite markers, D9S1870 and D9S1814, that are strongly correlated with the at-risk alleles of the markers rs10116277, rs1333040, and rs2383207. Table 1b shows the association of each of the alleles of the microsatellite markers to MI in the same cohort of MI patients and controls that was used in the genome-wide association scan. For marker D9S1814 the associated allele was allele 0,
 25 however for D9S1870 multiple alleles (alleles -4, -2 and 0) showed increased risk of MI. By investigating the correlation between the different alleles of D9S1870 to the at-risk alleles of the markers rs10116277, rs1333040 and rs2383207, observed that by pooling together all alleles of D9S1870 shorter than 2 (alleles -6, -4, -2 and 0 respectively), the composite allele, denoted X, was strongly correlated to the original at-risk alleles of the SNP (**Table 2**). Composite allele X of
 30 D9S1870 and allele 0 of D9S1814 show similar association to MI as the at-risk alleles of rs10116277, rs1333040 and rs2383207 (**Table 1c**) and all five at-risk alleles are highly correlated (**Table 2**).

Further investigation of all SNPs in the HapMap v9 CEU dataset that are located in the chromosomal region defined by LD block C09 identified further 88 markers that are strongly
 35 correlated with the at-risk allele of at least one of the five markers rs10116277, rs1333040, rs2383207, D9S1814 and D9S1870 (**Table 3**) and hence those markers could also be used as surrogate markers to tag the observed association to MI in LD block C09.

We genotyped the micro-satellite marker D9S1870 in a large cohort of over 70,000 Icelanders that included, among others, 668 additional MI cases and 58,643 additional controls without known history of coronary artery disease (Cohort B). In addition we typed the microsatellite D9S1870 in three replication cohorts from US including; 549 MI patients and 606 controls from Cleveland; 580 MI cases and 404 controls from UPenn; and 400 MI cases and 477 controls from Emory. All individuals in the US cohorts are of Caucasian origin. We tested the composite allele X for association to MI in all four cohorts (**Table 4a and b**), and all but one (Cleveland) showed significant association. Combining the results from the four replication cohorts (**Table 4c**) yielded a combined P-value = 2.65×10^{-8} . Combined with the original Icelandic cohort used in the genome-wide association (Cohort A) the P-value is 1.44×10^{-12} and, assuming a multiplicative model, each allele X confers an estimated relative risk (RR) of 1.214 [95%CI:1.151-1.281] per copy carried, compare with the risk for non-carriers. The corresponding combined population attributable risk (PAR) is 17.1%.

If we investigate separately the risk conferred for individuals heterozygous for the risk allele X and individuals homozygous for X, relative to individuals that do not carry X (**Table 7a**), the estimated genotype relative risk (GRR) for heterozygous individuals is 1.204 [CI:1.094-1.324] and for homozygous individuals GRR is 1.507 [CI:1.360-1.670]. This is consistent with the multiplicative model, i.e an additive contribution of the allele X to the risk of MI.

We further investigated the correlation of the risk allele X to age of onset of MI in all four cohorts. Restricting the analysis to early-onset MI cases, defined as a MI event before the age of 50 for males and before the age of 60 for females, the relative risk for the cohorts combined increases to 1.331 [CI:1.223-1.449; $P = 3.96 \times 10^{-11}$; PAR = 24.7%] compared to 1.214 for all MI cases (**Table 6c**). Correspondingly the genotype relative risk increases to 1.314 [CI:1.105-1.562] and 1.790 [CI:1.517-2.113] for heterozygous and homozygous carriers of allele X respectively (**Table 7b**). Alternatively, we tested using multiple regression the correlation between the number of copies of X carried by individuals in the MI case group and the age of onset of MI (**Table 8b**). Combining results from all four cohorts, we observed that the mean age of onset decreased by 0.95 year [SE=0.25] for each copy of X carried by the MI individuals ($P = 0.000099$).

Among individuals typed for the marker D9S1870 in the Icelandic and the Emory cohort are individuals that have undergone percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), both indicative of severe coronary artery disease (CAD). We tested if those individuals also had an increased frequency of the risk allele X compared to controls, speculating that the variant might predispose individuals to a more general coronary artery disease than just MI (**Table 5a and c**). In both cohorts we observed similarly increased risk for PTCA and CABG as for MI, if not stronger, that was very significant in the Icelandic cohort, although for the Emory cohort only the association to PTCA was significant. It should be noted, however, that the number of individuals with PTCA and CABG in the Emory

cohort is small. This association remained in the Icelandic cohort even after removing known MI cases from the PTCA and CABG groups (**Table 5b**).

In addition, in the Icelandic cohort we investigated the association to other diseases related to coronary artery disease, such as peripheral artery disease (PAD) and stroke phenotypes such as infarct or transient ischemic attack (TIA). For 1661 PAD cases we observed a very significant association, $P = 5.36 \times 10^{-5}$ and $RR = 1.154$ [CI:1.074-1.239] (**Table 5a**) - this association remained significant after removing MI cases from the PAD cohort in the analysis although the effect was somewhat weaker (**Table 5b**). For 1678 individuals with infarct or TIA we did not observe significant association to X, however, for individuals diagnosed with large vessel diseases (LVD) - the stroke sub-phenotype that is most closely related to coronary artery disease - we observed an increased risk, $RR = 1.120$ or 1.172 if we include or exclude MI cases respectively (**Table 5a and b**). There are however only 197 individuals in the Icelandic cohort diagnosed with LVD and this association is not statistically significant.

We investigated the frequency of the risk variant X of marker D9S1870 in a group of 454 Icelandic individuals for which we had information on in-stent restenosis and that are genotyped for the variant. The cohort was divided into individuals with severe in-stent restenosis (50% or greater) and individuals with mild in-stent restenosis (less than 50%). As all those individuals have undergone PTCA, and hence have coronary artery disease, both groups have significantly higher frequency of the variant X than is observed in controls (Table 9a). However, the frequency in the group of individuals with severe restenosis is higher than in the group with mild restenosis, $RR = 1.067$ [CI:0.827-1.376], and although this difference is not significant (**Table 9b**), this suggests that the variant could be indicative of the severity of in-stent restenosis in coronary artery disease patients that have undergone PT

Example 2.

A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction

Coronary artery disease (CAD), including acute myocardial infarction (MI), is the leading cause of death worldwide (Thom, T., *et al.*, *Circulation* **113**:e85 (2006)). Identification of the underlying genetic architecture of heart disease may provide improved risk assessment and better measures for prevention and treatment.

To this end we conducted a genome-wide association study on Icelandic patients with MI, using the Illumina Hap300 chip. After quality filtering, 305,953 SNPs were tested for association to MI in a sample of 1607 cases, with age at onset before 70 in males and 75 in females, and 6728 controls without a history of CAD (Helgadottir, A., *et al.*, *Science* **316**:1491 (2007)). The results were adjusted for relatedness between individuals and potential population stratification using a method of genomic control (3). Although none of the SNPs were significant after adjusting for the number of tests performed more signals bordering on significance were

observed than expected by chance. Hence, we further explored the SNPs that were closest to genome wide significance.

The strongest association to MI was observed with three correlated SNPs, rs1333040, rs2383207 and rs10116277, each with odds ratio (OR) around 1.22 for the risk allele and P of approximately 1×10^{-6} (**Table 15**). All three SNPs are located within the linkage disequilibrium (LD) block on chromosome 9p21 denoted herein as LD block C09 (Fig. 1). Apart from these three SNPs, eleven other SNPs in the same LD block showed nominally significant association to MI. The associations to these SNPs tended to become weaker after accounting for the association to the three SNPs mentioned above (**Table 15**). After adjustment, a few remained nominally significant ($P < 0.05$), but none had a $P < 0.01$.

To replicate the observed associations we genotyped the three SNPs, rs1333040, rs2383207 and rs10116277, in an additional 665 Icelandic MI cases and 3533 controls and in three case-control sample sets of European descent from three cities from the United States: Philadelphia, Atlanta, and Durham (2). For consistency we used the same age at onset criteria in the association analysis as for the discovery group. The association to MI was replicated with significance in all four groups (**Table 16**). When the replication sets were combined using a Mantel-Haenszel model (Mantel, N. & Haenszel, *J. Natl. Cancer Inst.* **22**:719 (1959)), all three SNPs showed highly significant association to MI ($P < 1 \times 10^{-8}$), with ORs comparable to those observed in the Icelandic discovery samples. When all groups were combined, rs2383207 showed the most significant association ($P = 2.0 \times 10^{-16}$), with an OR of 1.25 (95% CI 1.18-1.31) for the risk allele G. It is noted that rs2383207 and rs10116277 are highly correlated ($r^2 = 0.90$) and their effects could not be reliably distinguished from each other in these data. The SNP rs1333040 is also substantially correlated with rs2383207 and rs10116277 ($r^2 = 0.57$ and 0.67 respectively). In an attempt to refine this association signal, we identified the SNPs that are substantially correlated with rs2383207 ($r^2 > 0.5$) based on the Hapmap CEU data and are not part of the Illumina Hap300 chip. Among the 36 such SNPs, we selected eight to be genotyped. Each of the 36 SNPs was either one of the eight or it had a very good surrogate among them ($r^2 > 0.90$) (**Table 21**). With data from all case-control groups combined, allele G of the refinement SNP rs10757278 showed the strongest association to the disease (OR = 1.28, $P = 1.2 \times 10^{-20}$; **Tables 12 and 16**). Furthermore, while rs2383207 was no longer significant after adjusting for rs10757278 ($P = 0.25$), rs10757278 remained significant with adjustment for rs2383207 ($P = 2.0 \times 10^{-5}$). Among the SNPs in this region that showed very significant association to the disease when tested individually, none was significant after adjustment for rs10757278 with the exception of the refinement SNP rs13330406, which was marginally significant ($P = 0.044$) with adjustment (**Table 22**). Henceforth, for simplicity of presentation, we focus on the most significant SNP rs10757278 in the main text but additional results for other SNPs in the region are provided **Tables 16 to 20**.

To investigate the mode of inheritance in more detail, we computed genotype specific ORs for rs10757278. With results from all groups combined, relative to non-carriers, the ORs for

heterozygous and homozygous carriers of the risk allele G were 1.26 and 1.64, respectively (**Table 13**). Assuming a frequency of 45.3% for the allele, the average of the frequencies in Iceland and the US, the corresponding PAR is 21%.

Because the impact of genetic factors on CAD has been shown to be greater at early ages (5) we investigated the correlation of allele G of rs10757278 to age at onset of MI. Note that in this analysis we used all cases with a known age at onset including those who had onset after the age of 70 or 75 for males and females, respectively. This added a total of 973 cases to the study groups compared to what was used in the case-control analyses. Regressing the age at onset on the number of risk alleles showed that, for each copy of the risk allele, the age at onset of MI was on average reduced by approximately one year ($P = 2.9 \times 10^{-7}$) (**Table 18**). Alternatively, restricting the case-control analysis to early onset MI, defined as an MI before the age of 50 for males and before the age of 60 for females, the allelic OR for rs10757278 G in all groups combined increased to 1.42 (95% CI 1.31 - 1.53) (**Table 19**). Relative to non-carriers, genotype specific OR for early onset MI is 1.49 and 2.02 for heterozygous and homozygous carriers of the risk allele, respectively (**Table 13**).

Having established that allele G of rs10757278 is associated to MI, we explored its impact on the broader phenotype of CAD (**Table 14**). To eliminate bias that could have arisen from the selection of the most significant variants in the initial genome-wide study, the cases and controls from the Icelandic discovery group (Iceland A) were not included here. We do note that if the latter were included, there would be little change to the estimated effects, but the results would become more significant due to the larger sample sizes. Also, the group from Durham did not have CAD cases without MI. As expected, rs10757278 was associated with high significance to CAD ($OR = 1.29$, $P = 3.6 \times 10^{-14}$ for the groups combined). After removal of MI cases from the analyses, the associations remained significant for the groups from Iceland and Atlanta, but not in the Philadelphia group. Combining results from the three groups gave an OR of 1.24 ($P = 0.000011$).

The variants on chromosome 9q21 associated to MI are located in an LD block that contains the *CDKN2A* and *CDKN2B* genes. The proteins encoded by these genes, called p16^{INK4a}, ARF and p15^{INK4b} have a critical role in regulating cell proliferation, cell aging/senescence, and apoptosis in many cell types (Kim, W.Y. & Sharpless, N.E. *Cell* **127**:265 (2006)). These are all important features of atherogenesis, the underlying cause of MI and CAD (Lusis, A.J. *Nature* **407**:233 (2000); Minamino, T. & Komuro, I. *Circ Res* **100**:15 (2007)). Sequencing of 93 early onset MI patients across exons, exon-intron junctions, and regulatory regions of *CDKN2A* and *CDKN2B* did not reveal obvious candidates for functional variants or other variants that could account for the observed association to rs10757278 (**Tables 25 and 26**). In addition to *CDKN2A* and *CDKN2B* genes, the LD block contains two exons of the mRNA transcript AF109294, a hypothetical methylthioadenosine phosphorylase fusion protein mRNA and several ESTs that are expressed in various tissues (Helgadóttir, A., et al., *Science* **316**:1491 (2007)). The functional relevance of the variants of this genomic region to MI/CAD remains to be elucidated.

In summary, we have shown that a common genetic variant located in the vicinity of the tumor suppressor genes *CDKN2A* and *CDKN2B* on chromosome 9p21 associate to MI. This is the first common variant discovered to consistently confer substantial risk ($OR > 1.20$) of MI in multiple case-control groups of European descent. Due to its high frequency, the population attributable risk of the variant is approximately 21% for MI in general and approximately 31% for early onset cases, which is substantial from a public health point of view. However, as the relative risks are not extremely high, it explains only a small fraction of the familial clustering of the disease and would not generate large linkage scores. Hence, others susceptibility variants remain to be identified and some could be located in candidate regions identified by genome-wide linkage scans (Zintzaras, E. & Kitsios, G., *J Hum Genet* **51**:1015 (2006); Wang Q., *et al.*, *Am J Hum Genet* **74**:262 (2004); Samani, N.J., *et al.*, *Am J Hum Genet* **77**:1011 (2005)). There is evidence supporting that the variant identified here could increase the risk of CAD in general in addition to their impact on MI, an observation that warrants further investigation. The mechanism whereby the genetic variants exert their effects in the pathogenesis of MI remains to be elucidated.

Example 3.

Genotyping of polymorphic markers identified through sequencing

Sequencing of the exons of *CDKN2A* and *CDKN2B* genes, the exon-intron junctions and potential regulatory regions using the primers as indicated in Table 25 resulted in the identification of a number of SNPs, as shown in Table 26. Flanking sequences for three of those SNPs that were not found in public databases are indicated in Table 31. As it is possible that SNP markers or other polymorphisms in LD with the markers found to be associating to MI in this region of chromosome 9 show association with a higher risk, we genotyped these additional markers by sequencing, as indicated in Table 28. Several of the markers show association to MI with RR values as high as 1.7-1.8, in particular markers SG09S291 and rs2069416.

Example 4

Association to related cardiovascular disorders

We have investigated association of the at-risk variants of the invention to the related disorders peripheral artery disease (PAD), abdominal aorta aneurysm (AAA) and large vessel disease stroke (LVD) for three of the markers giving signal on Chromosome 9 as presented herein. As can be seen in **Table 29**, these markers are associated with these related disorders. The association is particularly compelling for AAA, wherein significant association is observed for a large number of markers in addition to these three, as shown in Table 30. These results

illustrate that the markers and haplotypes of the invention are indeed reflective of disorders related to coronary artery disease, MI and in-stent restenosis, such as abdominal aorta aneurysm.

5 Example 5

Further refinement of association to the arterial phenotypes AAA, IA and Stroke.

To investigate the effect of rs10757278 on other cardiovascular diseases in more detail, we further explored the association to abdominal aortic aneurysm (AAA) and Stroke, and also investigated the arterial disorder intracranial aneurysm (IA).

10

Methods

Study Populations

Coronary artery disease groups

The coronary artery disease groups from Iceland and the United States were as described above (see also Helgadottir, A., *et.al.*, *Science* **316**:1491-3 (2007))

15

Icelandic controls

The 14278 Icelandic controls used in the association study were selected among individuals who have participated in various GWA studies and were recruited as part of genetic programs at deCODE. The medical histories of the controls were unknown unless they had also participated in one or more of the CVD genetic programs (i.e. MI, stroke, PAD, T2D, obesity, familial combined hyperlipidemia, coronary restenosis, and hypertension). Individuals with known MI, stroke, PAD or CAD, or with T2D were excluded as controls. Of the 14259 controls 9202 overlap with those used in our previous GWA study in MI (Helgadottir, A., *et.al.*, *Science* **316**:1491-3 (2007)). The controls included 5615 males and 8644 females and their mean age was 55.2 (SD 21.7). The breakdown of the control group into the various genetic programs was approximately (with the frequency of the two variants, rs10757278 allele G and rs10811661 allele T in parenthesis): Schizophrenia 500 (0.428/0.825), Prostate cancer 900 (0.447/0.815), Breast Cancer 1300 (0.433/0.817), Colon Cancer 700 (0.413/0.817), Addiction 2600 (0.444/0.814), Anxiety 900 (0.442/0.824), Infectious diseases 1200 (0.434/0.821), Population Controls 700 (0.427/0.830), Microarray expression studies 400 (0.445/0.817), Longevity 1100 (0.450/0.819), Migraine 1100 (0.446/0.818), Restless Leg Syndrome 400 (0.439/0.812), Alzheimer disease 350 (0.457/0.822), Asthma 1300 (0.419/0.819), Dyslexia 600 (0.438/0.830). No significant differences in frequencies were observed between the disease groups for either of the two variants ($P = 0.52$ and $P = 0.99$ for rs10757278 and rs10811661, respectively).

35

Stroke groups

Icelandic stroke patients were recruited from a registry of over 4000 individuals which includes individuals diagnosed with ischemic stroke or TIA at the major hospital in Reykjavik, the Landspítali University Hospital, during the years 1993 to 2002. Stroke patients have been
5 enrolled over the past nine years through the cardiovascular disease (CVD) genetics program at deCODE. Swedish patients with ischemic stroke or TIA attending the stroke unit or the stroke outpatient clinic at Karolinska University Hospital, Huddinge unit in Stockholm, Sweden were recruited from 1996 to 2002 as part of an ongoing genetic epidemiology study, the South
10 Stockholm Ischemic Stroke Study (SSISS). All patients from Iceland and Sweden had clinically relevant investigations performed, including brain imaging with computed tomography (CT) or/and magnetic resonance imaging (MRI) as well as ancillary diagnostic investigations including duplex ultrasonography of the carotid and vertebral arteries, echocardiography, Holter
monitoring, MR-angiography, CT-angiography and standardized blood tests. Patients were classified into ischemic subtypes according to the Trial of Org 10172 in Acute Stroke Treatment
15 (TOAST) classification by a physician reviewing original imaging and data (Adams, H.P. Jr., *et al.*, *Stroke* **24**:35-41 (1993)). Patients classified with cardioembolic stroke and documented atrial fibrillation were excluded from the analysis. The Swedish controls used in this study are population-based controls recruited from the same region in central Sweden as the patients, representing the general population in this area. The individuals were either blood donors
20 (recruited in 2001) or healthy volunteers (collected in 1990-1994) recruited by the Clinical Chemistry Department at the Karolinska University Hospital to represent a normal reference population. These stroke studies from Iceland and Sweden were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

Intracranial aneurysm groups

Icelandic IA patients were identified through an inpatient database from 1994-2006 at the Landspítali University Hospital, which is the only hospital with a neurosurgical service in the country. All patients in the years 1996-2006 with the ICD10 diagnosis I60.0-7 (aneurysmal
30 subarachnoid hemorrhage), I67.1 (ruptured cerebral aneurysm) and I69.0 (sequelae of subarachnoid haemorrhage) were enrolled, as well as patients with the ICD9 diagnosis 430 (subarachnoid hemorrhage from ruptured cerebral aneurysm) in the years 1994-1996. This totalled 367 IA patients. All patients had clinically relevant investigations performed, including CT scan of the head and or conventional cerebral angiogram, CT- angiogram or MRi angiogram.
35 DNA samples were available for 170 of the 367 patients.

Dutch patients with ruptured (91.5%) or unruptured (8.5%) IA admitted to the University Medical Center Utrecht were used for the study. Ruptured intracranial aneurysms were defined by symptoms suggestive of subarachnoidal hemorrhage (SAH) combined with subarachnoid blood on CT and a proven aneurysm at angiography (conventional angiogram, CT-
40 or MR-angiogram) and unruptured intracranial aneurysms were identified by CT or MR angiography or conventional angiography. Multiple intracranial aneurysms were found in 20.5%

of cases. Mean age at time of SAH was 49.5 years (range 10-84) and 66.1% of the patients were females. The controls were healthy Dutch blood bank donors of European origin.

Finnish IA patients admitted for treatment of intracranial aneurysm at either the University Hospital of Kuopio, or University Hospital of Helsinki, in Finland, were used for the study. This study group and the Finnish controls used have been described previously (Weinsheimer, S. *et al.*, *Stroke* **38**:2670-6 (2007)).

The Icelandic, Dutch and Finnish IA studies were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

10 *Peripheral arterial disease groups*

Icelandic patients with PAD were recruited from a registry of individuals diagnosed with PAD at the major hospital in Reykjavik, the Landspítali University Hospital, during the years 1983 to 2006. The PAD diagnosis was confirmed by vascular imaging or segmental pressure measurements. PAD patients have been enrolled over the past nine years as part of the CVD genetics program at deCODE.

Italian patients and controls were recruited among subjects consecutively admitted to the Department of Internal Medicine and Angiology of the A. Gemelli University Hospital of Rome, from 2000 to 2001. Inclusion criteria for the PAD group were European descent and presence of PAD. Diagnosis of PAD was performed in accordance with established criteria (*J Vasc Surg* **4**:80-94 (1986)). All patients had an ankle/arm pressure index lower than 0.8 and were at Fontaine's stage II, with intermittent claudication and no rest pain or trophic lesions. Inclusion criteria for the control group were European descent, absence of PAD and CAD and no relationship with cases. Additional, exclusion criteria from the study were tumours, chronic inflammatory diseases, and autoimmune diseases (Flex, A., *et al.*, *Eur J Vasc Endovasc Surg* **24**: 264-8 (2002)).

Swedish PAD patients and controls were recruited at the Department of Vascular Diseases at Malmö University Hospital, a single referral centre for all patients with critical limb ischemia in the three southernmost health-care districts in Sweden (723,750 inhabitants in 2001). The diagnosis of critical limb ischemia was made in accordance with TransAtlantic Inter-Society Consensus scientific criteria of ulceration, gangrene, or rest pain caused by PAD proven by ankle pressure (<50 to 70 mm Hg), reduced toe pressure (<30 to 50 mm Hg), or reduced transcutaneous oxygen tension (Dormandy, J.A. & Rutherford, R.B., *J Vasc Surg* **31**:S1-S296 (2000)). Diagnosis was confirmed by an experienced vascular surgery consultant and toe pressure measurements in patients with arteries in the affected leg that were noncompressible and the ankle pressure was >50 to 70 mm Hg. The control group consisted of healthy individuals included in a health screening programme for a preventive medicine project. None of those had symptomatic PAD (Barani, J., *et al.*, *J Vasc Surg* **42**:75-80 (2005)).

New Zealand PAD patients were recruited from the Otago-Southland region of the country, the vast majority (>97%) being of Anglo-European ancestry as reported previously (Jones G.T., *et al.*, *Clin Chem* **53**:679-85 (2007)). PAD was confirmed by an ankle brachial index<0.7, pulse volume recordings and angiography/ultrasound imaging. The control group consisted of elderly individuals with no previous history of vascular disease from the same

geographical region. Controls were asymptomatic for PAD and had ankle brachial indexes >1. An abdominal ultrasound scan excluded concurrent AAA from both the PAD and control groups.

The Icelandic, Italian, Swedish, and New Zealand PAD studies were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

Abdominal aortic aneurysm groups

Icelandic patients with AAA were recruited from a registry of individuals who were admitted either for emergency repair of symptomatic or ruptured AAA or for an elective surgery to the Landspítali, University Hospital, in Reykjavik, Iceland in the years 1980-2005. Subjects with AAA were enrolled over the last nine years as part of the CVD genetics program at deCODE. In some of the analyses AAA cases that overlapped with a comprehensive list of CAD patients (Helgadóttir, A., *et al.*, *Science* **316**:1491-3 (2007)) diagnosed in Iceland in the years 1981-2006 were excluded. Of the 397 (288 males and 109 females, mean age 75.3 (SD 8.7)) AAA cases, 208 overlapped with the CAD patients. Of the 189 (131 males and 58 females, mean age 75.5 (SD 9.3)) remaining CAD, information was not available for 138 cases and 51 individuals reported in a questionnaire as not having been diagnosed with CAD.

UK patients with AAA referred to vascular surgeons at 93 UK hospitals were entered into UK Small Aneurysm Trial. For the purpose of the current study those randomised to surveillance in the UK Small Aneurysm Trial with AAA diameter 4.0-5.5 cm were selected as a patient group, although some patients had been monitored before their aneurysm reached the 4.0cm threshold for the trial. Mean AAA diameter at baseline was 4.5 cm (3.2-5.5 cm) (Eriksson, P., *et al.*, *Br J Surg* **92**:1372-6 (2005)). Information on the occurrence of CAD was available for 97% (466 out of 479) of AAA cases. History of CAD was regarded as positive if the subject was under treatment for angina, had a previous MI, coronary artery bypass graft surgery or angioplasty or if ECG coding had any indications of ischaemia, as judged by two independent expert observers. Among those with this information, the frequency of CAD amongst the AAA subjects was 52%. Controls were of European descent, recruited from England.

Belgian and Canadian patients with AAA who were admitted either for emergency repair of ruptured AAA or for an elective surgery to the University Hospital of Liège in Belgium and to Dalhousie University Hospital in Halifax Canada, respectively, were used for this study. Details of these case-control sets have been previously reported (Ogata, T., *et al.*, *J Vasc Surg* **41**:1036-42 (2005)). All patients were of European descent and had a diameter of infrarenal aorta $\geq$ 3 cm. Thirty-five patients were diagnosed with AAA using ultrasonography and did not undergo surgery because of old age or because the aneurysm was relatively small. Approximately 40% of AAA patients had a family history of AAA. For Belgian AAA patients, information on CAD history was ascertained for those who underwent surgery through interviews as well as from medical files. In addition, all patients underwent cardiologic explorations such as transthoracic echography, stress tests and coronary angiography if CAD was suspected. CAD information for this study was available for 45% (79 out of 176) of AAA cases from Belgium. Among those with this information, the frequency of CAD amongst the AAA subjects was 29%. Control samples (51%

males) of European descent were obtained from spouses of AAA patients or from individuals admitted to the same hospitals for reasons other than AAA.

Patients admitted to the University Hospital of Pittsburgh for either elective or emergency surgery for AAA were selected for the study (St Jean, P.L., *et al.*, *Ann Hum Genet* **59**:17-24 (1995)). History of CAD was self-reported and was available for 86% (87 out of 101). Among those with this information, the frequency of CAD amongst the AAA subjects was 48%. Controls were selected from participants of the PENN CATH study program at the University of Pennsylvania Medical Center Philadelphia. The control group represents individuals who were without significant luminal stenosis on coronary angiography (luminal stenosis less than 50%) and did not have a history of MI. These are the same controls as were used in the association analysis for the CAD samples from Pennsylvania (Helgadottir, A., *et.al.*, *Science* **316**:1491-3 (2007)).

New Zealand patients with AAA were recruited from the Otago-Southland region of the country, the vast majority (>97%) being of Anglo-European ancestry as reported previously (Jones, G.T., *et al.*, *Clin Chem* **53**:679-85 (2007)). Approximately 80% of patients had undergone surgical AAA repair (typically AAA's >50mm in diameter). Controls were the same vascular disease free individuals as described for comparison with the New Zealand PAD group. CAD information was available for 98% (575 out of 588) of the AAA patients. Of those with information the frequency of CAD was 40%.

AAA sample set from the Netherlands was recruited from 8 centres in the country, mostly when patients visited their vascular surgeon or in rare cases during hospital admission. The controls were healthy Dutch blood donors of European origin. Information on other CVD was self-reported and available for 69% (330 out of 480). Treatment for angina pectoris, previous MI, coronary bypass surgery or stent insert was considered as CAD. Of the 330 with information, 96 had CAD (29%).

These AAA studies from Iceland, UK, Belgium, Canada, Pennsylvania, The Netherlands and New Zealand were approved by relevant Institutional Review Boards or ethics committees and all participants provided written informed consent.

SNP Genotyping.

SNP genotyping for all samples was carried out at deCODE genetics in Reykjavik, Iceland. Individual SNP genotyping was carried out with the Centaurus (Nanogen) platform (Kutyavin, I.V., *et al.*, *Nucleic Acids Res* **34**:e128 (2006)). The quality of each Centaurus SNP assay was evaluated by genotyping each assay in the CEU and/or YRI HapMap samples and comparing the results to the HapMap data. The key markers rs10757278 and rs10811661 were re-genotyped on more than 10% of samples and a mismatch was observed in less than 0.5% of samples. For some of the samples we had previously genotyped the SNPs rs1333040, rs2383207, and rs10116277 either with the Illumina 317K Bead chip or with the Centaurus method. These SNPs are highly correlated with rs10757278 ($r^2 = 0.57, 0.87, \text{ and } 0.90$, respectively, in the HapMap CEU dataset) and were used to impute the genotypes for rs10757278 where they were missing. In addition, for a large number of the Icelandic samples the SNP rs2383208, which is present on

the Illumina 317K Bead chip, was previously genotyped. This SNP is a perfect surrogate for the SNP rs10811661 ($r^2 = 1$ in the HapMap CEU dataset) and was used to impute genotypes for rs10811661.

5 The SNPs did not deviate from Hardy Weinberg Equilibrium in any of study cohorts used for the analyses.

Association Analysis

We used a standard likelihood ratio statistics, implemented in the NEMO software (to calculate two-sided P values and odds ratio (OR) for each individual allele, assuming a
10 multiplicative model for risk, i.e., that the risk of the two alleles a person carries multiply. Allelic frequencies, rather than carrier frequencies are presented for the markers, and, for the Icelandic study groups, P values are given after adjustment for the relatedness of the subjects by simulating genotypes through the genealogy of 708,683 Icelanders as previously described (Stefansson, H., *et al.*, *Nat Genet* **37**:129-37 (2005)). When estimating genotype specific OR
15 (**Table 34**) genotype frequencies in the population were estimated assuming HWE. Heterogeneity tests were performed assuming that the estimates of OR for various groups have log-normal distributions. A likelihood ratio chi-square test was used with associated degrees of freedom equal to the number of groups compared minus one.

In general, allele/haplotype frequencies are estimated by maximum likelihood and tests
20 of differences between cases and controls are performed using a generalized likelihood ratio test. This method is particularly useful in situations where there are some missing genotypes for the marker of interest and genotypes of another marker, which is in strong LD with the marker of interest, are used to provide some partial information. To handle uncertainties with phase and missing genotypes, maximum likelihood estimates, likelihood ratios and P values are computed
25 directly for the observed data, and hence the loss of information due to uncertainty in phase and missing genotypes is automatically captured by the likelihood ratios.

The correlation of rs10757278 allele G and rs10811661 allele TT to both age and sex was tested in the Icelandic control population. Neither of the alleles demonstrated significant association to these covariates. In addition, no significant difference was detected in the
30 frequency of the variants between males and females within the AAA cases (data not shown). Furthermore, including age and sex as covariates in the association analysis of rs10757278 allele G to AAA in the Icelandic samples had negligible impact on the results. Thus, for simplicity, the association analysis is presented without adjustment for age and sex.

The possibility that the association results observed for rs10757278 allele G to AAA was
35 influenced by population stratification was addressed for the UK AAA cases and controls by typing 13 SNPs identified by the WTCCC as showing strong evidence for geographic differentiation in the WTCCC samples (*Nature* **447**:661-78 (2007)). Only one of those SNPs showed nominally significant difference between the UK AAA cases and controls ($P = 0.017$), which is not significant if we adjust for having tested 13 SNPs. If we adjust for this SNP in the
40 case-control analysis, the association of rs10757278 allele G to AAA in the UK case-control group

is not affected ($P = 0.0052$ and $OR = 1.36$ instead of $P = 0.0063$ and $OR = 1.35$). In the Icelandic case-control analysis we have adjusted for the relatedness of the study individuals. This adjustment has been shown to agree very well with the adjustment based on genomic control, which would include adjustment for any population stratification, in recent publications of genome-wide association studies in the Icelandic population (Steinthorsdottir, V., *et al.*, *Nat Genet* **39**:770-5 (2007); Gudmundsson, J. *et al.*, *Nat Genet* **39**:631-7 (2007)). Most importantly, the very similar allelic odds ratios obtained from the five AAA data sets makes it highly unlikely that population stratification has any substantial impact on the estimates of the effect.

Results from multiple case-control groups were combined using a Mantel-Haenszel model in which the groups were allowed to have different population frequencies for alleles, haplotypes and genotypes but were assumed to have common relative risks (Mantel, N. & Haenszel, W. *J Natl Cancer Inst* **22**: 719-48 (1959)).

Results

The results shown in **Table 32** shows results from the Icelandic IA cohort, replication cohorts, and a combined analysis for the cohorts. When data from the multiple case-control groups studied were combined separately for IA, AAA, PAD and LAA/cardiogenic stroke, rs10757278 allele G showed significant association to all of the four phenotypes. However, the estimated effect size differed substantially and was strongest for AAA (combined analysis, $OR = 1.31$, $P = 1.2 \times 10^{-12}$) and IA (combined analysis, $OR = 1.29$, $P = 2.5 \times 10^{-6}$). In addition to the high overall statistical significance, it is also important to note that the estimated risk conferred by rs10757278 allele G to IA and AAA was very similar across the three IA sample sets from Iceland ($OR = 1.36$), Finland ($OR = 1.33$), and the Netherlands ($OR = 1.24$) (P_{het} , the P -value for the test of heterogeneity = 0.75), and the seven AAA sample sets from Iceland ($OR = 1.37$), Belgium ($OR = 1.21$), Canada ($OR = 1.29$), Pennsylvania US ($OR = 1.39$), United Kingdom (UK) ($OR = 1.35$), Netherlands ($OR = 1.31$), and New Zealand ($OR = 1.25$), ($P_{het} = 0.98$). The effect of rs10757278 allele G on IA and AAA is comparable to that previously reported for CAD (Helgadottir, A., *et al.* *Science* **316**:1491-3 (2007)) (**Table 32**).

Because of high co-morbidity between AAA and CAD, we explored the nature of the effect of the variant on the two conditions, by repeating the association analysis for AAA after removing cases with evidence of CAD. As shown in **Table 33**, the effect of rs10757278 allele G on AAA without evidence of CAD was only slightly smaller than that for the whole sample sets, or $OR = 1.3$ for the Icelandic, 1.31 for UK, 1.19 for Pennsylvania, 1.20 for Belgian, 1.25 for The Netherlands, and 1.18 for the New Zealand sample sets. For the six different groups with available CAD information, after removing known CAD cases the combined OR was 1.25 and $P = 3.0 \times 10^{-6}$, indicating that the association to AAA is not simply a consequence of the association between rs10757278 allele G and CAD. To our knowledge there is no evidence in the literature suggesting co-segregation of IA and CAD. Furthermore, the gender ratio in IA is also different

from that for the atherosclerotic diseases such as CAD; IA is more frequent in females than in males, and the peak incidence is also at a younger age than for CAD (Schievink, W.I., *N Engl J Med* **336**:28-40 (1997)). The effect of rs10757278 allele G on IA is thus not mediated through CAD.

5 When genotype-specific effects were studied based on data from all seven AAA and the three IA sample sets the ORs for heterozygous and homozygous carriers of the risk allele G were estimated to be 1.36 and 1.74, respectively for AAA and 1.38 and 1.72, respectively, for IA (**Table 34**). Assuming a population frequency of 47.5% for the G allele, the corresponding population attributable risk is about 26% for both AAA and IA. It is noted that rs10757278 allele
10 G is the first common sequence variant described that affects the risk of IA or AAA.

The prevalence of AAA (defined as > 3 cm aortic diameter) has been reported to be 4.3% and 1.0% in men and women over 50 years of age, respectively (Lederle, F.A., *et al.*, *J Vasc Surg* **34**:122-6 (2001); Lederle, F.A., *et al.*, *Arch Intern Med* **160**:1425-30 (2000)), and 2-5% of the general population have IA (Brisman, J.L., *et al.*, *N Engl J Med* **355**:928-39 (2006)). Both AAA
15 and IA represent a degenerative process of the arteries leading to their enlargement that is usually asymptomatic with natural history culminating in either a therapeutic intervention or rupture. Rupture of IA leads to subarachnoid haemorrhage, and rupture of both IA and AAA have high morbidity and mortality (Brisman, J.L., *et al.*, *N Engl J Med* **355**:928-39 (2006); Thompson, R.W. *Cardiovasc Surg* **10**: 389-94 (2002)). In the case of AAA the rupture risk
20 increases with the growth rate as well as the size of the aneurysm. While patients from the UK study group included only those with small asymptomatic aneurysms (aortas <5.5cm diameter), the other study groups included mainly patients undergoing aneurysm repair and are therefore likely to be biased towards larger and symptomatic aneurysms (aortas >5.5 cm diameter). Despite recruitment differences the ORs were similar, suggesting that the variant does not confer
25 direct risk of the growth of aortic aneurysms. This concept was further investigated in the sample set from UK, where the subjects with small asymptomatic AAA had been followed with sequential aortic aneurysm size measurements (Eriksson, P. *et al.*, *Br J Surg* **92**:1372-6 (2005)). As shown in **Table 35**, there is no evidence of an association between rs10757278 allele G and either aneurysm growth or rupture. Rather there is some indication that allele G is correlated
30 with slow growth. The difference in average growth rates between the homozygous GG group and the heterozygous AG group is -0.46 mm/year and is nominally significant ($P = 0.05$), an observation that warrants further investigation. If confirmed, this inverse association would echo previous findings where slower aneurysm growth rates were observed in patients with low ankle/brachial pressure index, a marker of generalised atherosclerosis (Brady A.R., *et al.*,
35 *Circulation* **110**:16-21 (2004)). These data suggest that the sequence variant leads to increased susceptibility of developing aneurysm rather than increasing the risk of rapid aneurysm progression.

The effect of rs10757278 allele G on the risk of PAD and LAA/cardiogenic stroke appeared to be weaker than that for AAA, IA and CAD (**Table 32**). In the Icelandic samples there was no

difference in the frequency of rs10757278 allele G between the AAA and IA cases, however the frequency was lower in both the PAD and LAA/cardiogenic stroke cases than in the combined group of AAA and IA cases ($P=0.012$ and $P=0.052$, respectively). Furthermore, after excluding PAD and LAA/cardiogenic stroke subjects with known CAD from the analysis the effect was reduced even further, particularly for PAD (**Table 33**).

We tested the association of several variants in the LD block C09 region with MI in African American samples. As shown by the results presented in **Table 36**, the effect in African Americans is comparable in magnitude, as measured by Relative Risk, to the effect in Caucasian samples. The lack of nominal statistical significance of the association (p-value less than 0.05) in the African American samples for many of the markers is due to the relatively small samples size. Most importantly, the association observed in African Americans, together with reported association in Asian samples originating from Japan and Korea with comparable risk to that determined for Caucasians (see *Arterioscler Thromb Vasc Biol.* 2008 Feb;**28(2)**:360-5. Epub 2007 Nov 29, and *J Hum Genet.* Epub 2008 Feb 9) shows that the genetic effects originally discovered in Caucasian samples from Iceland manifests itself in other human populations. The effect therefore has implications for cardiovascular disease in all major human populations..

These data demonstrate that rs10757278 allele G has less effect on the atherosclerotic diseases, PAD and LAA/cardiogenic stroke, than on CAD. In contrast, the effect on the two aneurysmal diseases, AAA with weaker association to atherosclerosis and IA with no such relationship, was comparable to that on CAD, suggesting that the variant plays a role in a pathophysiological component common to these arterial phenotypes. This may involve abnormal vascular remodelling and/or repair which has been identified as a key in the pathogenesis CAD, AAA and IA (Chatzidis, Y.S. *et al.*, *J Am Coll Cardiol* **49**:2379-93 (2007); Hashimoto, T. *et al.*, *Neurol Res* **8**:372-80 (2006); Moore, J.E., Jr., *et al.*, *Atherosclerosis* **110**:225-40 (2006)). The sequence variant rs10757278 allele G on chromosome 9p21, and/or variants in linkage disequilibrium with rs10757278, may thus function as a genetic determinant of the tissue response to unfavourable conditions that prevail in the lower abdominal aorta, in the circle of Willis where IAs occur, and in those regions of the coronary tree that are prone to develop unstable, rupture prone atherosclerotic plaques.

TABLES

Table 1: a) Results for the 12 SNPs in LD block C09 that showed nominally significant association to myocardial infarction in the Icelandic discovery cohort (Cohort A) of 1570 MI cases and 7088 controls. Shown is the frequency of the risk allele in cases and controls, the corresponding relative risk (RR), the unadjusted *P*-value and the *P*-value after adjusting for the relatedness of cases and controls. Also included are results for a test of association to MI for the same SNPs conditioned on the association of the SNP rs1333040. b) Association to MI for the different alleles of the micro-satellites D9S1814 and D9S1870 in Cohort A. c) Association to MI of the at-risk allele 0 for D9S1814 and of the composite at-risk allele X of D9S1870 in Cohort A. The composite allele X includes alleles -6, -4, -2 and 0 of D9S1870.

	SNP	Allele	Position	Frequency		RR	<i>P</i>	<i>P</i> *	Conditioned on rs1333040		
				Cases	Controls				RR**	<i>P</i> **	<i>r</i> 2 ***
a)	rs7041637	A	21951866	0.251	0.232	1.104	0.031	0.044	1.003	0.96	0.12
	rs2811712	A	21988035	0.890	0.874	1.171	0.010	0.016	1.146	0.040	0.05
	rs3218018	A	21988139	0.894	0.878	1.174	0.010	0.016	1.149	0.038	0.03
	rs3217992	A	21993223	0.376	0.344	1.149	0.00071	0.0015	1.015	0.80	0.28
	rs2069426	C	21996273	0.895	0.880	1.159	0.019	0.028	1.134	0.063	0.02
	rs2069422	A	21998026	0.891	0.874	1.174	0.0092	0.015	1.149	0.037	0.05
	rs1333034	A	22034122	0.890	0.874	1.168	0.012	0.018	1.143	0.043	0.05
	rs1011970	G	22052134	0.801	0.772	1.189	0.00034	0.00081	1.114	0.050	0.13
	rs10116277	T	22071397	0.463	0.419	1.195	7.05×10 ⁻⁶	2.63×10 ⁻⁵	1.054	0.52	0.67
	rs1333040	T	22073404	0.538	0.491	1.209	1.56×10 ⁻⁶	6.98×10 ⁻⁶	NA	NA	NA
	rs2383207	G	22105959	0.502	0.456	1.204	2.64×10 ⁻⁶	1.11×10 ⁻⁵	1.102	0.15	0.57
	rs1333050	T	22115913	0.694	0.672	1.107	0.017	0.025	1.005	0.92	0.27
b)	D9S1814	-2	22078225	0.019	0.019	1.049	0.79	0.81	-	-	-
	D9S1814	0	22078225	0.500	0.451	1.217	1.35×10 ⁻⁶	6.17×10 ⁻⁶	-	-	-
	D9S1814	2	22078225	0.359	0.385	0.895	0.015	0.023	-	-	-
	D9S1814	4	22078225	0.112	0.149	0.720	4.00×10 ⁻⁶	1.60×10 ⁻⁵	-	-	-
	D9S1870	-6	22093010	0.019	0.020	0.961	0.79	0.81	-	-	-
	D9S1870	-4	22093010	0.039	0.029	1.352	0.0090	0.015	-	-	-
	D9S1870	-2	22093010	0.376	0.339	1.177	0.00011	0.00031	-	-	-
	D9S1870	0	22093010	0.044	0.043	1.038	0.72	0.74	-	-	-
	D9S1870	2	22093010	0.072	0.074	0.974	0.74	0.76	-	-	-
	D9S1870	4	22093010	0.166	0.200	0.797	2.96×10 ⁻⁵	9.31×10 ⁻⁵	-	-	-
	D9S1870	6	22093010	0.104	0.114	0.905	0.14	0.17	-	-	-
	D9S1870	8	22093010	0.079	0.080	0.989	0.89	0.89	-	-	-
	D9S1870	10	22093010	0.072	0.077	0.931	0.37	0.40	-	-	-
	D9S1870	12	22093010	0.021	0.018	1.152	0.34	0.37	-	-	-
c)	D9S1814	0	22078225	0.500	0.451	1.217	1.35×10 ⁻⁶	6.17×10 ⁻⁶	1.118	0.099	0.53
	D9S1870	X	22093010	0.486	0.438	1.211	2.52×10 ⁻⁶	1.07×10 ⁻⁵	1.113	0.081	0.55

* *P*-value adjusted for relatedness of cases and controls.

** *P*-value adjusted for relatedness and conditioned on the association to rs1333040, and the corresponding relative risk.

*** Pair-wise correlation *r*2 between the SNP and the at-risk variant rs1333040

Table 2: Pair-wise correlation among the 5 markers, 3 SNPs and 2 micro-satellites, that show strongest association to myocardial infarction in LD block C09, based on the HapMap v19 CEU dataset. In the upper right corner are shown values for the correlation coefficient r^2 , while in the lower left corner are values for D' .

	Marker	r^2				
		rs10116277	rs1333040	D9S1814	D9S1870	rs2383207
D'	rs10116277	-	0.667	0.806	0.839	0.905
	rs1333040	1.000	-	0.528	0.550	0.569
	D9S1814	0.964	0.829	-	0.651	0.743
	D9S1870	1.000	1.000	0.954	-	0.779
	rs2383207	1.000	0.879	0.893	1.000	-

Table 3: List of all SNPs (from HapMap v19 CEU dataset) in LD block C09 that are correlated, with correlation coefficient $r^2 \geq 0.2$, with at least one of the five markers (rs10116277, rs1333040, D9S1814, D9S1870 or rs2383207). For each SNP shown the table includes the position (in Build 34 and in SEQ ID NO:94) and the correlation coefficient r^2 to each of the five at-risk markers.

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs7041637	21951866	31720	0.18	0.12	0.20	0.21	0.15
rs3218020	21987872	67726	0.46	0.33	0.37	0.55	0.41
rs3217992	21993223	73077	0.43	0.28	0.34	0.53	0.38
rs1063192	21993367	73221	0.22	0.09	0.27	0.28	0.16
rs2069418	21999698	79552	0.19	0.06	0.25	0.25	0.14
rs2069416	22000004	79858	0.41	0.24	0.32	0.50	0.36
rs573687	22001642	81496	0.23	0.07	0.28	0.20	0.17
rs545226	22002422	82276	0.31	0.18	0.24	0.40	0.27
rs10811640	22003411	83265	0.21	0.09	0.29	0.29	0.19
rs10811641	22004137	83991	0.41	0.27	0.33	0.50	0.36
rs2106120	22007101	86955	0.23	0.10	0.31	0.32	0.21
rs2106119	22007550	87404	0.23	0.10	0.31	0.32	0.21
rs643319	22007836	87690	0.22	0.09	0.29	0.32	0.20
rs7044859	22008781	88635	0.23	0.10	0.31	0.32	0.21
rs523096	22009129	88983	0.17	0.05	0.22	0.23	0.12
rs10757264	22009732	89586	0.21	0.09	0.29	0.30	0.19
rs10965212	22013795	93649	0.29	0.14	0.38	0.40	0.27
rs1292137	22014023	93877	0.24	0.09	0.31	0.34	0.21
rs1292136	22014351	94205	0.30	0.16	0.37	0.41	0.28
rs10811644	22015067	94921	0.25	0.11	0.33	0.34	0.22
rs7035484	22015240	95094	0.24	0.10	0.32	0.33	0.22
rs10738604	22015493	95347	0.49	0.35	0.41	0.60	0.44
rs615552	22016077	95931	0.17	0.06	0.21	0.20	0.10
rs543830	22016639	96493	0.23	0.08	0.28	0.31	0.17
rs1591136	22016834	96688	0.29	0.14	0.38	0.40	0.27

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs7049105	22018801	98655	0.29	0.14	0.38	0.40	0.27
rs679038	22019080	98934	0.23	0.08	0.28	0.31	0.17
rs10965215	22019445	99299	0.27	0.13	0.35	0.38	0.25
rs564398	22019547	99401	0.21	0.07	0.26	0.29	0.15
rs7865618	22021005	100859	0.24	0.10	0.29	0.31	0.18
rs10115049	22022119	101973	0.29	0.14	0.38	0.40	0.27
rs634537	22022152	102006	0.24	0.08	0.29	0.33	0.20
rs2157719	22023366	103220	0.26	0.11	0.32	0.33	0.19
rs2151280	22024719	104573	0.27	0.15	0.36	0.38	0.25
rs1008878	22026112	105966	0.24	0.12	0.30	0.32	0.18
rs1556515	22026367	106221	0.26	0.13	0.32	0.35	0.20
rs1333037	22030765	110619	0.28	0.12	0.34	0.36	0.21
rs1360590	22031443	111297	0.31	0.15	0.40	0.43	0.29
rs1412829	22033926	113780	0.23	0.08	0.28	0.31	0.17
rs1360589	22035317	115171	0.30	0.12	0.36	0.40	0.23
rs7028570	22038683	118537	0.31	0.14	0.40	0.43	0.29
rs944801	22041670	121524	0.30	0.12	0.36	0.40	0.23
rs10965219	22043687	123541	0.30	0.13	0.40	0.48	0.27
rs7030641	22044040	123894	0.30	0.12	0.36	0.40	0.23
rs10120688	22046499	126353	0.38	0.18	0.47	0.51	0.35
rs2184061	22051562	131416	0.50	0.24	0.59	0.44	0.40
rs1537378	22051614	131468	0.50	0.24	0.59	0.44	0.40
rs8181050	22054391	134245	0.47	0.22	0.55	0.40	0.38
rs8181047	22054465	134319	0.33	0.49	0.38	0.28	0.21
rs10811647	22055002	134856	0.70	0.49	0.59	0.83	0.62
rs1333039	22055657	135511	0.47	0.22	0.55	0.40	0.38
rs10965224	22057276	137130	0.45	0.21	0.53	0.40	0.35
rs10811650	22057593	137447	0.70	0.49	0.59	0.83	0.63
rs10811651	22057830	137684	0.48	0.23	0.56	0.41	0.39
rs4977756	22058652	138506	0.47	0.22	0.55	0.40	0.38
rs10757269	22062264	142118	0.94	0.66	0.80	0.78	0.84
rs9632884	22062301	142155	0.93	0.65	0.80	0.78	0.84
rs1412832	22067543	147397	0.32	0.48	0.37	0.28	0.22
rs10116277	22071397	151251	-	0.67	0.81	0.84	0.90
rs10965227	22071796	151650	0.28	0.02	0.13	0.18	0.31
rs6475606	22071850	151704	1.00	0.67	0.81	0.84	0.90
rs1333040	22073404	153258	0.67	-	0.53	0.55	0.57
rs1537370	22074310	154164	1.00	0.67	0.81	0.84	0.90
rs7857345	22077473	157327	0.36	0.55	0.43	0.32	0.26
rs10738607	22078094	157948	1.00	0.69	0.81	0.84	0.90
rs10757272	22078260	158114	1.00	0.67	0.81	0.84	0.90
rs4977574	22088574	168428	1.00	0.67	0.81	0.84	0.90
rs2891168	22088619	168473	1.00	0.67	0.81	0.84	0.90
rs1537371	22089568	169422	1.00	0.67	0.81	0.84	0.90
rs1556516	22090176	170030	1.00	0.67	0.81	0.84	0.90
rs6475608	22091702	171556	0.36	0.54	0.42	0.31	0.25
rs7859727	22092165	172019	1.00	0.66	0.80	0.84	0.90
rs1537373	22093341	173195	1.00	0.67	0.81	0.84	0.90
rs1333042	22093813	173667	0.97	0.63	0.81	0.81	0.94
rs7859362	22095927	175781	0.90	0.57	0.74	0.78	1.00
rs1333043	22096731	176585	0.94	0.60	0.74	0.81	0.97
rs1412834	22100131	179985	0.90	0.57	0.74	0.78	1.00
rs7341786	22102241	182095	0.88	0.54	0.71	0.75	0.97
rs10511701	22102599	182453	0.88	0.54	0.71	0.75	0.97

SNP	Position ^a	Position ^b	D9S1814	D9S1870	rs1333040	rs2383207	rs10116277
rs10733376	22104469	184323	0.90	0.57	0.74	0.78	1.00
rs10738609	22104495	184349	0.90	0.57	0.74	0.78	1.00
rs2383206	22105026	184880	0.90	0.57	0.74	0.78	1.00
rs944797	22105286	185140	0.90	0.57	0.74	0.78	1.00
rs1004638	22105589	185443	0.90	0.57	0.74	0.78	1.00
rs2383207	22105959	185813	0.90	0.57	0.74	0.78	-
rs1537374	22106046	185900	0.90	0.57	0.74	0.78	1.00
rs1537375	22106071	185925	0.90	0.57	0.74	0.78	1.00
rs1333045	22109195	189049	0.69	0.37	0.52	0.60	0.65
rs10738610	22113766	193620	0.94	0.60	0.77	0.78	0.97
rs1333046	22114123	193977	0.94	0.60	0.77	0.78	0.97
rs10757278	22114477	194331	0.90	0.57	0.74	0.75	0.87
rs1333047	22114504	194358	0.90	0.59	0.72	0.74	0.88
rs4977575	22114744	194598	0.90	0.59	0.72	0.74	0.88
rs1333048	22115347	195201	0.97	0.63	0.77	0.81	0.94
rs1333049	22115503	195357	0.90	0.59	0.72	0.74	0.88
rs1333050	22115913	195767	0.17	0.27	0.06	0.15	0.20

^aPosition with respect to NCBI Build 34, Build 35 or Build 36

^bPosition with respect to SEQ ID NO:94 (LD Block C09)

Table 4: a) Association of the composite at-risk allele X of the micro-satellite D9S1870 to myocardial infarction (MI) in a replication cohort (Cohort B) of 668 Icelandic MI cases and 58,543 controls and in the combined Icelandic cohort (Cohort A+B). Included in the table is the number of cases n and controls m , the allele frequency in cases and controls, the corresponding P value adjusted for relatedness of the study individuals, the relative risk (RR) with 95% confidence interval (CI), and the population attributed risk (PAR). Known CAD or CVD cases have been excluded from the control cohort. b) Association of allele X to MI in three distinct US replication cohorts. All cases and controls in those three cohorts are of Caucasian origin. c) Combined association results, using a Mantel-Haenzel model, for the composite at-risk allele X in all replication cohorts combined, and in all cohorts combined, respectively.

Cohort (n/m)	Frequency		P*	RR	CI	PAR
	Cases	Controls				
a) Iceland						
Cohort B (668/58643)	0.501	0.441	1.39×10 ⁻⁵	1.274	[1.142,1.420]	0.203
Cohort A+B (2238/65731)	0.491	0.441	8.91×10 ⁻¹⁰	1.221	[1.145,1.301]	0.169
b) US replication cohorts						
Cleveland (549/606)	0.501	0.478	0.27	1.097	[0.932,1.292]	0.087
UPenn (580/404)	0.539	0.483	0.014	1.252	[1.046,1.499]	0.205
Emory (400/477)	0.548	0.482	0.0064	1.299	[1.076,1.569]	0.236
c) Combined**						
Replication cohorts (2197/60130)			2.65×10 ⁻⁸	1.231	[1.144,1.324]	0.183
All cohorts (3767/67218)			1.44×10 ⁻¹²	1.214	[1.151,1.281]	0.171

* P-values for the Icelandic cohorts are adjusted for relatedness using simulations (see methods)

** Mantel-Haenzel model was used to combine the results from the different cohorts.

Table 5: a) Association of the composite at-risk allele X of D9S1870 in Icelandic cases with various cardiovascular disease phenotypes. Included in the table are association results for individuals who have undergone PTCA or CABG, for the combined MI and CAD (PTCA and CABG) cohort, individuals with PAD or that have had infarct or TIA, and stroke patients diagnosed with LVD. In all tests the same set of 65,731 Icelandic controls without known CAD complications is used. b) Association of allele X in Iceland to the same coronary artery disease phenotypes as in a) after excluding all known cases of MI from the list of cases. C) Association of allele X to PTCA, CABG and a combined phenotype MI and other CAD, in the Emory cohort.

10

Phenotype (n)	Frequency		RR	CI	P	P*	PAR
	Cases	Controls					
a) Iceland							
PTCA (1791)	0.489	0.441	1.211	[1.129,1.298]	2.69E-08	8.60E-08	0.163
CABG (642)	0.514	0.441	1.338	[1.189,1.506]	3.38E-07	1.31E-06	0.243
MI + other CAD (3513)	0.488	0.441	1.209	[1.148,1.273]	2.57E-14	6.24E-13	0.162
PAD(1661)	0.477	0.441	1.154	[1.074,1.239]	5.36E-05	8.58E-05	0.123
Stroke, Infarct + TIA (1678)	0.448	0.441	1.027	[0.958,1.102]	0.45	0.45	0.023
Stroke, LVD (197)	0.469	0.441	1.120	[0.915,1.370]	0.27	0.27	0.098
b) Iceland, excl. MI cases							
PTCA (941)	0.483	0.441	1.183	[1.077,1.300]	0.00033	0.00045	0.144
CABG (221)	0.501	0.441	1.270	[1.044,1.545]	0.013	0.017	0.202
PAD(1322)	0.464	0.441	1.096	[1.012,1.186]	0.021	0.025	0.079
Stroke, Infarct + TIA (1390)	0.450	0.441	1.037	[0.960,1.119]	0.35	0.36	0.032
Stroke, LVD (153)	0.480	0.441	1.172	[0.934,1.470]	0.17	0.17	0.136
c) Emory							
PTCA (141)	0.567	0.482	1.408	[1.079,1.839]	0.012	NA	0.302
CABG (112)	0.549	0.482	1.308	[0.977,1.751]	0.071	NA	0.242
MI + other CAD (476)	0.551	0.482	1.320	[1.103,1.581]	0.0025	NA	0.250

* P-value adjusted for relatedness using simulations.

Table 6: Association of the composite at-risk allele X of D9S1870 to early-onset MI or CAD a) in Iceland, b) in the three US replication cohorts, c) in all early-onset MI cohorts combined. Early-onset MI is defined as a MI event before the age 50 for males and before the age of 60 for females.

Phenotype (n)	Frequency		RR	CI	P	P*	PAR
	Cases	Controls					
a) Iceland							
Early onset MI (646/65731)	0.514	0.441	1.339	[1.193,1.503]	3.63E-07	7.51E-07	0.243
Early onset CAD (320/65731)	0.532	0.441	1.439	[1.227,1.687]	6.12E-06	7.40E-06	0.298
Early onset MI+CAD (877/65731)	0.511	0.441	1.325	[1.200,1.464]	9.87E-09	2.70E-08	0.235
b) US cohorts							
Emory EO MI (222/477)	0.559	0.482	1.359	[1.084,1.703]	0.0078	NA	0.273
Cleveland EO MI (183/606)	0.514	0.478	1.155	[0.914,1.459]	0.2281	NA	0.133
Upenn EO MI (275/490)	0.569	0.473	1.469	[1.191,1.811]	0.00033	NA	0.330
c) All cohorts combined							
Early onset MI (1326/67304)	-	-	1.331	[1.223,1.449]	3.96E-11	NA	0.247

* P-value adjusted for relatedness using simulations.

Table 7: Model-free estimates of the genotype relative risks (GRR) of the composite allele X of D9S1870. Included is the risk for heterozygous carriers (OX) and homozygous carriers (XX) compared with risk for non-carriers (00) and the corresponding 95% confidence intervals (CI). Results are shown for a) all MI cases versus controls and b) for early-onset MI cases versus controls for the whole Icelandic cohort, the three US replication cohorts and for all the cohorts combined using a Mantel-Haenzel model.

Phenotype (n/m)	Genotype relative risk (GRR)			
	OX	CI	XX	CI
a) All MI cases				
Iceland (2238/65731)	1.173	[1.060,1.298]	1.507	[1.338,1.697]
Cleveland(549/606)	1.077	[0.804,1.443]	1.204	[0.860,1.686]
UPenn (679/490)	1.443	[1.074,1.938]	1.728	[1.228,2.431]
Emory (400/477)	1.213	[0.836,1.760]	1.669	[1.144,2.435]
Combined (3866/67304)	1.204	[1.094,1.324]	1.507	[1.360,1.670]
b) Early onset MI cases				
Iceland (641/65731)	1.191	[0.982,1.444]	1.803	[1.453,2.237]
Cleveland (183/606)	1.432	[0.932,2.201]	1.867	[1.176,2.964]
UPenn (275/490)	1.692	[1.134,2.524]	2.237	[1.440,3.476]
Emory (222/477)	1.069	[0.567,2.017]	1.328	[0.827,2.133]
Combined (1321/67304)	1.314	[1.105,1.562]	1.790	[1.517,2.113]

Table 8: a) Association of the risk alleles of the markers rs10116277, rs1333040 and rs2383207 to age of onset of MI in the Icelandic Cohort A. The analysis is done using multiple regression where age of onset of MI is taken as the response variable and the number of copies of X is used as explanatory variable. The analysis is adjusted for gender by include sex of the individuals as an explanatory variable. Included in the table is the effect size, the standard error of the mean (SE) and the corresponding P-value. b) Association of the composite at-risk allele X of D9S1870 to age-of-onset of MI in the combined Icelandic MI patient cohort, and for the three US replication cohorts. Results for the four cohorts are combined weighting the contribution from each cohort proportional to the inverse of the standard error. In all tests only cases with known age-of-onset are included.

Cohort/Marker (n)	Effect	SE	P
a) SNPs in Iceland A			
rs10116277 (1293)	-0.94	0.32	0.0039
rs1333040 (1293)	-1.01	0.32	0.0018
rs2383207 (1293)	-0.79	0.32	0.015
b) D9S1870 allele X			
Iceland (2127)	-0.93	0.29	0.0016
Cleveland (424)	-0.47	0.79	0.55
UPenn (646)	-1.19	0.69	0.083
Emory (403)	-1.38	0.87	0.11
Combined (3600)	-0.95	0.25	0.000099

Table 9: a) Association of the composite risk allele X of D9S1870 to either mild (<50%) or severe (≥50%) in-stent restenosis in coronary artery disease patients that have undergone PTCA compared to controls without known history of CAD. b) Comparison of the frequency of the risk variant X in patients with severe in-stent restenosis to patients with mild in-stent restenosis.

Phenotype (n,m)	Frequency		RR	CI	P
	Cases	Controls			
a) Restenosis patients vs controls					
Mild restenosis, < 50% (323/65731)	0.492	0.441	1.228	[1.050,1.436]	0.010
Severe restenosis (≥50% (193/65731)	0.509	0.441	1.313	[1.071,1.608]	0.0086
b) Severe vs mild restenosis (193/323)					
	0.509	0.492	1.067	[0.827,1.376]	0.62

Table 10.

A. SNP markers within LD Block C09 (Between 21,920,147 and 22,149,982 on C09; NCBI Build 34, Build 35 and Build 36 (SEQ ID NO:94)).

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs7864029	C/G	21920147	+	1
rs2518714	A/C	21920303	+	157
rs10965187	A/G	21920505	+	359
rs2811715	G/T	21920571	+	425
rs2518715	C/T	21920700	+	554
rs12002708	A/C	21920762	+	616
rs10811639	A/G	21920803	+	657
rs11998828	C/T	21920812	+	666
rs7868374	A/G	21921609	+	1463
rs4977570	G/T	21921642	+	1496
rs7390564	G/T	21921642	+	1496
rs7869004	G/T	21921896	+	1750
rs974679	A/G	21922245	+	2099
rs2891010	A/G	21922261	+	2115
rs12003714	A/G	21922366	+	2220
rs28756321	C/G	21923029	+	2883
rs12000395	A/G	21923096	+	2950
rs2188126	C/G	21923125	+	2979
rs12003027	C/T	21924442	+	4296
rs7023582	A/C	21924684	+	4538
rs28613732	A/G	21925807	+	5661
rs10965188	C/G	21925874	+	5728
rs12552975	C/T	21926059	+	5913
rs7875199	C/T	21926381	+	6235
rs12236992	A/C	21927299	+	7153
rs7021848	C/T	21927351	+	7205
rs7036999	A/G	21927875	+	7729
rs12345808	A/G	21928367	+	8221
rs35148759	C/T	21929306	+	9160
rs7872310	A/G	21929387	+	9241
rs2811716	C/T	21930017	+	9871
rs10965189	A/C	21930588	+	10442
rs4308829	C/T	21931196	+	11050
rs10965190	A/G	21931385	+	11239
rs10965191	A/G	21932535	+	12389
rs12345373	A/G	21933199	+	13053
rs4977750	A/C	21934317	+	14171
rs10965193	A/G	21934544	+	14398
rs4246843	C/T	21934627	+	14481
rs4382559	A/G	21934818	+	14672
rs4360371	A/C	21935562	+	15416
rs16938595	A/T	21935605	+	15459
rs10965194	A/G	21936214	+	16068
rs2811717	C/T	21936322	+	16176
rs6475598	C/T	21936322	+	16176
rs2811718	A/T	21936891	+	16745
rs10965196	C/G	21937472	+	17326
rs2811719	C/G	21937472	+	17326
rs2811720	C/G	21937957	+	17811
rs6475599	C/G	21937957	+	17811
rs11521166	C/T	21938376	+	18230
rs2518718	A/T	21938489	+	18343
rs10965197	C/T	21938666	+	18520
rs2106117	G/T	21939527	+	19381
rs2106118	A/T	21939528	+	19382
rs2427852	A/T	21940432	+	20286
rs2157716	C/T	21940446	+	20300

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs2263145	C/T	21940452	+	20306
rs2427853	C/T	21940472	+	20326
rs2382894	C/G	21940523	+	20377
rs2427854	A/T	21940721	+	20575
rs7047211	A/T	21940722	+	20576
rs11532909	A/T	21940723	+	20577
rs13297154	A/T	21940725	+	20579
rs13298455	A/T	21940741	+	20595
rs2891092	A/G	21940782	+	20636
rs6415737	A/G	21940782	+	20636
rs4503179	A/G	21940879	+	20733
rs12349081	A/C	21941902	+	21756
rs2518722	C/T	21942926	+	22780
rs10757260	A/G	21943137	+	22991
rs28369665	C/T	21944487	+	24341
rs10965199	C/T	21944653	+	24507
rs10757261	A/G	21944953	+	24807
rs12335859	A/G	21945460	+	25314
rs12335941	A/G	21945669	+	25523
rs2027938	A/G	21946078	+	25932
rs9657608	C/T	21946230	+	26084
rs2518716	A/G	21946470	+	26324
rs2027939	A/G	21946492	+	26346
rs7869996	C/T	21946914	+	26768
rs10965200	C/G	21948142	+	27996
rs717326	A/G	21948524	-	28378
rs35116241	A/C	21949093	+	28947
rs2518717	C/T	21949751	+	29605
rs3948753	A/G	21949860	+	29714
rs2106115	C/T	21949900	+	29754
rs10965201	C/G	21949950	+	29804
rs2106116	C/T	21949966	+	29820
rs10965202	A/G	21951180	+	31034
rs1985742	A/T	21951227	+	31081
rs7041637	A/C	21951866	+	31720
rs2263146	C/T	21953048	+	32902
rs35732310	A/C	21953841	+	33695
rs4518744	A/C	21954015	+	33869
rs2188127	C/G	21955232	+	35086
rs3731257	C/T	21956221	-	36075
rs3731256	C/T	21956617	-	36471
rs11793581	G/T	21957446	+	37300
rs28695347	A/C	21957706	+	37560
rs3731255	C/G	21957855	-	37709
rs3731253	C/G	21957952	-	37806
rs3088440	A/G	21958159	+	38013
rs11515	C/G	21958199	-	38053
rs34011899	A/C	21958712	+	38566
rs2255962	A/G	21959827	+	39681
rs2518719	A/G	21960427	+	40281
rs3731249	A/G	21960916	-	40770
rs6413464	G/T	21960979	-	40833
rs34170727	C/T	21960988	-	40842
rs6413463	A/T	21960989	-	40843
rs35741010	A/G	21961054	-	40908
rs34886500	C/T	21961063	-	40917
rs4987127	A/G	21961085	-	40939
rs11552822	G/T	21961108	-	40962
rs34968276	A/C	21961109	-	40963
rs11552823	C/T	21961116	-	40970
rs3731247	C/T	21961352	-	41206

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs12377672	C/T	21961418	+	41272
rs3731246	C/G	21961989	-	41843
rs3731245	A/G	21962445	-	42299
rs3731244	A/G	21962813	-	42667
rs3731243	A/G	21963050	-	42904
rs2811708	G/T	21963422	+	43276
rs3731241	A/G	21963767	-	43621
rs13288666	C/T	21963857	+	43711
rs3731240	A/G	21964131	-	43985
rs3731239	C/T	21964218	-	44072
rs3814960	A/C/G/T	21965017	+	44871
rs3731238	A/G	21965561	-	45415
rs3731237	A/G	21965728	-	45582
rs3731236	C/T	21966976	-	46830
rs3731235	G/T	21967450	-	47304
rs12350633	C/G	21967553	+	47407
rs3731234	A/C	21967579	-	47433
rs3731233	A/T	21968358	-	48212
rs3731232	C/G	21968443	-	48297
rs2518720	C/T	21968979	+	48833
rs3731230	C/T	21969163	-	49017
rs2518721	A/G	21969204	+	49058
rs3731229	A/C	21969497	-	49351
rs3731228	A/G	21969602	-	49456
rs2811709	A/G	21970151	+	50005
rs3731227	C/T	21970744	-	50598
rs3731226	C/T	21970792	-	50646
rs13297747	C/G	21970941	+	50795
rs36170221	C/G	21970941	+	50795
rs36153543	C/T	21970944	+	50798
rs7874405	C/T	21970944	+	50798
rs13302595	C/T	21971034	+	50888
rs13301751	A/G	21971039	+	50893
rs13302611	C/T	21971068	+	50922
rs13302761	C/T	21971100	+	50954
rs13302792	C/T	21971168	+	51022
rs3731225	A/G	21971351	-	51205
rs3731224	C/T	21971411	-	51265
rs4074785	A/G	21971583	+	51437
rs3731223	A/G	21973834	-	53688
rs3731222	A/G	21973914	-	53768
rs3731221	A/G	21974010	-	53864
rs3731220	A/G	21974019	-	53873
rs3731219	A/G	21974086	-	53940
rs3731218	C/T	21974331	-	54185
rs3731217	G/T	21974661	-	54515
rs3731216	G/T	21975576	-	55430
rs3731215	C/T	21975771	-	55625
rs3731214	A/G	21975968	-	55822
rs3731213	A/G	21976218	-	56072
rs3731212	C/T	21976271	-	56125
rs3731211	A/T	21976847	-	56701
rs3731210	A/G	21976859	-	56713
rs3731208	C/T	21977155	-	57009
rs3731207	C/T	21977353	-	57207
rs12376353	C/G	21977433	+	57287
rs3731206	A/G	21977472	-	57326
rs3731205	A/G	21977522	-	57376
rs3731204	A/G	21977584	-	57438
rs10757262	A/T	21977874	+	57728
rs3731202	A/G	21978800	-	58654

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs3731201	A/G	21978896	-	58750
rs3731199	A/G	21979330	-	59184
rs3731198	A/G	21979477	-	59331
rs7036656	C/T	21980457	+	60311
rs7867492	C/T	21981016	+	60870
rs3731197	A/G	21981371	-	61225
rs3731196	A/G	21981652	-	61506
rs3731195	C/T	21981695	-	61549
rs3731194	C/G	21981752	-	61606
rs2811710	C/T	21981923	+	61777
rs3731192	G/T	21982274	-	62128
rs3731191	C/T	21983048	-	62902
rs2811711	C/T	21983964	+	63818
rs3731190	C/T	21984282	-	64136
rs2518723	A/G	21985882	-	65736
rs7860185	C/T	21986986	+	66840
rs3218024	A/G	21987437	-	67291
rs3218023	C/T	21987597	-	67451
rs3218022	A/G	21987723	-	67577
rs3218021	G/T	21987752	-	67606
rs3218020	C/T	21987872	-	67726
rs3218019	A/G	21987904	-	67758
rs2811712	A/G	21988035	+	67889
rs3218018	A/C	21988139	-	67993
rs3218016	A/G	21988273	-	68127
rs3218015	C/G	21988392	-	68246
rs3218013	C/T	21988556	-	68410
rs3218012	C/T	21988660	-	68514
rs3218011	A/G	21988676	-	68530
rs3218010	A/G	21988733	-	68587
rs3218009	C/G	21988757	-	68611
rs10965208	A/G	21988965	+	68819
rs2811713	A/G	21989328	+	69182
rs2811714	C/T	21989334	+	69188
rs3218007	A/G	21989800	-	69654
rs3218006	G/T	21989980	-	69834
rs3218005	A/G	21990247	-	70101
rs3218004	C/G	21990687	-	70541
rs3218003	C/G	21990770	-	70624
rs3218002	C/T	21990841	-	70695
rs3218001	C/G	21990959	-	70813
rs3218000	C/T	21991078	-	70932
rs3217999	C/T	21991572	-	71426
rs3217998	A/C	21991667	-	71521
rs3217997	A/G	21992316	-	72170
rs3217996	C/T	21992322	-	72176
rs3217994	A/G	21992864	-	72718
rs3217993	C/T	21993169	-	73023
rs3217992	A/G	21993223	-	73077
rs1063192	C/T	21993367	-	73221
rs3217990	A/C	21993521	-	73375
rs3217989	A/G	21993790	-	73644
rs3217988	A/G	21994082	-	73936
rs2285329	C/T	21994153	-	74007
rs10965209	A/G	21994669	+	74523
rs3217987	C/T	21995061	-	74915
rs11792943	A/G	21995123	+	74977
rs11792944	G/T	21995127	+	74981
rs3217986	A/C	21995330	-	75184
rs3217985	C/T	21995453	-	75307
rs3217984	C/G	21995493	-	75347

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs3217983	C/T	21995623	-	75477
rs3217982	C/T	21995647	-	75501
rs3217981	A/G	21996269	-	76123
rs2069426	A/C	21996273	-	76127
rs974336	A/G	21996348	-	76202
rs3217980	C/T	21996607	-	76461
rs2069425	C/T	21996793	-	76647
rs2285328	C/T	21996966	-	76820
rs2285327	A/G	21997048	-	76902
rs3217979	A/G	21997187	-	77041
rs3217978	G/T	21997330	-	77184
rs2069423	C/T	21997771	-	77625
rs2069422	A/C	21998026	-	77880
rs2069421	A/G	21998313	-	78167
rs3217976	A/C	21998439	-	78293
rs2069420	A/T	21998504	-	78358
rs2069419	A/C/T	21999337	-	79191
rs2069418	C/G	21999698	-	79552
rs3217974	A/C	21999908	-	79762
rs3217973	C/T	21999960	-	79814
rs2069416	A/C/T	22000004	-	79858
rs495490	C/T	22000412	-	80266
rs3808845	A/G	22000575	+	80429
rs3808846	A/G	22000946	+	80800
rs575427	C/T	22001477	-	81331
rs573687	C/T	22001642	-	81496
rs13298881	C/T	22002051	+	81905
rs16935753	A/G	22002229	+	82083
rs16935754	C/T	22002236	+	82090
rs545226	C/T	22002422	-	82276
rs7032979	C/T	22002457	+	82311
rs10811640	G/T	22003411	+	83265
rs10757263	C/T	22003805	+	83659
rs10811641	C/G	22004137	+	83991
rs7042051	C/T	22004758	+	84612
rs7027610	C/T	22004872	+	84726
rs7045307	C/T	22005057	+	84911
rs1101330	G/T	22005465	-	85319
rs13295358	A/C	22005465	+	85319
rs1101329	A/G	22005997	-	85851
rs1633381	A/G	22005997	-	85851
rs10217269	C/T	22006173	+	86027
rs10217281	A/G	22006617	+	86471
rs10965211	C/T	22006891	+	86745
rs28451206	C/G	22006921	+	86775
rs2157718	G/T	22007025	-	86879
rs2106120	A/C	22007101	-	86955
rs16905562	A/T	22007425	+	87279
rs2106119	C/T	22007550	-	87404
rs643319	G/T	22007836	-	87690
rs575237	C/T	22008108	-	87962
rs642323	C/T	22008121	-	87975
rs7044859	A/T	22008781	+	88635
rs523096	C/T	22009129	-	88983
rs518394	C/G	22009673	-	89527
rs10757264	A/G	22009732	+	89586
rs490005	C/T	22010493	-	90347
rs7858261	C/T	22010757	+	90611
rs34623146	A/G	22010822	+	90676
rs597816	A/G	22011172	-	91026
rs7048912	A/G	22011425	+	91279

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs568447	C/T	22011615	-	91469
rs567453	C/G	22011737	-	91591
rs7018665	A/G	22011819	+	91673
rs11515247	C/T	22012269	+	92123
rs581876	A/G	22012376	-	92230
rs7039304	A/T	22012786	+	92640
rs11789770	C/G	22012982	+	92836
rs10965212	A/T	22013795	+	93649
rs1292137	A/T	22014023	-	93877
rs504318	A/T	22014023	-	93877
rs1292136	A/G	22014351	-	94205
rs496892	A/G	22014351	-	94205
rs647188	A/C	22014965	-	94819
rs10811643	A/G	22014966	+	94820
rs10811644	A/T	22015067	+	94921
rs7035484	C/G	22015240	+	95094
rs10738604	A/G	22015493	+	95347
rs11791383	C/G	22015814	+	95668
rs615552	A/G	22016077	-	95931
rs1591137	C/T	22016483	-	96337
rs613312	C/T	22016594	-	96448
rs543830	A/T	22016639	-	96493
rs1591136	C/G	22016834	-	96688
rs10965214	A/T	22017274	+	97128
rs599452	C/T	22017402	-	97256
rs598664	A/G	22017551	-	97405
rs7049105	A/G	22018801	+	98655
rs679038	C/T	22019080	-	98934
rs10965215	A/G	22019445	+	99299
rs564398	A/G	22019547	-	99401
rs4977753	C/T	22020027	+	99881
rs662463	C/T	22020438	-	100292
rs7865618	A/G	22021005	+	100859
rs649436	C/T	22021085	-	100939
rs10115049	A/G	22022119	+	101973
rs634537	A/C	22022152	-	102006
rs2157719	A/G	22023366	-	103220
rs1759417	A/G	22023389	-	103243
rs1633383	A/G	22023532	-	103386
rs2151280	C/T	22024719	-	104573
rs1008878	G/T	22026112	+	105966
rs7029531	C/G	22026170	+	106024
rs1556515	A/G	22026367	-	106221
rs35975148	A/T	22027071	+	106925
rs17694478	C/G	22027171	+	107025
rs12376000	C/T	22029426	+	109280
rs1333037	A/G	22030765	-	110619
rs7028469	G/T	22031342	+	111196
rs1360590	A/G	22031443	-	111297
rs17694493	C/G	22031998	+	111852
rs12352425	A/G	22032086	+	111940
rs12686542	A/C	22032227	+	112081
rs10965216	C/T	22032879	+	112733
rs1412830	A/G	22033612	-	113466
rs1333036	A/G	22033819	-	113673
rs1412829	C/T	22033926	-	113780
rs1333035	C/T	22034059	-	113913
rs1333034	A/G	22034122	-	113976
rs10965217	A/T	22034317	+	114171
rs13290048	C/T	22034804	+	114658
rs28419335	A/G	22035035	+	114889

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs28621545	G/T	22035037	+	114891
rs1360589	A/G	22035317	-	115171
rs12338105	C/G	22035344	+	115198
rs1333033	A/G	22035653	-	115507
rs17834131	A/G	22036168	+	116022
rs12340618	A/G	22037050	+	116904
rs7851706	C/T	22037437	+	117291
rs12683931	A/G	22037916	+	117770
rs10120806	C/T	22037945	+	117799
rs7027950	C/T	22038391	+	118245
rs7028268	A/G	22038414	+	118268
rs7028570	A/G	22038683	+	118537
rs10757265	C/T	22038859	+	118713
rs10738605	C/G	22039130	+	118984
rs10757266	C/T	22039555	+	119409
rs10811645	A/G	22039656	+	119510
rs2151279	C/T	22039845	-	119699
rs6475603	A/G	22040612	+	120466
rs944799	A/G	22040613	+	120467
rs944800	A/G	22040898	+	120752
rs17694555	A/G	22041295	+	121149
rs944801	C/G	22041670	+	121524
rs6475604	C/T	22042734	+	122588
rs10757267	C/G	22042810	+	122664
rs4433231	G/T	22043244	+	123098
rs11790231	A/G	22043591	+	123445
rs7854869	A/C	22043651	+	123505
rs10965219	A/G	22043687	+	123541
rs7027048	A/G	22043709	+	123563
rs17756311	A/G	22043895	+	123749
rs7030641	C/T	22044040	+	123894
rs17694572	A/G	22044356	+	124210
rs7874604	C/T	22044690	+	124544
rs2383204	A/G	22045048	+	124902
rs7036489	A/G	22045992	+	125846
rs7039467	A/G	22046213	+	126067
rs7866660	A/T	22046233	+	126087
rs10965220	A/G	22046279	+	126133
rs7853090	C/T	22046295	+	126149
rs7866783	A/G	22046359	+	126213
rs10120688	A/G	22046499	+	126353
rs13292618	A/G	22047339	+	127193
rs10121501	C/G	22047390	+	127244
rs13299593	C/T	22048918	+	128772
rs7021816	A/C	22049277	+	129131
rs10757268	C/T	22049905	+	129759
rs2095144	C/T	22050136	-	129990
rs2383205	A/G	22050935	+	130789
rs2184061	G/T	22051562	-	131416
rs1537378	C/T	22051614	-	131468
rs4977754	A/C	22052012	+	131866
rs1011970	G/T	22052134	+	131988
rs10965221	G/T	22052999	+	132853
rs8181050	A/G	22054391	+	134245
rs8181047	A/G	22054465	+	134319
rs10811647	C/G	22055002	+	134856
rs1333038	A/G	22055572	+	135426
rs4144664	C/T	22055656	+	135510
rs1333039	C/G	22055657	+	135511
rs4977755	A/T	22056363	+	136217
rs28557075	A/G	22056572	+	136426

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs10965223	A/G	22057004	+	136858
rs10965224	A/T	22057276	+	137130
rs10811648	C/T	22057542	+	137396
rs10811649	C/T	22057554	+	137408
rs10811650	A/G	22057593	+	137447
rs10811651	A/G	22057830	+	137684
rs16905597	A/G	22058074	+	137928
rs1412831	A/G	22058646	+	138500
rs4977756	A/G	22058652	+	138506
rs16905599	A/G	22059144	+	138998
rs34871414	A/C	22059537	+	139391
rs7042970	A/G	22059580	+	139434
rs4451405	C/T	22061750	+	141604
rs4645630	A/G	22061751	+	141605
rs12555547	C/G	22062040	+	141894
rs10757269	A/G	22062264	+	142118
rs9632884	C/G	22062301	+	142155
rs9632885	A/G	22062638	+	142492
rs10757270	A/G	22062719	+	142573
rs17761197	C/T	22062730	+	142584
rs10965226	G/T	22063170	+	143024
rs16923583	A/T	22063334	+	143188
rs1855185	G/T	22063996	+	143850
rs7855162	C/T	22064793	+	144647
rs1831733	C/T	22066071	+	145925
rs1831734	C/T	22066208	+	146062
rs10757271	A/G	22066795	+	146649
rs10811652	A/C	22067085	+	146939
rs1412832	C/T	22067543	+	147397
rs7855660	C/T	22068305	+	148159
rs6475605	C/G	22069020	+	148874
rs16905613	A/G	22070363	+	150217
rs7858034	A/T	22070791	+	150645
rs12347950	A/G	22071128	+	150982
rs1412833	A/G	22071346	+	151200
rs10116277	G/T	22071397	+	151251
rs10965227	A/G	22071796	+	151650
rs6475606	C/T	22071850	+	151704
rs1547704	A/G	22072340	+	152194
rs1547705	A/C	22072375	+	152229
rs10965228	A/G	22072380	+	152234
rs7853953	A/C	22073017	+	152871
rs1333040	C/T	22073404	+	153258
rs1537370	C/T	22074310	+	154164
rs10122192	G/T	22074633	+	154487
rs1970112	C/T	22075598	+	155452
rs10120722	A/C	22076840	+	156694
rs16905635	C/T	22076883	+	156737
rs7857345	C/T	22077473	+	157327
rs10738606	A/T	22078090	+	157944
rs10738607	A/G	22078094	+	157948
rs10757272	C/T	22078260	+	158114
rs16905640	A/G	22078556	+	158410
rs13300638	G/T	22078937	+	158791
rs13284693	A/T	22079014	+	158868
rs12235973	A/T	22079193	+	159047
rs10757273	A/C	22080301	+	160155
rs10965230	C/T	22080416	+	160270
rs9644859	A/G	22080521	+	160375
rs7019916	C/T	22080683	+	160537
rs7020031	C/T	22080753	+	160607

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs7034707	C/T	22080811	+	160665
rs34597771	C/T	22081731	+	161585
rs34555767	G/T	22081924	+	161778
rs7866503	G/T	22081924	+	161778
rs7869527	A/G	22082097	+	161951
rs2210538	A/G	22082257	+	162111
rs7870178	A/G	22082551	+	162405
rs34184423	A/G	22082924	+	162778
rs34168773	A/T	22083299	+	163153
rs9722878	G/T	22083462	+	163316
rs7848875	A/G	22084281	+	164135
rs35537809	A/G	22084330	+	164184
rs4977757	A/G	22084330	+	164184
rs7388840	A/G	22084330	+	164184
rs10738608	A/C	22084796	+	164650
rs35869261	A/T	22085567	+	165421
rs35062160	G/T	22085730	+	165584
rs2891167	C/T	22085851	+	165705
rs10757274	A/G	22086055	+	165909
rs16905644	C/T	22087022	+	166876
rs6475607	A/G	22087693	+	167547
rs7037832	A/G	22088038	+	167892
rs1333041	C/G	22088374	+	168228
rs4977574	A/G	22088574	+	168428
rs2891168	A/G	22088619	+	168473
rs10965231	A/G	22088674	+	168528
rs11787814	A/G	22088683	+	168537
rs1537371	A/C	22089568	+	169422
rs7856476	A/T	22089940	+	169794
rs1556516	C/G	22090176	+	170030
rs12238050	A/C	22090726	+	170580
rs10965232	C/T	22091120	+	170974
rs13292938	G/T	22091259	+	171113
rs7028026	A/G	22091435	+	171289
rs6475608	C/T	22091702	+	171556
rs10125231	A/G	22092128	+	171982
rs7859727	C/T	22092165	+	172019
rs1537372	G/T	22093183	+	173037
rs10965233	A/G	22093314	+	173168
rs1537373	G/T	22093341	+	173195
rs7022719	C/T	22093748	+	173602
rs1333042	A/G	22093813	+	173667
rs4336695	C/G	22094450	+	174304
rs7872591	A/C	22095595	+	175449
rs7859362	C/T	22095927	+	175781
rs10757275	A/G	22096225	+	176079
rs6475609	A/G	22096271	+	176125
rs1333043	A/T	22096731	+	176585
rs7855190	C/T	22098069	+	177923
rs10217720	A/G	22098942	+	178796
rs10217426	C/G	22099387	+	179241
rs1412834	C/T	22100131	+	179985
rs17761319	G/T	22100478	+	180332
rs16905648	A/G	22101973	+	181827
rs7341786	A/C	22102241	+	182095
rs7341791	A/G	22102427	+	182281
rs10511701	C/T	22102599	+	182453
rs17834367	C/T	22102606	+	182460
rs7032115	A/G	22102943	+	182797
rs13301964	C/G	22103324	+	183178
rs16905652	A/T	22103924	+	183778

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs10733376	C/G	22104469	+	184323
rs10738609	A/G	22104495	+	184349
rs2383206	A/G	22105026	+	184880
rs10965234	G/T	22105078	+	184932
rs10965235	A/C	22105105	+	184959
rs4990722	G/T	22105217	+	185071
rs944796	C/G	22105285	+	185139
rs944797	C/T	22105286	+	185140
rs1004638	A/T	22105589	-	185443
rs10965236	C/G	22105633	+	185487
rs2383207	A/G	22105959	+	185813
rs1537374	A/G	22106046	+	185900
rs1537375	C/T	22106071	+	185925
rs1537376	C/T	22106220	+	186074
rs7851006	A/G	22107669	+	187523
rs17834457	C/T	22108026	+	187880
rs17761446	G/T	22108102	+	187956
rs7854631	A/C	22108378	+	188232
rs4977758	A/T	22108481	+	188335
rs4977759	C/T	22108885	+	188739
rs1333044	A/G	22109128	+	188982
rs1333045	C/T	22109195	+	189049
rs12685422	A/C	22111167	+	191021
rs10217586	A/T	22111349	+	191203
rs7860589	C/T	22111353	+	191207
rs7020671	A/T	22112193	+	192047
rs10965237	A/C	22112530	+	192384
rs13285121	A/T	22112912	+	192766
rs7869069	G/T	22113590	+	193444
rs10738610	A/C	22113766	+	193620
rs7854016	A/C	22113967	+	193821
rs1333046	A/T	22114123	+	193977
rs7857118	A/T	22114140	+	193994
rs17761458	A/G	22114368	+	194222
rs10757277	A/G	22114450	+	194304
rs10811656	C/T	22114472	+	194326
rs10757278	A/G	22114477	+	194331
rs1333047	A/T	22114504	+	194358
rs10757279	A/G	22114630	+	194484
rs4977575	C/G	22114744	+	194598
rs1333048	A/C	22115347	+	195201
rs1333049	C/G	22115503	+	195357
rs1333050	C/T	22115913	+	195767
rs12345199	A/G	22116454	+	196308
rs12336106	A/G	22116885	+	196739
rs10757281	C/T	22117613	+	197467
rs10811657	A/G	22117641	+	197495
rs17834529	C/G	22117777	+	197631
rs1889086	C/T	22117879	-	197733
rs10965238	A/G	22117883	+	197737
rs10965239	A/G	22117965	+	197819
rs12379111	C/G	22118180	+	198034
rs10811658	A/G	22118600	+	198454
rs12347779	C/G	22118709	+	198563
rs10965240	C/T	22119164	+	199018
rs7020996	C/T	22119579	+	199433
rs10965241	C/G	22119594	+	199448
rs10965243	A/G	22120065	+	199919
rs10965244	A/T	22120389	+	200243
rs10965245	A/G	22120515	+	200369
rs2891169	A/G	22121825	+	201679

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs4977576	A/C	22121861	+	201715
rs2383208	A/G	22122076	+	201930
rs10965246	C/T	22122698	+	202552
rs10965247	A/G	22122729	+	202583
rs10965248	C/T	22122878	+	202732
rs10965249	C/T	22123131	+	202985
rs7045889	A/G	22123251	+	203105
rs10965250	A/G	22123284	+	203138
rs10217762	C/T	22123645	+	203499
rs10811659	C/T	22123716	+	203570
rs12686509	A/T	22123767	+	203621
rs10757282	C/T	22123984	+	203838
rs10965251	A/G	22124029	+	203883
rs10811660	A/G	22124068	+	203922
rs10811661	C/T	22124094	+	203948
rs10757283	C/T	22124172	+	204026
rs10811662	A/G	22124253	+	204107
rs7019437	C/G	22124302	+	204156
rs7019472	C/T	22124395	+	204249
rs7019778	A/C	22124651	+	204505
rs13287212	G/T	22125071	+	204925
rs10965252	A/G	22125919	+	205773
rs12555274	C/G	22126440	+	206294
rs1333051	A/T	22126489	+	206343
rs10965253	G/T	22126687	+	206541
rs7018475	G/T	22127685	+	207539
rs9969854	G/T	22127710	+	207564
rs11791416	A/G	22128105	+	207959
rs10757284	C/G	22128458	+	208312
rs4977761	C/T	22128762	+	208616
rs35660019	A/G	22128865	+	208719
rs10811663	A/G	22129220	+	209074
rs10965254	A/G	22129485	+	209339
rs10965255	C/T	22130019	+	209873
rs2065501	A/C	22130224	+	210078
rs2065503	A/T	22130336	+	210190
rs7866021	C/T	22130339	+	210193
rs7866410	G/T	22130627	+	210481
rs12340450	A/T	22130678	+	210532
rs7854629	A/G	22131034	+	210888
rs7026735	C/T	22131269	+	211123
rs2065504	G/T	22131552	+	211406
rs2065505	A/G	22131790	+	211644
rs4977577	C/T	22131875	+	211729
rs6475610	C/T	22131894	+	211748
rs12376511	C/T	22132756	+	212610
rs10811664	A/G	22132907	+	212761
rs7859532	A/C	22132956	+	212810
rs7862936	A/G	22133133	+	212987
rs7849199	A/T	22133293	+	213147
rs7849302	C/T	22133377	+	213231
rs10757287	A/T	22133570	+	213424
rs2151285	A/T	22134255	-	214109
rs2151284	C/G	22134276	-	214130
rs2151283	G/T	22134305	-	214159
rs2151282	A/G	22134316	-	214170
rs7867100	A/G	22134460	+	214314
rs7853656	G/T	22134530	+	214384
rs2065500	A/G	22135694	+	215548
rs7030345	A/T	22135739	+	215593
rs13298423	A/C	22136196	+	216050

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs13298664	C/T	22136202	+	216056
rs10811665	C/T	22136604	+	216458
rs7022662	C/G	22137715	+	217569
rs13286296	A/T	22137761	+	217615
rs13285137	A/C	22137863	+	217717
rs28752115	A/G	22137944	+	217798
rs12341394	C/T	22138055	+	217909
rs28539212	A/G	22138269	+	218123
rs4614078	C/G	22140034	+	219888
rs7856219	C/T	22140261	+	220115
rs7043398	A/C	22140707	+	220561
rs12337417	C/T	22140792	+	220646
rs12115577	A/T	22140863	+	220717
rs10811666	A/T	22140867	+	220721
rs13293520	C/T	22140897	+	220751
rs7873930	C/T	22141050	+	220904
rs6475611	A/G	22141139	+	220993
rs7047414	A/C	22141412	+	221266
rs10965256	A/G	22141465	+	221319
rs10965257	C/T	22141528	+	221382
rs7849231	C/T	22142401	+	222255
rs4097833	C/G	22142520	-	222374
rs6475612	A/G	22142580	+	222434
rs6475613	G/T	22142643	+	222497
rs7021554	C/T	22142884	+	222738
rs6475614	C/T	22143265	+	223119
rs7853123	A/G	22143360	+	223214
rs10965258	A/G	22143663	+	223517
rs7853621	A/T	22143714	+	223568
rs7045424	C/T	22144009	+	223863
rs6475615	A/G	22144408	+	224262
rs12001831	G/T	22144411	+	224265
rs13295528	A/T	22144432	+	224286
rs7046009	C/T	22144458	+	224312
rs10965259	C/T	22144489	+	224343
rs10965260	A/T	22144539	+	224393
rs10965261	C/T	22144585	+	224439
rs10965262	C/T	22144592	+	224446
rs7030057	C/T	22144628	+	224482
rs10965263	C/G	22144648	+	224502
rs10965264	C/G	22144655	+	224509
rs7046289	C/T	22144664	+	224518
rs7029976	A/T	22144682	+	224536
rs10965265	G/T	22144683	+	224537
rs7046298	C/T	22144684	+	224538
rs7030278	C/G	22144691	+	224545
rs12343752	A/G	22145075	+	224929
rs7033903	A/G	22145090	+	224944
rs944802	A/G	22145709	-	225563
rs1930590	C/T	22146785	-	226639
rs7028213	G/T	22147360	+	227214
rs7856172	C/T	22147489	+	227343
rs7042842	A/G	22147512	+	227366
rs7856274	G/T	22147532	+	227386
rs7869966	C/G	22147546	+	227400
rs7869852	A/T	22147555	+	227409
rs7870203	C/G	22147567	+	227421
rs7870099	C/T	22147624	+	227478
rs7856433	C/T	22147671	+	227525
rs7856749	G/T	22147902	+	227756
rs1333052	A/C	22147908	+	227762

Marker	Type of polymorphism	Location (NCBI Build 34/35/36)	Orientation	Location (SEQ ID NO:1)
rs12238587	A/T	22148168	+	228022
rs10738611	A/G	22148598	+	228452
rs10122243	C/T	22148924	+	228778
rs10757288	C/T	22149416	+	229270
rs10811667	A/C	22149982	+	229836

B. Microsatellite markers markers within LD Block on C09 (between 21,920,147 and 22,149,982; NCBI Build 34/35/36).

5

Marker	Start position	End position	strand	Forward primer	Reverse Primer
DG9S762	21977346	21977478	+	TTATTACGAGCCTGGTCTGGA	CTGTTTCGTGCAGGATGAATG
DG9S761	21980412	21980677	+	CCCATCTAAGGGTAGAGAAGC	AAGCAAGATTCCAAACAGTAAACA
DG9S760	21994905	21995264	+	AGCAATCTAGGCGTTTGCAC	TGCTGGCCTTTGCTCTTACT
DG9S746	22034929	22035109	+	TGCTAAATGATCTATTTCCACCAT	CCTTTGCATAGGGAGACCAC
D9S1814	22078225	22078501	+	CTTCGATTGCTGGGATTATG	GGGCCTGTGAACCTACTGAC
D9S1870	22093010	22093220	-	TGGGTATGGTTTCTGG	TTGAGGCAGGTCAAATAA

Table 11. Amplimers for surrogate SNPs for rs10116277, rs1333040, and/or rs2383207 in the CEU population, as listed in Table 3.

5	rs7041637	TTTCGCAATGCTTATTTTCAATTTCTTCAGAAATGCCTTAAAGATATTAATGGAGGTAACAACTTAA TCTCAAATAGTAATCCATAGACAGAATATGTAA[A/C]AGCAATGTTCTCTGATCTGTTCTTTGGCTTCTATT CCCTAGAGAAATAGTTCTCTAAGACCAAACAGTCTATAGATAGAATTGTAGCAACAGTCAATTAT
10	rs3218020	GTGGAGAGAAAATGATTATACTTTGAGCTATATGGCTCCAATAAACAAAGATAGATCCCTCAATTT AAATTTGATCCTCAGAAAACCTGAGGGTCAGAGAA[C/T]CCCTCAGGCATGACGGGATAATGTGACAGTTA ATTTGGTATGTCAACTTGGCTAGGCTGTGGTACCCAGTGTTTGTAGTCAAACACCAAGTCTAAATATTGC
15	rs3217992	AGTACTATATTACACTGTTTTTTTTGTTTGTGTTTGTAGTTTTTTTTATTTAAAGCAAACCTCAAACA TTATTGGGTATCAATTACCACCTGGTTGTATT[A/G]AAATAGTAACTTATCAATGCCATGTAAAAATTAATTC CATTTTCGAAGCCACCTGGCAGACAGGTTTAGCTGTTTCATCAGCAGCCTAATATATACTGTT
20	rs1063192	CATTATACTGGGTCATGAAAAATTATCCCTTGAAATAGATATGAAACATGTTACTTCATTTCTGGTT TAAATAACTTGTGGAATCTTTCCTAATGACAAC[C/T]TGATATTAAGGGAAACTAAAGAAAATGTTATTGTG GATCCCACAGTACTATATTACACTGTTTTTTTTGTTTGTGTTTGTAGTTTTTTTTATTTAAAGCA
25	rs2069418	TGATACAAGTTATGAAACTTGTGAAGCCCAAGTACTGCCTGGGGATGAATTTAACTTGTATGACA GGTGCAGAGCTGTCGCTTTCAGACATCTTAAGAAA[C/G]ACGGAGTTATTTTGAATGACTTCTCTCGGTC ACAAGGGAGCCACCAACGTCTCCACAGTGAAACCAACTGGCTGGCTGAAGGAACAGAAATCCTCTGCT
30	rs2069416	AAATAAAAATAAGATACCTGACAAAGTGGGTTTAAATAGGTAAGAGTGCAAACAAAGATTTACTGT ACAAATATGATGAAACTGGGATCTCAGATTCTTA[A/C/T]AGTATAATTTTTTTTTGTCTTATGTGTGCCAGG TTGCCACTCTCAATCTCGAACTAGTTTTTTCTCTTTAAGGGTTGTATCCATAATGCAAAAATGGA
35	rs573687	GTCCAAGACAAATGTGCTATTGTATTACATGTGAAATGTCATCTTTGAAGTCTGGTAAGGGTGTGC TGTGAGGTGAGCCATCTGGAACACAGTGTAGA[C/T]TGAAAAATAATTATAAGCCAGTTTATTACTTTTT TCCAGTTAAGCCTACCATGACAGCTGCTAAAAAAACACTATGTAGTATAAAGGGTAAAAAGACTC
40	rs545226	GGGGTGCAGGTTGTTGGTGTGGCCACACTTCTTCTTGC GGCAATTGACAGCATAGGGGTGCAGG AGAGCATAGCGCTTATGGCAGATCATCTTGTTTCAG[C/T]TGTATTTCTAGGTGAGCTGGAAGAGTGAAGG CTCAATAATGCCACCTCGCAGGTGCAGCACCAGGTGCGGGGTGGGCTGTTTCTGGACGTTGTAGTCTGA
45	rs10811640	TCTTAATTTTTACACATTTTACTTTTCATTTCTTTTAAACTGTTATTAATAATTTATTCATTTGAATA AGGATTAAAATAAGGCTAGGATATTGAAATT[G/T]GTTGAAATTGCTACAGTCTCTGTATCTCTCTCTC TCTTTTTTTTCTTATAAGGGACAGGTTTCATTACCTTGTGACCAGGCTGGAGTGCAATACT
50	rs10811641	TGTGATTCTAGCAGCCATGGATAATTATTTTCATAGATTATTATTTTCTTGGGGATGGCAAAATGGT GATATTCTAATTTTACTATTCTTTCACTTACTAG[C/G]TGGAATGTCTTTTAAATTATTTATTTATTTA TTATTTGAGACAGAGTCTTGCACTGTCACCCAGGCTGGAGTGCAGTGGTGTGATCATAGCTCAC
55	rs2106120	TGCGCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCGCCTCGCCAACTTC CTTATTTTAAATGCCATTTCCCACTAAAAATAAAAC[A/C]AGTAATCTTTGAAAAAAGTTAATATTATGTA TAGGACTGGAAGTATATAAGATAAAACTGGAATATATTGTCATACCAGAAATCAAAGATTTTGTCAA

rs2106119

ATTACTGATGTGACAAGGTACACAAGCCAATGTTGACATAATGTTTTCAAAATGGGGTGTCTGCTG
TAACTGAACTAAATATAATAACTTTATTCAAGAA[C/T]GAGTTTCAATGATAGGACAAAACCTTGATAAAATG
AATAAATAAATAATTATATGCCAGAGTTCAGTAAACCCTGTGTGTACACCTGAAAAAGCTCAAAC

5

rs643319

GAACAGAGCAGAAGAGAGTCTGGATACACAAATTCACAATTATTGGCTCCCATCAACATATCTAA
CTCAAGCATAAAGTTGTTTCAGCAGTAGTTTAAG[G/T]TTGGTTACTAATGCAACACCTCTTGCATGCAAT
GGCCCATTAATATCTTCAACTTTAAAGGTTCTTTGTTTTAAATGCTTATAATGAACAAATA

10

rs7044859

TATGTGATGTAAAGAGCGCCAACATGTTTATATCCTCCTATTTCAATCTACTTTTACTTCATCTACA
TTTTTAGCAATAATGTGAACATGAAATCTTGAA[A/T]AATTAGCTATCTGTAATATATTTACTCATCCACTCA
AAATATTGAGCCCCCAATAAATATCATACACTATTTCTAGGTACAGGTGATAAACAATTCA

15

rs10757264

CCAGTGAAAAGTTAGAGAGAGGGGTCTAGAGCTCAGGGAGGAGTGTGTATCCCTAATTTAGACTA
ATTTGCATTAACAGCTGTAGTAATGCAATTTTCTCT[A/G]TACTGAAATGCAGACATTTGAGTATAGAAAAT
TAGCAGACATTTGAATATAGAAGAAAGATTTACTTTCCTTCAGAAAAAGAATAGTAGAGTATAAAGAA

20

rs10965212

TCGTGCCACTGCACTCCAGCCTGGGTGAGTTGAGAGTCCGTATCAAAGCAAACCTACACATTTT
TGTGGCCTGTTTTAGCTCTATCAAGTCAGTTACA[A/T]TCTTCTGTATTCTAGCTTTTTTATCTGTAAGCTC
CTGCAATGCTTTATTAGAATTTTTAGTTCTTTGCATTTGTTACAACATACTCCTATAACTCTGC

25

rs1292137

TAAAGAAAAAATAATCCAAATGTCAGCAACCTCAAAGATTGAAGGTAGATGAGCCCACAAAGAT
AAGAAATAATCAGCACAGAACAAGTCAAACTCAA[A/T]AATCAAGAGTACCTTCTTCTCCTCAAAGGACC
ACATCACCTCTCTGGCAAGCGTTCAGTACCAGGCTGAGGCTGAGATGGCTGAAATGATAGAAGCAGAA

30

rs10811644

CAAGACCACTCTGCAGATATCAAGTCTGAAAATCCCTAGGGCCAAAGTCTATTATGGGAGCAA
GTTGAGCCTAGAGGGATCGCCATCCCTGTCCATGC[A/T]CTGCTGTAGACACTCCTGCACTAAACCCTCTG
GGCTCCACATCAGCTGGCTTGCTGCTCTACCACTTGCTTGCTCTTGGGGGCTCCACCCAGAGAGA

35

rs7035484

GTCTCTTGGGGGCTCCACCCAGAGAGATGTGGGTGACGAATCATTAGTTCAATCAGCCCAGGA
TGGAGAGTCTGTGCTATGGGCCCAAGCCAGGGGCT[C/G]TCTGTCTGGTGACGAGCAGCTGGGGGGTGG
GGTGGGACCTGTGGGAGATGGACTGGCCTCCTCTCCTGAGTCAACTGCTGCTTATTGGAGGTGTGGATG

40

rs10738604

CCATTGCAGAGGTAGTGGCAGAGAGGCTTTCAGTTGTCCGTGGCGGCTCTGTCCAGGGAGTTGC
TGAGTTGCTATTGGCTTGATATCTCTGGTGGGGTGT[A/G]GCTAGAGGTCCAGGCCTGGAGGACCTGCTC
GTTGAAGAGATGTGGGAATGGGCACCCACATAACAGTCTGTTCACTTTTCCATAGGGCTGCTGTAGTATG

45

rs615552

GGGGAGCTTAAGCAGGGGTGGAAGGGGAACCCAGCACAGAACAGCTGCCCCACAAAAATGTG
GCCACACTGCTTTTTTTTTTTTTTAGCAGGTCCCCA[A/G]TCCCGTTCCTCATCACTGGGTAGAGTCTCCC
ATCTGGGGTCCCCGGCTACCCCACTGGTGTCTCTGACTGAGAGAGGTTTCAGACTTCCATGGGACCT

50

rs543830

TGGGCAAAAGTAGCTGCGACTTTGGCAAAGCTGGAGGTTAGACCCCCAAACATACCCCAGGAGG
TTAGACTCCCATACATACCCAGAAAAGAGGCTGAA[A/T]CCAGCGAGATCAGCAGAGAAGGTCTACAGG
CCCCACTTCCACAGCGCCTCACAGGATAAGACCCACTGGCTTGAATTCCAGCTAGCCACCAGTAGCAAC

55

rs1591136

AAGTGGTAAGTGAATGCGCAACTCTGGGAATCCACACTGCTCTCACAGATCTTTGCAAACCTCAG
ATCAGGAGATCCCTTGTGAACTCACTCCATTAGG[C/G]CCTTCACACACAGCCACGTGGAGTCTCAGCA
GAGCAGCCACTCAGGCATGCATGGAGACCCAAGAGCTTTAGCTACTCCAGCTTTCTGGGTGTCTGGGCA

60

rs7049105

CTTAACAGCAAAGTATCAGATTCATTTATAAAACAATGTGACTGATCTTTATGTATGGTTTGTGAAA
CATTTATGCAGTGTCACTTCAGAAAACCTGCCC[A/G]TTATAGATTTGAATTGATTAAGGATATCCACTCCT
TTCCTTGGCATGATACAAATAAATTACTAAAGTATAAATTGTAACAATGATAAATATAAGTGACAA

5

rs679038

CACCCTTTGGGGAAGGGGATCAAAATATAGTGATTTTCTAATTCTAAGATTCTGTTCTGTGTATATT
AGCTGCTATTCTTCTAGAAAAGAACTTTACCA[C/T]CGTCCCTTGGATTTTTTTTTTAATTTTTGTATGG
TTTAAATTGCATCATCATTCTTTTTGATGTCCAAATTGTCCCAATTAAGCCAGTTAGAGAAACA

10

rs10965215

TAATGGGATTCTGATGGAATGTTTAGTCTGAATCTAATCACATAGAGACTTGTCTGACAAATCCA
GATTTTTTGGATGTTTTGCAGGACTATTTGCCAC[A/G]ACATTTCAAAGGATTCCAAGAGAGAAATTTGGT
GTCCATGCTGTGATGATTCTCAGCTCCTCTCATCTGATCTCCGTCCTGGCCCCCATGACTTTCTTT

15

rs564398

CTCTTCTTTTATCACACAGACCTGAAAGATGATGGTTTCCCAAACAGCACTTACAGCAATAGGTGT
GGGCCTCAGTGGCACATACCACACCCTAACTACC[A/G]CAAAGAAAGTCATGGGGGCCAGGACGGAGAT
CAGATGAGAGGAGCTGAGGAATCATCACAGCATGGACACCAATATTCTCTTGAATCCTTTGAAATG

20

rs10115049

CAAATCTTTCCCTAAGGGAGATTTAGATGAGGCCCCCAGCCTTGGTAGACACCTTGATTGCAGT
CTTGTGAGAGATTGTGAAGCAGAGCTATTCTCAGA[A/G]TTCATGGGTGTTTTAAGCTATGAGGTTTTTTTT
GGGGGGAGAATGGTCATTTGTGATTCTCAGCTATACATAAGTCTACAAAAGTCATTCCAGAAGTGATTC

25

rs634537

TGGGGCTCACAAACCACATGATTCTACCTCCACTGAATCACTTCTGGAATGACTTTTGTAGACTTAT
GTATAGCTGAATCACAAATGACCATTCTCCCCC[A/C]AAAAAACCTCATAGCTTAAACACCCATGAATT
CTGAGAATAGCTCTGCTTCACAATCTCTACAAGACTGCAATCAAGGTGTCTACCAAGGCTGGGGG

30

rs2157719

TTTTATAGTGTGACTCATTTACATATGCATGTGTATGTTTAGGTGCTATTATTAATTTTGTCTGGC
ATATAGTGAGGAAATTGTGATTCAAATTCGTCC[A/G]TATGTACTCCTCCCCACCATCTGCTCTGCCCTC
CATTTACCAGAAGGCTAGCTTTAGCTACTTGTGCATGTAAAACAGAAGCAAGCAACACTGTGAAA

35

rs2151280

GAACATAGATACTCCTTCATTCATGTATTGTCTATGGGTGAGTCTTTATTACAACAGCAGAGATGA
GTAGTTGTGACAGAAACTCGATGGCCCTCAAAG[C/T]GAAACAAGCTACTATCAGGACCTCTATAGAAAA
AGTTTGCCAACTCTACACTGTAGTATGCCTTAAGGATTTTGAAGATTGAGTATGATAAACACTT

40

rs1008878

GAAGGGATGATCAGTCCTTCCCTCCTCTATTTCTTGAGCCCCGTTTTTACCTTTCTTTTTCTCTC
TCCTTTCTTATCATGAAGAATAAAGACAAATGA[G/T]AACAGATCTACCTTAGGCTGATACAGGCGAGGGA
ATCCATTTAATAATAAAACGTGGGTCAAATTCACTTTTCTCTTTTGAATTGAAATTATATTGTG

45

rs1556515

ATTTGATGCAACTTACACACTGTTGTTATACCTCTAGAATTAAAATGACAATTTTTTAAATAATTTTG
GGGGGCCTAGATTTGCTATTTAACCTATCAAA[A/G]AATTGTGTCTTACAGTATTATTCAAATGTAGTGTG
AAAGACTTATACTATTGGTCCTAAGCACTACTGGTTGTTTTAGGCTTTTTCTTTTCTCTGTAG

50

rs1333037

ACATTTATATAATTAAGATGCTAACACTGACTGACAGAAATGTCAGTAAGATGAAATCAGACTGCA
TGGGAGTTTTATGTTACATTAATTTGTAAATTGT[A/G]TATCTCTGTATTCTGTGAGTGTGGCTATCATGA
TGTTAGACATCCAGCTACAAAGGAGGCATTCTGTGCACACACACAGTCTCCAATCTTCTGTTTACCT

55

rs1360590

TAGACAAAGTTTAAATGTTCCCTTTTATATGTTTTCTGGTAAACAAAAATTGTCTCAGGGTTATTAT
GCATATATGATATTGTCAAGAACTTTCTGGGT[A/G]CTGTGGGGCAAAGTCTTCTCCATAAATAAGCTAG
GGTTGATTGGAGTTTTCACTTTGAAAAATATCGCACAGGAGGATCTCAACAGCTAGACAATTTCCA

60

rs1412829

AAATTAATGACATACGTAAAGTCCTCAATAAATAATAGCTCTTATTACCATTTGCTATGGTTACTAT
CACTATTTCTGTATTTTCTTTGCCATTCTCA[C/T]GCTTGAATATGAATCTCATGGGTAGAGTTTCCCAA
GCATGATATGTGTAGTACTACTAAAGGCAAGATTTTGGGTGCATACAGACAAAAAATAATTTA

5

rs1360589

AAACCAGAGGAGTAAAATTCTACTTTCACCAGTAATTAGCAGTGTGGAGTTGAGTAAATAAACCTC
TCTAAGTCTCAGTTTCTACATCTACTAAATCTAA[A/G]CAAATTCAAAACAGTGATTATTTATTAGATTAGA
TATTTTGATTAGTCTTAAATGTCTAATATATAATAAACACTCAACAGGTAGTAGCTATTCTATGT

10

rs7028570

TCATTTCTTCTTTAAGGTCTTAATTTCTTGTTTTTCGAGTTTCATGGGAGATATCCAGTCACCAAT
CCAATCCATATCGGGGAAAAGTACAACAAATGA[A/G]TGAAATTTGTAACCAACCTTGGATGATGGAATAA
GACATTTGGGAGAACACAGGAGAAGTGGGGAGGTTAAGGAGGGATAGCTCTGTGAAAATTTTGCAT

15

rs944801

AACTAATTCTCCAAATTTGCAATTTGGCAGCATCCTACTGGGACTCTAGAAGGCTGATAAATCATG
GAGAGTAGGTATTCATATAGGAACATGAAAGCT[C/G]TATGTAGTAAACACTACTTAAGAAGGCCTTACA
TTTCATAAAAAGTTGGAGATTTTGTGGAGACTCATAAATGCATCCTTTATATCAGTGAAGTTTTT

20

rs10965219

ACTCGTAGCCAGAGCTACCTTCCAGATGACTTCTTTCTACCACTTTCTTTCTTCCCAGTGTAAGAG
AATGCAAGTATATGCTGATGTTTGGAGCAAGAAC[A/G]TTCAAAAATTTTCTTATTAACATAACTTCTAATG
GAAATACAGTATACTACTATGGTGCATACAAAGAAGAAATAGCAACATATATTTGTTTTAGACCTG

25

rs7030641

ATAAGCAGCCTTAAATTAAAAAAGTTAACTCATAACTAACTGTGTGACCTGGGATAAGTT
ACTGACCCTCTTTAGGGCTTAGGGTCTAATCTG[C/T]AAAAACGGAAATTATAATAAACCTTAGCTAGCA
TTTCTGTGCACATACTATAAGCTGGTGATAAACAATTTATACACACTATCTCATTTAATCCTCAC

30

rs10120688

TCCAATGCAAAAGAATAATAGGAGCAAAAGCACAGTGGTGAGAAATTGGAGGGGAACTGTGAAA
ATTGCCACATAGATTAGAGGCAGGAAAATAAAGGAC[A/G]GCTAAGTTTATATAGTGAACAGTGAGCCGC
ATGGACACAGGTGACTGTTTTCTCCTTTTGAACCCCTGCTTACTCCAGAGTCACCACCTCTCCTGGCTT

35

rs2184061

TATTCTGAGTATTAATTCCTGTTTCCAAATAGATTACTCTTTTAAACATAGCACTACTACTTACCTAA
TGAAATTTAGTTGCTATTAATGGATGAATTTT[G/T]TATCTAACAGGCTTGATTTTGATTATGCATTTTAAAT
GTCAGTCAGACACATATTAATAATGATCCATGTTTGTAGCTAATAGGCCCAATATATACTTTT

40

rs1537378

GTAAGGGCTGGGACAAATAAACACAAGTAATTTCAAATATATTAATAATAATATTCTGAGTATTAA
TTCCTGTTTCCAAATAGATTACTCTTTTAAACA[C/T]AGCACTACTACTTACCTAATGAAATTTAGTTGCTAT
TAATGGATGAATTTGTATCTAACAGGCTTGATTTTGATTATGCATTTTAAATGTCAGTCAGAC

45

rs8181050

TGGTGGTCCTAAAGTGGCATTAAAGGAGCCAATAAATTGTCATTCTACCTTAGCTCTGTGTCAGAT
GAAATACACAGCATAGTGTGGGGAGAAAATGTTG[A/G]GCTTATTGGGGATGGGGTCTTTCACATAAAGG
AAGAAGGTTTCAGAAGGCATAGTGGTATGAAAAGAGGAGAAACCAAGGGAGGAAGGTCAATAAAGG

50

rs8181047

CAGCATAGTGTGGGGAGAAAATGTTGGGCTTATTGGGGATGGGGTCTTTCACATAAAGGAAGAA
GGTTTCAGAAGGCATAGTGGTATGAAAAGAGGAGAA[A/G]CCAAAGGGAGGAAGGTCAATAAAGGGTTA
AGAACGAGGGGAGGCAAATTGACTTTCTTTCAGCATATGAGGATTATAGGAATGGAAACCTTAATTGGAAT

55

rs10811647

GAGGATTTAATGCAATTGTTTGTGGGAAAGCACTTTAACAACCTCTAAATTACGATATATATGCTAG
GTTTTATTGTTACCCACACCTTTGATGTATTTCT[C/G]TTTGTACTCTTCACTGTATCTGTAACACATTCCT
AGGATAATTAGGGCTACCCTTTAACAAGCCAAGATTCTATTTATAGTGGTAAGCTGGCACCTGG

60

rs1333039

CTTCTGCTATTGAACGAACTTTTGTTAAGGTAGCTCCCAAGCAGGTTTCAGTAGCTTTGTTCTATTA
TCACTTTTCTACTGACAGTGATTTTTTCTTT[C/G]AAGGCCTGGGACATGGAGACTGCTTTTCTGCAGAA
ACCACATCCCTTGGAGTAATGAGCTACACCTACCTCAATTATTTCAGTGCAGTACAACACTCCAGG

5

rs10965224

ACATTGTGCACATGTACCCTAGAACTTAAAGTATAATAATAAACAAAAAAACCCTGCACAATCT
CTAGTATTTCAGATGGAGACTAAGCATGATTTTT[C/A/T]TATAAAAGAGCAGATCAGAATGTTGTATCTTTA
TTCAGAAAGACTGGAGTTAATCACTGTTATCTTTAGTACTTAGTGCTGCCAAGGCTGTGTGTTTACA

10

rs10811650

ACAGAGTGCTTATTTAAAGAAAAATAAAAAAGAACACACACACACACGCACGCACACACACACGCA
CGCACACACACACACATGTAGCTACATGTCTAGGA[A/G]GGATGTGGAGAGCTGAAATATGAAGGCAAAA
TAAACATCTTTTTCAAAGTATACAGCCTACAGTGGTTAGCACAGAGCTGGCCACATAGCAGGGGTTTC

15

rs10811651

CAATAATGTAGAAGCAAAGAGCCTAAAGTGTTTTCATAAATCTTAAGTGGTAGCTTTATGTTCCAG
TTCAGCAAAACACAAATTTGAAGGCAATCTGTAC[A/G]TAGGGTTCAGGTGAAGAAGGCAAAGGAATCA
ATGAAATTGTAAAGCTTTCAAATTTGCCTTTCTCTTAAGATTGTCTTTCTCTCATTCTCTTCTCC

20

rs4977756

TTTCTGTAGCAGAAGTGTAAGGGTGTTACTCGTAGGAGGCCTCTATTGAACTCTTTCCAGTGAC
GTAGTGTGTGGTCTTTAAGTGGCTTTGCAATGATA[A/G]TAAGATCAGCATTGCATTACTGAATGAGCTCC
TTAGTAAACGTGGATATGTGCTTTCTGAATCTATTTGTTTGTTCCTTCCCAAGTCATAAACAGTGAAT

25

rs10757269

CCATTTAGAGTACTTGCCTCTGAGGGAAATAAAAAATTTGCTAGCAATTTTCTCTAAATGACATTATC
ATAGGCACTTAATTCCTTGATAGGTTCTTTTAG[A/G]TAATTTTTTATAATGAAGCAATTAATTTGATTCAC
GAAAGTAAGTTTCTAGTTTATATAAAGACCAGATCTGGCCTATTTCTTAGCTTGTCTACATTTG

30

rs9632884

TGCTAGCAATTTTCTCTAAATGACATTATCATAGGCACTTAATTCCTTGATAGGTTCTTTTAGATAA
TTTTTTTATAATGAAGCAATTAATTTGATTCAC[C/G]AAAGTAAGTTTCTAGTTTATATAAAGACCAGATCTG
GCCTATTTCTTAGCTTGTCTACATTTGAGTAGTTCATTGCTGGAAAATGACCCTGGAGCTTTT

35

rs1412832

AAGTTGCTCTCAACATACTTAAAGTTTTCCAATAACTGAATTAATATCAGTTTATCAGTTTAATATA
AACAATTAGGGTAAATGAAAATAAAATTTAG[C/T]TCTTTGGTTCCATTAGCCATGGTTCAGGAGCAGAAT
AGTCACCTGAGGCTAGTGACAACGCTTTTGGATCACAGGAAAGAAGAAAAAAATCAAATAAT

40

rs10116277

TTATACTAATGAGGCAATGTGTCTTGAGTATTTGAATTAAGTCTCTAGAATCGATTCTTGGGGA
GGTTATTTACTTTGAAGTGATGGACAGAGTGAG[G/T]AGATTTATGAGTGAAGTCTTGTCTGATTGGAA
ATATAGAGTTGTTTAGGCTAGGTATTACCAACCCAAAGTTGACACTTGAGTCACCTAAGTTCTTCTC

45

rs10965227

TATTAGTTGTGTAATCTTGAAAAATCTCTGACACTTTTCCCTCTGACTCAGTTTCCCCATCTGGCA
CCCAATCTTTTACAGTGTTATGAAAAATAGGGA[A/G]AATGTAGAAAGGAAGAACATGGCACCCAATCCTT
AATGGACACTCAGTGAAAGCTGGCTATCATCATCTTTTGGGGTTGTTGTGTTCTACAAATGTAT

50

rs6475606

TCCCCATCTGGCACCCAATCTTTTACAGTGTTATGAAAAATAGGGAAAAATGTAGAAAGGAAGAAC
ATGGCACCCAATCCTTAATGGACACTCAGTGAAAG[C/T]TGGCTATCATCATCTTTTGGGGTTGTTGTG
TTCTACAAATGTATTTCCAGGAGTTTTTTTACTCTGTCTCCTCTTCTCATATACCCCCAGCC

55

rs1333040

TGGGAAGGATGAATTAATGGGATGGAGTGCAGGGGATGCAGAGTGCCCACTTATGGAATGATTT
CATTCAAGAGAGACAGGAGGGTCAGAGGTAAGAATG[C/T]TACCGCTGGGACAGAGAGGAAGGTACAGA
TATGAGATATGGTAAGAAGGTATACTACAACAGTGGCTCCCAAATCTCAATGAGTAGCCAGTTCTCATGGA

60

5

10

15

20

25

30

35

40

45

50

55

60

rs7859362

GGAGCATGATGTGCTTTGATTTCAACTATGGGCTTTATTACTTACTAACTGGGTTACTTTGGTTAA
GTTGTTTGACTCTTGTTTTTGAGATGGAGTCAG[C/T]CTGGGAGACTCCAGCTCTGTCGCCCAGGCCGGA
GTGCAATGGCAGCATCTTGGCTCACTGCAACCTCTGCCTCCCGGATACAAGCGATTCTCATGCCTTA

rs1333043

CTGGCACAAAGTAGGCACTTCATATATAAAAAGCTGTGATTATTGATGAACCAGTAGTGAGGTACAT
AACTGGGGAAGGAGAAGGGGCCAGTTTGTGGGAA[A/T]GCTTTTTTAGTTATTAATAGTAAGGTGGTAAA
ATAATAATAGTAATAATAACCAAAAGTTACTGAAAACATAACAGTGCTAAACTCTTAAAAGGAGT

rs1412834

CTTCTTTAGCTGTAAATAAGTAATTGTATGAGGTGATGGTTAAGGTGATTTACTAATTTTACAATTC
TATTATTTTATGAATAGACCCTAGTTAGGATAG[C/T]TTGAAATAGATACTTAATCCACTATTATTCTCTCTT
CTAAGATATAGTTACTAGTTGATCATACTTTTCTTAAAGGCTGAACTGAATTCTCTGATATCA

rs7341786

GAAACATACTGGTTAATGGAATTCCAGAAAGGACTGAACAATCAAACCATTTTGAAGGACAGCAT
AGAGCTGGACTCTAGAACAGCCAAAACAAGGGGTT[A/C]AACCACTGCGAGGGATCTCTCTCAACTCTT
GCTCAGGCTTTTCTCCCTGGCTTGACTTTCTCTTTCACTGTAGATTGGCTTCTCTCACATGGCAAG

rs10511701

TATTATGTGTGGCTGACTATATAAAAACATGGATATTTTCTTGAATCACTTGGTTTGACTGGGAG
AAGACCATTTCTCAAAACAAAGGAAGTGCAATTTA[C/T]AGAAGGTAGTAGAATAGGCAGATAAAACAATAA
TTCTTCACTATATTGCTCAAATAATCCCCATGACATTTTGTATATTATAAAGAGAGTTCTAAAGT

rs10733376

GAGAAAGATGTTAAGATGAAATTAGATGTGCAAGAGATTGCGCGAGGTAAACCTTGTGGGAGAAA
ATGGAGAGGTACATAGAGGAGCCTGGGCAGACTGT[C/G]TGGCTACTATGTAAGACTCATCCCCATGAAG
GAGAAAGGAGAGGAAGGCAAAGAAGAAAAACCTTAAGATTCAATTCTAAGAACGTTTTGACAAAGCTG

rs10738609

TGTGCAAGAGATTCGCGAGGTAAACCTTGTGGGAGAAAATGGAGAGGTACATAGAGGAGCCTG
GGCAGACTGTGTGGCTACTATGTAAGACTCATCCCC[A/G]TGAAGGAGAAAGGAGAGGAAGGCAAAGAA
GAAAAACCTTAAGATTTCAATTCTAAGAACGTTTTGACAAAGCTGATTAGGAGTATTTAAGGCAAAGCTGC

rs2383206

AAATACTTTAACTCATGGCCCCGATGATTTTCAGTTAACCAAATTCTCCCTTACTATCCTGGTTGCCC
CTTCTGTCTTTTCTTAGAAATGTTATTGTAGT[A/G]TTTGCAAGATGGCCTGAATCCTGAACCCCCCATCT
TCAATGAGCACCAAATGGTAATTATAGATTCCAGCTGTAGAGCTATGTCAGACAAAGGAACTT

rs944797

CTCTTCCTTGGTGGCTTAAAGTTAGGCTGAAGAAGATTTACATTATGTTGTGCATGACCTCTTTAG
TTTGGTTCTACTTATACTTTCAAGGAGGGAAGAC[C/T]GGGGAAGGTGTCCCTTAGTGAGCATATTTTGTA
CAAATGAAAACAGGGTACTAACCTTATGCCAGGACGCATGCATAAACTAGGATGGTTCTGAGAAAA

rs1004638

AGAACCTTAATGGGAGCACAGGTCCCACCCACCCCTTGCTACCCCATGTACTTGTTCCTATCTTCA
CCCAAGAGAGGAAACACTCTGGAAGTGGGCAGC[A/T]TAAGTGAAGCAGAGTGAAAAGGAATGTGAAG
TTTTGAGAAGAAAGAAAGGCTAAAGTGTCTATCTTTCCACATTGCTTTTTTCAGGTTTCTCTTCGGAA

rs2383207

GATGAAAAATTCATATTCATCTGAATTTTATAAGTGAATCATGAGAACTCAAAGATACTTAGCCCTT
GGGACCATTTTTTACTCCTGTTTCGGATCCCTTC[A/G]GCTAAGCATGATTATTTACTATTTTCAGCTATTAG
TTATGTCTTGTTGAAAAAGTATGAAAAGAGCTGCCCAATAAATTAGAGTGATGCTCAACATTCT

rs1537374

TTCGGATCCCTTCAGCTAAGCATGATTATTTACTATTTTCAGCTATTAGTTATGTCTTGTTGAAAAA
GTATGAAAAGAGCTGCCCAATAAATTAGAGTGT[A/G]TGCTCAACATTCTCTTAGCTTCTTTATCTCTTTCC
AAAATTGGATCAAATGACATTGGACATGATCAACTTCTTACTGTTTTGACAAACATCTGAGGATA

rs1537375

TTATTTACTATTTTCAGCTATTAGTTATGTCTTGTTGAAAAAGTATGAAAAGAGCTGCCCAATAAAT
TAGAGTGTATGCTCAACATTCTCTTAGCTTCTT[C/T]ATCTCTTTCCAAAATTGGATCAAATGACATTGGAC
ATGATCAACTTCTTACTGTTTTGACAAACATCTGAGGATACTTTTATAATTGATAAATTGGACTA

5

rs1333045

TTTTGTGCCTCAGTTTCCTCATTCAATATGGGTGTAATAACTGTGCCTGTCTTGTAGGATTATTGTG
AGGCCCAAGTGCAATAATATATAGTACACTGTG[C/T]CTGGCATCTAGTAAGCATTCAATTAAGATGACATG
AAGATAACACAGATATATCTTAACATGTAATTATGATTTTGCTTATTCAAGGCCAAGCATTCCAAT

10

rs10738610

GAAGAAGAAGACAGTCAGAGAGAAGTGAGGGCTTACTTTTCATGTTTAAAGTCTGTTATGTGGTA
AAGGGATTAGATTTATCTGTGTTGTTCCAGGGGAC[A/C]GAAATAGGACAAATGGATGCAAATAGAGTGA
GGAAGATTTAAACAAATGGAGAAGACATTCTAAAATCAACTACAATGAGCGTAAACAATGACAACGGA

15

rs1333046

TCATATGCATAGACAAATACACCAAAGTATGAATATTTGCCTTGATAATCTTTTTGTAGTTTTTTT
ATGAACATATATTACTCAAACAATTTAGAACA[A/T]TTGGCAATATATATATATTTTCAATTTATAAAGGTTAG
GAAGATTAATTACACTTTCTGAGGTCGCAACTAAAAGCCAAGATTTTAATCCATTTCTATTTG

20

rs10757278

AGTGTCACTGGAAAGTGACAAAGAGGACAGTTAAGTTAGTTGGAAGTGAAGTGAAGGCCAGACAG
GGCTGTGGGACAAGTCAGGGTGTGGTCATTCCGGTA[A/G]GCAGCGATGCAGAATCAAGACAGAGTAGT
TTCTCCTTCTCTCTCTCTTTAATTGTAACGCCTTTATAACAAACAAATATTATGCTTATTTCTGTCTT

25

rs1333047

CAGTTAAGTTAGTTGGAAGTGAAGTGAAGGCCAGACAGGGCTGTGGGACAAGTCAGGGTGTGGTC
ATTCCGGTAAGCAGCGATGCAGAATCAAGACAGAGT[A/T]GTTTCTCCTTCTCTCTCTCTTTAATTGTAA
CGCCTTTTATAACAAACAAATATTATGCTTATTTCTGTCTTTAAATTTTTTGTAGTAATTTCTCATCA

30

rs4977575

TTTTCTAGTTGAGCTATCATTATTTTATTATGTGGAAGTGAAGGTAGTCCTGGCTACTTGGGAA
CAGCGTGGAGTCTAGCCATGTCAGGGCCAGAAGT[C/G]GTCTCAGCTAAGTTAGAATGTGATACCATTGT
TTACACAAGTGTGGCCTGCCTTCAAGATAGGGTGAGGTGTTTTATGACCACAGGCTTTATGAGTTATA

35

rs1333048

TGACTCTGAAGATCATACCCGAAGTAGAGCTGCAAAGATATTTGGAATATTGGTAATATCCAATAA
AGAATGACCTTCATGCTATTTTGAGGAGATGTTT[A/C]AATGTCGAATTATTGAAATATTTATAAAATACAA
ATAAACTAACTCTGCTTCATATTCCAAGTGTGTATGACACTTCTTAGGCTATCATTTTCATTCCAA

40

rs1333049

TTCCAAGTTGTGTATGACACTTCTTAGGCTATCATTTTCATTCCAAATTTATGGTCACTACCCTACTG
TCATTCCTCATACTAACCATATGATCAACAGTT[C/G]AAAAGCAGCCACTCGCAGAGGTAAGCAAGATATA
TGGTAAATACTGTGTTGACAAAAGTATGCAGAAGCAGTCACATTTATACAGTAGTGAAGGAAATGT

45

rs1333050

AATTACAGTATATCTAAAAAAGAATAATATATAACAACTGAAAAAATAAATAGTTGATATAAGCA
GATATTCGAAGATCTGCCAGACATATTGTTAAA[C/T]GAAAAATCTAGATACAAAATTGTTTATAGTTCTCTT
TCATACTATAGCCAAAGAAAATTGAGAAAAAAGTACTTACAGTTGATCCTTGAATAATGCAGCA

50

Table 12: Association results for the MI phenotype for rs2383207 (G) and rs10757278 (G), in 9p21 in Iceland and the US. Results are shown for the initial Icelandic discovery MI case-control group (Iceland A), an independent Icelandic replication group (Iceland B) and for the three US replication groups of Caucasian origin. Also included are the results for the MI case-control groups combined.

Study population (n/m) ^a	Frequency		OR (95% CI)	P
Variant (allele)	Controls	Cases		
Iceland A (1607/6728)				
rs2383207 (G)	0.455	0.506	1.22 (1.13-1.33)	1.4×10 ⁻⁶
rs10757278 (G)	0.434	0.489	1.25 (1.15-1.36)	1.5×10 ⁻⁷
Iceland B (665/3533)				
rs2383207 (G)	0.462	0.525	1.29 (1.15-1.45)	0.000026
rs10757278 (G)	0.436	0.503	1.31 (1.16-1.47)	0.000014
Atlanta (596/1284)				
rs2383207 (G)	0.541	0.593	1.23 (1.07-1.42)	0.0030
rs10757278 (G)	0.484	0.551	1.31 (1.14-1.50)	0.00015
Philadelphia (582/504)				
rs2383207 (G)	0.524	0.602	1.37 (1.16-1.63)	0.00026
rs10757278 (G)	0.470	0.550	1.38 (1.17-1.64)	0.00019
Durham (1137/718)				
rs2383207 (G)	0.513	0.559	1.20 (1.05-1.37)	0.0060
rs10757278 (G)	0.460	0.521	1.28 (1.12-1.46)	0.00027
Combined Iceland^b (2274/10260)				
rs2383207 (G)	0.458	0.511	1.24 (1.16-1.33)	3.3×10 ⁻¹⁰
rs10757278 (G)	0.435	0.493	1.26 (1.18-1.35)	5.3×10 ⁻¹²
US groups^c (2315/2508)				
rs2383207 (G)	0.526	0.585	1.25 (1.15-1.36)	1.1×10 ⁻⁷
rs10757278 (G)	0.471	0.541	1.31 (1.21-1.43)	1.5×10 ⁻¹⁰
Replication groups^d (2980/6041)				
rs2383207 (G)	0.494	0.555	1.27 (1.18-1.36)	1.4×10 ⁻¹¹
rs10757278 (G)	0.454	0.522	1.31 (1.22-1.40)	1.0×10 ⁻¹⁴
All groups^{b,d} (4589/12768)				
rs2383207 (G)	0.492	0.548	1.25 (1.18-1.31)	2.0×10 ⁻¹⁶
rs10757278 (G)	0.453	0.517	1.28 (1.22-1.35)	1.2×10 ⁻²⁰

^a Number of MI cases (n) and controls (m). ^b When combining the Icelandic cohorts they are analysed together and the results adjusted for relatedness in the combined group. ^c For the combined groups OR and P value are calculated using a Mantel-Haenszel model and the frequency in cases and controls is a simple average over the frequency in the individual groups.

^d When combining Icelandic and US groups, the frequency in cases and controls is the average over the two populations.

Table 13: Genotype specific odds ratio for the risk allele of rs10757278. Shown is the risk for heterozygous carriers (0X) and homozygous carriers (XX) compared to the risk for non-carriers (00), together with 95% confidence intervals (CI), and the population attributable risk (PAR). The lower part of the table includes the corresponding values when the analysis is restricted to early-onset MI cases.

Study population (n/m) ^a	Genotype specific Odds Ratio ^b			PAR ^b
Variant (allele)	00	0X (95% CI)	XX (95% CI)	
Iceland^c (2272/10261)				
rs10757278 (G)	1	1.25 (1.12-1.39)	1.58 (1.38-1.81)	0.19
US groups (2315/2508)				
rs10757278 (G)	1	1.28 (1.14-1.45)	1.72 (1.45-2.03)	0.23
All groups (4587/12769)				
rs10757278 (G)	1	1.26 (1.16-1.36)	1.64 (1.47-1.82)	0.21
Early onset MI (< 50 for males; < 60 for females)				
Iceland^c (621/10261)				
rs10757278 (G)	1	1.38 (1.13-1.69)	1.94 (1.53-2.46)	0.27
US groups (1080/2508)				
rs10757278 (G)	1	1.56 (1.32-1.85)	2.08 (1.69-2.58)	0.34
All groups (1701/12769)				
rs10757278 (G)	1	1.49 (1.31-1.69)	2.02 (1.72-2.36)	0.31

^aNumber of MI cases (n) and control (m). ^bGenotype specific odds ratio for heterozygous (0X) and homozygous carrier (XX) compared to non-carriers (00).

^cPopulation attributable risk (PAR). ^dFor the Icelandic groups, P values and OR were adjusted for relatedness using simulations.

Table 14: Association of the G allele of rs10757278 to coronary artery disease (CAD). The association results are shown for CAD, both including and excluding known MI cases. Results are shown for the Icelandic case-control group (excluding the discovery group), for two of the US groups, and for the groups combined.

5

Study population (n1/n2/m) ^a	All CAD cases				Excluding MI cases		
Variant (allele)	Cont.frq	Case.frq	OR (95% CI)	P	Case.frq	OR (95% CI)	P
Iceland^b (1563/773/3533)							
rs10757278 (G)	0.439	0.496	1.26 (1.15-1.37)	1.9×10 ⁻⁷	0.490	1.22 (1.09-1.37)	0.00050
Atlanta (724/128/1284)							
rs10757278 (G)	0.484	0.552	1.31 (1.15-1.50)	0.000036	0.557	1.34 (1.04-1.73)	0.026
Philadelphia (709/126/504)							
rs10757278 (G)	0.470	0.547	1.36 (1.16-1.60)	0.00019	0.528	1.26 (0.96-1.66)	0.10
Combined							
US groups^c (1433/254/1788)							
rs10757278 (G)	0.477	0.550	1.33 (1.20-1.47)	2.7×10 ⁻⁸	0.542	1.30 (1.08-1.57)	0.0059
All groups^c (2996/1027/5321)							
rs10757278 (G)	0.458	0.523	1.29 (1.21-1.38)	3.6×10 ⁻¹⁴	0.525	1.24 (1.13-1.37)	0.000011

^a Number of all cases (n_1), cases excluding MI patients (n_2), and controls (m). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is a simple average over the individual groups or, when combining Icelandic and US groups, the average over the two populations.

Table 15: Association to MI on 9p21

Shown are all SNPs in the region 21.92 to 22.12 (NCBI build 34) on 9p21 that show nominally significant association to MI in the genome-wide association study. Results are shown for 1607 MI cases and 6728 controls from the Icelandic discovery cohort. Also included are the corresponding results if the association test is done adjusting for the observed association to the three SNPs, rs1333040, rs10116277 and rs2383207 (indicated in bold).

SNP	Allele	Position	Frequency		OR	P^a	OR ^b	P^b
			Controls	MI cases				
rs10757260	A	21943137	0.606	0.627	1.09	0.041	1.10	0.037
rs7041637	A	21951866	0.233	0.253	1.12	0.021	0.99	0.91
rs2811712	A	21988035	0.875	0.893	1.19	0.0076	1.16	0.022
rs3218018	A	21988139	0.879	0.896	1.20	0.0074	1.17	0.021
rs3217992	A	21993223	0.344	0.378	1.16	0.00055	0.98	0.75
rs2069426	C	21996273	0.881	0.897	1.18	0.0146	1.15	0.038
rs2069422	A	21998026	0.875	0.894	1.20	0.0059	1.17	0.018
rs2151280	T	22024719	0.464	0.486	1.09	0.038	0.96	0.43
rs1333034	A	22034122	0.875	0.893	1.19	0.0073	1.17	0.021
rs1011970	G	22052134	0.772	0.806	1.22	9.2×10^{-5}	1.14	0.020
rs10116277	T	22071397	0.418	0.468	1.22	1.9×10^{-6}	na	na
rs1333040	T	22073404	0.490	0.542	1.23	6.1×10^{-7}	na	na
rs2383207	G	22105959	0.455	0.506	1.22	1.4×10^{-6}	na	na
rs1333050	T	22115913	0.671	0.693	1.11	0.020	0.97	0.61

^a P value adjusted using genomic controls. ^b P value and OR adjusted for the observed association to rs1333040, rs2383207 and rs10116277.

Table 16: Association to MI. Shown is the association for the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to MI in the combined Icelandic case-control group and in the three US case-controls groups.

Study population (n/m) ^a	Controls		Cases		OR (95% CI)	P
Variant (allele)	AA/Aa/aa	Frq.	AA/Aa/aa	Frq		
Iceland A (1607/6728)						
rs1333040 (T)	1770/3315/1636	0.490	342/783/478	0.542	1.23 (1.14-1.34)	6.1×10 ⁻⁷
rs2383207 (G)	2022/3280/1418	0.455	389/811/408	0.506	1.22 (1.13-1.33)	1.4×10 ⁻⁶
rs10116277 (T)	2305/3212/1208	0.418	454/805/350	0.468	1.22 (1.13-1.33)	1.9×10 ⁻⁶
rs10757278 (G)	592/869/318	0.434	413/770/376	0.489	1.25 (1.15-1.36)	1.5×10 ⁻⁷
Iceland B (665/3533)						
rs1333040 (T)	893/1750/889	0.499	135/312/188	0.541	1.18 (1.05-1.33)	0.0065
rs2383207 (G)	1016/1770/746	0.462	146/319/171	0.525	1.29 (1.15-1.45)	0.000026
rs10116277 (T)	1160/1770/602	0.421	178/317/148	0.480	1.27 (1.12-1.43)	0.00010
rs10757278 (G)	224/366/128	0.436	160/329/161	0.503	1.31 (1.16-1.47)	0.000014
Atlanta (596/1284)						
rs1333040 (T)	190/588/369	0.573	63/253/230	0.648	1.37 (1.19-1.58)	0.000016
rs2383207 (G)	273/603/381	0.541	100/270/206	0.593	1.23 (1.07-1.42)	0.0030
rs10116277 (T)	296/571/310	0.503	114/273/190	0.565	1.28 (1.12-1.47)	0.00041
rs10757278 (G)	341/618/287	0.484	119/291/175	0.551	1.31 (1.14-1.50)	0.00015
Philadelphia (582/504)						
rs1333040 (T)	80/225/172	0.585	55/263/232	0.661	1.38 (1.16-1.65)	0.00031
rs2383207 (G)	105/250/127	0.524	86/274/197	0.602	1.37 (1.16-1.63)	0.00026
rs10116277 (T)	120/222/125	0.505	86/262/178	0.587	1.39 (1.18-1.65)	0.00013
rs10757278 (G)	137/254/103	0.470	116/281/169	0.550	1.38 (1.17-1.64)	0.00019
Durham (1137/718)						
rs1333040 (T)	101/364/230	0.588	159/520/427	0.618	1.14 (0.99-1.30)	0.067
rs2383207 (G)	156/377/176	0.513	230/535/353	0.559	1.20 (1.05-1.37)	0.0060
rs10116277 (T)	166/366/174	0.504	256/526/334	0.534	1.13 (0.99-1.29)	0.076
rs10757278 (G)	189/370/134	0.460	261/545/304	0.521	1.28 (1.12-1.46)	0.00027
Combined						
Iceland^b (2274/10260)						
rs1333040 (T)	2663/5065/2525	0.493	477/1095/666	0.542	1.21 (1.14-1.30)	1.6×10 ⁻⁸
rs2383207 (G)	3038/5050/2164	0.458	535/1130/579	0.511	1.24 (1.16-1.33)	3.3×10 ⁻¹⁰
rs10116277 (T)	3465/4982/1810	0.419	632/1122/498	0.471	1.23 (1.15-1.32)	1.1×10 ⁻⁹
rs10757278 (G)	816/1235/446	0.435	573/1099/537	0.493	1.26 (1.18-1.35)	5.3×10 ⁻¹²
US groups^c (2315/2508)						
rs1333040 (T)		0.582		0.642	1.27 (1.17-1.39)	3.6×10 ⁻⁸
rs2383207 (G)		0.526		0.585	1.25 (1.15-1.36)	1.1×10 ⁻⁷
rs10116277 (T)		0.504		0.562	1.24 (1.14-1.35)	3.1×10 ⁻⁷
rs10757278 (G)		0.471		0.541	1.31 (1.21-1.43)	1.5×10 ⁻¹⁰
Replication groups^d (2980/6041)						
rs1333040 (T)		0.541		0.592	1.24 (1.16-1.33)	1.3×10 ⁻⁹
rs2383207 (G)		0.494		0.555	1.27 (1.18-1.36)	1.4×10 ⁻¹¹
rs10116277 (T)		0.463		0.521	1.25 (1.17-1.34)	1.3×10 ⁻¹⁰
rs10757278 (G)		0.454		0.522	1.31 (1.22-1.40)	1.0×10 ⁻¹⁴
All groups^{b,d} (4589/12768)						
rs1333040 (T)		0.538		0.592	1.24 (1.17-1.30)	4.1×10 ⁻¹⁵
rs2383207 (G)		0.492		0.548	1.25 (1.18-1.31)	2.0×10 ⁻¹⁶
rs10116277 (T)		0.492		0.548	1.24 (1.17-1.30)	1.8×10 ⁻¹⁵
rs10757278 (G)		0.453		0.517	1.28 (1.22-1.35)	1.2×10 ⁻²⁰

^a Number of MI cases (n) and controls (m). ^b When combining the Icelandic cohorts they are analysed together and the results adjusted for relatedness in the combined group. ^c For the combined groups OR and P value are calculated using a Mantel-Haenszel model and the frequency in cases and controls is a simple average over the frequency in the individual groups. ^d When combining Icelandic and US groups, the frequency in cases and controls is the average over the two populations.

Table 17: Genotype specific odds ratio.

The upper part shows the genotype specific odds ratios for the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, for all MI cases. Shown is the risk for heterozygous carriers (0X) and homozygous carriers (XX) compared to the risk for non-carriers (00), together with 95% confidence intervals (CI). Also included is the population attributed risk (PAR). The lower part of the table includes the corresponding values when the analysis is restricted to early-onset MI cases.

Study population (n/m) ^a	Genotype specific Odds Ratio ^b			
Variant (allele)	00	0X (95% CI)	XX (95% CI)	PAR ^c
Iceland^d (2272/10261)				
rs1333040 (T)	1	1.18 (1.05-1.32)	1.46 (1.28-1.68)	0.17
rs2383207 (G)	1	1.26 (1.13-1.40)	1.53 (1.34-1.76)	0.19
rs10116277 (T)	1	1.23 (1.11-1.37)	1.52 (1.32-1.74)	0.17
rs10757278 (G)	1	1.25 (1.12-1.39)	1.58 (1.38-1.81)	0.19
US groups (2315/2508)				
rs1333040 (T)	1	1.34 (1.16-1.55)	1.65 (1.38-1.97)	0.28
rs2383207 (G)	1	1.18 (1.04-1.34)	1.54 (1.30-1.82)	0.19
rs10116277 (T)	1	1.16 (1.03-1.31)	1.52 (1.29-1.79)	0.17
rs10757278 (G)	1	1.28 (1.14-1.45)	1.72 (1.45-2.03)	0.23
All groups (4587/12768)				
rs1333040 (T)	1	1.24 (1.14-1.35)	1.52 (1.37-1.69)	0.22
rs2383207 (G)	1	1.22 (1.13-1.32)	1.54 (1.39-1.71)	0.20
rs10116277 (T)	1	1.20 (1.11-1.30)	1.53 (1.38-1.69)	0.18
rs10757278 (G)	1	1.26 (1.16-1.36)	1.64 (1.47-1.82)	0.21
Early onset MI (< 50 for males; < 60 for females)				
Iceland^d (621/10261)				
rs1333040 (T)	1	1.28 (1.01-1.63)	1.94 (1.50-2.50)	0.27
rs2383207 (G)	1	1.30 (1.04-1.62)	1.80 (1.40-2.32)	0.24
rs10116277 (T)	1	1.32 (1.06-1.63)	1.86 (1.44-2.40)	0.24
rs10757278 (G)	1	1.38 (1.13-1.69)	1.94 (1.53-2.46)	0.27
US groups (1080/2508)				
rs1333040 (T)	1	1.58 (1.29-1.94)	2.00 (1.58-2.53)	0.38
rs2383207 (G)	1	1.40 (1.16-1.67)	1.88 (1.52-2.33)	0.31
rs10116277 (T)	1	1.50 (1.26-1.79)	1.90 (1.53-2.35)	0.32
rs10757278 (G)	1	1.56 (1.32-1.85)	2.08 (1.69-2.58)	0.34
All groups (1701/12769)				
rs1333040 (T)	1	1.46 (1.25-1.70)	1.95 (1.65-2.32)	0.34
rs2383207 (G)	1	1.36 (1.18-1.56)	1.84 (1.56-2.17)	0.28
rs10116277 (T)	1	1.43 (1.25-1.64)	1.87 (1.58-2.20)	0.29
rs10757278 (G)	1	1.49 (1.31-1.69)	2.02 (1.72-2.36)	0.31

^aNumber of MI cases (n) and control (m). ^bGenotype specific odds ratio for heterozygous (0X) and homozygous carriers (XX) compared to non-carriers (00). ^cPopulation attributed risk (PAR). ^dFor the Icelandic groups, P values and OR were adjusted for relatedness using simulations.

Table 18: Association to age at onset of MI.

Shown is the association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to age at onset of MI. The results are based on regressing the sex adjusted age at onset on the number of risk alleles an individual carries. The combined analysis is done by including a cohort indicator as a explanatory variable in the regression. All MI cases with known age at onset, including late-onset MI, from the four study groups are included in the analysis; this adds 973 MI cases to the study groups compared to the case-controls analysis.

Study population (n/m) ^a	Effect (s.e.m.)	P
Iceland (2896/750)		
rs1333040 (T)	-1.20 (0.31)	0.00012
rs2383207 (G)	-1.04 (0.31)	0.00080
rs10116277 (T)	-1.05 (0.31)	0.00069
rs10757278 (G)	-1.08 (0.31)	0.00042
Atlanta (611/40)		
rs1333040 (T)	-1.36 (0.69)	0.050
rs2383207 (G)	-1.16 (0.65)	0.075
rs10116277 (T)	-1.47 (0.64)	0.023
rs10757278 (G)	-1.35 (0.65)	0.038
Philadelphia (555/82)		
rs1333040 (T)	-0.85 (0.79)	0.28
rs2383207 (G)	-1.01 (0.76)	0.19
rs10116277 (T)	-1.01 (0.76)	0.18
rs10757278 (G)	-1.25 (0.74)	0.092
Durham (1213/101)		
rs1333040 (T)	-0.89 (0.48)	0.19
rs2383207 (G)	-1.11 (0.46)	0.017
rs10116277 (T)	-1.14 (0.46)	0.013
rs10757278 (G)	-1.19 (0.46)	0.0098
Combined		
US groups (2379/223)		
rs1333040 (T)	-0.97 (0.36)	0.0014
rs2383207 (G)	-1.09 (0.34)	0.0014
rs10116277 (T)	-1.19 (0.34)	0.00039
rs10757278 (G)	-1.26 (0.34)	0.00019
All groups (5275/793)		
rs1333040 (T)	-1.10 (0.23)	2.7×10 ⁻⁶
rs2383207 (G)	-1.06 (0.23)	3.5×10 ⁻⁶
rs10116277 (T)	-1.12 (0.23)	9.2×10 ⁻⁷
rs10757278 (G)	-1.16 (0.23)	2.9×10 ⁻⁷

^a n is the number of MI cases used in the regression and m is the number of MI cases used that were not included in the case-control analysis.

Table 19: Association to early-onset MI.

Shown is the association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to early-onset MI in the combined Icelandic case-control group and in the three US case-controls groups. Early-onset MI is defined as a MI event before the age of 50 for males and before the age of 60 for females.

Study population (n/m) ^a	Controls		Cases		OR (95% CI)	P
Variant (allele)	AA/Aa/aa	Frq.	AA/Aa/aa	Frq		
Iceland^b (621/10261)						
rs1333040 (T)	2663/5065/2525	0.493	114/293/210	0.576	1.40 (1.24-1.57)	1.9×10 ⁻⁸
rs2383207 (G)	3038/5050/2164	0.458	133/310/176	0.533	1.35 (1.20-1.52)	3.4×10 ⁻⁷
rs10116277 (T)	3465/4982/1810	0.419	156/308/153	0.496	1.36 (1.21-1.53)	1.9×10 ⁻⁷
rs10757278 (G)	816/1235/446	0.435	142/299/166	0.518	1.40 (1.24-1.57)	3.5×10 ⁻⁸
Atlanta (305/1284)						
rs1333040 (T)	190/588/369	0.573	27/131/121	0.659	1.44 (1.20-1.74)	0.00011
rs2383207 (G)	273/603/381	0.541	45/145/105	0.600	1.27 (1.06-1.52)	0.0082
rs10116277 (T)	296/571/310	0.504	47/150/97	0.584	1.38 (1.16-1.65)	0.00035
rs10757278 (G)	341/618/287	0.484	53/161/86	0.558	1.35 (1.13-1.61)	0.00099
Philadelphia (211/504)						
rs1333040 (T)	80/225/172	0.585	17/102/83	0.661	1.38 (1.09-1.75)	0.0075
rs2383207 (G)	105/250/127	0.524	30/95/75	0.618	1.47 (1.17-1.85)	0.0011
rs10116277 (T)	120/222/125	0.505	27/97/66	0.593	1.42 (1.13-1.79)	0.0026
rs10757278 (G)	137/254/103	0.470	39/103/63	0.561	1.44 (1.15-1.81)	0.0017
Durham (564/720)						
rs1333040 (T)	101/364/230	0.588	64/249/234	0.651	1.31 (1.11-1.54)	0.0012
rs2383207 (G)	156/377/176	0.513	91/271/192	0.596	1.40 (1.20-1.64)	0.000026
rs10116277 (T)	166/366/174	0.504	97/278/178	0.572	1.31 (1.12-1.53)	0.00070
rs10757278 (G)	189/370/134	0.459	105/278/168	0.559	1.49 (1.28-1.75)	5.0×10 ⁻⁷
Combined						
US groups^c (1080/2508)						
rs1333040 (T)		0.582		0.657	1.37 (1.23-1.52)	1.6×10 ⁻⁸
rs2383207 (G)		0.526		0.605	1.37 (1.23-1.52)	4.8×10 ⁻⁹
rs10116277 (T)		0.504		0.583	1.36 (1.22-1.51)	9.5×10 ⁻⁹
rs10757278 (G)		0.471		0.559	1.43 (1.29-1.59)	1.7×10 ⁻¹¹
All groups^c (1701/12769)						
rs1333040 (T)		0.538		0.617	1.38 (1.28-1.50)	1.6×10 ⁻¹⁵
rs2383207 (G)		0.492		0.569	1.36 (1.26-1.47)	8.2×10 ⁻¹⁵
rs10116277 (T)		0.462		0.540	1.36 (1.26-1.47)	9.2×10 ⁻¹⁵
rs10757278 (G)		0.453		0.539	1.42 (1.31-1.53)	3.3×10 ⁻¹⁸

^a Number of MI cases (n) and controls (m). ^b For the Icelandic group the P value and CI are adjusted for relatedness using simulations. ^c For the combined groups, the frequency in cases and controls is a simple average over the frequency in the individual group or, when combining Icelandic and US groups, the average over the two populations.

Table 20: Association to coronary artery disease.

Association of the risk alleles of the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277, and the most significant refinement SNP, rs10757278, to coronary artery disease (CAD) in an Icelandic group of CAD patients and in groups of CAD patients from two of the US study groups. The study group from Durham does not include any CAD patients in addition to the MI patients and was excluded from this part of the analysis. Also included are the corresponding results if all known MI cases are excluded from the CAD patient group.

Study population ($n_1/n_2/m$) ^a		Controls			All CAD cases			Excluding MI cases		
Variant (allele)	AA/Aa/aa	Freq.	AA/Aa/aa	Freq.	OR (95% CI)	P	AA/Aa/aa	Freq.	OR (95% CI)	P
Iceland^b (1563/773/3533)										
rs1333040 (T)	893/1750/889	0.499	308/697/413	0.533	1.15 (1.05-1.25)	0.0020	152/328/192	0.527	1.12 (1.00-1.25)	0.057
rs2383207 (G)	1016/1770/746	0.462	353/732/387	0.513	1.23 (1.13-1.34)	2.2×10 ⁻⁶	186/353/185	0.500	1.17 (1.04-1.31)	0.0067
rs10116277 (T)	1160/1770/602	0.421	409/707/333	0.474	1.24 (1.14-1.35)	9.5×10 ⁻⁷	204/333/158	0.468	1.21 (1.08-1.35)	0.0010
rs10757278 (G)	224/366/128	0.439	393/745/376	0.496	1.26 (1.15-1.37)	1.9×10 ⁻⁷	203/365/188	0.490	1.22 (1.09-1.37)	0.00050
Atlanta (724/128/1284)										
rs1333040 (T)	190/588/369	0.572	75/310/281	0.649	1.38 (1.21-1.58)	2.4×10 ⁻⁶	12/57/51	0.655	1.42 (1.09-1.86)	0.010
rs2383207 (G)	273/603/381	0.541	117/335/249	0.595	1.25 (1.09-1.42)	0.00093	17/65/43	0.606	1.30 (1.00-1.69)	0.046
rs10116277 (T)	296/571/310	0.503	130/341/228	0.571	1.31 (1.15-1.50)	0.000038	16/68/38	0.598	1.47 (1.13-1.90)	0.0039
rs10757278 (G)	341/618/287	0.484	139/362/207	0.552	1.31 (1.15-1.50)	0.000036	20/71/32	0.557	1.34 (1.04-1.73)	0.026
Philadelphia (709/126/504)										
rs1333040 (T)	80/225/172	0.585	59/273/235	0.648	1.31 (1.11-1.55)	0.00170	24/49/47	0.588	1.02 (0.76-1.35)	0.92
rs2383207 (G)	105/250/127	0.524	89/285/200	0.600	1.36 (1.15-1.60)	0.00023	25/52/46	0.587	1.29 (0.98-1.71)	0.072
rs10116277 (T)	120/222/125	0.504	90/274/180	0.582	1.37 (1.16-1.61)	0.00017	26/52/43	0.556	1.23 (0.93-1.62)	0.14
rs10757278 (G)	137/254/103	0.470	146/339/208	0.547	1.36 (1.16-1.60)	0.00019	30/57/38	0.528	1.26 (0.96-1.66)	0.10
Combined										
US groups^c (1433/254/1788)										
rs1333040 (T)		0.579		0.649	1.35 (1.22-1.50)	1.9×10 ⁻⁸		0.621	1.23 (1.01-1.51)	0.044
rs2383207 (G)		0.533		0.598	1.29 (1.17-1.43)	9.8×10 ⁻⁷		0.597	1.30 (1.08-1.57)	0.0068
rs10116277 (T)		0.504		0.577	1.34 (1.21-1.48)	2.1×10 ⁻⁸		0.577	1.35 (1.12-1.63)	0.0018
rs10757278 (G)		0.477		0.550	1.33 (1.20-1.47)	2.7×10 ⁻⁸		0.542	1.30 (1.08-1.57)	0.0059
All groups^c (2996/1027/5321)										
rs1333040 (T)		0.539		0.591	1.22 (1.14-1.31)	3.2×10 ⁻⁹		0.590	1.14 (1.04-1.26)	0.0082
rs2383207 (G)		0.497		0.555	1.25 (1.17-1.34)	1.3×10 ⁻¹¹		0.565	1.20 (1.09-1.32)	0.00019
rs10116277 (T)		0.462		0.525	1.28 (1.20-1.37)	1.7×10 ⁻¹³		0.541	1.25 (1.13-1.37)	7.8×10 ⁻⁶
rs10757278 (G)		0.458		0.523	1.29 (1.21-1.38)	3.6×10 ⁻¹⁴		0.525	1.24 (1.13-1.37)	0.00011

^a Number of all cases (n_1), cases excluding MI patients (n_2), and controls (m). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is a simple average over the individual groups or, when combining Icelandic and US groups, the average over the two populations.

Table 21: Markers correlated with the at-risk signal.

All SNPs in the LD-block (based on the HapMap v19 CEU dataset) that are correlated, with $r^2 \geq 0.5$, to at least one of the three SNPs, rs1333040, rs10116277 and rs2383207, together with the correlation coefficients D' and r^2 . Additional markers selected for typing on both the Icelandic and all the US case/control groups are indicated in bold italic.

SNP	Position ^a	Position ^b	Frq	rs1333040		rs10116277		rs2383207	
				D'	r^2	D'	r^2	D'	r^2
rs10811647	22055002	134856	0.449	0.95	0.49	0.92	0.70	0.92	0.62
rs10811650	22057593	137447	0.450	0.95	0.49	0.93	0.70	0.92	0.63
rs9632884	22062301	142155	0.521	0.96	0.65	1	0.93	0.93	0.84
rs10116277	22071397	151251	0.500	1	0.67	1	1	1	0.90
rs6475606	22071850	151704	0.500	1	0.67	1	1	1	0.90
rs1333040	22073404	153258	0.600	1	1	1	0.67	0.88	0.57
rs1537370	22074310	154164	0.500	1	0.67	1	1	1	0.90
rs7857345	22077473	157327	0.733	1	0.55	1	0.36	0.81	0.26
rs10738607	22078094	157948	0.504	1	0.69	1	1	1	0.90
rs10757272	22078260	158114	0.500	1	0.67	1	1	1	0.90
rs4977574	22088574	168428	0.500	1	0.67	1	1	1	0.90
rs2891168	22088619	168473	0.500	1	0.67	1	1	1	0.90
rs1537371	22089568	169422	0.500	1	0.67	1	1	1	0.90
rs1556516	22090176	170030	0.500	1	0.67	1	1	1	0.90
rs6475608	22091702	171556	0.737	1	0.54	1	0.36	0.8	0.25
rs7859727	22092165	172019	0.496	1	0.66	1	1	1	0.90
rs1537373	22093341	173195	0.500	1	0.67	1	1	1	0.90
rs1333042	22093813	173667	0.508	0.96	0.63	1	0.97	1	0.94
rs7859362	22095927	175781	0.525	0.88	0.57	1	0.90	1	1
rs1333043	22096731	176585	0.517	0.92	0.60	1	0.94	1	0.97
rs1412834	22100131	179985	0.525	0.88	0.57	1	0.90	1	1
rs7341786	22102241	182095	0.533	0.84	0.54	1	0.88	1	0.97
rs10511701	22102599	182453	0.533	0.84	0.54	1	0.88	1	0.97
rs10733376	22104469	184323	0.525	0.88	0.57	1	0.90	1	1
rs10738609	22104495	184349	0.525	0.88	0.57	1	0.90	1	1
rs2383206	22105026	184880	0.525	0.88	0.57	1	0.90	1	1
rs944797	22105286	185140	0.525	0.88	0.57	1	0.90	1	1
rs1004638	22105589	185443	0.525	0.88	0.57	1	0.90	1	1
rs2383207	22105959	185813	0.525	0.88	0.57	1	0.90	1	1
rs1537374	22106046	185900	0.525	0.88	0.57	1	0.90	1	1
rs1537375	22106071	185925	0.525	0.88	0.57	1	0.90	1	1
rs1333045	22109195	189049	0.548	0.68	0.37	0.92	0.69	0.85	0.65
rs10738610	22113766	193620	0.517	0.92	0.60	1	0.94	1	0.97
rs1333046	22114123	193977	0.517	0.92	0.60	1	0.94	1	0.97
rs10757278	22114477	194331	0.491	0.95	0.57	0.96	0.90	1	0.87
rs1333047	22114504	194358	0.492	0.96	0.59	0.97	0.90	1	0.88
rs4977575	22114744	194598	0.492	0.96	0.59	0.97	0.90	1	0.88
rs1333048	22115347	195201	0.508	0.96	0.63	1	0.97	1	0.94
rs1333049	22115503	195357	0.492	0.96	0.59	0.97	0.90	1	0.88

^a Base-pair location in NCBI Build 34, Build 35 and Build 36.

^b Position in SEQ ID NO:94 (LD Block C09)

Table 22a: Association to MI for additional markers typed in the LD block C09.

Association to MI of the three SNPs from the genome-wide association study and of the 10 highly correlated refinement markers. The association is calculated for the combined Icelandic and US case-control groups with OR and P-values combined using a Mantel-Haenszel model. Also included are the corresponding adjusted P values for each marker when the association is tested conditional on the observed association of each of the other markers.

SNP	Allele	Position ^a	Frequency ^b		Adjusted P values													
			Controls	Cases	Unadjusted		rs10811650	rs10116277	rs1333040	rs10738607	rs4977574	rs6475608	rs2383207	rs1333045	rs1333046	rs10757278	rs1333048	
					OR	P												
rs10811650	G	22057593	0.398	0.449	1.21	3.0×10 ⁻¹²	na	0.79	0.10	0.43	0.47	1.6×10 ⁻⁶	0.47	0.063	1.00	0.51	0.86	
rs10116277	T	22071397	0.461	0.516	1.24	1.8×10 ⁻¹⁵	1.2×10 ⁻⁴	na	0.011	0.47	0.83	3.0×10 ⁻⁹	0.20	0.0046	0.38	0.67	0.65	
rs1333040	T	22073404	0.537	0.592	1.24	4.1×10 ⁻¹⁵	6.6×10 ⁻⁵	0.040	na	0.18	0.11	1.6×10 ⁻⁸	0.011	2.3×10 ⁻⁴	0.027	0.15	0.050	
rs10738607	G	22078094	0.463	0.525	1.27	2.1×10 ⁻¹⁹	6.2×10 ⁻⁹	2.5×10 ⁻⁵	4.2×10 ⁻⁶	na	0.056	7.1×10 ⁻¹³	2.8×10 ⁻⁴	8.0×10 ⁻⁶	0.0015	0.61	0.0079	
rs4977574	G	22088574	0.465	0.525	1.27	1.1×10 ⁻¹⁸	1.6×10 ⁻⁸	1.8×10 ⁻⁴	1.7×10 ⁻⁵	0.43	na	2.7×10 ⁻¹²	0.0021	7.3×10 ⁻⁵	0.033	0.61	0.076	
rs6475608	C	22091702	0.700	0.737	1.18	6.3×10 ⁻⁸	0.058	0.52	0.84	0.71	0.72	na	0.70	0.83	0.93	0.73	0.93	
rs2383207	G	22105959	0.492	0.548	1.25	2.0×10 ⁻¹⁶	9.2×10 ⁻⁶	0.017	3.8×10 ⁻⁴	0.42	0.73	3.2×10 ⁻¹⁰	na	0.0020	0.56	0.25	0.78	
rs1333045	C	22109195	0.508	0.563	1.24	6.3×10 ⁻¹⁵	3.4×10 ⁻⁵	0.024	4.1×10 ⁻⁴	0.92	0.85	1.2×10 ⁻⁸	0.15	na	0.50	0.17	0.62	
rs1333046	A	22114123	0.468	0.526	1.25	2.5×10 ⁻¹⁷	6.2×10 ⁻⁷	0.0036	1.5×10 ⁻⁴	0.20	0.68	5.0×10 ⁻¹¹	0.038	5.0×10 ⁻⁴	na	0.044	0.74	
rs10757278	G	22114477	0.453	0.517	1.28	1.2×10 ⁻²⁰	4.8×10 ⁻¹⁰	2.7×10 ⁻⁶	4.8×10 ⁻⁷	0.039	0.0041	5.0×10 ⁻¹⁴	2.0×10 ⁻⁵	2.6×10 ⁻⁷	2.4×10 ⁻⁵	na	1.1×10 ⁻⁴	
rs1333048	C	22115347	0.472	0.532	1.26	6.0×10 ⁻¹⁸	1.6×10 ⁻⁷	9.5×10 ⁻⁴	4.6×10 ⁻⁵	0.39	0.94	1.2×10 ⁻¹¹	0.017	2.4×10 ⁻⁴	0.24	0.10	na	

^a Base-pair location in NCBI Build 34. ^b The frequency in cases and controls is a simple average over the frequency in Iceland and in US.

^a Base-pair location in NCBI Build 34. ^b The frequency in cases and controls is a simple average over the frequency in Iceland and in US.

Table 22b: Genotype count for additional markers typed in the LD block C09.

Genotype counts in cases and controls for the eight additional refinement SNPs typed in the LD block C09 and for the three SNPs from the genome-wide study, rs1333040, rs2383207 and rs10116277. Genotype counts are shown for the combined Icelandic case-control group (Iceland A+B) and for the three US replication cohorts. For each SNP counts are shown for the risk allele a and the wild type allele A.

SNP	Risk Allele	Position ^a	Iceland A+B			Philadelphia			Atlanta			Durham		
			Controls	Cases	AA/aA/aa	Controls	Cases	AA/aA/aa	Controls	Cases	AA/aA/aa	Controls	Cases	AA/aA/aa
rs10811650	G	22057593	819/1015/279	652/878/336	143/193/74	107/239/119	293/394/147	165/271/133	202/380/112	344/527/222				
rs10116277	T	22071397	3465/4982/1810	632/1122/498	120/222/125	86/262/178	296/571/310	114/273/190	166/366/174	256/526/334				
rs1333040	T	22073404	2663/5065/2525	477/1095/666	80/225/172	55/263/232	190/588/369	63/253/230	101/364/230	159/520/427				
rs10738607	G	22078094	1502/2326/933	558/1099/547	131/244/116	105/278/173	332/603/312	114/283/186	187/373/137	261/552/312				
rs4977574	G	22088574	1507/2335/964	554/1105/556	130/246/119	103/286/180	332/597/325	115/274/188	187/383/144	267/549/316				
rs6475608	C	22091702	235/980/1135	170/870/1059	36/200/250	26/199/342	101/476/616	24/210/330	58/276/353	67/415/588				
rs2383207	G	22105959	3038/5050/2164	535/1130/579	105/250/127	86/274/197	273/603/381	100/270/206	156/377/176	230/535/353				
rs1333045	C	22109195	610/1264/638	433/1102/655	115/262/114	95/289/180	286/605/347	93/290/200	159/378/169	218/548/345				
rs1333046	A	22114123	1519/2266/959	583/1078/554	123/244/120	102/274/181	315/586/330	114/273/191	182/378/154	251/539/323				
rs10757278	G	22114477	816/1235/446	573/1099/537	137/254/103	116/281/169	341/618/287	119/291/175	189/370/134	261/545/304				
rs1333048	C	22115347	1372/2202/926	473/947/478	119/247/120	99/274/184	210/418/231	108/286/188	175/379/154	247/532/325				

^a Base-pair location in NCBI Build 34.

Table 23: Primers in the AF109294 gene and ESTs used for PCR screening of cDNA libraries.

ESTs*	Forward primer	Reverse primer
AF109294	TTGGTGTCCATGCTGTGATGATT	GGTTGGGGACCCCTGGTGTA
CN277071	GGTTCAAGCATCACTGTTAGGTGT	GAGGCGGGCGAATCACGA
AW169296	GCTCAGAGCAATTCCAGTGCAAG	GGTTCAGTCCTGGTTCTGC
BX100299	TCTCATTGGGGATACGAAGCTCT	TCTGGCCCTAGCCTCCATGT
ESTs*	Nested forward primer	Nested reverse primer
AF109294	AACTCCAAAGAAACCATCAGAGG	TGGGGACCCCTGGTG TAGTG
CN277071	CTTTCCCGAGTCAGTACTGCTTTCT	CGGGCGAATCACGAGGTC
AW169296	TTCCAGTGCAAGTATGGTCTGTGA	CCAGTCCTGGTTCTGCCACA
BX100299	TCATTGGGGATACGAAGCTCTACA	CAGAAAGCTGCAAAGGCCTCA

ESTs* names are from NCBI Build 36.

Table 24. Expression analysis of ESTs and AF109294 in various cDNA libraries by PCR screening

ESTs	cDNA libraries						
	Whole blood	EBV transf. lymphoblasts	Whole heart	Aorta	Cardiac fibro-myocytes	Ventricular fibroblasts	Endothelial cells (HUVEC)
AF109294	positive	nd	nd	positive	positive	nd	nd
CN277071	positive	positive	nd	positive	positive	positive	positive
AW169296	positive	positive	positive	positive	positive	positive	positive
BX100299	positive	positive	nd	positive	positive	positive	positive

nd: not detected. positive: generated PCR products that were confirmed by sequencing

Table 25: Primers used for sequencing of *CDKN2A* and *CDKN2B*.

Primer alias	Forward primer	Primer alias	Reverse primer
CDKA.1e-f.F	AAAGAAGCCAGACACGGAAG	CDKA.1e-f.R	GTAAGTGAATCCAGCCAACC
CDKA.1f.F	GGATGAGGCAGCGTGGAC	CDKA.1f.R	AAGCCGTGTCTCAAGATCG
CDKA.1g.F	TCCGGTTTGGCAGCAGTC	CDKA.1g.R	CTAGCAAATGGCAGAACCA
CDKA.1h.F	CAACAGTGTGAGAAACGATGC	CDKA.1h.R	ATCAGTCACCGAAGGTCTTA
CDKA.3b.F	CTTGATCTCCCAAAGTGAAGG	CDKA.3b.R	CGACTCTGGAGGACGAAGTT
CDKA.4d.F	AGATCTCGGAACGGCTCT	CDKA.4d.R	GAGGCGTGCAGCGGTTTA
CDKA.4e.F	GGAAGAAAGGAAAGCGAGGT	CDKA.4e.R	CGGGATCAAGGGGAGTCCG
CDKA.4f.F	TCCTCGCGTAGAATGGTTGT	CDKA.4f.R	AGCCCGCAGAGTTTAGGAC
CDKA.4g.F	CCTGAGCGCGGTCTAAGC	CDKA.4g.R	CGTTTTGTCTTGGGTTTGTACC
CKDN2A.1.F	CCCCTTCAGATCTTCTCAGC	CKDN2A.1.R	AGCACCGGAGGAAGAAAGAG
CKDN2A.2.F	CCCGCACCTCCTCTACCC	CKDN2A.2.R	AGTGAACGCACTCAAACACG
CKDN2A.3.F	TTGGCAAGGAAGGAGGACTG	CKDN2A.3.R	TACCAGGCAATGTACACGTC
CKDN2A.4.F	GGTTCATAAGTCAGAAACCCTAGT	CKDN2A.4.R	AGCTTAGGATGTGTGGCACT
CKDN2A.5.F	AGTCTTCATTGCTCCGCAGT	CKDN2A.5.R	GACACGCTGGTGGTGTCTG
CKDN2A.6.F	ATCTATGCGGGCATGGTTAC	CKDN2A.6.R	ACAGTGCTCTCTGCCTGTGAC
CKDN2A.7.F	CAAAATGCTTGTCTGAAGTCG	CKDN2A.7.R	GTGAAGCCATTGCGAGAA
CKDN2A.8.F	TTTCAATCGGGGATGTCTGC	CKDN2A.8.R	CCACTGAGACTCATTATATAACACTCGTT
p14.1.F	ATCCCCACCCAGGATATTCG	p14.1.R	GGTCCCAGTCTGCAAGTTAAG
p14.2.F	CTGCGCACCATGTTCTCG	p14.2.R	CGAGCAGCACCAGAATCC
CDKB.06.F	CCCTACTGACTATTACATATCAATGC	CDKB.06.R	CAGAAAATTAAATATACCTGTTAAGTTCG
CDKB.07.F	TTTTAACCATTTAAGGCATAGGA	CDKB.07.R	GCAAACCTCAAACATTATTGG
CDKB.08.F	CTGCTGATGAAACAGCTAAACC	CDKB.08.R	GCACTCAATCATTAGAGGCTACA
CDKB.09.F	TCTTGAATTTAAGATATAGAGGTCAA	CDKB.09.R	TGCACAAAGAAGTGCATCTAGT
CDKB.10.F	GTTAGAGAAAGAAAAGCCACCTTAG	CDKB.10.R	ACAAGTCATTTGAGAGTGGAGAC
CDKB.11.F	AACATATGCTCTGATTCTCAACTAAC	CDKB.11.R	GGGATTTAATTTCCAGGGTTG
CDKB.12.F	CAAACATTGAGAGAAGGGAACC	CDKB.12.R	GGAAGAACTACAGCTCTTAAATGTAGC
CDKB.13.F	TCTGCACCCTGAGACACTCTA	CDKB.13.R	GGAGACCCTCGCCCAACT
CDKB.14.F	TAAGAGCAAAGGCCAGCATCC	CDKB.14.R	CACTCACCATGAAGCGAAAC
CDKB.15.F	TAATCACTGCCTTCTCCCACTC	CDKB.15.R	GGAGGGCTTCTCTGGACAC
CDKB.16.F	GGGTGGGAAATTGGGTAA	CDKB.16.R	GGAAAGTGGATTGCATCAGC
CDKB.17.F	GGCAGGTATGGGAGATGC	CDKB.17.R	TCTCCCCTAAACCATTACTCC
CDKB.23.F	ACAATACAACAGATTTTATATAGTAGCTTAG	CDKB.23.R	TAGTGGAGAAGGTGCGACAG
CDKB.24.F	TAGGTTCAGCCCCGATCC	CDKB.24.R	GGCTGGCTCCCCACTCTG
CDKB.25.F	TTCCTGGCGCTCAAGAACC	CDKB.25.R	CACAAGGGAGCCACCAAC
CDKB.26.F	CACTGCCCTCAGCTCCTA	CDKB.26.R	CCTGACAAAGTGGGTTTAAATAGGT
CDKB.27.F	TGCATTATGGATACAACCCTTA	CDKB.27.R	TCTTCTCAGCACTCCGAAC
CDKB.28.F	CGGATGCTACATTGGATAGG	CDKB.28.R	GGCTCAAGAATTGGGTCA
CDKB.a29.F	GAAGGGAACCGGGTAGCA	CDKB.a29.R	CCATAATGTCCTTTCTATTTGACG

Table 26: Sequencing variants in *CDKN2A* and *CDKN2B*.

Shown are all SNPs identified through sequencing of *CDKN2A* and *CDKN2B* for 93 early onset MI cases using primers in **Table 25**. Many of the SNPs identified in the sequencing effort are rare, and have low correlation with rs10757278. These SNPs cannot account for the correlation of rs10757278 to the disease. Two common SNPs, rs3217992 and rs2069416 have modest correlation with rs10757278 ($r^2 = 0.36$ and 0.37 respectively). rs3217992 is a part of the Illumina Hap300 chip. For Iceland A, rs10757278 gave a P value of 1.5×10^{-7} , while rs3217992 gave a P value of 5.4×10^{-4} . Hence rs3217992 cannot account for the association of rs10757278. Neither can rs2069416 since it is highly correlated with rs3217992 ($r^2 > 0.8$ both in HapMap CEU and Iceland). SNP rs1063192, which has r^2 of 0.23 with rs10757278 in these sequenced individuals, is also an Illumina SNP and did not even show nominal significance in Iceland A ($P > 0.05$). Rs2069418 is highly correlated with rs1063192.

MAF ^a	A	a	Position ^b	Position ^d	rs names	D' ^c	r ² ^c	Location
CDKN2A								
0.069	A	G	21958159	38013	rs3088440	0.5	0.02	Exon3
0.176	C	G	21958199	38053	rs11515	0.44	0.03	Exon3
0.005	C	T	21960674	40528		1	0	Intron2
0.042	T	C	21960916	40770	rs3731249	1	0.04	Exon2
0.005	A	G	21961188	41042		1	0	Exon2
0.01	G	C	21964859	44713	rs1800586	1	0.01	Exon1
0.356	C	T	21965017	44871	rs3814960	0.18	0.02	5'UTR
0.042	A	T	21965319	45173	SG09S293*	1	0.04	5'UTR
0.036	T	C	21965561	45415	rs3731238	1	0.03	5'UTR
0.057	A	C	21965807	45661	SG09S291*	0.49	0.01	5'UTR
0.094	C	T	21983964	63818	rs2811711	0.42	0.02	5'UTR
CDKN2B								
0.005	A	G	21957014	36868		1	0.01	3'UTR
0.01	A	G	21957207	37061		1	0.01	3'UTR
0.01	G	T	21957291	37145		1	0.01	3'UTR
0.005	C	A	21957479	37333		1	0.01	3'UTR
0.005	G	C	21957838	37692		1	0.01	3'UTR
0.071	A	G	21958159	38013		0.33	0.01	3'UTR
0.38	G	A	21964218	44072	rs3731239	0.41	0.13	3'UTR
0.005	G	C	21964355	44209		1	0.01	3'UTR
0.01	G	T	21985044	64898		1	0.01	3'UTR
0.005	T	C	21985467	65321		1	0.01	3'UTR
0.323	T	C	21985882	65736	rs2518723	0.29	0.07	3'UTR
0.422	T	C	21993223	73077	rs3217992	0.78	0.36	Exon2
0.398	G	A	21993367	73221	rs1063192	0.53	0.23	Exon2
0.005	C	A	21993417	73271		1	0	Exon2
0.005	C	T	21993591	73445		1	0.01	Exon2
0.078	G	T	21995330	75184	rs3217986	0.58	0.03	Exon2
0.005	C	G	21995493	75347	rs3217984	1	0.01	Exon2
0.104	T	G	21996273	76127	rs2069426	0.08	0	Intron1
0.005	A	G	21996303	76157		1	0.01	Intron1
0.104	T	C	21996348	76202	rs974336	0.08	0	Intron1
0.005	G	A	21996536	76390		1	0.01	Intron1
0.382	G	C	21999698	79552	rs2069418	0.55	0.23	5'UTR
0.011	G	A	21999915	79769		1	0.01	5'UTR
0.005	T	C	21999953	79807		1	0.01	5'UTR
0.1	del	A	21999996	79850	rs2069417	0	0	5'UTR
0.395	A	T	22000004	79858	rs2069416	0.8	0.37	5'UTR
0.089	G	A	22000412	80266	rs495490	0.03	0	5'UTR
0.021	A	G	22000681	80535	SG09S492*	1	0.02	5'UTR
0.005	C	G	22001083	80937		1	0.01	5'UTR

MAF ^a	A	a	Position ^b	Position ^d	rs names	D' ^c	r ² ^c	Location ⁿ
0.005	C	G	22001158	81012		1	0.01	5'UTR

^a MAF : minor allele frequency.

^b Base-pair location in NCBI Build 34.

^c Correlation to the refinement SNP rs10757278 based on the 93 sequenced MI cases.

^d Position in SEQ ID NO:94 (LD Block C09).

*Alternate names used herein for non-public SNPs

Table 27: SNPs in conserved TF bindings sites within the MI region.

SNP		TF binding site			LD to rs1333040		
Name	Location	TF Name	Start	End	D'	r ²	P
rs16935754	22002235	PAX2	22002234	22002253	nd	nd	nd
rs35113513	22023540	FOXO4	22023540	22023551	nd	nd	nd
rs35834365	22023550	FOXO4	22023540	22023551	nd	nd	nd
rs17694493	22031997	STAT	22031995	22032004	0.41	0.05	0.03
rs1412830	22033611	FOXO4*	22033601	22033615	nd	nd	nd
rs1412830	22033611	FOXO3*	22033601	22033615	nd	nd	nd
rs4977758	22108480	EVI1	22108480	22108496	nd	nd	nd
rs34974971	22126835	EVI1	22126830	22126839	nd	nd	nd
rs6475610	22131893	AREB6	22131892	22131905	0.11	0.01	0.36
rs10757289#	22150453	MRF2	22150444	22150458	0.14	0.02	0.22
rs10757289#	22150453	SEF1	22150452	22150471	0.14	0.02	0.22
rs1679013	22196986	BACH1	22196977	22196992	0.01	0	0.96
rs1679014	22197036	PAX6	22197025	22197046	0.21	0	0.57
rs10965296	22205659	GATA6	22205657	22205667	1	0.01	0.31
rs7043085	22323165	OCT1	22323163	22323176	nd	nd	nd
rs1969926	22347344	SOX9	22347334	22347348	nd	nd	nd
rs10113901	22364031	HNF1	22364024	22364039	0.06	0	0.64
rs7046709	22366969	MEF2	22366953	22366975	0.13	0.01	0.34

All coordinates are for human genome release 17 (build 35).

*Two related TFs recognize the same motif.

A SNP lands in two partially overlapping TF binding sites.

LD between SNPs and the rs1333040 is summarized by D', r² and a P value determined by Chi-square tests the CEU hapmap sample. nd: Measures of LD could not be ascertained for SNPs not represented in the CEU hapmap.

Table 28

Shown are all SNP association results from sequencing of CDKN2A and CDKN2B using primers in Table 25 and association results for early onset MI cases and controls.

location ^a	rs names	Allele	RR	#aff	aff.freq	#con	con.freq	p-value	Variation
21958159	rs3088440	A	0.7264	118	0.080508	674	0.107567	0.194719	G/a
21958199	rs11515	C	1.0349	118	0.161017	668	0.156437	0.858926	G/c
21960916	rs3731249	T	1.4053	119	0.037815	680	0.027206	0.384391	C/t
21964218	rs3731239	A	1.0712	96	0.619792	87	0.603448	0.748662	A/g
21965017	rs3814960	C	0.8697	118	0.347458	686	0.379738	0.34197	T/c
21965319	SG09S293	A	1.4498	119	0.037815	682	0.026393	0.344886	T/a
21965561	rs3731238	T	1.2498	120	0.033333	689	0.026851	0.582384	C/t
21965807	SG09S291	A	1.7884	120	0.058333	687	0.033479	0.077647	C/a
21983964	rs2811711	C	0.8364	119	0.088235	675	0.103704	0.458559	T/c
21985882	rs2518723	T	1.0818	65	0.323077	49	0.306122	0.784969	C/t
21993223	rs3217992	T	1.3279	96	0.421875	86	0.354651	0.188816	C/t
21993367	rs1063192	A	1.27	93	0.602151	80	0.54375	0.273278	A/g
21995330	rs3217986	T	1.1274	96	0.921875	86	0.912791	0.753194	T/g
21996273	rs2069426	T	1.0602	96	0.104167	86	0.098837	0.866531	G/t
21996348	rs974336	T	1.0078	96	0.104167	87	0.103448	0.982048	G/t
21999698	rs2069418	C	1.4107	93	0.61828	87	0.534483	0.107569	C/g
22000004	rs2069416	A	1.6529	93	0.387097	85	0.276471	0.026641	T/a/g
22000004	rs2069416	T	0.6509	93	0.569892	85	0.670588	0.050367	T/a/g
22000004	rs2069416	G	0.804	93	0.043011	85	0.052941	0.660944	T/a/g
22000412	rs495490	A	1.2051	95	0.910526	85	0.894118	0.600156	A/g
22000681	SG09S492	A	3.587	94	0.021277	83	0.006024	0.206723	G/a

^alocation applies to NCBI build 34. Allele: the allele shown is the one tested for association to myocardial infarction. RR is the relative risk. #aff: number of affected individuals. Aff.freq: frequency of allele in affected individuals. #con: number of controls. Con.freq.: frequency of allele in controls. Variation*: Shown are the alleles of the SNPs with major allele shown with capital letters.

Table 29: Association to atherosclerosis in other vascular beds.

Shown is the association of the SNPs, rs1333040, rs2383207 and rs10116277 to peripheral artery disease (PAD), abdominal aorta aneurysm (AAA), and to large vessel disease stroke (LVD).

Study population (n/m) ^a	Frequency		RR (95% CI)	P
	Variant (allele)	Controls		
Iceland PAD (1504/3533)				
rs1333040 (T)	0.499	0.503	1.01 (0.93-1.11)	0.75
rs2383207 (G)	0.462	0.481	1.08 (0.99-1.18)	0.082
rs10116277 (T)	0.421	0.438	1.07 (0.98-1.17)	0.12
Emory PAD (34/1284)				
rs1333040 (T)	0.573	0.721	1.92 (1.12-3.30)	0.017
rs2383207 (G)	0.541	0.692	1.91 (1.15-3.17)	0.012
rs10116277 (T)	0.504	0.676	2.06 (1.25-3.39)	0.0044
Iceland LVD (154/3533)				
rs1333040 (T)	0.499	0.527	1.12 (0.87-1.44)	0.39
rs2383207 (G)	0.462	0.488	1.11 (0.88-1.41)	0.38
rs10116277 (T)	0.421	0.457	1.16 (0.91-1.48)	0.24
Iceland AAA (287/3533)				
rs1333040 (T)	0.499	0.572	1.34 (1.12-1.60)	0.0012
rs2383207 (G)	0.462	0.536	1.35 (1.13-1.61)	0.00073
rs10116277 (T)	0.421	0.485	1.30 (1.09-1.54)	0.0035

^a Number of cases (n) and controls (m). ^b Individuals used in the initial discovery group have been excluded both from cases and controls. ^c For the combined groups, the allelic frequency in cases and controls is the weighted average over the individual groups.

Table 30: Association of refinement markers to MI, early-onset MI and AAA in Iceland.

Shown is the association to MI, early-onset MI and AAA case-control groups for 10 of the markers included in Table 23b. All tests use the same set of 10260 controls.

SNP	Allele	Position	MI (2270/10260)					Early onset MI (621/10260)					AAA (323/10260)					CAD ^a (508/10260)				
			Con.frq	Case.frq	OR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P	Con.frq	Case.frq	RR	P
rs10116277	T	22071397	0.419	0.471	1.23	3.2E-10	0.419	0.496	1.36	1.3E-07	0.419	0.488	1.32	6.0E-04	0.419	0.456	1.16	0.024	0.419	0.456	1.16	0.024
rs1333040	T	22073404	0.493	0.541	1.21	6.7E-09	0.493	0.576	1.40	1.3E-08	0.493	0.579	1.41	2.7E-05	0.493	0.519	1.11	0.130	0.493	0.519	1.11	0.130
rs10738607	G	22078094	0.441	0.497	1.25	8.4E-12	0.441	0.521	1.38	4.0E-08	0.441	0.522	1.38	5.8E-05	0.441	0.474	1.14	0.043	0.441	0.474	1.14	0.043
rs4977574	G	22088574	0.444	0.499	1.25	2.0E-11	0.443	0.522	1.37	8.3E-08	0.444	0.527	1.39	3.8E-05	0.443	0.474	1.13	0.056	0.443	0.474	1.13	0.056
rs6475608	C	22091702	0.683	0.709	1.13	1.7E-03	0.689	0.737	1.26	6.3E-04	0.693	0.752	1.35	1.8E-03	0.695	0.722	1.14	0.110	0.695	0.722	1.14	0.110
D9S1870	X	22093010	0.440	0.490	1.22	2.5E-09	0.441	0.513	1.34	1.2E-06	0.441	0.507	1.31	1.2E-03	0.441	0.471	1.13	0.073	0.441	0.471	1.13	0.073
rs2383207	G	22105959	0.458	0.511	1.24	6.5E-11	0.458	0.535	1.36	1.4E-07	0.458	0.537	1.38	7.4E-05	0.458	0.487	1.13	0.088	0.458	0.487	1.13	0.088
rs1333045	C	22109195	0.503	0.551	1.21	2.0E-08	0.506	0.575	1.32	3.5E-06	0.508	0.580	1.34	4.2E-04	0.508	0.554	1.20	0.007	0.508	0.554	1.20	0.007
rs1333046	A	22114123	0.439	0.494	1.24	4.8E-11	0.440	0.518	1.37	8.3E-08	0.442	0.528	1.42	1.7E-05	0.440	0.472	1.14	0.053	0.440	0.472	1.14	0.053
rs10757278	G	22114477	0.435	0.492	1.26	2.8E-12	0.434	0.518	1.40	1.2E-08	0.436	0.522	1.41	1.8E-05	0.435	0.474	1.17	0.016	0.435	0.474	1.17	0.016

^a Known cases of MI are excluded from the CAD cases. ^b For the microsatellite D9S1870, all alleles smaller than 2 have been combined in to a composite risk allele X.

Table 31. Amplimers for non-public SNPs identified in table 26.**SG09S293**

5 GGAAGCAGCCCTCGCCAGAGCCAGCGTTGGCAAGGAAGGAGGACTGGGCTCCTCCCCACCTGCC
CCCCACACCGCCCTCCGGCCTCCCTGCTCCCAGCCGCGCTCCCCCGCCTGCCAGCAAAGGCGTG
TTTGAGTGCGTTCACTCTGTAAAAAGAAATCCGCCCCCGCCCGTTTCCTTCCTCCGCGATACAA
CCTTCC[T/a]AACTGCCAAATTGAATCGGGGTGTTTGGTGTCAATAGGGAAAGTATGGCTTCTTCT
10 TTTAATCATAAGAAAAAGCAAACTATTCTTTCCTAGTTGTGAGAGCCCCACCGAGAATCGAAATC
ACCTGTACGACTAGAAAAGTGCCCCCTACCCCTCAACCCTTGATTTTCAGGAGCGCGGGGTTCA
CTAAGTCAGAAACCCTAGTTCAAAGGA

SG09S291

ATTGGAAGGACGGACTCCATTCTCAAAGTCATAATTCCTAGACCAGAAAAAGTGCTCAGTGTTCTA
15 GAAGCAGAGTTG[C/a]ACAGTGATCCAAAGACCAGCTTCAAATACTGTCCTGTCTCCTTCACACT
TCTCACATTTCTTTTCTACTGAAAATACCTTGCATTTTTCGTAATTATAAAGGGGAAGGGAATA
TGAGTGCCCCCTGCTTTATAGGGGTGTTGTGAGTTTAAATGATGTATTAATACATATAAGCCTTAA
GAACAGTGCCACACATCCTAAGCTAATACCTGTTAGCTCTTGAATTATCCGCTTTGAGGACTGGCT
TGCAATCTTGTTTTGAGGCATAGAAAAGAAATGCTTTGGAGCAGGACGCGGTGGCTCACACCTGT
20 AATCCCAGCACTTTGGGAAGCCGAGGCGGGCA

SG09S492

TGAATCAACATTTATTACTTAAAATATTTAAAACATTTAGCGGATGCTACATTGGATAGGAAGAGA
ACCGCAAGTTATGGATTTGTTGCCTAAAACTTTGGTGAGGAACTGCATAAGTGACCTCTCCTAA
25 AAGTGAACAaTTTTTGTTTACAGAATCATTTTGGTTCGGAGTGCTGAGGAAGACAAAGTCTTAACA
GGAGGGCAATTGCTTGTTGATTGCAAAATGAGAGTCTTCACATGTTTTTTTTAGGATACCTTAGCT
CTGACTCCTCATCCCCCAAATCCCTGTAGAATTAAAAAA_gCTCTTTCTTTTAAAGGCAGTGGAAGT
GCCACCACCATGGAAGTGCTGGTTAGGGCTGAAAATCTACTGACAGAGCCTCAACAGAGCTGAAA
TCCACCTGGACAGG[G/a]AAGGGAACCGGGTAGCATTAAATAACAATTTCTTTTCTTTCCCATCC
30 AACCCCATTTCTAGTCTTCAGTTTCTTAATTTCTCTACCTTTTACTCTTATGCTCTTGTTTTGACC
TTTGAGTTTCTCTGAAACTTATCAGAAAAAGTTAGGACAAGATAGTCTGACCCAATTCTTGAGCCATT
TTCTTAGGTAGTAAATATGTCAGAAAAATGAAAGCTGTTTGGAGTTGATAAGGAAATGGAAGATAA
TGTTTTTCTTTGAGGG_gGACATAAAGAATGGTGATAGGGAAAGAACCAATGACTAAGTAAATGAC
TGAGAATCTTGACGAGGCAGATGTGTGAGCTTCGCGAAGCAAGTTGACTGAATGAAAAACAAT
35 TTGGGTAGGGAAAACGTTGCCGGGGGCATTGCG

Table 32: Association between rs10757278 allele G and arterial diseases

Phenotype	Frequency		OR (95% CI)	P
	Study population (n/m)	Controls		
Abdominal Aortic Aneurysm (AAA)				
Iceland (14259/398)	0.437	0.515	1.37 (1.18-1.58)	2.6 × 10 ⁻⁵
Belgium (267/176)	0.527	0.574	1.21 (0.92-1.58)	0.18
Canada (150/206)	0.470	0.533	1.29 (0.96-1.74)	0.097
Pennsylvania, US (447/101)	0.468	0.549	1.39 (1.02-1.89)	0.037
The Netherlands (915/476)	0.461	0.529	1.31 (1.12-1.53)	0.00078
UK (252/478)	0.470	0.545	1.35 (1.09-1.68)	0.0064
New Zealand (442/588)	0.474	0.530	1.25 (1.05-1.50)	0.012
All groups (16732/2836)			1.31 (1.22-1.42)	1.2 × 10 ⁻¹²
Intracranial Aneurysm (IA)				
Iceland (14259/170)	0.437	0.514	1.36 (1.10-1.69)	0.0048
The Netherlands (915/644)	0.461	0.516	1.24 (1.08-1.43)	0.0029
Finland (307/320)	0.400	0.469	1.33 (1.06-1.66)	0.015
All groups (15481/1134)			1.29 (1.16-1.43)	2.5 × 10 ⁻⁶
Peripheral Artery Disease (PAD)				
Iceland (14259/1764)	0.437	0.473	1.16 (1.07-1.25)	0.00014
Italy (181/179)	0.510	0.499	0.96 (0.71-1.29)	0.78
Sweden (143/206)	0.427	0.507	1.38 (1.02-1.87)	0.036
New Zealand (463/450)	0.474	0.491	1.07 (0.89-1.29)	0.47
All groups (15025/2599)			1.14 (1.07-1.22)	6.1 × 10 ⁻⁵
LAA /Cardiogenic Stroke				
Iceland (14259/415)	0.437	0.473	1.16 (1.00-1.34)	0.046
Sweden (734/290)	0.433	0.468	1.15 (0.95-1.39)	0.16
All groups (15012/705)			1.15 (1.03-1.29)	0.015
Coronary Artery Disease (CAD) ^a				
Iceland (14259/3051)	0.437	0.492	1.25 (1.17-1.32)	1.9 × 10 ⁻¹²
Atlanta (1246/840)	0.479	0.544	1.30 (1.15-1.48)	0.000033
Philadelphia (447/724)	0.467	0.547	1.38 (1.17-1.63)	0.00017
Durham (614/1201)	0.455	0.521	1.30 (1.13-1.50)	0.00018
All groups (16566/5539)			1.28 (1.22-1.34)	1.2 × 10 ⁻²³

Association results for rs10757278 allele G for the arterial diseases: AAA, IA, PAD, combined LAA (Large Artery Atherosclerotic)/cardiogenic stroke, and CAD, and for T2D, in several study populations. Also included are the results for each phenotype after combining the study populations using a Mantel-Haenszel model. Number of controls (n) and cases (m) is shown. The results for the Icelandic population are adjusted for relatedness of the individuals.

^aThe results presented for CAD have been published previously ¹ (apart from the Icelandic control group that has been increased) and are presented here for comparison of the results with the other arterial phenotypes.

Table 33. Association between rs10757278 allele G and arterial diseases after excluding known CAD cases from the sample sets

Phenotype	Frequency		OR (95% CI)	P
	Study population (n/m)	Controls		
Abdominal Aortic Aneurysm (AAA)				
Iceland (14259/190)	0.437	0.503	1.30 (1.06-1.60)	0.013
Belgium (267/156)	0.527	0.573	1.20 (0.91-1.60)	0.200
Pennsylvania, US (447/62)	0.469	0.513	1.19 (0.82-1.74)	0.36
The Netherlands (915/380)	0.461	0.517	1.25 (1.06-1.48)	0.0097
UK (252/220)	0.470	0.538	1.31 (1.02-1.70)	0.038
New Zealand (442/360)	0.474	0.516	1.18 (0.97-1.44)	0.097
All groups (16639/2017)			1.25 (1.14-1.37)	3.0 × 10 ⁻⁶
Peripheral Artery Disease (PAD)				
Iceland (14259/732)	0.437	0.463	1.12 (1.00-1.25)	0.055
Italy (181/113)	0.509	0.488	0.92 (0.66-1.28)	0.62
New Zealand (463/326)	0.474	0.491	1.07 (0.87-1.31)	0.51
All groups (14882/1171)			1.09 (0.99-1.20)	0.075
LAA/Cardiogenic Stroke				
Iceland (14259/278)	0.437	0.458	1.09 (0.92-1.30)	0.32
Sweden (734/213)	0.433	0.467	1.15 (0.92-1.42)	0.22
All groups (14993/491)			1.11 (0.97-1.27)	0.12

Association results are shown for rs10757278-G for the arterial diseases: AAA, IA, PAD, combined LAA (Large Artery Atherosclerotic)/cardiogenic stroke, after excluding cases with known CAD. Number of controls (n) and cases (m) is shown. The results for the Icelandic population are adjusted for relatedness. No information on CAD was available for the AAA group from Canada and the PAD group from Sweden. Those study groups were excluded from this analysis. Information on the occurrence of CAD among the AAA cases was available for 97% (466 out of 479) of AAA cases from UK, 86% (87 out of 101) of cases from Pennsylvania, 45% (79 out of 176) of cases from Belgium, 69% (330 out of 476) of cases from The Netherlands, and 98% (575 out of 588) of cases from New Zealand. Among those with this information, the frequency of CAD amongst the AAA subjects was 52% in the UK group, 48% in the Pennsylvania group, 29% in the Belgium group, 29% in the Dutch group and 40% in the group from New Zealand.

Table 34: Genotype specific odds ratio for rs10757278 for abdominal aortic aneurysm and intracranial aneurysm

Study population (n/m)	Genotype Specific Odds Ratio		
	AA	AG (95% CI)	GG (95% CI)
Abdominal Aortic Aneurysm (AAA)			
Iceland (14259/398)	1	1.22 (0.95-1.56)	1.85 (1.39-2.45)
Belgium (267/176)	1	1.42 (0.91-2.20)	1.52 (0.87-2.66)
Canada (150/206)	1	1.04 (0.69-1.57)	1.62 (0.90-2.91)
Pennsylvania, US (447/101)	1	2.00 (1.17-3.44)	2.06 (1.06-4.03)
The Netherlands (915/476)	1	1.43 (1.12-1.84)	1.76 (1.28-2.43)
UK (252/478)	1	1.60 (1.19-2.15)	1.95 (1.26-3.03)
New Zealand (442/588)	1	1.22 (0.94-1.58)	1.50 (1.04-2.17)
Combined (16732/2836)	1	1.36 (1.21-1.52)	1.74 (1.49-2.02)
Intracranial Aneurysm (IA)			
Iceland (14259/170)	1	1.39 (0.96-2.02)	1.90 (1.24-2.93)
The Netherlands (915/644)	1	1.34 (1.08-1.66)	1.61 (1.20-2.16)
Finland (307/320)	1	1.45 (1.06-1.98)	1.79 (1.12-2.86)
Combined (15481/1134)	1	1.38 (1.18-1.63)	1.72 (1.39-2.13)

Genotype specific odds ratios for rs10757278 for AAA and IA cases versus controls. Shown is the risk for heterozygous carriers (AG) and homozygous carriers (GG) compared to the risk for non-carriers (AA), together with 95% confidence intervals (CI). Results are shown for the AAA case-control groups from Iceland, Belgium, Canada, Pennsylvania, US, UK, The Netherlands and New Zealand and for all the groups combined and for the IA case-control groups from Iceland, The Netherlands and Finland. Number of controls (n) and cases (m) is shown. Tests of heterogeneity showed no significant difference in the genotype specific odds ratio between the different study groups For AAA, $P_{\text{het}} = 0.38$ and $P_{\text{het}} = 0.95$ for the AG and the GG genotype, and for IA, $P_{\text{het}} = 0.91$ and $P_{\text{het}} = 0.81$.

Table 35: Correlation between growth rate of AAA and genotypes for rs10757278 from the UK Small Aneurysm Trial

Genotype of rs10757278	<i>n</i>	Mean baseline diameter (mm)	Linear growth rate (mm/year)	Mean difference (95%CI)
AA	79	45.3	3.20	0.03 (-0.38-0.41)
AG	214	44.8	3.15	reference
GG	107	44.7	2.53	-0.46 (-0.93-0.00)

Linear growth rates were determined as previously described¹⁶. At least three AAA diameter measurements and growth rate were available for 400 patients who had been genotyped for rs10757278 and *n* is the number of individuals with the different genotypes. The largest group (AG) was set as the reference group and then the growth rates in the other genotype groups were compared with the mean of the reference group. This leads to estimation of the mean difference [95%CI] of the growth rates in the homozygous groups. The analysis of the average difference was adjusted for age, sex, smoking status, baseline diameter and curvature in growth pattern. In this cohort there were 24 ruptured AAA; 6 with the AA genotype, 14 with AG, and 4 with GG.

Table 36: Association of SNPs in chromosome 9p21 region to MI in African-Americans. We tested 9 SNPs for association with MI in African Americans. These SNPs included 2 SNPs from the genome-wide scan on MI in Icelanders (rs10116277 and rs2383207) and rs10757278, which showed strongest association with MI in Caucasians, as well as six other SNPs that were correlated with rs10757278 in Caucasians. As shown in the Table all, SNPs have greater frequency in cases compared to the control groups and the odds ratios are comparable to that for Caucasians.

SNP	Allele	Position	Combined ^a		Philadelphia (93/139)				Durham (262/243)				Cleveland (46/81)				Atlanta (91/357)			
			RR (95CI)	Pa	Con.fq	Case.fq	OR	P	Con.fq	Case.fq	RR	P	Con.fq	Case.fq	RR	P	Con.fq	Case.fq	RR	P
rs8181050	A	22054391	1.30 (0.91-1.86)	0.14	0.921	0.920	0.99	0.98	0.912	0.926	1.20	0.43	0.887	0.913	1.34	0.51	0.934	0.967	2.08	0.075
rs10116277	T	22071397	1.37 (1.05-1.80)	0.022	0.889	0.893	1.05	0.89	0.870	0.901	1.35	0.13	0.856	0.891	1.39	0.41	0.866	0.934	1.82	0.049
rs10738607	G	22078094	1.12 (0.92-1.35)	0.27	0.238	0.290	1.31	0.22	0.233	0.254	1.12	0.43	0.228	0.244	1.09	0.77	0.226	0.220	0.97	0.87
rs4977574	G	22088574	1.20 (0.97-1.48)	0.096	0.175	0.250	1.57	0.051	0.184	0.204	1.13	0.430	0.160	0.163	1.02	0.95	0.173	0.187	1.10	0.68
rs2383207	G	22105959	1.34 (1.03-1.74)	0.027	0.881	0.877	0.96	0.88	0.872	0.906	1.43	0.078	0.877	0.880	1.04	0.93	0.888	0.945	2.18	0.015
rs1333045	C	22109195	1.22 (1.04-1.43)	0.014	0.455	0.497	1.18	0.38	0.472	0.525	1.24	0.093	0.416	0.435	1.08	0.78	0.473	0.544	1.33	0.094
rs1333046	A	22114123	1.19 (0.99-1.44)	0.069	0.227	0.294	1.42	0.11	0.257	0.291	1.18	0.24	0.204	0.213	1.06	0.86	0.240	0.258	1.10	0.61
rs10757278	G	22114477	1.19 (0.98-1.45)	0.08	0.183	0.257	1.54	0.059	0.194	0.223	1.20	0.250	0.160	0.152	0.94	0.86	0.187	0.198	1.07	0.74
rs1333048	C	22115347	1.16 (0.96-1.40)	0.12	0.277	0.301	1.13	0.57	0.288	0.321	1.17	0.25	0.251	0.304	1.30	0.37	0.283	0.303	1.10	0.61

^a Results for the four African-American cohorts are combined using a Mantel-Haenszel model. Shown is the association to MI in four African-American MI case-control groups for 9 markers in the chromosome 9p21LD-block (LD Block C09). These SNPs are correlated in Caucasians. The markers include 2 SNPs from the genome-wide scan (rs10116277 and rs2383207) and rs10757278 that showed strongest association with MI in Caucasians, and six other correlated SNPs.

Table 37. Key to sequence listing.

Sequence	SEQ ID NO:
rs7041637	1
rs3218020	2
rs3217992	3
rs1063192	4
rs2069418	5
rs2069416	6
rs573687	7
rs545226	8
rs10811640	9
rs10811641	10
rs2106120	11
rs2106119	12
rs643319	13
rs7044859	14
rs10757264	15
rs10965212	16
rs1292137	17
rs10811644	18
rs7035484	19
rs10738604	20
rs615552	21
rs543830	22
rs1591136	23
rs7049105	24
rs679038	25
rs10965215	26
rs564398	27
rs10115049	28
rs634537	29
rs2157719	30
rs2151280	31
rs1008878	32
rs1556515	33
rs1333037	34
rs1360590	35
rs1412829	36
rs1360589	37
rs7028570	38
rs944801	39
rs10965219	40
rs7030641	41
rs10120688	42
rs2184061	43
rs1537378	44
rs8181050	45
rs8181047	46
rs10811647	47
rs1333039	48
rs10965224	49
rs10811650	50
rs10811651	51
rs4977756	52
rs10757269	53
rs9632884	54
rs1412832	55
rs10116277	56
rs10965227	57
rs6475606	58
rs1333040	59
rs1537370	60

rs7857345	61
rs10738607	62
rs10757272	63
rs4977574	64
rs2891168	65
rs1537371	66
rs1556516	67
rs6475608	68
rs7859727	69
rs1537373	70
rs1333042	71
rs7859362	72
rs1333043	73
rs1412834	74
rs7341786	75
rs10511701	76
rs10733376	77
rs10738609	78
rs2383206	79
rs944797	80
rs1004638	81
rs2383207	82
rs1537374	83
rs1537375	84
rs1333045	85
rs10738610	86
rs1333046	87
rs10757278	88
rs1333047	89
rs4977575	90
rs1333048	91
rs1333049	92
rs1333050	93
LD Block C09	94

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for determining a susceptibility to arterial disease in a human individual, comprising determining the presence or absence of at least one allele of at least one polymorphic marker in a nucleic acid sample obtained from the individual or in a genotype dataset derived from the individual, wherein the at least one polymorphic marker is selected from the polymorphic markers rs1333040, and markers in linkage disequilibrium therewith as defined by a value for r^2 of greater than 0.2, and wherein the presence of the at least one allele is indicative of a susceptibility to arterial disease.
2. The method according to claim 1, wherein the at least one polymorphic marker is selected from the markers set forth in Table 3 and Table 21 that are in linkage disequilibrium with rs1333040, as determined by values for r^2 greater than 0.2.
3. The method according to claim 1 or claim 2, wherein the at least one marker is selected from the group of markers listed in Table 22.
4. The method according to any one of the preceding claims, wherein the at least one polymorphic marker is selected from the group consisting of rs10757278, rs2383207, rs10116277 and rs1333040.
5. The method of any one of the preceding claims, wherein the susceptibility conferred by the presence of the at least one allele is increased susceptibility.
6. The method according to claim 5, wherein the presence of allele T in rs1333040, allele T in rs10116277, allele G in rs2383207, or allele G in rs10757278, is indicative of increased susceptibility to arterial disease.
7. The method according to claim 5 or 6, wherein the presence of the at least one allele is indicative of increased susceptibility with a relative risk (RR) or odds ratio (OR) of at least 1.2.
8. The method according to claim 7, wherein the relative risk (RR) or odds ratio (OR) is at least 1.3.
9. The method of any of the preceding claims, further comprising assessing at least one biomarker in a sample from the individual, wherein the biomarker is a cardiac marker or an inflammatory marker.
10. The method of claim 9, wherein the at least one biomarker is selected from creatin kinase, troponin, glycogen phosphorylase, C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tissue necrosis factor-alpha, soluble vascular cell adhesion

molecules (sVCAM), soluble intervascular adhesion molecules (sICAM), E-selectin, matrix metalloprotease type-1, matrix metalloprotease type-2, matrix metalloprotease type-3, matrix metalloprotease type-9, serum sCD40L, leukotrienes, leukotriene metabolites, interleukin-6, tissue necrosis factor-alpha, myeloperoxidase (MPO), and N-tyrosine.

11. The method of claim 10, wherein the leukotriene is selected from LTB₄, LTC₄, LTD₄ and LTE₄.
12. The method of any one of the claims 1 to 4, comprising determining the presence or absence of at least one allele in at least two polymorphic markers, wherein the presence of the at least one allele in the at least two polymorphic markers is indicative of an increased susceptibility to arterial disease.
13. The method of any one of the preceding claims, further comprising analyzing non-genetic information to make risk assessment, diagnosis, or prognosis of the individual, wherein the non-genetic information is selected from age, gender, ethnicity, socioeconomic status, previous disease diagnosis, medical history of subject, family history of arterial disease, biochemical measurements, and clinical measurements.
14. The method according to any one of the preceding claims, wherein the arterial disease is at least one of Myocardial Infarction, Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Surgery (CABG), Restenosis, Peripheral Arterial Disease, Stroke, Abdominal Aorta Aneurysm and Intracranial Aneurysm.
15. The method according to any one of the preceding claims, wherein the arterial disease is at least one of Myocardial Infarction, Coronary Artery Disease, Restenosis, Intracranial Aneurysm and Abdominal Aorta Aneurysm.
16. The method according to claim 15, wherein the arterial disease is Myocardial Infarction and/or Coronary Artery Disease with an early onset before age 50 for males and 60 for females.
17. An apparatus when used in a method for determining a genetic indicator for arterial disease in a human individual, comprising:

a computer readable memory; and

a routine stored on the computer readable memory;

wherein the routine is adapted to be executed on a processor to analyze marker information for at least one human individual with respect to at least one polymorphic

marker selected from the markers rs1333040, and markers in linkage disequilibrium therewith as defined by a value for r^2 of greater than 0.2, and generate an output based on the marker information, wherein the output comprises a risk measure of the at least one marker as a genetic indicator of arterial disease for the human individual;

wherein the method comprises:

determining the presence or absence of at least one allele of said at least one polymorphic marker, and wherein the presence of the at least one allele is indicative of a susceptibility to arterial disease.

18. The apparatus of claim 17, wherein the routine further comprises an indicator of the frequency of at least one allele of at least one polymorphic marker in a plurality of individuals diagnosed with arterial disease, and an indicator of the frequency of at the least one allele of at least one polymorphic marker in a plurality of reference individuals, and wherein a risk measure is based on a comparison of the at least one marker status for the human individual to the indicator of the frequency of the at least one marker information for the plurality of individuals diagnosed with arterial disease.
19. A method according to claim 1, substantially as hereinbefore described.
20. The apparatus according to claim 17, substantially as hereinbefore described.




Fig. 1

SEQUENCE LISTING

<110> deCODE Genetics

<120> GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE

<130> 2507-PC00

<160> 94

<170> PatentIn version 3.4

<210> 1

<211> 201

<212> DNA

<213> Homo sapiens

<400> 1

tttcgcaatg	cttattttca	atttcttcag	aaatgcctta	aagatattaa	tggaggtaac	60
aacttaatct	caaatagtaa	tccatagaca	gaatatgtaa	magcaatgtt	ctctgatctg	120
ttctttggct	tctattccct	agagaaatag	ttctctaaga	ccaaacagtc	tatagataga	180
attgtagcaa	cagtcaatta	t				201

<210> 2

<211> 201

<212> DNA

<213> Homo sapiens

<400> 2

gtggagagaa	aatgattata	ctttgagcta	tatggctcca	ataaaciaaag	atagatccct	60
caattttaa	ttgatcctca	gaaaactgag	ggtcagagaa	yccctcaggc	atgacgggat	120
aatgtgacag	ttaatttggg	atgtcaactt	ggctaggctg	tggtaccag	tgtttgagtc	180
aaacaccagt	ctaaatattg	c				201

<210> 3

<211> 201

<212> DNA

<213> Homo sapiens

<400> 3

agtactatat	tacactgttt	tttttgtttg	ttttgttagt	tttttttatt	taaagcaaac	60
ctcaaacatt	attgggtatc	aattaccacc	tggttgatt	raaatagtaa	cttatcaatg	120
ccatgtaaaa	attaattcca	ttttcgaagc	cacctggcag	acaggtttag	ctgtttcatc	180
agcagcctaa	tatatactgt	t				201

<210> 4

<211> 201

<212> DNA

<213> Homo sapiens

<400> 4

cattatactg	ggtcatgaaa	aattatccct	tgaaatagat	atgaaacatg	ttacttcatt	60
tctggtttaa	ataacttgtg	gaatctttcc	taatgacaac	ytgatattaa	gggaaactaa	120
agaaaatgtt	attgtggatc	ccacagtact	atattacact	gttttttttg	tttgttttgt	180
tagttttttt	tatttaaagc	a				201

<210> 5

<211> 201

<212> DNA

<213> Homo sapiens

<400> 5

tgatacaagt	tatgaaactt	gtgaagccca	agtactgcct	ggggatgaat	ttaacttgta	60
tgacaggtgc	agagctgtcg	ctttcagaca	tcttaagaaa	sacggagtta	ttttgaatga	120
ctttctctcg	gtcacaaggg	agccaccaac	gtctccacag	tgaaaccaac	tggttggtcg	180
aaggaacaga	aatcctctgc	t				201

<210> 6
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 6
 aaataaaaat aagatacctg acaaagtggg tttaaatagg taagagtgc aacaaagatt 60
 tactgtacaa atatgatgaa actgggatct cagattctta hagtataatt tttttttgtc 120
 ttatgtgtgc cagggttgcca ctctcaatct cgaactagtt tttttctctt ttaagggttg 180
 tatccataat gcaaaaatgg a 201

<210> 7
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 7
 gtccaagaca aatgtgctat tgtattacat gtgaaatgtc atctttgaag tctggtaagg 60
 gtgtgctgtg aggtgagcca tctggaaaac acagtgtaga ytgaaaaata attataagcc 120
 agtttattac ttttttccag ttaagcctac catgacagct gctaaaaaaa acactatgta 180
 gtataaaggg taaaaagact c 201

<210> 8
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 8
 ggggtgcagg ttgttggtgt ggccacactt cttcttgccg caattgacag cataggggtg 60
 caggagagca tagcgcttat ggcagatcat cttgtttcag ytgatattct aggtgagctg 120
 gaagagtga ggctcaataa tgccacctcg cagggtgcagc accagggtgc ggggtgggctg 180
 tttctggacg ttgtagtctg a 201

<210> 9
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 9
 tcttaatttt tacacatttt acttttcatt tctttttaaa ctgttattaa taattttattc 60
 atttgaataa ggattaaaat aaggctagga tattgaaatt ygttgaaatt gctacagtct 120
 cttgtatctc tctctctctc ttttttttct tataagggac aggtttcatt caccttgctg 180
 accaggctgg agtgcaatac t 201

<210> 10
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 10
 tgtgattcta gcagccatgg ataattattt catagattat tattttcttg gggatggcaa 60
 aatgggtgata ttctaatttt actattcctt catttactag stggaatgtc tttttaaatt 120
 atttatttat ttatttatta ttgagacag agtcttgcac tgtcacccag gctggagtgc 180
 agtggtgtga tcatagctca c 201

<210> 11
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 11
 tgcgcgcctc ggcctcccaa agtgctggga ttacaggcgt gagccactgc gcctcgccaa 60
 cttccttatt ttaaattgcca tttcccacta aaaataaaaac magtaattct ttgaaaaaaa 120
 gttaatatta tgtataggac tggaagtata taagataaaa ctggaatata ttgtcatacc 180
 agaaatcaaa gattttgtca a 201

<210> 12
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 12
 attactgatg tgacaaggta cacaagccaa tgttgacata atgttttcaa aatgggggtgt 60
 ctgctgtaac tgaactaaat ataataactt tattcaagaa ygagtttcaa tgataggaca 120
 aaacttgata aaatgaataa ataaataatt atatgccaga gttcagtaaa ccctgtgtgt 180
 acacctgaaa aagctcaaac t 201

<210> 13
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 13
 gaacagagca gaagagagtc tggatacaca aatttcacaa ttattggctc ccatcaacat 60
 atctaactca agcataaagt tgtttcagca gtagtttaag yttggttact aatgcaacac 120
 ctctttgcat gcaatggccc attaaattat cttcaacttt aaaaggttcc tttgttttta 180
 aatgcttata atgaacaaat a 201

<210> 14
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 14
 tatgtgatgt aaagagcgcc aacatgttta tatcctccta tttcaatcta cttttacttc 60
 atctacattt ttagcaataa tgtgaacatg aaatcttgaa waattagcta tctgtaatat 120
 atttactcat ccactcaaaa tattgagccc ccccaataaa tatcatacac tatattctag 180
 gtacaggtga taaacaattc a 201

<210> 15
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 15
 ccagtgaag ttagagagag gggcttagag cttagggagg agtgtgtatc cctaatttag 60
 actaatttgc attaacagct gtagtaatgc aattttctct rtactgaaat gcagacattt 120
 gagtatagaa aattagcaga catttgaata tagaagaaag atttactttc cttcagaaaa 180
 agaatagtag agtataaaga a 201

<210> 16
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 16
 tcgtgccact gcactccagc ctgggtgagt tgagagtcgc tatcaaaagc aaacctacac 60
 atttttgtgg cctgttttta gctctatcaa gtcaggttaca wtcttctgta ttctagcttt 120
 tttatctgta agctcctgca atgctttatt agaattttta gttcctttgc attttgttac 180
 aacatactcc tataactctg c 201

<210> 17
 <211> 169
 <212> DNA
 <213> Homo sapiens
 <400> 17
 taaaagaaaa aataatccaa atgtcagcaa cctcaaagat tgaaggtaga tgagcccaca 60
 aagataagaa ataatcagca caagaacact gaaaactcaa wacatcacct ctctggcaag 120
 cgttcagtac caggctgagg ctgagatggc tgaaatgata gaagcagaa 169

<210> 18
 <211> 201

<212> DNA
 <213> Homo sapiens
 <400> 18
 caagaccact ctgcagatat caagtctgaa aattccccta gggccaaagt ctattatggg 60
 agcaagttga gcctagaggg atcgccatcc ctgtccatgc wctgctgtag acactcctgc 120
 actaaaccct ctgggctcca catcagctgg ctgtctgctc taccactttg cttgtctctt 180
 gggggctcca cccagagag a 201

<210> 19
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 19
 gtctcttggg ggctccaccc cagagagatg tgggtcagca atcattcagt tcaatcagcc 60
 caggatggag agtctgtgct atgggcccaa gccaggggct stctgtctgg tgacgagcag 120
 ctgggggggtg ggggtgggacc tgtgggagat ggactggcct cctctccttg agtcaactgc 180
 tgcttattgg aggtgtggat g 201

<210> 20
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 20
 ccattgcaga ggtagtggca gagaggcttt cagttgtccg tggcggctct gtccagggag 60
 ttgctgagtt gctattggct tgatatctct ggtgggggtg rgctagaggt ccaggcctgg 120
 aggacctgct cgttgaagag atgtgggaat gggcacccac ataacagtct gttcaactttt 180
 ccatagggct gctgtagtat g 201

<210> 21
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 21
 ggggagctta agcaggggtg gaaggggaac cccagcacag aacagctgcc cgacaaaaat 60
 gtggccacac tgcttttttt ttttttttag cagggtccca rtcccgttcc tcatcaactgg 120
 gtagagtctc ccatctgggg tccccggcta cccaactgg tgttctctga ctgagagagg 180
 tttcagactt ccatgggacc t 201

<210> 22
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 22
 tgggcaaaag tagctgcgac tttggcaaag ctggaggtta gacccccaaa cataccccag 60
 gaggttagac tccatacat accccagaaa agaggctgaa wccagcgaga tcagcagaga 120
 aggtctacag gccccacttc cacagcgct cacaggataa gacccactgg cttggaattc 180
 cagctagcca ccagtagcaa c 201

<210> 23
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 23
 aagtggtaag tgaatgcgca actctgggaa tccacactgc tctcacagat ctttgcaaac 60
 ctgagatcag gagatccct tgtgaactca ctccattagg sccttcacac acagccacgt 120
 ggagtctcag cagagcagcc actcaggcat gcatggagac ccaagagctt tagctactcc 180
 agctttctgg gtgtctgggc a 201

<210> 24
 <211> 201
 <212> DNA

<213> Homo sapiens
 <400> 24
 cttaacagca aagtatcaga ttcattttata aaacaatgtg actgatcttt atgtatgggt 60
 tgtgaaacat ttatgcagtg tcacttcaga aaactctgcc rttatagatt tgaattgatt 120
 aaggatatcc actcctttcc ttggcatgat acaataaat tactaaagta taattgtaac 180
 aatgataaat ataagtgaca a 201

<210> 25
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 25
 caccctttgg ggaaggggat caaaatatag tgattttcta attctaagat tcgttctgtg 60
 tatattagct gctattcttc tagaaagaag actttcacca ycgctcccttg gatttttttt 120
 ttttaattttt gtatggttta aattgcatca tcattctttt tgatgtccaa attgtcccaa 180
 attaagccag ttagagaaac a 201

<210> 26
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 26
 taatgggatt cctgatggaa tgttttagtct gaatctaatc acatagagac ttgtctgaca 60
 aatccagatt ttttgatgt tttgcaggac tatttgccac racatttcaa aggattccaa 120
 gagagaatat tgggtgtccat gctgtgatga ttcctcagct cctctcatct gatctccgtc 180
 ctggcccca tgactttctt t 201

<210> 27
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 27
 ctcttctttt atcacacaga cctgaaagat gatgggtttcc caaacagcac ttacagcaat 60
 aggtgtgggc ctcaagtggca cataccacac cctaactacc rcaaagaaag tcatgggggc 120
 caggacggag atcagatgag aggagctgag gaatcatcac agcatggaca ccaatattct 180
 ctcttggaat cctttgaaat g 201

<210> 28
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 28
 caaatctttc cctaaggag atttcagatg agggccccag ccttggtaga caccttgatt 60
 gcagtcttgt gagagattgt gaagcagagc tattctcaga rttcatgggt gttttaagct 120
 atgagggtttt ttttgggggg agaatggtca tttgtgattc agctatacat aagtctacaa 180
 aagtcattcc agaagtgatt c 201

<210> 29
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 29
 tggggctcac aaccacatga ttctacctcc actgaatcac ttctggaatg actttttag 60
 acttatgtat agctgaatca caaatgacca ttctcccccc maaaaaaacc tcatagctta 120
 aaacacccat gaattctgag aatagctctg cttcacaatc tctcacaaga ctgcaatcaa 180
 ggtgtctacc aaggctgggg g 201

<210> 30
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 30
 tttttatagt gtgactcatt tacatatgca tgtgtatggt taggtgctat tattaaattt 60
 tgctggcata tagtgaggaa attgtgattc aaattcgtcc rtatgtactc ctccccacc 120
 atctgctctg cccctccatt taccagaagg ctagctttag ctacttgtgc atgtaaaaca 180
 gaagcaagca acactgtgaa a 201

<210> 31
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 31
 gaacatagat actccttcat tcatgtattg tctatgggtg agtctttatt acaacagcag 60
 agatgagtag ttgtgacaga aactcgatgg ccctcaaaag ygaaacaagc tactatcagg 120
 acctctatag aaaaagtgtg ccaacctcta cactgtagta tgccttaagg attttttagaa 180
 gattgagtat gataaacact t 201

<210> 32
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 32
 gaagggatga tcagtccttc cctcctctat tttcttgagc cccgtttttc acctttcttt 60
 ttctctctcc tttcttatca tgaagaataa agacaaatga kaacagatct accttaggct 120
 gatacagggc agggaaatcca ttttaataata aaacgtgggt caaaattcac ttttctcctt 180
 ttgaattgaa attatattgt g 201

<210> 33
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 33
 atttgatgca acttacacac tgttggtata cctctagaat taaaatgaca attttttaaa 60
 taattttggg gggcctagat ttgctattta acctatcaaa raattgtgtc ttacagtatt 120
 attcaaagt agtgtgtaaa gacttatact attggtccta agcactactg gttgttttag 180
 gctttttctc tttctctgta g 201

<210> 34
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 34
 acatttatat aattaagatg ctaacactga ctgacagaaa tgtcagtaag atgaaatcag 60
 actgcatggg agttttatgt tacattaatt tgtaaattgt rtatctctgt attcatgtga 120
 gtgtggctat catgatgtta gacatccagc tacaaaggag gcattcgtgc acacacacag 180
 tctccaatct tctgtttacc t 201

<210> 35
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 35
 tagacaaagt ttaatgttcc cttttatatg ttttctgggt aaacaaaaat tgtctcaggg 60
 ttattatgca tatatgatat tgtcaagaaa ctttctgggt rctgtggggc aaagtcttct 120
 ccataaataa gctagggttg attggagttt tcactttgaa aaatatcgca caggaggatc 180
 tcaacagcta gacaatttcc a 201

<210> 36
 <211> 201
 <212> DNA
 <213> Homo sapiens

<400> 36

```

aaattaaatg acatacgtaa agtcctcaat aaataatagc tcttattacc attgctatgg      60
ttactatcac tatttctgta ttttcttttg ccattcctca ygcttgaata tgaatctcat      120
gggtagagtt tcccaaagca tgatatgtgt agtactacta aaggcaagat tttgggtgca      180
tacagacaaa aaaataattt a                                         201

```

<210> 37

<211> 201

<212> DNA

<213> Homo sapiens

<400> 37

```

aaaccagagg agtaaaattc tactttcacc agtaattagc agtgtggagt tgagtaaata      60
aacctctcta agtctcagtt tctacatcta ctaaactctaa rcaaattcaa aacagtgatt      120
atttcattag attagatatt ttgattagtc ttaaattgtct aatatataat aaacactcaa      180
caggtagtag ctattctatg t                                         201

```

<210> 38

<211> 201

<212> DNA

<213> Homo sapiens

<400> 38

```

tcatttcttc ttttaaggtc ttaatttctt gtttttcgag tttcatggga gatatccagt      60
caccaatcca atccatatcg gggaaaagta caacaaatga rtgaaatttg taaccaacct      120
tggtgatggg aataagacat ttgggagaac acaggagaag tggggagggt aaggagggat      180
agctctgtga aaattttgca t                                         201

```

<210> 39

<211> 201

<212> DNA

<213> Homo sapiens

<400> 39

```

aactaattct ccaaatttgc aatttggcag catcctactg ggactctaga aggctgataa      60
atcatggaga gtaggatttc atataggaac tatgaaagct statgtagta aacactactt      120
aagaaggcct tacatttcat aaaaagttgg agatttttgt ggagactcat aaaatgcatc      180
ctttatatca gtgaagtttt t                                         201

```

<210> 40

<211> 201

<212> DNA

<213> Homo sapiens

<400> 40

```

actcgtagcc agagctacct tccagatgac ttctttctac cactttcttt cttcccagtg      60
taagagaatg caagtatatg ctgatgtttg gagcaagaac rttcaaaaat tttcttatta      120
acataacttc taatggaaat acagtatact actatggtgc atacaaagaa gaaatagcaa      180
catatatttg ttttagacct g                                         201

```

<210> 41

<211> 201

<212> DNA

<213> Homo sapiens

<400> 41

```

ataagcagcc ttaaattaaa aaaaaaaaaaag ttaactcata actaactgtg tgacctggga      60
taagttactg accctcttta gggcttaggg tcctaactctg yaaaacggaa attataataa      120
taaccttagc tagcatttct tgtgcacata ctataagctg gtgataaaca atttatacac      180
actatctcat ttaatcctca c                                         201

```

<210> 42

<211> 201

<212> DNA

<213> Homo sapiens

<400> 42

```

tccaatgcaa aagaataata ggagcaaaaag cacagtgggtg agaaattgga ggggaactgt      60

```

gaaaattgcc	acatagatta	gaggcaggaa	aataaaggac	rgctaagttt	atatagtga	120
cagtgaagccg	catggacaca	ggtgactgtt	ttctcctttt	tgaacccctg	cttactccag	180
agtcaccacc	tctcctggct	t				201

<210> 43

<211> 201

<212> DNA

<213> Homo sapiens

<400> 43

tattctgagt	attaattcct	gtttccaaat	agattactct	tttaaacata	gcactactac	60
ttacctaattg	aaatttagtt	gctattaatg	gatgaatttt	ktatctaaca	ggcttgattt	120
tgattatgca	ttttaaatgt	cagtcagaca	catattaata	atgatccatg	tttgtagcta	180
ataggcccaa	tatatacttt	t				201

<210> 44

<211> 201

<212> DNA

<213> Homo sapiens

<400> 44

gtaagggctg	ggacaaataa	acacaagtaa	ttttcaaata	tattaataat	aatattctga	60
gtattaattc	ctgtttccaa	atagattact	cttttaaaca	yagcactact	acttacctaa	120
tgaaatttag	ttgctattaa	tgatgaatt	ttgtatctaa	caggcttgat	tttgattatg	180
cattttaaat	gtcagtcaga	c				201

<210> 45

<211> 201

<212> DNA

<213> Homo sapiens

<400> 45

tggtggctct	aaagtggcat	taaggagcca	ataaattgtc	attcctacct	tagctctgtg	60
tcagatgaaa	tacacagcat	agtgtgggga	gaaaatgttg	rgcttattgg	ggatggggtc	120
tttcacataa	aggaagaagg	tttcagaagg	catagtggta	tgaaaagagg	agaaaccaa	180
gggaggaagg	tcaataaagg	g				201

<210> 46

<211> 201

<212> DNA

<213> Homo sapiens

<400> 46

cagcatagtg	tgaggagaaa	atgttgggct	tattggggat	ggggctcttc	acataaagga	60
agaagggttc	agaaggcata	gtggtatgaa	aagaggagaa	rccaaaggga	ggaagggtcaa	120
taaagggtta	agaacgaggg	gaggcaaatt	gactttcttt	cagcatatga	ggattatagg	180
aatggaaacc	ttaattggaa	t				201

<210> 47

<211> 201

<212> DNA

<213> Homo sapiens

<400> 47

gaggatttaa	tgcaattggt	tgtgggaaag	cactttaaca	actctaaatt	acgatatata	60
tgctagggtt	tattgttacc	cacacctttg	atgtatttct	stttgtactc	ttcactgtat	120
ctgtaacaca	ttccctagga	taattagggc	taccctttaa	caaagccaag	attctattta	180
tagtggttaag	ctggcacctg	g				201

<210> 48

<211> 201

<212> DNA

<213> Homo sapiens

<400> 48

cttctgctat	tgaacgaact	ttttgttaag	gtagctccca	agcaggttca	gtagctttgt	60
tctattatca	cttttctact	gacagtgatt	tttttccttt	saaggcctgg	gacatggaga	120

ctgcttttct gcagaaacca catcccttgg agtaatgagc tacacctacc tcaattattc 180
 agtgcagtag aacactccag g 201

<210> 49

<211> 201

<212> DNA

<213> Homo sapiens

<400> 49

acattgtgca catgtaccct agaacttaaa gtataataat aaacaaaaaa aaccactgca 60
 caatctctag tattcagatg gagactaagc atgatttttc wtataaaaga gcagatcaga 120
 atgttgatc ttttattcag aagactggag ttaatcactg ttatcttttag tacttagtgc 180

tgccaaggct gtgtgttcac a 201

<210> 50

<211> 201

<212> DNA

<213> Homo sapiens

<400> 50

acagagtgtc tatttaaaga aaaataaaaa gaacacacac acacacgcac gcacacacac 60
 acgcacgcac acacacacac atgtagctac atgtctagga rggatgtgga gagctgaat 120
 atgaaggcaa aataaaacat ctttttcaaa gtatacagcc tacagtgggt agcacagagc 180
 tggccacata gcagggggtt c 201

<210> 51

<211> 201

<212> DNA

<213> Homo sapiens

<400> 51

caataatgta gaagcaaaga gcctaaagtg ttttcataaa tcttaagtgg tagctttatg 60
 ttccagttca gcaaaacaca aatttgaagg caatctgtac rttaggggtc aggtgaagaa 120
 ggcaaaggaa tcaatgaaat tgtaaaagct ttccaaattt gccttttctc ttaagattgt 180
 ctttctctca ttctcttctc c 201

<210> 52

<211> 201

<212> DNA

<213> Homo sapiens

<400> 52

tttctgtagc agaagtgtaa ggggtgttact cgtaggaggc ctctattgaa ctcttttcca 60
 gtgacgtagt gtgtgggtct taagtggctt tgcaatgata rtaagatcag cattgcatta 120
 ctgaatgagc tccttttagta aacgtggata tgtgctttct gaatctattt gtttggtttt 180
 cccaagtcat aaacagtga t 201

<210> 53

<211> 201

<212> DNA

<213> Homo sapiens

<400> 53

ccatttagag tacttgctc tgagggaaat aaaaatttgc tagcaatttt ctctaaatga 60
 cattatcata ggcacttaat tccttgatag gttcttttag rtaatttttt tataatgaag 120
 caattaattt gattcacgaa agtaagtttc tagtttatat aaagaccaga tctggcctat 180
 ttcttagctt gtctacattt g 201

<210> 54

<211> 201

<212> DNA

<213> Homo sapiens

<400> 54

tgctagcaat tttctctaaa tgacattatc ataggcactt aattccttga taggttcttt 60
 tagataattt ttttataatg aagcaattaa tttgattcac saaagtaagt ttctagttta 120

tataaagacc agatctggcc ttttcttag cttgtctaca tttgagtagt tccattgctg 180
gaaaatgacc ctggagcttt t 201

<210> 55

<211> 201

<212> DNA

<213> Homo sapiens

<400> 55

aagttgctct caacatactt aaagttttcc aataactgaa ttaaatatca gtttatcagt 60
ttaatataaa caattagggt aaatgaaaat aaaatttcag ytctttgggt ccattagcca 120
tggttcagga gcagaatagt cacctgaggc tagtgacaac gcttttggat cacaggaaag 180
aagaaaaaaa atcaaaataa t 201

<210> 56

<211> 201

<212> DNA

<213> Homo sapiens

<400> 56

ttataactaa tgaggcaatg tgtcttgagt attttgaatt aactctctag aatcgattct 60
tgaggaggtt atttactttg agtgatgga cagagtgtag kagatttatg agtgaactct 120
tgtctgattt ggaaatatag agttgtttg gctaggtatt accaacccaa agttgacact 180
tgagtcacct aagttcttct c 201

<210> 57

<211> 201

<212> DNA

<213> Homo sapiens

<400> 57

tattagtgt gtaatcttga aaaaatctct gacacttttc cctctgactc agtttcccca 60
tctggcacc aatcttttac agtggtatga aaaataggga raatgtagaa aggaagaaca 120
tggcaccaa tccttaatgg aactcagtg aaagctggct atcatcatca ttttgggggt 180
tgttgtgttc tacaaatgta t 201

<210> 58

<211> 201

<212> DNA

<213> Homo sapiens

<400> 58

tccccatctg gcacccaatc ttttacagtg ttatgaaaaa tagggaaaat gtagaaagga 60
agaacatggc acccaatcct taatggacac tcagtgaag ytggctatca tcatcatttt 120
tggggttggt gtgttctaca aatgtatttt cccaggaggt ttttttactc tgtctcctct 180
ttccttcata tacccccagc c 201

<210> 59

<211> 201

<212> DNA

<213> Homo sapiens

<400> 59

tggaaggat gaattaatgg gatggagtgc aggggatgca gagtgccac ttatggaatg 60
atttcattca agagagacag gagggtcaga ggtaagaatg ytaccgctgg gacagagagg 120
aaggtacaga tatgagatat ggtaagaagg tatactacaa cagtggctcc caaatctcaa 180
tgagtagcca gttctcatgg a 201

<210> 60

<211> 201

<212> DNA

<213> Homo sapiens

<400> 60

tttgagccca agtctctttc tgactctagg cttagagctt tagggctatt tcacaaaagg 60
gctgttctta ggtcaggcat gacaacttct atattacctt ygtaaaagaa gcaatataat 120
ctaccactat taaattttgc aggttaattt tatattatgt ttaaatacag aaaactttat 180

ttaaaactca gttgaatttc t 201

<210> 61

<211> 201

<212> DNA

<213> Homo sapiens

<400> 61

gaaactggat ccctgatgac attgaaccat tgactgaatc taccctggaa ccatcaggaa 60
ataatcctta gttttttaaa gatgctttta gttgtgtttt ytattacaag tacctgaaag 120
catcctaact aatcaatgct aaatgcatct ctcacagttt atgcttattt ttcagaaatg 180
cctagtggaa atttctattg c 201

<210> 62

<211> 201

<212> DNA

<213> Homo sapiens

<400> 62

tccttccact gactgagact atttccttgc cacaatcaga agaactaaaa gaaaggaggaa 60
tatctgttaa tatatgaatt tatctaaatg tcatgcagtg rcttctaaaa tcatctgggtg 120
tgctctgttt ccccttggag gtgacttagg cctggcatcc caaacaatac atactggagt 180
gaagctccag gaaaccctga g 201

<210> 63

<211> 201

<212> DNA

<213> Homo sapiens

<400> 63

atacatactg gagtgaagct ccaggaaacc ctgaggagaa gagaagggct taaagagcaa 60
tcagccttcg attgctggga ttatgaaagg tcgtaagaag ygaatgttgc aatgttttat 120
tatacttgat attgaagcaa ggacaagtaa taatttatta ttctctccat gtcagtggta 180
tttacctttt tggaatcatg t 201

<210> 64

<211> 201

<212> DNA

<213> Homo sapiens

<400> 64

ataaaaaataa aataaaataa aaaatgaaaa acaaagtcca cttgtaacca catgtcagta 60
gcatgtttgc tttcagggtta catcaaagtc attctatagc rcaggatgtt ccagtcactc 120
taacaaaaga tgtcctgttt ggaacaccaa ctctgtatca gttacttcag acactttctc 180
tcattgagtc ccttcagcaa g 201

<210> 65

<211> 201

<212> DNA

<213> Homo sapiens

<400> 65

aaccacatgt cagtagcatg tttgctttca gggtaacatca aatgcattct atagcacagg 60
atgttccagt cactctaaca aaagatgtcc tgtttggaac rccaactctg tatcagttac 120
ttcagacact ttctctcatt gagtcccttc agcaagccct tttagggtta tgttcttaga 180
tgaggaaacc aagtcttaga a 201

<210> 66

<211> 201

<212> DNA

<213> Homo sapiens

<400> 66

atattttctt gtttttagat gcacatatatc gtactttttt agctgggtcat ttctttctga 60
aattggaatg aatcttataa tcaatggcat gttataattt mattggcagc attatttgctc 120
tcttaagggc ccccaaataa tagtgtgtca cataactgat agcatctcaa attagatgaa 180
atacagtagt ccaggcaaga a 201

<210> 67
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 67
 gttatgggat aaaggcgata gtatatttatt gactatatatt tattctttta attattcctc 60
 taatttctta aaacaacttt attgaggtat aacttccacg stataatttc acccatttta 120
 agtgcattgaa ttcagtgtt ttttagtagag tcattgagta gtgtaacct tcctacaatg 180
 gttatagcac atttttatca t 201

<210> 68
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 68
 tgttttcttt tatttttctt tctaaaataa tcacacgttt cattgcaacc ctaaccctct 60
 tcaacacaca cacacacaca cacacacaca cacacacaca yggcttctag attctacatg 120
 tacaagagtg caaatcaaac taccatagaa aaactaagaa gagaggccta gaagcaagag 180
 gctgatacac tatctcaggc t 201

<210> 69
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 69
 aaccaacact taaaatgcag ggaatttaag ataaaaattt gataaaaatg ggaagatttg 60
 gccgtattgg gctcatggta actgagatgc atctgaatga yaggcattcc tttgaattgc 120
 acatttgctc ttgtttttac tataggccac tctcactttc tgtttttttc cccggctttg 180
 aaacgatcag ttttagtact g 201

<210> 70
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 70
 atgactgggc aattatgtca ttatcaccac tgatatatag ctggaagagt ttagtggtgc 60
 cctgctaaga tctggatttt cttttctgga gcttggctat kggggcattg agaagtccag 120
 ccaggagggt ggctcagaggc taacccaaaa agctttgctt aactctgggc tacagctggg 180
 ggttgccaga gagaagtgcc t 201

<210> 71
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 71
 aatttatattg agtagacagc caacccccctg tattgtactc ctttaaaaaa tatttttaggc 60
 tttttaaatg ctgaggcaag gggacatacc aaacactaac rggcacattg gggttttctg 120
 gctattgaaa taaaaatgtc cttacataac actgatgtac tggaatagca ctgcgttcca 180
 gtgacgggta ttgcaactca g 201

<210> 72
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 72
 ggagcatgat gtgctttgat ttcaactatg ggctttatta cttactaact gggttacttt 60
 ggttaagtgt tttgactctt gttttttgag atggagtcag yctgggagac tccagctctg 120
 tcgcccaggc cggagtgcaa tggcacgatc ttggctcact gcaacctctg cctcccggat 180
 acaagcgatt ctcatgcctt a 201

<210> 73
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 73
 ctggcacaaa gtaggcactt catatataaa agctgtgatt attgatgaac cagtagtgag 60
 gtacataact ggggaaggag aaggggccag tttgtgggaa wgctttttta gttattaata 120
 gtaaggtggt aaaataataa tagtaataat aacccaaaagt tactgaaaac taaatacagt 180
 gctaaaactct ttaaaaggag t 201

<210> 74
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 74
 cttcttttagc tgtaaataag taattgtatg aggtgatggt taaggatgatt tactaatttt 60
 acaatttctat tatttttatga atagacccta gttaggatag yttgaaatag atacttaatc 120
 cactattatt ctctcttcta agatatagtt actagttgat catacttttc cttaaaggct 180
 gaactgaatt ctctgatatc a 201

<210> 75
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 75
 gaaacatact ggttaatgga attccagaaa ggactgaaca atcaaaccat tttgaaggac 60
 agcatagagc tggactctag aacagccaaa acaaggggtt maaccactgc gagggatctc 120
 tctccaatc ttgctcaggc ttttctccct ggcttgactt tcttctctt cactgtagat 180
 tggcttctct cacatggcaa g 201

<210> 76
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 76
 tattatgtgt ggctgactat ataaaaacat ggatattttc ttggaatcac ttggtttgac 60
 tgggagaaga ccatttctcaa aacaaaggaa gtgcaattta yagaaggtag tagaataggc 120
 agataaaaaca ataattcttc actatattgc tcaaataatc cccatgacat ttttagtata 180
 ttataaagag agttctaaag t 201

<210> 77
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 77
 gagaaagatg ttaagatgaa attagatgtg caagagattc gccgaggtaa accttgtggg 60
 agaaaatgga gaggtacata gaggagcctg ggcagactgt stggctacta tgtaagactc 120
 atcccatga aggagaaagg agaggaaggc aaagaagaaa aaccttaaga tttcaattct 180
 aagaacgttt tgacaaagct g 201

<210> 78
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 78
 tgtgcaagag attcgccgag gtaaacccttg tgggagaaaa tggagaggta catagaggag 60
 cctgggcaga ctgtgtggct actatgtaag actcatcccc rtgaaggaga aaggagagga 120
 aggcaaagaa gaaaaacctt aagatttcaa ttctaagaac gttttgacaa agctgattag 180
 gagtatttaa ggcaaagctg c 201

<210> 79
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 79
 aaatacttta actcatggcc cgatgatttt cagttaacca aattctccct tactatcctg 60
 gttgcccctt ctgtcttttc cttagaaatg ttattgtagt rtttgcaaga tggcctgaat 120
 cctgaacccc ccatcttcaa tgagcaccaa atggtaatta tagattccca gctgtagagc 180
 tatgtcagac aaaggaaact t 201

<210> 80
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 80
 ctcttccttg gtggcttaaa gttaggctga agaagattta cattatgttg tgcatgacct 60
 ctttagtttg gttctactta tactttcaag gagggaagac yggggaagggt gtcccttagt 120
 gagcatattt tgtacaaatg aaaacagggt actaacactt atgccaggac gcatgcataa 180
 actaggatgg ttctgagaaa a 201

<210> 81
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 81
 agaaccttaa tgggagcaca ggtcccaccc accccttgct accccatgta cttgttccca 60
 tcttcaccca agagaggaaa cactctggaa ctagggcagc wtaagtgaag cagagtgaaa 120
 aggaatgtga agttttgaga agaaagaaaa ggctaaagtg tctatctttc cacattgctt 180
 ttttcaggtt tctcttcgga a 201

<210> 82
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 82
 gatgaaaaat tcatattcat ctgaatttta taagtgaatc atgagaactc aaagatactt 60
 agcccttggg accatttttt actcctgttc ggatcccttc rgctaagcat gattattttac 120
 tattttcagc tattagttat gtcttggtga aaaagtatga aaagagctgc ccaataaatt 180
 agagtgtatg ctcaacattc t 201

<210> 83
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 83
 ttcggatccc ttcagctaag catgattatt tactattttc agctattagt tatgtcttgt 60
 tgaaaaagta tgaaaagagc tgcccaataa attagagtgt rtgctcaaca ttctcttagc 120
 ttctttatct ctttccaaaa ttggatcaaa tgacattgga catgatcaac ttcttactgt 180
 tttgacaaac atctgaggat a 201

<210> 84
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 84
 ttattttacta ttttcagcta ttagttatgt cttgttgaaa aagtatgaaa agagctgccc 60
 aataaattag agtgtatgct caacattctc ttagcttctt yatctctttc caaaattgga 120
 tcaaattgaca ttggacatga tcaacttctt actgttttga caaacatctg aggatacttt 180
 tataattgat aatttgact a 201

<210> 85

<211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 85
 ttttgtgcct cagtttcctc attcaatatg ggtgtaataa ctgtgcctgt cttgtaggat 60
 tattgtgagg cccaagtgc ataatatata gtacactgtg yctggcatct agtaagcatt 120
 cattaagatg acatgaagat aacacagata tatcttaaca tgtaattatg attttgctta 180
 ttcaaggcca agcattccaa t 201

<210> 86
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 86
 gaagaagaag acagtcagag agaagtgagg gcttactttt catgttttaa gtctgttatg 60
 tggtaaaggg attagattta tctgtgttgt tccaggggac mgaaatagga caaatggatg 120
 caaatagatg gaggaagatt taaaacaaat ggagaagaca ttctaaaatc aactacaatg 180
 agcgtaaaca atgacaacgg a 201

<210> 87
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 87
 tcatatgcat agacaaatac accaaactga tgaatatttg ccttgtataa tctttttgta 60
 gtttttttat gaacatatat tactcaaaca atttagaaca wttggcaata tatatatatt 120
 tcatttataa aagggttagga agattaatta cactttctga ggtcgcaact aaaagccaag 180
 attttaatcc atttctattt g 201

<210> 88
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 88
 agtgtcactg gaaagtgaca aagaggacag ttaagttagt tggaactgaa ctgaggccag 60
 acagggctgt gggacaagtc aggggtgtgtt cattccggta rgcagcgatg cagaatcaag 120
 acagagtagt ttctccttct ctctcctctt ttaattgtaa cgccttttat aacaaacaaa 180
 tattatgctt atttctgtct t 201

<210> 89
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 89
 cagttaagtt agttggaact gaactgaggc cagacagggc tgtgggacaa gtcaggggtg 60
 ggtcattccg gtaagcagcg atgcagaatc aagacagagt wgtttctcct tctctctctc 120
 tctttaattg taacgccttt tataacaaac aaatattatg cttatttctg tctttaaatt 180
 ttttgtagta atttctcatc a 201

<210> 90
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 90
 ttttctagtt gagctatcat tcatatttat tatgtggaac tagaggtagt cctgggtact 60
 tgggaacagc gtggagtcta gccatgtcag ggccagaagt sgtctcagct aagttagaat 120
 gtgataccat tgtttacaca agtgtggcct gccttcaaga taggggtgagg tgttttatga 180
 ccacaggctt tatgagttat a 201

<210> 91

<211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 91
 tgactctgaa gatcataccc gaagtagagc tgcaaagata tttggaatat tggtaatatc 60
 caataaagaa tgaccttcac gctattttga ggagatgttt maatgtcgaa ttattgaaat 120
 atttataaaa tacaaataaa ctaactctgc ttcattattcc aacttgtgta tgacacttct 180
 taggctatca tttcattcca a 201

<210> 92
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 92
 ttccaacttg tgtatgacac ttcttaggct atcattttcat tccaaattta tggtcactac 60
 cctactgtca ttctcatcac taaccatattg atcaacagtt saaaagcagc cactcgcaga 120
 ggtaagcaag atatattggt aatactgtgt tgacaaaagt atgcagaagc agtcacattt 180
 atacagtagt gaaggaaatg t 201

<210> 93
 <211> 201
 <212> DNA
 <213> Homo sapiens
 <400> 93
 aattacagta tatctaaaaa aagaataata tataacaact gaaaaaataa aatagttgat 60
 ataagcagat attccaagat ctgccagaca tattgttaaa ygaaaaatct agatacaaaa 120
 ttgtttatag ttctctttca tactatagcc aaagaaaatt cagaaaaaac tacttacagt 180
 tgatccttga ataatgcagc a 201

<210> 94
 <211> 229836
 <212> DNA
 <213> Homo sapiens
 <400> 94
 gtaaaactcaa aattctcttt ttttgggaaa atgaaaccaa gggagctaata cagagccaaa 60
 ccccatgtac ccaagtgtta gcaggcatga atgtagctac cagctacctg ggtgtgttgt 120
 catccttggg atttttgggg gctgtcctca tctcttcttt tgttttgaca tctctacttg 180
 tcttaaaacc caaggagcct tctgtgtttg tggccaatca gtttaccat gctcctcat 240
 taaatggact ggaacttgta ccatagatta tgtacccttg gacatcttta tactccttg 300
 caatctctct cttccagcac caatccatgg gaattctatc ttgccagggg tgaaaagggc 360
 tatccaatta attccccttc ttatgggcct cagcattata gctgggtatg gaacctaaac 420
 tgccggaatc tcaaaagcct ccttgacctc tagccaactc tgaaaggaaa tagccagcaa 480
 gtttaatatc atggctaaaa cctcaaccat ggccagagca aattaacact ttagcagttg 540
 tagtcctcca aaactgtcaa ggactagata tgtaaatggc agcacaggga ggaatttgtt 600
 tagctttaga tgaaaaatgt tgcttttggg taaatcaatc agtaaaagta caaaacaaca 660
 tcagacaact cctaaatcga gcctccagct tacaagaaca agcctctcgt ggttagttag 720
 attggttaag aacctggaaa tgggatcttc cctgggttct tccttttta ggcccacatg 780
 ttagcctcta cttttgctcc tttcagtcga tgtcttcaaa aatctaataa cccaatttgt 840
 ctcccttctc tcacctttag atgatcaagt tccagatgat cctcagttag ggataccatc 900
 ctttcaatat tcaagagtca cccttctaca gaggactcct agacttccca tcagtgggac 960
 atggcagagg tgaaatcctg cccctgtctc ccttagacct ggctggatac tgcttccaac 1020
 aacccatgca gccaccctgc cctgacagct agcaagaggc caagaccac agaacaatca 1080
 ccatcacacc tctgtcagca ggaagcagtt acagaagact gaccttcac cagtttccca 1140
 aagaattggg tcatggattt ttgcggggga aaatgttaga gtaggtaatt aggcagacat 1200
 gagtaaggga ggagagaccc cctccaacta ggaatgtcag gtgagcatca gatgatcatc 1260
 aggtggttgt taaactctct ctctaaaata ataataggtt gcaactggca gcagggaaag 1320
 acaatctccc aatagataga aaagtctga agctggtgat cagcagcttc ctagtaagat 1380
 ctcaggattt gggcaagcag gctcaaacat gggcactaag aggcaaaatc gtggagttta 1440
 actggtatac agacttcctc taaaaacaca tgactcatgc acatgtggac agcctgcccc 1500
 aaggaaaaat caaaagagga gagatgcaaa accccagaag catgccata tataaaaccc 1560
 caagtctaag gtcaaacagc gcacttggat ttctcaagtt gccacttgg cctcttctc 1620

agtgtacttt	atttcctttc	attcctgctc	taaaactttt	taaatttcac	tcctgctcaa	1680
aaacttgcc	cagtctttca	ctctgcctta	tgccccttgg	aagaattatt	tccttcaaga	1740
tggcaaaaag	caagctgctg	cagaccata	cagatttgct	gctgctaaca	ggaggataac	1800
ttgagcccag	aagggttaagg	ctgcggtgag	ccttgattat	gccactgctc	tccagcctgg	1860
caacagaatg	agactctatt	tttttttctt	ttaaaaagac	tttttacaaa	aggcaaatg	1920
ataatggaac	taaaaatgta	cgttgactga	cttaactcca	actgcttctt	ccctcaattg	1980
aaaccacctt	tgcaaaaatt	ataacagtga	gaaaattatg	gcagtagggg	tgatctgac	2040
aagccaaaac	ccatcttgcc	tttagccttc	aagctgcccc	taattattcc	tggtgcttagg	2100
ccaagctaac	tttgggagac	acttggtcta	tagtttaaat	gataatagtc	cttccttaaa	2160
attcaaccac	ctcagcaaag	ctgatgagag	gccaccaggc	aaggaggata	gaggagtcta	2220
aattctgcta	aggtgtagat	ataaacagtt	tccagccatt	attctggagg	tcacaaaatg	2280
tgcaacttct	tcaattactc	ctgcagataa	catcagttat	ttagaacctt	agattggcct	2340
tttgagatgt	cttttcaggt	ttttttgtgt	gtctgactac	cgatggctcc	acctggaccc	2400
accaaccact	cctgtggccc	catccagaag	caactcagca	tgcataagga	ctatttcccc	2460
ccccctatg	attgcacccc	caaccaatta	gcagcaagga	cttattgcct	aaaacagccc	2520
cattcatccc	ccaaccatc	catgaaaaac	cctagctttc	aaatttccgg	ggaagctgat	2580
ttgagcaata	ataaaatacg	tctcccattt	agccaactct	acatgtataa	aactctttct	2640
ctattgcaat	ttcccctgct	tgataaatga	taaatcagct	ctatctgggc	agcaggcaag	2700
aagaacccgt	tgagtcctta	caatatcctt	ctttctaccc	tcctctgcct	aattactctg	2760
aatctactaa	ctttttcact	cagttatttt	tccactttga	agacaaaaag	ttagaaaaaa	2820
aatgcctta	tgaaattagt	ccctcagaat	aaaccagctg	ggctttcttt	agccacctgt	2880
atgctttagt	caaaatctaa	gctcagaggc	aatagtgaag	ggctttctta	tcccaaagga	2940
aaactctcag	aaatttgctg	aagctatcca	cactgagtgt	aggtatagaa	catgctttgc	3000
cctatttatt	catgggcacc	atcctgaact	cagtaatcta	gcttttttct	tttgaagctg	3060
gatggggaag	acacagatct	agctgaatta	gttgccaaaa	tatgctatct	ggcataaaga	3120
ttattttgag	agagttattt	tgagactctt	tgtaagagaa	atttatatct	acaaagggaag	3180
tctccattta	taagcttgct	tctctgcac	aggaagaaaa	gaaggactaa	atcaccagac	3240
actcttaacc	aatggagaag	gagtttaagt	aacaaacctt	acctttgttt	aaggtgcttt	3300
ttctggctct	ctgccattaa	gatctacatt	ttccaccctg	tctcctctag	gacctgaggg	3360
ttatctcttt	gatattgcaa	tgccagggag	attactcacc	agaagaagaa	gaagaaatag	3420
agcttaattg	aaattgagca	aataaaaaaa	tcttgttttt	tctcccagaa	acagtgaaaa	3480
gcttttagcca	tccttttagat	aatcttaact	tgttccatct	gccagaaaca	caatttggat	3540
tcagaaaattc	tttatgaact	gtttttgtat	tattgtacct	ggcacatggc	tacagttttc	3600
aatgaaaaac	tgtgaaatct	gcttctgtct	gtattttatg	tatgtctgtg	tatgcatgta	3660
tgtgtaatat	ttttctacct	ctagagacta	tcctaaaatt	aacttataaa	gagctgtatt	3720
taattgcctt	aaagaaaaag	cacttatata	aattaagtat	tttttaaaact	ttcagaaaaa	3780
taagacctag	cgcaaatgtt	cttcaagttg	atattgttaa	aagaagaaac	ttcagccaaa	3840
ttaaacttaa	agaagtttaa	ttgagcaatg	aatgattcac	aatcaggca	gcctccagag	3900
ttacagctga	ttcatggaga	ctccagggat	gcctcatggg	cagaacaaat	ttatagacaa	3960
aaaaagggaa	gtgacataca	gaaattagaa	gtgaagtaca	gaaagagctg	gactgggttac	4020
aggttggtgt	ttgccttatt	tgaacacagt	ttgaacactc	agcagtgtct	aagtggttga	4080
agtatggcta	ctagaatttg	ccaagactcg	gctattgtta	caggaacgta	ctcctaaatt	4140
aggttttcaa	tcttgtctac	ctgttaagtt	aggttacagt	tcacccacaa	ggactcaaat	4200
atagaagtac	ggagtccttc	tcaggctatc	ttcagttctc	tttaacagta	tgatacggga	4260
taatcttcag	taaataaaaa	tttctttaag	tttggttgat	taactaaagc	aggcatgtct	4320
tcagagttgt	caacattaaa	tataatacat	acatacagtt	tttttctacc	aggggttact	4380
aggcaaatat	gtttgtttat	gtaactagat	gtttaagatt	ataaaactgt	cagtttaatc	4440
taagagcaaa	agtgaataatg	tggtagctat	tttattaagt	acagcggtaa	agcaagtata	4500
tattaagtat	agcagtaaaag	caaaaaaaca	aaaaaaaaca	agtatttaac	tttttttttg	4560
tttttttttt	tgagacggag	tctctctctg	ttgccaggc	tggaatgcag	tggcacaaatc	4620
tcagctcact	gcaacctcca	cctcccgggt	tcaagcgatt	ctcctacctc	agcctcctga	4680
gtagctggga	ttacaggcgt	gcaccaccat	gcccggctaa	tttttgattt	tttagtagag	4740
atggtgtttc	accatgttgg	tcaggctggt	ctcgagctcc	tgacctcatg	atctgctcgc	4800
ctcggcctcc	caaagtgtctg	ggattacagg	catgagccac	caagcccggc	cttaactttt	4860
ttttaggttc	ttgcttttgt	gatatttggc	taacatacat	atgctgtaaa	aattgttaat	4920
aggaaaaat	taataatgag	atgttgacta	gctttgtctg	tctaataaaa	tttcataagt	4980
caattaaaaat	taagaacaat	tgaattatag	aatagaattc	aattgaattc	tattgaatac	5040
acttgctgaa	tacaacaatt	gaattgtaaa	tagaataaaa	attataaaatg	aacttttcaa	5100
tagtaattat	tttttaatac	gggtacttaa	aattgtgtca	acttcttaac	aaaagaaatg	5160
gaggcaaaaat	tagtataaac	agtttatattg	ggccaaaattt	gagaactgca	atgtggggaga	5220
cacgtcttca	agttgctatg	aatataaaact	ccaattagca	gcagttacaa	gcggtttttt	5280

ttttttaaag	aaggggcagt	tcttttagttg	catataaact	attgattggc	tatacatttt	5340
tttttaacca	taaattccag	gagcatgaac	ataatgggtg	agggtcacat	cccctgggca	5400
tggatttggg	gcaggatgtg	acaaaaatct	catactcatg	tctctctggg	cctgataaat	5460
tttgcatact	ttatatagtt	cagactcttc	tgagctacgt	ttctttctct	tccttttggg	5520
tgagtttttt	tttcttctga	aagtattgat	gatcaacatt	ttagatgtaa	gtttgtccca	5580
tgtcactgga	agacttagtt	ttagtttagt	tcatcccaca	ttggagggaag	agaggagaga	5640
taaaatggct	taagaatgca	gtgaagtctc	aaggccaagt	tgattggcaa	cacaaagggg	5700
cagggcaatg	gtatttcagg	tcatctgctt	acaaaggagc	tatggcatgt	tggtatcattt	5760
ctaagcatct	agctatcatt	attttagtgt	ttttgttgat	tttggacatc	tagaagtgca	5820
aagtataatc	aatttgagaa	taaaagacat	gatgcaaata	aagacaatta	ctaacaaaag	5880
ccagatctga	aaaatgtttt	tatttccgaa	ggcgacccaa	taaatatgtt	ttctacttct	5940
tgtgctgata	taaagatcaa	tgtataggag	atctccagtg	atgagtttgt	ccactcaggc	6000
agagctgcct	ttttaaaata	aaaattatga	atgcataagt	caatgtattt	gaatttaact	6060
ccacaagtat	tggttaacaa	tacagatatg	gtcgttccca	aggtgtttgg	agggagtttt	6120
gtatttgatg	gcattccaca	ttggaggcca	tgcattttga	tgtcttcac	tcctggaacc	6180
acactgtatt	gtttggacat	atctatccag	acagatgatg	ataaattttg	catatctcac	6240
atagttcaga	ctgctctggg	ctacttttct	ttctcaatag	cttctcattg	ttactttatg	6300
cctgtagagt	tttgctaaac	taaattagat	aatggacatt	tattaaatat	ttagatcatt	6360
tccaaataac	ataaaatgct	gaaacattaa	ttgcttaaca	taagttaatc	tacttttggg	6420
ttttattaca	aaggaactaa	atatattttac	atctgttaaa	aaacacttta	aactgtacta	6480
tgagaaagaa	tatacttcta	tagaaattat	aaaatggtat	atttatagat	ttaccatttt	6540
atggaatacc	ccataaccgt	tcacaatttc	ttatttccta	gttttcacta	gaaattgaag	6600
ttactaagag	ttaacaattt	taactaatat	agagtagtta	aaaagactaa	aaataataag	6660
ggagataact	atatgcaaag	aaagtaagac	atgttttttg	taaggaaagc	cataagggtat	6720
aaggatgtgc	ttttttttta	ggaaaaggaa	gaataatttg	gtctagtttg	gagggttattt	6780
aaaggttggt	tcagaatgaa	tgaaagataa	aatctaaatg	gatacaaaaa	ggaagagaga	6840
tgacacacac	acaaaatgaa	tgactcttgt	atggacaagt	tggttagaac	tgaatgtatt	6900
ataaggtttt	aaaaatgagt	cttgaccaag	cactgtggct	cacgcctgta	atcccagcac	6960
tttgggaggc	caaggcgggc	agatcatgag	gtcaagagat	caagaccatg	gtgaaactcc	7020
atctctacta	aaaatacaaa	aattagctgg	gcgtggtggt	gcgcacctgt	agtcccagct	7080
actagggagg	ctgaggcagg	agaatcgcat	gaacccagga	ggcagagggt	gcagtgaact	7140
gagatcacac	cactgcactc	cagcctggcg	acacagtggg	actccatctc	aaaaaaaaaa	7200
agagtcttaa	tatcaaaagt	aaactgatgc	aaaactagaa	tttgggtctc	tctgtgaaaa	7260
tgacagtttt	cttttttaag	agtattgtct	cagtttttta	aagtgattgt	gaaaaatttt	7320
cctttccctt	gtaactaatc	ggcctacaaa	atgaagattt	tgtgttttct	caaaaataatt	7380
ctttgtgctt	cgtgttgctt	ttttttggtc	tttaattact	taagaaaatt	gaatcttccc	7440
aacaaaagag	ctagttttgt	ttgttttgtt	tttacagtta	ttaaactttc	tctatttgcc	7500
tttgaaacct	cttagtttgt	actttttgtg	tcttcacagt	gacttttgat	atattttaatc	7560
aagtgtttta	aacatttgat	atttttgcca	gacttcctaa	aaccaaattc	taaactaaat	7620
ctttttttta	acctcaagct	aagtaggatt	ttccagatgg	attcctggaa	tatctcaaaa	7680
gactttgttt	tctttcccta	tagaaagaga	ggtcaggcac	agtggctcag	gcctgtaatt	7740
ctagcacttt	gggaggccaa	ggtaggcaga	tcacttgagc	ctgggagttt	gagaccagcg	7800
tgagtaacat	agggagaccc	ttctctacaa	aaattagcct	ggcagcccag	cgtggtggct	7860
catgcctgta	atcctagcac	tttgagaggc	taaggtgggc	tgattgcctg	agctcaggag	7920
tttgagacca	gtctgggcag	caaggtgaaa	ccccatctct	actaaaaata	caaaaaatta	7980
tctgggcatg	gcggcgtgtg	cctgtagtgc	cagttacttg	ggaggctgag	gcaggaggat	8040
tgtctgaatc	cgggaggcag	aggttgcagt	gagccaagat	cacaccactg	cactccagcc	8100
tcggcaacag	agcgagagtc	cttctcaaaa	aaaaaaaaaa	aaattagcct	aacatggtgt	8160
catgcctgta	gtcccagcta	cttgggaggc	tgaggtggga	ggatcacctg	aacctaagga	8220
ggttcaggct	gcagtgaagc	atgattatgc	tactgtattc	cagcctgggc	aagaaaagta	8280
gaccttggaa	aaaaaaaaag	agaaaagaa	ggaaaaagaa	agaaaagaa	aaaaaaaaag	8340
aattgcatag	gaagttgtca	aataaggggt	atgtttaacc	ttcttatgtt	ataatattat	8400
tcatgtaagt	tttccagatg	ttctgtgaac	ttctacaact	ccgatatgtc	ctgatattgt	8460
atcagtcata	attttagtta	ccttaaaaat	tttgttttct	cagaaataac	aaattacatt	8520
gtcaattgca	ttataatgaa	ctttcatcag	atctttaacc	atggccattt	ttaagtctgt	8580
tgtcatccac	aaacagtagt	tttactctga	tactttcctg	aaagttattc	caaagtcttt	8640
gtttgcagga	agatttatgg	aaaatattga	aatgtgtggg	tttctggtaa	ctttaagatc	8700
ataacattgg	actgcataag	aatttccagg	actctattgg	aaaaactaaa	tttataaaat	8760
tgctaaccga	agatcaagta	gaagaaaaat	taattacatg	gtgatattgt	ttggctgtgt	8820
ccctactgaa	atctcaactt	gaattgtatc	tcccagaatt	cccacatgtt	gtgggaggga	8880
cccagggaga	ggttattgaa	tcatggagtc	tggtctttcc	catgctattc	tcgtgatagt	8940

gaataggtct	catgagatct	gatggggttaa	tcagggggttt	ctgcttttgc	ttcttctctca	9000
tttcaccatc	aggtaagaag	tgccctttcag	ctccccccat	aattctgagg	cctccccagc	9060
cacgtggaac	tgtaagtcca	attaaacctc	tttttcttcc	cagtctctgg	tatgtcttta	9120
tcagcagtgt	gaaaacggac	taatgcacat	gggataaaat	gtattgataa	taatgataat	9180
tttatgactt	ttcgtttgaa	acattgctgt	ttctttaatg	tctaattttt	cagatttaac	9240
gtaacttttt	ctttctttcc	ttaagctatc	tatagcttac	agaaatttag	cagattatac	9300
ctttatcaac	agaaaagaag	catatacttt	ctctcttacc	tgatccctcc	agaattcaga	9360
aactattagc	aagtattatt	atttccaagg	caatatagtt	atatgcataa	ctgcaataag	9420
aatatgttct	tctgggctgg	gcgcagtatc	tcatgcctgt	aatcccagca	ctttgggagg	9480
ccaaggaggg	ctgatcactt	gaggccaaga	gtttgagacc	agcatggcca	acatggtgaa	9540
accccgagtc	tatgaaaaaa	taataataat	aataataata	caaaaaattaa	ctaggtatgg	9600
tgggtgcacgc	ttgtaatccc	agctactcag	gtggctgagg	cacaagaatt	gcttgaacct	9660
gggaggtgga	ggctgaagtg	atctgagatt	gtgccactgc	actctagcct	gggtgacaga	9720
gtgagactct	gtctcaaaaa	aaaaagaata	tattcttctc	ataacaggac	acaattagaa	9780
acactggtta	tattaccaag	gttttaataa	gaatatcata	cttaaaaaata	tgtgtaaaat	9840
tttatatgac	cagccgggtg	tggtagctca	cgctgtgaat	cccagcactt	tgggaggccg	9900
aggcaggtgg	atcacctgag	gtcgggagtt	tgaaaccaag	cctggccaac	aggaccctta	9960
aggaccctta	aggagatttt	aagaacctaa	tgaagaagag	aattcaccca	aaattatagg	10020
cattgcagat	gaagtctgat	gacaagtcct	tggcttgcc	tcctagcttg	gaaagacttt	10080
ttaaattcta	atttgagact	ccttattaaa	agtcccagca	aagtatactt	tgaaaaagct	10140
tatgtaatga	atcactattc	ttactatact	tatgtaagta	atcaggccaa	gtgtaacggg	10200
actaggccta	ttttgcaaac	aaatcagttt	tactgtgatt	atttttgtaa	tgggcatgac	10260
tataaagaga	aaaactatat	attagtagaa	aactatagca	caccattgt	tagattctag	10320
cctagttcac	tgtctttgag	gttttgttat	ctacttgtaa	actgaactgg	atcctgaatt	10380
ctaatttctc	ccagtatctg	gctatgactt	ctaccgagct	gactacaaat	ttgagggttc	10440
ccttgacctc	ttcctcatgt	tcaataattt	actaggacaa	ttaacgggaa	ctcaggaaaa	10500
cacatatgat	tgccagttta	taatgaaaaa	tacaatttag	gaatagccaa	gtggaagaga	10560
ttcatggggc	aaggatggg	ggctctttct	tccatgcctt	ctccaggtgc	accatcatcc	10620
tagcacctca	ttgtgttcac	caaccagaa	gctctctgaa	ccccaaagtt	tagaggttag	10680
tatggaggtt	ttattacata	ggtatgatta	gttaaatg	caaccattgg	tgtgtgaaca	10740
ttatctttac	tgccctttct	cccccaacct	ccagaagtgg	aaaggggtgc	taaaagttag	10800
aacctcttta	tatttgcttt	caggtgacaa	ctttcacaagt	gagttggagc	aaagaccaa	10860
catatatattg	catgaaatca	tgacatccta	tagtaatatt	tgattttcaa	actctgcatg	10920
tataatagtt	acttaaaatt	taaattaaat	tttaaaatgt	accagttatg	cagctgaatt	10980
ttggtacttt	ttcccttggc	tttgtctggt	atctgaatcc	accatcattt	ccctgtacaa	11040
tatctgccat	tggagatcca	attgggaaaa	tacatttaaa	gaaaaaatct	aagaagcatc	11100
tcataggttg	tggttccctt	gcatccacac	tcattatcat	ggtattatct	tccccaaagt	11160
gggtaatagt	atatccctgg	ctaatatcaa	gattagcact	agctgtctgt	agataccatt	11220
tagaaaagtt	ttctctacat	gtcctctctc	accactccta	ttcaacatag	tattggaagt	11280
taaaaaaaaa	gttttctcta	cttgaaacta	aaatttatgg	cagactatat	gcttccgaat	11340
gttctaaaaa	cttactagaa	gacaaacatt	gtcaaaggta	ggaatgtggc	caacatgtca	11400
ggtaacgcct	ataacaaatt	aaaatctggc	gattgctgcc	aagataccca	caaaactatc	11460
ggaggcaact	gctgctaaaa	gaccataaag	atgattctgg	agacaaaggc	ctgtggaagt	11520
caataaaaata	atggtcaaag	tggaacaagt	ttaaaaaaat	taggattcag	aaagaagcca	11580
attgtcattt	aggaaacaat	tatctgataa	caaagctcag	tgccctctta	gggctgacat	11640
tcattgtatc	attaaaattt	gtagaactga	taaggcttag	tggattatat	ttgacaaaag	11700
ttatttgc	ttcaaaaagg	aatcaacttt	tgagacaaag	gaatgcttta	attcattcaa	11760
caaataattt	ccaagtacct	acttttagga	tatgatgggtg	tgtaaaaaaa	tttttgctgc	11820
tatcatggag	tttagaatat	agaggtaagg	ccaatatata	tctagcaaca	ttaaatcttg	11880
tgtaatgtga	aactgaggta	gataagtgt	caagaaaaaa	aggttctgta	aaagtttata	11940
tcaaaagatc	ctgatcaaa	aagtattcta	ggggaaataa	tcattaaact	gagagctgaa	12000
ggaagagttg	gggtgaatgg	cataaatctt	aaaatgagac	agggtttata	cctgagggtt	12060
ggtatattag	tttactaggg	gtgtataaca	aagtatcaca	aactgggtag	tttaataaac	12120
agaaatgtat	tgccctctaag	ctctggaggc	taaatatctg	agatcaaggt	gctggtaagg	12180
ctgtttcctt	ctgggttgat	gagggagatt	ctttttcatg	actctctcct	agattctagt	12240
gatttgctgg	aaatctgggtg	tttcttgact	tgtacacctt	tgcccttggt	atagactgat	12300
gttgtctccc	cctaaaactt	atgtgttaaa	atcctaacct	ccagtgtgat	gggattagga	12360
ggtggctctt	ctttggggaa	ataattaggt	aatgagtgtg	caaccctcat	caatggaatt	12420
agtaccctta	gaaaaatgac	tccagaaagc	tctctcatcc	cttctgctat	gtggggacac	12480
agtgacaagg	gggccatctg	taaagcagaa	agcaggccct	caccagacac	taattctgcc	12540
agtgccctga	tctgggactt	cccagcctcc	agaacctaga	taaataaatt	tctgttggtt	12600

aagccactag	cttatggtat	ttttgttgtt	agtccaaaca	gactgagata	gccttcattc	12660
ccacatggca	tttttttctc	tgtgtctttt	tgaataaatt	tcttcttttt	ataaggacac	12720
cactcatatt	tgattaggag	tctaccctaa	tccagtataa	gcttatctta	atgaattatg	12780
cctgcaatga	ctctatttcc	aaactaagtc	acattttgag	gtattgcagt	taggacctca	12840
acatatgtat	ttttggggga	gacacaatac	aactcttacc	agttgagaaa	gagacaatgg	12900
gagcaaagaa	gatttgaaat	ttacctgctg	acttagctag	gttaatcatg	agagaacaaa	12960
aagctttcat	ttgaaaacgc	ttcaggaaat	tcagtgttct	caaaggagag	ttggattgtg	13020
tttatacca	gaagggggct	gaaactatct	gaggaggagg	ttcaggctat	aaagattata	13080
cagattgatt	attgagaaaa	gtacaaagga	gcacagtgca	aagtttggga	ggtggagaag	13140
tttgagtcaa	aaataaggaa	gtatagagag	cattattggg	atgatgggaa	ggtaaaaata	13200
actggccagg	attaattgct	tctattcata	tctctgcctg	atgaaaatgg	gagtgagaag	13260
tgtgatggct	ttagtctcaa	atgccttctt	gagaaaggcc	aaagaattta	gactgccag	13320
tccagaacaa	tgctcagccc	aataggtata	gtctctgttc	tcctggccag	aactagaatc	13380
aattactggc	tccatcattc	actagatgtg	tgcgtttggg	ccagttacag	tacctctcta	13440
agaccgagct	ttctcattct	taaaatgagt	ataataataa	cacttagttg	aggaaagctg	13500
tgtagtacgt	ctcagtatca	ctattgaagg	gctggaggat	tctcatgccc	tcgataaact	13560
gtgtgatctc	tcagatcctc	tattttctga	ttttaaaact	gtcatagtaa	tgcttttagag	13620
tactgtaata	acaacttatg	gagatcttat	ttataaaaag	taatttgaga	aatagaaaag	13680
taacacctag	ttactttttt	cctagttatt	ttgggccagg	atttgtttct	gtgactgtgt	13740
ctaaatgcac	catgagagga	cgcccaggga	aggcacctcc	actccattct	atctcattcc	13800
tctttcctag	tgtgagttca	tcctgtgtgc	tgatttattt	tccttaatcc	acctggctct	13860
atcaaagggc	catttcagtt	agttgctcca	cttcagttta	tgggagataa	gtcttgtcca	13920
gattttccta	atggccaaaa	aagtcaaatc	cttatcctct	ttgggcttta	ctcaaaaatg	13980
cttgttcagt	tagggctcta	gttttattcc	ccagagattc	tgcatgtttt	atactgatct	14040
tgccagggcc	ttcatctttt	gggctagtct	ctggaaaatc	tacctctggt	cctgtgcact	14100
tttccccctc	tagattctag	aaggaaaagc	aatgaatagc	gtctcccaca	aagatatttc	14160
caagacctaa	cccccagtac	ctgtgaatag	tgagagtaaa	atgattagt	gctgccagag	14220
gttcaagaga	aggagagaaa	tattgaatag	gtgaaggaca	ggggattttt	tagagcagt	14280
aagtatttct	gtatactgta	atttgttatg	catgacatgt	tttttcataa	cccattggac	14340
tttacaata	aaagaatgaa	cttaaggtat	gcaaaattta	aaaatcactt	aggagggggc	14400
agggccaag	tggtagatta	gaagcagctc	atgtgtgctg	ctctcataga	gaggaaacaa	14460
aagggtcagt	gaacattgac	cctccaggct	gatcatctga	aaaaccatgc	tgggatccat	14520
caaggcagtg	ggtgaacaca	gagtacagag	atgagcaaa	ttgggcacca	gcctttcagg	14580
actcagagtg	aagccaagag	aacctctcca	acatgggaaa	gggtgagtga	gtgagagccc	14640
ccagaggaat	tcacactctg	cacagggacc	cacacaagac	ttggaatggg	agaatcccc	14700
tggaccccct	ggacacctgc	caccaccatg	ctcctagact	gaggcagaga	gccaactaga	14760
tgttttgcag	gggcaactct	tgagtccaag	gggacctcta	caagccttgg	ccccttgagt	14820
agaccagcac	tggttccaca	gccccaaaag	aggccacagt	tgcatgtcct	gggagaagta	14880
agattgcccc	gccccctctt	gctggacagg	gcttgatggc	agcttctggc	ccagcagtc	14940
cacttcagcc	tgaacttgct	tggccactcc	aatcacccct	caccactggt	atcctggcgg	15000
gcaaccctcg	atagagcttc	cagcccagta	gtcccacttc	tgtgtcaact	tagcccattg	15060
acacagcctc	ctgttgtccc	aggaagcact	cagacattag	ggcaggagaa	tgtacccatc	15120
ctcaccactg	atagccaggt	ggcccagtg	tcctacttca	atggggactc	agctggagg	15180
ctcagcctcc	cattgtccca	agaaatgcat	agacagcagg	gtgtgtagcc	ccaacctacc	15240
ctgccactgg	tagacaggcg	ggcaatgcct	cctagacctt	ctggcccaga	ggtcctatat	15300
ctgtgggaac	tcagccagtg	cgcacagcct	cctgtgtccc	caggaagtat	ctggttagta	15360
gggtgggtgt	ccccaaacac	ccctgtgctt	ggaagccagg	tgagccatgc	ctgttagaac	15420
ttctggctca	gtggtcctac	ttctgccaga	atttgctgag	ggtcacaacc	tcctgtgtcc	15480
ctggaaacac	ccagagagca	gggtgagcaa	ctccactcac	acctgcctcc	catagccaga	15540
caggggccac	ccaatagagc	ttccaaccca	gcagttctgt	tctacctgca	ctctgtgaaa	15600
aggcacaagc	ccgtgtttct	ccaagaagca	catggatagt	atattagtgc	tgacttggca	15660
aggatacagc	ttgtctgcca	acagcagctc	ctgcctgagg	gaacaccatg	gacccgaaaa	15720
cccaacaaaa	aacataggca	cagagacagt	aattggagg	ggctcctcca	agacccagga	15780
gtggactaga	attgaaacca	gtcaacccaa	gccaccttat	acaataatga	aacccccaa	15840
ggcatcaaa	aagaaaaaag	caaaaaaaa	aaaaaaaat	ccactcaaat	tacagcaatg	15900
ttaaagactg	aaagaacaac	agcccataca	aatgagaaa	atccagcaca	agaactctgg	15960
caactcaaaa	aaccagagtg	ccttctttac	tccaagcaac	tgactagt	tcccagcaag	16020
ggtccttaac	taggctgaaa	tggctaaaat	gatggaaata	aaactcagaa	tacagataag	16080
aatgaagatc	attgagattc	agacaatgtt	gaaacccaat	ccaagtaagc	taagaatcac	16140
aataaaatga	tacggaaatt	gatcgatgaa	atagccatca	taaaaaagaa	cccaactgat	16200
ctgatatagc	ttaaaaaacac	actacaggaa	ttgcacaatg	taattacaaa	tattaacagc	16260

agaacagacc	aagctgagga	aagaacctca	gagctcaaag	actggctctc	tgaaataact	16320
cattcagata	aaaaattaaa	aaagaataaa	caaaacctac	aagaaataga	agattatgta	16380
aagagaccaa	ttataggact	cactggcatc	tatgaaagag	atggggagaa	agcaagaaac	16440
ttggaaaaca	tatttttagga	tgtcatacat	aaaacttcct	caacctcatg	agacaggcta	16500
acattcaagt	ccaggaaatg	cagagaaccc	ctgctgacat	tacacaaaaa	gaccatcccc	16560
aagacccata	attatcagat	actccaaggt	tgaaatttaa	aaaaaaaaaa	aaaaagacaa	16620
aggcagctag	agaaaacggg	caagtcgctt	gcaaagggaa	tcccatcagg	cttacaggag	16680
acctttcagc	agaaactcta	caagccagaa	gaggtttgga	gcctatattc	agcattcctt	16740
ttttatgaga	cagagtctcg	ctgtttcacc	caggctggag	tgacgtgggt	cgatctcggc	16800
tcactgcaag	ctccgcctcc	tgggttcaca	ccattctcct	gcctcagcct	cccagtagtc	16860
tgggactaca	ggtgccacc	accatgcggg	gctaaatttt	tttttttttt	tttttgtatt	16920
tttagtagag	acgggggttc	accatgttag	ccaggatggt	cttgatctcc	tgacctcgtg	16980
aggaggtcct	cctgacccgc	ctcggcctcc	ccatatattc	agcattctta	aagaaaaaat	17040
ttacaatcaa	gaattttaca	tctggccaaa	ctaaacttca	caagtaaaaa	gaaataagat	17100
tcctttctta	caagcaaatg	cttagggaa	tcattacca	cacacctgcc	ttataaaaa	17160
ccttgagag	agcactaaat	atggaaagac	cattacaagc	cactacagga	acacatttaa	17220
gtacacagac	cgatgacact	gaaaagcacc	cacagaaaaa	aaagtctgca	taataatcag	17280
ctaaaagcat	gattacaaaa	tcaaatccac	acataattag	actaagctaa	tgggctaaat	17340
gatccaatta	aaaggcgag	agtggcaagc	tgaataaaga	agcaaggccc	aatggtatgc	17400
tgtcttcaag	agaacctct	cacatgcagt	gacatctata	ggctcaaaat	gaagggcg	17460
agaaaagtct	atgaaacaga	agaaatcaga	ggttacaatc	ttaatttcag	acaagatgga	17520
ctttaaacia	acaaacatca	aaaaatataa	agaagggtat	tatataatac	ccttcaattc	17580
aatggttcaa	ttcaacaaga	aggtataact	ctcctaaata	tgacagacat	ctaacacaag	17640
agcaccacga	ttcacaaaac	aagtctctag	agacctacaa	agggacttag	aacccccaca	17700
caataatatt	gggagccttc	aacatcccac	tgacagaatt	agacagatca	tcaaggcaga	17760
aaattaacia	acataattta	gacctgaatg	caataacttg	ccaaagggac	ggaatagata	17820
cctatagaac	ttgccatcca	aaaacaacia	aaaatacatt	cttctcattg	ccacatggca	17880
catactccaa	aatcaaacac	aaaattggac	ataaaacaat	actcagcaaa	ttaaaaaaa	17940
aacagaaatt	ataccaacca	caatcttaga	ccacagcaca	acaaaaatag	aaataagttc	18000
taagaacata	actcagaacc	ataaaattac	ataggaatta	aacaatctgc	tctggaataa	18060
cctttgggta	aacaacaaaa	ttaaggcaga	aataaagaaa	ttctttgaaa	ttaatgagaa	18120
aaagatataa	catatccaaa	tctctgggaa	acagctaagg	ccatgttaag	agagggaagt	18180
ttatagcact	aaatacccac	atcaaaaatt	tagaaagatc	tcaaatatac	gacctaacat	18240
cacaaccagg	agaactagag	aagcaagagc	aaagtaagac	cccaaagcca	ccagaagaca	18300
agaaataacc	aaaatcacag	ctgaactgaa	gaaaactgag	acactgaaaa	ccatacaaaa	18360
gatcaacaaa	tccaggagtt	ggttattaga	aaatattgat	aagatagata	gactactggc	18420
tagactgata	aagaaaaaaa	gacagaagtt	ccaaataaac	acaattagaa	atgacaaagg	18480
agacgttacc	actgaacca	cagatataaa	aaaaaacatt	gaagactact	ataaacactt	18540
ttaagcacac	aaactagaaa	atttagaagg	ctgggtgtgg	tcgatcacgc	ctataatccc	18600
agcacttttg	gaggccaagg	agggtggatc	acaaggctag	tagatcatga	tcactcctgg	18660
caacatggtg	aaaccccatc	tctactaaaa	tataaaaaaa	aaaaaaaaaa	ttagctgggc	18720
ccagtggcat	gtgcctgtag	tcccagctac	ttgggaggct	tgaggcagag	gaatcacttg	18780
aacctgggag	gcgagggttg	ctgtgagctg	agggttagcc	actgcactcc	agcctggtga	18840
cacagtgaga	ctccatctca	aaaaaaaaaa	aaaagaaaga	aaaagaaaa	gaaaatttag	18900
aagaaatgga	taaattccaa	gacacataaa	ccaggaagaa	actgaatccc	taaacaaaca	18960
aacaatgagt	tccaaagtta	aatcagtagt	aaaaagccaa	ctgtattaat	gcattcttat	19020
gttgctataa	agaaatacct	gagattgggt	aaactataaa	aaaagaggtt	taattggtta	19080
acagttctgc	aagctgtaca	ggaagcatga	cagcttctgg	gaaggcctca	gggaactttt	19140
aatcattgca	gaaggcaaa	ggaaagcatg	tatgtcttac	atggccagag	cagggggaag	19200
agagagagag	gggaggtgct	acatactttt	aaacaaccag	atttgtgaga	attctatcac	19260
gagaacagca	gtagtgggat	ggtgctaacc	cattagaaac	cacccccatg	atctaatac	19320
ctcccacaag	tccccacctc	caacactggg	gattaaaatt	gaacatgaga	tttggttg	19380
ttcacaggta	taaaccatat	catctactaa	acataaaaa	cccaggacta	cacagattca	19440
cagccaaatt	ctaccagatg	tagacagaat	agctggtgcc	attaataatg	aagctattcc	19500
aaaaaattga	ggaagaggga	ctcctcccca	actcctctg	tgaggccagc	atcatcctga	19560
taacgaaacc	tggcagagac	aaaacaaaaa	aagaaaactt	caggccatta	tccttgatgc	19620
acatagatgc	aaaactcctc	aacaaaatac	tagcaactga	atccagcagc	acagtgtaaa	19680
gctaataccac	cactatcaag	caggctttat	ccctgggatg	caagattggt	ttaacataga	19740
caaaacatat	gtttgtgtga	ttcattacac	aaacagaact	aaaaatgaaa	accacatgat	19800
aattccaata	catgcagaaa	aggcttttga	taaaattcag	catcccttca	tgttaaaaa	19860
tctcgataaa	ctatgcattg	aagaaacata	cctgaaaata	attagagcca	tgtatgacaa	19920

atccacagac	aacatcatac	tgaatgggca	aaagttggaa	gcatttcctt	tgaaaactag	19980
aacagccaga	cacgatggct	catgcctgta	atctcagcac	tttgggaagc	aaaggcaggc	20040
agaccacttg	agcccaggag	tttgagacca	gcctgggtcaa	catagggaaa	ccctgtcttt	20100
acaaaaaaat	aagaaaaatt	agccaggcgt	gatggcacac	acctgtggtc	ccagctactc	20160
gggaggctga	aatgggagga	tcacctgagc	ctgggagctc	aaggctgcag	tgagctatga	20220
tcacactact	gcactcaagc	ctgggtaaga	gtgaaaccct	gacaaaaaaa	aaaaaaaaaga	20280
aaagataaaa	gaaagaggcc	aggcgtgggtg	gctcaggcct	gtaattctag	cactttggga	20340
ggccgaggga	ggcggatcac	ctgagattgg	gagctcgaga	ccagcctgac	caacatggag	20400
aaaccctgtc	tctactaaaa	atacaaaatt	agcgggctgt	atggtgcatg	cctgtaatcc	20460
cagctgctcg	ggaggctgag	gcaggagaat	cgcttgaatc	caggaggcag	agggtgcagt	20520
gcgctgagat	tgtgccattg	cactacagcc	tgggcaacaa	gagcaaaaaa	aaaataaaaa	20580
taaaaaataa	aaaataaaaa	aaaaataaag	aagaaagaaa	agaaaaactgg	cacaaacaag	20640
aatgctctct	ctcaccactc	ctatttgaca	tagtattgga	agtcttggct	gcagcaatta	20700
ggcaagagaa	agaaaataaa	ggcatccaaa	taggaagaga	gggagtcaaa	ctatccctgt	20760
ttcaaatgac	atgattctat	acctagaaaa	ccccatagtc	tctgccccaa	agcacattaa	20820
tctgattcac	atcttcagca	aaagtttcagc	atacaaaagtc	aacatacaaa	agtcagtttc	20880
attcctatac	cccgatagct	ttcaagctga	tagcaaaatc	aggaacacta	tcccaccaca	20940
attgttataa	aaagaacaaa	atacctagaa	atacagctag	ccagggatgt	ggaagatctc	21000
tacaacagga	attatataac	actgctcaaa	gaaatatgag	atgatgcaa	caaagtggaa	21060
aacattttat	tctcatggat	aagaaaaatc	aatatcatta	atatggccat	agcgcccaaa	21120
gcaattttaca	gatgcattgt	tattcctaac	aaactaccaa	tgccattagt	cacaaaacct	21180
aaaaaaataa	aaaaactgtt	ttaaaatcca	tatgaaacca	aaaaagacct	ttatagccaa	21240
ggcaatctta	agcaaaaaga	acaaagctgg	aggcatcacg	ttacccaact	tcaaactatg	21300
ctacggggct	acagtaacca	aaacagcatg	gtactggcac	aaaaacaggc	acatggacca	21360
atggaacaga	atagagagcc	cagaaaataag	gccacaacca	ctggatattt	gacaaagctg	21420
acatcattct	accataaaga	tacatgcaca	caaagtgtca	ttgcagcact	attcacagta	21480
gcaaagatgg	gaatcaacct	aaatgcccat	caaaggtaga	ttagataaag	gaaatgtgat	21540
acataatac	cacataatac	tatgcagaca	taaaaaggaa	tgagatcatg	tcctttacag	21600
caacataaat	ggagctggag	gtcattatgc	taagcaaaact	aacacaggaa	cagaaaacca	21660
aaataccaca	tgttcttact	tataattggg	agctaaagga	tgagaacaca	tggaatactag	21720
gaggggtaca	acagacactg	gtgcctactt	gagggcggag	ggtgggagga	gggagaggat	21780
cagaaaaaat	acctgttggg	tattatgctt	attgccagtc	gatgaaattt	tctgtacacc	21840
aaacccttct	aacacacagt	tcatctatat	aacaagtctg	cacatgtacc	cttgaacctt	21900
aaataactat	tacaataagt	aaatacatat	ttttaaaaaat	catttagaat	gtcagaaaaat	21960
tccaggattg	tattagtctg	ttcttgcact	gttatgaata	aacacctgtg	actgggtaaa	22020
tttataaaga	aaagaggttt	aattggctca	cagttccact	ggcagtagag	aaagcatgac	22080
agcttctggg	gaggcctcag	gaaactttca	atcatggtgg	aaggcaaaga	gcaagcaggc	22140
atgtcttaca	tggccagagc	aggaggaaga	gagaaggtag	acgggctaca	cacctacaca	22200
accagatctc	gtgtgaactc	tatcacaaga	atagcactag	gaggatggtg	ctaaaccatt	22260
agaaaccacc	cccatgatcc	aatcaccaga	cccacaagga	cgcacctcca	acattgggga	22320
ttatgattga	acatgagatt	tgtttaggga	cacagatcca	aactatatca	aggatagagt	22380
gtagaatatg	acaaaataat	ctaactgtat	tacaaatgtg	tgaaacaacc	tcactgcagg	22440
tggtggtaaa	agaagtgcag	acctaagtaa	cttttggaat	ttagtggagt	ctgtaatact	22500
aaatgaaaaa	ctgtttataa	acgccacact	cttggttttc	acagggatat	gggttaacaa	22560
ttctaatact	tctatacgtg	tgtattggaa	ttgagcagtt	aagtaaatta	tggtaaattg	22620
tggttagtga	ggctggtttc	tctctgctgg	agtgagagtt	tatgcctaata	caaaggagg	22680
gagctaaaat	aatctctgtg	gtaatggatt	acagtgggat	atattaatat	taaatacatat	22740
ttggcttaat	gtagatacac	atggctacat	acacgtacac	atggctacat	atagacacat	22800
atagatatgt	gtacatacat	gattagatata	cacaaacggt	cccttccatt	gacaaatgag	22860
aaggcctaga	agcaacagta	ccccagtagt	aacaagcaca	tctggcatcc	agttcatggt	22920
ttgtaatagc	actctgcaat	aaagggaac	agggtctctt	agaaaaattg	gtgtttctag	22980
gactagggga	ggaaatatac	atgatgagcc	tgtaacattt	tgtagtgcc	gaaaggaaag	23040
aagtgtctaac	aacaaaaaca	agcccacaaa	gatggggctg	tgtcaaatag	atgtactgaa	23100
agagccaata	ccaagaactc	ctgacgccaa	atctggaaca	ctttggggaa	acaaataaag	23160
cagtattgaa	ttgtaacaca	aagtataaaa	taaatagcca	tgagtctaca	ctaataataag	23220
taaataagtg	aataaataaa	taaatggggg	caaagaaaca	atcttccatg	cagaaaaact	23280
ccaaatgatt	tatgtagata	tgccaacctt	aaggagataa	agcataaactc	ctcactgttt	23340
cagttcaggc	cacacatagt	gactttcttc	caaagagtat	agtatgaaaa	agggaataaa	23400
aagagtaact	tgtgatggaa	aagcctgaca	agcacaatt	acctcagcag	agtgatcagg	23460
gtcaacataa	acagtaataa	atcatatcaa	cagtatgttc	tcttgatatg	atacagtgaa	23520
aatcatctag	tcactctttt	tttttttttt	gatggagctc	tgctcttgctc	accaggctg	23580

gagtgcattg	gagtgatatt	ggctcactgc	aacatccacc	tcctgggttc	aagcgattcc	23640
cctgcctcag	cctcccgagt	agctgggatt	acaggcgccc	gccaccatgc	ccagctaatt	23700
tttgtatttt	tagtagagac	agggtttcac	cactttgacc	aggctgggtg	cgaactcctg	23760
accttgggtg	gtccactctc	ctcatccccc	caaagtgcgt	ggattacagg	cgtaagccac	23820
cgcgcttggc	tgaaaatcgc	ccttaacctc	tgtagtcttc	ttccccaaaa	aaacattatc	23880
cctgtctaatt	aatgacaaa	acatctaaca	aatcccaaaa	gatagatatt	taaaaaatac	23940
ctgacccatt	cttctcaaac	tgtcaagatg	accaaagcaa	ggaacaactg	aaaagctgtc	24000
ataaccaaga	ggggcctgag	aagacatgat	gatgaaatgt	tatatgatat	tctggatggg	24060
ttcttgggtt	gcaaaaaggga	atztatgcaa	aaactaagga	aatttgatta	aaacatggac	24120
tttcagttat	ggtaatgtct	tgatattggg	tcattaattg	caataaatac	accttgctaa	24180
tgtaatatat	tcataaagg	gaaactgggt	acagagttaa	tgagaactcg	ctagactata	24240
ttctaatagt	tctgtaaaac	taaaactatt	gtaaaaatca	agtttacttt	aaaaatatta	24300
ctgactgtct	tggttctgtt	ttactacttt	ttttttttct	tttttttgag	tcagggtctc	24360
cctctgtcac	ccaggctgga	gtgcagtggg	gtgatcttgg	ctcactgcaa	cctctgcctc	24420
ccgggttcaa	gcaattctcc	cacctcagcc	tcagaggttt	gaataatact	tctttgtttt	24480
aatcattcag	ctcagattaa	aaacaacgcc	taatttctta	atgtcaacta	ttgccttgcc	24540
ctctgttata	tcctaccttc	tcccattcgt	tatagtcact	ctctagtatg	gtattgagtt	24600
ggggatgtgc	atctgcccac	caaattttta	tattttttgt	agagatgggg	ttttgtcatg	24660
ttgcccaggc	tagtctcaaa	ctcctgagct	caagcagtc	gccacacttg	gcctcccaaa	24720
gcgctgagat	tacaggtatg	agccacattg	tccagccatt	tccatttact	tttctttccc	24780
attgagccca	attcttaaaa	acatccagtg	gcagcttagc	ttgggtgtct	tggtcagct	24840
ctggagggtt	gaatgatact	tctttgcttt	tctttgcttt	aatcattcag	ctcagattta	24900
aaaatttctt	aatgtcaact	attggcttgc	cccctgttat	attctacctt	cttccattcg	24960
ctatcctaac	tctctagtat	ggtattgagt	tggggatgtg	cacacacagg	caaacacaca	25020
cacatacaca	tccccataca	tatacagtgg	tgtgctgaaa	ctgtgtcaga	ccagctagag	25080
agaccaatt	gttaaatatt	caagaatgag	gcaagccagt	tattaagcac	atccattatt	25140
aaaaattaaa	ggataaagt	acaattaagt	aaatcatatt	aaaaagaaag	gttataaata	25200
atatcattac	ttctatttat	tttactatta	tctatacttt	ttgagggtta	gtctactgta	25260
tttctataat	ggaattacta	catactgggt	tgctacttct	tgattccgta	tttgggtgat	25320
tcaccctgat	atgacatcat	atcattgata	tgatattgaa	tagaccatgg	gtggagtatt	25380
tgtaccatgg	atattgaaaa	aacttaaatc	agagcttgag	ttattgtttt	gttgattttc	25440
tactttaaaa	agatggatgt	gcttaataac	cggccttaaa	aagatggggg	aaaatgttat	25500
cacgggtta	actgtagggt	aagctctaaa	atgtttgtag	ctgttacatt	tgaatagcac	25560
aaaatattga	ggaatattct	ttaagtgttt	gaaaacagtt	ttaaactcag	caaagagggt	25620
aactgatatt	gttaacaaga	ttcaacttca	ttcaattcta	ttgttatact	ctcatcttac	25680
tcgtcaatat	aaatgaaaat	gtcaattgat	attcatttga	gagttactct	catttggtta	25740
ttgcaacat	agggttaacta	aagatacaag	agtttggtca	aatcagtgag	aacattgtat	25800
gagaataagt	tcattataca	gaatagagaa	tattatata	tttattatta	tttgtaagtt	25860
ttgtattaca	tatcctttat	gtcagtaaaa	tttataataa	acatgtacat	atttattttt	25920
tgcagtttgt	tattaaacag	ttactagcaa	attgctatgt	acacacattc	cttatcaaaa	25980
atgtgggaat	tatttgcaac	ataaatgaga	acatatgagg	ttatacgtag	taggtacaat	26040
cttaagaga	caaaccacaa	gtatgattga	tacttccact	agacatcttg	tcaagagaat	26100
tatattccca	aataagtatc	accaaaaatt	ttgttgaaac	tagaccttcc	cacaagctat	26160
gggtcctct	aaatacatat	ttttaccaga	gtttcttcat	ctaattaggt	ttttaaattg	26220
tggtagaagt	aagatacaga	taaatgaatt	agatgcagcc	tgccaatat	ggtgaaaccc	26280
cactcttact	aaaaatacaa	aaattagctg	gggtgtgggt	cagacgcctg	taatcccagc	26340
tactcggag	gctgaggcag	aagaattgct	gggagccggg	aggcagaggt	tgcatgagc	26400
tgagattgcg	ccactgcact	ccagcctggg	cgacagagcg	agactccaac	tcttaaaaaa	26460
aaaaaaaaac	aatcaatta	gatgtattaa	ttagggaatct	gctatgaact	gaattgtgtt	26520
cccccaagat	ttacatgttg	aagcgctaac	ctccaatgtg	gcaatattta	cagatcgggc	26580
ctttaaagag	gtaattgagg	ctacaagagg	ttgtaagggt	ggagccctaa	tccagtagaa	26640
ctggagtctt	tacaagagga	agacacacca	aagggtgcag	ggcacagaga	aaaggccatg	26700
taaggacaca	gtgggaagg	gccatctaca	agccaatgag	agaggcctca	ggagaaacca	26760
aatctgtcaa	catcaacatc	ttgatcttgt	acttccagcc	tccagactat	gaaaaaacia	26820
ctattgtttg	agccgccttg	tctgtgggtat	accatgtacc	atgggtgtttg	tagggaagcc	26880
ctagtaaact	aaaacaaaat	cttagattgt	aagtaataga	aatcaactgt	aggtagatta	26940
tagcagaaag	aggacagaaa	tgcaggtaaa	agttacaact	ggaaactgca	gtgctatagg	27000
aagcccaaga	tgttctcttt	ttctgtatct	cctctctgct	atagcctatc	tattttattc	27060
tgaacatctt	tattccacac	atctttattc	cacagctata	ctgtccaata	tgatagtcac	27120
aaggaacatg	cggcttttta	aatttaataa	aattcagttc	ttcagtcaca	ttaaagatat	27180
tgcaaatatt	aaatagctac	atatggctac	tgtgttgagc	actgtagata	tagcacacct	27240

ccatcattgt	agatagttct	tttggacagc	actggattat	aggattacca	gagatcaagg	27300
taaacttccc	ttgaagttga	aggtaaactt	ccattttaacc	attaggacac	ctcagctgta	27360
tcactccctt	ttaaggccta	tatttagttt	tgaatttata	attttttatc	atttttctta	27420
gggactgata	tcaccagtga	cctctagggg	aaggattagt	agtgaggaga	aacattatit	27480
tgtattgttt	gaatgtaa	acatccatgt	acaaactgca	taatatitit	taaggtattg	27540
gagttttgta	ttgctcatca	ttgtatccaa	acaccagta	tagtacctta	acaggtaatg	27600
ttagggaagtc	gaagagatgg	acatacggtt	aatgctaaat	cctgtgatgg	tgagaagatg	27660
ctctgggtat	gcctaattct	ttctgcttca	agcccagcta	ggtctgggaa	ttgcttgggg	27720
aaactggaag	cctgaaccag	aggactgtgt	gcattgtgtc	atgctgtcgt	gcgtgtgtgt	27780
gtactggtag	gtaataaata	actactgtgt	atctgacact	atggtagttt	atacttttta	27840
tgtctactct	aaacaacaac	actacaaagt	agtcaccctt	gtaccctttt	tataaatgag	27900
gaaactaaga	ctaactcatt	tatcctgggtg	tgttcttttt	tcttttcttg	ttagtgaat	27960
ttgacagtta	cacaattgtt	actaaataga	atgtagccag	ttctagagaa	acttcattct	28020
accagtgttt	attttattat	tttatttttt	attagataat	tcatactctt	ggatcaaaaa	28080
ctggtagcaa	attgtattta	gcacgaagta	aatcttctct	cacacactac	cctcaggcaa	28140
ccgtcaacaa	cttcttgtgt	gtctttacag	aaatatitit	tgtgtataca	acacatatat	28200
gaatatitit	aaaattttaat	ttggagtatt	ttacatactc	caaactcttt	ttttcacttg	28260
acaatatatc	ttgaaaatca	ttatatatta	ctagatctgc	tgaatttctt	ttaatagcta	28320
tatgttattt	gtttagaggaa	agcctcaaaa	tttattcaaa	tccctactca	tttatgattg	28380
ttgtttcata	tcttttggtt	ttacaaagct	tcagtgaacca	ttctataaaa	taggccattt	28440
tgacatgtg	gaaatatatc	tgacagaata	atttctagag	gtagagtgtc	tgagtcaaat	28500
ttaaaggcaa	agagtcttta	aactcttcat	agatattgct	aatttttatc	catagatgtt	28560
atacaaatat	acttcccctc	agcaatgttt	atccataccc	tttccaatac	taagggaacc	28620
ctttcttgta	caagagaaaa	agaaagaaag	aaaaatcaat	ctaatttgct	tataggcacc	28680
taaagatttt	tttttttttg	gccttgccca	gaagtattgc	atttcagtga	accctaccct	28740
caccatcccc	atttctctgga	ataatattaa	tactactttc	caactgaaac	tctgagatca	28800
cattctttct	tttctatttt	atataatact	ggcctacttt	atatatgact	gggatggagg	28860
ttgttcattc	tgctcatctg	tgtattatgc	aaatttgctt	ccaagcagat	tggcctcttg	28920
caacctgggt	gagaggtgac	agcatgctgg	cagtcctcag	agcctctcgt	tgacacctcc	28980
ctgcctgggc	tcccactttg	gcggcatttg	aggagccctt	cagcccccac	ctgcactgtg	29040
ggagcccctt	tctgggctgg	ccaaggctgg	agccactccc	ctcagcttgc	agggaggtgt	29100
ggagggagag	gcgcgagcgg	gaaccggggc	tgcgtgcggc	gcttgcgggc	cagctggagt	29160
tccgggtggg	cgtgggcttg	gcggccccgc	actcagagca	gccagccagc	cccgtctggc	29220
ccgagggaatg	agggaacttag	caccggggcc	agtggctgcg	gagagtgtac	tggatcccc	29280
agcagtgcgg	gcccaccggc	gctgtgctcg	atttctcgcc	gggccttagc	tgccctcccg	29340
cggggcaggg	cttgggacct	gcagcccgcc	atgcctgagc	ctcccaccca	ctccatgggc	29400
tctgtgctg	cccagacctc	cccagcagc	accacccctt	gctccacggc	gcccagtccc	29460
aacgaccacc	caagggtgta	cgaatgcgag	cgacggcg	aggactggca	ggcagctcca	29520
cctgcagccc	tggtgcagga	tccactaggt	gaagccagct	gggctcctga	gtctggtggg	29580
gacgtggaga	acctttgtat	ctagttcagg	gattgtaaac	gcaccaatca	gcgcctgac	29640
aaaacaggcc	actgggctct	accaatcagc	aggatgtggg	tggggccaga	taagagaata	29700
aaagcaggct	gccggaggca	gcattggcaa	cccactcggg	tccccttctg	caccgtggaa	29760
gttttgttct	ttcactcttt	gcaataaatc	ttgctactgc	tcactctttg	ggtccacgcc	29820
gcttttatga	gctgtaacac	tcagtgcgaa	gatctgcagc	ttcactcctg	agcccagcga	29880
gaccacgagc	ccatggagag	gaacaaacaa	ctccagacgc	gctgcgttaa	gagctgtaac	29940
attcaacgct	aaggtctgca	gcttactctc	tgagccagcg	agaccaggaa	cccaccagaa	30000
agaagaagct	ccgaacacat	ctgaacatca	gaaggagag	actccagacg	cgtcatctta	30060
agagctgtaa	cactcacggc	gaaggctctg	agcttactc	ctgagccaac	gagaccacga	30120
accaccagga	aggaagaaac	tccgaacaca	tctgaacatc	agaagggaca	gactccagac	30180
gcaccacctt	aagagctgta	acactcaccg	cgagggtccg	cggttctatt	cttgaagtca	30240
gtgagaccaa	gaaccaccca	attccggaca	cactgggtca	ctttctgact	gcactttctt	30300
gaagtattcg	tctttgggtc	tgtggtagta	cccagtggac	aacctcactt	gcctgtaaac	30360
tacttctctg	aggtattttc	cctaacaacg	tgaataacat	tccatttctc	tgcttgctct	30420
tttcatgact	ctcatttcaa	tggtccttag	aaaacacttt	ttttgattat	tattcagctt	30480
tgtaataactt	atttcttcag	ttccccatcc	ataaagtctt	tgatttagag	gtcaaatctg	30540
ttttgcttta	ctatttcctat	ctaaagcttg	aaagtatgg	aattaataaa	aacattccac	30600
atgttaaatt	agctttaatg	ttagctttta	aagaagatag	cagttaatca	gtcttgatga	30660
cgtagagggt	gacaggtaga	aggatcctaa	aattttaattc	ctgggctgct	aacttcaaat	30720
ctcatctgta	tcaacagttt	tctcacttaa	gtcattaaca	tcgaaaatta	ttttattaaa	30780
tgatttataa	ttgggagagt	actatttctc	tttctcccca	cctccagtta	tgagaagata	30840
cttattccca	gctttttctg	ggtagagcta	ttcaattttt	tttttttttt	tttttttttt	30900

tttttttttt	tttttgagat	ggagtttcac	tcttgttacc	taggctggag	tgcaatgctg	30960
caaaatctgc	tcaactgcaac	ctccacctcc	caggttcaag	cgagctcct	gcctcagctt	31020
ctggggtagc	tgagattaca	ggtaagtgcc	cccacgcca	gctaattttt	gtatttttag	31080
aagagatggg	gtttcaccat	attagtcagg	ctgatctcga	actcctgacc	tcatgtgatc	31140
caccgccttc	tgccctccaa	agtgcctggg	ttgcaggcgt	gaaccaccgc	atccagcca	31200
atttgttttt	taaatctttt	tggcactcta	ccaaatcacg	aaggctcttc	ttagttaggg	31260
gaacagaagg	gatttagtct	taataaattt	ttctccatgc	catggggaag	actctctcag	31320
aaggtagcat	ctagaacaga	acattgaaaa	gtttataaac	aacaccagta	cttcatactt	31380
ttgttttatc	ttccctttga	gatagacgtt	tagtccttta	ctgttattac	ctagcacaat	31440
atctggcaca	cagtaggtgg	ccactgatta	tttcttgaat	gaagtaagga	atgagaatat	31500
tacctacaga	gttagagctc	tgcgcatcac	ttccttccag	atttcataca	tcttttttta	31560
gtaatgaatg	caaacaggct	ctggggcagc	tacattatcc	ttctgaatca	agacagggat	31620
ttcgcaatgc	ttattttcaa	tttcttcaga	aatgccttaa	agatattaat	ggaggtaaca	31680
acttaatctc	aaatagtaat	ccatagacag	aatatgtaac	agcaatgttc	tctgatctgt	31740
tctttggctt	ctattcccta	gagaaatagt	tctctaagac	caaacagtct	atagatagaa	31800
ttgtagcaac	agtcaattat	gatgttagct	atttgagaga	cggttgagaa	ttcagaaaaa	31860
actactgaaa	tgttgtaaga	caactcactc	aaagaacagt	tcaaatagtg	gaaaagggaa	31920
atgatgatgt	atccatttat	tttgttctat	tttttccaat	ttcataggat	agcaaagtct	31980
gcccatttat	ttattttttt	atttttcata	agttattggg	gtacagggtg	tgtttggtta	32040
catgagtaag	ttcttttagtg	gtgacttgtg	agatatgggt	tcacccttca	cctgagtagg	32100
atacactgaa	ccatatttgt	agtcctttat	ccctcgcccc	ctccatctct	tccccgtaag	32160
tctccaaagt	ccattgtatc	attcttatgc	ctttgcattc	tcatagctta	gctcccacat	32220
atcagtgaga	acatacaatg	cttggttttc	cattcctgag	gtagtccact	tagaatagta	32280
gtctccattc	tcatccaggc	cactgcaaat	gctgttaatt	cattcctttt	catggctgtg	32340
tagtattcca	ttatatatat	atatatatac	cacagtttct	ttatacactc	attgattgat	32400
gggcttttgg	gttagttgca	cgattttgct	attgtgaatt	gtgctgctat	aaacatgcgt	32460
atgcaagtat	cttttccaaa	taatgattcc	ttttcctttg	ggtagaaaacc	cagtagtggtg	32520
attgctggat	caaatggtag	ttctactttt	agttctttta	ggaatctcca	cactgttttc	32580
catagtagct	gtacttgitt	acattcccac	cagtgggtga	aagggtttcc	ctgctcacca	32640
caccatgcc	aacatctact	gttttttgat	tttttgatta	tggccattct	tgcaggagta	32700
tagcattgtg	gttttgattt	gcatttctct	gatcattagt	gatgttgagc	attttttcat	32760
gtttgttgg	cagttgtata	tcttcttttg	agaattgtct	tttcatgtcc	ttagcccact	32820
ttttgatgaa	attgtttgtt	tttttttctt	acagatttgt	ttgagttcat	tgtagattct	32880
ggatatcagt	cctttgtcag	acgcatagat	tgtgaagggt	ttctcccact	ctgtgggttg	32940
tctatttact	ctgctgactg	ttccttttgc	tgtggaaaaa	ctcttttagt	taactgggtc	33000
ccagctacgt	acctttgatt	ttattgcatt	tgcatttttg	ttcttggtca	tgaatccctt	33060
gcctagtcaa	tgtctagaag	ggtttttcca	atgttatcgt	ctagaatttt	tatagtttca	33120
ggtcttaggt	ttaagtcctt	aatccatctt	gagttgattt	ttgtataagg	tgagagatga	33180
ggatccaggt	tcattctcct	attatgtggc	tagccaatta	tcccagcaac	atttgtttaa	33240
aagggtgtcc	tttccccgtt	ttatattttt	gttcgctgtg	tcaaagatca	gttggtgtga	33300
agtatttggg	tttatttctg	agttctctgt	tctgttccat	cagtctatgt	gcctattttt	33360
atactagtac	atgctgtttt	ggtgactgtg	cctttatagt	atagtttgaa	agcaggtagc	33420
atgatgcctc	cacatttggt	ctttttgctt	agtcttactt	tggctgtgca	ggctcttttt	33480
tggtttcata	tgaattttag	aattgttttt	tctaattctg	tgaagaatga	tgggtgtatt	33540
ttgatgggga	ttgcattgaa	tttgtagatt	tttttggcgg	tatggtcatt	ttcacaatat	33600
tgattctgct	catccatgag	catgggatat	gtttccattt	gtatgttgtc	tattatttgt	33660
ttcagcagtg	ttttgtagtt	tttcttgtag	aggtcctttt	actccctggg	aaggcatatt	33720
cctaagttat	tgatttgatt	tgattttttt	tttttttttt	ttgccgctac	tgtaaaaggg	33780
gttaagttct	tgatttgatt	ttctgcttgg	tcgctgtttg	tgtatagaag	agctactgat	33840
ttgtatacac	taatcttgta	tccagaaact	ttgctgaatt	cttttatcaa	ttctagtagc	33900
tttctggagg	agtccttagg	gttttcaagg	taaacgatca	tatcatcagc	aaacagtgc	33960
agtttgactt	cctttttact	gatttggata	ccctttttat	ttttctctct	catctgattg	34020
ctctggctag	aacttccagt	actatgttga	agaggagtgg	tgagagtggg	catccttggt	34080
ccagttttca	gaggaaatgc	tttcaacttt	tcccattcag	tattatgttg	gctgtgggtt	34140
ttcatagatg	gcttttatta	cattaaggta	tgtcccttgt	atgccaat	tgctgagagt	34200
tttaatcata	acaggatgct	gaattttgtc	aaatgctttt	tctgcatcta	ttgagatgat	34260
catgtgatgt	tttgttttta	attctgtttt	cgtggtgtat	cacatatgtt	aaatcatccc	34320
tacattcctg	gtatgaaacc	cacttgatca	tgtcatgggt	gattattttt	tgatatgttg	34380
ttggattctg	ttagctagta	ttttgttaag	gatttttagca	tcaatgcca	acaaggatat	34440
caatctgtag	tttttaaatg	tgcttttctg	gaccggcacg	gtggctaagg	cctgtaatcc	34500
caacactttg	ggaggctcag	gagggcggac	cacttgaggt	caggagtctg	agatcagcct	34560

ggccaaaatg	gtgaaaatcc	gtctctacta	aaaaggtggt	gtggcggggc	cctgtaatct	34620
cagctactga	ggaggctgag	gcaggagaat	cgcttgacc	cgggaggcgg	aggttgagct	34680
gagccgagat	cgcaccactg	caactccagcc	tgggcgacag	agaaagactc	cgctctcaaaa	34740
aaaaaaaaaa	aaaaaaaaaa	gttggtttct	gctatttcct	gaactttatt	acgtaaatga	34800
gacacgtgag	atctggaagg	aggtggaggt	gaagaccctc	ccacctggcc	tgcattccaga	34860
gtacttgggg	tgtggcactg	gcgtgggccc	caggaaggat	cccagccagt	tttgggtgctg	34920
gaggccccgc	caaaggaagg	gctgctctcc	cgctccgcgg	gctccgaggt	cgccgcaccc	34980
gggcgcgcct	gggcctcgct	acccgcgctc	gtgacgcgtg	cttacaaagg	aaacttttac	35040
aggtttcggg	gggcagggcc	ttttattgcc	cttctgctcc	acagcccccg	tgcttaatcg	35100
gttgggtggg	aggtttcttt	cgctccgtgt	tttggaaggt	ccccgcctcc	aaaccgcagt	35160
cccgagctca	gttctgcagc	ctcagggcct	cgaacagcca	tgcttagaat	ccgtccttct	35220
ttcctgctcc	atctaccctt	cccctctggc	ttcttttttt	tacttgga	aagcccaccc	35280
gagctctctc	gcctgcttcg	gaggttactg	cggcctcctc	cacgggtagt	tctgggaccc	35340
gggtctagtc	cgcggttccg	gagcaggtcc	ctccctggag	tcgtcaggcc	cagtatgctg	35400
gtgctcagtg	tgtcgggaa	acacgcgtgg	gctttaacag	cagatctcca	taaaagggtc	35460
ccggagatag	cctctgcctg	gcccagggcc	cagtgcctca	aagcggacgc	ctttgcgctc	35520
ccggagggtg	tcacaccaca	gcggagcctg	ctggcgagtg	gagcgtagga	ctgcgaacca	35580
gcaatctccc	gagaagcggc	gagggggagg	ggaatgtctg	tgaatcggtt	atccctccca	35640
ccccagcag	aagtcgggga	aatgggggtg	gaagggggaa	aaagggagag	aacaggagtg	35700
gggttgagga	agggttaagg	ggaaggtgag	cttctctacg	ctgcggggga	aggtggagaa	35760
aattttcagg	gggacagctg	agtggtagag	ctagcgagct	tcagagaaat	gttgacagac	35820
agatgccag	aaagtgagga	tgcggggcat	gggactgcg	taccaggcac	aggagatata	35880
tggaggcagg	aaattggcac	atcataagca	tttgaccatc	ctgccctaaa	acaaaacaaa	35940
ttgaacaaca	acaacaacaa	aagataatag	caaaagtggc	acagtagtga	gctcgcaggg	36000
cccattccta	tatagaaaca	cagaaaaata	agcaaaagct	gccagaattg	acttcgtggg	36060
aactctggga	aacagtaaga	aagttttaca	gcaaccaagt	gagtgtctgaa	ccaaggcaaa	36120
ggtaaactgaa	acgcaatgat	agagaagagg	ggcaggggaa	tggtgggtag	acaaaggcgg	36180
gtccctggta	agggccctcc	cctggggcctg	tgcccactgg	acctaggtga	ggacaggcac	36240
tccttctctc	acgccccaaat	gttgcatatc	ccaagaccac	cctgtcccgc	cacgccccca	36300
tcctttgcct	atgaaaaccc	tgagacccta	gcaggcgagc	acacaagcgg	ctctatgtcc	36360
agaggaactc	atcgagggaa	ctggacgtgg	agcggggcac	cccagcggaa	gggagcacgc	36420
cagtgggaaga	gcacactgac	agaccatagg	agtcagctctg	ttatattatc	atagtataat	36480
attataaaat	tattataata	caataaaaaat	ataaaaaatat	aaataatgta	ataaatatgg	36540
ataaaaaata	taattacata	tttatattta	tatgagaaca	ctatgaataa	ttttaagcca	36600
aaaaacaact	cgatgttcat	caactggatga	gtagacgagc	aatttccagt	atattcatac	36660
aatggaatat	gattcagcca	taaaatgaaa	tgaggtactg	atacatgctg	cagcaggaat	36720
gaacccccaa	aacactacac	ttggtgaaag	aagccagaca	cggaagggtca	catattgtat	36780
gatcccat	ataagaaata	ttcagaatag	gtaaatccat	agagacaaaa	ggagttttgt	36840
agttgccagg	agttggaggc	aagaagagtt	taacagggtat	gcttaatggg	gcctcctatg	36900
cagttgacga	aaatgttttg	ggctagatag	gagtgatggt	tgcataacat	tgtactaaat	36960
gccactgaat	tctactcttt	aaaattttta	gttttatggt	atgtggcgtg	taccctaaaa	37020
aaaaaaatag	aggtgcagtg	ctccagcacg	ggatgaggca	gcgtggacag	gagcatctcc	37080
caacctcagt	gaagtctgag	ccgcgtgcct	gcaacaatcc	caactgtggca	gagaaccgca	37140
gagttccttc	cggtttgga	gcagtcattc	gcaacctcac	agccctctgg	aaccccagcc	37200
tgggggtctc	agaacgccga	ggcggggact	gggagccgag	tcggattccg	agactatggg	37260
ccagggttgg	tgaggttcag	ttacctggct	gagggcctgt	gagcaaaata	tcccaaacct	37320
cgcgtgatct	ggaaggggaa	gccggataaa	tacggatctc	cagatgtgcc	agtctcgagt	37380
ctatcgatat	gaggtcccc	tagagtttct	attcatcatt	ttaaccgcat	ttcatcgatc	37440
ttgagacacg	gcttttgata	ttttatcacc	tcaagataaa	tagtggttaga	tgtctaatag	37500
cagcgttttt	ctaagagata	catgaaacaa	cagtgctcaga	aacgatgctg	tcttccatgc	37560
gatgaaattg	ttgtaatagg	tgctcaataa	atggtgacaa	taaatgagtg	aatgaatgaa	37620
aattattttta	tttttatttg	agctttgggt	ctgccatttg	ctagcagtg	gactcaagag	37680
aagccagtaa	ccccctgag	cttccctagt	tcacaaaatg	cttgtcatga	agtcgacagc	37740
ttccggaggc	tgcgaggctc	gcaagaaatg	cccacatgaa	tgtgcgctta	gggcgtgagt	37800
gctcactcca	gaaaactcca	acacagtgaa	aaggcagaag	cgggtgtttt	cttttttaca	37860
tttttataag	aatatataaa	aaatgatata	aatggacatt	tacggtagtg	ggggaaggca	37920
tatatctacg	ttaaaaggca	ggacattttt	aaaagctcta	ttttctaaat	gaaaactacg	37980
aaagcggggg	gggttggtgg	gggggcagtt	gtggccctgt	aggaccttcg	gtgactgatg	38040
atctaagttt	cccagggttt	ctcagagcct	ctctggttct	ttcaatcggg	gatgtctgca	38100
gagggcagaa	agaaaacagg	cgttagaaac	ctgaggtcaa	agatgtgtgg	cacatcccgc	38160
cctcctctct	tgccgtccct	accggcattg	aaatacttat	ggataaagtt	ctcgcgaatg	38220

cttcacgtgc	atgtaccgcg	cgccaccgct	ctccacacac	tccctggtcc	agcagctagt	38280
ccactgcccg	cctggctgct	ccaggcgcg	cgaccgctca	agcgtccag	gtccacccgg	38340
cggagggcag	agaaagcgcg	accgcgcg	ccgcagggtt	gcaagaagaa	aacgagtgtt	38400
atataatgag	tctcagtgg	tgctcacaat	gccaggcg	aaggcgtgaa	gatgtggcct	38460
ttcccttccc	gcatccccag	gcatctttt	cacctggtgc	ggagtgagcc	agccagcttg	38520
cgataaccaa	agggcgcc	aggctctggc	gctcctcg	ggaatcccgt	agcttcccta	38580
cgcatgcctg	cttctacaaa	cccacaaatg	gtttccgatc	atttctgaaa	caaaatggat	38640
gctcatttat	tcatgtgctc	tggcttctgc	cttcctctct	aatctcgttg	cgtatgggct	38700
ccagctcgcc	gttcggttct	cccaggcag	catttacact	tgagagtctc	aagattat	38760
tattcctgag	ggagcatttg	cacttgaaag	tctcttttta	cgtttattcc	tgaggcagca	38820
tttgcacttg	agtttctttc	tcccgtagct	tgcattagat	tctccgacca	ctcttagct	38880
tctcctccta	ttcacacttc	atatttaccc	attgcattgg	ttttataaac	tcgctctctg	38940
aaaatagatt	gttatcttcc	ttaacgtctg	tttcccagg	cgggcaagat	agcttgggac	39000
tgtaatccca	gtactttagg	aggaggagg	gggatgatcg	cttgagccca	gataacatgg	39060
tgagaccttc	gtctctatta	aacaaacaaa	caaacccagg	cgctgtggcg	tgacctgtg	39120
gtcccagcta	gtcgggagg	tcagggtgga	gaacccttg	agccaggagg	tttgaggctg	39180
cagtgaagctg	tgatcgcgcc	actgcactcc	agggtgggca	acagatcgac	tctgtctcca	39240
aatgtaaaacc	ccatgagggc	aagactcttg	tttggtctca	ttcaccttg	cgtgcccacc	39300
acctagaaca	gggctgatca	cgcatgagaa	tctaaccata	taattaattg	tgcttgaaga	39360
gggggtgttg	gggagtaaga	gaagggaagg	aggagggaag	aaatgaaaga	cttgtgtgtt	39420
tggattaaat	atattaggtt	tgggttaagag	tcgttcagtt	tattcatttg	cttgtggccc	39480
aattcagtag	ttttactccc	tctcccactt	ggctcctcag	gctttttgct	cagccctgga	39540
accgcgctgt	aattggcagc	tccttctaaa	tcgggacccg	gatgctagct	gtaactggag	39600
ccgaagtctc	cttcttcacc	tcccgggacc	tggatgctag	ctgtaactgg	agggaattgg	39660
cgggggggag	gggaggagg	gccgagtaaa	gaagaacttc	gcgtctttaa	cttcgaaggt	39720
gattttgcgt	tctgtattta	cagcatctcc	aagcagagg	cttagagcta	actcttcacc	39780
ctgtcctccc	cagctcccct	atggcccaag	gagcccaatg	ccccggttct	gggccaaaat	39840
aagatggatt	tcataatctt	caaggtcatg	ttttacctta	aatattcgtg	ttaattccc	39900
tgtactgttt	catatatcta	ttttgtttca	aaaaaaaaatg	ttctcccc	cagaaacaat	39960
tgagtaatgt	tggcagtttc	agcagacagc	tgtgggagta	gggaactggg	gccatggaat	40020
ggggcgagg	ggagtagct	ttgagatcac	aaaaaggaaa	ggcaagggca	aggaggacca	40080
taattctacc	ttcatcgctc	agcgaatctt	tgacaaagt	taagagggaa	aggagccaac	40140
tccgtgacac	agactgcccag	ggctcagcga	gtcttggctc	tgatgtcccc	agaaccccc	40200
ggggcagctc	tggaaaactc	taccgcataa	agcggagggt	cagattagct	gaggagggtc	40260
agattagttg	agttgtgcag	aagagccgag	atcgagagat	ctccagatga	tgccacgcac	40320
aattgggttt	ggaaatcctg	agggtggtcc	agccagcttg	gtatgcaaat	gaggaaacag	40380
acctggtaag	tggatgcaac	tggccctagt	ttggagggaag	agggggcact	agacctctag	40440
cctcttgagt	cttcattgct	ccgcagtcta	ggccttgaa	tagcagagg	taggtgtttg	40500
ggtggtggtg	tgctttggga	agtataatgt	acaaaatggg	ctttcacgtg	cgcaagtcca	40560
tttcgggatt	atttcccatt	tgccgcccgt	gcggggcagg	gcgataggga	gactcaggcc	40620
gtcccaccga	ttggcgcgctg	agctgaggca	agaccggaga	ctggtctccc	gggctgaact	40680
ttctgtgctg	gaaaatgaat	gctctgagct	ttggaagctc	tcagggtaca	aattctcaga	40740
tcacagctcc	tcacctgagg	gaccttccgc	ggcatctatg	cgggcatggt	tactgcctct	40800
ggtgcccccc	gcagccgcgc	gcaggtaccg	tgcgacatcg	cgatggccca	gctcctcagc	40860
caggtccacg	ggcagacggc	cccaggcatc	gcgcacgtcc	agccgcgccc	cggcccggtg	40920
cagcaccacc	aggctgtcca	ggaagccctc	ccgggtgagc	tcgtgcacgg	gtcgggtgag	40980
agtgcgggg	tcggcgagct	tgggctccgc	gccgtgagag	agcagcagct	ccggcactcg	41040
ggcgctgccc	atcatcatga	cctgccagag	agaacagaat	ggtcagagcc	aggggtgggg	41100
ccggcatgac	ggaaagggaag	cttgtgtaga	gccccctcac	cgccaagcag	acccccacac	41160
aagccccagg	tgtctaatta	cccctacatt	tgcttccagt	ttccaatttc	cttcttgagt	41220
tctctatcca	ttcttcagta	cacaatgaat	tccattatat	cctccgaact	tctgaggagc	41280
tgtcgtcaca	ggcagagagc	actgtgaggc	acgggcaaaa	tagcaaagg	gcagggacag	41340
actgactttt	actccaggct	aacttctctg	atttcccctg	agatacaact	actgaaattt	41400
cttctgaaa	ttatgttagg	cctggagatt	tttttttttt	tttttgttca	ctgctgtata	41460
tccaagcgca	gaatgtggta	attgttaaaa	agagaaaact	tgtttgtttg	ttaaaacaaa	41520
ttctcacaaa	acttttaagt	tacacttagc	ttctgggaat	gttgaacttc	aatttctttt	41580
tcattatatt	agtttttaaa	ttatatattg	ggatagtaca	gttgtatata	tttatgtgg	41640
acaatatgaa	gttatgatct	ttgaacacaa	tggggaatta	ttaagtcaag	ctaagtaacc	41700
tatccatcat	ctcaaatatt	tgacattttt	gtcaaatgag	agcatttggg	atttactatt	41760
tagctatatt	catcatgcta	tgaaacacat	ctcaaaaaaa	acaatcaaac	ttattcctcc	41820
catcttaact	gaggctttat	atcttgatta	ccatctcccc	attcctccca	ccccccagct	41880

ctagtaacca	ccattctact	ctttactgct	aagaatgtaa	ttgtttttata	tttcacagat	41940
aagtgagaac	atgtgatatt	tgtctttctg	tgtttggctt	atttcattta	gcataatgct	42000
ctccaattcc	aaaacttcaa	tttcttcaag	tataaaataa	gaaggctagt	ttaattaacc	42060
ctaaaattcc	ttcctgtggt	aggctgaata	atgccccccc	acccccaatg	tctatgtcct	42120
aatcctcaaa	aacttttaat	acattaactt	atgtggcaaa	agaggctttg	cagatgtgat	42180
ttaattaatg	gtcttgaggg	agattatcca	gaattttcag	ggtgggcccc	acataacccc	42240
aagtgttttt	attagagggg	cacagtcaga	gagaagatac	aagaatggaa	gcacaggcca	42300
cagagaaaat	acagagacca	tgagccaagg	aatttgatgg	tcactagaag	ctggaaaaga	42360
caaggaaaca	gattgcccc	tagagtttcc	aaaaggaatg	aaaccttggt	gacccatttt	42420
tgacttctga	tctctagaac	tgtaaaataa	taattttgtg	tttgttttag	ctaacacatt	42480
tgtgataatt	tgtaacagca	gcagtaggaa	actaaaacac	ttcccagggt	tatgatttga	42540
gagttcatta	aacaagagat	ggtcacctct	ttggttccta	aatcatcttg	gaaacaaagc	42600
catttccaga	gaggaatttt	aaaatactgt	ctgcagtcac	agcaacctta	aaatttgagt	42660
gctgcatggg	ggaagttagc	aattttattt	aggataactg	ttatttggtt	tattagtttg	42720
aggatggtgg	tgttaaagag	gagttactta	tttttaggta	catttcatac	taaacacaaa	42780
ttgcataatt	tgccctaaatc	aaggaattat	actaaattat	attatgggtt	ttaaactcctg	42840
tcctgagaaa	gtgaaactga	ctcagttttc	aaagagacaa	agagaaaagta	taagcaaacc	42900
aaattgcagc	tacaaaaaga	aagacaaaat	gttgtagtat	atttattggt	ttgtgtattc	42960
aatgaagtcc	ttcgtcttgg	tcataaaaact	agccttaaag	gtttttctta	tatttcatag	43020
tatgaaaaat	ctaaaaagta	acccatatgt	aaatatttaa	atcatgatag	aaatccaaag	43080
caaaaagaaa	atgaatcaat	tgaattaaaa	tgtgtaggat	gcttaaacc	atttgataat	43140
atatccattt	gataatatac	taatatgaat	ttagtacttt	aaaatgttat	ataaataaat	43200
gttcctatat	taaacaccaa	tgtagttagg	attctaagcc	aacatcattt	ccccttttct	43260
acatgttctt	ctcccgtctc	cattaaaaat	tgtcaaaaact	atccactttt	ctttttcctt	43320
tttgttttta	aacaaataag	gtctcttcta	agatattgta	ggactacaaa	gccaaactcc	43380
cgggttcaag	ctgttggcaa	aatttttagag	atgctaagtt	acccatgtat	taattacttt	43440
taaatcctcc	cctaactccc	tcacaaaaca	ggagtaggga	gaggagaaac	acctctgttc	43500
aaaaatgagg	aattgaaaac	tcttatcaca	aataaaacta	atcaagtaag	ctaaagatag	43560
taaaagagca	aaaatgttag	cagatattcc	caaaaaggta	actacatatt	acctctggaa	43620
tgatcacatg	aatgtggctc	attatttcct	aagttctctac	agcaaacata	tattttattg	43680
ccctactcag	ttaaaaataa	acacaatatg	tgttgcttct	tgaataattt	ttctctctct	43740
ctttctctct	ttctttcttt	cgacaaagtc	tcactctgtc	acccaggctg	gagtgaagtg	43800
gctccatctc	gctgttcact	acaacctcag	cctcccgggt	tcaagcgatt	ctcctgcctc	43860
aacctcccga	gtagctggga	ttacaggcgc	ctgccaccac	ccccggctac	tttttgattt	43920
tttagtagag	gcgaggtttc	acctgttggc	caggctggtc	tcgaactccc	gacctcaggt	43980
gattcccccc	gccttgatct	cccaaagtga	agggattaca	aggcgtgagg	caccgcgcc	44040
ggccgcttct	gaataatttc	gatcaaaatt	tatattcgat	atttattcca	acatacacca	44100
cagatttcca	ctgataatcc	ctcctagtaa	gaaagataag	ctccatccag	gtatctgtga	44160
attggagggt	aagtagtccc	agcacatctt	acatttcttt	aagactccct	ttttatccca	44220
aacgttcgta	aattttgtat	ctgataaaga	gcataacttc	atctaataca	aatatgttcc	44280
ccccttcaga	tcttctcagc	attcgagaga	tctgtacgcg	cgtggctcct	cattcctctt	44340
ccttggtctc	ccaagcccc	agggcgctcg	caggaggagg	tctgtgatta	caaaccctt	44400
ctgaaaactc	cccaggaagc	ctcccccttt	tccggagaat	cgaagcgcta	cctgattcca	44460
attccccctg	aaacttcgtc	ctccagagtc	gcccgccatc	ccctgctccc	gctgcagacc	44520
ctctaccac	ctggatcggc	ctccgaccgt	aactattcgg	tgcggtgggc	agcgcccccg	44580
cctccagcag	cgccccgacc	tctctacccc	gacccccggc	cgcgcccggt	gccagccagt	44640
cagccgaagg	ctccatgctg	ctccccgccc	ccggctccat	gctgctcccc	gccgcccgt	44700
gcctgctctc	cccctctccg	cagccgcccga	gcgcacgcgg	tccgccccac	cctctggtga	44760
ccagccagcc	cctcctcttt	cttctctccg	tgtgtggcga	agagccccct	ccgacctgt	44820
ccctcaaatc	ctctggaggg	accgcggtat	ctttccaggc	aaggggacgc	cgtgagcgag	44880
tgctcggagg	aggtgctatt	aactccgagc	acttagcgaa	tgtggcacc	ctgaagtcgc	44940
cccaggttgg	gtctcccccg	ggggcaccag	ccggaagcag	ccctcgccag	agccagcggt	45000
ggcaaggaag	gaggactggg	ctcctcccca	cctgcccccc	acaccgccct	ccggcctccc	45060
tgctcccagc	cgcgctcccc	cgccctgccag	caaaggcggt	tttgagtgcg	ttcactctgt	45120
taaaaagaaa	tccgcccccg	ccccgtttcc	ttcctccgcg	atacaacctt	cctaactgcc	45180
aaattgaatc	gggggtgtttg	gtgtcatagg	gaaagtatgg	cttcttcttt	taatcataag	45240
aaaaagcaaa	actattcttt	cctagttgtg	agagccccac	cgagaatcga	aatcacctgt	45300
acgactagaa	agtgtcccc	tacccccctca	acccttgatt	ttcaggagcg	cggggttcac	45360
taagtcagaa	accctagttc	aaaggattcc	ttttggagag	tcggactgct	ctctccttcc	45420
cctccccctc	ccctcctgcg	tgtaaaacgg	ctgtctgggg	caagggtttc	tcagacgtgt	45480
acattgacctg	gtataagagc	agactctgaa	aagatgagggt	ttattttaata	cggacggggg	45540

agaattctgc	ctgtaggcag	ataggaaaat	ggggagggag	tcattggaag	gacggactcc	45600
attctcaaag	tcataattcc	tagaccagaa	aaagtgtctca	gtgttctaga	agcagagttg	45660
cacagtgatc	caaagaccag	cttcaaatac	tgtcctgtct	ccttcacact	tctcacattt	45720
ctctttccta	ctgaaaatac	cttgcaattt	tcgtaattat	aaagggggaa	gggaatatga	45780
gtgccccctg	ctttataggg	gttgttgtga	gtttaaatga	tgtattaata	catataagcc	45840
ttaagaacag	tgccacacat	cctaagctaa	tacctgttag	ctcttgaatt	atccgctttg	45900
aggactggct	tgcaatcttg	ttttgaggca	tagaaagaaa	atgctttgga	gcaggacgcg	45960
gtggctcaca	cctgtaatcc	cagcactttg	ggaagccgag	gcgggcagat	cacctgaggt	46020
caggagttcg	aggccagctt	ggccaaaatg	gtgacacccc	gtctctacta	aaaatacaaa	46080
aattagctgg	ccatggtggc	gcacgtgtgt	aattccagct	actcaggagg	ctgaggcagg	46140
agaatcgctt	gaaccgggga	ggcagaggtt	gcagtaagcc	gagatcgcg	caccaccctc	46200
cagcctgggt	gacagaatga	gactccgact	caaaaaaaaa	aaaaaaaaatg	ctttggatag	46260
aattatcact	attacataaa	aggaaaagtc	ggatgcggtg	gctcacgtct	ataatcccag	46320
cattctggga	ggccgagaca	ggcggatcac	ctgaggccag	gagttcgaga	caagcctgac	46380
caacatggcg	aaaccctgtc	tctactaaaa	aatacaaaat	tagcggggct	tgggtggcga	46440
tgctgttaat	cccagctact	cggaggctga	tgtaggagaa	tcgcttgaac	ccaggagaag	46500
gcggaggttg	cagttagccg	agatcgcgcc	attgcactcc	agcctgggag	acaagagcga	46560
aacttggtct	caagaaaaaa	agaaagaaag	aaagaaagaa	agaccaagaa	gaacttactc	46620
cctgaaaaga	ttatgggcac	cctccaccac	cctcacttac	aaagaaaagt	taaacagcac	46680
taaagagtat	aacaagcgca	aggaggtaaa	agttctaatt	tttctgtga	ctactacttt	46740
ttaagcttat	caaaaacatg	tactacgttt	taaaaaatgg	attgctcaga	ctttgctgat	46800
gccttaagca	catgcttaat	ctgcctactg	gataatccag	ctctgtttaa	aagttatatt	46860
tcaatccctg	gttgacttaa	accttgtaga	cccagtatat	cttgactttt	tagtgtctgc	46920
ttgattttaa	aacatgtagt	ttttaaaatg	aagccaatga	aaacaatttg	ggatgtcaag	46980
tatgttatta	aaatctacaa	tgcattactg	taccatttat	attttcctcg	gggtacctct	47040
caattagctg	tgtagcaatg	atagggaaaa	ttcaaactat	cgataaataa	aattatttta	47100
gtttagttta	agatatttta	tgatggagga	ggaagaaagt	ggttgccagg	atgggagggg	47160
gggaacacat	ttccatcact	aatacaatgg	ttctttcttt	ttgtttgttt	gttttgtgtg	47220
tttttttgag	atggagtttc	gctctgttgc	ccaggctcga	gtgaaatggc	accgcacgat	47280
ctctctcggt	tcactgcaac	ctccgcctcc	cgggttcgag	caattctcct	gcctcagcct	47340
cccagtagtg	tgggtattaca	ggcacatgct	ggcataccca	gctaattttt	gtattattag	47400
tagagacggg	gtttcactat	gttggctagg	cttgtctcga	actcctgacc	tcagggtgatc	47460
caccacacct	agcctcccaa	agtgtctggg	ttacaggcat	gagccatcgt	gcccggccta	47520
cagtggttct	taatgggggt	gggagagtgg	gaagagttag	ctccttcaag	agtctgttga	47580
aataaatacc	ttcttctcaa	aaaagaaagt	aggtaatgat	ttttttttaa	aaagatgtgt	47640
tcacttgcac	atgtattttc	agataaaaact	ttcagtgaat	tcagggtatt	ctctgaaact	47700
ctaccatgga	ttcctacatc	aagaactctt	tcagctcttg	tgaaaaatat	atatagctat	47760
tggtgaagaa	gatgggagat	gcaaccatat	aaaaacaaca	tttgatgca	ttataaacag	47820
gtgtaaaagt	tgactgcttt	ggaaatacca	agaacaagtt	ttagatatgt	atatctcata	47880
tcttgcahta	gagctctgga	aggattatgg	catccttggg	tggggccatt	ttgctctaga	47940
aattgaagtc	cattatccat	tataaatctt	atgtaggggg	gaggggggag	ggatagcatt	48000
aggagatata	cctaattgcta	aatgatgagt	tgatgggtgc	agcacaccaa	catggcacat	48060
gtatacatat	gtaacaaacc	tgacatttgt	gcacatgtac	tctaaaactt	aaagtataaa	48120
taataataaa	attaaaaaaa	tattatgtaa	ataatttaata	atagtgggaa	aactttccta	48180
gtttttctgt	taaagagccc	attatactcc	cagtttactc	atacatatcg	acctgaggtg	48240
caaaatccta	gaagaatgaa	aatataaaagt	cctggtcttc	tgtgctcctt	atgccagtct	48300
cagatttcct	atgtgcaaaa	tgggattata	atatatttca	tgtggccata	aaatatgata	48360
atgtatgtcc	aaaagctttt	aatgtaaaaa	tttactacat	ttactaaatt	tactaaagtt	48420
tgttggttat	tgttattatt	attctcacac	ttacttttcc	tctttcctga	gaatgccatt	48480
cttttttttag	atttgactcg	cctttgcagt	tttgaaaatt	ctacacgtga	aattttaaacc	48540
tgtcttaatt	ctgatcagtc	ttataacaaa	aaaagactac	cacctgttca	ttcattcaac	48600
aagctcagaa	actaagggca	gacatggggg	gggggcagag	gggagttagt	caaacatagt	48660
atctctacag	tcagactgcc	agggttcaaa	cctcaactgt	tccacttatt	ggttctttta	48720
cttttatcaa	agttactcaa	catgtctggg	cctctgtttt	ctcatttgca	tgattaggat	48780
aataactgta	cttgccctcaa	acagttgttt	agggattaaa	tgaagcatgt	aacgctctta	48840
gaagagcaaa	ataaagcaca	gaatgatata	agaaaatgaa	aagggtgacca	aactcattct	48900
catttgtctc	tagtaggcaa	aggcttccgg	atgctgagag	ctgatcccag	tcttgaagaa	48960
tgatgtgaga	gtttaaagat	ggaaaagaag	gagaaagata	ttctaggcag	aggtaagagg	49020
atgtgcaaa	gcatagaagt	ttaggaaaac	tgaaagtgat	tcatttagac	ttattcctga	49080
aaaccagcct	gtgaaggact	cctcagagag	ccaaaagaaa	aactaggata	atgggatggc	49140
aaggaagtgg	ggacactgcg	ttgactactc	tttcatagct	tggttgtgat	agttcaaggc	49200

cctatgccat	gaagtgaggc	agatggaagg	tggaggagac	ctgagcacac	atatacctgg	49260
aagggcaagt	gccaaagtga	gagaagggaa	agttagaaaa	gaataaaaaga	aaagttaagt	49320
acacaggcaa	gataggatat	ttttgaggac	ttgaggtccc	tcaaaaaataa	tgaagaaata	49380
gaactcaaa	tacagcgggtg	gttatagatt	ttgtcacaag	agatacatag	atttgggagg	49440
gagaaaaggt	cagaacgggg	aggaagttga	ggcacttcct	tctatgaatg	aggaggttag	49500
cttgtttgca	gagtgaaaat	aagatggctg	gttaggaagt	ttgagaatcg	taaaggtttg	49560
gaatacctct	tatgagtaga	gaggatgggt	tgagtaagac	tcagacagag	aagccttttg	49620
ttttgttctt	taaaaccaga	ctggagaacc	cagctgaggg	tggagatcat	gacacagtag	49680
ggacacctga	ttacttttctt	taaactaaag	aaagccctgc	agtggtgcta	ctacttcagc	49740
aaccctacaa	atcaaagact	agtcataata	gatgtgaata	ttaattcaac	atattaccat	49800
aaagagacag	aaagatactt	gagaaggtag	tgttccagag	ttgggttctg	gttctgatgc	49860
ggcattgtag	gattggcaat	atgcacgtat	ttcatgggat	aagcaagatg	attttgttag	49920
gaaaataaa	ggagttgagg	caatagctct	acactgagac	caagtgacag	ttctcatgta	49980
tctaataaac	tattttttga	ctgcaaaaac	ttttgagatt	atttctagat	tcattgtcca	50040
taattttcaa	aatgggctct	ctcttgttct	attgtttacg	cttgaggtga	gataatacac	50100
acataatttc	ttaccagttt	caatattaac	attattatta	aagataattg	ttttaaatat	50160
agcttgggtg	taaaaacaaa	atatacatag	aatatctctg	gggagataca	ggaaaagctg	50220
ttacctgtga	ggtaaggaaa	tgaagaactg	ggatgggcat	gtgacttact	tttcacattc	50280
catgatttat	attgtttgaa	ttttgtacta	tgtccatggc	cttttctaag	aattaaataa	50340
acataataaa	actagtagac	aaataagtta	cttttattag	aatcatcatt	cataacttta	50400
gttgaaaaag	agtaactgag	tacctaatat	atgtcaggca	ctcggcttaa	agttgtcaat	50460
attaattaag	aaagaaggtt	tcttagtcaa	gagcatgtat	tggtaaacaac	catcaatata	50520
tttgcttctc	tgccaggcgc	ggtgggtcac	gcctgtaatc	ccagcacttt	gggaggccga	50580
ggcgggcgga	tcacgaggtc	aggagatcta	gaccatccta	ggtaaacacg	tgaaacccca	50640
tctctactaa	agatacaaaa	aattagccag	gcgaggtggc	gggcacctgt	agtcccagct	50700
actccggagg	ctgaggaagg	agaatggcgt	gaaccggggg	ggcggagctt	gcagtgaagg	50760
gagatcgcg	cactgcactc	cagcctgggc	aacagagcga	gactccgtct	caaaaaaaaa	50820
aatgtatat	atatatatac	acgtatatat	atatacgtgt	atatatatat	atacgtgtat	50880
atatatatac	gtgtatatat	atatatacgt	gtatatatat	atacgtgtat	atatatatat	50940
acgtgtatat	atatacgtgt	atatatatat	atacgtgtat	atatatatat	acgtgtatat	51000
atatatatat	gtgtatatat	atatatacgt	gtatatatat	atatacgtgt	atatatatat	51060
ttgcttctct	ggaggaggaa	ggtgggtctg	aactggatg	agctcttgag	tggagcctac	51120
agtaatcatt	tgaggaggga	agactggggg	gatgcattct	gataaatgac	acctcacact	51180
tgtgttacca	ggaaaaaaa	atttcagagt	ctggaaaagc	tcccataatt	aaagagaatt	51240
ccttaggaag	tagcttatga	gagcgagata	tatgccctgt	aatggagctc	ccaggtacag	51300
ctgtgttaag	ccttcataga	tgagttctag	aataggatgt	tgggtgcaat	agataattat	51360
ttgaaggcaa	aggcaatgga	ggaataattc	catgcatccc	tttaatttag	aaaagcaata	51420
atgtaaggaa	attagagtc	ctgtcctagt	tctaccacct	actttgttac	cctgaaaaaa	51480
tgactttttt	ttttttttac	tagcttcaat	gtcttgatct	acaaaacggg	tataatcaca	51540
aacatgtaaa	aacagattgt	ggtttagccc	cgaagtgcc	aagtgtcctc	gaagctgccc	51600
cggataaaaa	ttctgataat	cgagtcctaat	gtgggtggta	agagcatttt	aaacgggaaa	51660
gaaacacttt	cttaggtaaa	taattgcaag	gtatttaatt	acttatgttc	cacaaggaaa	51720
aaagatagct	tcagcatgaa	agggagacct	ctgagaaagt	agagcagacc	tccaaacaga	51780
tttgctaaga	aaaaacaatg	tgtccctggg	agtagatctc	tagaagtttc	aaaacatttg	51840
atgtttcttt	ctccctttta	ctattctcta	tttaattaaa	ttcaatatag	cacaattatt	51900
tagtatttgc	tataaggaag	gtactctttt	agaaactctg	tgccaacttc	cctcattcag	51960
aattactgtg	aaatttatct	tcctactcaa	actggatctt	agtaaggagt	acaaaatgca	52020
aaattctttg	atgtgtttga	gatttaatgc	ataattatag	ttaagtcaca	attttcaacc	52080
ttagttttcca	aaatgttaac	tgggtataga	attagcagta	cctattatca	tcttcccaag	52140
aatattttga	aggaaactta	aaagtatat	acttattata	tagcaggtat	cttttctaaa	52200
ttatgtgcaa	aacaaatgtg	attttaaatc	tatgtgagaa	atttactatt	aaaatatctc	52260
taggggtgtac	tcttgtgaaa	tgagggatct	ttgcagctca	tggagacaat	tattccttaa	52320
ctttttttgta	aatttttttt	atgttgataa	attacttgtg	gcgaattact	tatatctatt	52380
tgtagctatt	tgatcagctg	agaacactaa	aagattagca	cagtatgtat	gtatgtacat	52440
actatatgca	catattttgg	atatatgtat	attatgtaca	gcacagatat	tgagaattga	52500
cctcatcctg	aggaacaaaa	taagtaataa	acataattag	aggagatagg	cagaaagaaa	52560
tagagataat	aaaaaattca	ttaaaagttg	ccaagaaaat	aatggctatc	attttttcaa	52620
ccccagcta	tgtgacaagc	atcaagcagt	tttatatgtg	taattttataa	ttccacagct	52680
gtcccatggg	atagagagta	ttattctttc	ttcataatgc	agacaaaaaa	aaaagctcag	52740
agtgtcttaag	taataaggaa	aagaaaagtt	caaacttaag	gttctcagtt	ctgttttgaga	52800
ggtcctcact	ctccctacta	caatatgttt	tcctaattgat	aattttatcca	gtacattgtg	52860

gacaactcat	caatgcttcc	ttttctttga	ggactctgct	ttagagcaag	ttgcaaaacc	52920
tgggccaaga	ttactgactc	tccattttca	gaaactactg	tgcttctatg	attattcttc	52980
agtagtaata	catagtata	gaaatttga	actcaaagac	acgcaaagtc	ccctgaaagt	53040
cacttaattc	agtccctca	tttttgaatg	atttgcttcc	ctgattaaag	ctcacatatt	53100
taaaaaataat	taaggaatta	gctgcacata	gaaaaatgaaa	aactacccca	cacaaagcaa	53160
taattattaa	cattttgaaa	tacttcttcc	tttttctttg	cttaatcttt	acattgtgaa	53220
tattatgcaa	ttttgaaatg	agctttttct	aacttattac	agcattttcc	aaacttctcc	53280
aaaaacactt	cataaatgct	acttttaaca	gctgtaaacac	atcccactgg	aaaaagtat	53340
aatttactta	atgatgtccc	tgtgtgcaga	tattttaaggt	gtttctaatt	gctactaaaa	53400
atagtattgc	agtttttcaa	agggtagaag	gctcttgaat	atattgtaaa	actgcttttt	53460
aaaaagccac	cattttgatt	tatagataac	aaaatggagg	agtggtagat	attgaggaac	53520
tatgtagcta	tggttactca	gctaataaat	gtttgctgta	gctgttgaag	tcagttcctc	53580
tctccattct	ccattctttc	tatggccaca	gctacttaat	tggacttaat	gtgggtggcg	53640
ggaaatgcc	accatattct	taatcataat	tttggaatg	acacatatgc	aagtgggaca	53700
agcctagtct	ttaaactcag	atagaactga	cctctcattt	accagctctg	tgggcttgaa	53760
taagtattgt	aaactttctg	agcctttatt	tctcaccctc	acaaagtggg	gaaaaataaaa	53820
tttaccat	aaggttactg	tgaggaataa	agaatgtcag	atatataaaa	atccgggtgc	53880
acggtaggct	ctcaataaat	ggtgcttttt	aattttttga	gaatatatat	gacatttact	53940
atgaagtatt	tcatttaggt	catcaaaaata	aatgtccttt	tgagtaattt	ttcattaatt	54000
cctgtacatt	ctagcaggta	tctgtggttt	caacaagcaa	attctcttct	aaaaggtagt	54060
atgctacctc	tgaattctaa	ccctctgaaa	aaacagcttc	tttgtaacaa	agtttcccat	54120
ggtatgacag	aagaatttcc	aaaaaaaaacc	cctcattaaa	tcagtagaag	tgacactgga	54180
gagtgtcact	gtgttcagt	tttctctg	attcattgct	acccacctcc	actgcttgga	54240
gtgcatttca	agtgggaagt	acaatggaga	aactacagtt	aaaactgagg	aattgcaaaa	54300
tttactttct	ctaaactact	tttccctaacc	tccctctttt	tcattcttga	taggacagat	54360
tttccctct	caaatatgct	gtccttttta	attgctaaca	caagcatata	taatatctca	54420
tttctgctta	tgctgctgat	gtacgcagt	gctgttagag	ttctgagata	atgttgaaag	54480
tcacagataa	ataataatgt	attcggtttt	cactactggg	agtggagggt	taatattcat	54540
gtttcactga	taggtttaac	actggtttag	gatactctaa	tttcaggggc	accatctaca	54600
tggaagcttt	tctcatcaaa	tgagaaatgg	ttgtccctct	tttgccctc	taaaaaacta	54660
tcttttaaaa	gtagcttgct	ttcttgggac	tctatagtct	tactgttatg	ttcaattttc	54720
tggttctctt	cctgaactta	ggagagtctt	gaagccaatc	tccctctga	tattattaaa	54780
gattgcaaga	aaattttctt	gtgttagacc	attcttcccc	aaatcacatt	cttcacctga	54840
tatgtgattc	aactccactc	aagggaatca	acttcttgat	gaaatataat	caactttgat	54900
taaataagta	actgcttcct	attcatgttt	tagcactttt	cacatacaga	tttaacattt	54960
ccactcatgt	tttcttttga	gtctctgggt	tgagggtaga	gttttatctt	ttgtgtgtt	55020
acggttaaga	tgataacttc	cataattaat	ttttcaaaaa	ggcaatgata	acagaatata	55080
ctgtatgttt	actctgtact	gatttaaaac	ccccaaagtca	atttagcctt	aagaaagcat	55140
actatttagt	gtattttgtg	ttactctttg	atatcctact	tctaaataac	ttcttcacat	55200
ttgcataaaa	ataactgaag	gtcaccctcc	aaggtaggca	ttttgaatgt	cgtaaggatg	55260
acagtaatgt	ttctgcctat	cattcctttc	atcacacaga	cacacacaca	cataattttt	55320
tatactaaag	aattttttaga	aaattgtttt	ggtcaaaact	gttgattcag	atattcagac	55380
tgtgacaacc	attctgaagg	aattaaaaat	ccagttatct	tcagtgattc	ctttggaaat	55440
tattattctg	ggttattaga	tagatagact	aataactttt	tttccagttt	tctaaagcta	55500
ccttgatttc	ctgtcttaga	aaacaggggt	tcacaaacac	tgcttaatat	ctctttaatg	55560
attatgaata	ctagaatagc	ttagaggtat	accctaaagg	ccaccatata	ctcttctgt	55620
acagatgtga	atttaaaagt	atgcaaattt	acactgattt	tacctaacac	catggaacat	55680
accaggagtc	tgaatacata	aatatatattt	tattatgata	tgtatatattt	taaagtggag	55740
tttagaaaatt	tctagctaca	ctgaaaaaatt	ataatgaagt	aggtattttac	tgtaaaaaaac	55800
taatgtgctt	tcttaagggc	atagtttaatt	taggcactat	aataactgac	aaacgtacac	55860
tgtgtaaaaag	tttacagtga	ctcttcacac	atactatttt	atctacctct	tattacggga	55920
ctaccatagg	gtctcagggt	tacagatgag	aacatgaaag	cactgagagt	ttctcact	55980
tcattctgggt	accatgacag	ctaataagca	aaagaaatag	aatctgctca	cagggtcatgt	56040
gaatgctaaa	gaaagtaatc	tttcaactgc	acgcttcaag	tggttctgt	gctgggtgaat	56100
aggtatccca	cttattgctt	ttaaatttaag	gtaggaataa	gtaattttata	tgtacagtca	56160
tatgagaatt	tttactgggt	tttatttttg	tcaaaaaata	aatttttgaa	agatgttaac	56220
ctcctttcaa	ccaataaata	tttactgtga	cttatacggc	tgatgcttga	gtatagtaga	56280
ggcccaaagg	ggttaagcga	ctttcaaaat	aatagttaac	taaaagagat	ggaactgaaa	56340
ccatatacat	atttatagca	ctccatgggc	aaccaagttc	aactatatat	gaattactag	56400
tcaatgactt	ttggtaggcc	atgcaacct	tctgagcctc	agtctccaga	tctacaaaat	56460
gaaaaaatga	aacattgaaa	acataaggat	attgtgataa	ttaaattaga	taatggaagt	56520

tgaagtgtcc	tattattggt	aagctcctcc	taattgtttt	tgaagaaaac	aataacttta	56580
ccatgtgatt	taggaagaaa	gtttcaataa	gcttttataa	attaaatgtt	aatataata	56640
tattcaactt	caactattca	gcatgtaaat	tgcattgagt	aaaattcaaa	gtgtccgatg	56700
ttggacattt	aacaattaga	tggtcaactg	ggggagtcat	tggtctctag	acagctgctg	56760
tttctttaaa	ttgggtgaga	gagttataca	attgctgagt	cagatgatct	ggcagcctga	56820
aagagaatga	gagcaagaaa	atgggtggac	tcgagaaaag	aaagcaaaac	aagctttttc	56880
ctaatacatc	agcaaagtca	ctgggtgtaat	attagacaaa	ttttagctta	aaagcagaaa	56940
aatgatcatt	tgaaaggcat	gatatttttag	tttttcttat	aattgttact	ttttagctta	57000
catttttcat	ctatatttcc	ccccccatca	ctgtgctttt	acagagacat	aaagacccat	57060
cattttgtcc	ataaatgctt	tattctgtta	tggctacatt	ttcctgcaat	cttgccctga	57120
tcttagataa	gcataagtta	aacctgtgaa	acacttgtgc	tttgattttt	cttttttaca	57180
taatttttagg	ttgtcatggt	tattacgagc	ctggctctgga	tcataaaaatg	aaagaaaccc	57240
cttattacaa	cacacacaca	cacacacaca	cacacacaca	cacacagaga	gagagagaga	57300
gagagagaga	tccattcatc	ctgcacgaac	agaaagaagt	gtatatagtg	ttttaaaaag	57360
acaacgtatc	ttatatagct	tatgtggaaa	ttttctgtct	ggttctgtaa	gctttaaaaac	57420
acaaatatat	cttggttatat	tttttctctt	caaactatgt	tctgactgta	aaaaatgtggt	57480
atctacaaga	cattctttttc	caattcatatc	aaagggtcac	ataataataa	agggtctcct	57540
tcatttggtg	aaataactcc	tccactgatt	actcagactc	tcctccctgg	gatccagtaa	57600
actgactcta	aacttaaaat	cttacctaaa	atcctggacc	tcaattcaaa	gataaagaag	57660
cagaaataag	gtttaaaaag	taaaattggt	catatttgtc	aaattgtgtc	ccaatgggcc	57720
acttgtatta	gtatctcctt	caagtgttta	tttaaaatgc	agatttctgg	gaccacagc	57780
aaatctgaat	caaattttct	gaacgtgaac	cccagaaata	tgtattttta	aaggcagccc	57840
aggtataaat	gctgttggtta	acctttgcc	tacttttaaa	atttctagtt	actcacataa	57900
ttcaattaag	aaagcagagg	cttttttatt	tacgttacct	tgattgtacg	attttattag	57960
tttcaatttg	cttaagagat	tacatgtcct	tggtcatgta	attctgaacc	tctataaaaac	58020
ttttctctct	taaaaaaatc	ctactgcctt	cacaaccatt	taaataattt	atgatatttt	58080
attttgaagg	tgaaagagaa	aactgagaaa	tagttgaatt	aaaaaatcct	ttgtgataac	58140
atgtttatat	tttcatgaac	aaagccaata	agtcataaaa	attaaaaatc	aacatactat	58200
tttttgaaag	gacctctgat	gctttgggaa	tttcaatcct	gtagttgatg	gctttcactt	58260
ttttttccct	tttattactt	ctttttgatt	gtagagtctt	gccc aaatga	aaccatcatt	58320
ccagggtcca	tgaattaaat	gaatgactg	agagacactg	acaagcactg	agaatttctt	58380
caaccaccct	ttttaaaaaa	caaagtctaa	ttggacataa	atatgagaac	aatagacatt	58440
ggggactact	agatggagga	gaaagggaat	gagcgagggc	tgaaatacta	cctactgtgg	58500
gtactgtgct	cactacttga	gtgacagatt	cagtcgtact	cgaaacctca	gcatgggtgca	58560
atataccttt	gtaattaacc	tgacatgtg	ccctctcctc	ctaaataaaa	gttgaaaaaa	58620
aatctacgag	gcactatatt	tttaaaaaata	ccactatgta	caaggcactg	tgctatatct	58680
ggaactacaa	atattagtta	aatagtccaa	gattcagtg	gttcagagac	tctaagtatt	58740
tgccattccc	tttagatgga	aacgttcttt	gggtccacca	gccctatcgt	tctgctcttt	58800
ggaaattctc	cctcactttc	ttcataatgc	cgtccttgac	taactctcct	ctagcaatac	58860
tattggtttt	gtatgtgatt	taaaatcatt	cctgtaattt	cttctgttta	tatggcttcg	58920
tacaagagat	tcacattcaa	caaatagaaa	aaaaacgcta	ttgacatttg	gtagcttcga	58980
caattgtaaa	cacatgtggg	tttgctgaat	acacattaaa	atagcatgaa	ttaggatatg	59040
gtaaatctgt	tgcggtccca	agttggtggg	tttttctagg	aagagtcaga	ccctttaaaa	59100
ggacctttta	tcacttacca	aaacaaatcct	tcattttatta	attcccaagg	ttttctccat	59160
cggttggctt	actgtcatgg	aaattgatct	tggttttaata	gctacttact	tttttttatt	59220
ctaatacaatg	atttcatttg	aaaagaaaat	tttcaaacta	ggggaagct	gcaatataag	59280
aagaaaacaa	tgagagagaca	tcgtcactgg	aaaaatacta	cgggacctc	tctataccat	59340
cctgcacccc	cagatggaga	aaactgagga	agtcgtggcc	tttcaacact	cttgggtctc	59400
catctggctt	ggaagggaac	gaaatggctg	tcaagagtct	cagaagcgca	ctttcccgct	59460
ggttcctccg	ggtaaccctg	actcactttt	catctaccca	tccctccaa	aacaaggcct	59520
agccagttcc	aagctggaga	ggtgacctag	agttgccttc	tgctcatgtcc	tgctcttctg	59580
ctcagatcca	ctaaccacac	tcagactctg	tctgctccca	ccccaccgc	ggccagtga	59640
atcccaatcg	tcttccacgt	ggaacccag	gtccgcagtt	atgataacgg	atcacatcgc	59700
tcttgcgga	agtgcgcgcg	gtggagtgat	aattggacct	agcgtctaaa	ttcttggttg	59760
aggacctcgt	tccagctgcc	agttaagcct	ctgggatccg	cagcgtctct	aggaattgag	59820
agagtgggga	agttaggatc	caggaggagg	atgggtgggg	ctgaggagt	gaggagcagc	59880
gtgcatctca	tctcttgctg	ccgggcgggc	gctctttcgg	gtccaggggc	cttgaccccc	59940
cagcgtggct	ccggaggcgg	cgagacctgc	ctgaaattga	ttggagggga	ctagagtgtg	60000
cttgtggggg	ggggtagtgg	gggaggagag	aagagatccc	aagaaggggc	ccaagtgtcg	60060
tgaccagagg	cctaacacga	ggcaccttgg	aaacaggtat	agctacggat	ttatgggttt	60120
taaaatggaa	cgtcttggtg	aatggacata	gcgtgcattt	cacagtctga	cgtcacagcc	60180

ctcgcaggtt	ttcccagacc	ttaaagccac	gttctcgtgt	atgacactta	aacaactcag	60240
tttccttgtc	tttcctccct	ccctacccat	ctaagggtag	agaagctctt	agttcatcca	60300
ctgtgtagga	ctgttaccgt	gtgtcaaagg	ctttggaaat	gtatatttta	ctgatgatgg	60360
tcatagcact	ttggaaaact	caaaagtga	acgaagaaaa	taaatatcac	caaacttttt	60420
cccaaccctt	ctcatcctgc	ggaaaccatt	ataactaatt	tggtagagaga	gagagagaga	60480
gagagagaga	gagagagaga	gagaaaactgt	ttactgtttg	gaatcttgct	ttaaaaaac	60540
ctgactttat	aatgcaatca	tttaacagtc	tatgaaatat	tcttcagata	cctgatgatc	60600
cagaatgtaa	ctgtaccata	atttaacact	ttattgctag	aattttatgc	agtttttgat	60660
ttcttgctac	tacttatcca	tctgtattaa	tctttgtcag	aacctttctt	tccttaggat	60720
gatgcctgaa	tataaaaatag	ctgaatgaaa	gtggatgggt	tcatttttaa	atacaaaatt	60780
gtttttcttg	atggtgaagt	gtttaagagg	tggattaatc	tcattgggca	acaaaatagag	60840
aagatattag	tagttaggtg	tatgagaatc	agaattcaga	taatttgctt	taaaaattca	60900
tattcaatgt	aaaaatttta	tatttagaaa	atgaaactgt	acccattggt	tatataactt	60960
aaactgccaa	aataaagcac	cacaaaaact	ttttatcacg	ttggtttttg	tatcaggctg	61020
ggctttgcag	cagatggagg	agctagggca	agcttgctca	acctgtgggc	ccgaggggtca	61080
catgcagccc	aggatggttt	tgaatgctgc	ccaacacaaa	ttcatacact	ttcttaaaagt	61140
atcatgagtt	tttttttttt	tttaagctca	tcagctattg	ttagtgttag	tgtatttaat	61200
gtgtgtccca	agacaattct	tcttcttctt	atgtggccca	gggaaggtaa	aagattgaac	61260
acccttggcc	tacagtgttc	tactatgaag	tttcagtttt	agttcggcct	agaatgtttt	61320
agtacagaag	gcaagtgaga	ttttctctgt	ttctccaagg	acttttgaaa	aagtgtaaaa	61380
gcactgggcc	cactgttgaa	ccttgctata	aaaaagtatt	tttgatacca	tttgtatcac	61440
tttagtaata	ggagtttttc	atatgttggg	aaaatgggtt	agcttaactc	tatcatggta	61500
gttgatagtg	atgaactaac	gtggaataat	agatctgtaa	accatcatag	acggtaaatag	61560
gctatgttgt	tgctacctta	ggatcataat	ggactttcta	aaattcaaga	gtactcaaag	61620
aagtaaaatg	aatataagtc	ttgatttctg	aaagggttat	ggttcacttg	gaacacaata	61680
caaactgtga	atcatgtaca	catggggaat	aatggtttat	actaactgca	cagtgcctac	61740
cttgagagga	ctctgtgcta	ttaaagaaaa	aaataacctg	agccttctga	agtagctata	61800
aacaaatgaa	tatttaactt	cataataaaa	atatgactat	tttgtaaatg	caccaaggta	61860
gaagtaacaa	atcaactatg	gcaatttttc	aggtttctgt	ggttaagaaa	ctggtaacgt	61920
ggaattttag	tatatgtatt	tccaatcata	taaaaataaa	aagtcataat	aaacataatt	61980
gcagaaaact	aaaaaaagtt	aaaataacat	ttatttgca	atgatattaa	ataattcata	62040
caagtaattt	ttagcacttg	tgctctctca	ggaattgtat	gaatcctaac	ataattagta	62100
tccatatata	ttcccaaact	aatatagcca	tgggcataaa	atatattaat	gtgaaatata	62160
taattacata	tcattataat	taacaccgct	agattttata	ttatgtatat	cattttacat	62220
atgaaattgg	aaaattgcat	atatttcaag	acattctatc	caagctgtgt	tctatcttga	62280
gaaacttctt	gaagattgct	cttttcacat	acgtcctgaa	aattgattta	tacctaaata	62340
acaaaaaatg	atctatttca	atgaacctat	catttaaaata	tttttgcat	tcatgcatat	62400
acattaacat	actataaaaat	attttctcta	acttaaaaatc	accacaatgt	tatgttttat	62460
aggcctaaac	taaaaaatac	ataattatgg	catttatata	cattgacatg	ttctactttg	62520
ttactacaga	ttttcagagg	caacttaata	atttaaaacaa	aatgatttta	tatagaataa	62580
tattaactag	agtaataaat	atttttatat	agacaataat	attaagaact	atattcatac	62640
agttaccggt	cacagtggct	aaacttttgc	tgatacggat	aaaccactgt	taaaaaaaac	62700
aacaaccagg	gtcttgctca	tgtttcaaaa	tgaattaaaa	tcaaatccag	caacaggccc	62760
tgaaatcctt	tataagctcc	tttgactaaa	ttaaaaaaat	taacttgcat	aatatgaaaa	62820
gtaaaaaata	aaatgtgcat	ttatcctata	gattataaat	ttttgcta	agaaattgag	62880
acactaaatt	aaacactgat	agtttttaaca	ggttttatatt	tccatgtcaa	agagacaatt	62940
aacattgcag	taaaaaaata	attacccttc	cgctggcctt	tgctttttga	agctatatat	63000
tcctggcgaa	gcataccaca	aggacggtca	taaaagtga	gcctcattaa	attactttta	63060
gacttattac	acaagtttta	attagcattg	tacatatatt	aactgtacat	atattctttc	63120
agttttcctg	gttataggaa	attacactgg	ctgtgtcaac	atgtgtcaat	gtgaggacaa	63180
aactaccttg	gattctgttt	ttcaagaagt	aggcctcatt	tttaaaactgt	gctaactgtc	63240
gtctgagatg	actaaaatac	tatcagttgg	gattttctcag	gaacagttct	acagttctgt	63300
cgtttgctaa	acatacgagc	attgtcccga	gcagtttcaa	tcaactcaggc	cgccggacct	63360
ctacctctaa	ctcaciaaaga	aagcccattt	ccctgttggc	tgcaaaaactc	ccccaagaag	63420
caagtgcctg	ctcctcgag	cagtaactga	tcctacgatc	cttggttagca	tttcagggaag	63480
tcgctgcctg	cgtgccccgt	atctcacggg	tcctccactc	tcctggaagg	tgggagaggg	63540
tgaccccgcc	gggaggctgg	ggagaaaaaa	ggccgcctcc	agaaaactta	gatgggttagc	63600
aataattctc	cccaaggaga	aagaaaagtgt	gcttgaaata	cacctttcct	actgtgtgtg	63660
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtc	ttagtcattc	ccaccagga	63720
tattcgggac	tactgactt	ctgaggtggg	tttagaagct	ctgttcgcct	cagtttccca	63780
cgattgaggg	gctgtgtgaa	gggaggtcca	ggttcaatgg	tactgcgaga	accacatgtc	63840

taagtcgttg	taacccgaat	ggggaagcct	ccaccggcgg	ttatctcctc	ctcctcctag	63900
cctgggctag	agacgaatta	tctgtttacg	aaatcacacc	aaacaaaaca	agtgccgaat	63960
gcgccccgga	cttttcgagg	gcctttccta	cctggtcttc	taggaagcgg	ctgctgccct	64020
agacgtggc	tcctcagtag	catcagcacg	agggccacag	cgggggcg	ccctggcgct	64080
gcccactccc	ccgtgagccg	cggtatgtga	accacgaaaa	ccctcactcg	cgggggcg	64140
cacgcgcgcc	gaatccggag	ggtcaccaag	aacctgcgca	ccatgtttctc	gccgcctcca	64200
gggcccagct	cggcagccgc	tgcgccgccc	tttggcacca	gaggtgagca	gcgccactcc	64260
tgccccctta	actgcagact	gggaccacg	caccgcccc	tgcccatctc	cgccccgag	64320
gcgcgcaccc	gccttccttg	agcgcgccc	ccccccacct	tcacccccac	ccccaccca	64380
ccccactcc	cacccggacc	tccaagatct	cggaacggct	ctgagccctg	cgacgcggg	64440
aagggctgcc	ggaggcgccc	gtagggaggc	gcgcgcgcgg	gcggctcagg	gcccgcgttc	64500
ctctccctcc	cgctaccgc	cactttcccg	ccctgtgtgc	gccccaccc	ccaccaccat	64560
cttcccaccc	tcagcgcggg	cgccccgagg	tgacggccca	ggggccggac	gcttgaacg	64620
caactccagg	cagctcgccc	cctagctaca	tccgtcacct	gacacggccc	taccaggaac	64680
agccgcgctc	ccgcggattc	tgggtgctgt	cgcgccccg	ctcccctatt	ccccttattt	64740
tattcctggc	tccccctgtc	gaaagtcttc	cattcttcaa	actagattat	ttaaaaatga	64800
aaaaggaaga	aaggaaagcg	aggtcatctc	attgctctat	ccgccaatca	ggaggctgaa	64860
tgctcagttt	gaactaaaag	ccgctccgct	cctcttctag	atttggaata	caagcgaaat	64920
taaactaaac	cgctgcacgc	ctctgacgcg	acatctggac	acggcgcggc	gctggcgctg	64980
ccggagctgt	cgacccggcc	tggcgccgga	ctaggttaggt	ggagtcgcac	ccgggggtcc	65040
cagctgggtc	cgggcgccca	ttccccctcc	agctgccgcg	gtcgccgagg	gcgcctggct	65100
gggacaagca	ccgagtcctt	tgtgtctagc	ccatttttat	tttcggtttt	aaccttcacg	65160
acagccgcgg	agcatctgag	cgcttcttcc	tcttctctct	tcccccgcg	tccccctccc	65220
tgctggccgc	tccccctcctg	tcgccgcgct	ctcgcgtaga	atggttgtct	tggcgaccgt	65280
tggccgctgc	cgctccacg	ctctgccccg	cgccagaca	ccccgactcc	ccttgatccc	65340
gcccctgac	tcctcggcgt	acgttctctc	tccggtctcc	ccctccatgt	cccctctctc	65400
ccttttcttc	cacatcaccg	atcctttctg	gactctctcc	cttctctctt	tccagctggg	65460
agacaggaaa	agcgtcctg	tttggaaca	gtaaaagcag	ggcaaggaaa	ggaaggagcg	65520
gcagaaagga	gggtgagtc	gaggacacag	gggcagccgg	agaatgcgga	ggagccgggt	65580
cctgaaagga	gtctaagcga	ggctcggtc	tcgtccagga	actcgacgc	gggtcgccg	65640
gctctccg	cgcggaagt	cgagccagg	acgcccctt	caggccggcg	cgctgacccg	65700
gtgccccgac	ccggagcctg	cggtctgct	ggatccgtcc	taaacctcgc	gggctggacc	65760
cgggccctga	gtgggtgggt	gtgtgccaga	ggattcgga	ctaggcccag	ctccgggaac	65820
ctggaaatgt	ggcccgcttc	tcagtggctt	cctgttcatg	cgcttggg	tagtggccta	65880
gttgaagaag	tgaaccaca	gcgtgagccg	acaggccctt	acagatcaga	cgtcaagccc	65940
cccagacctt	acaggggagg	aaagtgaggc	ctgcaactgg	cgagccaccc	acttaaggcg	66000
gtgcggtagc	ctagaggagc	ggcagacttc	tctttcccca	tcccccgccc	catcacttga	66060
cgttgctgcc	ggacctcggt	acaaacccaa	gacaaaacgg	ggccctttgg	aaaaagtga	66120
athtagcgat	cactcttacg	tagccactct	aaatatctat	ctagatattt	acaaatgcac	66180
ctccccggta	ggtagatttc	actcagaatt	tacccaacac	cgtgctttgt	gctggggcca	66240
catgccacct	ttctgtctag	tatggctgct	ctttctccct	cttcgcaaat	atagctcttt	66300
ttccttcagg	tctcttctga	agtaagtagc	ccttctcag	aaatgcttcc	cttttcaggc	66360
accctcatat	caccgtgatt	ttttcttcta	tagcacttag	gacgaagaga	ttattttact	66420
tatgtacttg	tttacttggt	tgttgtag	aatgtcagct	ctatgggaac	cagatccttt	66480
tatgggtctt	cctctgcacc	tatgccacgc	ccccagcatt	cccctcctac	caccaccttc	66540
agccggcctc	cgctctgta	ggggggcatt	aggtttctg	tcccacagag	gaagggcgct	66600
ttagaaaagg	ttagttcatc	ctggaagaaa	aacgatgtcg	gatgccagca	tagtgtcatt	66660
taaagatact	ggaggaatgg	agtgggagcg	gtgagggttt	cttgggccta	gacaatgtaa	66720
ctagttgttg	caataaagca	tgggtgggaa	aggagaaaag	gcacgtatta	aacatctttt	66780
gaagtcgcta	tctatatcag	tcagttctcc	agggaacacg	aaccatttgt	gtgtgtgtgc	66840
gtgccagtac	cacacatatg	tatatgtata	tacacaccgt	catgggggtg	cttaacaaca	66900
gggatacatt	ctcagacatg	tatcttttag	cgatttcatt	gttgtgcaaa	catcatatac	66960
aaacctaggt	ggtatagtct	attatacatc	taggtgtgat	ggtatgggct	attgtctcta	67020
ggctgcaaac	ctttacaaca	tgttactata	ctgaatactg	tagataattg	taacaaaatg	67080
tagttttata	tctaaacaca	tctaaacata	gaaaaggtag	tatgttgtgc	tacaacttta	67140
ggacagctat	gacatcacta	ggggatagga	atttttcaca	tccattataa	tcttatggga	67200
caccaccaat	atgtgactgt	ggttgactga	agcatcggtt	tccagcacat	gactctgtgt	67260
gtgtatacaa	ttttatatat	acgtacatta	tatgtctaca	cacacatatg	tgggggagag	67320
aaagagaggg	agggagagag	agagagagag	agagagaaa	agaaagagag	aaaatactta	67380
ttttaaggaa	ttgtctcaga	aaatgggtgg	ggttgacaaa	ttggagaccc	agggagaggt	67440
tgttgttgca	agacttgaat	ccaaaggcaa	tctggaagca	gaatttcttc	ttccttgagg	67500

gacctcagtc	atttctctta	agctcttcaa	ctgcttggat	gaggaccacc	catattattg	67560
aggataatct	gctttttcaa	gtctactgac	ttaaagtgtta	atcatatcta	aaaaatacct	67620
ccacagcaat	atttagactg	gtgtttgact	caaacactgg	gtaccacagc	ctagccaagt	67680
tgacatacca	aattaactgt	cacattatcc	cgtcatgcct	gaggggttct	ctgaccctca	67740
gttttctgag	gatcaaattt	aaattgaggg	atctatcttt	gtttattgga	gccatatagc	67800
tcaaagtata	atcatttttct	ctccacagga	actagaccta	gggataaggg	taattgctta	67860
tttcagagga	atgccatctg	aataaaaagga	taattatata	gtaagctctc	tgttcaaaaa	67920
atgtaaatat	taaagtttga	acatctaaat	tccatcttgg	tttccccac	tgccgctgcc	67980
caatacctgt	tctctttcag	ttgcagtatg	caggggaatt	ctaagtttaa	tattagtctc	68040
agcaaaatac	aatggtgaag	atgactcttt	ctagcataac	aatgggtatg	tggtattcca	68100
aatacttttg	gaatgcgag	tgactattgg	ctatgtgctc	ttcaaaaaat	taataatgaa	68160
gaactgagca	tgaattttca	cttatattac	ttattttatc	ctcacagtgg	cctttcaaaa	68220
ttgggattat	tactcctggt	ttacaggtgg	aaagaatgag	gcctagaaaag	gctcaaattc	68280
tgaacacttc	atggccagca	agagccaggg	ctggaatcat	caggcaggcc	tttgggttac	68340
aagccttgtg	ccttttctgt	tgtcccaaag	gccagggtca	ataggagtg	agttatctgt	68400
gggtcactta	tgcagacaga	atcactgaat	attggaagt	tttggggttc	tcttccactg	68460
gcctaaaaac	ctgagttaat	tgagtttttt	ttacagggg	taaataattt	tctgttttag	68520
atcagcaaat	tcattccata	ggcagggata	ggggagaaaa	atcttactga	atatcccttg	68580
tcttgttctc	ctcctcccca	aacttaatgt	cctatgacac	tagctttatc	ccttaggtaa	68640
ctcttgatta	tccaaatttc	atgagaaact	ttcctaacat	tgacatgct	caaactcaaa	68700
accccaaagt	cataagaaaa	aagataacat	aagcaagaat	aaaaaacaat	tatttgatca	68760
tatatgtcaa	aagattaatt	actagactat	ataaataaat	acataatcca	gtaaaacaac	68820
aatccaataa	aaaaggcaaa	ggatataata	gtttatagta	gaatatgtgc	aaatagtaaa	68880
aaataaaaaag	ataatcttac	tcattaataa	atgtaaacag	aaacaatggc	atataaccac	68940
aagtgtggca	aaaagaaaaa	agactacttt	gacaaagtgt	tcaggaaaca	atcactctta	69000
ctattacaac	ttggtgtaat	tgttttgaaa	ggcagcattt	caatatctag	tcaaaactgt	69060
atgagaatat	aggtaccctt	tgactcagct	attccactat	tttaagtatg	taaagacaca	69120
cacaaataat	gtatggaaat	atatatacac	atatatacta	tatagtatat	atagttcata	69180
tgatgtttat	atgtttgtgt	atatatctat	atacttatat	acaccctttg	actcagcaat	69240
tctattccta	taactcatgt	atgtaacata	tataatacat	atctttatat	acacatatgt	69300
acacacatat	ctgtaagtat	gggaagatgt	atacactatg	acacatatat	atacatatat	69360
atgtatatat	gtattttatg	tatggatata	tatgtatata	tggaatagatt	ttacacctac	69420
agacacattt	agatatgtaa	cttcagctaa	agcaattcac	tcctatataa	attgctacag	69480
ataacttgta	taagtatgca	gaaatgtttc	tttatagcag	tgtgtattag	caaacaaagt	69540
gcaagaaaga	gaaaaatgat	tgacatgctt	gtgaggagac	tttttttgtt	gttgttgttg	69600
ttagggtctc	ttcataaaat	aataaaaactg	tgcatccata	aacaataatg	aagcacatct	69660
atatgcaactg	acaatggaag	ttgtcaaaga	tctattgcta	attaaagaaa	gcaagtgaca	69720
gaatagtatg	atcccattca	tgttttccaa	atatgcatgc	tgggggagag	atgtttgcaa	69780
ttatatgtac	ttatatattct	ggaaggataa	ttaaatattt	gtaatagtgg	ttacctttgg	69840
gtagtaagaa	tgagggtggg	aaaaatttca	gatttttgct	tactactttt	tgctttctgg	69900
actgtttgaa	agttttaccat	gagcaagaat	tattaaataa	caaccacagg	aatattgggg	69960
ctcaaacctc	gagattctaa	ttttgtagac	ctggagctga	tcaacaagtc	taaatgttaa	70020
aacatcctca	cgggtgattc	tgacatggag	ccaggattga	gaaacaattt	tctgaaatgg	70080
aaggggtttt	aaacttggtg	tcctcaaagt	actactgagg	caaacaccat	tcttatagac	70140
ataagacata	cttgggagca	aatgtataat	aaagtggat	gcttccctag	aaaggggacg	70200
accttaaatc	tttctgttta	tggtgttatt	taaacatatt	aaaaactact	aattttggaa	70260
tagtcttact	tgataagtc	taactatcaa	aggcagtcca	gagattagca	aataatgag	70320
gatgatcaaa	tgtttttcag	aaaatattat	aggtggcact	ttggcaggag	attctgagaa	70380
tggtgagagg	gtgcctctgt	gccctaggaa	aggtgataga	gcttagaaac	tcagaactca	70440
gatggaatga	ggagccatgc	catatacatc	tttacaacag	tcaccctcta	gaagaaaact	70500
ctgtgttgac	aataatctgc	tgacttgtct	gtgggttttt	gaacagaata	aactgtttct	70560
tcttttatgt	ttgtgtatta	ttgcttataa	atatattcta	aaatatataa	taacaaacaa	70620
taacagtact	tgcagcttaa	ttaaagaaaa	aatgcaagta	tcttattttat	actaagagaa	70680
gagagaaacc	cgaagaacaa	tggtattatc	ttacatattt	ggtttgggat	tacattgaga	70740
gctacctaaa	taccagacac	tcattcttgg	tcctgactcc	tactctgtta	tccatagctc	70800
agtacctagt	atctggcgca	gaaagaagtg	gaatggaatt	atcaggggaga	cccagttttt	70860
agccaagact	aaaaggtttt	agccaagggg	atggaagaat	ttgtgcatag	atagacggca	70920
gatgggaatt	cgtttaaaat	ggaatggaga	cccagaggtc	acataagaca	gggttcagag	70980
gaagttagccc	caacaacatc	ataatagaga	acattgataa	tgagaggata	gatagattat	71040
gcatttgggg	aggaggccaa	atatgagaaa	taagacatgg	tttacttact	gtaattgggtc	71100
ttaaagtttt	gagtggaact	ctgttgtaaa	atattttctg	tgccagagct	gactccatat	71160

atctactgga	agtctaattgc	caggggcttc	tgagtgtgaa	gtggattaat	aggtgttttg	71220
ggctccttgt	aaacttctag	tgtaattgtg	atagctgtga	ggtagtcagt	gtgtcatctt	71280
aatacattgt	tcttagttct	ttttccagca	aactcttttg	ttttacattt	agttcacacc	71340
acaaattagt	aagtcaggct	tggtgctttt	tgaccatac	attaattttc	attactgtgc	71400
ttaatatata	atccatgcca	attacatatt	attaattagt	ggcactagta	ttagttcata	71460
ttttctttta	ttatgttaatt	aatagggcct	atatgtgaaa	gttactgtgt	ttctgtaaaa	71520
tgaagtattc	tttttcctta	cgcaagggaat	gacattaaaa	tcttctgagt	aggggaattta	71580
agaggcaaga	aaggagtaat	ttcattttgga	tagctgaaat	tgagaaacgt	tttatagaaa	71640
cttttcagg	atgaaggata	gtagtagaga	tgttacatga	gttagcactc	atatattgaa	71700
ttagttaagg	aaccaatgtg	ggaatctagg	tcttctatct	tccagtcaag	tccttgtttc	71760
acttttcttc	attccctctt	tctttcctgt	cggtataagt	agaataggaa	aatattgaaa	71820
gtattgaggc	tcaactgttg	ttgccccttt	aagtaatttc	taaaattaaa	attgtcctat	71880
tttcataata	gtgtgattgt	gtatctagg	atctctttgt	agcttagtaa	ttgaacactg	71940
tgaactacac	caacctaaagc	attattctcc	aagttttcat	caaataacta	gacagtttct	72000
gtaataactg	aaaatctagt	aaacgtgtca	gaatttggtt	atgattagtt	gctgacataa	72060
aacatgagg	cagacctcac	tgactcttag	aagatactgg	ctttcacatt	tgccccagta	72120
ggtagttcac	atgagtgtct	cttcagataa	tgtctctaag	ttttgcatat	cattagttct	72180
acttgctcca	cttttgatag	agtggcaatg	tattgaacat	tgtaaaaaatt	atgctctatg	72240
atttaaaaaa	tccatctctg	gtaaagcata	aatgagtat	atgttttact	gtttaaaaata	72300
attgaggggt	aattatagaa	tcagcaaaaa	gaaaaaaaaa	ccctactgac	tattacatat	72360
caatgcacac	agtgtgttaa	tattttcaaa	aaagggagg	caatctcagt	gtaagtgtaa	72420
atgaaattag	tttttgata	tatttgctga	agatcagtta	cctagcttca	tatgataaat	72480
tatttggtgc	tggtcacaa	attgtgcttg	ccatattagg	gaaataaaa	atcatgaaag	72540
tattcctaag	tatacatttt	cccagaggcg	tttgggggtt	tatcagtcct	gagctctcct	72600
cttgaaactg	tttcattcct	tagttatgaa	attactaatt	ttaaccattt	aaggcatagg	72660
aaattttaca	tagattttgc	tttaacagca	aaacaccctt	taaaaaattc	atccacttag	72720
gtgaaaaata	aaagataaaa	atgaagccaa	atgaatgtta	ttaaatttat	aaattttatt	72780
aactttccag	atcttcttgg	aataaatgtc	aggtagtaga	atttgtaaaa	accttggtaa	72840
tgctttaggt	ttagatacga	acttaacagg	tatatatta	tttctgtatt	ccacaatgga	72900
gctagaagca	ggactcatga	aaatagtaac	tatatgtttt	gcatgtatcc	ttcaaagtga	72960
aatccttaac	aaatttaaca	gtatatatta	ggctgtgtgt	gaaacagcta	aacctgtctg	73020
ccaggtggct	tcgaaaatgg	aattaatttt	tacatggcat	tgataagtta	ctattttcaat	73080
acaaccagg	ggtaattgat	acccaataat	gtttgagggt	tgcttttaaat	aaaaaaaaact	73140
aacaaaacaa	acaaaaaaaa	cagtgtataa	tagtactgtg	ggatccacaa	taacattttc	73200
tttagtttcc	cttaatatca	ggttgctcatt	aggaaagatt	ccacaagtta	tttaaacacc	73260
aaatgaagta	acatgtttca	tatctatttc	aagggataat	ttttcatgac	ccagtataat	73320
gcaactagca	aatttaaaaca	tcttggaatt	taagatatag	aggtcaaatt	aagggttttt	73380
ataaaccaaa	tgggagattt	taaaagtatca	actgacttct	tttatataga	atgttttcta	73440
ataattgtaa	aatactgtaa	ctttaaaaat	attattcctg	tagcctctaa	tgattgagtg	73500
cttaagtgat	aactagaaat	atattttctg	tccctgtgct	tcagtttgaa	aatggagggt	73560
ccattatctt	tgttccaaaa	atttggggtt	ttataggtgt	gttggggggg	gttattctcc	73620
atattgttga	catttttaaaa	tagttttcaa	acaaaccgtt	tatatttact	agaagttaga	73680
gaaagaaaag	ccaccttagg	agcttacaag	ggagatcatt	gtgtatttct	gctttttttt	73740
aaaaaaagtt	atcttcatgt	gtatcattca	tgattttgga	ggacaagctg	gtgcaatggg	73800
aagaaaagca	agacaaccat	aatcagctgt	ggaactagat	gcacttcttt	gtgcatccat	73860
ggaatgaata	tcttgtaacc	tttggaagt	tacttgatat	ttctttgcct	cattgtcctc	73920
atctgggaaa	caatacctat	ctctcaggtt	taaatattaa	attaacaaat	atattttcaat	73980
gcataacctg	tacagattat	gtgtcaataa	acatatcctt	tcccaataa	catatgctct	74040
gattctcaac	taactttccc	cagtaatatg	ttcatttttg	gaataggaat	tggtagagaa	74100
gtaaagattt	gtgtattcaa	ctcaaatgta	ctccttctta	taagtctcca	ctctcaaatg	74160
acttgtttct	gttccttttt	tctcttttaa	atgtgtatct	ggtagaatga	gcatttagaa	74220
gcataatata	tgtatacact	ttgtgtttta	ttttctatgg	cataagtaag	cagtttttat	74280
gaattgctgg	tattgcttat	gagcaattat	tacaaacatt	gagagaagg	aaccctgtg	74340
aacctttaac	atttctcagg	agtttagtgg	aaacccatga	acatgtattt	ttaaaccaa	74400
ttaccacact	cttggaagtt	aatctctgtt	aattctttat	taaagtagtg	aagtatcagt	74460
tgttccaatg	atataatgat	caagcaaccc	tggaaattaa	atcccaaagc	agtgcacctt	74520
tagtttggtc	agtgatagta	ggacatccca	cgagccatca	tatattttca	agtttttata	74580
ctcaatctac	tttttcagca	atcttttggg	aactatccca	agataattta	ctgcataagt	74640
gcacttatct	tctaaaagac	atttggaata	tttcttagtc	tgacctctgc	accctgagac	74700
actctataaa	ggaaacaatc	agaaaaattt	aacaaagaaa	taaataggtt	aagaagaaag	74760
caatctaggc	gtttgcactg	agtttgcaac	agtgccattg	ctacatttaa	gagctgtagt	74820

tcttcctcac	attttaactg	agagccacta	gttatgttac	ttaaaatctc	cccatataat	74880
aagacagttg	ctgaacaact	aaaaagtaca	aaatatcaca	aaatcaaaaa	gtagcaagtc	74940
ataaggggat	ttccgcatcc	tagcatgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgaaaga	75000
aaacgttaca	gttaaccgtt	acaattgtct	tactccact	ccaccacctc	atcctgtgta	75060
gtctgcctgc	ggaacccgcg	ggaatctctc	ctcagtgtag	taagagcaaa	ggccagcatc	75120
ctgtgcaaa	gtgctctgca	gcgtcgtgat	ccagggattt	tagcatctgt	cgctcgttgc	75180
acatcctctc	ttacccctct	gctatctggt	ggagtgggc	gagggctctc	agggcttcca	75240
gagagtgtcg	tttacgcatg	tgacttgcca	tgcgctcaaa	ctaaagcgcc	gccggggact	75300
tactgaagcc	cacctcggcc	ctcctccact	ttgtcctcag	tcttcaggtt	ttcctttctg	75360
ccgctagggc	ctaagttgtg	ggttcaccat	aactcctcag	cagacattgg	agtgaacgca	75420
tcgactgccg	tcaccaaggt	gctaactact	gccttctccc	actcagcgct	ggagtgggag	75480
attcatccat	cggaagattc	gtagccacca	gttccagtca	aggatttcat	atgcactttc	75540
cctcagaaaa	ccctgaaaa	caaacgaccc	ctggaatgtc	acacactcct	aaatatccct	75600
ggaaatcccg	ttctctgtgt	ttcgcttcat	ggtagtgtc	gagggccaga	taagacaaag	75660
aaaaaaatgt	atggaaggtt	attcccggtc	ggctcctcct	tcctgtgagt	ctcagacagg	75720
cttgacggct	tacaggcttt	ccgccgctcc	ccgttggcag	ccttcatcga	attaggtggg	75780
tgggggtggg	aaattgggta	agaaaataaa	gtcgttgtgg	gcggctgggg	aacctggcgt	75840
cagtcccccg	tggctgtgcg	caggtaccct	gcaacgtcgc	ggtggccccg	ctcctcggcc	75900
aagtccacgg	gcagacgacc	ccaggcatcg	cgacagtcga	gccgcgcccc	ggcccggtgc	75960
agcaccacca	gcgtgtccag	gaagccctcc	cgggcagcat	catgcaccgg	tcgggtgaga	76020
gtggcaggg	ctgcgcagtt	gggtcccgcg	ccgtggagca	gcagcagctc	cgccacgcgg	76080
gcgctgcccc	tcacatgac	ctgccagaga	gagcagagt	gtcagagcca	gggtgggggc	76140
aggtatggga	gatgccggcc	ggggcaaggc	aggtggagcc	atttaaagaa	acacctaatt	76200
gcaaagtttt	caccagtgct	agaggtgttc	aggtctctga	tgtctggtgt	ttcttcattt	76260
gctgatgcaa	tccactttcc	cacccacact	tcaggttata	ctcagtacaa	attaaatgcc	76320
attttattct	ctaaacgtgc	agagacaaga	aagttgatgg	taaagtgatg	atcatcatta	76380
tggaaaaaca	aatcttgatt	tccattggaa	catgggaatc	tattttgtta	aatgatttag	76440
gggcagagtt	aaattttatt	ggcttttaaa	gttttaaaat	atttgcttgc	ctgacccctc	76500
ctccataatc	caggtctaca	aatattttat	aggtagtcaa	ctactgtttg	ttagaagttg	76560
ggagtaattg	tttaggggag	aaaataaaca	actaagtttt	tttctttctt	ttttttttaa	76620
tttatttagt	tctcatagca	aatcccgtgc	ggaaggcttt	tgtttgtcat	gtgtctgagc	76680
tcataactgg	cttgtagtgt	gataatttga	gccaaagtgt	gagattagaa	gggaaaagta	76740
aattaaatca	tgcaaaatct	tataaaatta	taataaatga	tttttcctta	acagttcatc	76800
attttaaatt	tagactataa	tatttttaat	gtaataataa	actaactata	tttgtatact	76860
acaggatttt	ataatagcta	agattttaaa	atgttaaaaa	gtaaatatat	tgctatataa	76920
aaagagcttg	ggccaggccc	agtggcttat	gcctgtaatc	ccagcacttt	gggaggccat	76980
agcaggcaga	tcacctgagg	tcaggagtcc	gagaccagcc	tggccaacat	ggtgaaatcc	77040
cgtctctact	acaaaaaata	aaaaattagc	tgggcatgg	ggggcggtgc	tgtagtccca	77100
gcaactcagg	aggctgaggc	aggagaatcg	cttgcatcct	ggaagaggtt	gcagtgagct	77160
gagattgtgc	cactgcactc	cagcctgtcc	gacagagtga	ggcctcatct	caaaaaaat	77220
aaaataaata	aataaataaa	tagagcttgg	atgttagcag	tcaatcagga	tgatgcataa	77280
cttagaaaaa	atgatgtttt	gcaggagtaa	tcctgtagca	gccatttgtg	tacatgaaca	77340
ttatgaaaac	atttgctgtc	atattttaag	tcaattataa	gacaattttt	ggtaactaaa	77400
tgtctaaaat	cgagttattt	gttatgggtt	tatgcacttt	aaaatatacc	atttaattga	77460
aaggcagtat	acttctcatg	ttttgttggc	ttgtttcatt	aatattagaa	atgttcattt	77520
catctcctaa	aaaccgtgat	aagttatatc	tactagtgat	gtaaggatat	ttatcataga	77580
aaaaaagggg	aaaatagctg	ctgttagtat	ttcagaaaaa	ggtgaattac	atatataact	77640
tgttttttata	attattaata	aaatttttaag	tttttaagat	gcactttaca	atatttttgc	77700
tccttttaaaa	atccctcatt	tgttatacca	ttattctaag	aattcaaaa	aaatgaacac	77760
ttcttttaaaa	tctatactat	taacaagatc	ccttaatat	agcttagttt	tagagggtga	77820
tagtgagggtg	agtactgaat	atgaccacta	gccaacggta	aagtacaaaa	gagttgtccg	77880
agattgtaaa	agaaataaaa	aatatcagta	ctaattaaag	caggattcgt	acttaaacat	77940
tgaataagtg	tatttttaaca	atgaagataa	agatgcatta	tttatgaaga	tcctttgcc	78000
ttcaaaaagg	acctaacagt	tgctgcagga	atatttttgt	aatctgggca	ctgagtatga	78060
taattaaaga	atgagaaacc	tatagaacta	tatatTTTTT	ctcttatgca	tcactcataa	78120
gacactgcta	acataaaaagg	aactaagtac	tgtggttgag	gaatcccgtc	tcattctcaa	78180
ttaacctcta	tgagaaaaaca	atacaacaga	tttcatatag	tagcttagaa	gtttacattg	78240
attttttcca	tgtactatga	ttttgtagaa	ttccttaaat	ccaatctaga	atgcgtaact	78300
tatactttac	ttatctttat	cgttgaaagc	agacagacaa	gataatcttc	ttccctaaat	78360
aagctttcct	tttctccttt	tctccccaat	tcagtctatt	ccttgcatct	ctgatcatga	78420
gatggcagaa	caaaaaccac	taaaaaaagc	ttaaacagt	ggtttttcaa	tgtctctctt	78480

taggattttt	gctgggtaaa	agcctgtttt	acgcgtggaa	tgacacacctc	cggccaacgg	78540
agactcctgt	acaaatctac	atcggcgatc	taggttccag	ccccgatccg	ccgaggccgc	78600
gccccgcgtt	cgcgcgcccc	ctgcccgcga	ggccttgggg	ccccagctac	ctggatcgcg	78660
cgctccccga	aacggttgac	tccgttggga	tccgcgcccg	cttccaggag	ctgtcgcacc	78720
ttctccacta	gtccccgcgc	cgcgcgctg	gccagaccct	catcgctgcc	gccccactg	78780
ggcatgccct	tgttctcctc	gcgcattccg	cagccccag	acgcgcagcg	gccccgataa	78840
tccaccgttg	gccgtaaact	taacgacact	cttcccttct	ttcccacgct	gctccggcgc	78900
actctctcct	tcctaggaga	cctgggctca	gcttcattac	cctcccgtcg	tccttctgcg	78960
gcttggggcc	ccgtgcagt	gccgagcggc	cggtcgttag	ctccgggctt	ttcctggcgc	79020
tcaagaacca	gcgggcgcgc	ctggattgct	tctgggaaaa	agcgccctagc	gcggacgcag	79080
ccgagctcaa	agccgctctg	gccgcagggt	gcggacgcgt	cgcggaagtcc	tactgcccc	79140
gcctcgctct	ggcagagtgg	ggagccagcc	ggcaaagaat	tccgttttca	gctgggccaa	79200
ggggccggcg	tctccccacc	cccttaggct	ccgccccctg	tccgctgtga	tcgcccggag	79260
gccaggcccc	ggccgacgcg	tcacgagggc	ggggaagcct	gcccagaagt	gctaggacgc	79320
atgcgcaga	gactgggcca	gggagccgcc	aggaatgctg	gctgcactgc	tcgctggatg	79380
tccagttaag	ccaaggctaa	tattttggga	atgttcacca	ctgccctcag	ctcctaattcc	79440
ccagtaggcg	gagcagagga	tttctgttcc	ttcagccagc	cagttggttt	cactgtggag	79500
acgttggtgg	ctccctgtg	accgagagaa	agtcattcaa	aataactccg	tgtttcttaa	79560
gatgtctgaa	agcgacagct	ctgcacctgt	catacaagtt	aaattcatcc	ccaggcagta	79620
cttgggcttc	acaagtttca	taacttgtat	caaacttagc	aattttctct	tggatgtgtc	79680
tttctgtttg	aattagtcaa	ccataaaaaat	agagaaaaat	cccgagaatc	atgttttgcg	79740
tgtgcttttt	aattctttcc	atttttgcat	tatggataca	acccttaaaa	gagaaaaaaa	79800
ctagttcgag	attgagagt	gcaacctggc	acacataaga	caaaaaaaaa	ttatacttta	79860
agaatctgag	atcccagttt	catcataatt	gtacagtaaa	tctttgtttg	cactcttacc	79920
tatttaaaacc	cactttgtca	ggtatcttat	ttttatttat	catgagtaat	aaaggaaatt	79980
tatgcagtaa	taatgaaaca	tcataagaga	ggggtgtggt	gctgggcttg	tcattaaaca	80040
ggctgaacct	gtcattaaat	tctcttctga	agatttaaat	gccaagtgtc	ttttttcccc	80100
ttcctaattct	tcctagggtga	gtttgaatca	acatttatta	cttaaaatat	ttaaaacatt	80160
tcagcggatg	ctacattgga	taggaagaga	accgcaagtt	atggatttgt	tgccataaaa	80220
ctttggttgag	gaactgcata	agtggacctc	tcctaaaaag	gaacaatttt	tgtttacaga	80280
atcatttttg	ttcggagtgc	tgaggaagac	aaagtcttaa	caggagggca	attgtctgtg	80340
tattgcaaaa	tgagagtctt	cacatgtttt	tttttaggata	ccttagctct	gactcctcat	80400
cccccaaattc	cctgtagaat	taaaaaaaagc	tctttctttt	aaaggcagtg	gaagtgccac	80460
caccatggaa	gtgctggtta	gggctgaaaa	tctactgaca	gagcctcaac	agagctgaaa	80520
tccacctgga	caggggaagg	aaccgggtag	cattaataac	aatttctttt	tctttcccat	80580
ccaacccccca	tttctagtc	ttcagtttct	taatttctct	accttttact	cttatgtctc	80640
tgttttgacc	tttgagtttc	tctgaaactt	atcagaaaaag	ttaggacaag	atagtctgac	80700
ccaattcttg	agccattttc	ttaggtagta	aatatgtcag	aaaaatgaaa	gctgtttgga	80760
gttgataaag	aaatggaaga	taatgttttt	ctttgagggg	gacataaaga	atggtgatag	80820
ggaaagaacc	aatgactaag	taaaatgact	gagaatcttg	cacgaggcag	atgtgtgagc	80880
ttcgcgaagc	aagttgactg	aatgaaaaac	aactttgggt	agggaaaacg	ttgccggggg	80940
cattcgcgct	tactagcacc	acggacagcg	ctttgcttat	actcaggcct	gggtggctct	81000
aaccagctcc	agacagaatt	ctaaagcttc	acacttgatc	ttccaaagcc	ccttttctcc	81060
cgtcaaataag	aaaggacatt	atggaagctc	aatgaatttc	tttgaaaaac	caacctgctc	81120
aacctgggtt	tcaaataatga	ttggatttta	tctaattatc	tctgtataaa	gaatattata	81180
tgttctatat	ttagaagacg	agaagagaaa	tcaaacttat	tgtgtactct	gtacgaagt	81240
ctttacagct	gttgtttcat	ttaatactca	taaaactcct	ctgtggcatg	tgtccatatt	81300
tcaatttttac	agacaagcca	aaaggatcag	agaattttgag	tgacttgtat	actagctaatt	81360
cattgttgga	ggtgggtata	acttttgcca	cttcagagtc	tttttaccct	ttataactaca	81420
tagtggtttt	tttagcagct	gtcatggtag	gcttaactgg	aaaaaagtaa	taaactggct	81480
tataattatt	tttcagtcta	cactgtgttt	tccagatggc	tcacctcaca	gcacaccctt	81540
accagacttc	aaagatgaca	tttcacatgt	aatacaatag	cacatttgtc	ttggacaata	81600
gagtgaatt	atgaaacatt	ttacctctcc	ttgaaacca	gctgtctcta	gggtgaaaca	81660
caatctgttg	ttaatgcttt	aaacacattt	aaaagatgaa	gtggatggga	acatagtggg	81720
cagctgaaac	ttggaattgt	cagagccatg	tcttttaata	aggtggagaa	tttataattg	81780
agaagaaaga	aagagaaagt	taatggtaaa	ttggcataga	attttgagg	tcagtagaag	81840
ggaatgagt	gcatccattc	caatgttgca	cataactcag	atcactagta	ataatatttt	81900
tatattctag	ttggtgaaat	tgtctgtata	tgaccttgat	atagaagtat	gaacagatct	81960
gccatcctct	ttttcttcag	cgaggcagcc	gagctgcaga	cacagagatg	cagatctttg	82020
tgaagacctc	cacgggcaag	accatcacc	ttgaggtcga	gcccagtgac	accattgaga	82080
atgtcagtgc	gaaaattcaa	gacaaggagg	gtatcccccc	tgacaagcag	cgtctgatatt	82140

ttgccagcaa	acagctggag	gatggccgca	ctctctcaga	ctacaacgtc	cagaaacagc	82200
ccacccccga	cctggtgctg	cacctgcgag	gtggcattat	tgagccttca	ctcttccagc	82260
tcacctagaa	atacagctga	aacaagatga	tctgccataa	gcgctatgct	ctcctgcacc	82320
cctatgctgt	caattgccgc	aagaagaagt	gtggccacac	caacaacctg	caccccaaga	82380
aggtcaaata	aggctcttcc	ttcctcggag	ggcagcctcc	tgcccaggcc	ccatggccct	82440
ggagcctcaa	taaagtgtcc	ctttcattga	ctggaaaaaa	aaaaagtatg	aatagaactg	82500
gttgactggc	caagagaaac	agcgacctaa	ccttgccctc	atztatgcac	acttttgcac	82560
atgattagga	ctaagatagt	gtttataagt	gagaagagaa	ggaaattcat	aatcactttt	82620
ggggcttttt	caaatttttt	atgaacacac	cttcccacca	agaggtttga	ttttctccat	82680
tttatgagtt	gggtttattg	ctccgtgac	cacagtatat	ccacttctat	attcccattg	82740
atttttcaag	attaattaaa	tggtggactt	gttcattcatt	ttagtatccg	tattagtttg	82800
ctagggctgc	cataacagaa	taccacagac	tgagtagctt	aaacaacaaa	tatttatttt	82860
ctcagagttt	taacttctcc	tgaggcttct	cttcttgact	tgacatggc	catcctactg	82920
ctgcctcttc	acatagtcat	ccctctgtgc	acacgtgccc	ctggatctct	tgtgtgtgtc	82980
caaatttccct	cctcttttga	ggacaccagt	cagattggat	tagggcccac	cccaatggcc	83040
ttatttttaac	ttagtcactt	ctttaagggc	tctattttcca	aatacgggtca	aattgtgagg	83100
tattgggctt	aggactttta	tataaaaaatt	tagagggtgac	agaatttaac	ccataacaac	83160
agcatcttaa	tttttacaca	ttttactttt	catttctttt	taaactgtta	ttaataattt	83220
attcatttga	ataaggatta	aaataaggct	aggatattga	aattggttga	aattgctaca	83280
gtctcttgta	tctctctctc	tctctttttt	ttcttataag	ggacagggtt	cattcacctt	83340
gtcgaccagg	ctggagtgca	atactgtgag	caagggtcac	tgctgcctcg	aattcctggg	83400
cttaagggat	gctcctgcct	catcctccag	agtagatggg	actacagggt	ttggccacca	83460
tgactggcta	atattttttac	ttttttgaag	agatgaagtc	ttgccatctg	gccagggtg	83520
gtcccgaact	cctgggctca	cacaatttct	tcacctcggc	cccccaaagt	gctggattgc	83580
aagtgtgaac	cactgcacct	ggcgtcttgt	ttcctcttaa	tctacagttt	cccccttttg	83640
ccttcttttt	ttttctttca	atztatctat	tgcagaaatt	ggctttatct	gtagttttct	83700
aaagcttggga	ttttgctgaa	tgcttcttta	taatgacact	taacattttt	ctttgtcatt	83760
tgtattttctc	ataacttatt	atttaggcct	agagtctgta	tgtgattcag	gtttgatatt	83820
tgggcaaaaag	tatttaataa	gtgggattac	gtactttcac	caagagacac	ataatatggt	83880
tgtctctttc	tgtgattcta	gcagccatgg	ataattattt	catagattat	tattttcttg	83940
gggatggcaa	aattggtgata	ttctaatttt	actattcctt	catttactag	ctggaatgtc	84000
tttttaaaatt	atttatttat	ttattttatta	tttgagacag	agtcttgac	tgtcacccag	84060
gctggagtgc	agtgggtgtga	tcatagctca	ctgcaacctg	caactcccag	gctcaagtga	84120
tcctcccacc	tcagcttccc	caatagctag	gactacaggc	acacatcacc	tggctaattt	84180
ttaaatttttt	tgtagagatg	agggtcttgc	ttttttgccc	aggctggtct	ctaactactg	84240
ggctcagcct	cctaagctcc	tcctgcttca	gcctcccaaa	gtgttgggat	tacagacata	84300
agccactgtg	cctggcctgg	aatatttcta	tatagaaagt	tctcttcatt	atctacttca	84360
ttgctttcag	gtatatgtaa	gaaagacagg	ataaaccact	agattttgaa	atgtatttat	84420
aaattttcaa	aataatgagt	tgagtcctag	aatctttctt	ttattattat	tattattata	84480
ctttaagttt	tagggtagat	gtgcacaatg	tgcagggttag	ttacataggt	atacatgtgc	84540
catgctgggtg	tgctgcaccc	attaacttgt	catttagcat	tagatatata	tcctaattgct	84600
atccctcccc	cctcccccca	ccccacaaca	gtccccagag	tgtgatgttc	cccttccctgt	84660
gtccatgtgt	tctcattggt	caattcccat	ctatgagtga	gaacatggcg	gtgtttgggt	84720
ttttgtcctt	gtgatagttt	actgagaata	atgatttcca	atttcatcca	tgtccctaca	84780
aaggacatga	actcatcatt	tttatgactg	catagtattc	catggtgtat	atatgccaca	84840
ttttcttaat	ccagtcctatc	attggtggac	atttgggttt	gttccaagtc	gattgtattg	84900
tgaatagtgc	cgcaataaac	atacgtgtgc	atgtgtcttt	atagcagcat	gatttataat	84960
cctttgggta	tataccaggt	aatgggatgg	ctgggtcaaa	tggatatttct	agttctagat	85020
ccctgagaaa	tcgccacact	gacttccaca	atgggtgaac	tagtttacag	tcccaccaac	85080
agtgtaaaag	tgttcctatt	tctccacatc	ctctccagca	cctgtttttt	cctgactttt	85140
tttttctatt	tctagactct	ttattaagat	tcatttttct	atgaaaaagt	ccattcttta	85200
gtcagttcta	cactgtcttg	attaaggtag	ctttatagga	agttttttaa	tcaggtaatg	85260
taacccctcc	aaattcatcc	tcccttttgc	aaattgtttg	gtcattctga	atcctttact	85320
ttttaatatata	aattttaaaa	ttatcttgcc	aaataatctt	gtttgaattt	taattgggat	85380
tgtgtggaat	ttatagatca	atttggggaa	gactgtcatc	taaaaatatt	gaatcttcaa	85440
ttcattaaca	tgaattttatt	ccccatttta	tttttattta	tttattttatt	tttctttatt	85500
attattatac	tttaagtttt	agggtacatg	tgcacaatgt	gcagggttagt	tacatatgta	85560
ttcatgtgcc	atgctgggtg	gctgcaccga	ctaactcatc	atctaccatt	agtttccctga	85620
ctgtttaatg	attgccattc	taactgggtg	gagatgggat	ctcattgtgg	ttttgatttg	85680
catttctctg	atggccagtg	atgatgagca	ttttttcatg	tgtcttttgg	ctgcataaat	85740
gtcttctttt	gagaagtgtc	tgttcatatc	cttcgcccat	tttttgatgg	ggttgtttgt	85800

ttttttcttg	taaatttggt	tgagttcatt	gtagattctg	gatattagcc	ctttgtcaga	85860
tgagtaggtc	gcgaaaat	tctcccat	tgtaggttgc	ctgttcactc	tgatgatagt	85920
ttcttttgct	gtgcagaagc	tcttttagtt	aattagatcc	catttgcata	ttttggcttt	85980
tggtgccatt	gcttttggtg	tttttagacat	gaagtccttg	cccatgccta	tgctcctgaat	86040
ggtaatgcct	aggttttctt	ctaggggtttt	tatgggtttta	ggtctaatac	aagggacgtg	86100
aaggacctct	tcaaggagaa	ctacaaacca	ctgctcaatg	aaataaaaaga	ggatacaaac	86160
aatggaaga	acattccatg	cttatggata	ggaagaatca	atatcgtgaa	aatggccata	86220
ctgcccgaag	taatttatag	attcaatgtc	atccccatca	agctgccaat	gactttcttc	86280
acagaattgg	aaaaaactac	tttaaagttc	atatggaacc	aaaaaggagc	ccgcattgcc	86340
aagtcaatcc	taagccaaaa	gaacaaagct	ggaggcatca	tgcaacctga	cttcaaacta	86400
tactacaagg	ctacagtaac	caaaacagca	tggtactggt	acaaaaacag	agatatagat	86460
caatggaaca	gaacagagcc	ctcagaaaata	acaccgcata	tctacaacta	tctgatcttt	86520
gacaaacctg	agaaaaacaa	gcaatgggga	aaggtattccc	tattgaataa	atgggtgctg	86580
gaaaactggc	tagccatatg	tagaaagctg	aaactggatc	ccttccttac	accttatata	86640
aaaattaatt	caagatggat	taaagagtcg	tagcatcttt	caaaggtgac	taatgatatt	86700
aacattatta	ctataaacct	atagatttaa	acataattgc	tatgttttaa	cccattatag	86760
ttattattcc	tggtgatgat	caagctctat	ctttggccag	tgaggagcctc	tgcaaatgga	86820
ttagtgaatc	tttttgacat	ggaactatta	gtctttgaca	aaatctttga	tttctggtat	86880
gacaatatat	tccagtttta	tcttatatac	ttccagtcct	atacataata	ttactttttt	86940
ttcaaagaat	tactgggttt	attttttagtg	ggaaatggca	tttaaaataa	ggaagttggc	87000
gaggcgagc	ggctcacgcc	tgtaatccca	gcactttggg	aggccgaggg	gcgcagatca	87060
caaggtcagg	agttcgagac	cagcctggcc	aatatggtga	aaccccatct	ctactaaaaa	87120
caaacaaaat	tagccagacg	tggtggcaca	cacctgtagt	cccagctact	caggaggctg	87180
aagcagaaaa	aaataaataa	aataaggaag	tctgcctata	tggttatctt	acctcttttt	87240
tagggctcaa	cctaccggtt	tcacacaaac	ccaactgaat	tcggactcta	tatgtgctag	87300
gcaagtttga	gctttttcag	gtgtacacac	agggtttact	gaactctggc	atataattat	87360
ttattttatt	attttatcaa	gttttgctct	atcattgaaa	ctcattcttg	aataaagtta	87420
ttatatttag	ttcagttaca	gcagacaccc	cattttgaaa	acattatgtc	aacattggct	87480
tggtgtacct	gtcacatcag	taatgtacag	ttctcattta	ccagaaat	ttatatgaac	87540
aacatattga	agttattaag	ttaatgaatt	ctgccaaagt	attggtatat	atgtgtcat	87600
tataagcatt	taaaaacaaa	ggaacctttt	aaagtgaag	ataatttaat	gggccattgc	87660
atgcaaagag	gtgttgcat	agtaaccaac	cttaactac	tgctgaaaca	actttatgct	87720
tgagttagat	atgttgatgg	gagccaataa	ttgtgaaatt	tggtgatcca	gactctcttc	87780
tgctctgttc	ttaatggatc	tagtgtaaat	gttagaatct	agtgcatttc	acaactgttg	87840
ctattataga	tggaatatca	ggaggggtag	tgaggtattg	agatagatga	aaacattttc	87900
taaaagtggc	tcacgcctgt	aatcccagca	ctttgggagg	ctgaggtggg	tggtcacct	87960
gaggtcagga	gttcaagacc	agcctgacca	acatggtgaa	accatgtctc	tactaaaaat	88020
acaaaaatta	gctgggggtg	gtgtcaggca	cctgtaatcc	cagctaccag	ggaggctgag	88080
gcaggagaat	tgcttgaacc	caggaggcag	aggttgagtt	ttctccacag	ctttggatcc	88140
tgatgacttt	ttttttttta	attgttactt	tcaacttcct	tgctttgact	gaagccatac	88200
ttacatatta	ctgataacat	atgccatggg	ccgcgcagtg	tggtctacgc	ctgtaatccc	88260
agcacttttg	gaggccgagg	cgggtggatc	acctgaggtc	agcagttcag	accagcctgg	88320
ccaacatggc	gaaaccccg	ctctactaaa	aatacaaaa	ttagctgggc	ttggtggtgg	88380
gctcctgtaa	tcccagctac	tcgggaggct	gagggaggag	aatcgcttga	acctgggagg	88440
cagaggttgc	ctgtgcactc	gggccactgc	cgctcagcct	gggtgacagc	gcaagacttc	88500
atctaaaaac	aaacaaagaa	aaacataatc	catgtatgtg	atgtaaagag	cgccaacatg	88560
tttatatcct	cctattttcaa	tctactttta	cttcatctac	attttttagca	ataatgtgaa	88620
catgaaatct	tgaataatta	gctatctgta	atatattttac	tcatccactc	aaaatattga	88680
gcccccccaa	taaatatcat	acactatatt	ctaggtacag	gtgataaaca	attcagagag	88740
tattaattttc	aaaacatggt	aagtgcatag	tgagagagct	gatctggtct	ggtggttgag	88800
ggaatcaaga	gatattttgag	ttgaggtctg	cagtattata	gaaaattaac	taatcaaaag	88860
agaggcagtc	attccaagga	aggggatgtg	agtcagaaga	aactgcattg	ggcaagctct	88920
gaggtgggac	aaagcaagga	catattgaag	gaattgtgac	tgagagcatag	ggatggagga	88980
aaacattgta	gctagctgag	aaataagcat	ggaaaaatgt	tgtagagctg	tataggccat	89040
gttaggactt	ttgtctttat	cttaaggata	agccattgat	gtgtttataa	agacacatga	89100
tgtgatcaga	ttttcagtta	aatttaaaaa	atacttgga	tgcattttgg	agaatggttt	89160
aggggagagg	caagagtggg	ttctgtgggc	cagtagttca	gaggataggt	tatggtagct	89220
tggaactaaag	tgcttgagcc	aagatggaga	gaagtagatt	gctttaagac	atatttaaaag	89280
aataacatca	gcacttagca	atgaactgga	gatggaagat	gagggaaggg	aaggtgttag	89340
gcaggttttt	acaatgagag	aggttggtga	tcatggtcac	caaggtaggg	aatgctggat	89400
gaggatgcag	tttaaggtga	agattatgag	ttcaggttca	gcaaaaactga	acttgagaca	89460

tggtgaacta	tcaaggtgga	gatatccagt	gaaagttaga	gagaggggtc	tagagctcag	89520
ggaggagtgt	gtatccctaa	tttagactaa	tttgcattaa	cagctgtagt	aatgcaat	89580
tctctatact	gaaatgcaga	catttgagta	tagaaaatta	gcagacattt	gaatatagaa	89640
gaaagattta	ctttccttca	gaaaaagaat	agtagagtat	aaagaataat	atttaatcct	89700
aggaattaat	accaaaccct	ttaaaaaaaa	cttttaagtt	caggggtaca	tgtgcagggt	89760
tgttacatag	gttaaacttc	tgtcatgagg	gtttgttgta	cagattgttt	catcacccag	89820
gtattaagtc	tagtacttgt	tagttagtta	tttttcctta	ttttctccct	ccacccatct	89880
tccaccttct	gataggcccc	ggtgtgtgtt	gttccctctc	gtgtgttcat	gtgttctcat	89940
catttatctt	ccacttataa	gtgagaacat	gtggatattg	gttttctgtt	cctgcattag	90000
tttgctaagc	ataatggctt	ccagctccat	ccatgtccct	gcaaaaggac	atgctattgt	90060
tcttttttta	tggctgcata	gtattccatg	gtgtatatgt	accacatttt	ctttatccag	90120
tctatcaactg	atgggcattt	atgttgattc	aatttttttt	ggctattgtg	aatactattg	90180
caataaacat	acacatgcaa	gtgtcttcat	aatagaatga	tttatattcc	tttgggtgta	90240
taccacgtaa	tgggtattgt	gggttgaatg	gtatttctgt	ctttaggtct	ttgaggatc	90300
atcgcacagt	ccccacaat	ggttgaacca	atttacactc	ccaccagcag	agtctaagtg	90360
ttcctttttc	tccactacct	caacagcatc	tgttatTTTT	tttgactttt	taataatagc	90420
cattctgact	tgtgtgagat	agtatctcat	tgtggttttg	atttgcattt	ttctaataat	90480
cagtgatgtt	gagcttttct	tcatatgatt	gttagccaca	tgtatgtctt	cttttgaaca	90540
gtgtctgttc	atgtcccttg	cccatttttt	aataggggtg	ttttattctt	gtaaatttgt	90600
ttaaggtctt	tatagatgct	ggatattaga	cctttgtcag	atgcatagtt	taaagaaatg	90660
ttctcccatt	ctgtagggtg	tctgtttact	ctgttgatag	tttcttttac	cgtgcagaag	90720
cttttttagtt	taattagatt	gcatttgtca	attttttctt	ttgatgcaat	tgctctgtgt	90780
cttcctcatg	aaatctttgc	ctgtacctat	gttctgaatg	gtactgccta	gactgtcttc	90840
caggggtttg	atagttttgg	gttttacatt	taagtcttta	ctctatcttg	agttaagttt	90900
tgtatatggt	gtaaggaagg	ggtccagatt	taatcttctg	catatggcta	gccagttatc	90960
ccagcaccat	ttattgaata	gggaatctgt	tctccattgc	ttgtttttgt	caggtttgtt	91020
gaagatcaga	tagttggagg	tgtgtagtct	catttctggg	ttctctgttc	tgttccatta	91080
gtctgtgtct	gctttttttt	atgttcttaa	cttttattta	tttatttatt	catgtattca	91140
tttattttta	ccagtgccat	gttgttttgg	ttctgttagc	cctgtagtat	agtttgaagt	91200
caggtaaatgt	gatgcctcca	gctttgttct	ttctgtctag	gattgggttg	gaaaaatagg	91260
gcactttttt	ggttccatat	gacttttaaa	atagtttttt	ctagttctat	gaagagattc	91320
aatggtagtt	tcataggtat	agcactgaat	ctataaattg	ctttggccag	tatggccatt	91380
ttcacaatac	tgattcttcc	tatacatgag	catagaatgc	ttttccattt	gtttatgtta	91440
tctctgattt	ccttgagcag	tagtttgtgg	ttctccttgt	agagattttt	ttttgtatcc	91500
tgagactttg	ctgaagttgt	ttatcagctt	aagaagcttt	tgggctgaga	caatggggtc	91560
ttctagatat	aagatcatgt	cacctgcaaa	gaaagatagt	ttgacttcct	ctcttcttat	91620
ttggatgcct	ttatttcttt	ctcttccctg	attgcccttg	ccagaatatt	caatactatg	91680
ttgaatagaa	gtgttgaata	gaaactaatg	ctgcaagcat	tagtttcaaa	gaacttcttg	91740
atcttctgct	taatttgatt	gtttacccaa	aagtcattca	ggagcaggcg	tttcaacttt	91800
cgtgtaattg	tatggttttg	agtgaatttc	ttagtattca	tctctaattt	aattgtgctg	91860
tggctctggga	gacagtttgt	tatgatttca	gttcttttgc	atltgtctgag	gagtgtttta	91920
attccaatta	tgtgatcaat	tttagagtat	gtgccatgtg	gtaatgagaa	gaatgtagat	91980
tctgttgttt	ttcactggag	agttttgtat	atatctatca	ggttcatttg	atccagtggt	92040
gagttcaggt	cctgaatatc	ttggttaatt	ttctgtctcg	gtgatctgtc	taataattctc	92100
actgggggtg	taaagtctcc	cactattatt	gtgtgggagt	cagtctcttt	gaaggctctgt	92160
aagaacatga	ttatgaatct	gggtgttccct	gttatgtggt	tatatatatt	taggatagtt	92220
agattttctc	gttgaattga	accctttacc	atttgtaaat	gcgtttcttt	gtcttttttg	92280
ttcttgttgg	tttaaagtct	gttttgtcag	aaactaggat	tggaaacctg	cttttttctg	92340
atltgcattt	ccttgatata	tttttctcca	tccttttatt	ttgagcctat	ctcattgcat	92400
gtaagatgga	tctcttgaag	acagcatacc	gatgggtctt	ggctctttac	ttggcttgcc	92460
gctctgtctt	ctaattgggtg	catttagcct	atltacattt	aaggttatga	tcctgtcatc	92520
ataatgctag	ctggttgctt	tgcagacttg	tttttgtgg	tgttttatag	tgttactaat	92580
ttgtgtactt	cagtgtgttt	ttatagtgac	tggtaatgg	ctttcctttc	cacaattagt	92640
gcttccctca	ggagctcttg	taaggcaggt	ctgggtggt	ctaattcctt	cagcatttgc	92700
ttgtctgcaa	aggatcttat	ttttccttct	cttatgaaac	ttagtttgac	cagatataaa	92760
attctgggtt	ggagtttctt	ttcttttaaa	acattgaata	ttggcctcca	atcacttctg	92820
gcttgtaggg	tttcagctga	gaggtctgtt	gttagtctga	tgggggtccc	tttgaacct	92880
gggctttctc	tctggctgcc	tttaacattt	gttctttcat	tttgacctta	gagaatatga	92940
tgattatgtg	tcttggggat	gaacttatta	tggggatatct	tactgggggt	ctctgcattt	93000
cctgaacttg	aatgttggcc	tctctggcta	ggatggggaa	gttctcatgg	atgatatttt	93060
aaaatatgct	ttccaagttg	gttccactat	cttccatttt	tttcaggtaa	accaatgaat	93120

tgtagatgtg	gtctctatat	aatcctatat	ttctaggagg	ttttgtttat	tcatttttat	93180
tcttttttct	ctattcttgt	ctgcttgtct	aattttggaa	aggtagtctt	caagcttgga	93240
aattctctcc	ttcacttagt	ctattctgtt	attaatactt	gtgattgcat	tatgaaattt	93300
tgggggttgg	gagtggtggc	tcacacctgt	aattccagca	ctttgggagg	ctgaggtggg	93360
tggatcattt	gaggtcagga	gtttgagacc	agcctggata	atgtggtgaa	accccacctc	93420
tactaaaaat	accaaaaaaa	aaaatcatag	ctgggcatgg	gggaacatgc	ttataatctc	93480
agctactggg	gagactgagg	caggagaatt	gcttgaacct	gggagatgaa	ggttgcagtg	93540
agctgagatc	gtgccactgc	actccagcct	gggtgagttg	agagtcctga	tcaaaagcaa	93600
acctacacat	ttttgtggcc	tgtttttagc	tctatcaagt	cagttacatt	cttctgtatt	93660
ctagcttttt	tatctgtaag	ctcctgcaat	gctttattag	aatttttagt	tcctttgcat	93720
tttgttacaa	catactccta	taactctgcy	aacttcattc	ctatccatat	tctgaattct	93780
gcttctatca	tttcagccat	ctcagcctca	gcctggtact	gaacgcttgc	cagagaggtg	93840
atgtggtcct	ttggaggaaa	gaaggtactc	ttgattattg	agttttcagt	gttcttgtgc	93900
tgattatttc	ttatctttgt	gggtcatctc	accttcaatc	tttgaggttg	ctgacatttg	93960
gattattttt	tcttttatcc	tatttgatga	ccttgagggt	ttgattgtgt	tataaggtca	94020
attcaaccaa	ctagctttgt	atctggaaga	ctttaggggg	ccatcgttca	cctcccaact	94080
cctggagctg	atgttctaac	tctggatgac	ttgtatttgg	ccccaacttt	gttctctggt	94140
tcctcgaggt	ttggagctta	ctttgttggg	ggaccaaggt	gtggcagctc	cagctgggtg	94200
ctagcggatt	caggggtgcc	tgccctccctg	caggcattca	ccatgctagt	gaaggcaagg	94260
cattttttgtg	gggaacagga	ggctcctgct	atagactgtc	tgtgcttttg	cactggtgat	94320
ggtgttgggt	tggtgagagg	cactgaccag	tgcagatctg	agtgccttct	tggtcacctg	94380
caagcaggag	ggattgctca	gggtgtggga	ggatcctctg	ttctccatgc	agcattacca	94440
caagagttag	gcactggcag	ctgcagggct	tgctggctgt	gtgctgctaa	ggttctgtct	94500
gcaatggtgg	ttgacagagg	tcaaggggca	tacttcctc	ctgtatgcta	gtggggcaac	94560
taaagcaaat	tccacctgtg	cagacatgtg	cctgcaaagt	gatgtgggga	ggtgccatgg	94620
gctcagggga	agttgcagta	tgggtagcga	acaccggct	ggtgtgcgca	gtaagggctg	94680
tcttgctgga	gttctccact	ggtcaggcat	ggcccactgg	tgcagaagct	attctgtggg	94740
ccaccacagc	acccaagatg	gccctagaag	aggccagcag	accaaggagt	gctcaggttg	94800
caccagccct	gactgatgta	caagaccact	ctgcagatat	caagtctgaa	aattccccta	94860
gggccaaagt	ctattatggg	agcaagttga	gcctagaggg	atcgccatcc	ctgtccatgc	94920
actgctgtag	acactcctgc	actaaacct	ctgggctcca	catcagctgg	cttgctgtct	94980
taccactttg	cttgtctctt	gggggtcca	ccccagagag	atgtgggtca	gcaatcattc	95040
agttcaatca	gcccaggatg	gagagtctgt	gctatgggcc	caagccaggg	gctctctgtc	95100
tggtgacgag	cagctggggg	gtgggggtgg	acctgtggga	gatggactgg	cctcctctcc	95160
ttgagtcaac	tgctgcttat	tggaggtgtg	gatgagacac	ttagggtctt	tgctccttta	95220
ttagtcagag	ggtagcaagg	acagttccat	tgcagaggta	gtggcagaga	ggctttcagt	95280
tgtccgtggc	ggctctgtcc	agggagttgc	tgagttgcta	ttggcttgat	atctctggtg	95340
gggtgtggct	agaggtccag	gcctggagga	cctgctcggt	gaagagatgt	gggaatgggc	95400
acccacataa	cagtctgttc	acttttccat	agggctgctg	tagtatgctg	ggggccagct	95460
ccagtccctg	gtcactttag	attttccagt	acctggaggt	gtcaccagtg	aaagctgcga	95520
aacagcaaa	atggtggcct	tcctttctct	ctgggagctc	catccctggg	aaatacaggc	95580
ctggtgctgg	cccgaacaca	ctggtaggac	atggctgaag	acgctagtgt	ggagacctca	95640
cccagccagg	aggaatagga	tcagggacct	gctttcaaaa	gtagtcttgc	cccattttca	95700
tagaggagtt	gtgccatact	gggggtatgc	tttagccctt	gattgcctca	gacactctga	95760
agcccaaagg	ctggaatggc	taagttgttc	taacagcaaa	tatggtgggc	tgctcctctc	95820
cctgggacaa	aggtcccatg	gaagtctgaa	acctctctca	gtcagagaac	accagttggg	95880
gtagccgggg	acccagatg	ggagactcta	cccagtgatg	aggaacggga	ttggggacct	95940
gctaaaaaaa	aaaaaaaagc	agtgtggcca	catttttgtc	gggcagctgt	tctgtgctgg	96000
ggttccccct	ccacccttgc	ttaagctccc	caaagcctga	aggctggaat	gggtaagttg	96060
cccaaacagc	aaagatggca	gcctgccctt	ccctctggga	gctctgtccc	agggagtttt	96120
cagatctctg	tcagctggag	aacactggca	ggtgtggctg	gaggccccag	ttgggaggtc	96180
ccgcctgtaa	ggatgaatgg	gatcggggac	caacttaaa	cagcagctctg	gccacatttt	96240
aatagagcaa	ctgtgctgtg	ctgggggata	tctttggccc	ctggttagtt	tggactctcc	96300
aaagcccaaa	ggccataatg	gctaagttgc	ccaaacagca	gagatggggg	cctgcccctc	96360
ctcctgggag	ctttgtacca	gggaggcaca	atgttgctac	tggtggctag	ctggaattcc	96420
aagccagtgg	gtcttatcct	gtgaggcgct	gtggaagtgg	ggcctgtaga	ccttctctgc	96480
tgatctcgct	ggattcagcc	tcttttctgg	ggtatgtatg	ggagtctaac	ctcctggggg	96540
atgtttgggg	gtctaacctc	cagctttgcc	aaagtgcgag	ctacttttgc	ccagacaccc	96600
agaaagctgg	agtagctaaa	gctcttgggt	ctccatgcat	gcctgagttg	ctgctctgct	96660
gagactccac	gtggctgtgt	gtgaagggcc	taatggagtg	agttcacaa	gggatctcct	96720
gatctgaggt	ttgcaaagat	ctgtgagagc	agtgtggatt	cccagagttg	cgcattcact	96780

taccaattcc	ctgggaaggg	gagtttccct	tgactccacg	tctttcccaa	gtgggctgtc	96840
ttctgcctt	gatttgctct	ggtctccgtg	ggtcgagttg	tttcttgat	tacttccaat	96900
gagagtacct	taatgtttca	gttgaaggtg	ctatathtag	tcaccccttt	ctttccgccc	96960
tgtgagagtc	acacacatta	actgcttcta	gttggccatc	ttggccactc	ctgccctaaa	97020
cctttctagc	aaaaaaaaaa	aaaaaattaa	taacatgttg	atctaccgct	tctctctctt	97080
taaatttatt	taatcattat	gaattttttt	acattttattt	acattgttaa	gctgttttat	97140
tttaaaaatt	ctaggtccag	ctcttcctgg	attgctttta	tataagggaac	atatctcatg	97200
aaataaataa	aattcacatt	caaatgcaga	agaatctatt	ggaaaaaact	cagaggacag	97260
gataaaagca	ctcagaaaaa	atgccaggag	aaggcgttta	tcacataata	tcgctgataa	97320
gagtctctcg	aaaatttttc	tctctattca	ttcttaccac	atatagaaag	tgaacaaaac	97380
aatattagta	ttagaaaaaa	catccaaaaa	taatgacctt	tctgaatgaa	gactgctttt	97440
ttcatggtaa	ctcttttttg	ggtacagttc	tatgttgatt	tatccaattt	atcaaatagc	97500
cattcagcaa	atattttattg	agtgtctgtt	atgtcacagg	cactcttttc	ggctctcaaa	97560
atacatccgt	gacaaagagt	aaaagattcc	tgttcatggc	tcttacattc	caggagggat	97620
agcaattttc	tttgtaaaagt	taatcacaca	acagaaatgt	gaaataatat	tgatgctgtt	97680
aggaaaggaa	aaataaatga	aataaattga	aaaagaaatg	tgaagggaata	attaaaagag	97740
gctatatattt	attgaataaa	aataaaagag	gctatgtttt	attgaatatg	ctccatgttt	97800
tatactatat	cataaaacat	acaagatctg	gcttttaaga	aatcaatata	ttcatcaata	97860
tcttcattca	gactcatcta	gattagatta	ctctgaatct	aatcacatag	agacttgtct	97920
gacaaatcca	gatttttttg	acgttctgca	ggactatttg	tcaggatatt	tcacaggatt	97980
ccaagaaata	atattgggtg	ccatgctata	atgattcctc	agctcctccc	atctgataaa	98040
atattgattt	cttatacata	taaaacatat	aaaaatattt	aaaatatttt	ttgttatatg	98100
agtgaatcaa	taataaaacc	actatctcaa	taatcatcaa	ctgattgcaa	actgattgtt	98160
catctcagaa	aaaccttggtc	agagttaaaa	taaaagtttc	aaaatacaga	acttagtacc	98220
aaaattaagg	cagtgttagg	tttctaattt	tgctattcac	atgttaaagt	aattttcaaa	98280
attcagtagc	taatactagc	tagggtttta	aacaagacat	agttaaaagt	aaactttaaa	98340
aaaagaatca	taaacttcag	tatcatcatg	atggcagttt	taggatttta	atgttgacac	98400
cctagtctca	aatttgtagt	taatgtggtt	atatagctag	gcagtgtctg	agtgaaggtt	98460
tcaaaaacaa	ttaaaatcaa	aagttaagaa	aaaaatatga	aggcaatttt	aagggtgtta	98520
atttggcaat	gtagtttcaa	aatagtacct	gaaacttaac	agcaaagtat	cagattcatt	98580
tataaaaaca	tgtgactgat	ctttatgtat	ggtttgtgaa	acatttatgc	agtgctactt	98640
cagaaaactc	tgccattata	gatttgaatt	gattaaggat	atccactcct	ttccttggca	98700
tgatacaaat	aaattactaa	agtataaattg	taacaatgat	aaatataagt	gacaatacca	98760
ccatattact	atgaaacaca	gattgattat	ggtataatac	aatttagcat	ctccatattt	98820
ttgaaaatga	acttgtttct	ctaactggct	taatttggga	caatttggac	atcaaaaaga	98880
atgatgatgc	aatttaaacc	atacaaaaat	taaaaaaaaa	aatccaaggg	acggtggtga	98940
aagtcttctt	tctagaagaa	tagcagctaa	tatacacaga	acgaatctta	gaattagaaa	99000
atcactatat	tttgatcccc	ttcccccagg	ggtgacaaaa	ccattggtag	acagtgggtg	99060
agaaacagaa	tagtctcagg	atatcactcc	gtagatttat	tcattaatta	aaaagagaaa	99120
atgtgctttg	agagagagaa	agctattacc	gtctttatca	aataggagag	cctgatcatg	99180
tgtggtctga	agtttatcta	atgggattcc	tgatggaatg	tttagtctga	atctaatac	99240
atagagactt	gtctgacaaa	tccagatttt	ttggatgttt	tgaggactta	tttgccacga	99300
catttcaaag	gattccaaga	gagaatattg	gtgtccatgc	tgtgatgatt	cctcagctcc	99360
tctcatctga	tctccgtcct	ggcccccatg	actttctttg	tggtagttag	gggtgtggtat	99420
gtgccactga	ggcccacacc	tattgctgta	agtgtgtttt	gggaaacat	catctttcag	99480
gtctgtgtga	taaaagaaga	gccttgggga	aatgttctct	tccaaattta	atctttacat	99540
tattgaaaaa	tattttgatg	acctgttttc	aaatattttc	ttataacttt	ccattttcat	99600
gtgtttattc	tgacagttta	ttttatcttg	tattttataat	cactaagatg	ttagtattgt	99660
aatattaata	ttacatgatt	taaattagga	aaaatgtgtt	ttctattaca	aaatggatag	99720
tgataaattt	aagtatagaa	agtaaatattt	tctatatggg	actatttcac	tctctgtaat	99780
atcctgaatt	ctaattccca	ctgtagttag	ctataacttt	actaatcagt	tttcttacia	99840
tcgattttta	gtctattttg	ttagatctaa	agacataaag	ccaaaagtcc	ttcttgaaga	99900
gaagcacatt	tcagttacgt	ttataacttg	aaatatctgg	ttttactcaa	aactcacatg	99960
tcatactgaa	aaacagaagg	gagatgttgt	cttttcttga	ggagagactt	ctctgcagtt	100020
aaacagctca	ccacatgttt	agagtacata	gacaatacac	ttcctctttt	gtaatgtaga	100080
tttcagcttt	ttgcttgtag	aattatcatt	ggcgtggagg	ttatacaggg	gaagtagtga	100140
aaaatgtagc	caataccagg	aaccttagga	agtgtctgaa	cttcatcttt	tctgtgttcc	100200
tttgccctta	gggggtcagt	gtaagagttt	gggctaggaa	gagattgctt	cttttactct	100260
atttagtttg	tacttcctat	ctgggtattt	gacaataaat	gactcattct	ctttgtttgc	100320
cctggtgttg	aaaaattttc	ccatatgcc	gagaaaaaat	gttacagtga	cacaatgtaa	100380
aattgtaaga	ggtggaaaaa	gatgaggtat	ggacatagtg	aatggaagtt	cagcccttta	100440

aaactactgg	cagagtagat	tttactcagg	cttcaattaa	gtagacctga	atgtaaattc	100500
aggtctagct	ctgcaactta	ctaggtaagt	gacttttagtc	ctctttaaga	tttagtttcc	100560
tcattacagg	atataataat	actatttttc	ttatgaggta	agtattaatt	gaaatagtat	100620
atgtacattc	tagcatacag	tgatccccta	ataaatggaa	cttatcatta	atacattgct	100680
aggaaaagaa	aaacacatca	gggaacaaaa	gatataactg	tcttattgat	aacaggggat	100740
ggattcttgt	ggacaaaaaa	atttagaatt	gaattttcaa	ggggtcattt	ctttcaccag	100800
gtgtagttag	gtttgtctct	atggtaacaa	tgaatatgtt	tgtttagctt	cttaaaccgg	100860
catcatggaa	cgtaatttaa	taaacagaat	tcaatgtatt	tgtggggcat	tttatttttt	100920
atgcaatcat	ttgtatatgt	caccttcaca	atgcatgccca	cattctcaga	ccacctatta	100980
tgttattttc	ttaacatttt	tcttcaaatt	cactcaccct	tttaaaaact	ttactgaagt	101040
ctcacttaag	cacataattt	gtaaaatcat	gggtttgttg	tgcaagtttt	gtttttctaa	101100
tacactctaa	aacaaatacc	ttaaaagagt	tacacctaca	gtccatatac	cacccataat	101160
catctcaagt	acctccagtg	cttgttactg	cactttggaa	aacactaaca	tacattatct	101220
tcattagttt	ttataatagt	tatatgaggt	gaatagagaa	ggcataacta	taccattttt	101280
aaagatgaga	aaagcaggtt	catggataaa	atctcatagt	aaattgctag	aattggctct	101340
gatactcatg	ctttcttttag	atcaaccagg	tgctcttact	gtaattgata	ccaaattctt	101400
taaggaaaact	tagagctaaa	agtaaaaattt	tttgatttta	gacctgatta	ttttgtggta	101460
atttgaatat	aggtcaatat	gaaaaaaaat	aaaagatgaa	acaaagaaac	tgagagcaga	101520
tcaccaagtt	gcggtaggtt	agcctaagat	agcttttggg	tttctcagcc	ttctactatt	101580
cacagctttg	tgtaatcccc	tccacttgag	tatcttgctc	ataccaatag	aatatggtag	101640
tagagtagag	gtcacctctc	tgataagttt	acagaagatt	gcgacctccg	tcttgccaga	101700
gtacttcctc	tcttgctggg	tttgatgaag	caggctgccca	cagaagagag	gctcacatgg	101760
cagggacctg	agggcagcct	ctggccaaca	gcaagcagta	aacagatgcc	ctcagttcaa	101820
tatccctcaa	agaaatgaat	cttaccaaca	gccagttgtg	ttagctggga	agcaaattctt	101880
tccctaaggg	agatttcaga	tgaggccccc	agccttggtg	gacaccttga	ttgcagtcct	101940
gtgagagatt	gtgaagcaga	gctatttctca	gaattcatgg	gtgttttaag	ctatgaggtt	102000
ttttttgggg	ggagaatggg	catttgtgat	tcagctatac	ataagtctac	aaaagtcatt	102060
ccagaagtga	ttcagtgagg	gtagaatcat	gtggttgatg	gccccaggca	cttgaggattc	102120
tgatagaatt	gtgacttcta	acactggaca	ccttttcttt	ttctcttatt	ctcccatttt	102180
tctcctttcc	ccttttcttc	ccttccttcc	cttcattcct	tctacttttt	ccgtactttt	102240
aattaataga	gcagttggaa	acacaaaagc	aatgtctgta	tctacaaaat	gtcattattt	102300
atactttgta	tccacagtgt	gctgcctagg	gctgcatgcc	tgaggtgcat	ctgtagaagg	102360
tgctcaacaa	aggcttggct	gttgggtatta	ttgaatcact	gtggagttaa	ttcattgttg	102420
tccatgccat	tttgagtttt	cattttttta	tttatgggag	tgtctttatt	cttttaagaa	102480
gctttgtttg	tacactcatt	ttctctctct	ctcttttctt	ccacaggcaa	tttatagcac	102540
tgatctgtca	tcaataccac	ttgctgtctt	ggatgtgaag	atgatttttc	ctgcagggat	102600
tccctctaca	aaattaaaaa	cactgggcat	gtggaaataa	tattcatgct	ttaaattgtc	102660
ttttctcttc	actacaccag	gggtcccca	cccctaggcc	acagactgtg	gccctagtgt	102720
agtgaataga	aaagacaatt	taaagcgtga	atattatttc	ctcatgccca	gtgtttttta	102780
ttttgtactg	gtctgtggct	tgttagaaac	caggctgcac	agcagaaggt	gggcagcagg	102840
tgagcaagca	ttactgcttg	agttccgcct	cctgtcagat	cagcagtggt	attagattct	102900
cataggagca	caaaccctat	tgtgaactgc	acacgcaagg	gatctaggtt	gtgcgcctct	102960
tatgagaatc	taactaatgg	ctgatgatct	gacgtggaac	agtttcaacc	cagagcaccc	103020
cccaccacc	tgcagaagaa	ttgactttta	cgaaccaggt	ccctgggtgc	aaaaagggtg	103080
gggaccaccg	ctgcactaca	ctacctaaaa	gatttttact	ttcacagtgt	tgcttgcttc	103140
tgtttttacat	gcacaagtag	ctaaagctag	ccttctggtg	aatggagggg	cagagcagat	103200
gggtggggag	gagtacatac	ggacgaattt	gaatcacaat	ttcctcacta	tatgccagca	103260
aaatttaata	atagcaccta	aacatacaca	tgcatatgta	aatgagtcac	actataaaaa	103320
cttttaacaa	gtactggcaa	gtcagatggc	agacttaccc	tgaaacctgc	cactccaata	103380
aaaacctcat	aattaaaaac	aaggctgtct	ataaagcata	acataataata	acaattattt	103440
gcaactggta	caaggctaga	ttagaaagtt	gaaagttatc	tttctcaggt	aaaaatgctt	103500
ttcctataca	gtatgcagcc	agcagattat	catccatagt	ttgagttagt	agatgccact	103560
tgctccaaca	attaacacct	gctgatgttg	gtccaagaag	agactgaggt	gatgcagttt	103620
cacctgtttt	gtaagaataa	cgctgggtgt	tgccatctat	tgacagagt	cctactacgt	103680
gccagatgct	ttgttggcac	tgaatgtgct	atctcattcc	agtttcttta	tactcaatga	103740
aaaaccaact	acattttatat	tgcattgagg	cttaaagtgg	tttactgact	tgcttaagat	103800
tatacaagta	gtaggtggct	acagcagggt	ttgaacccaa	gtatgcttga	ttccccaac	103860
catgcttttt	aaaaaatcaa	aggtgtaact	tcgataaaaag	acatgaagtt	aatgaatata	103920
tgaaagatgg	tgaatagata	cagatacaat	gtggccttag	gccagatcat	gttgaacatg	103980
tggtgggata	gataagagaa	ggttcttctt	tggtgttacc	tggttctcaa	ttggttatta	104040
ctttatgtgc	tttccatatt	aaaattctat	tattctggtc	tataaattca	cccaccaga	104100

cttgcctaaa	ctaattaaac	cctgaagttt	ggcatgtctc	ttttttggg	tgccctctatg	104160
ataggtggta	gaaatgaaaa	tggaattaaa	agttttgtga	agctatagca	ctactttttc	104220
atttgtttcc	cccctgactt	tctgccttag	gtgtttactt	tggtgagata	tcctggggaga	104280
aattgaggtg	aaaagaagcc	cgagtttaga	ttagggaaga	gatgaagtag	tcaataaaat	104340
tcaaattctt	gtattctgaa	acgcaactat	tcttttctcca	acttggtttt	ggacagaatg	104400
tcttagtgta	gctgttaaca	aagaaattga	tgacaattaa	ctcccatttc	tcagaatttc	104460
atcattcttt	gaaagtgttt	atcatactca	atcttctaaa	aatccttaag	gcatactaca	104520
gtgtagaggt	tggcaaactt	tttctataga	ggctctgata	gtagcttggt	tcgcttttga	104580
gggccatcga	gtttctgtca	caactactca	tctctgctgt	tgtaataaa	actcacccat	104640
agacaataca	tgaatgaagg	agtatctatg	ttccaataag	acttttaaaa	ataaaattag	104700
gcagcaagac	tgatttgaca	taaggggtcat	aatttgctaa	cctgtggtat	agtgaaggga	104760
gttcaactag	agtttgatta	tggctgtgcc	attctagttg	ggtagtttta	ggaaagttaa	104820
ttaattttaga	tttgatgtag	ttttctcata	tgtaaaatgg	ggataataaa	acctgcttca	104880
caagactact	atgaggagta	agctatgtag	ctaaatatag	caaaatatct	ggcatctaatt	104940
agatgcctaa	taaatgggtga	ctataatgat	tcttatcatt	actgtattat	tttaaaccat	105000
tatctttttt	ttttaggttg	ttgtctaact	aaggtattta	gagaaaataa	gtgctgctga	105060
gggcagctgg	aactgttttg	ctggttctac	actgaaattc	tagttcttgt	tggtgcttat	105120
ttcataatta	tgaactaat	tcttttgaaa	agaacttgaa	gtagagcaac	aagaactaag	105180
atagaactaa	taccattctc	tctcagttct	tattgcttta	cttcaagttc	ttttgaaaag	105240
aattacatag	atatgggtgc	atgtgtttgt	ttattttcct	tgttgggtaa	tcgtgaatat	105300
gttgattggc	gtcaaacatg	ggtctcacct	atacccatgg	cagtaagctt	ctattgattt	105360
gaattcagac	tagccctggg	ggccctgtga	gtgggaaagt	ctaggtgtgc	ctagcttggt	105420
ctgtggttcc	acgaggggtt	ggatgcatct	gttctacttg	tggaatgttg	gcaccaatat	105480
attggctgct	tctccgagta	tttgcccttg	tcttctttgt	gaaaggtcac	tggtggtttt	105540
gagctattgg	gctgtttatg	ccacatcctg	tgcatgccac	actggctttc	tttctgtggt	105600
gtttccagag	ataagtttgc	ctgatagaag	tcagactctg	tggtttttta	tcattataga	105660
tttttctaga	aggagaagag	gccatgatca	catctgagga	tcctgagtca	ttgtagacat	105720
gtactgaatt	aaagagaatt	ttttgactaa	aggagaattg	catcaatcac	ggtgaaggag	105780
atgccacagg	acagggcctg	aggtgttggc	ttagccacag	atgtaagggc	tacagttaac	105840
agacaacttt	cagtttccac	tattggaagg	gatgatcagt	ccttccctcc	tctattttct	105900
tgagccccgt	ttttcacctt	tctttttctc	tctcctttct	tatcatgaag	aataaaagaca	105960
aatgagaaca	gatctacctt	aggctgatac	agggcaggga	atccatttaa	taataaaacg	106020
tgggtcaaaa	ttcacatttc	tccttttgaa	ttgaaattat	attgtgcatg	ggctaattag	106080
attgaaatgct	gtaaacatga	agataatgct	tgcaaagtag	ctacagagaa	agagaaaaag	106140
cctaaaacaa	ccagtagtgc	ttaggaccaa	tagtataagt	ctttacacac	tacatttgaa	106200
taatactgta	agacacaatt	ctttgatagg	ttaaatagca	aatctaggcc	ccccaaaatt	106260
atttaaaaaa	ttgtcatttt	aattctagag	gtataacaac	agtgtgtaag	ttgcatcaaa	106320
taacaaagtt	agtctacagc	ctaaattggt	tcgtcctgct	tttttcaact	ctatgcata	106380
ttttatactt	ccatgctaga	gctacctcat	tcttttaaaa	ttgtgagata	ttctataatt	106440
tatttgtatt	cccctattaa	tatattttta	gcttattagt	ttacttaaaa	agatttatgt	106500
ttgccttcta	atgtcaaagt	taggagtcac	ctgtccattt	aacagggtgt	gttttcttgt	106560
gtaactcctc	tgcccttcac	caaacccttg	agaacaatct	cctgaaacaa	ggctaaaatg	106620
cctttggaga	ggtattatag	atgatcatat	ctactttgtg	cctctttcca	ttacttagct	106680
gcattagagg	cccagctgtg	taggtgtaac	tcaaaatcca	ccaaaactaa	tactgtggtt	106740
agattctggt	caaacaagtt	gccattaatc	cagatgtaga	atgggattga	aagggtggctc	106800
ttccacaccc	tgacataaat	gtaccagttt	ggctctgtgc	attctttctc	cccttctccc	106860
tttaccaccc	tcatataaatt	gtttgtgtac	atgtctggtt	tcgtcactac	gctgatggca	106920
aggatcatgc	atgccttatt	catatttgtg	ttattcaagg	attctactct	gggttctatt	106980
atggggcctg	gcctaaagtg	gttgttcaag	aaatgtgtgt	tagagaaatc	atacataaac	107040
tagcaattct	ccatttgatt	cctgtatctg	aacaactaac	tttcagcttc	ttcagtgagg	107100
taaagaagaa	aaatggggtt	taaagtacat	actattcagt	attaatgtag	aatttaacag	107160
ctgccatcca	agtgcagaat	cctctgtagt	ttcccagtg	taacctcact	tctatctcta	107220
gccatgtctc	agtgtgtggg	gactctctcc	tggcatgttc	tggcaagact	ctacctgggt	107280
tgcgtaatct	acatcggtct	ctagtttcca	caagaattgt	ttatatgcat	ttaattttag	107340
ctcttgggct	ataacatgtc	attgttcttt	ttacttatct	cctcttactt	ctggaaacag	107400
ggcaggcatc	ttcaataact	gctgttccct	tttgggtgtg	tcttagatta	attttaactt	107460
tcctcttcag	ctttcatgac	acttcaagac	attttccagt	catatttcct	gtataagaaa	107520
atacagacta	tgtcaccaca	aagggtagtg	gagattgggg	ggcataatct	aattcattca	107580
gggaactcat	attttgggtg	gaatggaaat	taaagcaagg	tatttggatt	aatttacctc	107640
atttggttct	atattccatt	tagaggataa	cacattaagc	ttttattcaa	ttttatctgt	107700
tatggtcaca	gtgaatctgg	aaaaaaatat	atatggggct	tagttttcat	atttagggga	107760

aaatgaatat	cctagagaat	aataataaaa	gttagggaaa	ataatgtttt	cctaagagta	107820
ggcaatgaaa	atctgaaggt	actcaaagca	gtcttgacac	agtgccttga	aaagcctctt	107880
gcacaatttt	atttctttat	agtacttaca	caatcatatt	tcataatgac	ttgctataaa	107940
caatgttctt	gacaagaagc	ttaaagatac	aaaactgaag	gaagcacttt	tgggagaaaa	108000
tactttttata	tttgcttact	tctacactac	aacagacata	aaattatgga	tttttttttc	108060
agtgcatttt	tcatatgtca	gttctaggag	acaggaaatg	tgaaacactg	taggaggtat	108120
gagtttgcca	cctagaggag	agaggtgaaa	ttcaactttt	ctccaatttc	tttagtataa	108180
ttcattaatt	tattttaatta	tttactcggt	taattattca	aaaataatta	tctaccaagc	108240
ttaactattt	tgccagcgca	gatttgataa	atctgttcaa	gatttatgag	ctcaaagaaa	108300
ccacaaagtg	catcttactt	taattgctca	gctgcctctt	ttaaaaatct	tttactttta	108360
agagagtata	gcacaaatat	ctgaacaact	ctaaatatcc	atacttgga	tggatattac	108420
tttgagctct	tgactataaa	taaaacttta	ttcttttgta	ctaattcagt	ccttttactt	108480
tttctttttt	aatgtttaag	aaacaagttg	gatatggaca	agatgtaatt	tcttctgtca	108540
aggaaccac	aggataatag	gttaatgata	gagaccaaca	atgctgatgc	atttttaagt	108600
acggagataa	tgtctagaaa	aaaatccatt	atttggtaaa	gacaaagtat	gcatagtat	108660
tcctttgttt	caattatttt	taaagttaaa	aaacaactgc	ttatctcctt	ttgtactaca	108720
agcaatatct	ggtatagtgt	atgcatagta	agtattctag	aaatagtaat	ttcattgttg	108780
acttgattat	attggagtgg	aacttactct	ggaagagatc	ctaactttca	tttatctgag	108840
aaaattttcca	gttaggacat	ggaaattttt	tccttgtaaa	tatttattct	taatgtgttt	108900
agaatttttag	aaaatgggtt	tagggattta	gaaattttct	tactaaataa	ctctagggaa	108960
cagtacctta	aaaatattca	aaatgacaaa	aacttaaaat	gacatctaata	tttttaaggc	109020
caagaatcat	taaaaaggga	tccaaatctt	tagactttgt	tgctcgggtg	aactagaatc	109080
attaatatct	cagtcagggg	aagccatgtc	aacttactgg	tttaatttcc	tgtgagcttc	109140
ccatgttctc	tccctgcaag	gaccacctca	aatccctcag	tagtcctgtc	tttatgaaac	109200
cagtataatt	tttcttttctg	ctcttgctct	tcaccttcct	gtggcaacaa	gagtcaattc	109260
tccatatata	aatactcggc	ccctgtttta	gctgtgtctt	aattgcgcaa	catctgttta	109320
ctctgtgttt	taacatctgt	gtggatagca	ttgttgttgt	aatattttga	ctgtaagctt	109380
ctaggaggta	gaggccagca	ttattttctc	cattttttgga	atgagaaaat	acagattacc	109440
acaatcaaag	tagaatggca	gcttatagta	gttattttgga	taattttatat	agtctcttaa	109500
aaaaacagat	tatagtaaga	agtggctgag	caattagcta	tggcacactg	cacggttttt	109560
ctgacctctc	agctcctaaa	taaactttgc	caaatcttca	ggccctcaaa	attttttcat	109620
tccatttggt	atgggtcgaa	ttgtgttccc	ccgaaatgac	tatgctgaag	tcctaactcc	109680
tagtgcttca	gaatgtgacc	ttattttgaa	acagggatcat	tgcaaatata	attagtttaag	109740
atgcatctt	actgacatag	gagaagctcc	taatcatggt	gtccttataa	aaaggagaat	109800
tttggccata	gagacatgca	ctgggagaat	gctctctgaa	gactggagtt	atgctgctaa	109860
aagtcacaaa	attaacagaa	gctacggaag	agaccttgaa	taaattcttc	cctgtagcct	109920
tgagggagag	gatggcccag	ccaactgcta	atctcagacg	tctagcttcc	agagctgtga	109980
gacaattttct	cttttttaggc	cactcagttt	gtggcacttt	gtacagcagt	cctagccgac	110040
taacacacca	ctctaactgt	tgatcaaggc	aagagcctgt	gatcatgtat	tatcttgctt	110100
attccttatc	agcattctat	ggtgtagata	ttagtgccat	ctatatacaa	attaggaaat	110160
ggagcctcat	agaaattaaa	tgacaagttc	aaggtgtcat	ggctatttca	ttatagtgcc	110220
agtgtttgaa	cacaaatcaa	tttgactcca	aaacatcatt	actctactca	attctagttc	110280
aatccagatg	ttcacaaaca	accagactat	agtggagatg	tgggtgggtg	gttgagaagg	110340
agatcataac	caacatcaga	ctgtcagtga	agcagactgg	gagaagtttt	atgaagccaa	110400
gcagctgtgc	aaggtacagt	agagatggtc	agattgttca	tgtgtatgga	ttccatcttc	110460
tgaggaatga	actccttgat	attcctgagt	tagtccagtt	taggcaggag	taaacagaag	110520
gtaaacagaa	gattggagac	tgtgtgtgtg	cacgaatgcc	tcctttgtag	ctggatgtct	110580
aacatcatga	tagccacact	cacatgaata	cagagataca	caattttacaa	attaatgtaa	110640
cataaaactc	ccatgcagtc	tgatttcatc	ttactgacat	ttctgtcagt	cagtgttagc	110700
atcttaatta	tataaatgtg	gaaactgaaa	tactcaagag	gttccctgac	ttcccaggcc	110760
acacagtaag	ctttggtgcc	agaatgtatc	tctaggtttt	ctcatctcaa	cccagcattc	110820
attatactat	tgctcactgc	gtgtagaatc	agatttgatt	tctctgactt	ttcttagtca	110880
cttctgtggt	tttgtaccac	tccctctctc	actaaataac	tgcttgcaaa	agtaaaaaatt	110940
tccatgaaaa	cagaaaacaa	atgtaccaga	aatgttgatg	gtgtaagaga	taaaactggg	111000
ataaagagaa	aatgtgttgg	aaagtgggtg	cctttaatgc	aacagaaaag	tatattggga	111060
gaaaaagaaa	agagagaaaa	atagacaatc	tgaagtgtatg	agaagagcaa	atgctacaga	111120
tgtacctgaa	cctcttcagt	aggtgtgatc	ctgaagagtt	gtgtataaca	acaatgaaca	111180
aaaataaaat	gtactgtgga	aattgtctag	ctgttgagat	cctcctgtgc	gatatttttc	111240
aaagtgaaaa	ctccaatcaa	ccctagctta	tttatggaga	agactttgcc	ccacagtacc	111300
cagaaaagttt	cttgacaata	tcatatatgc	ataataaccc	tgagacaatt	tttgtttacc	111360
aggaaaacat	ataaaaggga	acattaaact	ttgtctagtt	ctactgcata	aacatgtgat	111420

aatgtgcatg	gtgaccttct	gttgtaaagt	gaaagagtta	agctctctga	atctactgct	111480
gaaaggtgaa	aacactttct	tagggctttg	aacttcattt	gaaatcttac	tgaaaaaaca	111540
ctacagactc	tattttcttt	atatttgaag	atactttaca	taaaaatcta	aagcattttg	111600
acttatgttt	tcatctactt	gagaaggaaa	ctcacagact	ccaaagcaac	tgttgtctgt	111660
tttgaaaaaa	atttcagaaa	tcaccagaag	caatagggag	tggccttgat	tcctgttctt	111720
gtatttatgg	gtagctaaag	ttcatatttc	tcaacatacc	ataatctctg	tgtaattggc	111780
caaattccat	ggtggataat	tagatctagc	ttaccagggc	agatttggtg	ggtgagagca	111840
gtcacactgt	tctgggaata	tgtagccaa	gtttactatg	ttttacatga	ggtgacagac	111900
tcacctcact	tgctgaagga	ctagcccagc	aggttctacg	ggtgagatca	ctgctagctc	111960
attcactgct	gggcctggta	ggcacaagag	gccaaagaaat	aaataatgtg	aatttgggct	112020
tcagaagttc	tctttcctat	tttctttcct	aaaccctttc	ttctaccagc	tgtctagggg	112080
ctaaaaacatt	tgttcatacg	tttattaact	aattcaacaa	atattttacca	accatgtttc	112140
aggcactgga	cactagaaat	ataatagtga	actagacatt	ttctgccttc	aagggtctat	112200
gaacaatttat	aatattctga	aaaatattac	aattcacaga	gctcagtaat	ccaaatcctt	112260
attatttctg	tctttaaaaa	gcagaaagtg	aaaaatgctc	ttaaaagagg	atggcataga	112320
aatgtatttta	tgcatgtcaa	cagataaaat	taaggaatgc	atgaagactg	gttcatctgt	112380
gtggttgtga	gtcaagaata	aatcccaccc	tccctgaagt	actcagactc	taccttgccc	112440
catggccacc	actgtggccc	aatggaagca	ccagtccagg	gggtctccat	tcatgctgtc	112500
tttggtatgtc	ttcagaatgt	tgtttcacaa	gtactcagac	ccaacagtaa	gatttttaaaa	112560
attgtccata	atattaacct	tggcattatt	atgttaaaga	aagcaaaaca	gatatactctg	112620
agtttacttc	tcaaaaaaac	cttgcgttcc	tgcaaaaagtt	tcttgaattc	tgactcttgt	112680
cacacaatca	cacaagaatg	gctatactta	aacccttcta	atcaattata	tccttaatat	112740
gtatgactga	gtgatgtgtt	ttcatgacta	tgaaatgtat	acatgttttg	aaaatctatt	112800
cacaatagag	ttttatgata	ttcctgttaa	caggctgtca	ttgtaacact	gtttatgcag	112860
gaattgtaat	tctatctgtt	tttattttta	gcgtcttttc	tctccatccc	ccaaatttta	112920
aggagctatc	aggctctgtat	tttatttggg	tttgaagttt	taggttattt	gtagttataa	112980
tagccatata	aattattcat	ttagcaaaca	tgtattgagt	gctactatgt	gcttagattt	113040
ttccaatggt	gtgaaggata	attggctaaa	acttttccac	ttttattagt	aatttgagag	113100
ttttttcttc	catggatttt	agtcactggt	aaaggctggt	tcatattcat	agattttttt	113160
ctacggtaag	aaacatatga	tgttgaataa	ggatgaattt	acaaattaag	gcttttccac	113220
attcgctgcc	tttataagat	ttttttttct	tcatcaaaat	ctattcacac	acacacagac	113280
acacatgcgc	tgttttgatt	ttcttcaaat	atatccagtg	ttcagttctt	gggcacatat	113340
taatatactt	gcctagatga	agactatgtg	tcctcaggaa	tttataatct	agcagggtgaa	113400
agatttgctt	ctttcaaaat	gtgactctac	ttccccactc	cttaggttgt	gaaagcagtt	113460
gtttacgctt	tatttcattg	ttttccaaac	tttagttatt	tatgtgccat	cttcatgatt	113520
atgctattca	cataccacct	atactattat	gcttctgaaa	atatactatg	attttcaact	113580
taattaaatt	tgtttagtaa	taacagtagc	tgttacatca	ctaggttgat	gtgctagtta	113640
aaaattttta	aatatacttt	aatataaata	tgttactact	aaattatttt	tttgtctgta	113700
tgcacccaaa	atcttgctt	tagtagtact	acacatatca	tgctttggga	aactctaccc	113760
atgagattca	tattcaagca	tgaggaatgg	caaaagaaaa	tacagaaata	gtgatagtaa	113820
ccatagcaat	ggttaataaga	gctattattt	attgaggact	ttacgtatgt	catttaattt	113880
tattttatcc	tcacaacaaa	ttttagccat	gagtatcaga	taaatatgag	gcaaaagggc	113940
aggaaagaag	gaacagtgga	agtcaagctt	tttttcgcct	aggtcagcta	taactaacac	114000
gacaagatgt	tttagtattt	gtactttatt	tttagtcagc	tcagatttca	cacctgacta	114060
ttttacaaaa	atltggatgt	gatgggtggca	gattaacata	attactttta	gcaattatta	114120
tgggacaaat	tagttaaagg	ttgtaaaatg	cctagaaaca	gagtagaata	tccttagtagg	114180
atatacctaga	atatacctata	attaagttat	caaacaatta	ctctgattat	ttttcacagt	114240
agttcaatca	aagtgtaaact	ttgggtctgt	tagtatacat	gagtgtgaat	actctggaga	114300
tttgatcttt	ggctttcctg	tgtaagttca	tatatatttt	tgttattatc	ctgtaaataa	114360
ctgaattata	gtacagtgat	tctgtaaaaa	acactttagt	tattaatatt	ctttggtgtg	114420
aagttcacat	taaaaattgt	tatatttcca	gaacctgggt	tttacctgtg	aaagtcaatg	114480
catccttctt	ttaatcctct	gcattgggtt	tgcatagctt	gatgaaatat	gacttgcttc	114540
tcctccctcc	ccctccttcc	tgtgcctgta	tccccatcat	ttttttttct	attcctcttg	114600
gtatctggac	ttctttttct	gccaaatgag	tcagtaagag	aggaaatggt	taaccacat	114660
ttgtcatctt	ggctgggaaa	gaagtgtgaa	ggcaaaaggt	gcctgaatat	gtttcactag	114720
gatgctgaca	caaccttttt	gactctctcc	taagaatact	actctatatt	caagttataa	114780
agtgtcaaat	gatctatttc	caccatgtat	acatttcata	tgatcaatac	ttattttgta	114840
acttttttct	ttgaggagaa	gtatttttct	tttgaaaaaa	tattatttat	ttgtgtgtgt	114900
gtgtgtgtgt	gtgtgtgtgt	gtgtatttat	tttcttttaa	tatgtggtct	ccctatgcaa	114960
aggatttgat	tttataaaca	gaagcaatag	gattaagagg	ataaaggaaa	aataggagaa	115020
ggggaaatat	gagtatcatg	ataaggtaaa	aatgaattgc	ttgtattcta	acatagaata	115080

gctactacct	gttgagtgtt	tattatatat	tagacattta	agactaatca	aaatatctaa	115140
tctaatagaa	taatcactgt	tttgaatttg	cttagattta	gtagatgtag	aaactgagac	115200
ttagagaggt	ttattttactc	aactccacac	tgctaattac	tggtgaaagt	agaatttttac	115260
tcctctgggt	ttctcatcca	gcacatcatc	actataaccc	ttatagtttg	cttttggcac	115320
aagtattcat	tattaatgga	aatgcatagt	attatctcag	caaagtaca	aatagtttag	115380
cttcactaaa	ctagtcaatt	ttttttttct	aaacatcaat	gcttaggaag	caaaacaggc	115440
tgggggaaca	gtagttgtac	tggtggcagc	tgtggtgctg	atggaggaag	tggtggaatg	115500
cataggctgc	tcatgctttt	tgccacaatg	aagggtcaaaa	agtagatcac	ttaaagtcta	115560
aagttaacct	tgggggtcat	attcttcacc	aaaaactatg	tttatacata	tagacttagc	115620
agtatgctat	aaaagtgaag	atatagcact	ataaaattcc	accataaagt	aaattgttca	115680
agattgtggt	ccaagctctt	caaaatgctc	ataaatcaga	aggtgtatit	attaaacaat	115740
attttatatg	tacctataat	aatacaatac	tatactacac	aaattggacc	taaaatgaat	115800
tctcttgcta	tattaaatat	taaacattaa	ataggcagaa	attttgtttg	cactggactt	115860
agaatataag	aagaaaattt	gggacaacct	gaatagtga	ggtctcttga	gaaacccttc	115920
agcttctttt	cctccaaata	aatttctctg	tagcaaatgg	aagccatcca	aatgattccc	115980
tagctacctc	aaagtactgt	aatttgtcta	cttcacaaag	tggaggacta	tatctagcaa	116040
taattcaaga	aaaatgcagt	gactcccatt	atatcttagg	cactatgcta	ggaagtttat	116100
gcatatcatt	ttgtttgatt	ttaatagcaa	cttcatgaaa	taaatcatca	taataaatca	116160
ctatttcaga	tattgagaaa	ccacagaaag	agagaagtta	aataattttc	ctgtcaaaga	116220
ccacatcaat	gatgaagcca	gaatttgagc	tcatgtactt	aaccactgga	ctacctgcct	116280
gccctgtcga	ggaacagcta	aggttgtcat	agagtcttga	ctgtgtatag	atagttgttt	116340
gaagagagaa	aaaaggcagg	aggatctggg	gcatatgttt	aaatcaggca	ttggcatctg	116400
tactagaatt	gaaaggtgga	actattattg	tgttctatit	attgagtata	ggtataccat	116460
attcaatgta	tttctctgct	tcatacacta	tccaaggtga	taaaagtgtt	tatgaagagg	116520
gattagggaaa	tatctgctgt	gttttaggtca	tagtccaacc	aaaggattaa	ttaacattttg	116580
cctctttttt	ctcctacatc	cagtgtccct	tttgatgaga	agaataagcc	tcattctgat	116640
tcaacagcag	agatcaaaga	aaagacttct	gttttctggc	caccagatat	atgttatctg	116700
tgcttaaaga	attgaaaaac	acacatcaaa	ggagaatttt	cttggaaga	gaggtaatga	116760
gatacagtga	aagagaatgg	agattcttta	aatcacagag	acctaggatc	aaatcctgtg	116820
attagcactt	tttagtaatg	tagcctactt	cattttcttg	agccctcggt	tatttttctg	116880
aaaaagagg	tgtactaaat	tacgtctgga	gtagtaataa	agattaaatc	catgtgatac	116940
aggtaaaactc	atgacaataa	tagacatgaa	acaaatagtc	tttcatctcc	ctcctttgct	117000
caagcattgc	tctgctcttc	tcacctcctt	tcccttccct	tttcttttct	cctctttatt	117060
ttgtctgtac	ccaatagctt	ttcccaagcc	ttaaaactat	gtataggtat	attgttgcag	117120
caaaatgcat	aaaggagaca	ctcattatit	gcatccattt	atatgctgat	ataaatatit	117180
catcctcaca	agtttcagag	ggaaagacca	catgctggtg	atitgggtgag	aaagaagcaa	117240
ctatttctgt	gatttaattt	caacctgagc	attaaagagg	caccctttca	ctactagtgg	117300
taactccatg	cttccaagaa	ctaagagct	gaagaactta	gcacttgtga	tgaattagtc	117360
aagcaaaaat	tatgaagcga	gtaatctata	acattatagt	acattacaaa	tgctgaaata	117420
tattagttat	tatttattat	gattcttata	gctcatttat	actgtacaaa	attcttctgt	117480
catttttatga	agatgttaca	catatacata	acaaaactta	gctaattaga	tacaaagact	117540
atagaaccaa	ataactcttt	tctaaatatt	ttccctttta	ggaggttttg	caatccagct	117600
ttgctgtggt	tagacactgt	tgatgagaaa	actttttttt	tctttctttt	tttttttttag	117660
acaggggaatc	attctgttgc	ccaggctgta	atgcagtggc	acaatcatgg	ttcattgcag	117720
cctcaacctc	ttgggctata	gtcgtcctcc	tgctcagtc	ttctgagtag	ctgggactat	117780
ttgatgtgca	ctcccatagt	cggctaattt	ttgtattttt	ttttttttgt	agagatgggt	117840
tttcaacatg	ttgcctaggc	tggtctcgag	ctcctaggct	caaggatatcc	acctgcctca	117900
gcctctcaaa	gtgctgggat	tacaggcgtg	agtcagtcg	cctgacctgg	atgagaaaat	117960
attgagttgg	aaacccaaaa	tatgacataa	ataattggta	tatttttagag	ctggatttca	118020
acaacttttc	aacactgtca	tcctgtaaat	gtctttccgt	cctaattcca	ttgcccatgc	118080
actcagcaga	agtgtgtgcc	tctaagggtg	atgctggtat	gaaatatctc	agctggggca	118140
ggctctgaaa	gggagagatc	tggttaaagt	gctcatacca	aacaaagctc	ctcatgatgc	118200
tggcctaact	ctcccaatcc	tgcatttctc	aacaaaactt	tttgctcttc	tctttcacat	118260
aactcccgtg	gaataatttc	cattgaattg	catggaagag	gctgttcatg	gggttagtct	118320
ggcagataag	aggtctccac	tggatttttt	cattttgcaa	tcagtttcat	acatatagct	118380
acatactttt	cttgaggtca	tagttcattc	tcaggctctt	tagagttaaa	tatctttcat	118440
ttcttctttt	aagggtctta	tttcttgttt	ttcgagtttc	atgggagata	tccagtcacc	118500
aatccaatcc	atatcgggga	aaagtacaac	aatgagtgga	aattttgtaac	caaccttgga	118560
tgatggaata	agacattttg	gagaacacag	gagaagtggg	gaggttaagg	agggatagct	118620
ctgtgaaaat	tttgcattac	tcttgcttga	ggtctactct	tccttgtcat	gttggtggct	118680
gttttgacaa	tgagaaatat	ttaatggcaa	acttagtctt	ctaatttgaa	aatggaaatc	118740

ataacagttc	ttgcctctta	gggatagtg	gagacaagt	aaataatcca	tgtaagaggt	118800
atagtactat	gcttgccatt	ctttaagagc	tcaacaaata	ttcacttttt	acctattagt	118860
atcaatctta	attctaaaat	tctattat	aataat	agtggtgtt	ctaaataata	118920
tctaagtact	aggctaatac	actatgtggt	tcttctaggg	ttcaagcatc	actgttaggt	118980
gtgctggaat	cctttcccga	gtcagtactg	ctttctagaa	gaaaaccggg	gagatctatt	119040
tggaatgtat	ctaactccaa	agaaaccatc	agaggtaaca	ggtaggagat	atgaaacgac	119100
cttttagata	tgaaccctaa	ttgaataaaa	gttgccaaac	aactgttccc	aaacatctaa	119160
agaagagttt	tagtctaagt	ggaatggctg	gagagtattg	gaagagttct	ttcctactct	119220
gtccaaacac	aagcctctgt	gacatttata	aaagaaatgc	agccctttaa	atctgggtat	119280
aagtccgaaa	ggtgctttcc	ttgtgaagct	tcttttgtcc	tctgctttta	ggactctctg	119340
cacactgcat	cctctatgtc	accctccagt	acatctgtct	ttacacaagg	ggccccacag	119400
ggactggccc	acacaccagc	cagggcacat	gggccaactt	ttaacagcaa	aaggaaatgc	119460
taaatcctag	agttagggcag	atgagaaaaa	tggcattctt	cagagagctg	ggatgactca	119520
cattaagatc	aaggggccctg	aagtaagaca	gacctgagtc	tgaatctcaa	ttccaacaat	119580
aaatttgttt	atacacttaa	ggcatcatgt	atagtattgt	taaatagata	ctttacaaga	119640
ttgtaactaa	gaggaagcaa	aataatatct	gtaaagcgtt	tcatagattg	gccagcatat	119700
agtaaacatt	taataattag	tagctattat	tatttttctt	taaatatttt	ttttctggct	119760
tcctagcaat	cataaaaattt	agtcttgtat	agactccatg	gctaggactt	gcagaattaa	119820
aaatggctctg	aacaatttag	acattgcctt	tttgtcctca	aaccaagggg	tgaattttta	119880
ttctaaaata	tccagattgt	ccatatcact	taaccagttg	attgctaagt	ctgtatttct	119940
cttttatgca	attgggaaac	attaaaaagt	tgaatgtata	tactgtacac	atacatgcac	120000
acacatagac	ttaagtacat	aaatgtgtat	gtaccttcca	tagcacttag	ctcatctgtt	120060
ctttcctatg	accttttcta	taatcctgtg	aagtaggttt	tatattatcc	tattttatga	120120
ttaaaggaga	agggagagaca	gaaaagcagc	ctggcttggc	cagaggcctt	gcaattgatt	120180
acgtatagag	ccaggagagtc	ctgacccctt	ttcagttttt	cttcctctgt	actgctgtga	120240
tgactgtgga	agtgaagtac	ttctttggct	gccaaggaag	tcccagctga	aaggtaacca	120300
aaggaaagga	gtatttggga	gcagcatggc	tgaaatccag	ttaacagtta	aaatcccgtt	120360
gggcaatttc	tcgttaattg	acaacaggaa	ttgctgtcac	tgtcctgtct	agccactttc	120420
aaacgggtggg	gatgttagca	agagctccca	gtgaatgctt	cctaggagag	cagtgtatgc	120480
ttttggctagc	ttcttctgta	gcagttttct	ggcgggtgaa	agtctgtact	aagacaattg	120540
gaggtggtaa	tacttttcta	ataaccacct	caggcttttg	gcacctaat	cgctggcact	120600
gtctagggaa	gctccttatg	ctaactcatg	cttcttgcca	tgtcaatctg	cttatcta	120660
tttgcctggga	aatctgatata	cacccttcaa	atagttcacc	tcagtgggat	ccagtgtgtg	120720
acctgcaaa	tgctcaagga	agagtctgat	cagctctgac	aagcaaacag	cagaaagaag	120780
ttttgaaaaa	acggctaccg	tttttgcagc	tttttctactg	tggttccatg	gtgtttgaaa	120840
tcagaatgta	atattgagtt	aatgacacaa	ggaaacactt	ggatgttcat	attgtctact	120900
tggttttcat	gaacctcaca	tggactggct	tcactcctgtt	tcagagtcca	ttcaactgta	120960
atttccactc	tacttcctgt	gcaggccttc	ctctgggttg	tgggctgtac	atttcagcct	121020
gctcctttaa	ggggcccccct	gagctgaaaa	tgaaagagac	attttgttgc	ttctgtacc	121080
tgcttatcgt	ccaatcccaa	tctcagattt	tctttttcta	ttttttaaac	ccgagtagca	121140
cttttccaa	tagtgtgtag	tttttcttct	aattctctgc	tcttcacagt	aattaaacaa	121200
gagctagcct	ccttttccaa	atcttgtttt	tgtaatacct	ttattcccaa	agagttatgc	121260
ttataagagt	aacataaatg	tgttaaactt	ggtattgatt	tgatgatttc	ataaacccca	121320
gactccttga	aattctgcag	gtttttgtga	aaggacttgc	ttaaaatctt	tgctaactcta	121380
cctgaatttt	cttccaaagg	cagttatata	caatgtttct	taaaactaat	tgtccaaatt	121440
tgcaatttgg	cagcatccta	ctgggactct	agaaggctga	taaatcatgg	acgtagagga	121500
ttcatatagg	aactatgaaa	gctgtatgta	gtaaacacta	cttaagaagg	ccttacattt	121560
cataaaaaagt	tggagatttt	tgtggagact	cataaaatgc	atcctttata	tcagtgaagt	121620
ttttgcttct	aggtatatta	tactcacatc	gaaacactcc	agggattttg	ttttcagcct	121680
gcataatacca	cgtatatatta	ttatctggat	agataaatta	gacgtatata	tttaaaggag	121740
tttgcactcag	ctgctgctag	gaagttttct	ttgtgttagt	taagatcctg	tgaacaacc	121800
cttgacattt	cactagctgc	acagtttgta	ataaaatcca	tttttagcctg	aggttaaatc	121860
atgactgtgg	tcctcacatc	atgggtgggg	atcctgggtg	ccagattaaa	ggaaactcca	121920
cattctcatt	tctgacttcc	ctacaacctt	gtattaagac	cttaattgaa	aaacttattg	121980
cctctctcac	caaaatattt	caaattttta	tagtttcccc	caatgaaatt	acaagtacta	122040
ttttactttt	ttcagtgccc	ttggaatttc	gaggctggat	ggggggcttc	aatgtctgac	122100
tcattaagtg	ttctatatac	aaagccctac	atggctcccta	gagcatagca	ggcattcagt	122160
gaatgaaatg	aatgaatgaa	aagctagagt	cacatttttag	tgacctaaact	gtatattttc	122220
agagtaatgt	agtgtctaaa	aaaggacaat	gataacacgt	ttctacaaag	agatgcatga	122280
cagataacac	ttctcaagaa	gaaggaattt	agcttctgtc	atttgatcta	ggttttcaat	122340
tacagaagca	ttgagaattt	cctgtggctg	gataagggcg	aatctttaag	gcaagttgaa	122400

gacccaggct	gccccatgtgg	acatcaatac	tcccacagag	cactcttcat	gaagaaaagt	122460
gtgggcttgc	tgtcttttca	tcaaaactcg	tagaatttgg	ctgactgcct	ggtttatccc	122520
aggacattag	tcagcccaca	aatcccgcat	ttgtttattc	agtccagagc	aagtgaatac	122580
tgccattttc	tcatctcctt	tggtggcaac	actttgttaa	cctgaattgg	gttctcaaca	122640
taaaatgaag	tgactaatct	tttggggggg	tccccctccc	aggttcttgt	atgagcaact	122700
aaatctacac	accacaaagc	cccatgctgt	catttttttct	catcctgccc	ctttattttg	122760
atgattccac	attgtagttc	atgaaaccaa	taccttctag	agtgtggctg	aactggcgcc	122820
agcattaaga	aaaggagttt	ccaaactttt	tagttttgtg	agaaaatggt	agaggaagag	122880
ggaggttagg	ttgactattd	atacttatgt	aatcttctgt	gaatttgcag	tagttatcac	122940
cttgactact	caaaagttdt	ctagctctga	gtatgtgaat	ctgaaagtgc	aggaagtagg	123000
aatcttagca	caaaacaacc	agtttggatt	atcacacaat	taatatggga	cggagctgga	123060
ggatggacct	gaacagaatg	tatattcttt	atcactaggt	tatttatcta	tctacagatg	123120
tctagaaaaga	cctgggcttt	tttagcaaat	gtttgagaat	ctaggtttct	aagtttccat	123180
tgaccatgaa	agagtgatta	gttttagaag	acagttgggg	gcaacattgt	gcaagtcaga	123240
agaggggatg	aagaaaaatc	taaagctaaa	catgtttgcc	ataggcccag	gctgtttttc	123300
agcatgtttc	accttagcag	ttggcagata	attcccagtg	atcattaggt	ctgtggaaat	123360
tctgttttgt	ttataaaagt	ttggccctga	ctatgtgtac	cactgataac	ttgtttttct	123420
ctctcttccc	ttttcttcca	actcgtagcc	agagctacct	tccagatgac	ttctttctac	123480
cactttcttt	cttcccagtg	taagagaatg	caagtatatg	ctgatgtttg	gagcaagaac	123540
attcaaaaat	tttcttatta	acataacttc	taatggaaat	acagtatact	actatggtgc	123600
atacaaagaa	gaaatagcaa	catatatgtg	ttttagacct	gattgctgta	ttttattcct	123660
taggtcctcc	ttgatgtctt	gtagaccgtc	actagctaata	tgttacagcc	atcgaaggaa	123720
aaaataagga	tttttactta	ggacatacgt	aacagaaaaa	gagatgggtt	agcaaaaaag	123780
cacaggcttt	gcaataagca	gccttaaaat	aaaaaaaaaa	aagttaactc	ataactaact	123840
gtgtgacctg	ggataagtta	ctgaccctct	ttagggctta	gggtcctaata	ctgcaaaacg	123900
gaaattataa	taataacctt	agctagcatt	tcttgtgcac	atactataag	ctggtgataa	123960
acaatttata	cacactatct	catttaatcc	tcacaacaat	cctgtgagat	aggtagctatt	124020
atcattttcta	ttttacagat	gaagaatcca	gacataagaa	gtgaagttaa	gtaactttct	124080
caaggtcgca	cagctaccat	atgatggagc	tggaatgtga	atctctgcag	tttgacgcca	124140
gagtgcctgc	tcttagtcac	tacatttgc	tacaaatcta	aaacacgtaa	gacacatagg	124200
aggtgctcag	ttagtggat	ctattattaa	atcagactat	aaataatcac	caggcaatac	124260
ttgaaaggcc	acaaacaatt	tcttaggatt	tgtgacaata	ctaataatta	taactgatta	124320
tgagcatacc	ttgtgtcagg	cacttctttt	catagtattt	cagtcattat	ttaagagatt	124380
tattcttatt	tttatttttc	tagtgagaaa	actgaggctc	aaaaaagccg	acaaatttgt	124440
ttaggattac	aaaaatatca	aatgatagga	ttgaaaatca	aatccatata	ctttctatgt	124500
gaaaacctgt	gttcttttcag	ctttttttat	ttttattttt	ttatttttta	tttatttttt	124560
taaattttta	tttattttat	ttttttat	tataagcctt	tttattttta	tttattttac	124620
tttatttgtt	gttgctgggt	ttttttctt	gagacagagt	ctcactctgt	ctcagctcac	124680
tgtaacttct	gcctcccggg	ttcaagcaat	tctcctgcct	ctgcctccca	aggagctggg	124740
attacaggca	cctgccacca	tgctgggtc	acttttgtat	ttttagtaga	gatgggggtt	124800
caccatgttg	gccaggctgg	tctcgaaact	ctgacctcaa	gtgatctgcc	tgcttggcc	124860
tcccaaagtg	ctgggattta	caggcatgag	ccaccacgcc	cagcctgcct	gattttttaa	124920
attattaaat	tcataattgt	tatttatcag	atgcctctgc	cactttattt	tttaaaaatt	124980
tatttttatt	aaggtatagt	taacaaataa	aaattctata	tattttattgt	gtacagtgga	125040
atgttttgat	atatgtatac	attgtgaaat	ggttaaatca	aactaagata	tctgtcatct	125100
catatctctg	ccatattttt	gtggtagaaa	catttatgat	ctactctctt	agcaattttt	125160
aatattctgc	cttttgactt	ttaaaccaag	gcttggatta	ggacagtctt	tgtagcttag	125220
ttttaggttc	agggataaca	aaagtgtgtt	tatcctttgg	gcttttgcaa	cttgccattt	125280
tcttaatgaa	gatctgggag	aaaaattagt	ttaaagtgtt	tttaaaatag	ccatttagctc	125340
aggacatact	cagccaaggc	aggataagta	gttttgccag	catttctctg	taggtaggtt	125400
ggttggtttt	tggttttttg	ccacagtctt	tttaaaaaat	ataactttaa	aaaaaccttg	125460
gttttctgtg	attgatcttt	ttcactattd	tttatagagg	gccaggaata	tgagtaaata	125520
attcttgggc	ttgggtgcag	atgatccacg	tgctggcaga	cagaaatcta	aagggaacaa	125580
agaggctgtc	ctttgaagat	acttttctct	gcttgggttt	tatatatttt	gatttgattt	125640
agtgaataat	tttattgagg	acctaactga	taccagacac	tcggctacat	tatgagaggt	125700
ttggggggcc	tatatgggca	tataggggag	atgaataaag	aatacaaaaca	attatagtac	125760
aaatcagaat	aaaatttggc	atgcaacggg	ctatcagata	gtatggagga	agaaagcata	125820
ttttattagt	ggagctagga	aatacgttac	aaagtgtgata	gcattcttga	tgggtcttga	125880
aggttacata	gatttttttt	tctttttttt	tttttgagac	ggagtcttgc	agtgtcgtct	125940
gggctggagt	gcagtgggtg	aatctcacct	cccgggttca	agtgactctc	ctgcctcagc	126000
ctcctgagta	gctcggatta	gaggctcctg	ccaccacatc	cagctaattt	atatatgtgt	126060

gtgtgtatat	atatatatat	atatatatatt	tttttttttt	ccagtagaga	cgggggtttca	126120
ccatgttggc	cagactggtc	ttgaactctc	gacctcgtga	ttcgcccgcc	tcggcctccc	126180
aaagtgtctg	gattacaggt	gtgagacacc	acacccggcg	gatagagaga	attttgacag	126240
gtgaggaggt	attccaatgc	aaaagaataa	taggagcaaa	agcacagtgg	tgagaaattg	126300
gaggggaact	gtgaaaattg	ccacatagat	tagaggcagg	aaaataaagg	acggctaagt	126360
ttatatagtg	aacagtggac	cgcattggaca	caggtgactg	ttttctcctt	tttgaacccc	126420
tgcttactcc	agagtcacca	cctctcctgg	ctttctgcca	atcttcttgg	ccacagtttc	126480
tcggtcttct	tttctggctt	ctcttccttg	gcctgaatgc	tacatgttaa	gtgatgtcag	126540
cttcagtttt	cttaacctct	cttctcttaa	gttgctatca	tttaaataatc	tttaaataatc	126600
atctacatcc	aagtgaacctc	taaaccagta	attttaccca	tgacccatct	cctcaactcc	126660
ggattgtata	taaaactgtc	tactcaacat	cttcactttt	gatgtctaaa	tctctatgtc	126720
caatttagaa	ttcttgattc	tttgctttcc	ctccctcctg	gaaatcctgc	tcttaccagt	126780
cttccccatc	ttaattaatg	aacctgacat	tcacctagta	gcttagtcct	caaaactagg	126840
gattaatcta	gatttagtca	tttttcttac	tcttgccata	taataacata	ttattctgag	126900
tttaccttta	cccgaaccca	aataggtaac	tgctgttttt	gttataagat	agtaatatatt	126960
gcctctgagt	gtatgtgaat	tatttttgata	aaaataaata	ttatttttaa	aatattaatt	127020
ttacagggat	tgtctcttga	tttctttcca	aaagttaact	cataagttgt	tcagcagagc	127080
tatgtattct	tcagtatgtt	ataatttcgt	tccatcttcc	aaaaggcctt	cacattctct	127140
tggtttacag	actcagatgc	tatggattag	atacacaagt	acatgttcct	gtatatctat	127200
tatatagtga	acataacaat	tatgattgtg	atcttccaaa	gctcgtattt	ttaatcaaaa	127260
ttaattaaat	attttaagcc	aaagaataaa	ggtagatgca	gcatctagtc	aaaaggatat	127320
ttctgctggc	cacactcagg	aagacataaa	gatatagttg	tagaaaagtga	tatagtattg	127380
gccaggtgtg	gtggctcaca	cctgtaatcc	cagcactttg	ggaggccaag	gtgggctgat	127440
tgcttgagct	caggagtctg	aggccagctt	gggcaacatg	gtgtaaacc	catctctaca	127500
aaatacaaaa	attagccagg	tgtggtggtg	ggcacctgga	gtctcagcta	ctcaggaggc	127560
agaggtggag	gattgcttga	gcctgcgagg	tggaggttgc	agtgaagctga	ggtagtgcc	127620
ctgcactcca	gcctgggcga	tagagtgaga	ccctgtcttg	agaaaaaaaa	aagcaaccca	127680
gtgataggct	gggcaagggtg	gctcatgcct	atatttctag	cagtttgaga	ggccaaggcg	127740
ggtggatcac	ctgaggtcag	gagtttgcaa	ccagccttgc	caacatggtg	aaacctgtc	127800
tctactaaaa	atataaaaaa	ttagccaggt	gtggtggtgg	gcacctgtaa	tcccagctac	127860
tggggaggct	gaggcaggag	atttgcttga	aaaaaaatta	gccaggtgtg	gtggtgggca	127920
cctgtaatcc	cagctactgg	ggaggctgag	gcaggagatt	tgcttgaatc	cgaggggcag	127980
aggctacagt	gagccgagat	tgcgccattg	cacttcagcc	tgggcagcaa	gagcgaaact	128040
ccatctcaaa	aatgaaacaa	acaaacccag	tgaaaaccag	tattgaaaat	agattgcctc	128100
tcccttgctt	catggtctgt	tcttacgtaa	ttttcaagat	aagttcattt	tggcgggtac	128160
tgacaaattt	ccatttattt	acttttttcc	cttacattca	tttcttctca	gtctctccaa	128220
tgaacgcctt	cactgatatc	caaagcatga	aggacacacc	agggaaaaac	atagacctaa	128280
cacaggacaa	atggaattat	tagaaacatt	ttctagcaga	agaacactat	tctgttgcca	128340
tttgaatctt	tgcttctttc	taggtttgac	aatgagccta	tcatataagc	ccaaatgtaa	128400
acagaaagag	gttgaatcag	tcacgataag	cccaattatg	ctgtggtaac	aaacaacctc	128460
aaaatctcat	tggcttaaaa	tatacagaat	tattcttact	catggcacat	atccatctat	128520
catctgcagg	ggatctgctc	actgaagtca	cttaggaact	tggactgatg	gaacggccac	128580
tttttggtca	ctatatgtat	taatctgttt	taatcctgct	gataaagacc	caaaattggg	128640
aacaaaaaga	agtttaacta	gacttacagt	tccgcatggc	tgaggaggcc	tcagaatcat	128700
ggtgggaggc	gaaaggcact	tcttacatgg	tggcagcaag	agaaaaatga	ggaagaagca	128760
aaagcggaaa	cctctgataa	acctcataga	tcttatgaga	cttattccac	tatcaagaga	128820
atagcatggg	aaagactggc	tcccataatt	tacctccctc	tgggtccctc	cctcaacatg	128880
tgggaattct	gggagaaaca	attcaagggtg	agatttggtg	gggatgcagc	caaaccacgt	128940
aatttcaccc	ctggcccttc	caaatctcat	gtcctcacat	ttccaaacca	accatgcctt	129000
cccaatagtc	acccaaagtc	ttaactcatt	tcagcattaa	tccaaaagtc	cacagtccaa	129060
attctcatct	gagacaaggg	tagtcccttc	tgcctatgag	cctgtaaaat	caaagcaagc	129120
tagttacttc	ctagatacaa	tgggtggtacc	agtattgagt	aaatacagct	gttccaaatg	129180
ggagaaattg	gccgaagcaa	aagggttaca	gggcccagtc	aagtccaaaa	tccagcgagg	129240
cagtcaaact	ttgaagctcc	aaaatgatct	cctgtgactc	caggtctcat	atccagggtta	129300
tgctgatgca	ggaggtgggt	tgccatggtc	ttgggcagct	ccgtccctgt	ggctttgcag	129360
ggtacagcct	ccctccaatc	tgctttcacc	ggctggtgtt	gagtgtctgt	ggcttttcca	129420
gatgaatagt	gtaagctatt	ggtagatcta	ccactctggg	gtctgaagga	cgatggccct	129480
cttctcacag	ctccactagg	cagtgcctag	ggactgtgtg	tgggggctct	aacccccacat	129540
ttctcttctg	cactgcccta	gcagaggttc	tccatgagag	ccccgcccc	gcagcaaaact	129600
tttgccctggg	cattcaggca	tttccataca	tcttctgaaa	tctaagtga	ggtttccaaa	129660
cctcaattct	tgacttctgg	gcacccacag	ggtcaacacc	acgtggaagc	tgccaaggct	129720

tggggcttcc	accctctgaa	gccacagcct	gagctatata	ttggcctctt	tcagccacag	129780
ctggagcagc	tgggacacag	ggcactaaat	ccctaggctg	cccatggcgc	agggaccctg	129840
ggtccagtc	atgaaaccac	tttttcctct	tgggcctctg	ggcctgtgat	gggaggggct	129900
gccatgaagg	tctctgacaa	ggcttggaga	cattttcccc	atggtctcgg	ggattaacat	129960
taggccccat	gctacttatg	caaatttcta	cagctagctt	gaattttctt	ccagaaaatg	130020
ggtttttctt	ttctattgca	tagtcaggct	gcaaattttc	tgaactctgt	ttccctttta	130080
aaactgaatg	cctttaacag	tacccaagtc	acatcttgaa	tgctttgctg	cttagaaatt	130140
tcttccgcc	aataccctaa	atcatctctc	tcaagttcaa	agttccacaa	atctctaggg	130200
cagaggcaaa	atgccaccag	tctctttgct	aaaacctaac	aagagtcaca	tttgctccag	130260
ttcccaacaa	attctctatc	tccatctgag	accacctcag	cctggatttt	attgtccata	130320
tcgctgttgg	cattttggac	aaagccatta	aacaaatctc	taggaaattc	taagcattcc	130380
cacattttcc	tttcttcttc	tgagcctttc	aaactgttcc	agtccttgcc	tgttaccag	130440
ttccaaagtc	atttccacat	ttttgggtat	ctattcagca	aagccccact	ctactggtag	130500
caatttactg	tattagtctg	tttcatgtct	gctgataaag	acataacctga	aactaggaac	130560
aaaaagaggt	ttcattggac	ttacagttag	ttccacatgg	ctggagaggc	cttagaatca	130620
tggcaggagg	tgaaaggcac	ttctcatgtg	gcagtggcaa	gagtaaaatg	aggaggaagc	130680
aaaagtggaa	acccctgata	aacccatcag	atctcgtgag	acttacttca	ctatcaggag	130740
aatagcacga	gaaagatcgg	ccctcgggat	tcagttacct	caccctggat	acctcccaca	130800
aaatgtggga	attctggggag	atacaattca	agttgagatt	tggtagggac	acaggcaaac	130860
catatcacta	taccacaagt	ttttttaaaa	aaacaaactt	ttgagaatct	tgtactgata	130920
attaatatct	ggtctggaag	tgaagcacat	ttctttttct	tgcaactgat	tggccagaac	130980
cagctagatg	gccccaccaa	gccaacattg	ggggagaact	gaaatatttg	gcaaacagca	131040
accatgacca	tcacagctgg	aagttctcag	tctggaactc	cttccccagg	cctcccattt	131100
ctggaactct	gagaacaaca	atccaggaat	ctgatgacat	cttttccttt	actagccaaa	131160
atctgatgac	attttttctt	ttactagcca	aaaggggagaa	caataagcaa	ataaattcaa	131220
ttttctccca	tttatacttt	taaactctgag	aacgaattgt	gtgtttataa	gaaagtggag	131280
gttgagcatc	atgaagaaaa	atataaagat	ctttaaaaaag	tatatattgg	gcctatttagc	131340
tacaaacatg	gatcattatt	aatatgtgtc	tgactgacat	ttaaaaatgca	taatcaaaat	131400
caagcctggt	agatacaaaa	ttcatccatt	aatagcaact	aaatttcatt	aggtaagtag	131460
tagtgcatag	tttaaaaagag	taatctattt	ggaaacagga	attaatactc	agaatattat	131520
tattaatata	tttgaaaatt	acttggtgtt	atttgtccca	gcccttacia	ggtgtgtggt	131580
aatggttaag	gtattttctcc	tctatatgcc	tgagttttct	tctttacaaa	agggggggag	131640
gaataatagc	acctgatttt	acttttgttg	tgaagattaa	atttgtacat	atataaatct	131700
atataatctat	atatacactt	atataatgtat	gtaaaatatg	taggcttgtg	cctgacatta	131760
aataactaaaa	aatactagct	attattttta	tcctcatatt	atcagatatg	acacattcat	131820
aatttaaaaca	gaagcctacg	aagaactcat	aaattaaaaag	aagataatct	tttcacaagg	131880
taacaaattt	tggaacaatt	ttttagagtc	tctagacatc	tgttactgac	ggtgtgagtg	131940
aaatgggtct	gtgaagggaa	gatacagggtg	gaactgggcc	agtgtttgca	gaggaccatg	132000
atattttctat	atctctgctg	gctccctatc	agttctagag	ctagttcaag	tgaagcctcc	132060
ataacctctg	gacaataaaa	atgcaccatg	ctattgttag	catgatgaat	gaatttattt	132120
ttgttttagct	tacagaaagt	tagtagtttt	caaaagggtc	tttatgtata	caattgaaga	132180
tactacattc	ttgaaaagga	aatctttaca	gcatacagg	ccctggcact	aatacctcat	132240
ttctgggcac	agcttgatat	ggaggtatag	tttgtgtttt	atctgaggaa	aatttagggt	132300
ggtgttatgt	tttgggctag	ctctgctgaa	acattattct	cttttctttt	agagccaggg	132360
ctgtgggctg	tgtcacttgt	gacttggcag	cccttaatgg	ggctacatga	ggaagacatg	132420
tcctttacatg	attccaagag	tctttctctg	gggttctgag	gtagtctctg	tgtttcttgg	132480
agatatcggt	ggctctaata	tttcccttaa	gtgaggtgat	attctgtcat	ctcatgcatg	132540
ggttttggag	gctgaggggt	gtctgggttg	gctccaccac	ctaccagttg	ggtaaatattg	132600
tgtagttttt	tttttaaac	tttctcagct	ttagtttcct	tatttgaaca	gggttaaaaa	132660
ttgggcttga	gagaaggatt	agagataata	ttagtagata	ttgttgatga	attgggcgaa	132720
gcagagggag	ggggcaaagt	tgactacctt	tgtttctgtc	tcaaacaagt	aggtggtgat	132780
gcctttgagg	agataagaaa	agtgacttgt	gtgtgtgtgt	gaaagacaga	cacacacaca	132840
tatatatata	tagagagaga	gagagagaga	gagagactta	taaatttttg	atatatgggt	132900
tcaaggcact	tttctggatg	cataagtgtg	aatgttcagt	tgaagtttta	atggtgctta	132960
ggagagagat	gtgaacgata	atagagattc	caaaggcctt	tacatcaaga	ggataactga	133020
agctatagga	gcagatgagg	cacacctgta	aagatgagac	aagaagaaag	cctagggttag	133080
ctctgagaac	tttgctattt	agtgtcctca	tagaggggat	ggaggattct	tcacaaaaag	133140
ttcagttttg	tgacaccaca	ttccctgat	tttactctta	cctcttgaga	caccaatttt	133200
ttaatgaaga	agaaaattat	gttgccctgct	taaagtaagg	aaagcagggtg	ttggtgggat	133260
tccttaatatg	aaatatagag	gtttaaaata	cctacaagag	taggagatag	aattgatcaa	133320
gtaaaaaaat	tgaagagatt	aattgaggac	ttaacatcag	agaccatatg	tttgttgtga	133380

caataatcca	aattattgta	ataatgtgtt	taggagtatt	tagccttgta	ggtaccaaga	133440
ttgcattgat	cctgtgttag	gagtttgcca	ggtgtgtgca	atagtgagaa	agacatgaag	133500
ggatttgagg	ttgctgatga	gtgaccagtt	tagatgacaa	ctactgtttc	ttcaactctt	133560
tcttcaactt	caactgtctg	ttttgggaaa	ggctagtggc	ctgtgaggaa	acgaagaccc	133620
cggagctgga	ggactcaaag	agtttggaga	gcagacgtgt	gcaagtgagg	gttttgtgag	133680
caactggagga	caggcagctg	gggaagagag	tgtgttattt	gcagttatga	tattgggtgt	133740
ggagctattt	ttggtggcag	caaagctcag	gatgtatttt	tttattattc	ccataggtga	133800
tggaggcttt	ttattttgcc	acaaaaccac	tgggtgacgtt	gcctgtggcc	accttgaggga	133860
agacactgga	ggtacacagg	atgtatccct	ggaagtggca	gggggtataa	gtttagtagg	133920
agatttgta	ctgagtattt	aaggtctagg	aacagattga	gggtgttggg	tggattgccc	133980
actaagacac	tgggttttct	agcatgatga	cagaaattgg	agtttggggg	gagaagagtt	134040
ctattgtgtc	ttgaagaatg	tgatcaggag	gtatttctaa	tgacacaaac	atagaagtat	134100
acacactggg	atagtccagt	ggcatgagta	ccaaggtgga	agtgtggtgg	tcctaaagtg	134160
gcattaagga	gccaataaat	tgtcattcct	accttagctc	tgtgtccagt	gaaatacaca	134220
gcatagtgtg	gggagaaaa	gttgggctta	ttggggatgg	ggtctttcac	ataaagggaag	134280
aaggtttcag	aaggcatagt	ggtatgaaaa	gaggagaaac	caaagggagg	aaggtcaata	134340
aaggggttaag	aacgagggga	ggcaaattga	ctttctttca	gcatatgagg	attataggaa	134400
tggaaacctt	aattggaatt	aattgaccac	aaatattcca	aagatggagt	gaatcagttc	134460
gagacagaga	tatctgaggg	tctgagggtc	tgaagttaga	tttgtcccag	tcgtgtgtgg	134520
gtgggttcac	tgtgtggagc	ctggggctct	gaggatctga	acatgggctg	cctcctgtgt	134580
gcacgggtga	ggcatctggc	ctgttctccc	tgggggtggac	tcatgatgag	ctgagtggcc	134640
aaacacacaa	tgggtttcat	ttaacatctc	atttctagcc	taacgacaaa	cctaaaaggt	134700
gggcataaca	ataatgttaa	taaaacatct	gcatttctcc	catccttgga	gttgtgagga	134760
tttaatgcaa	ttgtttgtgg	gaaagcactt	taacaactct	aaattacgat	atatatgcta	134820
ggtttttattg	ttaccacacac	ctttgatgta	tttctctttg	tactcttcac	tgtatctgta	134880
acacattccc	taggataatt	agggctaccc	tttaacaaa	ccaagattct	atttatagtg	134940
gtaagctggc	acctgggctg	attctctcta	gtgattatgt	agttttgatg	tggactggca	135000
ttcttccctg	gagtttgagt	acctccgtca	gcacttctcc	cgtccagaag	ttccatctct	135060
gtgtttttct	attacaaagc	ccagacaccc	atctaggcca	cccaccaggt	tcctctttcc	135120
agtcttaagg	acatcttttag	ctcctggctc	atttgtgaga	tggagtggac	tgacatggcc	135180
taagcaaaaga	ttgccagcct	ggtctagttt	tccaggctctc	ccttgactcg	acaataaagt	135240
aaccactaga	ctttgagaat	tgcagtttta	ctaggctctag	agtcttctag	actttcatga	135300
agataggcaa	atatgattct	aaccaagatg	tattaatacc	tcctacttcc	tttgaaatgt	135360
aactgagact	gtacttgaga	cgttacaatt	tcttggaagg	ggaaaggaag	cttctgctat	135420
tgaacgaact	ttttgttaag	gtagctccca	agcaggttca	gtagctttgt	tctattatca	135480
cttttctact	gacagtgatt	tttttctttt	gaaggcctgg	gacatggaga	ctgcttttct	135540
gcagaaacca	catcccttgg	agtaatgagc	tacacctacc	tcaattattc	agtgcagtac	135600
aacactccag	gtcagctatt	aagaggtgca	cacattattt	ttagaaaatg	tgagtccgtc	135660
ttggggaaaa	caaactctatg	ctatatgttc	tttttactca	cttgatttac	aacatactgt	135720
gatgtattct	ttttctattc	agcatctttt	tgtaccctga	gctctttgtt	ctgagcataa	135780
atgtgacctt	ttggcttcag	gtagaaactc	tgtctcatga	gcactccctg	gacacggaag	135840
ttctttgaaa	tagcattgat	tttgtttaag	ccttcatgtt	cccctggaag	gctgattaac	135900
cttagtgctt	tctttctgta	atagctcata	ttgaattatc	tccctctgtc	tgattatata	135960
catttgaaatc	acctgcaagt	ttctttttaca	tgtctagagt	gaggacaatg	tgggtgatga	136020
agagctgaaa	tcttctaggt	aaacattaga	tttttaaaaa	ttctattttt	ttttttttat	136080
ttttaagaca	gggtctcact	ctgtcaccca	ggctggagtg	tattggcatg	attacagctc	136140
actgaacctt	tgaactccca	ggctcaaaac	tgagcagctg	ggactacaga	tgaccaccca	136200
tgcattggta	gttttttaat	ttttttttgt	agatagaggt	tctcactatg	ttgccaggc	136260
tcatctcaaa	ttcatggcct	ccagagatcc	acctgcctca	gccttccaaa	gtgctgggat	136320
tacagacatg	agccactgca	ctaagccaaa	aactcttggt	caaattacat	tttctgcctt	136380
agtaatgctg	ctttcctagc	ttctgagaat	ttctaagacc	caatggtaac	tctatgctaa	136440
aattaaaata	cgaatgtcct	tttcaaaaact	gcacaatatc	tttgctattg	tcaataatgt	136500
ctcaataaac	ataaaatagc	aaagagattg	tgcagtttta	aaaagaacat	tcgtatttta	136560
attttagcat	agagttacca	tcgggtctta	gaaattctca	gaagctggaa	aagcagcgtt	136620
actaaggcag	aaaatgtatt	cacaatagca	aagacttgga	accaacccaa	atgtccatca	136680
atgatagact	ggattaagaa	aatgtggcat	atatacacca	tggaaatacta	tgagccata	136740
aaaagggatg	agttcttgtc	ctttgtaggg	acatggatga	agctggaaac	catcattctg	136800
agcaaactat	cgcaaggaca	gaaaaccaaa	cactgatgtt	ctcactcata	ggtgggagtt	136860
gaacaatgag	aacacttgga	cacaggggtg	ggaacatcac	acaccagggc	ctgttgtggg	136920
gtggggagag	gagggagggga	tagcattagg	agaaatacct	aatgtaaatg	acgagttaat	136980
gggtgcagca	caccaacata	gcacatgtat	acatatgtaa	taaacctgca	cattgtgcac	137040

atgtacccta	gaacttaaag	tataataata	aacaaaaaaaa	accactgcac	aatctctagt	137100
attcagatgg	agactaagca	tgatttttct	tataaaaagag	cagatcagaa	tgttgtatct	137160
tttattcaga	agactggagt	taatcactgt	tatcttttagt	acttagtgct	gccaaggctg	137220
tgtgttcaca	atgaggatag	gatgtcaaat	aaatgaagct	tcatagaaca	agagcaggat	137280
tgagtcatgt	aggcaactgt	ttcagcttcc	tcacctaact	tagcaccaaa	atgtgttatt	137340
gtcattacag	agtgccttatt	taaagaaaaa	taaaaagaac	acacacacac	acgcacgcac	137400
acacacacgc	acgcacacac	acacacatgt	agctacatgt	ctaggaagga	tgtggagagc	137460
tgaaatatga	aggcaaaaata	aaacatcttt	ttcaaagtat	acagcctaca	gtggttagca	137520
cagagctggc	cacatagcag	gggtttcata	aatgcttggt	gattaaactc	ttttttttga	137580
aaacaataat	gtagaagcaa	agagcctaaa	gtgttttcat	aaatcttaag	tggtagcttt	137640
atgttccagt	tcagcaaaac	acaaatttga	aggcaatctg	tacgttaggg	ttcaggtgaa	137700
gaaggcaaag	gaatcaatga	aattgtaaaa	gctttccaaa	tttgcccttt	ctcttaagat	137760
tgtctttctc	tcattctctt	ctccctattt	caggaatgca	aatatcctgt	ttcatcaatc	137820
ttttgttttc	tgactcaaga	taacaacaat	aatttattga	gcacaaacca	tgacttttgg	137880
gtctgtgtag	ccccgaagct	tcatagttca	atatctgcac	cataagaggg	gcttactcta	137940
cacttaaatg	ttagttttgt	cctcactttt	ttctctttct	cagagatctc	ccttttcccc	138000
tacttgtata	agcatgaaga	aatctttctt	ttcattctct	ccaagttaa	tcagacaact	138060
ccacatacat	acatctttgt	tcacaactat	gaacaagaca	gaaaagttgc	tggacctcaa	138120
ggactttaca	atcaatctgg	gaaggcaaac	attgaacata	taatgtccag	tctgataagt	138180
gttagggaag	gaaagctcag	aatgcaaggg	aatataatct	aatctaggag	atcgtgggaa	138240
atatcactgg	ggaatttggg	actgaaagaa	aaataagatt	tgattagggg	aaattgaagg	138300
atcagggagt	caggcggaga	agaatgtccc	ggcagatgag	acactatgta	ccaagcccga	138360
gtttgacaga	gagcgtgggt	tacagaagga	atctaaaagg	tgtagtttct	gtagcagaag	138420
tgtaagggtg	ttactcgtag	gaggcctcta	ttgaactctt	ttccagtgc	gtagtgtgtg	138480
gtctttaagt	ggctttgcaa	tgatagtaag	atcagcattg	cattactgaa	tgagctcctt	138540
tagtaaactg	ggatatgtgc	tttctgaatc	tatttgtttg	tttttcccaa	gtcataaaca	138600
gtgaatcaag	caaatagaac	ataatcaagc	ttggatagta	tcttccacta	atttcccttg	138660
tcttaagtaa	gactgacagt	aaactgatgg	tcaacctgtt	caatgggctt	taacaagtag	138720
tagccacatc	caagtcaaca	aacagtacag	gcaatcaggg	cccctggcct	acagtgaatc	138780
atgggaatta	ccccagggac	ctatgctttg	gggactcgct	cttccctggc	gctatagatg	138840
ccatcagaaa	ctcatttgca	cactcttata	accaagataa	gggcaatggt	tagtcccctg	138900
tcattgcatg	ttagctttct	ttcccttttc	taggcttttt	cagatgcctc	ttttacatta	138960
ttacttttcc	tgtgtgaaaa	taatgcgtgg	gaaatgggta	ggtcatacag	agcgataaatt	139020
tcattcctgg	gcccctgtct	tgacgtctcc	taagtaaagt	tttgcgcttg	gcactcctct	139080
ggcatagtaa	cctctgacaa	acccttgggt	aatagaggag	tagcaaaacc	catgggtaat	139140
ggaggagtag	caggaatatt	atgattagct	aacaaattca	caaagtacat	agaaattttt	139200
ttctcgaata	accactatag	ctgaggaata	tagattagtg	acaaaattgt	gcactcaacc	139260
aactctatta	aaagtatttc	attattcccg	tgaaaaaact	cctaggaaaa	tgattcactg	139320
agagatatata	gattgtataa	gtattgagaa	acagtctttc	ttttttgctt	tttattttatt	139380
tatttaatat	acattatagt	tacacataat	tatgggatac	aatttgatgg	ttcgatacat	139440
ttttatgttg	tataataatc	caatcaaggt	atatttagtg	tactcatcac	ttcatgcatt	139500
tattattcct	ttttgatgag	aacattcaaa	agcctctctt	ctagctcttt	cgtaatatca	139560
ataccttact	gttaatcata	gtcactctac	tgtgcaatag	aatgctagaa	tttattcctc	139620
ctattgaatt	gtaactttgt	acctgtcgac	cagcctctcc	ccatcttctt	ccccttccct	139680
cttgcttccc	cagtctctgg	taaccactgt	tctattcctt	tttttggttt	ttctttttgc	139740
agagttcctg	gtgccgccca	gactggagtg	cagtgcacaa	tcttggtcca	ctgtaccttc	139800
cgcctcccag	cttcaagtga	ttctttctat	tttttgaggaa	tgtgcgttat	ctaatactta	139860
ggtgcctcag	atttaaatggt	ggtaaatctc	actcattttta	tgaaaaccaa	atgaacacta	139920
tcctcacaat	ggttagaaaag	caagatcagc	tcaactttat	gaaaatatga	ctataaaacc	139980
atattattatt	gccaagtggg	tggagtggag	ttgacagaaa	gatgcattat	tttaaatgtt	140040
gttttagatg	acagaacagg	agtcagtaat	gttccagttt	ggaggaatta	gagtttaattg	140100
gttaattgat	tgattcgatt	cagtcaaatt	tattgaatga	ctgctgtttc	agacactgta	140160
tttggctctg	ggaaaacaca	gataaataat	atataattgt	attataaatt	aataaaatag	140220
ttttttccct	ccaaatgtca	gtagtccttg	gaaaggacat	gtaaaccaatg	aatataaagt	140280
gacacatagt	ccagtcaaga	taggtaggaa	gggtctaagta	caattgagtg	gtcaatttca	140340
cttcagggaa	gggcaatgat	caggggaagt	ttcccaggga	aagtgatgct	tggggcaata	140400
agtaagcatt	ttacaaaagag	acaaggaagg	atagggcgct	ctgggcagag	gaaggagtgt	140460
gtacaaaggc	caagtgcacat	atgacaacat	tgtacatgaa	ggaaactacc	atcaggcgaga	140520
gctgaaatgt	tggcacatgg	tgaagtgcta	gttaccggct	ccagccatga	cagtagtgta	140580
acaaatgcct	gcctctgggtg	cacagcaaga	tattaagatt	cctcaaaaca	gttcatatat	140640
tttataaatt	aagatagaca	ttaacagaag	ctcatagaat	caattaatgc	aatgtgaagt	140700

gacctaagag	gcatttttgtt	cagcatagtt	attgattttg	cctgaccag	aggatttgaa	140760
tttaggaaga	tgtaagccta	gagtagctgt	cagttatctt	gtgatacatg	ggccttgga	140820
gcaaggtaca	gggacacagt	ggaccaatgg	gggaagatta	ggtcctgggtg	atgtgattca	140880
agccactgga	ttaagccaca	tctgaaacgt	ctatttctgt	actcttcagt	tacaagagat	140940
gttagtttga	attattttgct	taagtcagtt	tttaaaaaat	tcaattgcaa	cttaggagat	141000
acatctggcc	tcttcatttt	acaacttagg	agactaatat	ctagtatgac	aaagtgactt	141060
gccaccaa	ggctggttaa	aaactgatac	caggaccag	atctaatac	tcagaggcca	141120
ggcttagaaa	tatctagctt	tttttttttt	tttttttttt	ttttttttta	gacacggagt	141180
cttgctctgt	tgaccaggct	ggagtgcagt	tgcgcgatct	tggctcacag	caaattttta	141240
aagcatctac	atgtgagggc	ctaagtatac	gagtacctag	aaatctat	tgcagcaact	141300
atatatttga	tagagtgatt	gagtttagtt	taaagatgac	atctctaagt	ggtagtgtctg	141360
tcaaaagagc	attgcattga	atcaagaatc	tggcattctg	tgctcatagt	tcacttttgc	141420
cactaattat	ttttgtgacc	ctgggtat	ctttctggga	ctgtattcat	tggatatgag	141480
tatctctaaa	tcttcttcaa	cttctatgat	tctaaatgga	agtacactca	atcttcaagt	141540
atccattgtg	gattttatat	actgctatgt	atcctgagaa	aatcttctct	ttgaatttatt	141600
tttcgtatta	atgagttcaa	cttcacaaat	atctactgaa	caccaactat	gagctagggtg	141660
atgtaaaagt	gaatagttac	ttctagtcag	tattacttac	ttacttttgt	attccacagt	141720
gcagtttgat	attgtttgta	gttccaaagc	atataacaat	gcctttta	ctaggacatg	141780
tggaaatctt	aaataagagc	agaattacaa	agagttttag	actgccactt	tgcattcatc	141840
tgagaggcaa	taccataagt	gttcagcagt	cagaagaagg	gacaggggaa	agtcctgagc	141900
agtgcagggtg	gattaagaac	taaatatgcc	tacaaaagca	cattcatgcc	taaatgtcat	141960
tgcatttgga	tcacaggcct	tgagaagatc	tgtaccatca	ctgtgggtaa	cttgggcca	142020
tttagagtac	ttgcctctga	gggaaataaa	aatttgctag	caattttctc	taaatgacat	142080
tatcataggc	acttaattcc	ttgatagggt	cttttagata	atctttttat	aatgaagcaa	142140
ttaatttgat	tcacgaaagt	aagtttctag	tttatataaa	gaccagatct	ggcctatttc	142200
ttagcttgct	tacatttgag	tagttccatt	gctggaaaat	gaccctggag	cttttcaatc	142260
tcatttgaag	agtccagggg	acagacagag	acactagtta	tgcagtttac	tagagccagg	142320
ttccatttca	tctctaataa	tttttgctctg	tgtgcgcctg	cacatgtagc	ttaaagtatc	142380
taagccttag	ttagttttgt	catcagtcac	aggggaatag	tgatatctcc	ctctaagggt	142440
tgtacaacat	ggtggttatt	tatagcacag	cttgaataaa	tgttattaga	tgatatagtc	142500
tcagtcaggt	tttctctgga	ccatgtttta	gtgacataat	agactccaaa	gaagcaaaa	142560
gctaggagca	caaggcagcc	taacttgtga	gttgatgtac	agtgtgaaga	tgcaccacag	142620
atctagaatt	tcagttgact	agaagaataa	gtggtagaat	ttgtccctgg	ttgactactg	142680
tcttaacttt	gtgtctttgg	ggaaatattt	aagctctcca	gacttctatt	tcttcatgtt	142740
taaatcgga	ataatattcc	tttctcattt	cgtagaaatt	gaaaggagat	aagtatgaaa	142800
gcgtttatga	gagtagaaat	catgagtgtg	aaagttcatg	ctattatggc	acaattgatg	142860
ttgaaagtta	atattacaga	ccattccttt	tttgcacagt	gaaaattgtt	ttatatccat	142920
attggccctt	gtcacatatt	aaaatattat	tttctcttat	taatttctat	gagaataata	142980
ctgccttcat	actttttata	agggacctag	gaaaccaata	tttgtctaat	gtttcaggct	143040
aaagagtaaa	aaggaatagg	tatactcttg	aaaatagatg	gctattgtca	atatttttcc	143100
taccaagaaa	ataattcctt	ctctataaag	aactgttact	gttttagagca	atattttcac	143160
gattcaaaaa	gattatctga	gcatgtgtcc	aaccataact	gaccctgca	aaatatttct	143220
aaaagcactg	tgcattctagg	ctgggaagta	tgcaaaatta	gcaaaaatcc	cctagcattt	143280
tcacaccaag	ccatgtgtat	ttaatataca	ccacctcaaa	gaggaaacatt	accaccctag	143340
cactatgagt	gaggtgagac	agagagattt	ctaagaatat	atgggtgtaa	ttttctgtta	143400
actgagagttg	attgacagtt	cgtggaaatc	tgccctccaa	aataacctgt	tttgcagcac	143460
ccttagtttt	atttgatattg	aagaaactgc	ctgctgtttt	gaccatttta	gctactagga	143520
actctatttt	ctaccctaac	tgccctaaatc	cctatggata	aattaggcag	tatctgttta	143580
tttttagttta	gattttattt	taaaaccagt	gttcccttga	ctgttcttac	tatttctatt	143640
tgagagttgg	ttgaaataag	atcatgtaaa	taaaaataca	atgtagtcta	gatctaaagt	143700
cactgtacat	acctagataa	tttttttttt	ttttgagaca	ggatcttgct	ctgtctccca	143760
ggctggagag	cagtgttatg	atcacagctt	actgcaacct	ctggctccca	gattcagggtg	143820
attctccac	ctcagcctcc	ctagtagttt	ggactacagg	tgtgtgccac	cacacctggc	143880
taatttttgt	atttttgtag	agatgggggt	ttgccatgtt	gcccaggctg	gtctcgaact	143940
cctaggctca	agtgatctgc	tcatcttggc	ctcccaaatg	agaaggatta	caggtgtgaa	144000
ccactgtgct	tggcacctag	aggatttcaa	taaaatttga	ggctctataa	ttttaagatc	144060
acatttccaa	aggaaggagt	tttgcttctt	ttcaaatgca	tggacaatga	gcaactatat	144120
tgttttggta	aaactagtag	tcccaataaa	gaaagagggtc	ctactagtcc	ctagtagtct	144180
agtcccttga	ctagaagaaa	aagtcaagcc	caatttattt	tatctgcagg	acttggttta	144240
agggggatta	taaaactatc	accacataaa	gtctttgatg	aagaggacat	agggggatgt	144300
agggagtact	tcagagatgc	atctgggtcac	tctcgaatac	ataacacatt	tacataaata	144360

tatatatcca	agtaaaacttc	agacttcaca	tatttgtttc	cttttgtttc	cttggtgaaa	144420
atctttatcc	aagctgacaa	tcacagtaca	ctgctcatgt	agattccact	gctgagagct	144480
ggaagctgag	agtagagtgg	gctggggagc	gactttcttg	ggactattat	gcttttcttg	144540
cactttacta	ggttcctggt	cttccccacc	cactacctct	cctgggcact	gattccaggc	144600
aagtgagatg	catatctgtg	gactatgggt	aagtgaagc	ctttgttctg	gaaagctcta	144660
tctggtttct	cttaagccag	acagaccagc	ttgccatgaa	ggctttcata	ggctctggtc	144720
cacactttag	acttccaaact	ggtctgctac	tgacattcta	ggctattggt	tctccaaagta	144780
atgaatgagt	ataccattgg	tgggtgaaga	gagaatttta	gatggtacat	agacaaatgt	144840
ttttattgtg	attgttatgt	atttttaatt	catatgagaa	aaatgttttc	cattcatggt	144900
agcaatatac	agtttcttct	ttaaatacat	ttacttaaaa	atgtgagttg	atttaaagag	144960
aaatattaat	aagacttctg	gggaaactca	ggcatgacaa	aatacatgaa	ggtgacatgt	145020
gagtagttga	ggtttagaaa	gcactgcaat	gttatagact	ctaggctagc	tccctgccta	145080
tccccagggc	agttaactag	ttgaattctc	tcaagagtca	ggatgtcttt	gcctgttggc	145140
cttcacctta	agaaagtcag	gcaatgatga	ggaatcacac	ctgaggagat	tgtaggagac	145200
ctttaactta	aagagtgggtg	atgaatatga	agaagagagt	catagtatat	gatcaaagca	145260
gagaggactt	tgagactcag	cgattgggat	gtaggaaggt	ttcctgtaaa	aataaagtct	145320
taactgggct	tcaaaggatg	aacaggaatt	atcctgtgga	gaaaagtagg	agaagaatga	145380
catatgccaa	gtttgtttct	taaaaccaca	acccccaaat	tgtgagctct	gggtcttaat	145440
ttggtgggga	tgggaagcgc	caatctatct	gtgacttctt	tcctgacatg	ggctttcaag	145500
tgcatgtaac	ttgacattta	tgatttcctc	tgcaaaagaa	gaaaggaaca	gggtgatggt	145560
gcctctgtga	tcagttgcat	ttatgggtgc	aacagcaaag	gaggtgggac	acctaaggga	145620
caaccgttca	cgtgaaatga	agcagggatg	agaagaaatg	cccgtttgta	tttaatacat	145680
cccagaaatg	aacccttcta	ttttctggga	ctgtagagc	agggaaacta	tatatttcta	145740
agaatggggg	ctctgctcaa	atctttgtat	tacagtacaa	agaagggtga	ggacaggaag	145800
cagtgggtgat	cttgctcttt	ttggaagagt	ttgtgtctgt	ccttttaaa	tcaggatga	145860
ttgataggaa	agtcaagtac	tggcatcctc	agattggaga	ggttttat	tattttat	145920
tttttaatgg	agtcttgctc	ttgtcatcca	ggctggagt	caatgccacg	atttcagctc	145980
actccaacct	ctgctcttg	ggttcaagca	attctcctgt	ctcaacctcc	caagtagttg	146040
gattacaggc	acctgccacc	atgcctatct	taatttttag	atttttagta	gagacagggt	146100
ttcaccatgt	tggcccggt	ggtcttgaac	tcctgacctc	aggtgatcca	cccgcctggg	146160
cctcccaaag	tgtgggatta	caggtgtgag	ccaccacacc	tggcctgagt	ttaacataaaa	146220
caaagaaata	aaaataatat	aatctctcaa	aatagcaaag	aacagggttg	tctaatacaa	146280
atatataact	atttattttt	aatagccaca	ttacaaaagt	aaaaagaaac	aggtaaaatt	146340
aatttaattt	aattttaaaa	atatatttta	aggtatacaa	cacggtgcta	tgggtaaaa	146400
ggttattaca	atgaaacaaa	ttaacatctc	catcatctca	catagttacc	tgcttccctt	146460
cccactccaa	acccctcatt	gcaagagcag	ctatagttta	ctcatttagc	aaaaatcctg	146520
aacgcaatac	accattttta	ttatttttta	aattttat	tttgagacaa	ggtctcactc	146580
tgtcacccag	gctggagtgc	agtggcgcaa	tcttggtcca	ctgcaacctc	cacctcccag	146640
gctcaagcaa	tcctctcacc	tgagccttgc	gagtagctgg	gactacaggc	acgggccacc	146700
acatttggtc	aatttttgta	gagacagggt	ttcaccatgt	tgctcaggct	ggtctcgaac	146760
tccttgggct	taagtgatct	gcccacctca	gcctcccaaa	gtgctgggat	tacaggcatg	146820
agccatcatg	cctggcctac	aatgcactaa	tattaactat	agttggcagg	ttgggcatta	146880
gatcttcaga	cttggttcac	ctacatattt	gctactttgt	atcctttgag	gtacatctac	146940
ccatttcttc	caccaccctt	acctctggta	atcactattt	tattctctat	ttctgtatat	147000
ttgactttta	aaaaaattct	acataatatg	aaaataatgc	aatagttttc	tttttgtatc	147060
ttggcatatta	tacttaatat	aattttaaata	atataactca	tttaactcaa	tatatttaaa	147120
gtattttaac	atacaatgaa	tgtaaaaata	ttgaaatgtt	ttgcactttt	ttcatgtaaa	147180
tattttaaaat	ttggggtata	tgttatagta	catgccattt	aggacattaa	attgccaatg	147240
gaaataatat	tcagatttta	taacatttgc	agttgaaaaa	gtagatacat	gtatccaagt	147300
tgctctcaac	atacttaaa	ttttccaata	actgaattaa	atatcagttt	atcagtttaa	147360
tataaacaat	tagggtaaat	gaaaataaaa	tttcagctct	ttgggtccat	tagccatggt	147420
tcaggagcag	aatagtcacc	tgaggctagt	gacaacgctt	ttggatcaca	ggaaagaaga	147480
aaaaaaatca	aaataatttt	tcttggtcac	atttagctcc	ttttcttcca	ggatgattac	147540
ggagctagga	atttcctacg	aagctgggtg	ataaaaggac	attggacaaa	aacacagata	147600
gcttcattct	ataccaggat	ccatcactga	ttagctgtat	tatatttgtc	tctactgtaa	147660
tttgaggaga	atgataacctg	cttctctatc	ttgttgggtt	ttacagatga	tgtattgaaa	147720
gttcaataaa	atctataaac	aatagatctc	tgtggcttga	atggctcctca	gatattctga	147780
ccaatgattc	tcaaagtctt	accatagacc	ataatttttc	cccacatgac	actgcttcat	147840
atttttaagt	tttttttcac	caaataattt	gttttactat	ctccaagccc	tgaaactttt	147900
tttctccctc	aaacatgact	tcaactttac	tatcctggtc	cctttctatt	gaatgtgttt	147960
tgtttgtgtc	tatatttctt	atagtgtctt	gaactgattg	tacttacgat	atgacttgac	148020

tagcataaga	tagaataggg	cagtcacctt	ctttgatcta	gactagatgc	tatccttcta	148080
ttaatgcagt	tgctagtttt	gtatttgctt	gctttcaatt	tttttttttc	agatttttgg	148140
aaccactgtt	acttgactcg	tatcaaactt	atcagtagct	aaaaccccc	ttttccctct	148200
tcctgtgctt	atttgactag	ttttgttgcg	ctttctgaaa	tgtttctcac	ttgtttttga	148260
ccaaaaaaat	aaaaataaca	aatgccattg	attctgtgtc	tatactatct	gaggcagtta	148320
ggcctttact	tacttcttcc	aacattttta	gcagtggtgc	attcaatttg	aacaagagga	148380
ataaaaaagg	ttgagaaatc	ttagggaagt	gtgtctcaag	cttttagcaa	caaacaacag	148440
atctgcagga	gatcttggtt	aaatgctaaa	ttctgattca	gcaggtctgg	agtagggctc	148500
aagattttac	atttctagta	agtttctatg	gattatgttt	tgagcaacaa	atttcttagag	148560
tgtctgaaag	gtttttaaaa	taactgattt	cccttcaaaa	tcttcttcat	taggagtaaa	148620
atatacatct	tctcactctg	taaatcagct	ctgagatctt	ctataatctt	agctgaggtt	148680
tgggtatgca	gagttttgaa	actcttattt	gcttaagaga	ggagccatgt	atgatcttct	148740
tttgggtttc	cccattgtct	ggtaaaatga	ggagcattac	taaacggcac	tcacttttac	148800
tgagtttggt	tgagctccac	agagaactga	aaaagtcacc	attatggaag	ccttatcaga	148860
gagatgggga	caagtcgccc	caaagcagtt	gtcaatatct	ggaagatatt	tttctagtgt	148920
gccttatatt	tcatttctat	tttccctcag	tctaattcag	tttatcacia	ttaaaaagaa	148980
accaatgaaa	aacataaata	ttggagatca	tttgatttca	ttggaggctg	gaaaggatag	149040
aaaggctgaa	aagtggccgg	gtgcagtgcc	tcacgcctgt	aatcccagca	ctttgggaag	149100
ccgaggcggg	aggatcacct	gaggtcagga	gttcgagacc	agcctggcca	acatggtgaa	149160
aaccatctct	tactaaaaat	aaatacaaaa	attagtgtgg	cgtggtggca	cgtgcctgta	149220
gttccggcta	ctcgggaggc	tgaggcagga	gacttgcttg	aatgcaggaa	gtggagggtt	149280
cagtaagccg	agactgtgcc	tctgtactcc	agcttggttg	acagagcaag	acagagtgtg	149340
acagagcaaa	acaccatcta	aaaaaaaaaa	aaaaagggaa	agaaaaaaaa	gaaaagctga	149400
aggggtgtgt	gggtccctgt	ctgggtgagg	gaacaacttg	tgaaaaagtg	aattgaggct	149460
tatcggaatg	tttggggctc	ctcaataatg	ttggcactct	gagatacaga	ccaaaagtga	149520
ggtaaaaaag	gagtgtttcc	tttttttcag	aataggactt	tactccagat	tttcttactc	149580
ttctcttgat	tccttcacca	tccttgatcg	acattcacct	cagatgcccc	tgtcccttct	149640
ccaccggcat	agcttggttt	cttcttaate	ttcttggtgt	catctagcct	cacattgcat	149700
ttgtcacact	tcgttgaaaa	cctactgttt	gtcaaagtgt	ctttctagta	atccagatat	149760
ctctctcccc	atgccttttg	tgtggtttcg	gtagatgcat	acagagcagc	aatgccttat	149820
gaaaacgaat	tttacagaat	ctgcctgttc	atcaaaaggag	gccagacagg	aggtgagaaa	149880
aaccagggtg	gtccacacac	agtctcaatg	aagccttttg	gggtgtcttg	tgctcttgac	149940
taaatctcag	atggtactga	atgaataatc	accaaaggcg	tgagctgtta	aggaatccca	150000
gtttggctgg	ctctgtgcag	tcagatgtag	ccagccctgt	ttatgtgtga	aaggattggg	150060
ttttcccca	gctgtttggg	aatgttgcaa	gaacagactt	ttccctccct	ggctccctgg	150120
agtaaaatgg	ctgccaaagt	attttggaac	agaaacttag	aaatgtaccg	accactagaa	150180
gagagtaaca	agggctcttt	gatattttcc	gtgttacta	tgatcaagct	ggcatcgttt	150240
ccttctgagc	taaagattct	gagctatcat	tggctgatgt	gagcttgtga	cctagctact	150300
tctgttcaca	atacactgtg	gaggggcagc	gggggcagcc	ctatttggtg	tgagagtctt	150360
taaggagagc	tttacagatg	agttctagt	aagcccatca	gggagaagaa	aatcaaacac	150420
aatgggaaat	gtttaacaat	taaaaccagg	ctttgcctgt	gtggctcctg	gttttaccac	150480
atcactctat	ggaaatgggc	tggttggaag	aagactgtat	ttctgacagt	ttgcagagcc	150540
aaaaacctgt	tgaaggcttt	ttgtaaggta	gtggagaaaa	tggaacaaac	tttaaaactt	150600
aagggaat	acttgatagt	tctgatgacc	acaggccacc	agactgctgg	gtcatggaat	150660
tatagctaca	tgacaaagaa	aataggaggg	tgggctgagc	cagactcaga	aactattcca	150720
aaagtactat	gactttttag	gaagctagtt	ctttttattt	gaaatatatt	tggttttttt	150780
gcatgagaat	tagcctatgc	ttcttaaaaa	tctcataaaa	tgctagctag	tagaaaaata	150840
aagagtttaa	tctccactcc	gactacctag	agtcaaccct	tgttcatact	gcagtacatt	150900
tttttctttt	agttctgttc	tatgctttta	ataaaaaata	aattagggtc	atatggcaat	150960
ataattttga	ctccttttaa	aactgtagct	tatatcataa	gtctattttg	tggtgttttg	151020
aagttgtcat	gtacattttg	tcatacaagt	ttttaatgac	tggtttttat	gggtgtgtgc	151080
ccaagttact	tattcattcc	catgttatca	gatattttgt	tcttttagctt	tttttttttt	151140
ttttttttaca	ttataactaa	tgaggcaatg	tgtcttgagt	attttgaatt	aactctctag	151200
aatcgattct	tggggagggt	atttactttg	aagtgtatga	cagagtgtag	gagattttat	151260
agtgaactct	tgtctgattt	ggaaatatag	agttgttttag	gctaggtatt	accaacccaa	151320
agttgacact	tgagtcacct	aagttcttct	ctactccaga	gacttggccc	tgccctggcc	151380
gatcccagga	aaagagattt	tagggattac	agaaatggga	acaagttgtg	ggtctgagca	151440
cagcatgcaa	attaattcaa	cacagccctt	gggacaggcc	catgatcagt	gagctgaaac	151500
tcccccttca	agtgttttca	tgattagact	ccagcctagg	aagcttgtct	attagttgtg	151560
taatcttgaa	aaaatctctg	acacttttcc	ctctgactca	gtttcccat	ctggcaccca	151620
atctttttaca	gtgttatgaa	aaatagggaa	aatgtagaaa	ggaagaacat	ggcacccaat	151680

ccttaatgga	cactcagtga	aagctggcta	tcatcatcat	ttttgggggt	gttggtttct	151740
acaaatgtat	tttcccagga	gtttttttta	ctctgtctcc	tctttccttc	atataccccc	151800
agcctgtggc	tggggctctg	cttcaaccac	catgcacctt	tctgaaaccc	aagttttact	151860
ccctgataaa	ggtattgacc	tcttgttggt	ctcatcctcc	agacctacct	atacttaaga	151920
aaatgacatc	tctttaaact	ggccccagtc	tcacttgttt	tccctaacat	tttaattcac	151980
aagattaatc	acttccctta	caggccagtc	ttactgcaga	gttgattttt	ataatttttg	152040
gcctgttggt	ctggttgtag	ttttctcttt	ctgctggctc	gctagttata	gcgggtcttg	152100
aaagcagtga	tatgttatga	cattgtcatc	accctcatta	ttgctcttta	tataacagta	152160
gcagcataac	tgtgttttga	tttcttgtag	aaggcataaa	gtgtgctagt	ggctcactat	152220
tcacatcaat	ctcatcagaa	aatgttattt	cctccttttg	ttgatcatga	tatagaggcc	152280
cagtgcatt	aggtaacttg	ctcaagatca	cacatgtgga	aagctacaga	gccagacttg	152340
gaactgagtc	cattatatct	taatcccact	gcactccaaa	atttgttgaa	tgaaggaata	152400
gataaacgta	tcatgatttt	gatgttctga	ctaattccta	gccagtactt	tattgctatc	152460
ggagcttaag	ctttaagtac	tggctaggaa	atagtcagaa	ctttattttt	aaggaggagc	152520
atataattat	gtatatttta	tacctgtagt	aaattgggaa	ctatagaaaa	catgtagagg	152580
attgtgttta	ccaacttcat	gtagagttag	gatacccgac	tctagcttgc	tggtagttag	152640
gtaagtcaga	catgggcagg	ggataaacca	aattagacta	tttccatttg	actaagccat	152700
ataatcaggt	gtaagccacg	gaaagaaatc	tggaaagaca	ggtgcaatat	tagaagatgg	152760
ctcatgatag	tgatcattag	aggttcaggc	ttgagaaagc	caattggaat	caagaaggcc	152820
taatcctggg	gttctgtcac	agaaaagaag	gctggtagca	ggaagaggac	atgtaacatg	152880
aattacatga	ttagatttgt	gtcataataa	caaaaacaat	aatgataata	acactaatag	152940
cttgttatat	gccatgccct	gtactaagaa	ctatacgtat	gttatcccat	ctaaatcaca	153000
tttaatagat	tcccattttt	ctcatgagaa	aattgcatca	tacagagatg	aactaacttg	153060
ctcaaggcta	tagacctggt	aattagcaaa	gcagggtatt	gaatttagat	gtatttttct	153120
ctgaaggctg	ggttttagata	aatggatctg	gaagcactgg	gaaggatgaa	ttaatgggat	153180
ggagtgcagg	ggatgcagag	tgcccactta	tggaatgatt	tcattcaaga	gagacaggag	153240
ggtcagaggt	aagaatgcta	ccgctgggac	agagaggaag	gtacagatat	gagatatggg	153300
aagaaggtat	actacaacag	tggctcccaa	atctcaatga	gtagccagtt	ctcatggagg	153360
ttttgttttt	atttttgaat	gaagattccc	atggcatacc	ttgaatatcc	tgaatcagaa	153420
tctctggaat	acaacttggt	attcttataa	agcaccttag	gtgatgctga	agctctgcca	153480
ggttcaagaa	ccacagctcg	atcagcctat	atttagatgt	ttgggggtgga	gaatgagaga	153540
aagaaaagat	tttaggggtg	catccagggt	tctgaatttt	gtgactcagt	gaagtttttg	153600
gagggtaggt	aagatgctga	gttcagtttt	ggatgtgttg	agatggactg	gtcctgtgga	153660
tttagttgga	tattagagtc	taacgcttag	aacagagggtc	aaggctgtag	atttagatat	153720
ggaggacact	ggtgtttggg	tggtagtggc	gctatatatt	acatggaatt	ttcaaaatac	153780
tcaaaacttc	agttttccct	caataattaa	tcactttaca	tctttgtgat	cttaaatctc	153840
tttctgacca	ttgattgaaa	cttttgcttt	taaaatttac	attaccttcc	ttacagtttc	153900
cttaagattc	atgcattggt	gtaagtagtt	acttgcacca	tttcattgga	ttcacaccaa	153960
caattgttaa	agtaaaattt	atttttcctg	tgtttttagat	gaagagattt	aggcagggtta	154020
tgtaacacac	ccaaggtaat	atagtcaaat	aattgagcca	gaatttgagc	ccaagtctct	154080
ttctgactct	aggcttagag	ctttagggtc	atttcacaaa	agggctgttc	ctaggctcagg	154140
catgacaact	tctatattac	cttcgtaaaa	gaagcaatat	aatctaccac	tattaaattt	154200
tgcaaggtaa	ttttatatta	tgtttaaata	cagaaaactt	tatttaaacc	tcagttgaat	154260
ttctcttgag	aaattggcca	tgtagttaat	tatatttaat	agaagagttt	gtgtacttcc	154320
cagggagcag	agtattggcc	tgatcaaagc	acctttcagc	ctttgtctaa	cagcatgtgg	154380
gtaggctaca	ttttttttac	tctcagagaa	aggggtggg	caggggtgtg	atatgggttt	154440
ttgtctctgg	gagttctgtt	gcatgatttg	acctcccaa	ttgttttgtg	gggcatatcc	154500
aactttgggt	tgaactaaa	atgggttctt	ggtaatccca	gattgaaaat	atgtctcagc	154560
agtaacattg	tttatcttta	ggtttaggta	aatacagaca	tttgccatgt	cttcttggtta	154620
gcactgtaag	aatgagttag	gctgtgaaaa	atgcacaggg	cattcattat	gaagactggc	154680
tggttaaaac	tgatacacta	aagaaattgc	attcttttcc	acaagctgag	tcatacagct	154740
gaaatttgtg	aatcatctga	gccagcagct	gtaatatgat	acttaatctc	cataagtgc	154800
agatatctaa	gataacacga	acaccagac	gacaactcag	gcaacccag	cacagtgttt	154860
tggtatgaga	acaggagaaa	tgttagtaga	gtgaacattt	ttccacagag	aactcaataa	154920
tggtaacatt	ctcatagctt	tgataatccc	caataaactg	tggttactaa	aatgcatgac	154980
aaaaagaact	tctatctata	aagaacttct	ttatacattt	ccaatacttg	ggttatgatc	155040
aaggagaaaa	aagtttatca	gttaattaag	agttaggtag	ctagtttgcc	cacagattaa	155100
tttgatgatg	gtaaaggaaa	tctcacctaa	ctgggaaaaa	gcaagcttac	cctcaaggta	155160
tgcttatccc	aaccccaccc	tgccaagtgc	attccttatt	cctcaggtgt	gcctgtttat	155220
cccaaggacc	tagccacacc	tacatcttgt	tctggcccca	caccaaggaa	catataaaa	155280
ttccctctct	ggccgggcgc	ggtggctcac	gcctgtaatt	cccagcactt	tgggaggctg	155340

```

aggcgggcg atcacgaggt caggagatca agaccaccct ggctaacacg gtgaaacccc 155400
gtctctacta aaaaatacaa aaaattagcc aggtgtggtg gcgggcccct gtagtcccag 155460
gtactcggga agctgaggca ggagaatggc gtgaaccctg gaggaggagc ttgcagttag 155520
ccgagatcgt gccactgcac tccagcgagg gcaacagagc gagactccgt ctcaaaaaaa 155580
aaaaaaaaaa aaagtccctc tctttatata tcagggtatc ttggagtcac tactgatcct 155640
tgacctccct cctttctctg accatgtcta gacaagtgtc caggtctcct gtgccaaatg 155700
tctatttgtt gcctggatta ggttttgact tgtttttcta tttctttgca tctcgtagcc 155760
catttctttg attcaatttc acaatctctt gattttgtcc ttaagtattt ggcaacacaa 155820
accctcgaga ggcaggatag ttcaacagaa agaagatgaa ccttgggggg cagaagattc 155880
aaacttccag aatttaaate ttcatctctg tattactaga ttataaaact ttatcaaate 155940
actctcctac tctatccctt aattcaacat atttaaaatt ggaataaaaa tctcaatgtg 156000
gtagagttat tattgagatg aaaatcagaa tagatacaaa gaacttgata gcccacagga 156060
gcttgatcag tgtttgttta atggcccttc ctctctcttc atatctcagt tcagatccta 156120
ctcagccatt tattttattc tgctcctttt ggagtagaga ataaagccaa gaattatgct 156180
taaaaagtag cataattaaa agtattttaa acacaagtaa cttgagaaa gtgagttgga 156240
agtttatata taacctcagt tttttttgga gagaaattta cccgtcaggg ccagattaaa 156300
acatttacaa gtcccaagca cacgtgagat gaagatgccc ctacttata tcacatgtaa 156360
gttgaaagtt aaaaagttaa aatgtctact agagtccaat aatattcttt ttttcccatg 156420
acttctctga agctttttag aaatatgaaa ttcttaaaaa caataacagt aaccacatt 156480
tttattgccc tggtttgccc tatcttatct ttctctgct cacagggtct gaggcagctg 156540
ggatagggga gaatgattac cagccaatca atattttttg aaccacagag attattttatt 156600
tatctatcca tttattttatt ttgagatctt atttttatct gaatcttaat aaacgattag 156660
tttccaaact gtatctactg tgtgtatttt atccatattg cccagatttg tattacttat 156720
ttgtgattct gaataatatt ttttccaaca ttaattatca gcctctctgt gcccctccag 156780
aattgttaca acctatgta atgcacacta tggcaagcca tgtgaattgc ctacgcaggg 156840
aagttttctt catacttctt tgccaagaga acccattat tggtcagtta ctagtacat 156900
gatcttcttt agccctctt tagccctgt agtgaatcag gtagtccta aggccatgg 156960
ggtaactccc ctttttcttg gaaatgtttg atttagatat ggagaagagg tgcaactttg 157020
cttatgaaat gggagggcaa atatgggaaa cttaaggtta agttttcttt cccctgaag 157080
gggacaaaa agttgtggtt tatactttct tgactctggt cactgttggg tgaagagttg 157140
gtgctatgga agccatcttc agaccatgag gggacaagtc tgaggatata attacatgct 157200
accggtggca gaggacagta tagcaagaaa ctggatccct gatgacattg aaccattgac 157260
tgaatctacc ctggaaccat caggaaataa tccttagttt tttaaagatg ctttttagttg 157320
tgttttttat tacaagtacc tgaagcatc ctaactaatc aatgctaaat gcatctctca 157380
cagtttatgc ttatttttca gaaatgccta gtggaaattt ctattgctga ttataatatt 157440
tgtcctaaat aaattgaata gactgtcaat cttttgaaaa taaaagcatg acttgattag 157500
caattgttta gtctgatgtt ttcttaattt ctgtcatttg cataccactt ctttgatttt 157560
gtcatatcct tgtatcatct gcactaatag aaatattttt ccttaagttg tctctccttt 157620
aaaaaattat atccatttat tttgaagaga aactttttca ctaactataa attgaaaacc 157680
gatatcattt gccttaaata gaagattgtc ataaaaagaa atgccatgag tgaaataatg 157740
ttattaaata tttgccagat atagtttctt atgaagactc tgagcttgtg gcttgcgtgc 157800
tctgttgaaa ggagagacta gggagtgtta tagaagtggg aaaataatcc ttccactgac 157860
tgagactatt tccttgccac aatcagaaga actaaaagaa aggaggatat ctgttaatat 157920
atgaatttat ctaaatgtca tgcagtgact tctaaaatca tctggtgtgc tctgtttccc 157980
cttgagggtg acttaggcct ggcattccaa acaatacata ctggagtga gctccaggaa 158040
accctgagga gaagagaagg gcttaaagag caatcagcct tgcattgctg ggattatgaa 158100
aggctgtaag aagcgaatgt tgcaatgttt tattatactt gatattgaag caaggacaag 158160
taataattta ttattctctc catgtcagtg gtattttacct ttttggaaatc atgtgcccc 158220
ttgagaattt ctggaatacc atggttcttc tactcaggag aatgcacaat tgcacacata 158280
cacaaatgtg caagcacaca cacacacaca cacacacaca gaattgccac agaaggtcag 158340
taggttcaca ggccttaggc taagaaccag cattctgtat attttacatg tgttctctta 158400
caagttaccg tgtgattcag ttactccaa actgcggtta agtgcaaac atggttttga 158460
atatttctat caattagtaa gagtggatg ttaattttaa tacaccaaag tggagaatta 158520
ctgtcctctc aatagctact ttaaatagac ataagttaca gtgatattgc cttccaggag 158580
gcttcaagaa atgagatcag gctctataaa agaaaatcac ccaaccctat aaagtcatct 158640
ttatgaactt tgaacacca ctgtatgtac ctagtaaaaa ttattcctgg gtaagcagac 158700
tcccaggcct ggggtggagt cecatgagtc cctttgctaa aataaacaga agtgactggg 158760
aactttggat tgcccttctg tgaacttgag tgtctggatg gatcagcatc agcagcatat 158820
cacacacctg cttgtccagc caaagagaaa cccaaagact tggcatttgt tttttacatt 158880
gtcaactgtg caaaaatata acgattctaa tttatgaggg tccatgagtt ttaaaaacac 158940
cccctgacat ttttctagcc aaataatttt tcctttaaaa ggcacaggat gagcaacaag 159000

```

attaggtaga	tcacttcaat	ctctaatttc	aaaagataat	agttaaaaat	tcaactgtag	159060
gactaacaca	ttaactatgt	aataagaccc	agaatagtct	ttggagcaaa	tttcagtggg	159120
tacttgatca	aaataatggt	gaagacaaaa	tcttgaattg	atgatattta	tctgatacaa	159180
ttattttacat	aacaaatggt	aaaagaatta	gaaaaatttc	ataggttaaga	tggttcattat	159240
cttcaagtga	agttacttgc	tttatattaa	gaaccacaaa	aacttactaa	actttttttt	159300
ttaaaagggg	ctcactctgt	cacccaggct	ggaccggagt	ggctcaatca	cagctcactg	159360
cagccttgat	ctacccagat	tcaagtgatc	ttcccacctc	tgccctccaa	gtaactggga	159420
ctataggcac	atgccaccat	gcctggctaa	tatctctctt	ttcttttttt	ttccccttat	159480
tttgtaggga	caagttttct	ccatgttgct	gaggctgggc	ttgaactcct	gggctcaagt	159540
gatcctccta	cctcagcctc	ccaaagtgtc	ggagttagat	gcatgagcta	ctttgcccc	159600
tagcagacgt	cttacttttt	tttttaattt	ggtattagat	tgagccaatg	actaatttca	159660
aacattttata	aattactaaa	ttcttttttt	taattatact	ttacgtttta	gggtacatgt	159720
gcacaacgtg	caggtttgtt	acctatgtat	acatgtgcca	tggttggtgtg	ctgcaccacg	159780
taactcgtca	tttaatatata	ggtatatctc	ctaagtctat	ccctccccc	tccccccacc	159840
ccacaacagg	ccccgggtgtg	tgatgttccc	cttctgtgtg	ccatttggtc	tcattgttca	159900
attcccacct	atgagtggag	acatgcagt	tttggttttt	tgctcttggt	ataaatttgc	159960
gagaatgatg	gtttccagct	tcattccatgt	ccccacaaag	gacatgaact	catccttttt	160020
tatggctgca	tagtattcca	tggtgtatat	gtgccacatt	ttcttaatcc	actctatcat	160080
tggtggacat	ttgggttggt	tccaagtctt	tgctattgtc	aatagtgcc	caataaacat	160140
acgtgtgcat	gtgtctttat	agcagcatga	tttataatcc	tttgggtata	gaccagtaa	160200
tggttggtg	gggtcaaagt	gtatttctag	ttctagatcc	ctgaggaatc	gacacactga	160260
cttcacacac	gggtgaacta	gtttacagtc	ccaccagcag	tgtaaaagt	ttctatttcc	160320
tccacatcct	ctccagcacc	tggtgtttct	tgacttttta	atgatcgcca	ttctgactgg	160380
tgctcagatg	tatctcattg	tggttttgat	ttgcatttct	ctgatgcca	gtgatgatga	160440
gcaatttttc	atgtgtcttt	tggtgtcata	aatgtcttct	tttgagaagt	gtctgttcat	160500
atccttcacc	cactttttga	tggtgtgtgt	tttttttctt	gtaaatttgt	ttgagttcat	160560
tgtagattct	ggatatttag	cctttgttgg	atgagtagat	tgcaaatatt	ttctcccat	160620
ctgtaggttg	gctgttcaat	ctgatggtag	tttcttttgc	tggtgcagaag	ttcttttagt	160680
taattagatc	ccatttgtca	attttggctt	ttgttgccat	tgcttttggg	gttttagaca	160740
tgaagtctct	gcccagtcct	atgtcctgaa	tggtattgcc	taggttttct	tctaggggtt	160800
ttatggtttt	aggctcaaca	tttaagtctt	taattccatc	tgaactaatt	tttgtataag	160860
gtataaggaa	aggatccagt	ttcagctttc	tacatatggc	tagccagttt	tccagcacc	160920
atctattaaa	tagggaatcc	tttccccatt	gcttggtttt	atcagggttg	tcaaagatca	160980
gattgttgta	gatattgtgc	attatttctg	agcgtttgt	tctgttccat	tggtctatat	161040
ctctgttttg	gtaccagtac	catgctgttt	tggttactgt	agtctttag	tatagtttga	161100
agtcaggtag	cgtgatgcct	ccagctttgt	tcttttggct	taggattgac	ttggcaatgc	161160
aggctctttt	ttggttccat	atgaacttta	aagtagtttt	ttccagttct	gtgaagaaag	161220
tcattggtag	cttgatgggg	attgcattga	atctataaat	tactttgggc	agtatggcca	161280
ttttcatggt	attgattctt	cctacccatg	agcatggaat	gttcttccat	ttgtttgtat	161340
cctcttttat	ttcattgagc	agtggtttgt	agttctcctt	gaagagggtc	ttcacatccc	161400
ttgcaagttg	gattcctagg	tattttattc	tctttgaagg	aattgtgaat	gggagttcac	161460
tcatgatttg	gctctctgtc	tggtattggt	gtataagaat	gcttgtgatt	ttcgcacatt	161520
gattttttat	cctgagactt	tgctgaagtt	gcttatcagc	ttgaggagat	tttggtctgag	161580
acgatggggg	tttctagata	tacaatcatg	tcattctgca	acagggacaa	tttgacttcc	161640
tcttttcccta	attgaatact	atttatttcc	ttctcctgcc	tgtattgccg	ggccagaact	161700
tccaacacata	tggtgaatag	gagtggtgag	agagggcatc	cctgtcctgt	gccagtttcc	161760
aaaggggaatg	cttccaggtt	ttgcccattc	agtagatata	tggtctgtgt	ttgtttatag	161820
atagctctta	ttattttgag	atacatccca	tcaataccta	atttattgag	agtttttagc	161880
atgaagggtg	ttgaattttg	tcaaaggcct	tttctgcata	cgttgagatt	atcatatggt	161940
ttttgtcggt	ggttctgttt	atatgctgga	ttatgtttat	tgatttgcgt	atgttgaaca	162000
agccttgcat	cccagggatg	aagcccactt	gatcatggtg	gataagcctt	ttggtgtgct	162060
actggattca	gtttgcccag	attttattga	agatttttgc	atcgatgttc	gtcagggata	162120
ttggtctaaa	attctctttt	ttttgttggt	tctctgccag	gctttggtat	caggatgatt	162180
ctggcctcat	aaaatgagtt	ggggagaatt	ccctcttttt	ctattgaatg	gaatagtttc	162240
agaaggaatg	gtaccagctc	ctctttgtac	ctctggtaga	attcggtgtg	gaatccatct	162300
ggctcctggac	tttttttggt	tggttaagcta	tttaattattg	cctcaatttt	agagcctgtt	162360
attgctttat	tcagagattc	aacttcttca	tggttttagtc	ttgagaggat	gtatgtgtcg	162420
aggaatttat	ccatttcttc	tagattttct	agtttatttg	catagagggtg	tttatagtat	162480
tctctgatgg	tagtttgat	ttctgtggga	ttggtggtga	tatccccctt	taatttttta	162540
ttgtgtctat	ttgattcttc	tctcttttct	tctttattaa	tcttgctagt	ggtctatcaa	162600
ttttgttgat	cttttcaaaa	aaccagctcc	tggtattcatt	gatttttttg	gagggttttt	162660

tgtgtctcta	tttcccttcag	ttctgctctg	atcttagttg	tttcttgcc	tctgctagct	162720
tttgaatctg	tttgctcttg	cttctatagt	tcttttaatt	gtgatgttag	gggtgtcaatt	162780
ttagatcttt	gctcccttct	cttggtggca	tttagtgcta	taaatttccc	tctacacact	162840
gctttgaatg	tgtcccagag	attctgggat	gttggtctt	tggtgtcttt	gggttcaaag	162900
aacatcttta	tttctgcctt	cattttgtta	tgtaccag	agtcattcag	gagtggttag	162960
ttcagtttcc	atgtagggtga	gcggttttga	gtgagtttct	taatcttgag	ttctagtttg	163020
cactgtggtc	tgagagacag	tttgttataa	tttctgttct	tttacatttg	ctgaggagtg	163080
ctttacttcc	aactatgtgg	tcaatttttg	aataagtgc	gtgtggttct	gagaagaatg	163140
tatattctgt	tgatttgggg	tggagagttc	tgtagatgtc	tattaggtcc	gcttgggtgca	163200
gagctgactt	caattcctgg	atatacctgt	taactttctg	tctcgttgat	ctgtcctaag	163260
ttgacagtgg	ggtgttaaa	tgtcctatta	ttattgtgtg	ggagtctaag	tctccttgta	163320
ggtttctaag	gacttgcttt	atgaatcttg	gtgctcctgt	attgggtgca	tacagattta	163380
ggatagttag	ctcttcttgt	tgaattgatc	ccttaccatt	atgtaatggc	cttctttgtc	163440
tcttttgatt	ttgttggttt	aaagtctggt	ttatcacaga	ctaggattgc	aaccctgccc	163500
tttttttggt	ttccatttgc	ttggtagatc	tccctccatc	cctttatttt	gagcctatgt	163560
gtgtttctgc	acattgagatg	ggattcctga	atacagcaca	ctgatgggtc	ttgactcttt	163620
atccaatttg	ccagtctgtg	tcttttaatt	ggagcattta	gcccatttac	atttaagggt	163680
aatatgttat	gtgtgaattt	gatcctgtca	ttatgatgtt	agctgggtat	tttgctcatt	163740
agttgatgaa	gtttcttcct	agccttgatg	gtctttacaa	tttggcatgt	ttttgcagtg	163800
gctggtagtg	gttggttcctt	tccatgttta	gtgctttctt	caggaactct	tttagggcag	163860
gcctgggtgt	gacaaaatct	cttagcattt	gcttttctgt	aaagtatttt	atttctcctt	163920
cacttatgaa	gcttagittg	gctggatatg	aaattctggg	ttgaaaattc	ttttctttaa	163980
gaatgttgaa	tattggcccc	cactctcttc	tggcttgtag	agtttctacc	gagagatcag	164040
ctgttagtct	gatgggcttc	cctttgtggg	taaccgcacc	tttctctctg	gctgccctta	164100
acattttttc	cttcatttca	actttggcaa	atccgcacaat	tatgtgtcct	ggagtgtgtc	164160
ttcttgagga	gtatctttgt	ggcattctct	gtatttccctg	aatttgaatg	ttggcctgcc	164220
ttgctagatt	ggggaagttc	tccctggataa	tatcctgcag	agtgttttcc	aacttggttc	164280
cattctgccc	gtcactttca	ggtactccaa	tcagaagtag	atttggctct	ttcacatagt	164340
cccatatttc	ttggaggctt	tgtttgtttc	ttttattctt	ttttcctcta	aacttcttgc	164400
ttcttttcat	tcatttgatc	ttccatcact	gatacccttt	cttccagttg	atcgaatcgg	164460
ctactgagcg	ttgtgcattc	gtcatgtagt	tctcgtgcct	tggtttttcag	ctccgctcag	164520
tccttttaaag	acttctctgc	gttggttatt	ctagttagcc	atttgtctaa	ttttttttca	164580
agggttttaa	cttctttgcc	atgggttcga	acttccctct	ttagcttggg	gtagtttgat	164640
catctgaaga	cttcttctct	caactcgtca	aagtcattct	ccatccagct	ttgttccatt	164700
gctggtgagg	agctgcattc	ctttggagga	ggagaggcac	tctgattttt	agagtttcca	164760
gtttttctgc	tctgtttttt	cccatctttg	tggttttatc	tacctttggt	gtttgatgat	164820
ggtgacgtac	agatggggtt	ttggtgtgga	tgtcctttct	gtttgttagt	tttcttctta	164880
acagtcagga	ccctcagctg	caggtctggt	ggagtgtgct	ggaggtccac	tccagacgct	164940
gtttgcctgg	gtatcagcag	cggaggctgc	agaacggcga	atgttgctga	acagcaaagt	165000
ttcctgcctg	attgttcctc	tggaagcttc	gtctcagagg	ggtacccagc	cgtgtgaggt	165060
gtcagtctgc	ccctactggg	gggtgcctca	cagttaggct	actcgggggt	cagggacca	165120
cctgaggagg	cagtctgtcc	attctcagat	ctcaaactgg	tttcaaagaa	catctttatt	165180
tctgccttca	ttttgttatg	taccagtag	tcattcagga	gtgggtagtt	cagtttccat	165240
gtaggtgagc	ggttttgagt	gagtttctta	atcttgagtt	ctagtttgca	ctgtggtctg	165300
agagacagtt	tggtataaatt	tctgttcttt	tacatttgct	gaggagtgtc	ttacttccaa	165360
ctatgtggtc	aatttttgaa	taagtgcagt	gtggttctga	gaagaatgta	tattctgttg	165420
ttttggggtg	gagagttctg	tagatgtcta	ttaggtccgc	ttggtgcaga	gctgacttca	165480
attcctggat	atccttggtta	actttctgtc	tcgttgatct	gtctaattgt	gacagtggg	165540
tgttaaagtg	tcctattatt	attgtgtggg	agtctaagtc	tccttgtagg	tttctaagga	165600
cttgctttat	gaatcttggt	gctcctgtat	tgggtgcata	cagatttagg	atagttagct	165660
cttcttggtg	aattgatccc	ttaccattat	gtaatggcct	tctttgtctc	ttttgatttt	165720
gttggtttta	agtctgtttt	atcagagact	aggattgcaa	cccctgcctt	tttttgtttt	165780
ccatttgctt	ggtagatctt	cctccatccc	tttattttga	gcctatgtgt	gtttctgcac	165840
atggtgatgg	gaggtactgg	tattacaaaa	agcttctccc	ccgtgggtca	aatctaagct	165900
gagtgttgag	acataaattga	aattcactag	atagatagga	gataggggta	gggaattcta	165960
atcagagggg	atagcacatg	taaggcaaac	aatacagtc	atctgggaaa	gctatacaat	166020
tttattgtta	taggacaaat	gttggggaat	gttgagagat	ggaactggag	agtgaggcag	166080
aagttagcat	ttattcattt	attcagcaga	cctttatcta	ttacctacat	tgcactaagt	166140
actgtgtgag	cattagagag	aaaaagatga	atgagattgg	acaccattcg	ttcattcctg	166200
actatgaact	tggcattgtt	ctaggtacca	gagatataat	aatgagaaac	agacatgctc	166260
cctcccctca	ttgaggttac	agcttagtgt	ggagacacac	agatgcctaa	cgcactatgg	166320

tatggaaggt	gctatggaca	cagtgtctcaa	atccatgatac	tacataggta	tgagagtgc	166380
ttttctacaa	cttaaatctg	atcttggtat	tccctgctta	aaatcctgca	gtagctccca	166440
gtagtgcctt	ctgggttaaaa	tacaagatat	atagtatgac	ctctcaagga	cctttgttat	166500
ttgtctctgg	ccacctctcc	aatttttcac	catgaccctg	gccctgtccc	actggcattc	166560
catctccaat	cacacggaac	tatgtggagt	tattaaaatg	ccctatgtta	tttcaagact	166620
cagagattta	gtgcctcagc	ctgttttgtt	ccctctcccc	tcctccacct	ggccttctcc	166680
agctcactca	tcaatctatt	agactcaggc	atcatctgct	tgcttctgta	accctcccca	166740
ccccgctcac	cttgctggat	tctgtgcctt	tgcttctgctg	ttcccagaga	tcctgtccct	166800
tatttttctt	tgctgtctgg	atttgcagtg	ttgtgtccta	tatggtgtag	aaaaccagct	166860
caggctccca	cttctctggg	cttatgtggt	cagatgcaga	cctgtcttcc	atccatacca	166920
aaggccatca	gggagtttct	tttgtcctct	tcaccagccc	attcttaatc	tttctgataa	166980
attttctgca	ctgtgtgcgc	gtgacaaatt	gggtcaaggt	gatggttaatt	tacagcatga	167040
gatggtgaac	ttgtgcctg	tgctgatgag	cccatgtgat	ttcccctaac	tagtctgttt	167100
ccctatccag	gtgggaaact	tcagtagagg	aagtggcagg	aatttgggaa	tgaggagcac	167160
agtatttaaa	ctggggccat	tcatatgaga	gtttaagaac	tcagaccagt	gacttaggtg	167220
agtaaaaaata	tcagaaaaag	ggaaagagga	taagagcaac	ttggggccata	attaaacttg	167280
tcaatgaaat	gaaggtctgt	tattctaatt	cctacatttt	gccaaacctt	tgtgcttata	167340
acttcatcat	ttgctgtgat	taacaaagtt	gaaagaataa	taactactta	caaggcccac	167400
atcacctcct	tataccacta	gcttttgctt	tccgtacaga	catagcttta	aaaagtgcga	167460
atcctattct	gtacctgagc	cacaacccta	aaagggaact	tgtttacaat	tctaagaata	167520
atattgtcct	ttaaagggtga	aggctcgtg	gaaaacatgc	cattcatgtg	ataaaaagca	167580
ggtagcaggt	agtgtctaaag	acttactaga	ctgcatgttt	gtgctttctg	ctgcattcct	167640
ctaattctcaa	ggcagtataa	ggagataaca	tcttcacagc	cctttcagcc	ctgttgcaat	167700
ttctttgacc	ctggcctgat	ataaaaggca	aacttggttt	ttcactgttc	tagtcatgca	167760
gtttctttgt	ggttcccttt	agaaagactt	gaggctatga	gtcaaagctt	ttacgtcttg	167820
ctgatagtgc	agagttgtga	tgtgaagcaa	taaataaaat	ccctccttcc	acatacttgt	167880
ctccttgatt	agaatcattc	tgggcaaatt	tagaggctca	taaagtccat	ttagatattt	167940
agtgaaaaaa	caccagcact	cagaacagaa	tgttgataat	gtagatggaa	tatctttctc	168000
tctctgtctc	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgta	tttatatatg	tgtgtattta	168060
tattatatat	gtgtatatatt	atatatgtgt	gtgtatatac	ttatatgtgt	atatgtattt	168120
atagtaaaata	tatcacatgt	atttatatat	agtaaaaaag	aggggactat	aatatatctt	168180
tatatgttag	catttatattt	aaaaagaaaa	cacaggaata	tctaaaagaa	actattactt	168240
ataggggtta	tgggaaatgc	catgggcaag	aatttttttt	ttttttatca	ccatgctttc	168300
tgaacaaca	cgatatgtat	cacctttata	aaaataaaat	aaaataaaaa	atgaaaaaca	168360
aagtccactt	gtaaccacat	gtcagtagca	tgtttgcttt	cagggtacat	caaatgcatt	168420
ctatagcaca	ggatgttcca	gtcactctaa	caaaagatgt	cctgtttgga	acaccaactc	168480
tgtatcagtt	acttcagaca	ctttctctca	ttgagtcctt	tcagcaagcc	cttttagggt	168540
tatgttctta	gatgaggaaa	ccaagtctta	gaaacattaa	ctggccaaac	taagatcaga	168600
gagttagaaa	tgtcagagcc	cagaactggc	atcttctgac	ttcagatccc	atgtactttc	168660
ccctacactg	tgctgaccac	acctccatta	ctacagatgt	gttgattaca	tctagggggc	168720
aaagtacaca	ttcatccaat	aaatgcttac	tgaatgctta	ccgtgttcag	ggcactgtgg	168780
caatcttttg	taatgcaaga	aaaataagag	tagtgaagac	agtcaaggaa	acaaagaagc	168840
ctaatactag	gcaagaagtg	cttttgatgg	aattaagcac	aatgaggggtg	ttagtacaga	168900
aaggacattt	aattgaactg	ggaaagtcca	tggcagtttt	cccagagatg	agtcttgaag	168960
gacaaatggt	attagccag	gaggaaaagg	ggtcaagtgt	attccagggg	gagggaaaca	169020
catgtacaaa	agcacagttt	tgaaagaaca	ctccattttt	gaggaatagc	caatagctgg	169080
gcacgtctag	agcatagggt	agtagagaga	aaggaggccg	gaaatgggaa	gagacttgaa	169140
tgccacattc	agttatgtgg	acttcatctt	gtagcaatgg	gagcctacaa	aatttttaagt	169200
agaggaataa	aaagattcca	tctaaaactt	agaaaaatta	ctttggcagg	ataagagaca	169260
atgaattgac	ggggagctgg	gtttgatagc	aagaaactgt	ttgggagact	gttctaatta	169320
catattttct	tgttttttaga	tgccacatata	cgtacttttt	tagctgggtca	tttctttctg	169380
aaattggaat	gaatcttaca	atcaatggca	tgttataatt	tcattggcag	cattatttgt	169440
ctcttaaggg	ccccaaata	atagtgtgtc	acataactga	tagcatctca	aattagatga	169500
aatacagtag	tccaggcaag	aaatactgag	atggtgggg	ggtaaagagg	gaaaagattt	169560
gagccacatt	tagatcctga	tgtggtatta	attattaagt	aaaaaaaagg	aatgtgcagt	169620
acatattcag	tatgccacaa	gttgtggaaa	aaaggtgtgc	atggatagat	gcacatgtat	169680
gtattcataa	agttaatgtg	gatgcataaa	gcgtctctag	aatgatacac	aagaaacaaa	169740
taacacccgt	ggcttttagt	ggggggcatt	gggtggctga	gggagaacag	cggtaggaaa	169800
atttttcatt	gtgttctatt	ttgtacattt	gatagtttga	actagtcgta	ttatgcactt	169860
caaatatgta	aaaagataaa	aagtaagaga	tatttagaaa	ggagcattga	cacatttgtt	169920
gacagattgg	ttatgggata	aaggcgatag	tattttattg	actatatattt	attcttttaa	169980

ttattcctct	aatttcttaa	aacaacttta	ttgaggtata	acttccacgg	tataatttca	170040
cccattttta	gtgcatgaat	tcagtgaatt	ttagtagagt	cattgagtag	tgtaaccatt	170100
cctacaatgg	ttatagcaca	tttttatcat	cctaatagaga	tccttcatgc	tcattttattt	170160
aatctccatt	cccattctcca	tccccaggca	accataatct	tccatgtttt	taaaatagct	170220
ttgcctattt	ttggatgttt	catacaaatg	gaatcataca	aaaggtggtg	ttctgtgtct	170280
agcttctttc	ccttaggata	atgttttctg	gtttataaat	gttgcaaag	tcagtatgat	170340
acttcattcc	tttttatttg	tgtctacaaa	atactctatt	ttatgtatat	accacctttt	170400
gtttttctgt	tcacagttg	aagaacattg	cagccgtttt	tgctttttga	cttttatgaa	170460
taatgctgtt	ataaacgttt	atgtttaagt	ctttgtgtgg	aagtattttt	tcatttcctt	170520
gggtagacac	ctagaagtag	gatgttgtat	ggaaaattaa	tgtttgactt	tttaagaaac	170580
tgttttccaa	agtggctgta	acagtttaca	cttctactaa	caatgtatgg	aggttcccac	170640
ttctccacat	ctttgcttac	acttattatt	gcctgtcttt	ttggcagact	taagcctagt	170700
gggtgtgaag	tggtacttca	ttgtgggttt	gacttccatt	cccctaatag	ccaatgattt	170760
cggacatctt	tcaagtgcct	attaaccatt	cacgtgtctt	ctgtgatgaa	atgtctattt	170820
gaatattttg	cccaatttaa	aactgggttg	tttacctccc	tattcttgac	ttgttaggat	170880
tctttgtatt	tttaacttta	atgtgactga	ggataatgat	ccaccagtaa	agagatgcat	170940
ttatttctgt	atttatgaaa	atctttaaaa	ttcctctacc	tttcagagac	acccttcaac	171000
agactgcgct	tcttattttc	agagtatgta	tttccatgat	aacacaagta	tcaattataa	171060
atattaatta	caactttccc	tcctcactgc	agactcaacc	aagagttata	aatctgtgta	171120
ttactttcaa	tgctcataac	aatcttctta	accaccataa	gcagactgaa	aaagtcaatc	171180
tagttgaatt	gttttacttt	ataatgcttt	tataagatac	tcagtctgaa	actgaaagat	171240
aggtagctct	agaaatgtga	taaatggcca	cagaagtaac	aacttttaat	aaattaaatt	171300
atggatgtta	tgtcaatttt	aagtaatgtc	tcagttttat	atcttgttac	ctgacctaaa	171360
tatcattccc	tttagtaaaa	tatctattaa	agctttgtgg	caaaataaga	acagaaaaat	171420
ggtttttgat	tttcagcttt	ctctggtgaa	taatttggtt	tcttttattt	ttccttctaa	171480
aataatcaca	cgtttcattg	caaccctaac	cctcttcaac	acacacacac	acacacacac	171540
acacacacac	acacatggct	tctagattct	acatgtacaa	gagtgcgaat	caaactacca	171600
tagaaaaact	aagaagagag	gcctagaagc	aagaggctga	tacactatct	caggcttcaa	171660
caaaatattt	atctctgact	ataccaagga	tgggcagagc	ttgcatgtaa	gtggcttggtg	171720
ctgacagact	gggttttgaa	ggaggacaac	atggccatgt	tcttggttcg	gtcattgaact	171780
gtctatggca	cataaccttaa	atactgttgg	aagcatccgt	tagctccaga	gactgcaacc	171840
aactgcctat	ggtcataaact	cagctctcag	acacattttg	ttgtgcccac	agagtgtctgt	171900
ttgcctgttt	ggttttttaa	ccaacactta	aaatgcaggg	aattttaagat	aaaaatttga	171960
taaaaatggg	aagatttggtc	cgtattgggc	tcattggtaac	tgagatgcat	ctgaatgaca	172020
ggcatttcctt	tgaattgcac	atgtgtctct	gtttttacta	taggccactc	tcactttctg	172080
tttttttccc	cggctttgaa	acgatcagtt	ttagtactga	aaaatttatct	aggatactaa	172140
aaccagaatt	tctctgctag	atggcttgct	cattacatta	cctacatgat	tctgtgtaag	172200
ggattgtgta	agttttctat	ggttgccata	actatcacaa	acttgatggc	tttataacaa	172260
cagaaatgta	tttacagttt	ggaggcagaa	ggtctaaaaat	caagacttct	gatttttagtc	172320
tgtccaagag	cctctgctgg	tagggccatg	ctctcggcag	aggctcttgg	ggagaatctg	172380
ttccttgccct	cttccacctt	ctggtggctt	caggtgtttt	gtggcttgtg	gctgtatcac	172440
tccaatttct	gcctctgttt	tcgtatggcc	ttctactctg	ctcctttagt	ctctccttta	172500
ggctgtttct	tataagacac	tcacctaaaa	cccaaaaaca	atctaaaaga	ttttgcaaat	172560
atgaacattc	taattacctt	agagtttaaga	ttttcttttc	tgctaagtga	gggcatggtg	172620
cagagagcag	gaaagatgtg	aaactagata	gcatacaaaa	ataggtgttc	atagatctgg	172680
gcctaacaag	ggtgtggcca	gcaactctgc	ctgcttttat	cagcattaga	aagccagtc	172740
tctcagaaag	tgcccagtta	gctaaattca	tgagattata	gactattaag	gtggaatgga	172800
cctcagagat	ggtccttgct	ctcatctgag	gcttcagttg	ggccagtcag	aaatgtggga	172860
aaattgaggc	aggtcaaata	accaggagta	caaacaaaca	caatctatcc	agaaaactag	172920
aaatcttact	agtgactatt	cacaggttac	tttctgcatt	ctggggtttt	cattctagaa	172980
cagatgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tggtgcgtga	173040
agagagggga	ggggtgcca	gaaaaccata	cccactttcc	cacatatccc	aactatgact	173100
gggcaattat	gtcattatca	ccactgatat	atagctggaa	gagtttagtg	ttgccctgct	173160
aagatctgga	ttttcttttc	tggagcttgg	ctattggggc	attgagaagt	ccagccagga	173220
ggttggtcag	aggctaacc	aaaaagcttt	gcttaactct	gggctacagc	tgggggttgc	173280
cagagagaag	tgccctggcat	tcctgcatgc	tgacatcaag	cttcgaagtt	gctgccctct	173340
ggtgagtcag	cagcaaaggc	ccacatcggt	cgagaatgct	gccaatcag	aagatgtgat	173400
gccacacctc	agaaaatctt	ctaaacctca	gcattctgta	gacttcaaac	aactcctcct	173460
gagaaagaat	gtagaaataa	ttaaatttat	aagattaaag	ttataaaaag	catagagcct	173520
ataataataa	cagcaataag	ataaactcca	catttgcttt	taaaacaatt	tatttgagta	173580
gacagccaac	cccctgtatt	gtactccttt	aaaaaatatt	ttaggccttt	taaatgctga	173640

ggcaagggga	cataccaaac	actaacaggc	acattgggggt	tttctggcta	ttgaaataaa	173700
aatgtcctta	cataacactg	atgtactgga	atagcactgc	gttccagtga	cggttattgc	173760
aactcagcca	gcataatctgt	agcttgtgag	cttttcttat	cagaatttta	tctataaata	173820
tacatatagc	taaattctat	tgtgaaataa	aaataaaaatg	tagaatcttc	tcatctttct	173880
tatttagtcaa	tattgtgcta	ctctttaata	atttctctca	attttttcat	taagcagata	173940
ttactagggga	aataatacatg	aggcagaagg	caaattatatt	gcttagtgca	atgcaaactt	174000
gcttaacagg	taagagcaga	gtcccttcca	tagcattgcc	accatatggc	attgccatat	174060
cgtggaggcc	ataaagaggga	atgacattgt	aaagattaac	tggattttac	ttggcaaggt	174120
caggcaccta	gatggcatgc	tataaaatgg	ttagaagtgc	aaaggaaacc	tgtagctaga	174180
ggccatgtga	gattatggaa	gtgacttttc	ttacaatcct	gccatctggt	ttggattgtc	174240
aggatcaaaa	catttctactt	gcccagtgga	ggatgctctc	tacatggttt	tggggatgag	174300
ggagactcag	aaataatggt	tgtggtactg	tagcaccact	aggaaaagag	aaaaattgga	174360
cctgacatga	agaaaagcat	gcagccagcc	actaagacta	cttcccacag	gactggaaat	174420
ctctaccacc	gtacctctcc	tacatgctgg	gtataagaag	ttaaagggaa	gccagattat	174480
atttacctac	tctttcattc	attcattcac	tcattcattt	attcatccat	ttaccatttg	174540
tttgtttttt	gttcattttac	ttatttaata	aaaattgtgt	tttgcataat	ctagggtgcca	174600
ggcattgaag	aaccactggt	attgttctca	aatgactgac	agtttagagg	agaaaatgga	174660
agaataaata	gacacttggt	atgcaatata	atagtgtctc	aataagagca	acatatattg	174720
aataccactg	aatattaaat	accagggact	ttgctaggag	ctataaatta	atctccacag	174780
tacatctaag	atagaagttt	tataattact	ctcttttagga	ggaaataggg	gtctatagag	174840
gttaagtctc	acagcctgga	aggagtcaac	aaaaaaaatac	tcagccttag	gtattctgac	174900
tagaagcttg	ggtccttaac	cacctaactca	ccaatttgaa	gaaagatgat	tgaaactgca	174960
acagctacac	tgactcttga	aagcaaagta	actcggtaaa	tgagggtatg	tgtatactgg	175020
ctgggatatt	gtgggctcat	gatgacttgt	aggccgaggc	agctgcacat	atgaagacta	175080
tggagggtat	atcatcagcg	gaaatgaaag	tgattagtgt	tggaggtttc	agtgcataat	175140
ctggttttct	attactgcat	aacaaatcac	cctaaaattt	agtgacttaa	ataaacatga	175200
tcatttattt	agctcatgaa	tttgcaagtt	gtgcagcact	tgggtgggat	agctcacctt	175260
tcttccatgc	agtgtctgct	gggactgcat	gattgcatga	agcggggctg	ggcagctaga	175320
gctcttcgat	aatctctatt	tttgcataat	attttcacaa	ggtctctcaa	gcatgggagc	175380
ttcaggtagc	agaaactctg	acagggcagc	ttagtctctt	gaaagtgtat	gtctgaaaag	175440
agagactcag	gcagatgcta	tattgccttt	tgtgaccaag	ccttggaat	cactagtctc	175500
tcttgtgttg	agggtggtat	aagagcctgt	ccaggttcag	tagggagcat	aaatttcacc	175560
tctgaatgga	gaagtgccaa	tgtcctgaaa	aagcatgtgg	gcccagaaat	actgttgtgg	175620
caattttttg	aaaatcaagt	gtgataaaga	cagcatagtg	tagtcataaa	aaacagatta	175680
ggagcatgat	gtgctttgat	ttcaactatg	ggctttatta	cttactaact	gggttacttt	175740
ggtaagtgtg	tttgactctt	gttttttgag	atggagtcat	tctgggagac	tccagctctg	175800
tcgcccaggc	cggagtgcga	tggcacgac	ttggctcact	gcaacctctg	cctcccggat	175860
acaagcgatt	ctcatgcctt	agcctcccga	gtagctggga	ttacaggcac	ctgccaccac	175920
atctggataa	tttttgtact	ttttttcttt	ttcgagaccg	tgtctcactc	tgtcacccag	175980
gctggagtgc	agtggcatga	actcggtca	ctgcaacttc	cacctcctgg	gttcaagcca	176040
ttctcctgcc	tcagcctcct	gagtagctgg	gagtacaggc	acacgccacc	atgccaggtt	176100
aatttttcta	ttcttagtaa	agatagggtt	tcagcatggt	ggccaggttg	gtctcaaact	176160
cttgacctca	tgatccgccc	gcctcagcct	ctcaaagtgc	tgggattaca	ggcatgagcc	176220
actgtgcccc	gcctaatttt	tgtattttta	gtagagacag	gattacacca	tgttgaccag	176280
gctggctctg	aactcctgac	ctcaggtgat	ctgcccacct	tggcttccca	aagtgtctcg	176340
attataggca	tgcgctaccg	tgcccagccc	aagtgtctg	actcttaatt	ctcagcttcc	176400
ttattttgtaa	aatgaaggta	ctagtactaa	tttgagaggt	tgttaaagat	taaataatat	176460
atgtaaatgc	cttggcataa	gggactggca	caaagttagc	acttcatata	taaaagctgt	176520
gattattgat	gaaccagtag	tgaggtagat	aactggggaa	ggagaagggg	ccagtttgtg	176580
ggaatgcttt	tttagttatt	aatagtaagg	tggtaaaata	ataatagtaa	taataaccaa	176640
aagttactga	aaactaaata	cagtgtctaaa	ctcttttaaaa	ggagtatcta	attggatctt	176700
aacaacaaag	ctatgaagca	ggactaatgt	tatctcattt	tataaatgag	gaaatgtaag	176760
atcaaacagg	ttaagaaact	ttcccaagtt	gatcagtagc	aaagacagga	ttcgaaccaa	176820
ggtaattgtc	ctatcagaaa	ctgtactagg	atagtctgca	tttcatggta	aagactatca	176880
gatgccacta	aaacttttta	aaaagggaag	tcttgtgtgc	aaatttgctc	tttagaaggc	176940
agtatggagt	gcagatcaga	tgctggcagc	agggagatca	gttagaagat	ggttgctcta	177000
attcagttga	gaaatactga	gacatctgaa	atattgaaga	catcagtagt	gtgggtgatg	177060
tgaaagtggg	tctaagaaac	tagcggcaat	catccttcat	tactgattgg	gcgtggagag	177120
aaagagaggt	agcattggta	gccgttagtc	aactctgagt	gcaggcactg	gcatgtgcat	177180
tattaccag	ggctctaagt	ggagaaagaa	aacaacccca	gggtgtcttc	aaacctaag	177240
catatttcct	aagcctttgc	actctcagtc	tagactaaaa	acaaacaaag	cagcctcctc	177300

tgaaatgctg	gaaactttcc	ccacttgaaa	ctctcagatc	tcttaccttg	caattctagc	177360
tttcaaattc	caagctgagc	ttcctttccc	acaccccgag	tccttgact	ggggattaca	177420
atgatcattt	gtatgtacta	ggtgattggt	ccttccacat	caggggcctt	ggagcggatg	177480
acctaaagct	gctttctcct	gtcctgactt	tctccacca	gcactgcaac	catacataca	177540
atcttctggt	ctttagagaga	atgactgact	ggtcattata	gtcttccaaa	aggataagag	177600
attagtgtca	tgatgtggcc	ttcaggcagc	cagggggaat	ctccatatga	ggtacttggt	177660
gactgtatta	cttagtttta	ggtgaacttc	ctgtggaggg	acaatatgtg	cttagaagga	177720
cagagaagga	atgtattagg	taaggcattc	tacatctcag	ataaagaact	tcaatgaatt	177780
gttgggtcaa	ggtctaagaa	acaaaccagc	cgtcaatggg	aaagttaact	aaaatgaaga	177840
acccaacata	caaccccaaa	tcctagtttt	tctgactatg	ttttcttaaa	ctgaaataat	177900
ttctgagatt	aaaaagaagt	tgctgtgact	ttgtctgata	gatgtatttt	tttgttatat	177960
attagtttgg	gccttctatc	tctcctactt	tggtttcttt	ataatagaat	taatctctga	178020
aaagtaactt	tactgtattc	tgatgtccca	ttttgaataa	gtcagttcct	ctccgaatgg	178080
gctctggaga	ttggcatttg	attgaacagc	ttttgtgtat	tgattgtttt	aggtagactg	178140
ggtactccat	ttaacttagt	atttctgaca	ataaatcagt	cgagaaggga	gtattactct	178200
aacgggttga	acacttgtct	atgcacattg	cttggctcatt	caataagtag	ttatttggtga	178260
gatcgggac	gttcagggtg	gtatggccat	agacaataaa	tggttacgac	tctgccttca	178320
gctgtaccag	tatttaagtt	ataaggtagt	taagttacac	cagtgcacaa	tcatacagtt	178380
tggtcacagt	cctacttgag	gatctcaaac	ctagctcccc	ttaacaaaca	tggaggctta	178440
atcttggcct	tgcacactga	attattcctt	tagaaaaata	cttgggtgtac	aactcatcct	178500
tttcattttac	aaagaaacaa	atttgagcag	tttcacaatt	taaaaagtct	cccaaattgga	178560
ttatatttta	ttgtccattt	ccaatgaaac	tcactaaatt	ggtaaatagc	agtgagtga	178620
taactgatga	ggtcatactt	tcttggtttg	gactactaca	aacaccacgg	agcaacaaca	178680
gattagaata	taaaggttaa	gcaagggttt	agtttttggt	caaaagccgt	tttgcttggt	178740
acaaaggcta	ccaaaccttt	gaacatcaga	ccaaaccaaa	aacaaaacaa	aacaaaataa	178800
aaaaaacccc	aaaactgaaa	gatgaaaaca	tagtttgata	atctaagctg	ctcttccttt	178860
atttaacctt	gaatttatga	gattattttt	ttcccagaa	gaaaaattct	cttagggaca	178920
ctttcagcaa	tttaacattt	tctaagcatt	acagcaaata	agaggcgatc	atcattcttc	178980
agtcataaag	ataagccaag	gaatgaaagt	gttttgagg	tcattgtacc	tgacagaaac	179040
tttgagactg	tcctttcctg	gttcaagagt	tcagccataa	tacctacttt	ccctatcagc	179100
ttggctcaagc	tgataaggct	ctgaagcaag	caaagcttct	ttatgagctt	ttatttaatt	179160
gtccttgcca	cataagggtt	gaggggattc	gtctgtacag	agttacttct	tgttggtcta	179220
ttttttcttt	ggaataaaatc	gctgtctccc	ctgactggat	agagtaaata	gagtttggtt	179280
aaacactttt	catcaaattc	ctagtgccta	gtacagagct	tttaacccta	atagctttcc	179340
tgctgtgact	tattgaagga	ataatgacaa	actctgcctt	agattggtga	ctggctaggg	179400
agaaacatgg	ttcaagagct	gaataagtaa	gagcaagtat	tttattgtat	gccccatcaa	179460
tgtattcgat	gctgggtgat	gaggtaaag	tgtgatagag	gctgagttct	ctgaaattac	179520
atatgagatg	tcattctgcca	tttagtatta	gctgtgtctg	tcttttttcc	aggaatttgg	179580
ccttaaaaga	gatcattcaa	aagtattacc	caaatagtga	tttatcaggc	tttattgtgg	179640
ggaacctaaa	gtggattgca	actgctatgg	tccctttgaa	gggagctggt	gcaagatttt	179700
ccatgcctaa	tcacactcat	tttcccttgc	tctcccaatg	acctcccatc	tttcccttcta	179760
tttggctctga	taaacaccaa	caataggatc	ctttctgcag	cttccatcct	aacttgattt	179820
ctagccttaa	cactgcaaca	aactcactgt	tacctagaag	tcaattgact	tccctgaatg	179880
ttagcttctt	tagctgtaaa	taagtaattg	tatgagggtga	tggttaaggt	gattttactaa	179940
ttttacaatt	ctattatttt	atgaatagac	cctagttagg	atagtttgaa	atagatactt	180000
aatccactat	tattctctct	tctaagatat	agttactagt	tgatcatact	tttccctaaa	180060
ggctgaactg	aattctctga	tatcagcaac	taaactatct	atatttgtca	gtatgaacat	180120
ccactgggtg	cctgttattt	aaccaggtag	aattcttagc	tgtgattgaa	aatctaggta	180180
tctcttctgg	tactatcact	tggatgagta	aagtttgaaa	accattaagt	tgacatttct	180240
aataggactg	tggatttaac	atagattccc	agaagtcttg	gaatacaaca	gtgtacacag	180300
atgaagatac	agtacttttt	ggtattttct	ttttgcaagt	gttacaaaata	tctgcatgtc	180360
ataacatcat	cactatggat	cccatctttt	aatgagagct	tagtatatgc	tacacactgt	180420
cactaaacat	gtaggatctt	gttttagttt	ctcaaaatgt	tgtagtact	atgattattt	180480
tttgtgtctt	gcaatcattg	tgtataagtg	cgtaaaccat	gtatctagag	tttatagaag	180540
aattaaaatt	caaaaaccct	atactcatct	ctcattttta	aaaaatacca	ttttacctgt	180600
cttttagatgc	cctgtatttc	ctccccaatc	tcattcccgt	cctactcttg	aaagtgatca	180660
ctatccaaat	tttgtgccaa	acattaactt	gttttcttta	gctttgccat	ctatgtatgt	180720
atccctaggt	aatacatggc	ttagttacac	ttgtttttta	atttgatgta	aatgtaatcc	180780
tatagtatga	atcttctaag	acttgattaa	tctatgaaca	ttttattttg	agattcatca	180840
atattgatgt	gtgtagctat	agttttattca	ttgtgtgtgc	tgaaaaatat	tctattggat	180900
gacttttgcta	caattttatc	taccattgtt	ggatatttga	gttgttccca	ttttatttat	180960

ttatttttatt	tttttgctgt	tatgaacaat	gtggccttga	acattcttat	actacctggc	181020
gtgtatatgt	atgtatctgt	ctgtctgttc	atcttaagat	gcactacaaa	actgaggcct	181080
agagtcacca	agcaacttgt	ttaatgtcag	agtgaagttg	tggtgaggcc	aaagtctgaa	181140
ttcagcagtc	tgttaccata	gttttcatcc	ttaaccacaa	tactctatga	atccttattt	181200
taaaaaggaa	ggctctggaga	atttaaaata	acttcctaaa	gagcagggat	tcaacaaagc	181260
tcagtctgac	taatgccttc	cattttttaa	aaatcaccca	aagcacatat	tatgattcta	181320
tttgtgaagt	attagctaatt	tacaagagaa	tgagttcata	cttggcacta	ctatctcttt	181380
cttacaagtg	atcagatgtc	aaaatgtgaa	aactatacat	ttcacattat	ccatatatat	181440
gtgacatttt	tccttttagga	atatgagtag	aaatagaaa	acagggtttt	acagtgaagt	181500
agattttttt	tctctctctt	tagcctacca	aatctctttc	gcaataccta	acacttataa	181560
atgcatttaa	tttcagtgcc	aattaaagaa	attcgaaagt	agataataag	tgagacaagc	181620
acccagtaaa	tgtttatgat	gtgacactga	caaattatgg	gctgctataa	tcaagatagc	181680
attaaaaaatt	ttaaagtgtt	tgtatgaaca	aacctttttg	gaaggagtgt	ttgggtgtgc	181740
agtgaacaaa	acaaccagtg	aactatggca	tttagtggtt	aagctctgat	tttgacatga	181800
aaggaaataaa	aatggaagtc	cagctaaatc	acaagtgtcc	tggagaaact	tggatgagtt	181860
tcttggttag	aggtttttcc	caccacagta	agtattttca	aaggaaaaca	aagtaaaatt	181920
tttctcttgt	atgagtcaca	tctctgttgg	ttgtaagtgg	ctgaaactca	tcttgaacta	181980
ccaaggtaag	agaagaaaca	tactggttaa	tgggaattcca	gaaaggactg	aacaatcaaa	182040
ccattttgaa	ggacagcata	gagctggact	ctagaacagc	caaaacaagg	ggttaaacca	182100
ctgcgaggga	tctctctcca	actcttgctc	aggcttttct	ccctggcttg	actttcttct	182160
ctttcactgt	agattggctt	ctctcacatg	gcaagaaaca	ttgctgctag	cacttcccga	182220
gttctacgtt	ctacaacatc	caccactggg	gagagattaa	cttatgggtt	ttctgttgaa	182280
aagtcaaaaa	ttacctggga	aaagtctgat	tgtctcagat	tggagatggt	gccccatctc	182340
ggaccaatac	actattatgt	gtggctgact	atataaaaa	atggatattt	tcttggaaatc	182400
acttggtttg	actgggagaa	gaccattctc	aaaacaaagg	aagtgcattt	tatagaaggt	182460
agtagaatag	gcagataaaa	caataattct	tcactatatt	gctcaaataa	tccccatgac	182520
attttttagta	tattataaa	agagttctaa	agtgtttcca	aactattata	gcaaaattta	182580
atcttataat	aatttcttct	tgaactatgt	ataatttacc	tgaaatattt	tccaaaaagc	182640
aatcaatgtg	agaaaatgag	agccctgtct	tcttaaaaaa	atgagtaaaa	gtccacaagt	182700
tcagaaacaaa	gtaaaatgag	gtaaggccta	aaataaattg	tgctaagaaa	gctaaaaattc	182760
tagacaaagt	cacatcggca	aaactagaag	gttggtactg	tgcttcagtt	tactgcttgc	182820
tgtttggtta	agaggagggg	tgatgtgata	aaaatagtga	cgaagtgaga	aaactgacgt	182880
attagttttc	tattgcatta	taacaagtca	ccacaaactt	agagggttga	aataacgccc	182940
atgtattatc	tcgcagttcc	tgtgtgtcag	acctccaggc	actgctgggc	tcggctgggt	183000
tctctgctta	gaatctcaca	ggtcaaaatc	aaagtatcaa	tgaggagctgc	agttctccca	183060
agctggagcc	tgtgtccctt	ttaaactctc	aggctgctgg	cataatttat	ttccttatca	183120
agccatccat	atgatccctt	ccatcttcag	gccagcaatg	gcctgtcaaa	tccttctcat	183180
tctttgaaaa	tctctgactt	ccctttctgt	cacagctctg	taacttcttt	tctcttctgc	183240
caccagcaga	agaggctttt	aagagtttat	gggattagat	tacatccgtc	tggataatct	183300
tttacttaaa	ggtcaactat	gctatataac	atagccaatc	acattcgcac	attgcagaga	183360
ctaggggtata	aatcttctcg	ggtcattcct	agaaattctg	cctgctgcag	cctggtttct	183420
tgcttggact	ctagtatata	tttgctaaat	ctcccaagcc	tcagtctcac	tatttgcaaa	183480
agtgaagttt	aatgctcttt	gccctgcttg	cctcacagga	tcttaacata	gacgtaagat	183540
caaatgcaat	agcatgtcaa	acaatgtgta	actccagtta	tacaaacatt	actgtatctc	183600
attggggata	cgaagctcta	cacacttgaa	gatggtgaag	gaatataaaa	atgtaagtat	183660
tgcttttata	ataaatgtgt	tcctattggc	tgaaaatttc	aatatctgat	acaaatagtc	183720
aacttttctat	tttacttttt	ctaattatgc	agacacttgc	aatcacaaat	gtaaaaattg	183780
caagccacat	gcccctaagg	ccaaataaaa	atttgtaaaa	ttctcttaaa	aagactctat	183840
agagtcacaa	tgaaaatacg	tcgagtcctt	ttaaaaggat	ccaaccacat	atatcaactg	183900
atatacatgg	taccaaaaa	aatggaatct	tttcagattc	tctaattggc	ctttggaact	183960
tatgtagcat	caggtatgca	aatgaacaac	ttcagacctt	gattactcca	acctcctctc	184020
ccactgtcac	agccacttct	gtcatgacct	agttgttctc	agaaagttcc	ctcttatacc	184080
tggtcaaaact	tctctttaca	tcacctgtga	ctttccctct	tggtcttgga	tcaaatcatc	184140
ctaaatacat	taaaagtcct	gattcttctt	gtcccttaaa	tatatctcta	cttgaatcac	184200
tgtgttagtt	caggtcctct	gagagaaaaga	tggttaagatg	aaattagatg	tgcaagagat	184260
tcgccgaggt	aaaccttggt	ggagaaaatg	gagaggtaca	tagaggagcc	tgggcagact	184320
gtgtggctac	tatgtaagac	tcatcccat	gaaggagaaa	ggagaggaag	gcaaagaaga	184380
aaaaccttaa	gatttcaatt	ctaagaacgt	tttgacaaa	ctgattagga	gtatttaagg	184440
caaagctgcc	caccagaaga	gtactgcac	tttcaggaac	ggacttgctt	tagtacatct	184500
gctgtgctta	gtaattgggt	gggagcagcc	atagaaaagca	tggactcagt	acaaacttgg	184560
tgatgaattt	cagaggcagc	ggctaagacc	atcagctcat	tattttcctt	gcaatagctg	184620

tcataattac	tatcagagca	aacaattttt	tgtgtgtgaa	ttcatgagat	aatgggtcttt	184680
tcttttctgc	tttcaagagc	catgtcattg	aaagagctaa	tcattcaaat	ttatgctgca	184740
ttactgacta	aatactttca	tttatcatac	tttatttttaa	aatacttttaa	ctcatggccc	184800
gatgattttc	agttaaccaa	attctccctt	actatcctgg	ttgccccttc	tgtcttttcc	184860
ttagaaatgt	tattgtagta	tttgcaagat	ggcctgaatc	ctgaaccccc	catcttcaat	184920
gagcaccaaa	tggttaattat	agattccag	ctgtagagct	atgtcagaca	aaggaaactt	184980
cattagtatg	taccaatggt	tggactccaa	atgcttttgt	gtctgagtca	caaggactcc	185040
tcttccttgg	tggcttaaaag	ttaggctgaa	gaagattttac	attatgttgt	gcatgacctc	185100
tttagtttgg	ttctacttat	actttcaagg	aggggaagact	ggggaagggtg	tcccttagtg	185160
agcatatttt	gtacaaatga	aaacagggtta	ctaacactta	tgccaggacg	catgcataaa	185220
ctaggatggt	tctgagaaaa	ctgcgatata	tgatcactcc	aggggtctccc	ctctcagaag	185280
cgaggggagac	ttaaaccttt	tacatcacca	agtacatgga	aagaaagaca	gcagggaagt	185340
gattccgaag	agaaacctga	aaaaagcaat	gtggaaagat	agacacttta	gccttttctt	185400
tcttctcaaa	acttcacatt	ccttttcact	ctgcttcact	taagctgccc	tagttccaga	185460
gtgttttctc	tcttgggtga	agatgggaac	aagtacatgg	ggtagcaagg	ggtgggtggg	185520
acctgtgctc	ccattaagggt	tcttccagaa	tcattttctat	gtgattatca	gcttggatca	185580
catggacttg	gggattattg	gtggttttct	agggtaaaca	gggcatattg	tgctggagga	185640
catattttat	atgtaacaat	ttggggaaat	tttcttttat	attaaataaa	actgagatat	185700
gtaatgaatt	aggatgaaaa	attcatattc	atctgaattt	tataagtga	tcatgagaac	185760
tcaaagatac	ttagcccttg	ggaccatttt	ttactcctgt	tcggatccct	tcagctaagc	185820
atgattattt	actattttca	gctattagtt	atgtcttgtt	gaaaaagtat	gaaaagagct	185880
gccaataaaa	ttagagtgt	tgctcaacat	tctcttagct	tctttatctc	tttccaaaat	185940
tggtatcaaat	gacattggac	atgatcaact	tcttactgtt	ttgacaaa	tctgaggata	186000
cttttataat	tgataatttg	gactagatta	tgcaatgtgt	gatgagacac	aaggtagtct	186060
gtactcccca	tgatatgtat	atctgtttga	tataactcaa	cgggtgtatat	caaacggata	186120
taagtttgag	taggtatgga	gatgagccag	ggtttatttc	ttcaactagt	atttactgaa	186180
tggtcttatg	tgccacaact	gttctggaaa	ctgtgatata	ttaatataca	gataaagcct	186240
ttccctcaca	atgcataaca	gacccaacag	agtatgaatg	tacatacaaa	ctagtaaata	186300
agaaaaacaaa	taaaagtatt	cagatagtgc	tataactact	gggatgaaaa	tcgagcagga	186360
aggaaaatat	agcctgcttg	atgtggaaga	cagggatagc	ctctctgagg	aggtgacatt	186420
tgacccaaga	cctaaatgag	gagaaggaga	cagtgaagt	aaaatgaggg	aaacagcaat	186480
ggcaaataca	gagaacttga	gacaacttgg	cccattggag	ggacagagac	aaagccaatg	186540
tgggaccaca	ggggatgaaa	gggaggctga	ttggagaaat	aggcagtgt	gaggccataa	186600
aaggtcctat	aggtcatgga	aagacatttg	gttaccattc	taatgacagt	gagatgttac	186660
tggggagttt	taaactggag	aatgtcataa	ctgtccagat	gtaaccaa	agtaaaacca	186720
ttcttctctga	ataacttggc	taaaaggaat	attatgacta	cagatgtaca	tgaagattaa	186780
gcagaacatg	gaagaaaggc	ctcaagtaaa	cttgacctca	cataaatatg	ggaggaagat	186840
caaatggaag	ctgggagtgt	tgaaagaatg	taaggggaat	gacttcta	aatgaacaaa	186900
aagctgttat	tttattatga	agaaaaatgt	tatgcatctt	atgcatgcag	aagaaattcc	186960
cattcaaaa	acttggaaaa	tgtcttgggt	gtttactata	ataaaccttt	taagatatag	187020
aaaattcaca	tatttagagc	ttaatttcta	aagagctcag	acttctcagt	ttatttatatg	187080
ctatgaaatt	ttgtttattt	ttaatttaac	ctacttgtgt	gcaaaatcaa	taaggaagct	187140
taaggaatat	aaacaactat	ttaacatggc	cattttaata	gattcaaa	aaagaatatc	187200
agcatagtgt	ttctttgata	tgacaacccc	tcctcccagg	gcacttaaat	gaagggttgg	187260
gggggaatct	taacctgaaa	ttgaaaaccc	tgaaatcatg	tttccaagga	aggagaagga	187320
aaataggaaa	aacaaaaaca	aaaagcagca	actcatttgg	aagctcgtgg	gagaggagag	187380
gaggattcat	acatctcgga	ctgggttggc	ttagcaagtg	aatcatttaa	ataggaaaaa	187440
acagggggct	gactcagctt	gagcaaacctc	ttgctatccc	ctgctgaggt	ccgcacttgc	187500
tgtggccctt	gccgtctctc	tcggaccttg	ctgccctcct	cctttgtcac	tgtggagaaa	187560
caggaaggaa	tgtttattag	caagactgac	tggggtcaca	cccaaggcaa	tatcaggttt	187620
ttacctctcc	caggcctggg	aagaggttca	aggatcaagg	acaagctccc	ggttagagt	187680
agaggcaagt	tcaaaccttt	gaaaaataaa	ctcacaacca	gcatttggca	caggcctctg	187740
gagtttacag	aatgtatctg	cctgtgtgtg	atttcattag	ttcctcctgc	caatcta	187800
agattttacg	tcctgtaaca	gtgaggcaat	tggagtctca	gcagggaaag	gaacttgcct	187860
aaaactgcag	gatgggtagc	gcttggatcc	tgactttctg	actcctagga	ctgtgctgtc	187920
ttcagatgat	cacatgcctt	cttggcagat	gtttctaaca	aaggagagag	ttgccagg	187980
tggggctctg	ctagctccct	tgtcatgagc	cattctctcc	acattgcctt	ttagttgcac	188040
cacatagtca	ccttcaatta	gctgtgcgaa	taggctcact	cttatgctaa	catgtactaa	188100
aagtgaaaat	ggggagagag	agagagagag	agaaagagag	acacacagag	agagagactc	188160
atattatggt	atgttccctg	ccccacccca	ctccactccc	tctcaacagg	gagaaagtac	188220
ctgaagaaaa	tcattgctat	gaagggcata	gccagctaaa	tgggtgtcac	ttagtctgaa	188280

aaatctcaaa	gatgtcaata	agccactcga	gacaacaagg	aacctgtttt	cctgtcatca	188340
ttcctttctca	gtccttggct	ttgggaagg	taactttatg	gagagagaag	aacctctgtg	188400
gagttaaaag	gtttatgaac	ttttttccct	gcaacaaatc	agtgcacagc	gttccacagg	188460
ctgatgggtt	tccctttacc	tttcgttttt	taacagctat	gtctcacagt	ccagacttgg	188520
agtacaagta	ataagaagaa	taaaacttaa	tcccttaagt	agattcacca	taagttagct	188580
cagagcaatt	ccagtgcag	tatggtctgt	gatccagtag	gtgagtgact	ctgctgctga	188640
aattcacatg	tatgtgaatt	tcacagtggc	ctttgctttg	tagcatgctg	taatcctttt	188700
gtccattttc	atcacacgaa	ctgctgaata	taggattgtt	aaatggatgg	ggagatatca	188760
tgaaaatgat	taaagaagaa	agttcttatt	taggggtgca	tacctgccta	tctgaccatt	188820
gtacttaggc	aatcgggac	ttgctttaag	aaaaggtagg	cattggagtc	aggctgctgg	188880
agtatgaatc	actatgctat	catttttcat	ttgtttttgc	tctgtttacat	taggaaagtt	188940
atgtagaatt	ttgtgcctca	gtttcctcat	tcaatatggg	tgtataaact	gtgcctgtct	189000
tgtaggatta	ttgtgaggcc	caagtgcagt	aatatatagt	acactgtgtc	tggcatctag	189060
taagcattca	ttaagatgac	atgaagataa	cacagatata	tcttaacatg	taattatgat	189120
tttgcttatt	caaggccaag	cattccaatt	taagtggagt	aggcaaacac	agtaaattca	189180
ttgctctttc	ctttttatgc	tacttccttt	gaagaggcag	tcaagttcca	tttgactgat	189240
tcggaacttt	ttagcaatgt	atattatgct	gacttcactc	ttatgcgctc	ttggggctat	189300
aattcatcaa	gttaggcgag	caaagaagtg	tgttggtgaa	agagaaatga	ggaagaacaa	189360
ggaagaaaaa	aagggtcatg	agcttattca	ctgccaatat	ttattatatg	gaacaatgac	189420
catccttcag	aagtgtttgt	tctctattat	actgtagggtg	tggagaat	atcattgtct	189480
aatagctgtc	tcagtcacta	cctgatagac	ttgggagggtc	tggctatttc	agggcgcat	189540
tgacatacag	tgacattttt	ggattaaagc	tttcatgatg	agtgccagtc	tgggtccaaa	189600
aggggtgaaa	gctgtcgcca	tctataggct	agttgtttgt	agtaaaatc	tttccctcac	189660
tgcattaggt	tcttggtacc	atztatctag	cagagttctt	cagtgggctt	gaggcttagc	189720
agtcaagtta	aaacaataac	caacatccca	aaccagtggt	ctgtcaaatt	tcagtgaggt	189780
ggcatagaac	tttagcatga	acttgagctt	gggttcagct	agactttcat	ataaatcctt	189840
gtttgaagtt	agtagctgtg	tgatcttggg	cactgatatt	aaacctttat	gagaaagtta	189900
tgtctgaaat	atgggaaata	aaccttccac	ttagggttgt	gtgaagattc	aatgagttgt	189960
aacgattgta	tacactataa	tgatctatat	tacagtttgt	tcataaatat	gattgccttc	190020
attttattct	ttccttgtct	cgttcttccc	agtatcttac	agacagcaag	ttgaacattg	190080
tgggatgc	gagctattga	ggcctttgca	gctttctgct	acatggaggc	tagggccaga	190140
gtcaagattt	atgctttgca	gcacactggg	cagctgtttt	tgcaaatcag	attaaatgat	190200
ttttaaatga	ggctgagagc	atgggagata	ctaagtgtgt	tttcttgtg	agctactgca	190260
taagtaagt	ctttgtaaaa	tgtcaggggc	tccaggatta	tatggtatta	ctgtcactat	190320
tgtaaagc	tctacctttt	ttttctcctt	ttacagggtta	ggaaattgaa	atacagaaag	190380
atgaaaagt	atgtgcccc	gcataatgat	caaagctgtg	gcagaaccag	gactggaacc	190440
tatatctctc	tactaatggg	ttttttaaaa	aaataacctt	gtttcaaaaa	tattaaaaag	190500
tcacaagaaa	ggtaaacatg	tggataaaca	aatgaagaa	aataaaaatt	atccagtaat	190560
aacatattgg	catatgtctt	tctggtatat	tttctgtgt	tgtcatcatt	atcatctcca	190620
tcatcattat	atccatcatt	atcatcatca	tcatcatcat	catcatcatt	atcatcacca	190680
tagtgaacat	gtaatgctta	cctagtgcca	gatgctgtct	aggcatttta	catgtgttac	190740
tggtaactca	tgtaatcctc	ataacaacct	tataagggtg	ttgctattat	ccccatgtta	190800
catatgaaga	gacagaagca	taaagaagtt	gcaccgctgg	taattggctg	ggatttgaac	190860
ttaagcagtc	taaccttaga	gtaatgattt	taacaactat	gctatatata	tacaaattta	190920
caaaataaaa	ctgggctcag	acaataaaaa	cagctctctt	ttcatgttat	aatacttttt	190980
caccccataa	cacataatca	ctaagtgttt	aaagatcaaa	acaatgcaca	taaaatgtac	191040
tggttttaaa	aaaaagagga	aatagccact	tacctcaacc	aaactaactt	ggagatgat	191100
tagattgata	atggcaagg	tgatgggtag	atgggtagag	gttgctcaaa	aagaaacaca	191160
aaatatatcc	tcttttaagg	atcctgatgc	tttgctcaaa	gtaattttta	ttctttttaa	191220
actaaaaaaa	aactgtacaa	aattcatagg	gtacatagtg	gcgctttgat	atatataatg	191280
tatagtgatc	agatcagggt	aattcgcata	cccagtcata	ctatagtggg	tatagaacac	191340
cagaacttat	tctttctatg	tagctataat	tttgatcctt	ttaacaattc	tctccctatc	191400
cctcccttcc	ccctactttt	cctagcttct	agtatcctct	gttctacttt	ttacttctat	191460
gaaatcaact	ttttcagctt	ctgtatgtga	gtgagaacat	gcggtgttta	gtaggaaatt	191520
tctgttctctg	gcttattttca	cttaacacag	tgtcctccaa	gagcatccat	ccaggatttt	191580
attgcttttt	atggcttaat	agtatttcat	tgtgtatata	taccatattt	tctttgtcca	191640
ttcctttgtt	tttggtatgcc	tggattgatt	ctataaacttg	gctattgtga	atagtactgc	191700
aataaacatg	gtctgtagat	gtctctttga	tataatgatt	ttctttcctt	tggataaatt	191760
gctagtaatg	ggattgctca	atcataccat	agtactattc	gtagtttttt	gaggaacctc	191820
cattctgtcc	tccatagtg	ttgtactagt	ttacgttccc	accaacagtg	tataagaatt	191880
ccctttttctc	caaatccctg	ccagcatttg	ttattttttt	ttttttgtct	cttttgacaat	191940

```

agtcaccccta actgggggtga gatgataacct cattgcagct tcaattcaca tctccctgat 192000
gattaggggat gttgagcatt ttttcatata tttattggcc atttgtatgt gttcttttga 192060
gaaacgtctg ttcagatcat tttcctactc ttttaattaga ttgtttttac tgttgagatg 192120
tttgagtcctt ttatatattc tagatattaa tctcttgcga gatgagtagt ttgcaaatat 192180
tttcttccat tctgtagttt gtatattcac tctgttgatt acttcctttg ctgtacaaaa 192240
gctattttgga ttgatataat cccattttgtg tattttgttt gtgttaccta tgtttttaag 192300
gtattattca gaaaattttt gccagacca aggtcctgaa gcatttcttc tatgttttct 192360
tctagtaatt ctatttttca tgtcttacat ttaggttttt gatccatttt gcaatgatat 192420
ttatataggg tgagagacgg gaatctagtt taattcttct gcatatagat atccagtttt 192480
cccagcacca ttcgttgagg agactgtcct ttaccactg agtgttcttg atatctttgt 192540
taaaaatcag gtggttgtag atatgtggat taatttctgg gttctctatt ctgttctatt 192600
gatctatgtg tctgttttta taccagtacc atgctatttt gtttactata gctttgtagt 192660
atactttgat gtctggtagt gtgataactc cagctttgtt ctttttgctt aggtattgctt 192720
tggctgtttg gggctctttt tggttccata taaattttag aatttttttt tctatttctg 192780
tgaagaacgt cattagtatt ttgatagga ttgcattgaa tctataggtt gctttgggca 192840
gcagatatct ttccattttg ttatgtcctt ttccatttct ttcacagta tttttagatt 192900
ttagttgcag aggtctttca cctccttggg tacatttatt ccttgggtatt ttattgtttt 192960
cgtagctatt gtaaatggga ttgccttctt gattgctttt tcagctagtt cattgttcat 193020
gtatagaaat actactgatt tttgtatatt gatatcgtat tctgcaactt tacagaattt 193080
gttatttagct ctgagttttt tggtagagtc attagatttt tctgtatata aaatcatgtc 193140
atctgcaaac aggaacaatt tgacttcctc ctttccaatt tggatgtcct ttatttcttt 193200
gtcttgcccta gttgcttggg ctaggacttc cattactgtg ttgaataaga atgttaagag 193260
tgggcatcct tgtcttgttt cagttcttag aggaaatgct agtgtagctg aggagagaaa 193320
tgaaaacaga ataaaaactt cagtagaagt tggggagaaa tgtgtttgca ccaaagagg 193380
tgagggatgg aactgagggg ggtctcgagg ggtaagagag gccaaagagc tggcaggtgc 193440
tgctattagg atggccaatg atccagaagt aatgatgaat gagaagatgg attaaaaaaa 193500
ccctgacatt gtttaactag aagaagaaga cagtcagaga gaagtgaggg cttacttttc 193560
atgtttaaag tctgttatgt ggtaaaggga ttagatttat ctgtgttgtt ccaggggaca 193620
gaaataggac aattggatgc aaatagagtg aggaagattt aaaacaaatg gagaagacat 193680
tctaaaatca actacaatga gcgtaaacaa tgacaacgga aaggactatt tttgcaatta 193740
tgtagctctt gttctctata gatagatgtg taagcagacg ctgaataacc atttactgaa 193800
aatataaata aaaacaaagc aaattgcagg caataaatat tgtattagtt ctcattttgt 193860
aaaacttata caggtatcat atgcatagac aaatacacca aactgatgaa tatttgcctt 193920
gtataatctt tttgtagttt ttttatgaac atatatctt caaacaattt agaacatttg 193980
gcaatatata tatatttcat ttataaaaagg ttaggaagat taattacact ttctgaggtc 194040
gcaactaaaa gccaaagatt taatccattt ctatttgatg taaagtctgg tcttttttca 194100
gcaaaccaca atcccacatt ttaagggcat taagaaaggg atgggtagac aaaatgtaga 194160
ggtagtaggt acagaataca aagtttcaag aaattaaaag cttctaaact aacaaacagc 194220
caattttgtg agtgtcactg gaaagtgaca aagaggacag ttaagttagt tggaaactgaa 194280
ctgaggccag acagggctgt gggacaagtc aggggtgtgt cattccggtg agcagcgatg 194340
cagaatcaag acagagtagt ttctccttct ctctctctct ttaattgtaa cgccttttat 194400
aacaacaaaa tattatgctt atttctgtct ttaaattttt tgtagtaatt tctcatcact 194460
taacctctat tttttaaaaa actaactttt ctcttgtttt tctagttagg ctatcattca 194520
tatttattat gtggaactag aggtagtctt ggctacttgg gaacagcgtg gagtctagcc 194580
atgtcagggc cagaagtcgt ctgagctaag ttagaattgt ataccattgt ttacacaagt 194640
gtggcctgcc ttcaagatag ggtgaggtgt tttatgacca caggctttat gatgtatagc 194700
tataaaacaa tcaatctttt aaagcaaaca caccacaatg tctacacgca aatgagaatt 194760
gtccttcagg gctgtgacct tgggaaactc ttcacacata ctagcataaa acatatttaa 194820
actcttcact gaaaatatta ttcagacctt gtttctctct cagtctctct ctatgtttct 194880
ctctcacatg tacgtgcatg cagcacacag tgtgcacaca cacatatgct cacatcattt 194940
taagatacat ctcattttta accaaaacca ttttatcttg cttgataacc aattttattt 195000
gttagatgac ttggctataa atgccttttg ctatcaggaa aatcaaata caaattaaaag 195060
acactgttac tactgaagaa gtaaaaaaag aatgggctgc tgactctgaa gatcataccc 195120
gaagtagagc tgcaaagata tttggaatat tggtaatatc caataaagaa tgaccttcat 195180
gctattttga ggagatgttt aaatgtcgaa ttattgaaat atttataaaa tacaataaaa 195240
ctaactctgc ttcattttcc aacttgtgta tgacacttct taggctatca tttcattcca 195300
aatttatggt cactacccta ctgtcattcc tcatactaac catatgatca acagttgaaa 195360
agcagccact cgcagaggta agcaagatat atggtaaata ctgtgttgac aaaagtatgc 195420
agaagcagtc acattttatac agtagtgaag gaaatgtaaa ttggacaaac tttttggaag 195480
ataagttgag aatgtcaaaa atcaaaacac actttctgtt ttattcagca attatgagcc 195540
ctttgtttta cagctatgct cacaatatata tacaacatg tatgcacaat tatgttctact 195600

```

gtggtattgc	gctagaaaaa	tactaaaaac	aaaccaaagt	ttcatcaata	gggaaattgt	195660
tcaacaaatt	acagtatatc	taaaaaaaga	ataatatata	acaactgaaa	aaataaaata	195720
gttgatataa	gcagatatcc	caagatctgc	cagacatatt	gttaaacgaa	aaatctagat	195780
acaaaattgt	ttatagttct	ctttcatact	atagccaaag	aaaattcaga	aaaaactact	195840
tacagttgat	ccttgaataa	tgcagcaggt	aggggcacca	gcttcctgcg	cagtcaagaa	195900
ttgcatataa	cttttgactc	ccccaaaact	ttgctaatag	cctactgttg	actggaagcc	195960
ttatcaacaa	catcaacagt	tgattaacac	tggaaaagga	ggggttggtc	ttactgtctc	196020
aagggtggca	aaggcggaag	aaaagccacc	tataagtga	cccttgaagt	tccaacctat	196080
gtttttccag	ggcaatcata	catccatgtc	catattcatg	atgaatatgt	gaaagggtag	196140
ataagaaaaa	gtgatagtcg	tttcctctgg	agaataaaaat	gagaggtcta	tcataggtga	196200
gaaaataaatt	ttttattata	tattcttttg	taggtttatt	tttttgtcat	gtgtatgtat	196260
tcttttcaaa	ataataaaaa	caataacaac	gattaaaata	tacaagggga	aatgcattgg	196320
ccaaggttta	gttgagagca	aagtttgctt	atctttcgaa	agaggtgaac	taagcttttc	196380
ctttttctct	ttgggtatac	ttgaatgggg	atggagtaag	tggattcttt	tttttttttt	196440
ttttttttga	gacggagtct	cgctcgccca	ggcgcactgc	agtggcgcta	tctcggtcca	196500
ctgcaaaatc	cgcctccgga	gttcacgcca	ttctcctgcc	tcagcctccc	gagtgaactg	196560
gactacaggc	gcccgcact	gcacccggct	aattttttgt	attttttagta	gagacggggt	196620
ttcaccatgt	tagccaggat	ggcctggatc	tcctgacctc	gtgatcagcc	cgcctcggcc	196680
tcccaaagtg	ctgggattac	aggcgtgaga	agtgaagtga	ttctaaggag	tatcgagaac	196740
agtgattaaa	acagaagggtg	gggaggtgtc	ataagcttat	ttgtaggtga	agtattaaaga	196800
ctagaagaat	gacattatgc	atcaaactct	ttacattgtt	tgatctcttt	tacctaaaaa	196860
caaaacaaga	tacttttttg	ttgtttgaca	tatgaccaat	tagcagccag	ttggagctaa	196920
atgttttctt	ttttcttttt	ctttcttttt	tttagatgta	gtgtcactct	gtcgcccagg	196980
ctggagtga	gtggcgatg	ctcggtcac	tgcaacctct	gctaccagc	ttcaagcgat	197040
tctcctgcct	cagcctccca	aggagctggg	attgcaggca	cctgccacca	cgcccagcta	197100
atttttgtag	ttttggtaga	gatggtgttt	caccattttg	gccaggctgg	tcttaaactc	197160
ctgaccttgt	gatccacctg	ccttcgcctc	ccaaagtgtc	ggtattacag	gcatgagcca	197220
ctgtgcccag	cctaaatgtt	ttctttaaaa	gcaaggtaag	tatgcctaga	tgactgcct	197280
cttagtaatt	tttgaggatg	gattattcat	taaattgctt	ccctttctca	cagctgggtga	197340
attagaacga	tagtgagctt	acaagagctt	taacgaggaa	aagatggtca	ttgtttaaca	197400
gagaaggatg	gtttgggtga	gcatttttgt	gtttttggag	gggaactttg	agggcaatga	197460
gtgttgacc	tgtgtccact	gaggatctct	ggggcggtga	aaaggaaggc	agggatgaga	197520
gtgaggaagg	gagacaggag	gggtccaaat	acgaactttg	acttaacgag	gatgattact	197580
agaagggaaa	gattgtggat	tcattgatga	gatgttgaa	catgaaaact	ctaattgtag	197640
aactcacttc	agactgaatt	gaactggctt	tcagtagcag	aagccctttg	tctacttctc	197700
tagtattgaa	gtgaatgcaa	atttctcaat	gtaagaaaag	tagagtgggtg	aaataagagt	197760
gtgggttcca	gggtcagaca	actgggtgca	taaaaagggt	aaggatgcta	caactggtaa	197820
gccctgtgag	aattatttaa	tccttccatg	tctcattccg	ctcatctgga	aatgatgat	197880
catactaact	tatgagatgt	gtgtacagac	tagatataat	attaaaacat	ttctgatacc	197940
tatgcattat	attggatcaa	tatatatttg	caataaatga	tcaacttttt	attaatgaag	198000
ttagtactta	tttcataacg	agattgttta	cttctaattt	actagtattg	tcattattac	198060
tgttgctgtt	atactgctac	tgctgttgct	actaactctt	tatgaagtac	ctaatatgct	198120
ctaagccttg	ctctaggtgt	tgtatatgaa	gtattttctaa	acctgaaaac	tatctaagat	198180
ggctcagtct	agcccatttt	atagacgaag	actgaagcca	agagagttga	aataatgagt	198240
aaagttgaga	tttgactttg	tcttccaaac	aactagaagc	ataaagcaat	ggaccaggtt	198300
ccaaagtga	agggaggggc	attagtttg	cccataggct	gcagagcctg	tgaccacaga	198360
gccctatata	ttccagtggg	gaattatgtt	tgggaatgtg	gcagaccata	tggctatggc	198420
atcgtagac	atgaggtgga	gagaggcaga	tgtgtggtta	ctcgattgag	ttgagagatg	198480
ccatggaaaag	gaggaagaag	agcctgagag	agcaacttca	ctcatgggga	gagaagctta	198540
tgtggagata	agcttcactt	cactaatggg	gagataagct	tcacttatgg	ggagacaagt	198600
aaggaagcag	ggatctccag	aggatgtgga	gtatgcctgg	tactttcatt	gttctttttc	198660
cttattcttc	tttattcttt	tcattatttt	acctaggtta	gatgttaaac	acttctctgt	198720
gtttagtcag	gcttcctttt	ctaattataa	gactaaacac	taagatttca	ttttagata	198780
taattattag	agaattttga	taaaatttcc	aagcagtgtt	ccctctgttt	atcatcgtgt	198840
tcctgtctgt	tattagttca	cagtttggtc	tgggaattact	ccagttaatc	ttggggtttc	198900
aggagagaaa	ttgtgctcag	ggtacatgag	aagagaaaag	ttagaaaagc	aagggtcttc	198960
ctgtctagtt	tctagctcag	aaaagcaaag	atattctact	ttcatatgta	tgataaattg	199020
agctgagctg	actttaaaaa	cagataaatt	ttctttttta	tccctaataa	ataatggtgc	199080
ttacagcaat	gagtgttgct	ggtaacagat	tccaccaatg	ggtgtggtgt	gaagtttagc	199140
atgtgtggat	tttgagctt	ctgctattgt	ctacagcatt	tcctctcttg	tctcggaggt	199200
tcatactttc	tcaggcaagg	acacttttaa	ctccagataa	atgtctgggt	tttctcactc	199260

caaggataag	aagggtggggg	tgatggagtg	gtgggtggtag	ttgtggagtt	gtcttcctgg	199320
cagggatttc	attgtggggg	aaagtctgtc	tttagaaaag	aaatgtaaac	tgggcaagta	199380
gtctcatcag	ttaaatgatt	tccttggtga	cataaggtga	ggaaaagaag	aacaactttt	199440
gggaaaagta	actgtgagaa	tacaaggga	gaagaaaaat	aaggggttga	acattgagga	199500
agacttatga	gacagataaa	gtataaaggc	aggtaatttg	ttctttcaat	ttggcatggg	199560
gacagtaaaa	atTTTTtctt	actaaacaaa	taaagcccat	gtatttcttc	tgctctggga	199620
gcaccaatta	tattgagcct	ctaaataaag	aaagtcaaca	tccacaagtg	ttctaaattc	199680
catctcgtag	tgagagtcct	gaaaattgca	atagctagag	tcaatacttg	gagtatatgc	199740
ataagacgtg	gtgtctcaaa	taggattaag	gcctactctt	ggcatcttct	gttattgggtg	199800
ttgtttctct	gtattgattg	gtataacgtt	agacaaaaict	gcagggtcatc	tttgagaaaa	199860
actcagtata	aacaatgaaa	aaaatgtgta	gctgcacatg	taatttgcat	gtaacaaaac	199920
caaaggatgc	tttagatagt	aacagcagcc	tgtactttac	tccaacccat	tagttttatg	199980
ataaatgtgg	tctgggggaag	tgctcgatct	agggtgttca	ctttgtgttt	ttgtttcttc	200040
ctatcattcg	ggtgttgagt	cacctgtttg	tctgtgtcag	tgtcagagca	ctgggtcaca	200100
tcctgcattg	tccaggtttt	attggtccct	ttcttaaatt	aaagctgatt	ttccacttaa	200160
agagaattct	gtctccttct	gcaattgttc	aaagtctagc	atctcaagtg	cagactctaa	200220
actgtatgta	tatgtattgt	gcaggctatc	tatcttctta	gctttgaatt	ctctagaaat	200280
attccagagg	tgtgattcct	ctgttattca	agagtgattt	ccaaattgcc	tcagccaatg	200340
tgcttcgaca	agttgtttgt	aactcagggg	gtaatgggaa	atgctttaga	gccacatttg	200400
tggtttttga	tgggaaaaaa	aaaaaatcag	tgtcctccta	agacttatac	agtccttgaa	200460
gccttttagg	ctattcctgc	atctcatggt	gcattccatac	ggactattta	gccatattca	200520
acaccatcct	cttgctatgt	tggttaagatt	tgactgttgt	tggtgttgtt	tttaaatata	200580
aatgtgtgat	cacatgcaca	tacacagaca	atgatgtgta	actcataaac	atgaaaagta	200640
aaaatttgaa	ttttaactga	agaaaaatca	gcattattca	taaaaagctg	gtaagatatt	200700
ctaaaagtgg	aaattcatgc	agaaaattga	ttcttaagca	cttactaaat	gccaggaata	200760
ttttaccagc	atattatcat	ttaattttta	aacaagtttg	agagatagag	atgtcttatt	200820
ttatagaaga	ggcaactggg	gttctgaaat	gtgaaataac	ttgcaaaggc	tatggttaag	200880
ggcagggcca	gccacgtgtc	tagtgtctct	gacacctgag	atcacacact	gtatgctggg	200940
cttcaattaa	tttgagcta	cttggttgcat	taaattcaca	atccttgctt	tcatacataat	201000
aaaaacaata	ataactatc	aacacaacta	ttttcagtg	gctctggcta	aggccatttg	201060
attcagagtc	aaaaccttct	atttgtatag	tattttatat	tgtcaaaatc	taataaggat	201120
agttttcata	tctgacgtaa	accaaactga	tctgtctcca	tttgatatag	tgacatatca	201180
aattgttact	ttcatatata	ttagtcaacc	tctatgttta	tcattctcta	tgtttttagaa	201240
agtaaagaat	ttaaaattac	ttcagaaaga	tttcttcttc	ataaacataa	aatgattaga	201300
tgctccctttt	aaaggcaaca	gcttcttctt	tttctttttt	cttttctttt	tttttttttt	201360
tttttttgag	aaggagtctg	gctctgccgc	ccaggctgga	gtgcagtggc	gccatctcga	201420
ctcactgcaa	gctccacctc	ccgggtttta	gccattctcc	tgctcagcc	tcccagtag	201480
ctgggactgc	aggcgctgc	cactacgcct	ggctaatttt	tcgtattttt	agtagagacg	201540
gcgtttcacc	gtgttagcca	ggatggtctg	gatctcctga	cctcgtgatc	cgcccgctt	201600
ggcctcccaa	agtgtctggga	taacaggcgt	gagccaccgc	gcccggccaa	ggcaacagtt	201660
tcttaatgag	agagtagaaa	tgagaattca	cattcataac	aaagagttta	ttgtctttcc	201720
tagtatactg	tactatctag	tagctaattc	gtctaaagac	atgtttctta	tctattaata	201780
gtcctattaa	taatgtaaag	tagctttaga	tatgccaaagc	tgttactggc	tggggaacta	201840
aaaaagcttc	cagagttata	tctagaaagt	ctttgggggt	tcttaatggt	atgtgattag	201900
caactaaaac	tgtgacagga	aggaagtcca	catgaattga	gcattacta	gtttcaagat	201960
ttatcattat	gatcattact	tataataact	tctgtgaagc	gatatttaact	ttacaatgga	202020
taaaaagata	gatgaattag	taatttacct	ccagtgggtg	agacagcagg	atttgaattt	202080
agtctgtcca	acaccaaagc	ctccgtactt	ttcattaccc	tgcatccatc	tagtttaaaa	202140
aataaatgta	ctaggcatag	tggttgacac	ctgcaatccc	agctgcttgg	gaggttgagg	202200
ccagaggatc	acttgagccc	agaagttcaa	ggctgcagtg	agttatgagc	acacaactgc	202260
actccagcct	gggtgataga	cagaccccat	ctcaaaaaaa	aaaaaaaaaa	aaaaaaaaaga	202320
gagagagaaa	ataaaagaaa	aatcgaatgt	attgcatttc	atgtctggac	cacctgtatg	202380
agaaaattgg	gcactttctc	tctgaagtaa	ctcatactaa	aaacaaacac	cttcttcttc	202440
ccaggagctt	cccaagggtt	aagagaggaa	ccctgaagct	ctaatatgcc	taagatgctc	202500
tctggtgtta	tctaaaatca	aaatatatca	cctagagcac	ttattttatt	atttatttat	202560
ttttgagatg	gagtctagct	ctatcaccca	ggctggagtg	caatggcatg	atctcggctc	202620
actgcaacct	ccgcctccca	ggttcaagcc	attctcctgc	ctcagcctct	gggattatag	202680
gtgcacgcca	ccatggccgg	ctaatttttg	tatttttagt	agagatgggg	tttcaccatg	202740
ttggtcaggc	tgggtctcgaa	ctcctgacct	cgtgatccgc	ccaccttggc	ctcctgaagt	202800
gctgggatta	caggcgtgag	ccaccacgcc	cggccagagc	actttttttt	cttaattttt	202860
tatgatggaa	aatttcaagc	atacatatag	tagagaaaat	agtataatga	acaactgaat	202920

acttaaatct	ggcttcaata	atttctaatt	ttatgttctg	tctaattgtt	acataaagta	202980
tagtttgtat	gtatttggtg	gtgagtacat	aatgggccac	atgattttta	ccttttaggc	203040
tgtagttcta	catcagtata	agatggttgt	ttttttcttc	caatacaaaa	tctaaagcgt	203100
tgtcggcagt	gacattttta	aaaacacaat	atgagacgca	acaataaatc	agttattaaa	203160
ataagataaa	gtaggtatat	aaatatttca	ccttggaat	aaagcaaagt	cagtggaaga	203220
gtgtgaagac	tgtgaagatt	aggagcatga	aaataaacga	ctattgggag	ccattctatt	203280
cccatgagtg	aatgtgtatt	ggttccattc	aatgtaggga	agagcagtaa	aagggaataa	203340
ccataaggat	aagaccactg	gattatctga	gagccacagt	tgctcctttg	cacatggagc	203400
atctgcccta	ggtattacag	ctctgtgaga	aacagagggt	caaggaaaga	aatttggtat	203460
ttttcaatta	tctgcataaa	ttctttggaa	caggggcatg	gattataaaa	gatgtaagat	203520
aataaaaaagc	atttgtattt	gactttggaa	tgtattgtac	ttacatttgt	ctagagggtg	203580
gtctattctg	gctattctct	ttaaaggagc	cattctatcg	tgaacagatc	ctggtggagc	203640
tgttttcttg	ttctaccaac	cttcagccac	ctctctgtct	ttcatattac	ttattggcag	203700
ggtttcaaaa	ggttttagtc	cttacttaat	ataaacaaaa	atgtacaata	ttgacaaagt	203760
ttcagttaag	cagatgaaat	tctaagagtt	aagctgggat	tttccaaaat	aatcctgtta	203820
acagacttga	aagcacttat	cagttctgtc	taatgaagac	attagaacac	cataaccttt	203880
ccggccccatt	ttctttgtca	ataagcgttc	ttgccctgtc	agcagctcac	ctccagcttt	203940
agtttttctca	tgacagtaag	tctattaccc	tctgtatctg	tcttctggct	cctcctaccc	204000
aggatgggga	aggtttttga	ctttactgat	attctcagaa	caaatttttg	gaagtaataa	204060
taagggttttc	cagtcgggtg	cagtggctca	cgcctatgat	cccagcgctt	tgggaaacca	204120
aggtgggtgg	atcacctgag	gtcaggagtt	tgagaccagc	ttggccaata	aggtgaaacc	204180
ccatctctac	aaaaattagt	tgggcgtggt	ggcggcacct	gtaaatccag	ctactcagga	204240
ggctgaggca	agaggattgc	ttgaatctgg	gagccggagg	ttgaagtga	ctgagattgg	204300
gccactgcat	tctagcctgg	gcgacaagag	tgaagctcca	tctcaaaaaa	aaaaaaaaag	204360
atgaggtttt	ccttaagagc	actaacctag	tatactgcac	aggtgcctgt	attcatgcat	204420
cccacacaga	aagagaaaaat	acttgtctga	acttgtccat	aaattcagaa	tcctgcccct	204480
taacttgtat	gccagggtttc	tggcatactc	ttatctgaaa	actcactcta	ttagaaaagc	204540
aaagcacagt	gattttccca	tcctgattac	ctggcactgt	tttttatttc	agtgtctctg	204600
tttctttgcc	atgtaaatgc	ctgtgatttg	ccaggtcatt	tgtcctgatt	tgccttgaaa	204660
cagtgacgtc	atcataattg	cagaatgata	caaaaataa	taaaatatat	tgcctttgta	204720
ctaaacagaa	gtgcctctct	gttggtgaaa	taatacatat	aaacaaaaat	aataattagt	204780
gatacttatt	gtgtgttcac	tatctactag	cactgtattg	agtgttttac	ctgcattgct	204840
tcatttttctc	ctcacaaat	ccctattagg	taaattcagt	tataattccc	attttacaga	204900
tgggggcatt	gaggcttgat	gaggttagtt	aacctgcttc	atggtagtaa	aagcagagct	204960
tggatttgag	cacagcatga	atgactccag	aacttacaca	cacacaccca	ctcacacaca	205020
tgcaaagaga	gagagagaga	gagagagaca	actgctgaac	atagacccaa	ggcaaaatat	205080
ccttgagtag	aggaacagtg	tgagagtga	gctgtagtgc	tgggtggggg	taatcaggat	205140
gggctcactg	ggcaagacca	ggttgtgggg	ggcaaaggag	atggaaaatt	gtgtgaagag	205200
aagaagggtg	gactaggtag	ataaaggtag	tggactaggt	aaataaagg	ggtaattcag	205260
acatccactt	taggcttcaa	atcactttag	gagaagtgg	ggtctattgc	tttgcccttt	205320
agtagcaaca	tgcttattat	acaatttaat	aagattctat	ccaatacact	gttttaagg	205380
ctcccactctc	ccgatttaga	gctgagttct	aacttccttt	tccaatgata	atgatctgag	205440
aaatttcctt	catgttgac	tttttttttc	tgaagacttg	acattgatgg	aaagaagtga	205500
aaccaccta	tgcttttgat	tttggtgact	aatattaatt	gtcatgtatt	actaatagt	205560
aatctgcatt	tttaaagctt	tgttggaag	cacattaggt	gtgtatataa	aggtattaac	205620
cctgaaagta	tgaacgtgtt	ttctataatt	agtcctatga	taatttaaaa	tttaacatgt	205680
gcttgacaca	tttgataaag	gctttgtcta	ctatggtttt	atttatgggt	gttaattaa	205740
taggagcagc	agcatactac	ttgaaagtat	gaagggtgtc	tctatagtta	gtcctatgat	205800
aatttataat	tttaacaggta	cttgacacat	ttgataaagg	ctttgtctac	tatggtttta	205860
ttggaataga	caacttatct	tttcttaaa	tatatatttt	cttggtacca	ggaaacttga	205920
gaccaaggta	aaatgtaata	ctttaaaaaa	tgccataata	ggaactgtca	tatatagtta	205980
tatttagggg	tgattcatat	tttgaaatat	attctagaat	ataaaaacta	ctatatttta	206040
caattacttt	accaagctct	ctaataatac	ctgtttacct	ttaaaatctt	ggtctttccc	206100
acagaggaca	agttattata	tttttaattg	ttaagccttc	tgatcatatg	aattcttttc	206160
atatttcatt	gaaattatat	aaaacatttt	acttcaaagg	aaaaatgtta	tgaatttata	206220
atgcttttag	aatttataaa	tctgtttcct	attttgttga	ttaagacaga	gaagcattgc	206280
ttgtgaataa	atagcatgct	atgttgaaaa	gaaaatttaag	gatcctgatg	tttctctgcc	206340
agataggaca	aaaactaagg	acgccacagg	aatttttcaa	cattttttaac	ctcttgacaa	206400
tatgtgggtc	gtataaagga	caaatgaatg	tttggaatgga	ctgagaatgc	caattttaac	206460
agattgtcca	atcactgtag	ataaatattt	gtgttcctgg	ggattatctg	attattatca	206520
agcaaattga	attggaaaca	tagcatgtat	taagtcatta	ctacttattg	tctagttctt	206580

tttctcatag	aagtgtctat	gtactagaag	agcactaagt	catcagttag	acatgatctt	206640
tatcatatcc	agacaaaaat	aaaaaccttt	taagaagcta	ctttacaaga	caactgcata	206700
gctttcttca	caggaacttg	ttaaataaat	aatgattatt	aaagcaattg	ggtcagtctc	206760
ttacactaat	ttaacaagag	cagttccaag	atgtctagcc	cattccacat	tccgtgtgac	206820
taaccatggg	atccagagct	tggaaaatat	ccaggcaacc	cacagtagct	tttcttaa	206880
gcattatgga	cactggaatg	taaggaaagt	gatagaacta	ggggaacaag	aagagagtct	206940
ttaaggcata	cccattgtca	gtgtcgtaaa	tggcctcaat	tgtatgttga	acattgttca	207000
aaagtaccca	tggctgaaac	agtgtagatt	tagctcctat	ctgtattgaa	gttgataaat	207060
gcataaatct	taatcattga	catggagggt	tattgtattc	aatgagacag	atatacttg	207120
agttttccac	aaaccaccaa	taagagtcta	ttgtgaattg	gaatgattag	cttttaaga	207180
tgtatacatg	ttaaccaccc	ttttatatta	agttggtgca	caagtaattg	tgctttcaac	207240
ggcaaaaacc	acaattactt	gtgcaccaac	ctaatactta	cagttatgcc	aagatagggg	207300
tagaagcaga	aggaaaattt	agagtgaaga	gatagagaca	agagataggg	aggacaggaa	207360
ttgagtcata	caaagattct	ggaaagtctg	tgattaattc	tgtggttgtt	aattaagtag	207420
gagcagcaga	tattataaaa	ctcaatatac	aagtggtcaa	gttcagggaag	agccaaggag	207480
gagaccagtt	gatattctag	gtccatgttt	cttgtaagca	aagtttgga	accagaactt	207540
tggatctggt	tcaagagccc	aaggtaagag	gctttagaat	aaagtctaac	ccaggccaag	207600
aatctgggta	acagaaccag	ggatctccta	gggcactagc	actaactggt	ggccaaggca	207660
agtacttcta	catttctctg	tttgagtcca	aacttgtgaa	aattttttaga	aggcctgagc	207720
ccacagattt	attttttcat	caattcatat	ttattaggca	cctatatgtg	ccaggcactg	207780
tattaggagc	atggactatt	ggtgatctca	atggacatat	tatccgtttt	tataaaggag	207840
atgtatcgtg	gaccagtaaa	taaagaagtg	aacaaatagc	actagaagga	aataaaaagg	207900
gcaataaatc	agataatcta	ggggaggggtg	ttttagatag	aatgatcagg	gaaagcctat	207960
ccaaagaagt	gatgtttgag	aatgagaatt	aagtttgaga	atgagcagat	acatgaggag	208020
ctggaaggag	gacactccaa	agtctaggcc	aagtggaag	gcttgaggag	gagaaaggcc	208080
ttggcatggt	caaggcttg	aaggaagtgg	atttagacgc	tagcaagcag	aaaagagagg	208140
gtgtgacttg	gggcatagag	aaattggtaa	gagccagatc	aagcagtggt	aggggaaaag	208200
ccacttagct	agagtaaggg	atggaccaag	tactctgtag	aacagatatg	aaattattca	208260
gtgtttttat	agctgtaaac	tggaaaatag	attacaggga	cttaaaattc	tccctaagta	208320
ctccatgcag	tgtgaagggt	ttactaatga	aatcttctta	gagatggaaa	catgaggcag	208380
accattagtg	gtggtcatat	tagttctggg	gagtcagggt	taatagccag	agagttttgc	208440
tagcttcagg	gcaaagcatt	gcagttcaag	agagtgggtg	gggtagttag	gcacccaggg	208500
ctttggatga	tgaactggt	tggcaaatga	cagtggagca	gatgcacatg	aataataaga	208560
tgggctgggt	tgaacagag	cataatgtga	gtgaacctgg	tcttccacag	agtcagctaa	208620
tggaagaaac	ataaagcatc	atccttctta	ggatttctct	tattattatgc	tcttcttttg	208680
gttatagggt	ccctgaggag	gtcttccaaa	tggttaacag	aatgatatacc	ttaccactct	208740
aatttttagt	ttgaaaattt	gttaatagcc	aaacaatagt	taagtcctaa	tccccagtag	208800
ttggattgaa	tgatgtcccc	caccaaacca	aaacatcagt	tgacattagt	taaatgaaga	208860
ctcagaatgt	ggtcttattt	ggaaacagag	tcattgcaga	gactggtgtc	tttacaagaa	208920
tgaggtcata	ctggaatagc	atggggcatt	tatccaacac	tacaaagatg	gctgcagtga	208980
gaggaaat	gaacacagtg	ggaagatggc	tgtataaaga	tgagaatttg	tctcaaagga	209040
gtcatgggtca	tgctactgca	ctccagactg	gagcacagag	tgtaaacctta	gcactttggg	209100
aaagaaaaag	aaaaaaaagc	taggcatagt	ggttcatgcc	acaagcatgg	gcaacatagc	209160
aggttaaagt	tggaggatca	cttgagctta	ggagtttgag	gtggtgcatg	cctgtagtcc	209220
aagaccccg	cttcgcaaaa	aataaaacta	gccagggtgt	cagcagggtca	aggttgaggt	209280
cagctactga	ggtgcttagg	gtgggaggat	tgccataagcc	agcaagacc	tgtcaaaaaa	209340
gaccatgtat	ctcaccactg	caatccagcc	ggcgcaaaag	gacagataca	atataatctat	209400
agaaagaaag	tagaaagaaa	gaaagagaaa	aagaaaaaaa	gattgaagtg	atataatctat	209460
gagctgcaga	aggagaatat	tatgtgaaga	aggagacaaa	ctgggagatg	gcattggaaca	209520
tatcaaggaa	atgctagggc	atgatgcctg	tcatacacaag	caccttgacc	tcagaattttt	209580
gatttcttct	tagggccttc	caaagggaacc	accactgcca	cacccagtgt	gtggtactca	209640
agcctccaga	actgtgatat	aataaatttc	tgtttaaagc	cctcttgctg	tattcttttc	209700
ttagggcagc	cgtagaaaag	gaaaactacc	ccttccatt	ttgctttttc	taccacttgt	209760
caccgttttg	tctcacacac	tacaatcgat	gaaaaccaa	tttttttttg	tctccaggga	209820
actctttcaa	cccagaatag	cctcctcttt	tttttttttt	tgatagtttt	ttaatcttca	209880
cctattttta	aataagaaaa	aagtttttaa	gcatagtacc	tgaaatattt	caagcaaaaa	209940
cccacaccca	ccccttcccc	ataacttttt	tgattgatta	atcagattac	aactttttgc	210000
cagaaaataa	tatgacagta	ttcttctaaa	atctacattc	aatattactg	agagagagaa	210060
catatttgct	tcaaatcact	ccttttcacc	ctaaaaagaa	atccttaatt	tttattttatt	210120
agtctcctct	cttcatactt	tctttcactt	cactgttcgc	tgtccaggct	agagtgcagt	210180
tattttta	ttttttttta	gagacagggt	ctctttttgt			210240

ggcacaatca	tagctcactg	cagcctcaaa	ctccttggct	caagcaatcc	tcattgtctca	210300
gcctcctgag	tagctgggac	tacaggtaca	tgccaccatg	ccccactcca	attctttat	210360
atTTTTaaag	tggcatcact	ttgttagtaa	agccttccca	ttatcactca	gatttactta	210420
actctatcac	ctattcccac	aatattttat	acacaaaatta	tattacagga	atgatcatat	210480
tgtatttttaa	ttgtagtcac	tttttctcta	taagaaaaaa	atgacttggg	catttttaat	210540
catctagtgc	ctatgcaata	tctaactctg	ggttaaactg	aatttttaata	taatagtgtt	210600
tacatcgaa	cgttgacct	tcaaaagagc	cctaagagtc	aggactagaa	ttgtcattct	210660
ttattccaga	aatggcaact	ttatgaattt	tacgtgttta	atgtggtcga	ttattgtttg	210720
tcactgttgg	tgaagtttac	ttccttgccc	tcctgatgtt	gggcttggcc	gtgtggtttg	210780
cttaggccag	tgggaaggcag	gtggaagtga	caacatgtca	gttccaaact	gaggctgtaa	210840
gaagttcaca	tatttctgct	ttcttctttg	tgcttctgac	attcaccgtg	aaaacattcc	210900
ctgagttagct	gttgggtcca	gaatgaagag	acagatggag	ccaacctgaa	cccaactgat	210960
aggctgaatg	ccaacaaaca	tagcaggatc	acagcaaacc	tgaagtgaat	gctcgctga	211020
gtcagttacc	aagatttggg	gtgggtggtta	cccagcatta	gcatagttga	aacctcacta	211080
atacacctag	atggttgata	ataaaggcag	aactagaata	cacgttatct	gattagcaat	211140
atagtgtctt	tttactaaat	tattctgtta	ttcatctgca	cattcaacaa	gtatttaatc	211200
atataatttac	tgtagaaaac	agcacatcat	taaacagaca	gactgtggtc	tctgccccca	211260
aggagaatat	gtttctagt	agggaaagag	atacaaattc	ataaatctaa	actatagaaa	211320
atggcaaact	ctatagcaca	aatgtctttt	gagagagaat	aatgggtgag	gggaaggaaa	211380
ggagatgaat	acctttaagg	tggcaggggt	agagctcttt	gagagactgc	aaagcagaga	211440
agatgcttca	agaaaaagaa	gtacacattt	ctctccctgg	aatggtctca	gtgggtctcag	211500
ataatggttt	cagttttcca	tattccttta	tttatgtagt	gtcaggccaa	cagtgtactt	211560
tagctccagg	ctaaccagtt	gtccttgggt	tgcatcccgt	gtattcagaa	agctattgga	211620
ttgttttgta	agttcttaaa	gaaggactga	aaaaggcttc	attttccctt	tttccaaagg	211680
gagcaattac	atactgtcac	tgggaataata	aacttaagtc	ctaggctgcg	aatgaaattt	211740
gatttctctc	aggtgagagg	tattttgtat	atggaaagct	aaggaaagaa	atgcaatgtt	211800
tttttttttt	tttttttttt	ttagcaatcc	agtagggaac	tgtggccagc	attgagctga	211860
taaagacctt	tgttttccat	gttttgattg	gccagtgag	aagcctcgag	cagtttgacc	211920
acctacgtgt	gtccatactg	gtggggcaga	aaagtgtcta	cacaggattg	cagattagcc	211980
cctgcagctt	gccagggtaa	acttgtgtaa	tgcatgtac	accactccta	acaacagtg	212040
tccttttgtc	acttaaacag	aggttattaa	gaatatgagt	cattaaaaag	agcttttagaa	212100
aagcaggcaa	cattttccaa	tacagtggct	ttaggggatc	tttgaaaagt	atcagaagtt	212160
ccggaagaag	taaagcatct	cattaataac	taacaataga	cacagaatca	aaatctgaat	212220
tgatgaaaaa	aagtaatat	taaaatgtaa	tttttgaatg	ttgaaaagag	cccatTTTTg	212280
tagagaattg	gatgaggatt	aacttagata	ttttcttgaa	tgtgtataaa	tattacatat	212340
aagaatactt	tcaagtctta	aattggcccc	gggatctcca	gcttgctgat	aaaaacaaat	212400
caaagaaaact	accttttagga	cttctttttc	ttatttttga	aacattaaaa	agttgcaagt	212460
gccggaataa	tggggaaaaa	gtctttattc	tattatccag	acaaaaagct	ggtcaacatt	212520
ttaatgctgt	ttctgctggc	atTTTTctct	acaaatactt	tctatgtagt	taagatcata	212580
tggatatagt	aatcttgttt	cattcatttt	ctttcacttt	tgttattcct	tattcagtga	212640
ttggaaaact	atggtttata	ggccaaatct	ggactactgc	tacacgtgga	acacagccac	212700
atgcattcat	ttacataattg	tgtatgactg	ctgtctctgt	accataatag	aattgagggc	212760
ggctacagag	cttaagtgc	tcacaaagcc	tgaatatatt	gctctctgga	cctttataga	212820
aacagttttc	cagtttgatga	gatagattat	tagagtcata	tgaacacaat	agaattttac	212880
aaaaatatac	caaaagttta	tacagccatt	gatactttaa	ctagcattgt	ctgataaaac	212940
tgtttttattg	cctataacaa	tatatatggt	aaatatatat	ggttatgcat	atataaccat	213000
atatatgtaa	tagccagcta	tatatatata	tgtataattt	tatatgtata	cagttttgga	213060
ttttaataga	catagaatgt	tagtgtatct	cttttttgct	ttaatattta	tttctttgag	213120
tagcagttag	acaaaatgat	tttccatttt	tttagttctt	taattttctt	tatcttcaac	213180
tgcttcttta	tgacgtttgc	ccctttttta	atagagggtt	tttttaaaaa	taaatttgta	213240
agggtcttat	atagatgcgg	aataccaact	cttattgttt	ttactttgac	tatattttct	213300
cagtttttta	atcctttaat	ttgagagatt	tttttgaaac	ttgaaagttg	tttaatcagt	213360
gtaaaatttc	ctctgtgatt	cctttccaag	ctccaatata	tcattgctgag	gaagtatctt	213420
atcatttttta	atTTTTtaaa	aattttataag	gattgatatt	ttatgaaagg	cctcttgagt	213480
gtctattttt	aaaaacatac	tttgttctta	gaatagtttt	ggacttacag	aaaaattgag	213540
aagatagtac	aaagggttct	cataaactcc	acagtgattt	ttccctgtca	ttaacatcat	213600
tcattagcat	tttgtcatta	gtatctttca	ttagtattgt	atgttcgtta	caatcaatta	213660
actaagattg	atgcattgtc	attaccta	gtccatattt	tattagaatt	gtttaagttt	213720
ttacctaata	tactttttgt	tctggtatct	tgctctagat	accaccattc	aaccattcat	213780
ttagttgtta	tgtctcctta	tgtttttctt	ggcttggtat	atTTTctcat	agttttttgg	213840
tttttgatga	ccttgacaat	tttaaggagt	attgactagg	catttttgtaa	aactcctttc	213900

tattagaatt	ggctactgtg	agcagtcac	atthtaggaa	taggaagttt	tatttcccca	213960
tcttgagggt	gaagttgttg	cataaacttt	tggggattct	tctgcatggg	agattttttc	214020
tactttctct	tttattttatt	tattcagtc	tttagtatga	gctcatagat	attaatttta	214080
tactttgggt	tataatctaa	tactttttta	ttattttgtt	gcttacatac	ttctagattt	214140
ggccactggg	agctctttca	gttgacttcc	gtattttctt	gacatacctt	ggcaaagtga	214200
ggattttgtg	gtgtgtgtgt	ttattagcac	atthtttcatt	tctggcacta	caagatcctc	214260
caggctcctc	ttgtttattt	cctgtgccag	tcctaggatt	agtcattttc	acaatgtgcc	214320
ctgattcctt	tagtcagttt	cctttttatta	ggaaccaata	tctggacact	ggttatgctt	214380
atthgtacaa	gcatgtagtt	acttctgggc	cctctcagct	tacagagcaa	ggaaccatac	214440
tatgctatgt	gtgtgtatgc	taagctgtgt	atacacacac	agaaaaaat	atatatatat	214500
atatgcacac	acatatattt	ctatacatag	ccatctgtat	caattttgag	ctaaacatga	214560
gtgttcatac	tgtgtctctc	aactctaate	cagtatcaca	tgtatcattt	tagccttatc	214620
cccttgttta	tctgtacact	cccatcccaa	cagtataaat	cctggctcct	gccctctgtc	214680
aattccagta	tacaggtatt	ggaatatcag	aatttttaac	ttgtactcta	gttattttta	214740
ccaagaaata	actttgttaa	ctagagtaca	atgcttatgt	actgtcaaac	gagattccac	214800
tcgtttccaa	agttattttag	gttctctctc	tgatttttaa	ctcttatttc	actgcatttt	214860
aatccggatt	tattttattgt	tcctggttgt	cagtcctgaa	actaaagtgg	taataaagga	214920
aacaggtggg	atacgtgaga	ggctttcaaa	ttccttgagg	tcataaaata	tatatgtatg	214980
tgcatatat	taaaataaag	ccttgaacag	gcagaaaaac	tgatattgca	ttgtagataa	215040
caaatggcat	aaaacactta	tgtagaatta	gtcccatcaa	aatatgtaaa	gaagtaaggt	215100
tcgataaaag	ttgtgggcat	tataataaaa	tatttctctc	cctttatatt	cactccttac	215160
ctgttctcag	taaaataagt	tcaactctgt	acaattaatt	ttctgccatg	tctactgctt	215220
gtacttggga	acaaatgcta	tattataata	taaagatatg	tgtggaactt	ggtttcaaaa	215280
gtcaggtaat	gcaaatatca	aaaaacaggt	gatctctcaa	acaccttatg	ataagtcagt	215340
cagataaagt	gctctgcaga	actccagcca	acaaacaggt	tgattatcag	tgaagtatct	215400
catattttca	ggtagtcctc	acactaagaa	agctaataga	aaagagtttg	agctcacata	215460
atcatgagaa	agtacatttc	aaaccacctt	cccaaatttc	ctgctgcagt	ttcttctctt	215520
tttactcatt	atthttcttt	ttacctcagt	ttactttctg	gttttcttgg	ctgagtgcct	215580
ttttactgct	tttgaagtaa	gatgctatct	tctttatcag	gtttgcaaac	tatttattga	215640
atthtagcaat	taaaattgtc	gctgtgggtg	aactggaaaa	tgtccttttg	gtacttgaat	215700
ttactgaata	taatgactga	aaaagcattt	caaacaaaac	aatcaacaaa	caaaaaatct	215760
caattagttt	gttgcataga	cacaatagta	actcacagca	ctggcatatt	atthtttgatt	215820
cacaaaacac	atatagagcc	tggcatctat	tagacatgga	agccacttat	taagtattta	215880
tttaatcaat	gaatgcatca	aaggattagt	aatatcaact	tcaacacaa	cctgtagtat	215940
atgtaatat	cttctctctc	cctaccttta	acaatgagga	atthgagctc	agaaggatta	216000
agtgaattac	ttgaagttat	attattaatt	aaactactga	agccagaaca	cgaatctaga	216060
acttaatcat	cagaagggca	actactacct	ccacctacgt	tactcatgat	agtattaaca	216120
tggttagcaca	gtggtacata	gtagttgctc	attgaatat	atthtagtaaa	agaaatgaaa	216180
agagtgggtg	tagatacttg	gaagaataag	aattctaaga	aggagaataa	aggtgtatat	216240
acatatctcat	ttgataagta	ttcaaataat	agttaaagag	atgcatagga	tactgcagag	216300
ctctttcaga	attgagaagc	tgaaattaaa	agatgtatta	gacttgtttc	catcttaaat	216360
catcatcata	tcaagtgata	gacattggta	cctgcagtat	ttcagtggca	tttgattttt	216420
ttcctgcaga	gttctattaa	tacagtattt	taaaatttta	ttgtatgtca	tttaaaaaat	216480
acttttaaaa	agcaagaaca	ccacattttt	ctgggcataa	gagacaaggt	tgtcttttgc	216540
atgcatgtat	gcaattctaa	cctttaaatt	tcctatgtct	ttattttttc	cctgactctt	216600
agagccta	attgactaac	agctcatttt	gaaagataaa	aatccacaaa	ataataattt	216660
agaaagtga	aatgaaaaat	tacattaatt	tctcctctac	cattgttttt	cgttcaaaa	216720
cacagttaac	atgagttgat	ttattttttt	taaatgaate	tactgtgacc	ggccttatga	216780
tccacccatt	cgcctaagtt	tgaaaccaca	ttgattcagt	caacaaactc	tataccacct	216840
actaattgat	aggtaatgac	tagttttgtt	aatacttggt	tacagcgata	gctttgagca	216900
aattttcaaa	gtgaagcttt	tctcaacttt	ttcttggtga	ttcggtatct	gaaatagctt	216960
attaattcat	tccttccttg	tttccactga	cactgccaat	cagttgtagg	tgaaaactct	217020
aaactggct	cctgtacttt	actatcccat	tttctgcctt	aattcatctt	ctccagtgtc	217080
tcaagtgtaa	tcttgctaaa	atacaaacct	aattatgtta	ctcctctgtt	tacagtcttt	217140
aaatgtttta	ccaaattaaa	tccaaactcc	ttgagaagtt	catacaaggt	tgtatcagag	217200
cctctgaaac	gctaaccac	atcttcacag	cttcatctct	tgattccagc	ctggatgcaa	217260
tgggcattct	ggatttgact	catattacaa	caacaaaata	atctcaagtg	aataccatgc	217320
actttttact	ttttttccac	tgggcttctt	cagtgcacac	cctgggaatg	gggttttact	217380
tgtaagctt	acctatggag	ctccaaaatg	caaggaagtt	taacttttga	gagcaatgtc	217440
caaccaatga	gggatggaaa	cataggaaaa	catgctttcc	caagttattc	ttctaacaaa	217500
cagctctaag	gtacgttctg	tatgcttatt	ccccctagat	gtcaggggtg	agttccagtg	217560

tcccaaagct	atataataaa	aatgcacctt	ggtatagact	ttcccgcctt	cccttactct	217620
cttttagtctc	cttttgtact	ccataggatt	atctcattga	ctgggctttg	ctttctagta	217680
gaacctaaagc	tatgacatat	agtactagac	tctctacca	ggagtgattt	aggacgagga	217740
ggcgttgaaa	actgaagctt	tggacatctc	agatagttaa	agcactcgca	atctctggca	217800
tttatgtgct	cataatgtag	tggatgaatgg	caattgcggc	aacctatggcc	tgacaagagc	217860
aagggtcatca	agagcttaga	ttgtttggag	ctgaaggctc	gagtcacccc	attaggctaa	217920
aaacctagaa	aagtagaagt	gctgatggag	ggtgaggaaa	atctaatatg	gattgtggag	217980
gaaggagacg	atacatataa	aacatgactg	caggacctgc	agttgtagca	gtgagggctg	218040
taacttattc	cattaatatt	tgtgtgttaa	gtcacatgta	gagattgtgg	ctaactacca	218100
ccttgaagac	ttagagggtt	ctggaactta	ttctagggcg	taggtgtatc	tgtgtggtag	218160
aaaggataga	ctgtatgggt	tgtttttggc	tttctgactc	atatacctct	ggcttcatct	218220
ctgattacag	tgtatagtca	gtgggtagtt	tggcttacgt	caggctgaca	tctttctcta	218280
agcactggat	gttttgcact	tttgcccttg	ggtttttcca	atgccacaat	tgccattggg	218340
aagccctctg	ttcaagcagg	catgctcagt	cgagaagcca	acaggggttt	acatcccca	218400
agcaaacctt	aactaatgga	ggatacaagt	tgatggataa	aaatagtcaa	accttaagta	218460
cataattcca	aaaggatttc	taaacactcc	ttagaagatt	ccaggcaggg	ctgagcacia	218520
gttgccctaca	atggtgatat	taataatgca	tctatatata	tgccttttca	cattccctcc	218580
ctcttctgtc	tctcactcct	gctccctgtt	cataaatttt	tgcagcaggc	tctgcttttg	218640
ggaaaactca	agctaaaaca	aaagtcctta	aattccagta	tgcctctgtc	ctccactttc	218700
tacccaattt	tgtgttgttt	cttttgggtt	tttccctgat	atatgccaa	aaaataaatg	218760
gagaaataga	aggggtgggac	tatcaacaaa	tactttaata	gaatttccag	aaggacttaa	218820
gctgtcagat	tgaagagatc	cactaagtag	cccagaaaat	agtttaaaa	ttgggtgttt	218880
tgaagttttt	ttctccctgg	tttggtttta	tctctacatc	tgggtgtacag	ctgtccctcat	218940
gagatgcctt	gttactatta	ttctcttgtg	ccaaaacttc	tatttcttat	ccctgtaatg	219000
ttttctttct	tggagcacct	cctaaatagt	cttagaaagg	atgcatggga	ggtaactttt	219060
ttgaggcctc	aaacatctaa	tgaagtctct	attttatttc	ctttgacctg	attgaatgat	219120
tatggattta	taggttagaa	actatttctt	tcaaatacat	gaagggagtg	tcttattttc	219180
tgtgttgcta	ttaaaaagtc	ctaagtcaac	tctttttatc	attctgtgta	cagtgtatgt	219240
gatttttttt	cttctctgga	agcatgtgga	gtcttcttta	gtccctgtg	ttctgaaatt	219300
tcaacagaaa	tacccttatt	aaggtctgct	gcttggtttc	tattctccat	gttaaaactt	219360
tccacacatg	tttggtaatc	cttgggaagt	tttaaaattt	cagttatctt	ttaaagtaag	219420
taagagaaga	aaaaacttta	aaaaggcagt	ttttatgttt	actcatgtat	ttcccatttc	219480
tgttgctctt	cattcttttc	tgtaatctt	agttcccat	taatgtcatt	ttcttcacct	219540
gaataacttc	ttttactgca	tattttctgc	ttataaattc	tctcagtttc	catttatccc	219600
ataaagtcta	ttttaccttt	attttcaaag	gatcttttca	ctggatatag	atttatgggt	219660
gacagtattt	tgtgtgtgtt	gttgtgtgta	atttacttca	gtacttacat	atattctagt	219720
ttcttctgtc	tccactgttt	ctgatgagaa	gtcattattg	gtatcagtgt	tcctttgtat	219780
ataatatgtt	cttttccctc	cagctacttt	caagagtttc	cccttgtctt	tgttttttca	219840
gtttgattgt	gatgtacttc	gttttcttta	tgtttatcct	gcttcagggt	ccctgaaatt	219900
cttggatatg	taggttgatg	ttttaaataa	atttttaaac	attagaccat	tatttcttca	219960
aatattttct	tcttctcttc	atctaagact	tcaatgatat	acatggagac	tccttgatat	220020
tgttccattg	tcacaaagcc	tttattaatt	tctttcaata	gttttttctt	tttgcagctt	220080
gaacttaaaa	ttcactgcac	tctgcacctc	cttttcccc	cgtgaagtct	ccaatccatt	220140
gttaagctca	ttcaggattt	ctccacttca	gatattatac	gctgtagttc	taaaatttcc	220200
atttttctgc	tgtatcccca	tatgcattca	ctgattatga	ccataatttc	tatacatttt	220260
tgagcatatt	tataataagt	gctttaaagt	ccttttctac	taattataca	ttcggggcat	220320
ttcagagttc	agtttctcct	gactactttg	tctcttgagt	atgctttttc	ttccaggtgc	220380
taataatttt	taaattatac	acaaagcatt	aaagataatt	tgttggccag	gagcgggtgg	220440
tcacgcctgt	aatcccagca	ctttgggagg	ccaaggcgga	cagatcatga	agtcaggaga	220500
ttgagatcat	cctggctatc	actgtgaaac	cctgtctcta	ctaaaaatac	aaaaaaaaga	220560
aaaaattagc	tgggcatggg	ggcgggcggc	tgtagtccca	gctacttggg	aggctgaggc	220620
aggagaatgg	cgtgaacctg	ggaggcggag	cttgtagtga	gccgagatcg	cgccactaca	220680
ctccagcctg	ggtgacagag	cgagactgtc	tcaaaaaaaa	taaataactt	gtagagattt	220740
tggagtctgt	tacctttctc	tgaagaatgt	tgatttttgt	tgtagcagca	gggcatcagt	220800
gaaatctctg	ctcgggtttac	aagtcttttt	ttcttttctt	ttcttttttt	ttgagatgga	220860
gtttcgctct	tgttgtcttg	ttgtccaggc	tggagtgcaa	tggcgtgatc	ttggctcacc	220920
gcgacctcca	cctcccgggt	tcaagagagt	ctcttgccct	agcctcctga	gtagttggga	220980
ttacaggcag	gcgccaccac	acctggctaa	ttttgtattt	ttagtagaga	cgtgggtttct	221040
ccatgttggg	caggctgggc	tcaactcct	gaccttaggt	gacccctcca	tctcagcctc	221100
ccaaactgct	gggattacag	gcgtgagcca	cggcgcccg	cctagtcttt	taactattgc	221160
tatctgctgg	gcttttttga	gtctctacca	tgcattgcata	gtccagtagt	tagtcaagga	221220

tttgaaggga	gttgatacac	agattttgtg	gcttctctct	ctgtgcgtct	ctcctttcag	221280
caatttttct	gtttaaattc	agtcaccctg	gaatccctga	gctcactctc	tgactccaca	221340
actcagaaa	acaatgactt	tctttatgaa	ttttagctac	cctgcatcac	ttgggctgca	221400
agatgctctc	cagagaaaat	ctacattaaa	acatgtcact	caatgcagtt	accttctttc	221460
aaaggttgaa	tcaccttctt	tttgaatccc	tggtggttgt	tattttgtac	cttaaataat	221520
tatttttaat	actggtccag	agtttataat	tggtatctat	gaggagtgtt	agtctaacac	221580
aagatatttt	gtcattttcta	gaacaagact	actccactct	tatgtagctg	tgacattgtc	221640
atgcatttct	ttaaaacatt	ttagtggttc	tttattgttt	atcaaataga	aaatattcct	221700
taaactgcat	gtactctatt	ttttcattgt	ttcccataac	aaagaaatat	tattttcattg	221760
aaatattgaa	atattgagca	tgccctcaaa	tattatgttt	caccatgttc	ttttgctcat	221820
accgttttcc	atccagaata	catttttccc	cctacatttg	aatgcccata	tcctgcctat	221880
tctttaagat	ctagctaaaa	tgccacctcc	tccacgaaa	ctattcttct	ccctccagtt	221940
tcagttttga	ctaaattatc	tgtttctatt	tcattgcttt	acttatgttt	tataaggaca	222000
ataagagatt	agtgccttta	taaaagagac	cccacaaagc	ttccttgccc	cttctactat	222060
gtgaggacac	agcaagaaga	cagccaacta	tgagcctgga	agcagggcct	catcaaacct	222120
tgagcatgct	ggtagactga	tcttggaact	tccagtctcc	aaaactgtaa	gaaataaatt	222180
tctgttggtg	atggctgggc	gtggtggctc	acgctgtat	tcccagcact	tgggaggccg	222240
aggtgggcga	atcacgaggt	caggagatcg	agaccatcct	ggctaacatg	gtgaaaccct	222300
gtctctacta	aaaatacaaa	aaattagctg	ggtgtggtgg	caggtgcctg	cagtcccagc	222360
tactcgggag	gctgaggcag	gagaatggcg	tgaacctgaa	aggtggagct	tgcatgagc	222420
caagatctca	ccagtgcact	ccagcctggg	tgacagagcg	agactccgtc	tcaaaaaaaaa	222480
gaaagaaatt	tctgtttttt	ataagccacc	cagtctatgg	tactttgtta	tagctgcctg	222540
aatggactaa	gacacaatgt	gaaagtacat	tatcttcttt	ttgattctca	agttaccacc	222600
ttttctcaaa	cgaccaccaa	ctctctctgg	actctgaaa	tattcttgta	actggtctct	222660
ctgcttccat	tcttgtacct	ttaaacctta	gtattccaca	gtagcctaag	aggtccttagg	222720
gtatataaac	aaaatgacgt	taatttcctg	catctaata	ttcaatagct	tcccattgca	222780
ctaaagtgga	accctttctt	tagagtccct	gccatgatca	ataaggctct	ctctcctaca	222840
aggtatgggc	actgcctact	actctgacct	catttattac	actcttccct	gccttaacat	222900
atgcaaaaag	tattcgacct	ttcccccaat	tctcaaacac	tgcaaaaaaac	cctccaaagg	222960
cctactactt	tacagttgct	ctatcttctt	cctcgaatgc	cctccttctc	tttatagatg	223020
gtccttctt	ttagtttctt	agtaaaaaata	tcactctcct	agagggacct	tcacccccct	223080
agtcacaacc	ttgttttaaa	ttcctcagac	cctcatgatt	atctgaaatt	tctctattat	223140
atttctttct	ttgttggttt	atgtttctct	ctgtcacaaa	gcaatacatt	tttttttaaa	223200
gcaggaatgg	gctatatatt	cttcattttg	ttgacctcta	ggagctgcat	cagttggggt	223260
cccctgcctc	tgccctccag	ttgagttcag	ttaagtaaag	accagaggat	aagaaagaag	223320
gctactgtgt	gtttctactg	agggttatag	ctcctttcag	gcagtcctct	tctacagctt	223380
ttgggttcca	taactatttc	ttctccttga	tgatctccgg	taattcaact	tggctccttg	223440
ttttctcttt	ctgtcctcct	cactgttgct	agccttaggg	tgcttcagtt	tccttcaacg	223500
cagttcacat	cttttaaaaa	cagactcttc	attaaattct	ctttaatgat	ttgtttcaag	223560
tatgacaaat	ctgtctttct	gggaccttga	attttattct	tcaaaatatt	accagccctt	223620
agcacagaac	ctgttacatg	gtgacgttca	acacatattt	gttgaatgaa	tggatgaatt	223680
aataggctct	tttgctcttc	attcagaatc	tattaagcta	tacactccct	cagtatttta	223740
aacccaaaat	tcagttttta	aaaactaaac	ttcttgagag	catagtctat	ctatatctct	223800
ttaaaattta	ggcctaagac	aggacactgc	cccacattga	gtcccacaca	acaacctgtg	223860
agtctggctc	cccaggaggg	ccccagaca	gtcccaggc	acttcatagg	caaagcctgt	223920
ccccccact	caggattccc	aaggtctggg	gtcccgttca	ccccgctttc	ctctcatgac	223980
cagctgacc	ccaggtttca	gctgggagag	ggcacttccc	ttagccaagg	aaaacagaaa	224040
ccccagggt	acaggaggaa	gctgggacag	gtccccttgg	gtgtcactcc	ctcacccccct	224100
gcccaggccc	actcccactg	gtgctggagt	acgcactggg	ggggggaccc	tgctcagccc	224160
agcctggagg	gccccagtgt	caccacaacc	aggggcacgg	caacatcatt	gatgggttct	224220
gcagcccagg	gccccgatg	cggggtcaga	gtgtgtgggg	cacaggggccc	ccgatgcggg	224280
gtcagtgtgt	gggggtgcag	ggccccgat	gtggggtcag	tgggggtggg	gcgcagggtc	224340
cccgatgcgg	ggtcagagt	gtggggcac	agggcccccg	atgcgggggtc	agtgtgtggg	224400
ggtgcagggc	ccccgatgcg	gggtcagtgg	gggtggggcg	cagggtcccc	gatgcggggg	224460
cagagtgtgt	ggggcgagag	gccccgatg	cggggtcagt	gggggtgggg	cgagggtccc	224520
ccgatgcggg	gtcagagtgt	gtggggcgca	gggccccga	tgcggggtca	gattgtgtgg	224580
agcgaggggc	cccctcgtgt	ccagggcact	ttggtacact	gtcccacaag	gcacctgtct	224640
cagaggaggg	gtcctggcag	gcagtgtggc	aactcccttc	cagagcccag	ctccatgcta	224700
acctgcccac	agcaacccca	cagagccaca	tcccctgctg	cacctggcct	gcaggagtgt	224760
cccaggacag	gcccaggtca	gcccagcatg	cagctgccct	cctaccctga	agaaggaggt	224820
gggctttcca	ggggacataa	ggatgccagg	cctggacctc	ctgggcagga	aagggagcag	224880

gtcctgaggg	cctgtgcccc	acagccccag	caccaggtgg	actgcagcgc	agtgggtggg	224940
ccagtggcag	ctggggagaa	gccccccgtc	agcaggctgg	ggtctgcccc	ccagggcctc	225000
cccacgtctg	cctttgaggg	tgcctgccat	gccctggggg	atcctggtat	ctttactgga	225060
ctggaagcag	gagacagaac	agtgtctgtc	ccggggtgac	ttcatcagga	gaccgcccac	225120
atagagctgg	accccgagc	tgaagcggaa	atgtgagaca	ggctggcacc	tccggaaaaa	225180
ctgcctttca	gccttggtgt	tccgtgcaag	gtgaaaaaaa	ataggtcctc	caagtttaca	225240
gcttgaaatc	aggctactgt	gtggccctgg	agaccacgag	gggagaattt	aaagtggccc	225300
cggctggcag	ggtctaggtg	gctggcagag	gcacatgcag	accctacctg	gagcccgccc	225360
tagggacgct	gggcaggtca	gtctccgtgc	aggatgtgag	cagcgtccct	gggctctatc	225420
cgcgaggtgc	cagtagcgtg	tgcaggtaca	tacacatgcg	tgcacactgt	tatgacaccc	225480
agaaatgtct	caggacgtcg	aaatgtgtcc	ttgggagcag	aagtgtcccc	ggttgagaat	225540
ctgtcccaga	ggaacacgac	cacgacaggc	ctcaggattt	tgtgttgatc	aagttccaag	225600
gaaaaggaac	atctcggcca	ggcgtggtgg	ctcacgcctg	gaatcccagc	acttgaggcc	225660
aggagttcga	gaccagcctg	ggcaacgcag	tgagagaccc	ccatctctac	aaaaaaaaaa	225720
aagaaaaaaa	aaagaaagaa	agaaagaaaa	gaaaatgaga	tctccaggtt	taaaaattca	225780
taaacaccac	aaggaaacaa	tacactatga	gatccagcag	aagcaacaga	ttgactctgt	225840
agaccagat	actggaatta	tcagagagaa	tataaagtaa	cagtgtttta	tatatctaaa	225900
gaaataaaa	agattttctg	aaaaaaaaat	ttaggcctaa	gaattagtga	aaatcccaac	225960
attaaggaag	ggattatatg	ttcagttttt	gaaaggataa	tgtgtcattt	ttaatatattg	226020
ctatttctctg	gaatcttagt	tctaggatac	accataaatg	tctgctttta	taggtgaaga	226080
aactgaggg	gagaactgaa	gagggattta	tctgaagacg	ttatggtagt	ggaaccaatt	226140
tttactttta	tgttgttgct	ctcttgatga	tattagatgg	tttcatcaat	tactaagtaa	226200
attcccaaga	tttacctcga	agtcacatta	ccctattaac	ttattctcca	gttgtacca	226260
tttgccattt	cattctggta	acaaagctct	cttactacaa	ttcagaaaat	atttgggagg	226320
cagctgccac	tgagcccaga	ctttgacaaa	atatcctccc	acagaggccc	agttaaaacta	226380
tggattgcac	tgagcattct	gtccttaggt	gctctggcct	cccagtagat	agcggatgct	226440
gtggtaat	atcacacccc	tctacccctc	cgattacctg	ccaggtgact	cttcaactct	226500
ggcttctgca	gcctctgctc	tccccaaagt	ccagctctct	cagcccccca	tctaagggtg	226560
cacagtttag	gtacatgctg	aaatcaccaa	tacagaatcg	ttttaaaatt	cgaattaatt	226620
ggctgagtg	tttgtaaga	cctgattgtg	ggcaagaact	atttgtaaaa	tactctaaat	226680
tcttagaacc	cagcccagta	cttgctagtc	atcattttaa	tacattgaat	gataagaaaa	226740
attcttctga	tcacaaacct	tataccagcg	ttgtcaaaat	tataatgata	aagtagctca	226800
ttttaagcgc	gtcctgggtt	gggaaaactta	acaattttta	aacttggaat	aaattcaata	226860
aaatgacata	gtatggttac	aatgtctgtc	tacagagtca	gggcaagaac	aaagaaaatt	226920
gaaagaagat	tgttttagtg	tagtaaaaat	actggataat	tttcatttcc	tttgctcttt	226980
aaagaattat	ttgtaagg	tatttgaaat	gaaaacaaga	ttggagaaaa	acaacttgga	227040
agaaaatcat	aggcaaataa	caataatgat	tgaagagttg	tgaataagga	gagttaggaa	227100
tcaagtgggt	ccaggcttgc	agaatctgaa	aggagcctag	agtgaggagg	ttgatctgtg	227160
aaggatgatg	atgatctcca	ttaaggacca	gacaggaggc	aataggctta	agctgcagta	227220
tgagggattt	agataagaga	aaaggaaaaa	ttttcagaca	gtgaggttca	tagatactgg	227280
aatgtgtaac	tgaggaagct	tgtggaattt	ccttctctag	aagtctttta	aaaatagggc	227340
agtgtctcat	ctgcctgaag	gatggactct	atttgacctc	tcaaattgtc	tactgaactc	227400
agaaggtgaa	ccacacctta	gataagaaa	agagcctgaa	tgatcctggg	tagcttgagt	227460
aataaaaagta	gggtgaacaa	gtcatattta	ttttgattta	tatatgtcat	atatgtaaat	227520
tatgtctgct	ataattcctt	tttttctttc	aattgaatgt	tttcattttt	aaggcctaga	227580
gattagagtt	caagtaaaaga	tattatagga	aaagcaagaa	gaactctttt	atcttactgt	227640
agaacaaatt	tttagaggaa	taaaaggaga	aaagagataa	ttggacatat	ttgattttga	227700
tttcaactccc	tattctaaat	aaaaaaaaat	acactgccct	ttctgttagc	tttagtattt	227760
taagggtaaa	tttcaaaaag	ttaatttagt	gtaagtgttt	ctcacggtgt	ttttggcaga	227820
accggtatcc	caaactggaa	gaggttctct	gtatttaatt	tcctctcagg	aagtttaccg	227880
tcagaagtcc	aaatgtgagg	tcaagttttg	ggttgccgga	aatggtaatg	tcctttactg	227940
tctgaacacc	cagacaacac	ttaatgaaac	attctacttt	gtggacattg	aaagaaatta	228000
aaatgctttg	tttctctcct	tttatgattg	gtgatttctg	tattcagtct	tctaaaactc	228060
agaaacaaga	ctatgtgtaa	gtaagagcat	ctgcattctc	aggatcaagt	tataactgca	228120
gattttcagt	tacagggtgat	atccatcttt	tttttccttc	ctaaaaataa	aaatgtactt	228180
acttcaggcc	aaaggagagg	caagctttag	aactcattag	ccttcaagaa	aaacaattcc	228240
agagcattct	aaacctgatt	tcttttcta	tctgtttgag	ttgacctgag	gacttttaca	228300
ggttaaagca	gtgagtcatt	atatctcaca	ttcatacagc	tctacatatt	tgtcaaagtg	228360
cttactcatc	taatatctaa	tatgatctta	ataagaacct	tgtgaatgtc	attatcttat	228420
agatgaaaaa	atgatatctt	cataagatac	agtttgctca	agatcacaaa	actagaaaaa	228480
gtagtttgaa	cacttctgat	ttcaaagcca	gagtccttct	cactgcccc	tgctgtactg	228540

tttttgagaa	tttgtgattt	cctggtgttg	tattatTTTT	accattgatg	agattttttgc	228600
ctgtgattta	tcctgaatca	aaatagatac	tgtgatatga	tactaaagta	attgtttacca	228660
aacaaaaagt	tgtgctagca	ttcttatgaa	gtacagcact	aaagattttc	aaaacatttt	228720
gttattttta	cataattggg	catgtaaaatt	tctggtagga	cactccttat	gagattacaa	228780
cccattctaa	tttatgctag	ctattttattg	ttaagcagta	tgttgttttt	attacaaaac	228840
ctcctttaat	cattgcatca	gtctctggca	gaatattaaa	aacaactccc	ataatccctg	228900
gcactctgtc	ctgggtgtct	ttgggggtac	agtggcttta	tttccttccc	taatagtctg	228960
gaagtttggt	taatactgac	tcagaggaag	cattctagct	gagtcctcac	atggtcttgt	229020
ttacagctcc	ggagtgtaca	taatagataa	gctactgact	tccacaagac	ccccacgctt	229080
cctgggtgtg	tgggtgtgtg	tgcttgtgct	tgtgaattaa	ggttgtgcaa	tctccctgct	229140
agctgcatca	ggttgcaaag	tcatttactt	ctctaaaata	ttcctctagc	cagcctgact	229200
tgataaacca	aaatcattgt	attccatggt	ggacatgctg	gtaactcatg	ataaacacta	229260
aaaatcctac	gggtttataa	caagataaaa	cctgatattg	gggcagggtg	tagagaaatt	229320
tgcccaagga	aatattgtga	aataaagttg	caaattggcta	tagatgaatg	cttttctatc	229380
tataggattt	cttttcttga	ttgtaattat	aaattctttt	actggttgta	aatataatta	229440
tgattcttat	gttaccctagt	ctgtaccaag	aactttgtta	ggccaacaac	atcttacttg	229500
attgtagtag	taaccttaaa	agataaatat	aggtataatg	ctttttcaga	agaaaaactg	229560
gagaattcaa	acatgttctg	cattgcacag	atggtaaattg	agtgatgaat	agggtccttt	229620
gactccaaag	atcaactagg	ttctttccac	atatctctct	ttggttcctt	tttttgatat	229680
gactgtatga	aatataattg	tatttacata	aagtgcagta	gagttcatta	gaaaaactat	229740
ttctgaatct	tagggttcag	actaaagggtg	tttgagggtg	gatgatagtg	ggctgcaaag	229800
agcttcatgg	tgggctgcga	atagcttcat	caaacc			229836